<SEC-DOCUMENT>0001144204-17-046061.txt : 20170831
<SEC-HEADER>0001144204-17-046061.hdr.sgml : 20170831
<ACCEPTANCE-DATETIME>20170831092137
ACCESSION NUMBER:		0001144204-17-046061
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20170630
FILED AS OF DATE:		20170831
DATE AS OF CHANGE:		20170831

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-53121
		FILM NUMBER:		171062205

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v473641_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%"><FONT STYLE="color: #000000">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>UNITED
STATES </B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>SECURITIES
AND EXCHANGE COMMISSION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"><FONT STYLE="color: #000000">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>FORM 10-K
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"><FONT STYLE="color: #000000">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>(Mark One) </B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt"><FONT STYLE="font-family: Wingdings; color: #000000">x</FONT></TD><TD><FONT STYLE="color: #000000"><B>ANNUAL
                                         REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;<B>For
the fiscal year ended June 30, 2017 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt"><FONT STYLE="font-family: Wingdings; color: #000000">&uml;</FONT></TD><TD><FONT STYLE="color: #000000"><B>TRANSITION
                                         REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Commission
File Number 333-146542 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"><FONT STYLE="color: #000000">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 24pt; color: #000000"><B>AYTU
BIOSCIENCE, INC.</B></FONT><B><FONT STYLE="color: #000000"> </FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>(Exact
Name of Registrant as Specified in Its Charter) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"><FONT STYLE="color: #000000">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; width: 50%"><FONT STYLE="font-size: 10pt; color: #000000"><B>Delaware</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 50%"><FONT STYLE="font-size: 10pt; color: #000000"><B>47-0883144</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>(State
        or other jurisdiction of</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>incorporation
        or organization)</B></FONT></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>(I.R.S.
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Identification
        Number)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>373
        Inverness Parkway</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Suite
        206</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Englewood,
        Colorado</B></FONT></P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center; width: 50%"><FONT STYLE="font-size: 10pt; color: #000000"><B>80112</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>(Address of principal executive
    offices)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>(720) 437-6580
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>(Registrant&rsquo;s
telephone number, including area code) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Securities
registered pursuant to Section&nbsp;12(b) of the Act: None </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Securities
registered pursuant to Section&nbsp;12(g) of the Act </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Common
Stock, par value $.0001 per share </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"><FONT STYLE="color: #000000">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="color: #000000">Indicate
by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Indicate by check mark if the
Registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Indicate by a check mark whether
the Registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12&nbsp;months (or for such shorter period that the Registrant was required to file such reports)
and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Indicate by check mark whether
the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter
period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Indicate by check mark if disclosure
of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K is not contained herein, and will not be contained, to the
best of the Registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III
of this Form 10-K or any amendment to this Form&nbsp;10-K&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Indicate by check mark whether
the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See
definition of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule&nbsp;12b-2 of the Exchange Act. (check one):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 18%"><FONT STYLE="font-size: 10pt; color: #000000">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Wingdings; font-size: 10pt; color: #000000">&uml;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 25%"><FONT STYLE="font-size: 10pt; color: #000000">Accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 7%"><FONT STYLE="font-family: Wingdings; font-size: 10pt; color: #000000">&uml;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Non-accelerated filer</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt; color: #000000">&uml;</FONT><FONT STYLE="font-size: 10pt; color: #000000">&nbsp;&nbsp;(Do
    not check if a smaller reporting company)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt; color: #000000">x</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Emerging growth company</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt; color: #000000">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Indicate by check mark whether
the Registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">The aggregate
market value of common stock held by non-affiliates of the Registrant as of December&nbsp;31, 2016 was $10.5 million based on
the closing price of $24.00 as of that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Indicate the number of shares
outstanding of each of the Registrant&rsquo;s classes of common stock, as of the latest practicable date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">As of August
15, 2017, there are 4,021,822 shares of common stock outstanding and 2,250 shares of Series A preferred stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%"><FONT STYLE="color: #000000">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><U>TABLE OF CONTENTS </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding-left: 0.1in; font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 80%; font-size: 10pt; text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; padding-left: 0.1in; font-size: 10pt; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>PAGE</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="color: #000000"><A HREF="#a_001"><FONT STYLE="font-size: 10pt"><B>PART
    I</B></FONT></A></FONT></TD>
    <TD STYLE="padding-left: 0.1in; font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item&nbsp;1</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">BUSINESS</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item&nbsp;1A</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">39</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item&nbsp;1B</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">UNRESOLVED STAFF COMMENTS</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">64</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 2</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">PROPERTIES</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 3</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">LEGAL PROCEEDINGS</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 4</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">MINE SAFETY DISCLOSURES</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">65</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="color: #000000"><A HREF="#a_008"><FONT STYLE="font-size: 10pt"><B>PART
    II</B></FONT></A></FONT></TD>
    <TD STYLE="padding-left: 0.1in; text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 5</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">MARKET
    FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt; color: #000000">66</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 6</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">SELECTED FINANCIAL
    DATA</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">67</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 7</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">MANAGEMENT&rsquo;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">68</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item&nbsp;7A</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">QUANTITATIVE AND QUALITATIVE
    DISCLOSURES ABOUT MARKET RISK</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">74</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 8</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">FINANCIAL STATEMENTS
    AND SUPPLEMENTARY DATA</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">74</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 9</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">CHANGES IN AND DISAGREEMENTS
    WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">74</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item&nbsp;9A</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">CONTROLS AND PROCEDURES</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">74</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item&nbsp;9B</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">OTHER INFORMATION</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">75</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="color: #000000"><A HREF="#a_017"><FONT STYLE="font-size: 10pt"><B>PART
    III</B></FONT></A></FONT></TD>
    <TD STYLE="padding-left: 0.1in; text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 10</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">DIRECTORS, EXECUTIVE
    OFFICERS, AND CORPORATE GOVERNANCE</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">75</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 11</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">EXECUTIVE COMPENSATION</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">78</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 12</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_020"><FONT STYLE="font-size: 10pt">SECURITY OWNERSHIP
    OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">82</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 13</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_021"><FONT STYLE="font-size: 10pt">CERTAIN RELATIONSHIPS
    AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">84</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item 14</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_022"><FONT STYLE="font-size: 10pt">PRINCIPAL ACCOUNTANT
    FEES AND SERVICES</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">85</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="color: #000000"><A HREF="#a_023"><FONT STYLE="font-size: 10pt"><B>PART
    IV</B></FONT></A></FONT></TD>
    <TD STYLE="padding-left: 0.1in; text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Item&nbsp;15</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_024"><FONT STYLE="font-size: 10pt">EXHIBITS AND FINANCIAL
    STATEMENT SCHEDULES</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">85</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="color: #000000"><A HREF="#a_025"><FONT STYLE="font-size: 10pt">SIGNATURES</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">88</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Exhibit&nbsp;23.1</FONT></TD>
    <TD STYLE="padding-left: 0.1in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.1in; text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Exhibit&nbsp;31.1</FONT></TD>
    <TD STYLE="padding-left: 0.1in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.1in; text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Exhibit 31.2</FONT></TD>
    <TD STYLE="padding-left: 0.1in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.1in; text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Exhibit 32.1</FONT></TD>
    <TD STYLE="padding-left: 0.1in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.1in; text-align: right; vertical-align: bottom"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">This Annual
Report on Form 10-K refers to trademarks, such as Aytu, Natesto, ProstaScint, Primsol, MiOXSYS, RedoxSYS, and Fiera which are
protected under applicable intellectual property laws and are our property or the property of our subsidiaries. This Form 10-K
also contains trademarks, service marks, copyrights and trade names of other companies which are the property of their respective
owners. Solely for convenience, our trademarks and tradenames referred to in this Form 10-K may appear without the <SUP>&reg;
</SUP>or &trade; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest
extent under applicable law, our rights to these trademarks and tradenames.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000"><I>Unless
otherwise indicated or unless the context otherwise requires, references in this Form 10-K to the &ldquo;Company,&rdquo; &ldquo;Aytu,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; or &ldquo;our&rdquo; are to Aytu BioScience, Inc. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Forward Looking Statements
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">This Annual
Report on Form 10-K, or Annual Report, includes forward-looking statements within the meaning of Section&nbsp;27A of the Securities
Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other
than statements of historical facts contained in this Annual Report, including statements regarding our anticipated future clinical
and regulatory events, future financial position, business strategy and plans and objectives of management for future operations,
are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words
such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;forecast,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo;
&ldquo;suggest,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; or similar words, or the negatives of such terms or other variations on such terms or comparable terminology.
Such forward-looking statements include, without limitation, statements regarding the markets for our approved products and our
plans for our approved products, the anticipated start dates, durations and completion dates, as well as the potential future
results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future
regulatory submissions and events, the potential future commercialization of our product candidates, our anticipated future cash
position and future events under our current and potential future collaborations. These forward-looking statements are subject
to a number of risks, uncertainties and assumptions, including without limitation the risks described in &ldquo;Risk Factors&rdquo;
in Part&nbsp;I, Item&nbsp;1A of this Annual Report. These risks are not exhaustive. Other sections of this Annual Report include
additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive
and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict
all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination
of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not
rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected
in the forward-looking statements will be achieved or occur and actual results could differ materially from those projected in
the forward-looking statements. We assume no obligation to update or supplement forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">We obtained
statistical data, market and product data, and forecasts used throughout this Form 10-K from market research, publicly available
information and industry publications. While we believe that the statistical data, industry data and forecasts and market research
are reliable, we have not independently verified the data, and we do not make any representation as to the accuracy of the information.</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>AYTU BIOSCIENCE,
INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="a_001"></A><B>PART&nbsp;I
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><A NAME="a_002"></A><B>Item&nbsp;1.
Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We are a commercial-stage specialty
healthcare company focused on acquiring, developing and commercializing novel products in the field of urology. We have multiple
urology-focused products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs
in the field of urology. We are concentrating on hypogonadism, prostate cancer, male infertility and, recently, female sexual
wellbeing and intimacy and plan to expand into other urological indications for which we believe there are significant medical
needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We acquired exclusive U.S. rights
to Natesto<SUP>&reg;</SUP> (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use
nasal gel, and we launched Natesto in the United States with our direct sales force in late summer 2016. Natesto is approved by
the U.S. Food and Drug Administration, or FDA, for the treatment of hypogonadism (low testosterone) in men and is the only testosterone
replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently available TRTs and competes
in a $2.0 billion market. Importantly, as Natesto is delivered via the nasal mucosa and not the skin, there is no risk of testosterone
transference to others, a known potential side effect and black box warning associated with all other topically applied TRTs,
including the market leader AndroGel<SUP>&reg;</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Outside the U.S. we market MiOXSYS<SUP>&reg;</SUP>,
a novel in vitro diagnostic device that is currently CE marked (which generally enables it to be sold within the European Economic
Area) and for which we intend to initiate a final clinical study to enable FDA clearance in the U.S. &nbsp;Our MiOXSYS system
is a novel, point-of-care semen analysis system with the potential to become a standard of care in the diagnosis and management
of male infertility. Male infertility is a prevalent and underserved condition and oxidative stress is widely implicated in its
pathophysiology. MiOXSYS was developed from our core oxidation-reduction potential research platform known as RedoxSYS<SUP>&reg;</SUP>.
We are advancing MiOXSYS toward FDA clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We currently market ProstaScint<SUP>&reg;
</SUP>(capromab pendetide), the only radioimaging agent indicated to detect the prostate specific membrane antigen, or PSMA, in
the assessment and staging of prostate cancer. ProstaScint is approved by the FDA for use in both newly diagnosed, high-risk prostate
cancer patients and patients with recurrent prostate cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On May 5, 2017, we acquired Nuelle,
Inc, or Nuelle, a women&rsquo;s sexual health company. This transaction expanded our product portfolio with the addition of the
Fiera<SUP>&reg;</SUP> personal care device for women. Fiera was recently launched in the U.S. and is a proprietary, revenue-generating
product scientifically proven to enhance physical arousal and sexual desire in the millions of adult women around the world impacted
by changes in sexual desire. This acquisition adds a novel, commercial-stage product in a complementary adjacency readily accessible
by our U.S.-based commercial infrastructure. Nuelle was previously a portfolio company of leading venture capital firm New Enterprise
Associates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In the future we will look to
acquire additional urology products, including existing products we believe can offer distinct commercial advantages. Our management
team&rsquo;s prior experience has involved identifying clinical assets that can be re-launched to increase value, with a focused
commercial infrastructure specializing in urology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Natesto&reg; (testosterone)
nasal gel.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On April 22, 2016, we entered
into an agreement to acquire the exclusive U.S. rights to Natesto (testosterone) nasal gel from Acerus Pharmaceuticals Corporation,
or Acerus, which rights we acquired on July 1, 2016. Natesto is a patented, FDA-approved testosterone replacement therapy, or
TRT, and is the only nasally-administered formulation of testosterone available in the United States. Natesto is a discreet, easy-to-administer
nasal gel that may be appropriate for men with active lifestyles as Natesto is small, portable, Transportation Security Administration,
or TSA-compliant, and easy to use. Importantly, Natesto is not applied directly to the patient&rsquo;s skin as other topically
applied TRTs are. Rather, it is delivered directly into the nasal mucosa via a proprietary nasal applicator. Thus, Natesto does
not carry a black box warning related to testosterone transference to a man&rsquo;s female partner or children &mdash; as other
topically (primarily gels and solutions) administered TRTs do by virtue of their delivery directly onto the skin. We launched
Natesto in the U.S. in late summer 2016 with our direct sales force, and we are positioning Natesto as the ideal treatment solution
for men with active, busy lifestyles who suffer from hypogonadism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>MiOXSYS&reg;.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">MiOXSYS is a rapid <I>in vitro
</I>diagnostic semen analysis test used in the quantitative measurement of static oxidation-reduction potential, or sORP, in human
semen. MiOXSYS is a CE marked system and is an accurate, easy to use, and fast infertility assessment tool. It is estimated that
72.4 million couples worldwide experience infertility problems. In the United States, approximately 10% of couples are defined
as infertile. Male infertility is responsible for between 40 &ndash; 50% of all infertility cases and affects approximately 7%
of all men. Male infertility is often unexplained (idiopathic), and this idiopathic infertility is frequently associated with
increased levels of oxidative stress in the semen. As such, having a rapid, easy-to-use diagnostic platform to measure oxidative
stress should provide a practical way for male infertility specialists to improve semen analysis and infertility assessments without
having to refer patients to outside clinical laboratories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Male infertility is prevalent
and underserved, and oxidative stress is widely implicated in its pathophysiology. The global male infertility market is expected
to grow to over $300 million by 2020 with a CAGR of nearly 5% from 2014 to 2020. Oxidative stress is broadly implicated in the
pathophysiology of idiopathic male infertility, yet very few diagnostic tools exist to effectively measure oxidative stress levels
in men. However, antioxidants are widely available and recommended to infertile men. With the introduction of the MiOXSYS System,
we believe for the first time there will be an easy and effective diagnostic tool to assess the degree of oxidative stress and
potentially enable the monitoring of patients&rsquo; responses to antioxidant therapy as a treatment regimen for infertility.
The MiOXSYS System received CE marking in Europe in January 2016 and obtained Health Canada Class II Medical Device approval in
March 2016. We expect to advance MiOXSYS into clinical trials in the United States in order to enable 510k clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>ProstaScint&reg; (capromab
pendetide).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We became a commercial stage company
by virtue of our acquisition of ProstaScint in May 2015 and are generating sales of this FDA-approved prostate cancer imaging
agent. As prostate cancer is a condition commonly diagnosed and treated by urologists, ProstaScint complements our urology-focused
product portfolio and pipeline. Prostate cancer is the most common cancer among men in the United States, with an estimated 241,000
annual cases (as of 2012). Further, more than 2.2 million men were alive in 2006 with some history of prostate cancer, and over
30,000 U.S. men die each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes
the need for accurate disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and
screening of prostate cancer is expected to total $17.4 billion by 2017, a compound annual growth rate, or CAGR, of 7.5% since
2012. At June 30, 2017, the ProstaScint asset was impaired based upon sales projections that we intend to only sell this product
through mid-fiscal 2019, when this product expires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Fiera<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>&reg;
</SUP></FONT>Personal Care Device</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Fiera Personal Care Device
is the first hands-free wearable product for women, specifically designed to increase interest in, and physical readiness for
sex, naturally. The product does so by creating a physically aroused state via the genitals. Co-created with healthcare professionals,
Fiera is a small, discreet, fast-acting, and hands-free product that is designed to be used in advance of physical intimacy to
help women feel ready and in the mood for sex. Fiera uses gentle suction coupled with stimulation to enhance blood flow to the
genitals, increase lubrication, and ultimately get a woman ready for partnered intimacy in as little as 5 minutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">With the
acquisition of Nuelle, Inc., Aytu is expanding into the women&rsquo;s sexual health and wellness market. Sexual wellness is inclusive
of female sexual dysfunction which is a term that describes various sexual problems, such as low desire or interest, diminished
arousal, orgasmic difficulties, and dyspareunia. Female sexual dysfunction is considered common, with an estimated prevalence
of 43% from the U.S. National Health and Social Life Survey and similar estimates from other large, population-based surveys in
the United States<SUP> </SUP>and the United Kingdom. In a study of over 31,000 women in the United States it was determined that
44% of women report a sexual problem. Specifically, the most common sexual problem is low desire, with a prevalence of 39%; followed
by low arousal (26%) and orgasm difficulties (21%). Additionally, the incidence of sexual dysfunction is expected to increase
through 2020 to effect more than 124 million women worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">Fiera has
been well studied and tested by health care professionals, and consumers and is scientifically proven to enhance arousal and interest
in women of all ages, including pre and post-menopausal women. Recent consumer study results in women ages 25 &ndash; 75 showed
that after 4 weeks of using Fiera:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 13.5pt"><FONT STYLE="color: #000000">97%
                                         of women felt physically aroused;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 13.5pt"><FONT STYLE="color: #000000">96%
                                         looked forward to being intimate with their partner;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 13.5pt"><FONT STYLE="color: #000000">93%
                                         felt excited and ready for sex;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 13.5pt"><FONT STYLE="color: #000000">89%
                                         of women felt more &ldquo;in the mood&rdquo;;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 13.5pt"><FONT STYLE="color: #000000">87%
                                         felt as ready for sex as their partner did;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 13.5pt"><FONT STYLE="color: #000000">86%
                                         of women felt a stronger emotional connection with their partner;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 13.5pt"><FONT STYLE="color: #000000">85%
                                         reported their orgasm felt pleasurable and intense;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify; padding-right: 13.5pt"><FONT STYLE="color: #000000">85%
                                         thought about sex more often; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">85%
                                         engaged in sexual activity more often and felt satisfied in her relationship.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Previous studies also showed that
87% of women felt increased desire and 67% felt increased lubrication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Key elements of our business
strategy include:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Expand
                                         the commercialization of Natesto in the U.S. for the treatment of hypogonadism with our
                                         direct sales force. We launched Natesto in late summer 2016 and are targeting high prescribing
                                         TRT prescribers with a primary emphasis on urologists and male health practitioners.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Expand
                                         the commercialization in the U.S. of Fiera, through professional promotion using our
                                         existing sales force.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Establish
                                         MiOXSYS as a leading in vitro diagnostic device in the assessment of male infertility.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Continue
                                         the commercialization of FDA-approved ProstaScint for the staging of both newly diagnosed
                                         high-risk and recurrent prostate cancer patients.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Acquire
                                         additional marketed products and late-stage development assets within our core urology
                                         focus that can be efficiently marketed through our growing commercial organization.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><P STYLE="margin: 0"><FONT STYLE="color: #000000">Develop
                                         a pipeline of urology products, with a focus on identifying novel products with sufficient
                                         clinical proof of concept that require modest internal R&amp;D expense.</FONT></P>


</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We plan to augment our core in-development
and commercial assets through efficient identification of complementary therapeutics, devices, and diagnostics related to urological
disorders. We intend to seek assets that are near commercial stage or already generating revenues. Further, we intend to seek
to acquire products through asset purchases, licensing, co-development, or collaborative commercial arrangements (co-promotions,
co-marketing, etc.).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our management team has extensive
experience across a wide range of business development activities and have in-licensed or acquired products from large, mid-sized,
and small enterprises in the United States and abroad. Through an assertive product and business development approach, we expect
that we will build a substantial portfolio of complementary urology products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Corporate History </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We were incorporated as Rosewind
Corporation on August 9, 2002 in the State of Colorado.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vyrix Pharmaceuticals, Inc., or Vyrix, was incorporated under
the laws of the State of Delaware on November 18, 2013 and was wholly owned by Ampio Pharmaceuticals, Inc. (NYSE American: AMPE),
or Ampio, immediately prior to the completion of the Merger (defined below). Vyrix was previously a carve-out of the sexual dysfunction
therapeutics business, including the late-stage men&rsquo;s health product candidates, Zertane and Zertane-ED, from Ampio, that
carve out was announced in December 2013. Luoxis Diagnostics, Inc., or Luoxis, was incorporated under the laws of the State of
Delaware on January 24, 2013 and was majority owned by Ampio immediately prior to the completion of the Merger. Luoxis was initially
focused on developing and advancing the RedoxSYS System. The MiOXSYS System was developed following the completed development
of the RedoxSYS System.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On March 20, 2015, Rosewind formed
Rosewind Merger Sub V, Inc. and Rosewind Merger Sub L, Inc., each a wholly-owned subsidiary formed for the purpose of the Merger,
and on April 16, 2015, Rosewind Merger Sub V, Inc. merged with and into Vyrix and Rosewind Merger Sub L, Inc. merged with and
into Luoxis, and Vyrix and Luoxis became subsidiaries of Rosewind. Immediately thereafter, Vyrix and Luoxis merged with and into
Rosewind with Rosewind as the surviving corporation (herein referred to as the Merger). Concurrent with the closing of the Merger,
Rosewind abandoned its pre-merger business plans, and we now solely pursue the specialty healthcare market, focusing on urological
related conditions, including the business of Vyrix and Luoxis. When we discuss our business in this Report, we include the pre-Merger
business of Luoxis and Vyrix.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 8, 2015, we (i) reincorporated as a domestic Delaware
corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and (ii)
effected a reverse stock split in which each common stock holder received one share of common stock for each 12.174 shares outstanding.
At our annual meeting of shareholders held on May 24, 2016, our shareholders approved (1) an amendment to our Certificate of Incorporation
to reduce the number of authorized shares of common stock from 300.0 million to 100.0 million, which amendment was effective on
June 1, 2016, and (2) an amendment to our Certificate of Incorporation to affect a reverse stock split at a ratio of 1-for-12 which
became effective on June 30, 2016. At our special meeting of shareholders held on July 26, 2017, our shareholders approved an amendment
to our Certificate of Incorporation to affect a reverse stock split at a ratio of 1-for-20 which became effective on August 25,
2017. All share and per share amounts in this report have been adjusted to reflect the effect of these three reverse stock splits
(hereafter referred to collectively as the &ldquo;Reverse Stock Splits&rdquo;).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Our Strategy&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We expect to create value by implementing
a focused, three-pronged strategy. Our primary focus is on expanding Natesto in the U.S, growing our current, revenue-generating
products, and building a complementary portfolio of aligned urology assets. In just over two years since our merger we have acquired
or in-licensed three FDA-approved, marketed assets (and have since divested one asset &ndash; Primsol&reg; Solution), launched
a specialty urology sales force, advanced our lead diagnostic asset MiOXSYS to CE marking, engaged in asset purchase and licensing
discussions for products aligned to our strategy, launched Natesto in the U.S. through our own sales force and acquired Nuelle
Inc., a wholly owned subsidiary focused on the Fiera product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We believe the strategy of focusing
on commercializing assets prescribed by urologists is logical for several reasons. First, urology is a large yet concentrated
specialty practice area that can be efficiently targeted. There are approximately 10,000 active urologists in the U.S., and we
believe that this audience can be efficiently reached with a relatively small, focused sales force. Additionally, 90% of urologists
practice in metropolitan areas where concentrated sales targeting can be achieved and &ldquo;windshield&rdquo; or sales representative
driving time between targets can be minimized. Importantly, 81% of urologists practice in group practices, and over 60% are in
practices of four or more physicians. Further, and important in building a balanced yet focused product portfolio, sub-specialization
within large urology clinics is common whereby there is frequently individual clinical focus on specific areas within urology
including prostate cancer and conditions, infertility, sexual wellness and vitality, urinary incontinence, hypogonadism, etc.
This enables a company to offer multiple products to the various sub-specialties within these focused, concentrated customer targets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Further, urologists treat a wide
range of conditions and are thus appropriate targets across a broad range of clinical assets (Natesto &ndash; hypogonadism; ProstaScint
&ndash; prostate cancer; MiOXSYS &ndash; male infertility; Fiera &ndash; female sexual wellness). Importantly, in urology, direct
physician office purchasing of drugs, devices, and diagnostics is common. Along with this, a significant proportion of urology
groups are privately-owned and often own and operate their own outpatient surgery centers and in-office laboratories. Further,
large urology group practices have substantial payer influence and can have the ability to negotiate as large groups to achieve
better reimbursement and coverage for favored treatments and procedures. Perhaps as important as these other factors, urologists
are exposed to relatively limited promotional focus by &ldquo;Big Pharma&rdquo; and we believe can therefore be accessed and impacted
more readily by an emerging company, such as Aytu, over time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Aytu BioScience&rsquo;s Strategic
Value Drivers&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><IMG SRC="v473641_img1.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The primary elements of our strategy
are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000"><I>Expanding the commercialization of
    Natesto , our revenue-generating, FDA-approved product in the United States via our direct commercial infrastructure. Launching
    Fiera in the United States via our direct sales force, and commercializing Fiera and MiOXSYS outside the United States via
    a developing distribution network.</I>&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Natesto is a novel, recently FDA-approved
testosterone replacement therapy, or TRT, indicated for the treatment of hypogonadism in men. Natesto is the only nasal formulation
of testosterone and is delivered via a proprietary nasal gel to enable simple, discreet application of testosterone into the nostrils.
By virtue of applying Natesto to the nasal mucosa, and not to the man&rsquo;s skin, there is no risk of transference to others.
As such Natesto is the only TRT that does not have a black box warning associated with this potential for transference. Additionally,
Natesto is a convenient form of testosterone that does not require application to large areas of the man&rsquo;s body (arms, shoulders,
upper torso, under arms) as required with market-leading products AndroGel and Axiron. A convenient form of TRT, applied two-to-three
times a day in the nostrils, may be an appropriate option for men with hypogonadism who have active lifestyles, travel frequently,
and value having a discreet way to treat their hypogonadism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Low testosterone is a condition
affecting approximately 13 million U.S. men, with U.S. revenues estimated at $2.4 billion in 2013. The market is expected to grow
and we believe multiple factors are in place to position Natesto favorably in gaining market share in this large, growing market.
By gaining less than a 5% share of the current U.S. market (assuming similar pricing and reimbursement), a novel TRT product could
achieve annual revenues in excess of $100.0 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProstaScint is the only imaging agent that specifically targets
prostate cancer cells and demonstrates high sensitivity, specificity, and accuracy. In multiple clinical studies researchers have
shown that when SPECT/CT scans were used in patients pre-treated with ProstaScint, ProstaScint imaging was highly sensitive in
detecting prostate cancer and significantly predictive of 10-year biochemical disease-free survival in prostate cancer patients
(86.6% vs. 65.5%; p=0.0014). Additionally, the American Cancer Society specifically recognizes ProstaScint by name in current
prostate cancer diagnosis guidelines. At June 30, 2017, the ProstaScint asset was impaired based upon sales projections that we
intend to only sell this product through mid-fiscal 2019, when this product expires.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Prostate cancer is the second
most common cancer among men in the United States, with an estimated 241,000 annual cases (as of 2012). Further, more than 2.2
million men were alive in 2006 with some history of prostate cancer, and over 30,000 U.S. men die each year from the disease.
The effect of prostate cancer on healthcare economics is substantial, which makes the need for accurate disease staging critical
for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate cancer is expected to total
$17.4 billion in 2017, a CAGR of 7.5% since 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Fiera Personal Care Device
is the first hands-free wearable product for women, specifically designed to increase interest in, and physical readiness for
sex, naturally. Sexual wellness is inclusive of female sexual dysfunction which is a term that describes various sexual problems,
such as low desire or interest, diminished arousal, orgasmic difficulties, and dyspareunia. Female sexual dysfunction is considered
common, with an estimated prevalence of 43% from the U.S. National Health and Social Life Survey and similar estimates from other
large, population-based surveys in the United States<SUP> </SUP>and the United Kingdom. In a study of over 31,000 women in the
United States it was determined that 44% of women report a sexual problem. Specifically, the most common sexual problem is low
desire, with a prevalence of 39%; followed by low arousal (26%) and orgasm difficulties (21%). Additionally, the incidence of
sexual dysfunction is expected to increase through 2020 to effect more than 124 million women worldwide.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>United States</I>. We have
launched a commercial infrastructure in the U.S. in order to support increased sales and distribution of Natesto, ProstaScint
and Fiera in the U.S. We have a highly experienced sales force that is distinctly focused on impacting the prescribing of urologists,
and through this efficient sales channel we are able to increase prescribing of our unique urology assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Ex-U.S</I>. Fiera has not been
previously marketed outside the U.S., therefore we believe we can realize commercial opportunities through efficient corporate
partnerships in key markets around the world. With MiOXSYS now CE Marked we have started developing a distribution network to
launch this first-in-class in vitro diagnostic device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000"><I>Developing a pipeline of novel urological
    therapeutics through assertive acquisition, licensing, or co-promotion, inclusive of both marketed and late-stage development
    assets.</I>&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In order to diversify our product
portfolio and create more value, we intend to seek to acquire complementary products or product candidates to develop and/or commercialize,
including marketed assets. Initially, the focus will be on acquiring products or product candidates for urological conditions
but we will opportunistically consider other products or product candidates based on their ability to create value and complement
our focus. We plan to pursue product acquisitions, inclusive of therapeutics, diagnostics, and devices, which we will evaluate
for their strategic fit and potential for near-term and/or accretive value to us. In a little over two years from the Company&rsquo;s
merger in April 2015 we began generating revenue from the acquisition of ProstaScint (which we have since divested), and we later
launched Natesto in July 2016 and Fiera in May 2017. We expect to continue to identify and acquire additional, complementary urology
assets in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000"><I>Completing U.S. studies in male infertility
    with the MiOXSYS System to enable 510k clearance by FDA.</I>&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">With MiOXSYS now CE marked and
available for sale in many markets outside the U.S., we are positioned to initiate our clinical studies in the U.S. to enable
510k clearance. We expect to receive guidance from FDA on clinical study design and patient criteria and implement the required
clinical program as soon as possible. If cleared in the U.S., MiOXSYS would be the first and only semen analysis diagnostic test
cleared by the FDA for the detection of oxidative stress in infertility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Male infertility is prevalent
and underserved, and oxidative stress is widely implicated in its pathophysiology. As such, we have bolstered our research focus
in this area with the MiOXSYS System to complement our focus on urologic conditions. The ex-US global male infertility market
is estimated at over $800 million in diagnostics, therapeutics, and procedure costs. Oxidative stress is broadly implicated in
the pathophysiology of idiopathic male infertility, yet very few diagnostic tools exist to effectively measure oxidative stress
levels in men. However, antioxidants are widely available and recommended to infertile men. With the introduction of the MiOXSYS
System, we believe for the first time there will be an easy and effective diagnostic tool to assess degree of oxidative stress
and monitor patients&rsquo; responses to antioxidant therapy and improve diagnosis of male infertility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Through our extensive network
of researchers developed at one of our predecessor companies Luoxis, the RedoxSYS System has demonstrated the potential to have
broad clinical applications inclusive of male infertility in semen analysis studies. Studies have been completed at the Cleveland
Clinic, a major U.S. university and Hamad Medical Corporation, major hospital in Doha, Qatar in the evaluation of male infertility.
As such, we developed the MiOXSYS System as a line extension to RedoxSYS to specifically assess oxidative stress in semen as a
tool to assess male infertility. In January 2016, the MiOXSYS System received CE Marking and is now available for sale in multiple
ex-U.S. markets including Europe, the Middle East, and parts of Asia. In March 2016, the MiOXSYS System obtained Health Canada
Class II Medical Device approval. With Health Canada approval in place, the Company has begun initial marketing of the product
in Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Our FDA &ndash; Approved Urology
Products&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Two of our products have received
FDA approval for marketing in the U.S.: Natesto and ProstaScint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Natesto for Testosterone
Replacement&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On April 22, 2016, we entered
into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto<SUP>&reg;</SUP> (testosterone)
nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we acquired effective on July 1, 2016. Natesto is a
patented, FDA-approved testosterone replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone
available in the United States. Natesto is a discreet, easy-to-administer nasal gel that may be appropriate for men with active
lifestyles as Natesto is small, portable, TSA-compliant, and easy to use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Importantly, Natesto is not applied
directly to the patient&rsquo;s skin as other topically applied TRTs are. Rather, it is delivered directly into the nasal mucosa
via a patented nasal applicator. Thus, Natesto does not carry a black box warning related to testosterone transference to a man&rsquo;s
female partner or children &mdash; as other topically (primarily gels) administered TRTs do by virtue of their delivery directly
onto the skin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: #000000">&nbsp;<IMG SRC="v473641_img2.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Image of Natesto (testosterone)
nasal gel&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The unique delivery of Natesto
also enables simple, discreet use by a single application into each nostril two to three times daily and may improve compliance
over topical forms that are applied to large sections of the arms, shoulders, and other large areas of the man&rsquo;s upper torso.
It also offers a more discreet method of TRT administration compared to films/patches (Androderm &amp; Testoderm, which is applied
to the scrotum) and doesn&rsquo;t involve the pain, potential for site injection infections, and the administration inconvenience
of the implantable and/or injectable TRTs such as Testopel and Aveed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">A concern associated with the
use of the currently marketed testosterone gels is the unintentional transfer of testosterone to women (or children) by skin contact
with the man&rsquo;s application site. In the event of a female partner receiving inadvertent testosterone exposure due to intimate
contact with her male partner, she may develop hyperandrogenism, a condition characterized by excess levels of androgens. This
condition may result in women developing acne, scalp hair loss, excessive facial or body hair, breast atrophy, and other symptoms.
Natesto, as it is nasally administered, does not present this potential complication of &lsquo;transference&rsquo; and thus does
not have a black box warning as is associated with the topically applied testosterone supplements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Natesto is an androgen indicated
for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Primary hypogonadism (congenital or
    acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome,
    orchiectomy, Klinefelter&rsquo;s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have
    low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH] and luteinizing hormone [LH])
    above the normal range.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">Hypogonadotropic hypogonadism (congenital or acquired):
    gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma,
    or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>The U.S. Testosterone Replacement
Therapy (TRT) Market</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We believe we have an opportunity
to increase revenue with Natesto in the U.S. Natesto competes in a large, growing market. The U.S. TRT market is large, with annual
revenues in the U.S. in 2013 of $2.4 billion. At the current market size of over $2.0 billion, a product with 5% market penetration
could achieve sales in excess of $100 million annually, assuming comparatively similar product pricing and reimbursement levels
as seen with other TRTs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The U.S. prescription testosterone
market is comprised primarily of topically applied treatments in the form of gels, solutions, and patches. Testopel&reg; and Aveed&reg;,
injectable products typically implanted directly under the skin by a physician, are also FDA-approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The actively marketed, FDA-approved
TRTs include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 17%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Brand Name</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 25%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>Form
    of Delivery</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 27%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>Company</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 12%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>Year
    Approved</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 15%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>Black
    Box Warning</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Androderm&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Film/Patch</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Actavis</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">1995</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">No</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">AndroGel&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Gel</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">AbbVie</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">2000</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">Yes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Aveed&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Injection</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Endo Pharmaceuticals</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">2014</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">No</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Axiron&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Solution</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Eli Lilly &amp; Company</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">2010</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">Yes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Fortesta&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Gel</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Endo Pharmaceuticals</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">2010</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">Yes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Striant&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Extended Release Tablet</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Endo Pharmaceuticals</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">2003</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">No</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Testim&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Gel</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Endo Pharmaceuticals</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">2002</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">Yes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Testoderm&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Film/Patch</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Johnson &amp; Johnson</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">1993</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">No</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Testopel&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Injection</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Endo Pharmaceuticals</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">1972</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">No</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Vogelxo&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Gel</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Upsher-Smith</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">2014</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">Yes</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">AndroGel&reg;, marketed by AbbVie,
is the leading TRT and had 2012 revenues of $1.15 billion. AndroGel had over half of the total TRT market across its 1.0% and
1.62% formulations of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Importantly, however, AndroGel
is now facing generic threats with the expiration of key patents for its 1.0% formulation, and is beginning to see generic equivalents
to its 1.62% formulation be introduced. Other products with significant shares of the TRT market include Axiron, Testim, Fortesta,
Androderm, and Testopel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>About Hypogonadism</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Male hypogonadism is a condition
in which the body does not produce enough testosterone &mdash; the hormone that plays a key role in masculine growth and development
during puberty &mdash; or has an impaired ability to produce sperm or both. Men can be born with male hypogonadism, or it can
develop later in life from injury or infection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Hypogonadism is formally defined
as deficient or absent male gonadal function that results in insufficient testosterone secretion. Hypogonadism may be caused primarily
by testicular failure, or secondarily by hypothalamic-pituitary axis dysfunction, resulting in the production or release of insufficient
testosterone to maintain testosterone-dependent functions and systems. It can also result from a combination of testicular failure
and hypothalamic-pituitary axis dysfunction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Hypogonadism affects an estimated
13 million men in the United States, and although it may occur in men at any age, low testosterone levels are especially common
in older males. More than 60% of men over age 65 have free testosterone levels below the normal values of men aged 30 to 35. Studies
suggest that hypogonadism in adult men is often underdiagnosed and under treated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Low testosterone, as male hypogonadism
is also known, is associated with a number of signs and symptoms, most notably loss of libido and erectile dysfunction (ED). Other
signs of low testosterone include depressive symptoms, a decrease in cognitive abilities, irritability and lethargy or loss of
energy. Deficient endogenous testosterone also has negative effects on bone mass and is a significant risk factor for osteoporosis
in men. Progressive decrease in muscle mass and muscle strength and testicular dysfunction, often resulting in impaired sperm
production, are also associated with low testosterone levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">A younger patient may have pure
hypogonadism as a primary event, whereas an older man may have an age-related decline in testosterone production that is a part
of his ED profile. However, because both ED and loss of libido are hallmarks of hypogonadism, for a patient who presents with
ED it is recommended that he have a basic hormone profile to determine if he has low testosterone. Treatments to normalize testosterone
can not only improve libido, energy level and the potential to have normal erections, but can also improve the response to sildenafil,
if that is deemed appropriate treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Natesto Clinical Studies
Demonstrating Safety and Efficacy&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Natesto has been shown to be safe
and effective in men with hypogonadism. It was approved by the FDA in May 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In its pivotal clinical trial,
Natesto was evaluated for efficacy in a 90-day, open-label, multicenter study of 306 hypogonadal men. Eligible patients were 18
years of age and older (mean age 54 years) and had morning serum total testosterone concentrations less than 300 ng/dL. Patients
were Caucasian (89%), African-American (6%), Asian (5%), or of other ethnicities (less than 1%).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Patients were instructed to self-administer
Natesto (11 mg of testosterone) intranasally either two or three times daily.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The primary endpoint was the percentage
of patients with an average serum total testosterone concentration (C<SUB>avg</SUB>) within the normal range (300 to 1050 ng/dL)
on Day 90.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The secondary endpoint was the
percentage of patients with a maximum total testosterone concentration (C<SUB>max</SUB>) above three predetermined limits: greater
than 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">A total of 78 hypogonadal men
received Natesto (11 mg of testosterone) three times daily (33 mg of testosterone daily). Of these, a total of 73 hypogonadal
men were included in the statistical evaluation of efficacy (total testosterone pharmacokinetics) on Day 90 based on the intent-to-treat
(ITT) population with last observation carried forward (LOCF). Ninety percent of these 73 patients had a C<SUB>avg</SUB> within
the normal range (300 to 1050 ng/dL) on Day 90. The percentages of patients with C<SUB>avg</SUB> below the normal range (less
than 300 ng/dL) and above the normal range (greater than 1050 ng/dL) on Day 90 were 10% and 0%, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The table below (Table 3 from
the Natesto Prescribing Information) summarizes the mean (SD) serum total testosterone concentrations on Day 90 in 69 patients
who had a full pharmacokinetic sampling profile and were treated with Natesto (11 mg of testosterone) three times daily for 90
days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Table 3:
Mean (SD) Serum Total Testosterone Concentration on Day 90 Following </B><BR>
<B>Administration of Natesto (11 mg of testosterone) Three Times Daily&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; padding-left: 140pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000"><B>Natesto
    </B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(11 mg of testosterone) Three Times Daily (N=69)</B></FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">C<SUB>avg</SUB>(ng/dL)</FONT></TD>
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">421 (116)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">C<SUB>max</SUB>(ng/dL)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">1044 (378)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">C<SUB>min</SUB>(ng/dL)</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">215
    (74)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In the same clinical trial studying
the safety and efficacy of Natesto, which was conducted at 39 U.S. outpatient sites, it was shown that 70% of the per protocol
patients in the twice-daily &lsquo;titration arm&rsquo; (n=141) achieved normal testosterone levels. Ninety-one percent of the
per protocol patients in the thrice-daily group (n=77) achieved normal testosterone levels, demonstrating that the majority of
men in both treatment groups achieved normalization of testosterone levels while taking Natesto. The efficacy of both B.I.D. (twice
daily) and T.I.D. (three times daily) dosing of Natesto is demonstrated in the graphs below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><IMG SRC="v473641_img3.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Newly Presented Natesto
Safety and Efficacy Data</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Secondary endpoints that were
measured in the above-referenced pivotal trial included the impact on Natesto &ndash; over 90 days &ndash; on erectile function
as well as on mood. The 90-day clinical trial demonstrated that &ndash; within 30 days of initiating treatment with Natesto &ndash;
subjects exhibited a statistically significant and clinically meaningful improvement in all five domains of erectile function.
Specifically, at the end of the 90-day treatment period, improvement from baseline for each domain were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">36%
                                         improvement in erectile function</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">42%
                                         improvement in intercourse satisfaction</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">35%
                                         improvement in orgasmic function</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">31%
                                         improvement in sexual desire</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">38%
                                         improvement in overall satisfaction</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><IMG SRC="v473641_img4.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In
addition to demonstrating a significant improvement in erectile function, Natesto also exhibits a substantial impact on mood as
measured by Positive Affect and Negative Affect Schedule (PANAS). As early as 30 days &ndash; and continuing up to day 90 &ndash;
Natesto demonstrates a substantial increase in Positive Affect and a substantial decrease in Negative Affect.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><IMG SRC="v473641_img5.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition to efficacy parameters,
safety parameters have also been examined and recently reported. Natesto restores serum testosterone to normal levels<U> </U>while
Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH)<SUP> </SUP>remained well within the reference range over 90 days.
Also, hematocrit (increased blood thickness) was not significantly impacted by Natesto over 360 days of treatment. Other testosterone
products alter levels of Follicle Stimulating Hormone (FSH) and Luteining Hormone (LH) and increase hematocrit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><IMG SRC="v473641_img6.jpg" ALT=""><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Natesto Product Features
and Patient Benefits</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We believe Natesto has a unique
opportunity to gain market share in the more than $2.4 billion U.S. market given the product&rsquo;s novel features and patient
benefits including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Ease of administration; Appropriate for men with busy, active lives;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #000000">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Established efficacy in pivotal FDA trials with a unique, low dose of testosterone;
    Effective in improving serum testosterone levels while using a proven, lower dose of testosterone; significant symptom improvement,
    notably: </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">Natesto
                                         caused statistically significant improvements in each of the 5 domains of erectile function
                                         (<I>P</I> &lt; 0.0001); The majority of the effect on erectile dysfunction was evident
                                         by Day&nbsp;30</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">Substantial
                                         Increase in Positive Affect <I>and</I> Substantial Decrease in Negative Affect (PANAS)
                                         as Early as Day 30 (<I>P</I> &lt; 0.0001)</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Discreet product presentation and ease of transport (TSA compliant); Important
    for men who travel frequently and desire a simple, portable solution that travels easily with them;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">No risk of secondary exposure to testosterone due to dermal transference,
    an important consideration when thinking about a hypogonadal man&rsquo;s partner&rsquo;s or child&rsquo;s safety; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Safety, with a lower incidence of rising PSA levels than the market leading
    product AndroGel; Natesto demonstrates a 5.5% rate of rising PSA levels in clinical trials, while AndroGel demonstrated a
    rising PSA rate of over 11% in clinical trials. This is an important consideration as physicians concerned with understanding
    and tracking prostate cancer risk frequently monitor PSA levels in men over 50 years of age. Additionally, Natesto restored
    serum testosterone to normal levels while Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH)<SUP> </SUP>remained
    well within the reference range over 90 days.&nbsp;&nbsp;Also, hematocrit (increased blood thickness) was not significantly
    impacted by Natesto over 360 days of treatment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Natesto has proven efficacy and
a product profile well suited for men suffering from hypogonadism who have active, busy lifestyles who want a simple, discreet
TRT option. We believe Natesto can play an important role in the treatment of hypogonadism, a condition affecting approximately
13 million U.S. men.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Natesto Market Opportunity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Two recent developments have presented
a unique opportunity for Natesto that we believe will enable us to effectively compete and be well positioned in the more than
$2.0 billion TRT market. As previously indicated, AndroGel&rsquo;s patent expired in 2015 and we expect a generic entrant to begin
eroding AbbVie&rsquo;s market share. As a result, we expect there to be diminished promotional support in the form of fewer physician
details and lower overall promotional spending by AbbVie. In conjunction with the market leader&rsquo;s diminished intellectual
property position and potential diminished promotional spending, the TRT market has received increased scrutiny from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On January 31, 2014 and subsequently
on March 3, 2015, the FDA issued Safety Announcements relating to the possible increased risk of non-fatal heart attacks and strokes
in patients taking testosterone. While the FDA has not concluded that the FDA-approved testosterone treatment increases the risk
of stroke, heart attack, or death, this recent safety consideration has caused patient advocates and consumer groups to ask for
increased scrutiny on the direct to consumer advertising associated with the leading testosterone replacement products, most notably
AndroGel and Axiron. As a result, we expect decreased advertising spending in the TRT category to enable newer, less established
products like Natesto to more effectively infiltrate the market through on-label, physician-directed promotion with a direct selling
effort. While the potential safety concerns may cause a decrease in physician prescribing, we expect that physicians will continue
to prescribe TRTs for patients for whom TRT treatment is appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Leading urology groups including
the American Urological Association, or AUA, have strongly commented in favor of continued prescribing of TRTs for appropriate
patients, and the safety data precipitating the FDA&rsquo;s comments have been called into question. Importantly, the FDA has
not called for discontinuation of TRTs. Rather, patients were encouraged to speak with their health care professional and not
stop taking TRTs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In the FDA&rsquo;s initial statement
about the potential cardiovascular risks associated with TRT treatment, the agency commented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><FONT STYLE="color: #000000">&ldquo;Patients
should not stop taking their prescribed testosterone products without first discussing their questions or concerns with their
health care professionals. ... The prescribing information in the drug labels of FDA-approved testosterone products should be
followed.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Importantly, following the FDA&rsquo;s
statement, the AUA issued a strong response reiterating the clinical importance of low testosterone and maintaining their support
for the appropriate use of testosterone replacement therapy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: left"><FONT STYLE="color: #000000">&ldquo;Men
with hypogonadism may also experience reduced muscle mass and strength and increased body fat. Hypogonadism may also contribute
to reduced bone mineral density and anemia. Testosterone therapy is appropriate treatment for patients with clinically significant
hypogonadism, including those with idiopathic clinical hypogonadism that may or may not be age-related, after full discussion
of potential adverse effects.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Additional publications publicly
refuted the validity of the data that precipitated the FDA&rsquo;s safety concern in a subsequent statement following the 2014
annual meeting of the AUA:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: left"><FONT STYLE="color: #000000">&ldquo;During
the last several months there has been a firestorm of negative media attention regarding testosterone deficiency and its treatment,
precipitated by a study reporting an increased rate of nonfatal myocardial infarction (MI) associated with testosterone prescriptions.
This public judgment of T therapy demands a response. As researchers and clinicians with extensive experience with T deficiency
and its treatment, we disagree that the recent study published in PLOS (Public Library of Science) One presents any credible evidence
that T prescriptions increase health risks, and we find baseless the general assertion that testosterone is prescribed to men
&ldquo;who are simply reluctant to accept the fact that they are getting older.&rdquo; We object to comments questioning whether
T deficiency is real, regardless of whether it is called hypogonadism or &ldquo;low T&rdquo; as used in advertisements.&rdquo;
(Note: The PLOS is an open access online publication venue, and while peer reviewed it is not a published medical journal.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">AbbVie&rsquo;s sales of AndroGel
dropped 5% in the first half of 2014, following the FDA&rsquo;s initial Safety Announcement and the subsequent reaction of the
AUA and others. In the face of significant new competitive entrants (Aveed, Vogelxo) at that time and the FDA&rsquo;s expressed
safety concerns, this represents a relatively insignificant sales decline. We believe this decline speaks to a real, present need
in hypogonadism and a substantial opportunity for newly marketed products like Natesto. Natesto has proven safety, a recent FDA
approval that speaks to the product&rsquo;s efficacy, and unique product features and patient benefits we believe will set Natesto
apart from the topically administered competitive products in the more than $2.4&nbsp;billion U.S. TRT market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>MiOXSYS In Vitro Diagnostic
System for Male Infertility&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Male infertility is a significant
medical condition that urologists and infertility specialists treat frequently in the office setting or specialized fertility
centers around the world. Of all sexually active couples, 8% to 12% are infertile and male infertility is the sole cause or contributing
factor up to 50% of the time. The global male infertility market is large and growing. The market for male infertility diagnosis
and treatments is expected to grow to more than $300 million globally by 2020, with a CAGR of nearly 5% from 2014 to 2020. Despite
the prevalence of male infertility, difficulties remain in effectively diagnosing root causes. Oxidative stress assessment is
considered a standard practice in complex andrology laboratories around the world, but due to various factors oxidative stress
testing is not routinely employed in clinicians&rsquo; offices or standard laboratory settings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Seminal oxidative stress has been
well established throughout the peer-reviewed literature to play a substantial role in unexplained male infertility, and researchers
and clinicians actively consider oxidative stress when conducting laboratory infertility assessment. While oxidative stress is
well established as a leading contributing factor to male infertility, a significant proportion of male infertility remains unexplained
in part because of the lack of standardized tests available to clinicians and researchers to assess oxidative stress in semen
and plasma. This lack of standardization has resulted in poor implementation of semen and plasma analysis around the world. Further,
current testing platforms are cost-prohibitive for small office settings or local medical laboratories and require extensive training
and on-site expertise. Additionally, antioxidant supplementation is frequently recommended to patients by clinicians without an
effective method of measuring treatment success. As such, we believe introducing the MiOXSYS System to assess oxidative stress
levels in semen and seminal fluid represents a significant commercial opportunity and novel way for clinicians to assess male
factor infertility and assess therapeutic responses of patients in a simple, reliable, and cost-effective way.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The MiOXSYS System was CE marked
in January 2016, and we have started early commercialization efforts outside the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">An attractive aspect of the reproductive
health market relates to reimbursement as infertility treatments and the associated diagnostic tests are generally paid directly
by patients. The current infertility treatments could cost in excess of $10,000 per treatment cycle, so the addition of a moderately
priced oxidative stress test would consume nominal relative costs while providing specific, actionable information needed to improve
the oxidative status of infertile patients. The current infertility treatments include antioxidant supplements and lifestyle modifications
that lower oxidative stress (e.g., smoking cessation, exercise, dietary changes, etc.), so the measurements reported by the MiOXSYS
System could effectively guide treatment in the infertile patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The global male infertility market
is expected to grow to more than $300 million by 2020. With a substantial base of conditions for which the MiOXSYS System may
present utility, we believe there is significant revenue potential from this first-in-class system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">As part of our strategy to develop
future clinical applications of the RedoxSYS System (the MiOXSYS System&rsquo;s predecessor product for plasma and whole blood
detection), we have conducted initial studies in male reproductive health. Male infertility is a significant medical condition
in which oxidative stress is well known to play a substantial role. As such, we believe developing a clinical application to assess
oxidative stress levels with the uniquely designed and programmed MiOXSYS System for semen analysis represents a significant commercial
opportunity. Oxidative stress is well established as a leading contributing factor to male infertility. Further, a significant
proportion of male infertility remains unexplained in part because of the lack of standardized tests available to clinicians and
researchers to assess oxidative stress in semen and seminal plasma. This lack of standardization has resulted in poor implementation
of semen and plasma analysis around the world. Further, currently available tests are cumbersome, time consuming to perform, and
costly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We conducted initial proof-of-concept
clinical studies in male infertility with a leading research center in the United States, which demonstrated that oxidation-reduction
potential effectively measures oxidative stress levels in semen and seminal plasma &mdash; and that these levels strongly correlate
with established markers of infertility. Semen analysis studies are routinely conducted to assess causes of infertility, so we
expect clinicians and oxidative stress researchers to readily integrate the MiOXSYS System into routine use upon the completion
of more extensive studies and regulatory clearance for this use. Additional studies are now in the late planning stages that will
evaluate the MiOXSYS System&rsquo;s performance in the detection of oxidative stress levels and correlations with key semen parameters
in both healthy and infertile males. The MiOXSYS System must receive 510k clearance from the FDA before we can market it for clinical
use in the United States. Of the $300 million male infertility market projected for 2020, the North American, Middle Eastern,
and Asia Pacific markets dominate due to prevalence, awareness of treatment, and availability of treatment resources. Thus, it
is important that we have already established distribution relationships and direct access to major oxidative stress researchers
in many of these important markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Following our initial proof of
concept studies with a leading center in the United States with the MiOXSYS system, we conducted our CE mark-enabling study with
over 300 infertile patients. The two key studies conducted with these leading centers are presented below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>United States-Based Proof-of-Concept
Clinical Study&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Fifty-one (51) male patients were
seen in a national clinic for suspected infertility. In addition to standard semen analyses (WHO 5<SUP>th</SUP> Edition, 2010),
samples were measured for oxidative stress using the MiOXSYS System. Raw sORP values were normed to sperm concentration (mv/10<SUP>6
</SUP>sperm/mL) and compared across six semen parameters that are associated with fertility: ejaculate volume, concentration,
total sperm number, total motility, progressive motility, and normal morphology. Higher sORP values are associated with a higher
state of oxidative stress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Patients with abnormally low ejaculate
volume had similar sORP values as those with a normal volume. Those with an abnormally low sperm concentration or overall total
number, have significantly higher sORP values than those in the normal range. Abnormally few motile sperm or few sperm with a
progressive motility were also associated with significantly higher sORP values than those in the normal range. Lastly, semen
samples that had fewer normal sperm had slightly, but not significantly, higher sORP values. Thus, most abnormal semen parameters
appear to be associated with higher measures of oxidative stress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">When samples that achieve all
six parameters of associated with fertile semen are compared to samples that fail one or more of the parameters, the samples that
meet the parameters have significantly lower sORP values than those that fail one or more. A cutoff value of 1.635 mv/10<SUP>6
</SUP>sperm/mL separated those that met fertility standards from those that did not. In the current study, 85.7% of samples that
met standards fell below this cutoff value, whereas 71.8% of those that failed one or more parameters had sORP values above this
cutoff. The probability that a semen sample with a measured sORP value higher than the cutoff is abnormal in at least one of the
semen parameters, is 96.5%. Lastly, the more parameters that a semen sample falls within the abnormal range, the higher the sORP
values, thus those that are abnormal on five or six parameters have higher sORP values than those that are abnormal on one or
two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Data derived from patients of
the national clinic confirms the results obtained in an international fertility clinic. Overall, semen that falls into the abnormal
range for concentration, total number, motility, and morphology have higher levels of oxidative stress as indicated by higher
sORP values. These values are uniquely obtained using the MiOXSYS System for semen analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In April 2016, we observed encouraging
data from two prospective studies of the MiOXSYS System that demonstrated its clinical utility as a tool for measuring ORP to
assess the degree of oxidative stress levels in human semen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The first study measured sORP
in the semen samples of infertile men that correlated well with the sperm concentration, motility, and morphology. The second
study further suggests that sORP is an easy to determine one-step indicator of increased oxidative stress in semen samples of
infertile men especially with leukocytospermia. The results are currently being validated in a larger cohort of infertile men.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>International Pivotal Clinical
Study&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Three-hundred sixty-six (366)
male partners from couples seeking fertility advisement in an international clinic were recruited. In addition to standard semen
analyses (WHO 5<SUP>th</SUP> Edition, 2010), samples were measured for oxidative stress using the MiOXSYS System. Raw sORP values
were normed to sperm concentration (mv/10<SUP>6</SUP> sperm/mL) and compared across six semen parameters that are associated with
fertility: ejaculate volume, concentration, total sperm number, total motility, progressive motility, and normal morphology. Higher
sORP values are associated with a higher state of oxidative stress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Patients with abnormally low ejaculate
volume had similar sORP values as those with a normal volume. Those with an abnormally low sperm concentration or overall total
number, have significantly higher sORP values than those in the normal range. Abnormally few motile sperm or few sperm with a
progressive motility were also associated with significantly higher sORP values than those in the normal range. Lastly, semen
samples that had fewer normal sperm had significantly higher sORP values than those that fell into the range of normal morphology.
Thus, most abnormal semen parameters appear to be associated with higher measures of oxidative stress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">When samples that achieve all
six parameters associated with fertile semen are compared to samples that fail one or more of the parameters, the samples that
meet the parameters have significantly lower sORP values than those that fail one or more. A cutoff value of 1.635 mv/10<SUP>6
</SUP>sperm/mL separated those that met fertility standards from those that did not. In the current study, 91.43% of samples that
met fertility standards fell below this cutoff value whereas 59.5% of those that failed one or more had sORP values above this
cutoff. The probability that a semen sample with a measured sORP value higher than the cutoff is abnormal in at least one of the
semen parameters, is 98.6%. Lastly, the more parameters that a semen samples falls within the abnormal range, the higher the sORP
values, thus those that are abnormal on five or six parameters have higher sORP values than those that are abnormal on one or
two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Data derived from patients at
this international clinic confirms the results obtained in United States fertility clinic. Overall, semen that falls into the
abnormal range for concentration, total number, motility, and morphology have higher levels of oxidative stress as indicated by
higher sORP values. These values are obtained uniquely using the MiOXSYS System for semen analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Proof of concept clinical studies
have been conducted at the Cleveland Clinic&rsquo;s Department of Urology, and two posters were presented at the 2015 American
Society for Reproductive Medicine in November 2015. These abstracts are presented below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Establishing the Oxidation-Reduction
Potential in Semen and Seminal Plasma&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">A. Agarwal,<SUP>1</SUP> S. S.
Du Plessis,<SUP>1,2</SUP> R. Sharma,1 L. Samanta,<SUP>1,3</SUP> A. Harlev,<SUP>1,4</SUP> G. Ahmad,<SUP>1,5</SUP> S. Gupta,<SUP>1
</SUP>E. S. Sabanegh<SUP>6</SUP>; 1. Center For Reproductive Medicine, Cleveland Clinic, Cleveland, OH, 2. Medical Physiology,
Stellenbosch University, Tygerberg, South Africa, 3. Redox Biology Laboratory, School of Life Sciences, Ravenshaw University,
Orissa, India, 4. Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel, 5. Physiology and Cell Biology, University
of Health Sciences, Lahore, Pakistan, 6. Department of Urology, Cleveland Clinic, Cleveland, OH</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Abstract:&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Objective:</B> Oxidation-reduction
potential (ORP) is a novel measure of oxidative stress or redox imbalance in biological samples. Static ORP (sORP) provides an
integrated measure of the balance between total oxidants and reductants in a biological system, whereas capacity ORP (cORP) equates
to the amount of antioxidant reserves. sORP has been shown to correlate well with illness and injury severity that accompanies
the state of oxidative stress; cORP correlates with the ability to respond to illness or injury. Our objectives were to evaluate
whether 1) ORP can be measured in semen and seminal plasma samples and 2) ORP levels correlate with sperm motility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Design:</B> Prospective study
measuring ORP in both semen and seminal plasma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Materials and Methods:</B>
Semen samples (n=18) from normal control subjects were divided into two fractions and the seminal plasma was isolated from one
fraction (300 x g, 7min). Sperm count and motility were assessed manually. sORP (mV/106 sperm) and cORP (&mu;C/106 sperm) were
measured in both fractions (RedoxSYS&reg;, Aytu BioScience). Values are reported as Mean &plusmn; SEM. Spearman correlation and
Receiver Operating Characteristic curves (ROC) were used for statistical analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Results:</B> sORP and cORP
levels in semen correlated significantly with the levels in seminal plasma. A significant negative correlation existed between
sperm motility and sORP in both semen (r=-0.609; p=0.004) and seminal plasma (r=-0.690; p=0.002). Furthermore, a sORP cutoff of
4.73mV/106 sperm in semen (sensitivity = 100%, specificity = 89.5%, AUC=0.947) and 4.65mV/106 sperm in seminal plasma (sensitivity
= 100%, specificity = 93.8%, AUC = 0.969) was highly predictive of abnormal sperm motility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Conclusions:</B> RedoxSYS&reg;
accurately measured sORP and cORP in both semen and seminal plasma samples. Based on high sensitivity as assessed by ROC analysis,
sORP levels can be used to screen infertile men with oxidative stress. These results are being validated in a larger cohort of
infertile men.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Effect of Time on Oxidation-Reduction
Potential in Semen and Seminal Plasma&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">R. Sharma,<SUP>1</SUP> S. S. Du
Plessis,<SUP>1,2</SUP> A. Agarwal,<SUP>1</SUP> A. Harlev,<SUP>1,3</SUP> L. Samanta,<SUP>1,4</SUP> G. Ahmad,<SUP>1,5</SUP> S. Gupta,<SUP>1
</SUP>E. S. Sabanegh<SUP>6</SUP>; 1. Center For Reproductive Medicine, Cleveland Clinic, Cleveland, OH, 2. Medical Physiology,
Stellenbosch University, Tygerberg, South Africa, 3. Soroka Medical Center, Ben-Gurion University, Beer Sheva, Israel, 4. Redox
Biology Laboratory, School of Life Science, Ravenshaw University, Orissa, India, 5. Physiology and Cell Biology, University of
Health Sciences, Lahore, Pakistan, 6. Department of Urology, Cleveland Clinic, Cleveland, OH</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Abstract:&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Objective:</B> Oxidation-reduction
potential (ORP) is a novel measure of oxidative stress or redox imbalance in biological fluids. Reactive oxygen species (ROS)
are highly reactive and have a very short half-life. ROS levels in the seminal ejaculate should be measured within an hour after
collection to prevent a reduction in ROS levels over time. The traditional methods of measuring seminal ROS are time sensitive
and time consuming, making it difficult to use them for diagnostic purposes. It would be highly advantageous to employ a method
that is independent of semen age and provides results in real time. The objective was to assess the effect of time on static ORP
(sORP), which provides a snapshot of current redox balance, and capacity ORP (cORP) which is indicative of the amount of antioxidant
reserves available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Design:</B> Prospective study
measuring ORP in semen and seminal plasma samples at time 0 and 120 minutes. Materials and Methods: The sORP and cORP of both
semen (n=18) and seminal plasma (n=15) samples from normal control subjects were measured after liquefaction (time 0) and after
120 minutes of incubation at room temperature (RedoxSYS&reg;, Aytu BioScience). Values are mean &plusmn; SEM. Spearman correlation
was used for statistical analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Results:</B> A significant
correlation was seen between sORP at time 0 and 120 minutes in semen and seminal plasma. Similar correlations were found for cORP
values at both time intervals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Conclusions:</B> ORP values
are not affected by the age of semen or seminal plasma for up to 120 minutes, making it easier to employ this new technology for
diagnostic use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Recently additional studies
have further demonstrated the clinical utility of the MiOXSYS System in Male Infertility. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Correlation of Sperm DNA fragmentation
and Seminal oxidation reduction potential in infertile men. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">M. Arafa<SUP>1</SUP>, El Bardisi<SUP>1</SUP>,
A. Majzoub<SUP>1</SUP>, S. Alsaid<SUP>1</SUP>, H. Al Nawasra<SUP>1</SUP>, K. Khalafalla<SUP>1</SUP>, K. Al Rumaihi<SUP>1</SUP>,
A. Agarwal<SUP>2</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">1. Hamad Medical Corporation,
Urology, Doha, Qatar, 2. Cleveland Clinic, American Center for reproductive medicine, Cleveland, OH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Abstract:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Objective: </B>To determine
if Sperm DNA fragmentation is really correlated to seminal oxidative stress.<B> </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Design:</B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective
study performed on 312 patients attending the male infertility clinic at a tertiary medical center between February and August,
2016. Patients receiving medical or surgical treatment for infertility prior to their presentation or who had a sperm concentration
less than 5 million/ml sperm were excluded. Patients were subjected to history taking, clinical examination as well as semen analysis
and SDF assessment using Halosperm kit (cut off value &lt;30%) and static oxidation reduction potential (sORP) using MiOXSYS system.
Patients were divided according to SDF result (normal/ high) and to age (&lt;40 years / &gt; 40 years).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Results: </B>A total number
of 312 patients were included in the study. Patients with high SDF had significantly higher age than those with normal SDF. The
mean total and progressive motility was significantly higher in the normal SDF group while sORP was significantly lower in the
normal SDF group compared with the high SDF group. Presence of varicocele did not significantly affect SDF level (Table 1). SDF
was negatively correlated with total (-0.526, p&lt;0.001) and progressive motility (-0.415, p&lt;0.001) and positively correlated
with abnormal morphology, sORP and age (0.351, 0.222 and 0.192, respectively, p&lt;0.001 for all). SDF was significantly lower
while total motility was significantly higher in patients &lt;40 years compared with patients &gt;40 years of age.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Conclusions: </B>Sperm DNA
fragmentation is positively correlated with seminal oxidative stress measured by Seminal oxidation reduction potential. Sperm
DNA fragmentation and seminal oxidation reduction potential should be included in assessment of male infertility. Using ORP testing
can help in detecting the target patients for antioxidant therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333"><FONT STYLE="color: #000000"><B>Effect of seminal
ORP value on embryo quality and clinical pregnancy rate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">A. Ayaz<SUP>1</SUP>, B. Balaban<SUP>2</SUP>,
S. Sikka<SUP>2</SUP>, A. Isiklar<SUP>2</SUP>, M. Tasdemir<SUP>2</SUP>, B. Urman<SUP>2</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">1. Tulane University, Department
of Urology, New Orleans, LA, USA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">2. VKF American Hospital, Assisted
Reproduction Unit, Istanbul, Turkey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Abstract:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Objective: </B>To
determine whether ORP in semen of men undergoing ART affects embryo quality during IVF and plays any role in predictive value
for clinical pregnancy.<B> </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Design: </B>Prospective study
was carried out in the VKF American Hospital, Assisted Reproduction Unit, Istanbul, Turkey. The study was approved by Koc University
the institutional review board and patients signed a consent prior to participation. The 154 male patients who were visiting Andrology
laboratory (between May 31, 2016 and Jan 1, 2017) were grouped in according to semen ORP values. IVF was performed using the semen
samples by our routine established protocol. Exclusion criteria included azoospermia, presence of STD or chronic disease, use
of any prescription drug or OTC medications or antioxidants. Semen samples were collected and assessed for routine parameters
using the WHO-2010 guidelines. sORP was measured (mV) using the MiOXSYS system and normalized to concentration (mV/10 sperm/mL).
Embryo was graded based on the quality (Grade 1 for best quality and Grade 5 is poor).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Results: </B>All semen samples
were grouped as 'High ORP&rdquo; and 'Low ORP&rdquo; based upon seminal ORP cut-off value of 1.36 mV/10 sperm. Mean Grade 1 embryo
quality in High ORP group (n=81) and low ORP group (n=26) was 2.88 &plusmn; 1.76 and 1.33 &plusmn; 0.47 respectively. In addition,
Mean Grade 2 embryo in High ORP group was 2.47 &plusmn; 1.54 and in low group was 4 &plusmn; 1.63 accordingly. Clinical pregnancy
rate (Mean 0.48; 19/40) was significantly higher (p=0.006) in low ORP group compared to high ORP group (1/8) however there was
no significant difference in embryo quality in both high and low ORP groups (Grade I embryo p=0.67, Grade II G2 embryo p=0.33).
Also, mean mother age in two groups was not significantly different (low ORP = 37.2 years and high ORP=35.2 years; p=0.23). These
data suggest that ORP may play an important role in determining the success of clinical pregnancy irrespective of oocyte quality
in women &gt;35 yrs. of age.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Conclusions: </B>Semen ORP
measurement can be used as an indicator of oxidative stress and help determine the successful embryo development during IVF. These
findings may have important diagnostic and prognostic implications for couples experiencing male infertility and undergoing assisted
reproductive technique (ART). Further studies are warranted to explore the mechanism of increased ORP in a subset of couples (male
factor, no female factor) undergoing ART to corroborate the significance of these findings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333"><FONT STYLE="color: #000000"><B>High levels
of seminal oxidation reduction potential (ORP) in infertile men with clinical varicocele</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333"><FONT STYLE="color: #000000">R. Saleh<SUP>1</SUP>,
A. Agarwal<SUP>2</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333"><FONT STYLE="color: #000000">1. Faculty of
Medicine- Sohag University, Dermatology- Venereology and Andrology, Sohag, Egypt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">2. Cleveland Clinic, American
Center for reproductive medicine, Cleveland, OH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Abstract:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Objective: </B>To determine
if seminal oxidation reduction potential (ORP) increases in infertile men with clinical varicocele.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Design: </B>A prospective controlled pilot study was conducted
on 36 men seeking medical advice for an infertility problem between October, 2016 and January, 2017. Following clinical examination,
and scrotal color Doppler ultrasound, infertile men were divided into two groups. Group1: infertile men with clinical varicocele;
and group 2: infertile men with idiopathic infertility (no detectable abnormality in their genital examination). Patients were
examined in an infertility center by the same Andrologist. Semen analysis was performed according to the WHO manual (2010). Seminal
ORP was measured using the MiOXSYS system (Aytu BioScience, Inc., Englewood, CO, USA). Absolute values of ORP, in millivolts (mV),
were normalized for sperm concentrations and results were expressed as mV/10 sperm/mL. Quantitative measures were presented as
median and inter-quartile range (25 and 75 centiles). P value less than 0.05 was considered significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Results: </B>The study included
17 patients in group 1 and 19 in group 2. Patient's age and duration of infertility in group 1 [ 32 (30, 34) years] &amp; [4 (1.5,
5) years] were not significantly different from group 2 [33 (30, 36.5) years] &amp; [2 (1.25, 3.5) years] (P values = 0.64 &amp;
0.27; respectively). Patients in group 1 had significantly lower sperm concentrations [ 20 (5, 30) &times; 10 /mL], and normal
forms [3 (2, 4) %] as compared to those in group 2 [ 30 (20, 72.5 &times; 10 /mL]; and [ 4 (3, 5) %] (P values = 0.03 &amp; 0.005;
respectively). Levels of seminal ORP were significantly higher in group 1 [3.04 (1.94, 7.75) mV/10 sperm/mL] as compared to group
2 [1.12 (0.42, 2.25) mV/10 sperm/mL]. A significant inverse correlation was found between ORP and sperm concentration (= -0.531,
= 0.001), total sperm count ( = -0.453, = 0.008), progressive motility ( = -0.460, = 0.007), total motility ( = -0.526, = 0.002)
and normal forms ( = -0.597, &lt; 0.001). A significant positive correlation was found between ORP and seminal leukocytes ( =
0.476, = 0.003).</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Conclusions: </B>Seminal ORP
is significantly higher in infertile men with clinical varicocele as compared to those with no</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333"><FONT STYLE="color: #000000">detectable abnormality
in their genital examination (idiopathic infertility). These findings may have important diagnostic and therapeutic implications.
Further studies are warranted to explore the mechanism of increased ORP in a subset of infertile men with clinical varicocele.
In addition, future studies may help determine those patients who would benefit from antioxidant therapy and/or surgical repair
of varicocele.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #333333"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>RedoxSYS System for Research
Use&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We completed the development of
the RedoxSYS System (MiOXSYS&rsquo; predecessor product) during the two years preceding the April 2015 Merger. In 2014, we received
ISO 13485 certification, demonstrating our compliance with global quality standards in medical device manufacturing. This enabled
the launch of the RedoxSYS System into the research market around the world. We also received a CE marking in Europe in January
2016 and Health Canada clearance in March 2016 to begin the market development of the RedoxSYS System as a clinical diagnostic
in Europe, Canada, and elsewhere around the world where CE marking is recognized. We launched sales efforts into the research
market in late 2014 and since that time have placed the RedoxSYS System at a number of prominent research centers in the United
States, Europe, and Israel. We expect to leverage these research relationships and build numerous applications in areas where
researchers are studying oxidative stress. Currently, there are no available research platforms that measure oxidation-reduction
potential in biologic fluids (i.e., blood, plasma, serum, semen, seminal fluid, cerebrospinal fluid, tissue, and cells). While
oxidative stress is commonly studied in research settings around the world (both academia and industry), the current assessment
methods are incomplete, time consuming, and often impractical for assessing oxidative stress completely. To position the RedoxSYS
System effectively in the research market, we have placed key personnel in the United States, Europe, and Asia to develop direct
research business relationships as well as distribution networks. Through these proof of concept studies and clinical exploratory
studies, we identified the application of oxidation-reduction potential in male infertility assessment. As such, MiOXSYS was developed
specifically for assessing semen and seminal plasma ORP levels. While we expect additional clinical applications to be developed
through these applications, our near-term focus is on completing the development of MiOXSYS for use in semen analysis for male
infertility assessment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Background on the MiOXSYS
System&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">MiOXSYS is a novel, portable device
that measures oxidation-reduction potential, or ORP, a global measure of oxidative stress. MiOXSYS is the first and only system
that measures ORP in biologic specimens to provide a complete measure of redox balance, which is broadly implicated across a wide
range of both acute and chronic conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Potential Role of ORP in
Diagnosing Male Infertility&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Oxidation-reduction potential
is defined in the published literature as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: left"><FONT STYLE="color: #000000">&ldquo;ORP
in a biological system is an integrated measure of the balance between total oxidants and reductants. In plasma, many constituents
contribute to the ORP. Reactive oxygen species (ROS), such as the superoxide ion, hydroxyl radical, hydrogen peroxide, nitric
oxide, peroxynitrite, transition metal ions, and hypochlorous acid, contribute to the oxidative potential. Plasma reductants include
thiols, vitamin C, tocopherol, &beta;-carotene, lycopene, uric acid, bilirubin, and flavonoids. Enzymes such as superoxide dismutase,
or SOD, catalase, and glutathione peroxidase, are involved in the conversion of ROS into less reactive species. ORP monitoring
of plasma represents a single measurement that integrates the overall quantitative balance among the oxidants and reductants of
the system.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Given that ORP represents a single,
global measure of oxidative stress in a biological system, we believe the potential for ORP to serve as a standardized marker
in semen analysis and other aspects of infertility assessment is significant. A major limitation of oxidative stress assays relates
to the fact that there is poor standardization in testing. As many factors contribute to oxidative stress (e.g., free radical
proliferation, antioxidant depletion, DNA damage, etc.), it is important to have an integrated measure that combines all known
and unknown oxidants and reductants in the respective system into one measurement. We believe ORP is an integrated measure of
oxidative stress that can be easily and quickly measured with the MiOXSYS System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In the context of infertility,
having an integrated value representing all relevant biologic constituents contributing to oxidative stress will enable simple,
robust analysis in a two to three minute test. There are various techniques in use to assess semen in cases of male infertility.
The most commonly implemented techniques involve DNA fragmentation, oxidative stress analysis, microscopic examination, sperm
penetration assays, sperm agglutination, computer assisted semen analysis, and others. The currently available oxidative stress
analysis tools are widely considered expensive and cumbersome to use in routine clinical practice. In both developed countries
as well as in the developing world, expensive analysis tools and recurring reagent expenses make routine testing nearly impossible
to implement with regularity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>The MiOXSYS System Overview&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The MiOXSYS System is comprised
of two distinct, patented components that enable a system capable of measuring the ORP and antioxidant capacity of a biological
fluid: an analyzer and sensor strips. In mechanical terms, ORP is defined as the potential between a working electrode, and a
reference electrode at equilibrium. The RedoxSYS System has been specifically studied in human whole blood, serum, semen, seminal
plasma, blood plasma, and other biological fluids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The MiOXSYS System measures two
distinct elements to determine a patient&rsquo;s oxidation reduction potential:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-size: 10pt; color: #000000">Static ORP &mdash; the standard potential between a working
    electrode and a reference electrode with no driving current (or extremely small current). This is proportional to the balance
    of redox agents and is what is classically defined as ORP. Low ORP values mean that the biological sample is in the normal
    range of oxidative stress. Higher than normal ORP values means that the biological sample is in a higher oxidation state.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-size: 10pt; color: #000000">Capacity &mdash; the measure of antioxidant reserve available
    in the body&rsquo;s system. High capacity values mean that the biological sample has levels of antioxidant reserves. Lower
    than normal capacity values means that the biological sample has below normal antioxidant reserves. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>The MiOXSYS Analyzer&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The MiOXSYS analyzer is a portable,
lightweight desktop platform that may be used in a clinical or research laboratory or near a patient care area. The analyzer is
a small device that accepts an inserted sensor that has collected a small specimen as obtained by traditional specimen collection
procedures. The analyzer is battery powered and equipped with a custom 5 lead strip connector. The reader consists of a Galvanostat
analog circuit with greater than 1012 MHz input impedance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The analyzer contains a 10 MHz
external crystal (internal 4X PLL for 40 MHz operation), and a programming/serial header is externally accessible. The device
has internal power/heart-beat indicator LED, primary storage of 128Mbit (16Mbyte) SPI Flash (3.3V) (Bulk data storage), and secondary
storage of 2Mbit (256Kbyte) SPI FRAM (3.3V) (Hi-Speed Storage).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The MiOXSYS analyzer contains
a user-friendly interface that is flexibly designed to accommodate multiple endpoints depending upon the specific clinical condition
being considered. The interface is LCD, 16x2, with a white backlight, variable delay auto-off time-out. Two status LED indicators
are visible through front panel mounted lenses. Further, the reader contains three DPDT push-button switches (Left, Center, Right),
power on button(s) for battery mode operation, switch usage switch, audible alerts, strip detection, and test completion signals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Further, the MiOXSYS analyzer
enables data transfer, has USB serial communication, and is configured for data download to a connected PC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The MiOXSYS analyzer&rsquo;s power
management consists of an external 5VDC power jack with input capacitance and filtering, a boost converter supplied by external
5VDC power or internal Li-Ion battery, and provides main 5VDC digital board supply. The reader functions with or without the battery
connected. The battery lasts in excess of 24 hours with continuous operation to enable prolonged use outside of a laboratory setting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Image of the MiOXSYS Analyzer&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;<IMG SRC="v473641_img7.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>The MiOXSYS Sensor Strips&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The MiOXSYS sensor strips, via
standard biological specimen collection techniques, receive 20 &ndash; 40 microliters of a specimen from which the ORP clinical
analysis is performed. The ORP sensor strips are small, disposable, and biocompatible and consist of a ceramic substrate and a
five-lead configuration. Significant intellectual property surrounds the design, construct, and electrochemical algorithms associated
with the sensors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Image of the MiOXSYS Sensor
Strips&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;<IMG SRC="v473641_img8.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Regulatory Pathway&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We achieved ISO 13485: 2003 in
late 2013 following the successful development of a compliant medical device quality system. Following the issuance of our ISO
certification, we obtained CE marking for the RedoxSYS System, which has enabled initial market development in Europe and markets
that accept a CE marking. In December 2015, we achieved CE marking for MiOXSYS following technical validation and clinical study
completion in male infertility. In March 2016, we obtained Health Canada Class II Medical approvals for MiOXSYS. In the United
States, we intend to pursue 510k clearance with the FDA for the MiOXSYS System. We have recent, ongoing correspondence with the
FDA and have confirmed that MiOXSYS is appropriate for the 510k pathway, and we are pursuing regulatory clearance through this
pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>United States Commercial
Strategy&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If the clinical studies to measure
oxidative stress in male infertility are successful, we expect to pursue that intended use for the MiOXSYS System via the FDA
510k pathway. If cleared for the infertility intended use, we intend to seek to commercialize the MiOXSYS System as a new tool
for the assessment of oxidative stress in infertility in men. We envision pursuing a direct sales effort to high priority urology/andrology
laboratories, infertility clinics and reference centers across the United States. We have identified the primary, influential
centers in the United States and believe our commercial deployment will be efficient through a focused sales and marketing effort.
We intend to seek to sell the MiOXSYS System into individual centers and laboratories but will focus our revenue model on the
repeat ordering of the disposable, single use MiOXSYS sensor strips. We expect to realize a favorable gross margin on the basis
of estimated low cost of goods sold on both components of the system. We envision an average selling price for the disposable
sensors of approximately $25. We envision selling the MiOXSYS analyzers for approximately $2,500 but will also pursue an instrument
rental agreement model with minimum disposable sensor purchase requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We also intend to leverage our
urology commercialization efforts with other products with a focus on urology centers, infertility clinics, and reproductive health
laboratories around the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We believe a focused sales force
at the onset of commercialization will enable effective representation of our products and penetration of the reproductive health
market. Our sales efforts into the research markets will be enabled initially through a full-time business development professional
who will focus on collaborative research and research sales to major oxidative stress centers in the United States. We expect
to pursue identical pricing in the research market and the clinical diagnostics markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>ROW Commercial Strategy&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to undertake a similar strategy outside the United States for the RedoxSYS and MiOXSYS Systems while
complementing our efforts in infertility and research with adjunct applications in critical care conditions. To efficiently execute
across our strategy, we intend to utilize a network of established distributors in the target markets in Europe and Asia. We have
already established distribution arrangements with multiple distributors in multiple countries, and through these distributors,
we have sold MiOXSYS in over 20 countries around the world. We anticipate slightly reduced pricing outside the U.S. for the disposable
sensors given the anticipated lower pricing observed ex-US for diagnostic and research products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Nuelle and the Fiera&reg; Personal
Care Device</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fiera is a revenue-generating women&rsquo;s personal care product
marketed in the United States primarily through consumer promotion. Fiera is the first of its kind, hands-free, personal care
device for women that enhances physical arousal and interest in sex. In scientific and consumer studies conducted with hundreds
of women with stated sexual desire and response concerns, Fiera has demonstrated highly consistent benefit. Importantly, Fiera
is also endorsed by and receives professional recommendations from leading sexual health experts across the United States and
has been studied and presented by the same experts.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Fiera was created with OB-GYNs
and has multiple&nbsp;scientific studies&nbsp;showing it works. Fiera helps women who have changing levels of arousal, interest,
and vaginal dryness, enter a sexual experience with enhanced&nbsp;levels of excitement and interest. Fiera works naturally with
a woman&rsquo;s body and provides a hands-free experience thanks to the innovative design. &nbsp;Fiera uses light stimulation
and a gentle suction action to enhance blood flow and increase lubrication in advance of sex, in as little as 5 minutes. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Product Features of <I>Fiera
</I>Personal Care Devices</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Proprietary
                                         dual-action technology enhances blood flow to the genitals</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Small,
                                         fast-acting and hands-free, typically worn for 5-15 minutes and<I> </I>then removed in
                                         preparation for sexual activity</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Features
                                         pattern and intensity settings for a customizable experience</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Made
                                         with comfortable, body-safe materials (phthalate free)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Uses
                                         rechargeable battery</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">Does
                                         not require a prescription (consumer device)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: center; text-indent: -13.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: left; text-indent: -13.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt auto; text-align: left"><FONT STYLE="color: #000000"><IMG SRC="v473641_img9.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt; color: #000000"><B>The Fiera Device</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>The Fiera Device + Remote</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;<IMG SRC="v473641_img10.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>The Fiera
SofSense&trade; Rings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Fiera SofSense&trade; ring refills are available and sold in two&nbsp;styles, for a custom fit. Each refill
box contains three SofSense&trade; rings, and each ring is designed to be used up to five times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>United States-Based Consumer
Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Fiera has been extensively studied
and tested by consumers and physicians. Fiera is scientifically proven to enhance genital arousal in women of all ages, including
pre and post-menopausal women.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Consumer study results in women
ages 25-75 showed that after 4 weeks of using Fiera + Remote:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">97% of women felt physically aroused</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">96% looked forward to being intimate with their partner</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">93% felt excited and ready for sex</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">89% of women felt more &ldquo;in the mood&rdquo;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">87% felt as ready for sex as their partner did</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Previous studies also showed that
87% of women felt increased desire and 67% felt increased lubrication. In a separate scientific study of pre and post-menopausal
women, arousal occurred on average in 5 minutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Clinical Data on the Fiera
Personal Care Device</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Fiera serves several important
functions:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #000000">1.</FONT></TD><TD><FONT STYLE="color: #000000">It helps to encourage blood flow
                                         in the clitoris (vasocongestion), a key physical reaction that signals your body that
                                         you are ready for sex.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #000000">2.</FONT></TD><TD><FONT STYLE="color: #000000">It provides direct stimulation,
                                         accelerating the effect of the suction.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #000000">3.</FONT></TD><TD><FONT STYLE="color: #000000">A soft, silicone ring adheres
                                         with a gentle suction holding the product in place so that your hands are free.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Fiera is tucked under the labia
and worn over the clitoris, a woman&rsquo;s most sensitive sexual organ to enhance arousal through a proprietary combination of
gentle suction and multi-focal stimulation. As the nerve endings in the clitoris respond, a woman begins to experience enhanced
sensation to the genital area, which triggers a physical state of arousal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our research shows that use of
Fiera regularly over a 4-week period also increases a woman&rsquo;s level of sexual desire. Women also report looking forward
to and enjoying sexual activity more.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">A study of 14 sexually active,
<I>premenopausal</I> women was conducted to determine the degree of engorgement &ndash; as measured by temperature change in the
external genitalia &ndash; produced by Fiera. Fiera produced statistically significant increases in vulvar temperatures, which
is a marker of genital blood flow and engorgement. 100% of study participants reported feeling &ldquo;In the Mood&rdquo; for sex
after use of Fiera. Additionally, 100% of study participants experienced genital sexual arousal during use of Fiera. Another study
of 12 sexually active, postmenopausal women demonstrated that Fiera produced statistically significant increases in vulvar temperature.
Use of Fiera in this population of postmenopausal women produced sexual desire in 100% of the subjects while 83% experienced genital
arousal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>ProstaScint for the Detection
of Prostate Cancer&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 20, 2015, we acquired ProstaScint&reg; from Jazz Pharmaceuticals. The ProstaScint Kit, or capromab
pendetide, is a radio-labeled monoclonal antibody, which is a biologic product that targets a specific antigen. ProstaScint targets
prostate specific membrane antigen, or PSMA, a protein uniquely expressed by prostate tissue. A radioactive substance called Indium
(In 111) is attached to the proprietary, mouse-derived antibody. The radiolabeled antibody is infused into the patient and is taken
up by prostate cancer cells which can be detected and visualized with a special nuclear medicine scan (single-photon emission tomography,
or SPECT). ProstaScint has been shown to be clinically effective in determining the course of treatment for a patient who has had
a prostatectomy and/or has suspected metastasis (spread of the cancer cells beyond the prostate). Further, ProstaScint has demonstrated
efficacy in patients classified as high risk or with recurrent prostate cancer. ProstaScint has been approved by the FDA and Health
Canada, and significant clinical data exist demonstrating the significant predictive value in prostate cancer staging. At June
30, 2017, the ProstaScint asset was impaired based upon sales projections that we intend to only sell this product through mid-fiscal
2019, when this product expires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Prostate Cancer Market&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">According to the American Cancer
Society prostate cancer is the most common cancer among men in the United States, with an estimated 241,000 annual cases (as of
2012). Further, more than 2.2 million men were alive in 2006 with some history of prostate cancer, and over 30,000 U.S. men die
each year from the disease. The effect of prostate cancer on healthcare economics is substantial, which makes the need for accurate
disease staging critical for treatment and management strategies. The U.S. market for the diagnosis and screening of prostate
cancer is expected to total $17.4 billion in 2017, a CAGR of 7.5% since 2012. Importantly, ProstaScint is the only FDA-approved
radiopharmaceutical (for use in radioimmunoscintigraphy) specifically indicated for prostate cancer screening and is specifically
highlighted in the American Cancer Society practice guidelines for prostate cancer screening and staging.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Prostate cancer is classified
into four stages based on severity: Stages 1 through 4. Stage 3 is considered &ldquo;high risk&rdquo; and Stage 4 is when cancer
has become metastatic. Radioimmunoscintigraphy has been established as a diagnostic to stage cancer malignancy and one of the
most widespread clinical uses has been for the detection of prostate cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>ProstaScint Clinical Data&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Multiple clinical studies have
been conducted in the United States and published in peer-reviewed publications that consistently demonstrate substantial clinical
efficacy of ProstaScint in staging prostate cancer patients and specifically identify whether the cancer is confined to the prostate
or has metastasized to other parts of the body. Through more accurate clinical staging and identification of metastatic prostate
cancer, clinicians are able to better direct therapeutic interventions and improve outcomes. A brief summary of key clinical findings
for ProstaScint from select studies are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 18%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Principal</B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt"><B>Investigator(s)/</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>Primary Authors</B></FONT></FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 18%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>Publication</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 31%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>Patient
    Population</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>Conclusion/Results</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Ellis RJ et al.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Int. J. Radiation Oncology Biol. Phy. (2010)</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Patients presenting for primary radiotherapy having a clinical diagnosis
    of localized primary prostate cancer; Patients evaluated for tumor stage using conventional staging and SPECT/CT (N=239)</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">SPECT/CT imaging with ProstaScint pre-treatment was significantly predictive
    of 10-year biochemical disease-free survival (86.6% vs. 65.5%; p=0.0014)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Haseman MK et al.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Urology (2007)</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Men with prostate cancer who underwent imaging with ProstaScint pretreatment;
    Patients were divided according to the presence or absence of central abdominal uptake (CAU) (N=341)</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">SPECT/CT imaging with ProstaScint pretreatment effectively predicted death
    rates among patients with central abdominal uptake (CAU), and demonstrated that prostate cancer-specific death rates were
    10 times higher in patients identified with ProstaScint as having central abdominal uptake (p=0.005).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Ellis RJ et al.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Brachytherapy (2005)</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Men with prostate cancer of all risk categories who underwent imaging with
    ProstaScint pretreatment; patients were divided into low, intermediate, and high risk and underwent brachytherapy (N=239)</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">SPECT/CT imaging with ProstaScint pretreatment effectively predicted biochemical
    disease recurrence regardless of the patient&rsquo;s risk category; 7-year outcomes data from brachytherapy patients with
    treatment based on the ProstaScint scan showed a significant difference in biochemical disease-free survival.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Radiation oncology experts have
published numerous papers expressing the potential for expanded use of ProstaScint in prostate cancer imaging due to advances
in imaging technologies since the product&rsquo;s initial approval. Since the early 2000s, significantly greater image resolution
has been enabled due to the advent of dual head cameras (and improved imaging in general) along with the use of co-registered
images where radiologists now combine the images of SPECT and computerized tomography, or CT, or magnetic resonance imaging, or
MRI. Because of these factors, we believe there is significant commercial opportunity for ProstaScint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>ProstaScint Product Information&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">ProstaScint is provided as a two-vial
kit which contains all of the non-radioactive ingredients necessary to produce a single unit dose for administration by intravenous
injection. The ProstaScint vial contains 0.5 mg of capromab pendetide in 1 mL of sodium phosphate buffered saline solution adjusted
to pH 6; a sterile, pyrogen-free, clear, colorless solution that may contain some translucent particles. The vial of sodium acetate
buffer contains 82 mg of sodium acetate in 2 mL of water for injection adjusted to pH 5 &ndash; 7 with glacial acetic acid; it
is a sterile, pyrogen-free, clear, and colorless solution. Neither solution contains a preservative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Each kit also includes one sterile
0.22 &mu;m Millex&reg; GV filter, prescribing information, and two identification labels. The hospital is responsible for addition
of Indium (In 111). ProstaScint may also be helpful in conjunction with other scans (CT or MRI) for higher risk patients, by detecting
lymph nodes in the abdomen that are involved with prostate cancer cells, but may still appear falsely normal on CT or MRI scans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The procedure to administer ProstaScint
is as follows: the patient is given an intravenous, or IV, infusion of the monoclonal antibody, and 30 minutes later, a scan is
performed. A second scan is done between 96 and 120 hours (4 &ndash; 5 days) after the infusion. The first scan (on the day of
the infusion) takes approximately 1 hour, while the second scan takes approximately 2.5 hours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>ProstaScint Uses&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">ProstaScint is indicated as a
diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer, thought to be clinically-localized after
standard diagnostic evaluation (e.g. chest x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases.
It is not indicated in patients who are not at high risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">ProstaScint is also indicated
as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic
evaluation in whom there is a high clinical suspicion of occult metastatic disease. The imaging performance of Indium (In 111)
ProstaScint following radiation therapy has not been studied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The information provided by Indium
(In 111) ProstaScint imaging should be considered in conjunction with other diagnostic information. Scans that are positive for
metastatic disease should be confirmed histologically in patients who are otherwise candidates for surgery or radiation therapy
unless medically contraindicated. Scans that are negative for metastatic disease should not be used in lieu of histological confirmation.
ProstaScint is not indicated as a screening tool for carcinoma of the prostate nor for re-administration for the purpose of assessment
of response to treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">ProstaScint was initially marketed
by Cytogen Corporation, which was acquired by EUSA Pharma. Jazz Pharmaceuticals acquired EUSA in June 2012 but significantly reduced
promotion of ProstaScint due to a lack of strategic focus. Despite limited commercialization efforts, peak annual unit sales of
ProstaScint of 8,216 kits were achieved. At current pricing, this unit sales volume would equate to approximately $14.6 million
in annual revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In late fiscal 2017, we decided
to implement a harvest strategy for the ProstaScint product, due to increased competition and the cost to continue manufacturing.
Based upon our current projections, we believe that we will continue to sell this product through fiscal 2018 and the first half
of fiscal 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Our Business Development Strategy
&mdash; Identifying &amp; Acquiring Complementary Urology Assets&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">A key growth and value driver
for our Company is the ongoing identification and acquisition of novel urology products for commercialization. We seek to identify
unique products with urologic indications that may be non-strategic, undervalued or under-resourced by the company that currently
markets the product. We believe that we can continue to acquire strategically aligned products at an appropriate valuation and
grow those products via our focused sales and marketing efforts. We will also consider acquiring novel, late-stage development
products that represent unique commercial opportunities and can be efficiently developed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will continue to look to identify unique product assets to acquire based on specific attributes including
but not limited to: therapeutic area/indication; growth potential; intellectual property position (patents, regulatory, manufacturing
or development technicalities, etc.); valuation; strategic fit; commercial orientation and other factors. Indications of interest
include products to treat conditions such as urinary incontinence, sexual wellness and vitality, hypogonadism, prostate and other
urological cancers, urinary tract infections, and other urological conditions. However, during fiscal 2018, our primary focus will
be on growing our current core assets and working towards cash-flow breakeven.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Government Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">While we do not have any pharmaceutical
product candidates that we are actively developing as of the date of this Report, we may in the future acquire such products.
Currently, we are developing two medical device candidates, the RedoxSYS and MiOXSYS Systems, for which regulatory approval must
be received before we can market them within the United States. Regulatory approval processes for our current and any future product
candidates are discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Approval Process for Pharmaceutical
Products&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>FDA Approval Process for Pharmaceutical
Products&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In the United States, pharmaceutical
products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal
and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping,
approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export
of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative
or judicial sanctions, such as FDA refusal to approve pending new drug applications, NDAs, warning letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Pharmaceutical product development
in the United States typically involves the performance of satisfactory nonclinical, also referred to as pre-clinical, laboratory
and animal studies under the FDA&rsquo;s Good Laboratory Practice, or GLP, regulation, the development and demonstration of manufacturing
processes, which conform to FDA mandated current good manufacturing requirements, or cGMP, including a quality system regulating
manufacturing, the submission and acceptance of an IND application, which must become effective before human clinical trials may
begin in the United States, obtaining the approval of Institutional Review Boards, or IRBs, at each site where we plan to conduct
a clinical trial to protect the welfare and rights of human subjects in clinical trials, adequate and well-controlled clinical
trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought, and the submission
to the FDA for review and approval of an NDA. Satisfaction of FDA requirements typically takes many years and the actual time
required may vary substantially based upon the type, complexity, and novelty of the product or disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Pre-clinical tests generally include
laboratory evaluation of a product candidate, its chemistry, formulation, stability and toxicity, as well as certain animal studies
to assess its potential safety and efficacy. Results of these pre-clinical tests, together with chemistry, manufacturing controls
and analytical data and the clinical trial protocol, which details the objectives of the trial, the parameters to be used in monitoring
safety, and the effectiveness criteria to be evaluated, along with other requirements must be submitted to the FDA as part of
an IND, which must become effective before human clinical trials can begin. The entire clinical trial and its protocol must be
in compliance with what are referred to as good clinical practice, or GCP, requirements. The term, GCP, is used to refer to various
FDA laws and regulations, as well as international scientific standards intended to protect the rights, health and safety of patients,
define the roles of clinical trial sponsors and assure the integrity of clinical trial data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">An IND automatically becomes effective
30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the intended
conduct of the trials and imposes what is referred to as a clinical hold. Pre-clinical studies generally take several years to
complete, and there is no guarantee that an IND based on those studies will become effective, allowing clinical testing to begin.
In addition to FDA review of an IND, each medical site that desires to participate in a proposed clinical trial must have the
protocol reviewed and approved by an independent IRB or Ethics Committee, or EC. The IRB considers, among other things, ethical
factors, and the selection and safety of human subjects. Clinical trials must be conducted in accordance with the FDA&rsquo;s
GCP requirements. The FDA and/or IRB may order the temporary, or permanent, discontinuation of a clinical trial or that a specific
clinical trial site be halted at any time, or impose other sanctions for failure to comply with requirements under the appropriate
entity jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Clinical trials to support NDAs
for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1 clinical trials,
a product candidate is typically introduced either into healthy human subjects or patients with the medical condition for which
the new drug is intended to be used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The main purpose of the trial
is to assess a product candidate&rsquo;s safety and the ability of the human body to tolerate the product candidate. Phase 1 clinical
trials generally include less than 50 subjects or patients. During Phase 2 trials, a product candidate is studied in an exploratory
trial or trials in a limited number of patients with the disease or medical condition for which it is intended to be used in order
to: (i) further identify any possible adverse side effects and safety risks, (ii) assess the preliminary or potential efficacy
of the product candidate for specific target diseases or medical conditions, and (iii) assess dosage tolerance and determine the
optimal dose for Phase 3 trials. Phase 3 trials are generally undertaken to demonstrate clinical efficacy and to further test
for safety in an expanded patient population with the goal of evaluating the overall risk-benefit relationship of the product
candidate. Phase 3 trials are generally designed to reach a specific goal or endpoint, the achievement of which is intended to
demonstrate the candidate product&rsquo;s clinical efficacy and adequate information for labeling of the approved drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">There are three main types of
NDAs, which are covered by Section 505 of the FDC Act: (1) an application that contains full reports of investigations of safety
and efficacy (Section 505(b)(1)); (2) an application that contains full reports of investigations of safety and effectiveness
but where at least some of the information required for approval comes from studies not conducted by or for the applicant and
for which the application has not obtained a right of reference (Section 505(b)(2)); and (3) an application that contains information
to show that the proposed product is identical in active ingredient, dosage form, strength, route of administration, labeling,
quality, performance characteristics, and intended use, among other things, to a previously approved product (Section 505(j)).
Section 505(b)(2) expressly permits the FDA to rely, for approval of an NDA, on data not developed by the applicant. In the pre-IND
briefing meeting with Ampio and in June 2012, the FDA agreed that our NDA may be submitted under Section 505(b)(2). As such, we
intend to rely on studies published in the scientific literature and reference FDA-approved NDAs for tramadol-containing products
(NDAs 21-693, 20-281 and 21-692) to support the safety and efficacy demonstrated in our clinical program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval
of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all pre-clinical,
clinical, and other testing and a compilation of data relating to the product&rsquo;s pharmacology, chemistry, manufacture, and
controls. The cost of preparing and submitting an NDA is substantial. Under federal law, the submission of most NDAs is additionally
subject to a substantial application user fee, currently exceeding $2.3 million and the manufacturer and/or sponsor under an approved
NDA are also subject to annual product and establishment user fees, currently approximately $100,000 per product and $600,000 per
establishment. These fees are typically increased annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The FDA has 60 days from its receipt
of an NDA to determine whether the application will be accepted for filing based on the FDA&rsquo;s threshold determination that
it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth
review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications for standard review drug
products are reviewed within ten months; most applications for priority review drugs are reviewed in six months. Priority review
can be applied to drugs that the FDA determines offer major advances in treatment, or provide a treatment where no adequate therapy
exists. The review process for both standard and priority review may be extended by the FDA for three additional months to consider
certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA
may also refer applications for novel drug products, or drug products which present difficult questions of safety or efficacy,
to an advisory committee &mdash; typically a panel that includes clinicians and other experts &mdash; for review, evaluation,
and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory
committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more
clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug
is manufactured. The FDA will not approve the product unless compliance with cGMP is satisfactory and the NDA contains data that
provide substantial evidence that the drug is safe and effective in the indication studied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">After the FDA evaluates the NDA
and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter
generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for
the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&rsquo;s satisfaction in a
resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or
six months depending on the type of information included. An approval letter authorizes commercial marketing of the drug with
specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation
and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">REMS can include medication guides,
communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited
to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring,
and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of
the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&rsquo;s
safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained
or problems are identified following initial marketing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>The Hatch-Waxman Act&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In seeking approval for a drug
through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&rsquo;s product. Upon
approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&rsquo;s Approved Drug
Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in
turn, be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides
for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug
and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement
for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, pre-clinical or clinical tests
to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &ldquo;generic
equivalents&rdquo; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original
listed drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The ANDA applicant is required
to certify to the FDA concerning any patents listed for the approved product in the FDA&rsquo;s Orange Book that: 1) the required
patent information has not been filed; 2) the listed patent has expired; 3) the listed patent has not expired, but will expire
on a particular date and approval is sought after patent expiration; or 4) the listed patent is invalid or will not be infringed
by the new product. A certification that the new product will not infringe the already approved product&rsquo;s listed patents,
or that such patents are invalid, is called a Paragraph IV certification. If the applicant does not challenge the listed patents,
the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If the ANDA applicant has provided
a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and
patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement
lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days
of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30
months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA
applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The ANDA application also will
not be approved until any non-patent exclusivity listed in the Orange Book for the referenced product has expired. Federal law
provides a period of five years following approval of a drug containing no previously approved active ingredients during which
ANDAs for generic versions of those drugs cannot be submitted, unless the submission contains a Paragraph IV challenge to a listed
patent &mdash; in which case the submission may be made four years following the original product approval. Federal law provides
for a period of three years of exclusivity during which FDA cannot grant effective approval of an ANDA based on the approval of
a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration
or combination, or for a new use; the approval of which was required to be supported by new clinical trials conducted by, or for,
the applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Post-Approval Regulation&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Even if a product candidate receives
regulatory approval, the approval is typically limited to specific clinical indications. Further, even after regulatory approval
is obtained, subsequent discovery of previously unknown problems with a product may result in restrictions on its use or even
complete withdrawal of the product from the market. Any FDA-approved products manufactured or distributed by us are subject to
continuing regulation by the FDA, including record-keeping requirements and reporting of adverse events or experiences. Further,
drug manufacturers and their subcontractors are required to register their establishments with the FDA and state agencies, and
are subject to periodic inspections by the FDA and state agencies for compliance with cGMP, which impose rigorous procedural and
documentation requirements upon us and our contract manufacturers. We cannot be certain that we or our present or future contract
manufacturers or suppliers will be able to comply with cGMP regulations and other FDA regulatory requirements. Failure to comply
with these requirements may result in, among other things, total or partial suspension of production activities, failure of the
FDA to grant approval for marketing, and withdrawal, suspension, or revocation of marketing approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If the FDA approves one or more
of our product candidates, we and the contract manufacturers we use for manufacture of clinical supplies and commercial supplies
must provide certain updated safety and efficacy information. Product changes, as well as certain changes in the manufacturing
process or facilities where the manufacturing occurs or other post-approval changes may necessitate additional FDA review and
approval. The labeling, advertising, promotion, marketing and distribution of a drug or biologic product or medical devices, also
must be in compliance with FDA and Federal Trade Commission, or FTC, requirements which include, among others, standards and regulations
for direct-to-consumer advertising, off-label promotion, industry sponsored scientific and educational activities, and promotional
activities involving the Internet. The FDA and FTC have very broad enforcement authority, and failure to abide by these regulations
can result in penalties, including the issuance of a warning letter directing us to correct deviations from regulatory standards
and enforcement actions that can include seizures, fines, injunctions and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Approval Process for Medical
Devices&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In the United States, the FDCA,
FDA regulations and other federal and state statutes and regulations govern, among other things, medical device design and development,
preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage,
advertising and promotion, sales and distribution, export and import, and post-market surveillance. The FDA regulates the design,
manufacturing, servicing, sale and distribution of medical devices, including molecular diagnostic test kits and instrumentation
systems. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial
sanctions, such as FDA refusal to approve pending applications, warning letters, product recalls, product seizures, total or partial
suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Unless an exemption applies, each
medical device we wish to distribute commercially in the United States will require marketing authorization from the FDA prior
to distribution. The two primary types of FDA marketing authorization applicable to a device are premarket notification, also
called 510k clearance, and premarket approval, also called PMA approval. The type of marketing authorization is generally linked
to the classification of the device. The FDA classifies medical devices into one of three classes (Class I, II or III) based on
the degree of risk the FDA determines to be associated with a device and the level of regulatory control deemed necessary to ensure
the device&rsquo;s safety and effectiveness. Devices requiring fewer controls because they are deemed to pose lower risk are placed
in Class I or II. Class I devices are deemed to pose the least risk and are subject only to general controls applicable to all
devices, such as requirements for device labeling, premarket notification and adherence to the FDA&rsquo;s current Good Manufacturing
Practices, or cGMP, known as the Quality System Regulations, or QSR. Class II devices are intermediate risk devices that are subject
to general controls and may also be subject to special controls such as performance standards, product-specific guidance documents,
special labeling requirements, patient registries or post-market surveillance. Class III devices are those for which insufficient
information exists to assure safety and effectiveness solely through general or special controls and include life sustaining,
life-supporting or implantable devices, devices of substantial importance in preventing impairment of human health, or which present
a potential, unreasonable risk of illness or injury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Most Class I devices and some
Class II devices are exempted by regulation from the 510k clearance requirement and can be marketed without prior authorization
from the FDA. Some Class I devices that have not been so exempted and Class II devices are eligible for marketing through the
510k clearance pathway. By contrast, devices placed in Class III require PMA approval prior to commercial marketing. The PMA approval
process is more stringent, time-consuming and expensive than the 510k clearance process, however, the 510k clearance process has
also become increasingly stringent and expensive. The FDA has provided initial guidance to us that the MiOXSYS and RedoxSYS Systems
are appropriate for the 510k clearance process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">510k Clearance. To obtain 510k
clearance for a medical device, an applicant must submit a premarket notification to the FDA demonstrating that the device is
&ldquo;substantially equivalent&rdquo; to a device legally marketed in the United States that is not subject to PMA approval,
commonly known as the &ldquo;predicate device.&rdquo; A device is substantially equivalent if, with respect to the predicate device,
it has the same intended use and has either (i) the same technological characteristics or (ii) different technological characteristics
and the information submitted demonstrates that the device is as safe and effective as a legally marketed device and does not
raise different questions of safety or effectiveness. A showing of substantial equivalence sometimes, but not always, requires
clinical data. Generally, the 510k clearance process can exceed 90 days and may extend to a year or more.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">After a device has received 510k
clearance for a specific intended use, any change or modification that significantly affects its safety or effectiveness, such
as a significant change in the design, materials, method of manufacture or intended use, may require a new 510k clearance or PMA
approval and payment of an FDA user fee. The determination as to whether or not a modification could significantly affect the
device&rsquo;s safety or effectiveness is initially left to the manufacturer using available FDA guidance; however, the FDA may
review this determination to evaluate the regulatory status of the modified product at any time and may require the manufacturer
to cease marketing and recall the modified device until 510k clearance or PMA approval is obtained. The manufacturer may also
be subject to significant regulatory fines or penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Before we can submit a medical
device for 510k clearance, we may have to perform a series of generally short studies over a period of months, including method
comparison, reproducibility, interference and stability studies to ensure that users can perform the test successfully. Some of
these studies may take place in clinical environments, but are not usually considered clinical trials. For PMA submissions, we
would generally be required to conduct a longer clinical trial over a period of years that supports the clinical utility of the
device and how the device will be used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Although clinical investigations
of most devices are subject to the investigational device exemption, or IDE, requirements, clinical investigations of diagnostic
tests, including our products and products under development, are generally exempt from the IDE requirements. Thus, clinical investigations
by intended users for intended uses of our products generally do not require the FDA&rsquo;s prior approval but may require approval
of an Institutional Review Board, or IRB, and written informed consent by the patient, provided the clinical evaluation testing
is non-invasive, does not require an invasive sampling procedure that presents a significant risk, does not intentionally introduce
energy into the subject and is not used as a diagnostic procedure without confirmation by another medically established test or
procedure. In addition, our products must be labeled per FDA regulations &ldquo;for research use only-RUO&rdquo; or &ldquo;for
investigational use only-IUO,&rdquo; and distribution controls must be established to assure that our products distributed for
research, method comparisons or clinical evaluation studies are used only for those purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Regulation after FDA Clearance
or Approval&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Any devices we manufacture or
distribute pursuant to clearance or approval by the FDA are subject to pervasive and continuing regulation by the FDA and certain
state agencies. We are required to adhere to applicable regulations setting forth detailed cGMP requirements, as set forth in
the QSR, which include, among other things, testing, control and documentation requirements. Noncompliance with these standards
can result in, among other things, fines, injunctions, civil penalties, recalls or seizures of products, total or partial suspension
of production, refusal of the government to grant 510k clearance or PMA approval of devices, withdrawal of marketing approvals
and criminal prosecutions, fines and imprisonment. Our contract manufacturers&rsquo; facilities operate under the FDA&rsquo;s
cGMP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Foreign Regulatory Approval&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Outside of the United States,
our ability to market our product candidates will be contingent also upon our receiving marketing authorizations from the appropriate
foreign regulatory authorities, whether or not FDA approval has been obtained. The foreign regulatory approval process in most
industrialized countries generally encompasses risks similar to those we will encounter in the FDA approval process. The requirements
governing conduct of clinical trials and marketing authorizations, and the time required to obtain requisite approvals, may vary
widely from country to country and differ from those required for FDA approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In the European Union, we are
required under the European Medical Device Directive (Council Directive 93/42/EEC) to affix the CE mark to certain of our products
in order to sell the products in member countries of the European Union. The CE mark is an international symbol that represents
adherence to certain essential principles of safety and effectiveness mandated in the European Medical Device Directive, which
are referred to as the &ldquo;essential requirements&rdquo;. Once affixed, the CE mark enables a product to be sold within the
European Economic Area, or EEA, which is composed of the 28 member states of the EU plus Norway, Iceland and Liechtenstein as
well as other countries that accept the CE mark.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">To demonstrate compliance with
the essential requirements, we must undergo a conformity assessment procedure which varies according to the type of medical device
and its classification. Except for low risk medical devices (Class I with no measuring function and which are not sterile) where
the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the
essential requirements of the Medical Devices Directive, a conformity assessment procedure requires the intervention of an organization
accredited by a member state of the EEA to conduct conformity assessments, or a notified body. Depending on the relevant conformity
assessment procedure, the notified body would typically audit and examine the technical file and the quality system for the manufacture,
design and final inspection of our devices. The notified body issues a CE certificate of Conformity following successful completion
of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with
the essential requirements. This certificate entitles the manufacturer to affix the CE mark to its medical devices after having
prepared and signed a related EC Declaration of Conformity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If we modify our devices, we may
need to apply for permission to affix the CE mark to the modified product. Additionally, we may need to apply for a CE mark for
any new products that we may develop in the future. Certain products regulated as medical devices according to EC-Directives are
subject to vigilance requirements for reporting of adverse events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We will be subject to additional
regulations in other countries in which we market, sell and import our products, including Canada. We or our distributors must
receive all necessary approvals or clearance prior to marketing and/or importing our products in those markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The International Standards Organization,
or ISO, promulgates internationally recognized standards, including those for the requirements of quality systems. To support
ISO certifications, surveillance audits are conducted by a notified body yearly and recertification audits every three years that
assess continued compliance with the relevant ISO standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Other Regulatory Matters&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Manufacturing, sales, promotion
and other activities following product approval are also subject to regulation by numerous regulatory authorities in addition
to the FDA, including, in the United States, the Centers for Medicare &amp; Medicaid Services, other divisions of the Department
of Health and Human Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission,
the Occupational Safety &amp; Health Administration, the Environmental Protection Agency and state and local governments. In the
United States, sales, marketing and scientific/educational programs must also comply with state and federal fraud and abuse laws.
Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of
1990 and more recent requirements in the Health Care Reform Law, as amended by the Health Care and Education Affordability Reconciliation
Act, or ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration,
additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled Substances
Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under
the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to
federal and state consumer protection and unfair competition laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The distribution of pharmaceutical
products is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security
requirements intended to prevent the unauthorized sale of pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The failure to comply with regulatory
requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable
regulatory requirements can result in criminal prosecution, fines, imprisonment or other penalties, injunctions, recall or seizure
of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm
to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements,
new information regarding the safety or effectiveness of a product could lead the FDA to modify or withdraw product approval.
Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in
an adverse way.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Changes in regulations, statutes
or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to
our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our
products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect
the operation of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>United States Patent Term
Restoration and Marketing Exclusivity&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Depending upon the timing, duration
and other specific aspects of the FDA approval of our drug candidates, some of our U.S. patents may be eligible for limited patent
term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman
Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost
during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining
term of a patent beyond a total of 14 years from the product&rsquo;s approval date. The patent term restoration period is generally
one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission
date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension
and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office,
in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future,
if any of our NDA&rsquo;s are approved, we intend to apply for restoration of patent term for one of our currently owned or licensed
patents to add patent life beyond the current expiration date, depending on the expected length of the clinical trials and other
factors involved in the filing of the relevant NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Market exclusivity provisions
under the FDCA can also delay the submission or the approval of certain marketing applications. The FDCA provides a five-year
period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a
new chemical entity, or NCE. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing
the same active moiety, which is the molecule or ion responsible for the action of the drug substance. Recently, the FDA stated
that it may change its interpretation of 5-year NCE exclusivity determinations to apply to each drug substance in a fixed-combination
drug product, not for the drug product as a whole. If this change is implemented, for example, a fixed-combination drug product
that contains a drug substance with a single, new active moiety would be eligible for 5 year NCE exclusivity, even if the fixed-combination
also contains a drug substance with a previously approved active moiety. During the exclusivity period, the FDA may not accept
for review an abbreviated new drug application, or ANDA, or a Section 505(b)(2) NDA submitted by another company for another drug
based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator
drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for
approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement
to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity
for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted
or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications,
dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received
approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing
the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission
or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference
to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.
Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.
Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted,
adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other
exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with
an FDA-issued &ldquo;Written Request&rdquo; for such a trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Reimbursement&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Natesto is covered by many commercial insurance providers and pharmacy benefit management companies and is
largely dependent upon reimbursement for continued use in the U.S. market. Natesto is also covered under a Rebate Agreement between
us and Centers for Medicare and Medicaid Services. This, in turn, enables states to offer public payer coverage of Natesto through
their separate Medicare and public assistance programs. Additionally, privately managed Medicare Part D plans may choose to cover
Natesto prescriptions through their plans&rsquo; pharmacy benefits. ProstaScint is dependent upon reimbursement for continued use
in the U.S. market, and ProstaScint does have a reimbursement code as assigned by the American Medical Association. ProstaScint
is currently reimbursed by Medicare, Medicaid, and various private health plans. However, reimbursement is not universally available
throughout the United States for ProstaScint. We do not anticipate that the sales of the MiOXSYS System, if approved for sale in
the U.S., will be heavily dependent upon reimbursement by third-party payors. Traditionally, sales of pharmaceuticals, diagnostics,
ad devices that are not &ldquo;lifestyle&rdquo; indications depend, in part, on the extent to which products will be covered by
third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party
payors are increasingly reducing reimbursements for medical products and services. The sexual wellness market is typically known
as a cash payor market, and because Fiera is not classified as a pharmaceutical or a medical device by the FDA, there will be no
reimbursement paid by third parties on the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Lack of third-party reimbursement
for our product candidate or a decision by a third-party payor to not cover our product candidates could reduce physician usage
of the product candidate and have a material adverse effect on our sales, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition, in some foreign countries,
the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary
widely from country to country. For example, the European Union provides options for its member states to restrict the range of
medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal
products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system
of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no
assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow
price structures of the United States and generally tend to be significantly lower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>DEA Regulation&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Natesto, already approved by the
FDA, is a &ldquo;controlled substance&rdquo; as defined in the Controlled Substances Act of 1970, or CSA, because it contains
testosterone. As a result, the U.S. Drug Enforcement Agencies, or DEA, regulate Natesto and have listed it as a Schedule III substance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Annual registration is required
for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific
to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import
and manufacturing, and each registration will specify which schedules of controlled substances are authorized. Similarly, separate
registrations are also required for separate facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The DEA typically inspects a facility
to review its security measures prior to issuing a registration and on a periodic basis. Reports must also be made for thefts
or losses of any controlled substance, and to obtain authorization to destroy any controlled substance. In addition, special permits
and notification requirements apply to imports and exports of narcotic drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The DEA establishes annually an
aggregate quota for how much of a controlled substance may be produced in total in the United States based on the DEA&rsquo;s
estimate of the quantity needed to meet legitimate scientific and medicinal needs. The DEA may adjust aggregate production quotas
and individual production and procurement quotas from time to time during the year, although the DEA has substantial discretion
in whether or not to make such adjustments. Our or our manufacturers&rsquo; quotas of an active ingredient may not be sufficient
to meet commercial demand or complete clinical trials. Any delay, limitation or refusal by the DEA in establishing our or our
manufacturers&rsquo; quota for controlled substances could delay or stop our clinical trials or product launches, which could
have a material adverse effect on our business, financial position and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">To enforce these requirements,
the DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure to maintain compliance
with applicable requirements, particularly as manifested in loss or diversion, can result in administrative, civil or criminal
enforcement action that could have a material adverse effect on our business, results of operations and financial condition. The
DEA may seek civil penalties, refuse to renew necessary registrations, or initiate administrative proceedings to revoke those
registrations. In some circumstances, violations could result in criminal proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Individual states also independently
regulate controlled substances. We and our manufacturers will be subject to state regulation on distribution of these products,
including, for example, state requirements for licensures or registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Intellectual Property&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu has an exclusive license
from Acerus Pharmaceuticals Corporation for the United States to intellectual property related to a nasal gel drug product containing
testosterone to treat hypogonadism in males, including the FDA approved product Natesto&reg;, as well as an authorized generic
version and OTC versions thereof. The license includes sublicense rights to intellectual property owned by Mattern Pharmaceuticals
and exclusively licensed to Acerus by Mattern Pharmaceuticals. The sublicensed intellectual property includes four Orange Book
listed patents directed at nasal gel formulations containing testosterone or methods of testosterone replacement therapy by nasal
administration of the same. It further includes three patents that are not listed in the Orange Book directed at a testosterone
formulation, a method of making a testosterone formulation and a method for reducing physical or chemical interactions between
a nasal testosterone formulation and a plastic container.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Acerus license also grants
rights to intellectual property owned by Acerus which includes ten nonprovisional patent applications, some of which may be abandoned.
These patent applications include at least four pending applications directed to testosterone titration methods, intranasal testosterone
bio-adhesive gel formulations, and controlled release testosterone formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We have an extensive range of
intellectual property for MiOXSYS, RedoxSYS, Fiera and ProstaScint. We have patent protection in the United States and several
other large markets worldwide. Specifically, we have numerous patents issued and pending for the RedoxSYS/MiOXSYS systems and
their use in the U.S., Europe, Canada, Israel, Japan, and China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our patent portfolio related to
RedoxSYS/MiOXSYS is focused on the United States and core foreign jurisdictions which include Europe, Canada, Israel, Japan and
China. The portfolio is supported in the United States and core foreign jurisdictions and consists of 20 issued patents and 27
pending applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The portfolio primarily consists
of seven families filed in the United States and in core foreign jurisdictions. The first family includes seven issued patents
and three pending applications with claims directed to the measurement of the ORP of a patient sample to evaluate various conditions.
The standard 20-year expiration for patents in this family is in 2028. The second family includes two pending United States applications,
two issued United States patents and four pending applications in core foreign jurisdictions with claims directed to the measurement
of the ORP capacity of a patient sample to evaluate various conditions. The standard 20-year expiration for patents in this family
is in 2033. The third family includes eight issued patents and three pending applications with claims directed to devices and
methods for the measurement of ORP and ORP capacity. The standard 20-year expiration for patents in this family is in 2032. The
fourth family includes one pending United States application, one issued United States patent, two issued patents in core foreign
jurisdictions and three pending applications in core foreign jurisdictions with claims directed to multiple layer gel test strip
measurement devices and methods of making for use in measuring ORP and ORP capacity. The standard 20-year expiration for patents
in this family is in 2033. The fifth family includes one pending United States application and one pending application filed under
the Patent Cooperative Treaty with claims directed to methods for monitoring food production and quality. The standard 20-year
expiration for patents in this family is in 2035. The sixth family includes one pending United States application and six pending
applications in core foreign jurisdictions with claims directed to methods for determining fertility characteristics from the
ORP of a biological sample. The standard 20-year expiration for patents in this family is in 2035. The seventh family includes
one pending United States application and one pending application filed under the Patent Cooperation Treaty with claims directed
to methods for evaluating stroke patients from the ORP characteristics of a biological sample. The standard 20-year expiration
for patents in this family is in 2036.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Fiera portfolio includes multiple
utility patent families in the United States and foreign jurisdictions with claims to the Fiera device. The United States portfolio
includes one issued patent and nine pending applications; the foreign portfolio includes six issued patents, nine pending applications
and one PCT application. In addition, Fiera is protected by a substantial design patent portfolio with four issued United States
design patents and three pending United States design applications. As well, the design portfolio includes forty-one issued design
patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">ProstaScint is protected by significant
trade secrets and manufacturing know-how related to the production of the product and linkage of the base monoclonal antibody
and imaging component. The antibody in the ProstaScint product is produced by a proprietary cell line.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We also maintain trade secrets
and proprietary know-how that we seek to protect through confidentiality and nondisclosure agreements. These agreements may not
provide meaningful protection or adequate remedies in the event of unauthorized use or disclosure of confidential and proprietary
information. If we do not adequately protect our trade secrets and proprietary know-how, our competitive position and business
prospects could be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We expect to seek United States
and foreign patent protection for drug and diagnostic products we discover, as well as therapeutic and diagnostic products and
processes. We expect also to seek patent protection or rely upon trade secret rights to protect certain other technologies which
may be used to discover and characterize drugs and diagnostic products and processes, and which may be used to develop novel therapeutic
and diagnostic products and processes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The patent positions of companies
such as ours involve complex legal and factual questions and, therefore, their enforceability cannot be predicted with any certainty.
Our issued and licensed patents, and those that may be issued to us in the future, may be challenged, invalidated or circumvented,
and the rights granted under the patents or licenses may not provide us with meaningful protection or competitive advantages.
Our competitors may independently develop similar technologies or duplicate any technology developed by us, which could offset
any advantages we might otherwise realize from our intellectual property. Furthermore, even if our product candidates receive
regulatory approval, the time required for development, testing, and regulatory review could mean that protection afforded us
by our patents may only remain in effect for a short period after commercialization. The expiration of patents or license rights
we hold could adversely affect our ability to successfully commercialize our pharmaceutical drugs or diagnostics, thus harming
our operating results and financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We will be able to protect our
proprietary intellectual property rights from unauthorized use by third parties primarily to the extent that such rights are covered
by valid and enforceable patents or are effectively maintained as trade secrets. If we must litigate to protect our intellectual
property from infringement, we may incur substantial costs and our officers may be forced to devote significant time to litigation-related
matters. The laws of certain foreign countries do not protect intellectual property rights to the same extent as do the laws of
the United States. Our pending patent applications, or those we may file or license from third parties in the future, may not
result in patents being issued. Until a patent is issued, the claims covered by an application for patent may be narrowed or removed
entirely, thus depriving us of adequate protection. As a result, we may face unanticipated competition, or conclude that without
patent rights the risk of bringing product candidates to market exceeds the returns we are likely to obtain. We are generally
aware of the scientific research being conducted in the areas in which we focus our research and development efforts, but patent
applications filed by others are maintained in secrecy for at least 18 months and, in some cases in the United States, until the
patent is issued. The publication of discoveries in scientific literature often occurs substantially later than the date on which
the underlying discoveries were made. As a result, it is possible that patent applications for products similar to our drug or
diagnostic products and product candidates may have already been filed by others without our knowledge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The biotechnology and pharmaceutical
industries are characterized by extensive litigation regarding patents and other intellectual property rights, and it is possible
that our development of products and product candidates could be challenged by other pharmaceutical or biotechnology companies.
If we become involved in litigation concerning the enforceability, scope and validity of the proprietary rights of others, we
may incur significant litigation or licensing expenses, be prevented from further developing or commercializing a product or product
candidate, be required to seek licenses that may not be available from third parties on commercially acceptable terms, if at all,
or subject us to compensatory or punitive damage awards. Any of these consequences could materially harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Competition&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The healthcare industry is highly
competitive and subject to significant and rapid technological change as researchers learn more about diseases and develop new
technologies and treatments. Significant competitive factors in our industry include product efficacy and safety; quality and
breadth of an organization&rsquo;s technology; skill of an organization&rsquo;s employees and its ability to recruit and retain
key employees; timing and scope of regulatory approvals; government reimbursement rates for, and the average selling price of,
products; the availability of raw materials and qualified manufacturing capacity; manufacturing costs; intellectual property and
patent rights and their protection; and sales and marketing capabilities. Market acceptance of our current products and product
candidates will depend on a number of factors, including: (i) potential advantages over existing or alternative therapies or tests,
(ii) the actual or perceived safety of similar classes of products, (iii) the effectiveness of sales, marketing, and distribution
capabilities, and (iv) the scope of any approval provided by the FDA or foreign regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a very small life sciences company compared to other companies that we are competing against. Our current
and potential competitors include large pharmaceutical, biotechnology, diagnostic, and medical device companies, as well as specialty
pharmaceutical and generic drug companies. Many of our current and potential competitors have substantially greater financial,
technical and human resources than we do and significantly more experience in the marketing, commercialization, discovery, development
and regulatory approvals of products, which could place us at a significant competitive disadvantage or deny us marketing exclusivity
rights. Specifically, our competitors will most likely have larger sales teams and have more capital resources to support their
products then we do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Accordingly, our competitors may
be more successful than we may be in achieving widespread market acceptance and obtaining FDA approval for product candidates.
We anticipate that we will face intense and increasing competition as new products enter the market, as advanced technologies
become available and as generic forms of currently branded products become available. Finally, the development of new treatment
methods for the diseases we are targeting could render our products non-competitive or obsolete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We cannot assure you that any
of our products that we acquire or successfully develop will be clinically superior or scientifically preferable to products developed
or introduced by our competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our current approved products
compete in highly competitive fields whereby there are numerous options available to clinicians including generics. These generic
treatment options are frequently less expensive and more widely available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Natesto</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Natesto competes in a growing market. The U.S. TRT market is large, with annual revenues in the U.S. in 2016
of approximately $2.0 billion. At the current market size of approximately $2.0 billion, a product with 5% market penetration could
achieve sales of approximately $100 million annually, assuming comparatively similar product pricing and reimbursement levels as
seen with other TRTs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The U.S. prescription testosterone
market is comprised primarily of topically applied treatments in the form of gels, solutions, and patches. Testopel&reg; and Aveed&reg;,
injectable products typically implanted directly under the skin by a physician, are also FDA-approved. AndroGel is the market-leading
TRT and is marketed by AbbVie.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>ProstaScint&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Currently, there are several FDA
approved imaging techniques for cancer in general, however there is only one SPECT-specific agent targeting prostate cancer &mdash;
ProstaScint. The other imaging methods are F18-fluorodeoxyglucose (F18-FDG), C11-Acetate, and C11-Choline. The primary advantage
of these methods is that they all use PET imaging, a technique with better resolution than SPECT. The use of PET is also a disadvantage,
however, since it uses radiolabels with short half-lives necessitating the need for a local or on-site cyclotron to generate the
labels. The half-life of fluorine-18 (F18) and of carbon-11 (C11) are approximately 110 and 20 minutes, respectively. The radiolabel
used by ProstaScint is Indium-11, with a half-life of about 2 &ndash; 3 days. This longer time period allows the radiolabel to
be made remotely and shipped to the imaging facility; however, it does use SPECT as the imaging modality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">As indicated, ProstaScint is the
only radio-imaging marker that is specific for prostate specific membrane antigen (PMSA). ProstaScint is based on radiolabeling
the antibody against PSMA, a protein express by prostate cells. This specificity for prostate cells is what allows ProstaScint
to detect the metastases of prostate cancer regardless of location. The mechanism of labeling for F18-FDG, C11-Acetate, and C11-Choline
is the intracellular accumulation of these markers in cancer cells, due to the fact that cancer cells typically have a higher
cellular metabolism than non-cancerous cells. Thus, these markers can accumulate in any type of cancer cell with a high metabolism.
Unfortunately for these technologies, prostate cancer cells tend to have a lower cellular metabolism resulting in higher false
positives attributed to hyperplasia and prostatitis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In a meta-analysis of 21 studies
evaluating accuracy, sensitivity, specificity, positive/negative predictive values, ProstaScint using combined SPECT/CT imaging
was comparable to PET/CT imaging based on F18-FDG and C11-Choline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>MiOXSYS/RedoxSYS&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">With respect to MiOXSYS competitive
offerings, there are other oxidative stress diagnostic tests available throughout the world, although none are approved in the
United States for clinical use. Diagnostic systems that are marketed for clinical use outside the United States include the FRAS
4 system (H&amp;D srl), FREE Carpe Diem (Diacron International), and the FORM and FORMPlus systems (Callegari srl). These systems
are used in both research and clinical settings but do not generate significant sales in the clinical setting. If approved in
the United States for clinical use, these systems could present competition to the MiOXSYS System. However, their testing parameters
differ significantly from MiOXSYS and would need to demonstrate clinical superiority to MiOXSYS in order to substantially detract
from MiOXSYS prescribing and sales. Additionally, to our knowledge these systems have not demonstrated clinical feasibility in
human semen or seminal plasma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Research and Development&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our strategy is to minimize our
research and development activities. When we do conduct research and development, we intend to utilize consultants with domain
experience for research, development and regulatory guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our MiOXSYS System has been developed
in conjunction with numerous medical device and diagnostic development consultants. Further, we have relationships with regulatory
consultants who are actively assisting in the development of our regulatory strategy with the FDA. To complement our internal
clinical research efforts with the MiOXSYS System, we have engaged with numerous universities around the world to identify and
develop research and clinical applications for the MiOXSYS System. Through these engagements we have access to data and analyses
that enable us to develop new uses for the MiOXSYS and RedoxSYS systems. Additionally, we have formal research agreements in place
with two prominent U.S.-based universities and one prominent European university for which we are paying a research fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Manufacturing&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our business strategy is to use
cGMP compliant contract manufacturers for the manufacture of clinical supplies as well as for commercial supplies if required
by our commercialization plans, and to transfer manufacturing responsibility to our collaboration partners when possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Natesto</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On April 22, 2016, we entered
into a license and supply agreement with Acerus pursuant to which we will pay Acerus a supply price per unit of the greater of
(i) a fixed percentage of Acerus&rsquo; cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) a low double
digit percentage of the net selling price for the first year of the agreement, that increases in each of the second and third
years and remains constant after that.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>ProstaScint&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acquired a two-year supply of ProstaScint through our asset purchase agreement with Jazz Pharmaceuticals,
which we project to last through fiscal 2018 and the first half of fiscal 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>MiOXSYS/RedoxSYS&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We have completed the technical
development of the RedoxSYS System by engaging contract development and manufacturing companies in the United States. We secured
supply and quality agreements with manufacturers for both the RedoxSYS and MiOXSYS instruments as well as the RedoxSYS and MiOXSYS
sensor strips. Both manufacturers hold long-standing ISO 13485:2003 certifications and are established medical device manufacturers.
Both manufacturers have high volume manufacturing capacity such that production volumes can be easily scaled. Both manufacturers
have been audited by our quality engineers and are fully compliant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Employees&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">As of August 15, 2017, we had
63 full-time employees and utilized the services of a number of consultants on a temporary basis. Overall, we have not experienced
any work stoppage and do not anticipate any work stoppage in the foreseeable future. None of our employees is subject to a collective
bargaining agreement. Management believes that relations with our employees are good.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Available Information </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our principal executive offices
are located at 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112 USA, and our phone number is (720)&nbsp;437-6580.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We maintain a website on the internet
at <I>http://www.aytubio.com</I>. We make available free of charge through our website, by way of a hyperlink to a third-party
site that includes filings we make with the SEC website (<I>www.sec.gov)</I>, our annual reports on Form&nbsp;10-K, quarterly
reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K and amendments to those reports electronically filed or furnished
pursuant to Section&nbsp;15(d) of the Exchange Act. The information on our website is not, and shall not be deemed to be, a part
of this Annual Report on Form&nbsp;10-K or incorporated into any other filings we make with the SEC. In addition, the public may
read and copy any materials we file with the SEC at the SEC&rsquo;s Public Reference Room at 100&nbsp;F&nbsp;Street, N.E., Washington
D.C., 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Code of Ethics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We have adopted a written code
of ethics that applies to our officers, directors and employees, including our principal executive officer and principal accounting
officer. We intend to disclose any amendments to, or waivers from, our code of ethics that are required to be publicly disclosed
pursuant to rules of the SEC by filing such amendment or waiver with the SEC. This code of ethics and business conduct can be
found in the corporate governance section of our website, <I>http://www.aytubio.com</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><A NAME="a_003"></A><B>Item&nbsp;1A.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk Factors </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Investing in our securities
includes a high degree of risk. You should consider carefully the specific factors discussed below, together with all of the other
information contained in this Annual Report. If any of the following risks actually occurs, our business, financial condition,
results of operations and future prospects would likely be materially and adversely affected. This could cause the market price
of our securities to decline and could cause you to lose all or part of your investment. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #000000"><B>Risks
Related to Our Financial Condition and Capital Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We have a limited operating
history, have incurred losses, and can give no assurance of profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a commercial-stage healthcare company with a limited
operating history. Prior to implementing our commercial strategy in the fourth calendar quarter of 2015, we did not have a focus
on profitability. As a result, we have not generated substantial revenue to date and are not profitable, and have incurred losses
in each year since our inception. Our net loss for the years ended June 30, 2017 and 2016 was $22.5 million and $28.2 million,
respectively. We have not demonstrated the ability to be a profit-generating enterprise to date. With the financing that occurred
in August 2017 of $11.8 million, we believe that we can get to cash flow break even and profitability but we still expect to incur
substantial losses during fiscal 2018. Even though we expect to have revenue growth in the next several fiscal years, it is uncertain
that the revenue growth will be significant enough to offset our expenses and generate a profit in the future. Our ability to
generate significant revenue is uncertain, and we may never achieve profitability. We have a very limited operating history on
which investors can evaluate our potential for future success. Potential investors should evaluate us in light of the expenses,
delays, uncertainties, and complications typically encountered by early-stage healthcare businesses, many of which will be beyond
our control. These risks include the following:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">uncertain
                                         market acceptance of our products and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">lack
                                         of sufficient capital;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">U.S.
                                         regulatory approval of our products and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">foreign
                                         regulatory approval of our products and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">unanticipated
                                         problems, delays, and expense relating to product development and implementation;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">lack
                                         of sufficient intellectual property;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         ability to attract and retain qualified employees;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">competition;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">technological
                                         changes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">As a result of our limited operating
history, and the increasingly competitive nature of the markets in which we compete, our historical financial data, is of limited
value in anticipating future operating expenses. Our planned expense levels will be based in part on our expectations concerning
future operations, which is difficult to forecast accurately based on our limited operating history and the recentness of the
acquisition of our products Natesto, MiOXSYS, ProstaScint and Fiera. We may be unable to adjust spending in a timely manner to
compensate for any unexpected budgetary shortfall.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We have not received any substantial
revenues from the commercialization of our current products to date and might not receive significant revenues from the commercialization
of our current products or our product candidates in the near term. Even though ProstaScint and Natesto are each an approved drug
that we are marketing, we only acquired ProstaScint in May 2015 and Natesto in April 2016. In addition, we only acquired Fiera
in May 2017 and launched our MiOXSYS device in early fiscal 2017. As a result, we have limited experience on which to base the
revenue we could expect to receive from sales of these products. To obtain revenues from our products and product candidates,
we must succeed, either alone or with others, in a range of challenging activities, including expanding markets for our existing
products and completing clinical trials of our product candidates, obtaining positive results from those clinical trials, achieving
marketing approval for those product candidates, manufacturing, marketing and selling our existing products and those products
for which we, or our collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement
for our products from private insurance or government payors. We, and our collaborators, if any, may never succeed in these activities
and, even if we do, or one of our collaborators does, we may never generate revenues that are sufficient enough for us to achieve
profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We may need to raise additional
funding, which may not be available on acceptable terms, or at all. Failure to obtain necessary capital when needed may force
us to delay, limit or terminate our product expansion and development efforts or other operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are expending resources to expand the market for Natesto, MiOXSYS and Fiera, none of which might be as
successful as we anticipate or at all and all of which might take longer and be more expensive to market than we anticipate. We
also are currently advancing our MiOXSYS device through clinical development. Developing product candidates is expensive, lengthy
and risky, and we expect to incur research and development expenses in connection with our ongoing clinical development activities
with the MiOXSYS System. As of June 30, 2017, our cash, cash equivalents and restricted cash totaling $878,000, available to fund
our operations offset by an aggregate $3.0 million in accounts payable and other and accrued liabilities. In November 2016, we
conducted a public offering of our common stock and warrants from which we received net cash proceeds of approximately $7.6 million.
We closed on a private placement of common stock, Series A preferred stock and warrants in August 2017 from which we received gross
proceeds of approximately $11.8 million. Our operating plan may change as a result of many factors currently unknown to us, and
we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other
third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements
or a combination of these approaches. In any event, we will require additional capital to continue the expansion of marketing efforts
for Natesto, ProstaScint and Fiera and to obtain regulatory approval for, and to commercialize, our current product candidate,
the MiOXSYS System. Raising funds in the current economic environment, as well our lack of operating history, may present additional
challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital
if market conditions are favorable or if we have specific strategic considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Any additional fundraising efforts
may divert our management from their day-to-day activities, which may adversely affect our ability to expand any existing product
or develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available
in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings
or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility
of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities
would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we
may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely
impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners
or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our
technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect
on our business, operating results and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If we are unable to obtain funding
on a timely basis, we may be unable to expand the market for Natesto, MiOXSYS or Fiera and/or be required to significantly curtail,
delay or discontinue one or more of our research or development programs for the MiOXSYS system, or any future product candidate
or expand our operations generally or otherwise capitalize on our business opportunities, as desired, which could materially affect
our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>If we do not obtain the
capital necessary to fund our operations, we will be unable to successfully expand the commercialization of Natesto, ProstaScint
and Fiera and to develop, obtain regulatory approval of, and commercialize, our current product candidate, the MiOXSYS System.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The expansion of marketing and
commercialization activities for our existing products and the development of pharmaceutical products, medical diagnostics and
medical devices is capital-intensive. We anticipate we may require additional financing to continue to fund our operations. Our
future capital requirements will depend on, and could increase significantly as a result of, many factors including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         costs, progress and timing of our efforts to expand the marketing of Natesto, ProstaScint
                                         and Fiera;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">progress
                                         in, and the costs of, our pre-clinical studies and clinical trials and other research
                                         and development programs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         costs of securing manufacturing arrangements for commercial production;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         scope, prioritization and number of our research and development programs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         achievement of milestones or occurrence of other developments that trigger payments under
                                         any collaboration agreements we obtain;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         costs of establishing, expanding or contracting for sales and marketing capabilities
                                         for any existing products and if we obtain regulatory clearances to market our current
                                         product candidate, the MiOXSYS system;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical
                                         trial costs under future collaboration agreements, if any; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         costs involved in filing, prosecuting, enforcing and defending patent claims and other
                                         intellectual property rights.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If funds are not available, we
may be required to delay, reduce the scope of, or eliminate one or more of our commercialization efforts or our technologies,
research or development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We will incur increased
costs associated with, and our management will need to devote substantial time and effort to, compliance with public company reporting
and other requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a public company, we incur significant legal, accounting and other expenses. In addition, the rules and
regulations of the SEC and any national securities exchange to which we may be subject in the future impose numerous requirements
on public companies, including requirements relating to our corporate governance practices, with which we will need to comply.
Further, we will continue to be required to, among other things, file annual, quarterly and current reports with respect to our
business and operating results. Based on currently available information and assumptions, we estimate that we will incur up to
approximately $500,000 in expenses on an annual basis as a direct result of the requirements of being a publicly traded company.
Our management and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company
and compliance with applicable laws and regulations, and our efforts and initiatives to comply with those requirements could be
expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>If we fail to establish
and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations
could be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting. Pursuant to Section 404 of the Sarbanes-Oxley
Act, our management conducted an assessment of the effectiveness of our internal control over financial reporting for the year
ended June 30, 2017, and concluded that such control was effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">However, if in the future we were
to conclude that our internal control over financial reporting were not effective, we cannot be certain as to the timing of completion
of our evaluation, testing and remediation actions or their effect on our operations because there is presently no precedent available
by which to measure compliance adequacy. As a consequence, we may not be able to complete any necessary remediation process in
time to meet our deadline for compliance with Section 404 of the Sarbanes-Oxley Act. Also, there can be no assurance that we will
not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section
404 of the Sarbanes-Oxley Act. The presence of material weaknesses could result in financial statement errors which, in turn,
could require us to restate our operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are unable to conclude that we have effective internal
control over financial reporting or if our independent auditors are unwilling or unable to provide us, when required, with an
attestation report on the effectiveness of internal control over financial reporting as required by Section 404 of the Sarbanes-Oxley
Act, investors may lose confidence in our operating results, our stock price could decline and we may be subject to litigation
or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley
Act, we may not be able to obtain listing on a securities exchange such as the NASDAQ Capital Market or the NYSE American, LLC.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Risks Related
to Product Development, Regulatory Approval and Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Natesto, MiOXSYS, ProstaScint
and Fiera may prove to be difficult to effectively commercialize as planned.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Various commercial, regulatory,
and manufacturing factors may impact our ability to maintain or grow revenues from sales of Natesto, MiOXSYS, ProstaScint and
Fiera. Specifically, we may encounter difficulty by virtue of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">our
                                         inability to adequately market and increase sales of any of these products;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">our
                                         inability to secure continuing prescribing of any of these products by current or previous
                                         users of the product;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">our
                                         inability to effectively transfer and scale manufacturing as needed to maintain an adequate
                                         commercial supply of these products;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">reimbursement
                                         and medical policy changes that may adversely affect the pricing, profitability or commercial
                                         appeal of Natesto, MiOXSYS, or ProstaScint; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">our
                                         inability to effectively identify and align with commercial partners outside the United
                                         States, or the inability of those selected partners to gain the required regulatory,
                                         reimbursement, and other approvals needed to enable commercial success of MiOXSYS, ProstaScint
                                         or Fiera.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We have limited experience
selling our current products as they were acquired from other companies or were recently approved for sale. As a result, we may
be unable to successfully commercialize our products and product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Despite our management&rsquo;s
extensive experience in launching and managing commercial-stage healthcare companies, we have limited marketing, sales and distribution
experience with our current products. Our ability to achieve profitability depends on attracting and retaining customers for our
current products, and building brand loyalty for Natesto, MiOXSYS, ProstaScint and Fiera. To successfully perform sales, marketing,
distribution and customer support functions, we will face a number of risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">our
                                         ability to attract and retain skilled support team, marketing staff and sales force necessary
                                         to increase the market for our approved products and to maintain market acceptance for
                                         our product candidates;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">the
                                         ability of our sales and marketing team to identify and penetrate the potential customer
                                         base; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">the
                                         difficulty of establishing brand recognition and loyalty for our products.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition, we may seek to enlist
one or more third parties to assist with sales, distribution and customer support globally or in certain regions of the world.
If we do seek to enter into these arrangements, we may not be successful in attracting desirable sales and distribution partners,
or we may not be able to enter into these arrangements on favorable terms, or at all. If our sales and marketing efforts, or those
of any third-party sales and distribution partners, are not successful, our currently approved products may not achieve increased
market acceptance and our product candidates may not gain market acceptance, which would materially impact our business and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We cannot be certain that
we will be able to obtain regulatory approval for, or successfully commercialize, any of our current or future product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We may not be able to develop
our current or any future product candidates. Our product candidates will require substantial additional clinical development,
testing, and regulatory approval before we are permitted to commence commercialization. The clinical trials of our product candidates
are, and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review and regulation
by numerous government authorities in the United States and in other countries where we intend to test and, if approved, market
any product candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate
through pre-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication.
This process can take many years and may include post-marketing studies and surveillance, which will require the expenditure of
substantial resources. Of the large number of drugs in development in the U.S., only a small percentage successfully completes
the FDA regulatory approval process and is commercialized. Accordingly, even if we are able to obtain the requisite financing
to continue to fund our development and clinical programs, we cannot assure you that any of our product candidates will be successfully
developed or commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We are not permitted to market
a product in the U.S. until we receive approval of a New Drug Application, or an NDA, for that product from the FDA, or in any
foreign countries until we receive the requisite approval from such countries. Obtaining approval of an NDA is a complex, lengthy,
expensive and uncertain process, and the FDA may delay, limit or deny approval of any product candidate for many reasons, including,
among others:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">we
                                         may not be able to demonstrate that a product candidate is safe and effective to the
                                         satisfaction of the FDA;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         results of our clinical trials may not meet the level of statistical or clinical significance
                                         required by the FDA for marketing approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA may disagree with the number, design, size, conduct or implementation of our clinical
                                         trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA may require that we conduct additional clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA may not approve the formulation, labeling or specifications of any product candidate;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         clinical research organizations, or CROs, that we retain to conduct our clinical trials
                                         may take actions outside of our control that materially adversely impact our clinical
                                         trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA may find the data from pre-clinical studies and clinical trials insufficient to demonstrate
                                         that a product candidate&rsquo;s clinical and other benefits outweigh its safety risks,
                                         such as the risk of drug abuse by patients or the public in general;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA may disagree with our interpretation of data from our pre-clinical studies and clinical
                                         trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA may not accept data generated at our clinical trial sites;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">if
                                         an NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have
                                         difficulties scheduling an advisory committee meeting in a timely manner or the advisory
                                         committee may recommend against approval of our application or may recommend that the
                                         FDA require, as a condition of approval, additional pre-clinical studies or clinical
                                         trials, limitations on approved labeling or distribution and use restrictions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as
                                         a condition of approval or post-approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA may not approve the manufacturing processes or facilities of third-party manufacturers
                                         with which we contract; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA may change its approval policies or adopt new regulations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">These same risks apply to applicable
foreign regulatory agencies from which we may seek approval for any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Any of these factors, many of
which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market any product
candidate. Moreover, because a substantial portion of our business is or may be dependent upon our product candidates, any such
setback in our pursuit of initial or additional regulatory approval would have a material adverse effect on our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>If we fail to successfully
acquire new products, we may lose market position.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Acquiring new products is an important
factor in our planned sales growth, including products that already have been developed and found market acceptance. If we fail
to identify existing or emerging consumer markets and trends and to acquire new products, we will not develop a strong revenue
source to help pay for our development activities as well as possible acquisitions. This failure would delay implementation of
our business plan, which could have a negative adverse effect on our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>If we do not secure collaborations
with strategic partners to test, commercialize and manufacture product candidates, we may not be able to successfully develop
products and generate meaningful revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We may enter into collaborations
with third parties to conduct clinical testing, as well as to commercialize and manufacture our products and product candidates.
If we are able to identify and reach an agreement with one or more collaborators, our ability to generate revenues from these
arrangements will depend on our collaborators&rsquo; abilities to successfully perform the functions assigned to them in these
arrangements. Collaboration agreements typically call for milestone payments that depend on successful demonstration of efficacy
and safety, obtaining regulatory approvals, and clinical trial results. Collaboration revenues are not guaranteed, even when efficacy
and safety are demonstrated. Further, the economic environment at any given time may result in potential collaborators electing
to reduce their external spending, which may prevent us from developing our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Even if we succeed in securing
collaborators, the collaborators may fail to develop or effectively commercialize our products or product candidates. Collaborations
involving our product candidates pose a number of risks, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">collaborators
                                         may not have sufficient resources or may decide not to devote the necessary resources
                                         due to internal constraints such as budget limitations, lack of human resources, or a
                                         change in strategic focus;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">collaborators
                                         may believe our intellectual property is not valid or is unenforceable or the product
                                         candidate infringes on the intellectual property rights of others;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">collaborators
                                         may dispute their responsibility to conduct development and commercialization activities
                                         pursuant to the applicable collaboration, including the payment of related costs or the
                                         division of any revenues;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">collaborators
                                         may decide to pursue a competitive product developed outside of the collaboration arrangement;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">collaborators
                                         may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">collaborators
                                         may delay the development or commercialization of our product candidates in favor of
                                         developing or commercializing their own or another party&rsquo;s product candidate; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">collaborators
                                         may decide to terminate or not to renew the collaboration for these or other reasons.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">As a result, collaboration agreements
may not lead to development or commercialization of our product candidates in the most efficient manner or at all. For example,
our former collaborator that licensed our former product candidate, Zertane conducted clinical trials which we believe demonstrated
efficacy in treating PE, but the collaborator undertook a merger that we believe altered its strategic focus and thereafter terminated
the collaboration agreement. The Merger also created a potential conflict with a principal customer of the acquired company, which
sells a product to treat premature ejaculation in certain European markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Collaboration agreements are generally
terminable without cause on short notice. Once a collaboration agreement is signed, it may not lead to commercialization of a
product candidate. We also face competition in seeking out collaborators. If we are unable to secure collaborations that achieve
the collaborator&rsquo;s objectives and meet our expectations, we may be unable to advance our products or product candidates
and may not generate meaningful revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We or our strategic partners
may choose not to continue an existing product or choose not to develop a product candidate at any time during development, which
would reduce or eliminate our potential return on investment for that product.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">At any time and for any reason,
we or our strategic partners may decide to discontinue the development or commercialization of a product or product candidate.
If we terminate a program in which we have invested significant resources, we will reduce the return, or not receive any return,
on our investment and we will have missed the opportunity to have allocated those resources to potentially more productive uses.
If one of our strategic partners terminates a program, we will not receive any future milestone payments or royalties relating
to that program under our agreement with that party. As an example, we discontinued the development of Zertane in June 2016 and
sold Primsol in March 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Our pre-commercial product
candidates are expected to undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable,
and for which there is a high risk of failure. If clinical trials of our product candidates fail to satisfactorily demonstrate
safety and efficacy to the FDA and other regulators, we or our collaborators may incur additional costs or experience delays in
completing, or ultimately be unable to complete, the development and commercialization of these product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Pre-clinical testing and clinical
trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any clinical
studies will be conducted as planned or completed on schedule, if at all. It may take several years to complete the pre-clinical
testing and clinical development necessary to commercialize a drug, and delays or failure can occur at any stage. Interim results
of clinical trials do not necessarily predict final results, and success in pre-clinical testing and early clinical trials does
not ensure that later clinical trials will be successful. A number of companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced clinical trials even after promising results in earlier trials and we cannot be
certain that we will not face similar setbacks. The design of a clinical trial can determine whether its results will support
approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced.
An unfavorable outcome in one or more trials would be a major set-back for that product candidate and for us. Due to our limited
financial resources, an unfavorable outcome in one or more trials may require us to delay, reduce the scope of, or eliminate one
or more product development programs, which could have a material adverse effect on our business, prospects and financial condition
and on the value of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In connection with clinical testing
and trials, we face a number of risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">a
                                         product candidate is ineffective, inferior to existing approved medicines, unacceptably
                                         toxic, or has unacceptable side effects;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">patients
                                         may die or suffer other adverse effects for reasons that may or may not be related to
                                         the product candidate being tested;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         results may not confirm the positive results of earlier testing or trials; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         results may not meet the level of statistical significance required by the FDA or other
                                         regulatory agencies to establish the safety and efficacy of the product candidate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If we do not successfully complete
pre-clinical and clinical development, we will be unable to market and sell products derived from our product candidates and generate
revenues. Even if we do successfully complete clinical trials, those results are not necessarily predictive of results of additional
trials that may be needed before an NDA may be submitted to the FDA. Although there are a large number of drugs in development
in the United States and other countries, only a small percentage result in the submission of an NDA to the FDA, even fewer are
approved for commercialization, and only a small number achieve widespread physician and consumer acceptance following regulatory
approval. If our clinical trials are substantially delayed or fail to prove the safety and effectiveness of our product candidates
in development, we may not receive regulatory approval of any of these product candidates and our business, prospects and financial
condition will be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Delays, suspensions and
terminations in any clinical trial we undertake could result in increased costs to us and delay or prevent our ability to generate
revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Human clinical trials are very
expensive, time-consuming, and difficult to design, implement and complete. Should we undertake the development of a pharmaceutical
product candidate, we would expect the necessary clinical trials to take up to 24 months to complete, but the completion of trials
for any product candidates may be delayed for a variety of reasons, including delays in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">demonstrating
                                         sufficient safety and efficacy to obtain regulatory approval to commence a clinical trial;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">reaching
                                         agreement on acceptable terms with prospective CROs and clinical trial sites;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">validating
                                         test methods to support quality testing of the drug substance and drug product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">obtaining
                                         sufficient quantities of the drug substance or device parts;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">manufacturing
                                         sufficient quantities of a product candidate;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">obtaining
                                         approval of an IND from the FDA;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">obtaining
                                         institutional review board approval to conduct a clinical trial at a prospective clinical
                                         trial site;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">determining
                                         dosing and clinical design and making related adjustments; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">patient
                                         enrollment, which is a function of many factors, including the size of the patient population,
                                         the nature of the protocol, the proximity of patients to clinical trial sites, the availability
                                         of effective treatments for the relevant disease and the eligibility criteria for the
                                         clinical trial.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The commencement and completion
of clinical trials for our product candidates may be delayed, suspended or terminated due to a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">lack
                                         of effectiveness of product candidates during clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">adverse
                                         events, safety issues or side effects relating to the product candidates or their formulation
                                         or design;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">inability
                                         to raise additional capital in sufficient amounts to continue clinical trials or development
                                         programs, which are very expensive;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         need to sequence clinical trials as opposed to conducting them concomitantly in order
                                         to conserve resources;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         inability to enter into collaborations relating to the development and commercialization
                                         of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">failure
                                         by us or our collaborators to conduct clinical trials in accordance with regulatory requirements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         inability or the inability of our collaborators to manufacture or obtain from third parties
                                         materials sufficient for use in pre-clinical studies and clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">governmental
                                         or regulatory delays and changes in regulatory requirements, policy and guidelines, including
                                         mandated changes in the scope or design of clinical trials or requests for supplemental
                                         information with respect to clinical trial results;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">failure
                                         of our collaborators to advance our product candidates through clinical development;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">delays
                                         in patient enrollment, variability in the number and types of patients available for
                                         clinical trials, and lower-than anticipated retention rates for patients in clinical
                                         trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">difficulty
                                         in patient monitoring and data collection due to failure of patients to maintain contact
                                         after treatment;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">a
                                         regional disturbance where we or our collaborative partners are enrolling patients in
                                         our clinical trials, such as a pandemic, terrorist activities or war, or a natural disaster;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">varying
                                         interpretations of our data, and regulatory commitments and requirements by the FDA and
                                         similar foreign regulatory agencies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Many of these factors may also
ultimately lead to denial of an NDA for a product candidate. If we experience delay, suspensions or terminations in a clinical
trial, the commercial prospects for the related product candidate will be harmed, and our ability to generate product revenues
will be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition, we may encounter
delays or product candidate rejections based on new governmental regulations, future legislative or administrative actions, or
changes in FDA policy or interpretation during the period of product development. If we obtain required regulatory approvals,
such approvals may later be withdrawn. Delays or failures in obtaining regulatory approvals may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">varying
                                         interpretations of data and commitments by the FDA and similar foreign regulatory agencies;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">diminishment
                                         of any competitive advantages that such product candidates may have or attain.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Furthermore, if we fail to comply
with applicable FDA and other regulatory requirements at any stage during this regulatory process, we may encounter or be subject
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">diminishment
                                         of any competitive advantages that such product candidates may have or attain;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">delays
                                         or termination in clinical trials or commercialization;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">refusal
                                         by the FDA or similar foreign regulatory agencies to review pending applications or supplements
                                         to approved applications;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">product
                                         recalls or seizures;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">suspension
                                         of manufacturing;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">withdrawals
                                         of previously approved marketing applications; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">fines,
                                         civil penalties, and criminal prosecutions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>The medical device regulatory
clearance or approval process is expensive, time consuming and uncertain, and the failure to obtain and maintain required clearances
or approvals could prevent us from broadly commercializing the MiOXSYS System for clinical use.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The MiOXSYS System is subject
to 510k clearance by the FDA prior to its marketing for commercial use in the United States, and to regulatory approvals beyond
CE marking required by certain foreign governmental entities prior to its marketing outside the United States. In addition, any
changes or modifications to a device that has received regulatory clearance or approval that could significantly affect its safety
or effectiveness, or would constitute a major change in its intended use, may require the submission of a new application for
510k clearance, pre-market approval, or foreign regulatory approvals. The 510k clearance and pre-market approval processes, as
well as the process of obtaining foreign approvals, can be expensive, time consuming and uncertain. It generally takes from four
to twelve months from submission to obtain 510k clearance, and from one to three years from submission to obtain pre-market approval;
however, it may take longer, and 510k clearance or pre-market approval may never be obtained. We have limited experience in filing
FDA applications for 510k clearance and pre-market approval. In addition, we are required to continue to comply with applicable
FDA and other regulatory requirements even after obtaining clearance or approval. There can be no assurance that we will obtain
or maintain any required clearance or approval on a timely basis, or at all. Any failure to obtain or any material delay in obtaining
FDA clearance or any failure to maintain compliance with FDA regulatory requirements could harm our business, financial condition
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>The approval process for
pharmaceutical and medical device products outside the United States varies among countries and may limit our ability to develop,
manufacture and sell our products internationally. Failure to obtain marketing approval in international jurisdictions would prevent
our product candidates from being marketed abroad.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In order to market and sell our
products in the European Union and many other jurisdictions, we, and our collaborators, must obtain separate marketing approvals
and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional
testing. We may conduct clinical trials for, and seek regulatory approval to market, our product candidates in countries other
than the United States. Depending on the results of clinical trials and the process for obtaining regulatory approvals in other
countries, we may decide to first seek regulatory approvals of a product candidate in countries other than the United States,
or we may simultaneously seek regulatory approvals in the United States and other countries. If we or our collaborators seek marketing
approval for a product candidate outside the United States, we will be subject to the regulatory requirements of health authorities
in each country in which we seek approval. With respect to marketing authorizations in Europe, we will be required to submit a
European Marketing Authorisation Application, or MAA, to the European Medicines Agency, or EMA, which conducts a validation and
scientific approval process in evaluating a product for safety and efficacy. The approval procedure varies among regions and countries
and may involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Obtaining regulatory approvals
from health authorities in countries outside the United States is likely to subject us to all of the risks associated with obtaining
FDA approval described above. In addition, marketing approval by the FDA does not ensure approval by the health authorities of
any other country, and approval by foreign health authorities does not ensure marketing approval by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Even if we, or our collaborators,
obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit
how we or they market our products, which could materially impair our ability to generate revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Even if we receive regulatory
approval for a product candidate, this approval may carry conditions that limit the market for the product or put the product
at a competitive disadvantage relative to alternative therapies. For instance, a regulatory approval may limit the indicated uses
for which we can market a product or the patient population that may utilize the product, or may be required to carry a warning
in its labeling and on its packaging. Products with black box warnings are subject to more restrictive advertising regulations
than products without such warnings. These restrictions could make it more difficult to market any product candidate effectively.
Accordingly, assuming we, or our collaborators, receive marketing approval for one or more of our product candidates, we, and
our collaborators expect to continue to expend time, money and effort in all areas of regulatory compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Any of our products and
product candidates for which we, or our collaborators, obtain marketing approval in the future could be subject to post-marketing
restrictions or withdrawal from the market and we, and our collaborators, may be subject to substantial penalties if we, or they,
fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Any of our approved products and
product candidates for which we, or our collaborators, obtain marketing approval, as well as the manufacturing processes, post
approval studies and measures, labeling, advertising and promotional activities for such products, among other things, are or
will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include
submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating
to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding
the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the
approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval,
including the FDA requirement to implement a REMS to ensure that the benefits of a drug outweigh its risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The FDA may also impose requirements
for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA
and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion
of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance
with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&rsquo; communications regarding
off-label use and if we, or our collaborators, do not market any of our product candidates for which we, or they, receive marketing
approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing.
Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription
drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state
consumer protection laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>If we do not achieve our
projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our product
candidates may be delayed, and our business will be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We sometimes estimate for planning
purposes the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives.
These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials,
the submission of regulatory filings, or commercialization objectives. From time to time, we may publicly announce the expected
timing of some of these milestones, such as the initiation or completion of an ongoing clinical trial, the initiation of other
clinical programs, receipt of marketing approval, or a commercial launch of a product. The achievement of many of these milestones
may be outside of our control. All of such milestones are based on a variety of assumptions which may cause the timing of achievement
of the milestones to vary considerably from our estimates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         available capital resources or capital constraints we experience;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         rate of progress, costs and results of our clinical trials and research and development
                                         activities, including the extent of scheduling conflicts with participating clinicians
                                         and collaborators, and our ability to identify and enroll patients who meet clinical
                                         trial eligibility criteria;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         receipt of approvals from the FDA and other regulatory agencies and the timing thereof;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">other
                                         actions, decisions or rules issued by regulators;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         ability to access sufficient, reliable and affordable supplies of compounds used in the
                                         manufacture of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         efforts of our collaborators with respect to the commercialization of our products; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         securing of, costs related to, and timing issues associated with, product manufacturing
                                         as well as sales and marketing activities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If we fail to achieve announced
milestones in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business,
prospects and results of operations may be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We rely on third parties
to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us
from successfully commercializing product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We rely, and will rely in the
future, on medical institutions, clinical investigators, contract research organizations, contract laboratories, and collaborators
to perform data collection and analysis and others to carry out our clinical trials. Our development activities or clinical trials
conducted in reliance on third parties may be delayed, suspended, or terminated if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         third parties do not successfully carry out their contractual duties or fail to meet
                                         regulatory obligations or expected deadlines;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">we
                                         replace a third party; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         quality or accuracy of the data obtained by third parties is compromised due to their
                                         failure to adhere to clinical protocols, regulatory requirements, or for other reasons.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Third party performance failures
may increase our development costs, delay our ability to obtain regulatory approval, and delay or prevent the commercialization
of our product candidates. While we believe that there are numerous alternative sources to provide these services, in the event
that we seek such alternative sources, we may not be able to enter into replacement arrangements without incurring delays or additional
costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Even if collaborators with
which we contract in the future successfully complete clinical trials of our product candidates, those product candidates may
not be commercialized successfully for other reasons.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Even if we contract with collaborators
that successfully complete clinical trials for one or more of our product candidates, those candidates may not be commercialized
for other reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">failure
                                         to receive regulatory clearances required to market them as drugs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">being
                                         subject to proprietary rights held by others;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">being
                                         difficult or expensive to manufacture on a commercial scale;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">having
                                         adverse side effects that make their use less desirable; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">failing
                                         to compete effectively with products or treatments commercialized by competitors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Any third-party manufacturers
we engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience
delays in, our product commercialization as a result of these regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The manufacturing processes and
facilities of third-party manufacturers we have engaged for our current approved products are, and any future third-party manufacturer
will be, required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the
design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices.
The FDA enforces the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could
lead to additional compliance requests that could cause delays in our product commercialization. Failure to comply with applicable
FDA requirements, or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party
manufacturers we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection,
can result in, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">administrative
                                         or judicially imposed sanctions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">injunctions
                                         or the imposition of civil penalties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">recall
                                         or seizure of the product in question;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">total
                                         or partial suspension of production or distribution;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA&rsquo;s refusal to grant pending future clearance or pre-market approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">withdrawal
                                         or suspension of marketing clearances or approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">clinical
                                         holds;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">warning
                                         letters;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">refusal
                                         to permit the export of the product in question; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">criminal
                                         prosecution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Any of these actions, in combination
or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition, a product defect
or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we
initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in
other countries have similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture
that could endanger health. Any recall would divert our management attention and financial resources, expose us to product liability
or other claims, and harm our reputation with customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We face substantial competition
from companies with considerably more resources and experience than we have, which may result in others discovering, developing,
receiving approval for, or commercializing products before or more successfully than us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We compete with companies that
design, manufacture and market already-existing and new urology and sexual wellbeing products. We anticipate that we will face
increased competition in the future as new companies enter the market with new technologies and/or our competitors improve their
current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical.
Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial
intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more
substantial experience in product marketing and new product development, greater regulatory expertise, more extensive manufacturing
capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully, we may
not generate sufficient revenue to become profitable. Our ability to compete successfully will depend largely on our ability to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><P STYLE="margin: 0">expand the market for our approved products, especially Natesto, MiOXSYS and Fiera;</P>


</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">successfully
                                         commercialize our product candidates alone or with commercial partners;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">discover
                                         and develop product candidates that are superior to other products in the market;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">obtain
                                         required regulatory approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">attract
                                         and retain qualified personnel; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">obtain
                                         patent and/or other proprietary protection for our product candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Established pharmaceutical companies
devote significant financial resources to discovering, developing or licensing novel compounds that could make our products and
product candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines before
us. Other companies are or may become engaged in the discovery of compounds that may compete with the product candidates we are
developing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Natesto competes in a large, growing
market. The U.S. prescription testosterone market is comprised primarily of topically applied treatments in the form of gels,
solutions, and patches. Testopel&reg; and Aveed&reg;, injectable products typically implanted directly under the skin by a physician,
are also FDA-approved. AndroGel is the market-leading TRT and is marketed by AbbVie.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">For the MiOXSYS System and ProstaScint,
we compete with companies that design, manufacture and market already existing and new in-vitro diagnostics and diagnostic imaging
systems and radio-imaging agents for cancer detection. Additionally, with respect to Fiera, we compete with numerous companies
who produce sexual wellbeing related products. There are any number of products available on the market that could compete with
Fiera.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We anticipate that we will face
increased competition in the future as new companies enter the market with new technologies and our competitors improve their
current products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical.
Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial
intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more
substantial experience in new product development, greater regulatory expertise, more extensive manufacturing capabilities and
the distribution channels to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient
revenue to become profitable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Any new product we develop or
commercialize that competes with a currently-approved product must demonstrate compelling advantages in efficacy, convenience,
tolerability and/or safety in order to address price competition and be commercially successful. If we are not able to compete
effectively against our current and future competitors, our business will not grow and our financial condition and operations
will suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Government restrictions
on pricing and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact our ability
to generate revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The continuing efforts of the
government, insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of
health care may adversely affect one or more of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         or our collaborators&rsquo; ability to set a price we believe is fair for our approved
                                         products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         ability to generate revenue from our approved products and achieve profitability; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         availability of capital.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The 2010 enactments of the Patient
Protection and Affordable Care Act, or PPACA, and the Health Care and Education Reconciliation Act, or the Health Care Reconciliation
Act, significantly impacted the provision of, and payment for, health care in the United States. Various provisions of these laws
are designed to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide health
care benefits, prohibit denials of coverage due to pre-existing conditions, establish health insurance exchanges, and provide
additional support for medical research. Amendments to the PPACA and/or the Health Care Reconciliation Act, as well as new legislative
proposals to reform healthcare and government insurance programs, along with the trend toward managed healthcare in the United
States, could influence the purchase of medicines and medical devices and reduce demand and prices for our products and product
candidates, if approved. This could harm our or our collaborators&rsquo; ability to market any approved products and generate
revenues. As we expect to receive significant revenues from reimbursement of our Natesto and ProstaScint products by commercial
third-party payors and government payors, cost containment measures that health care payors and providers are instituting and
the effect of further health care reform could significantly reduce potential revenues from the sale of any of our products and
product candidates approved in the future, and could cause an increase in our compliance, manufacturing, or other operating expenses.
In addition, in certain foreign markets, the pricing of prescription drugs and devices is subject to government control and reimbursement
may in some cases be unavailable. We believe that pricing pressures at the federal and state level, as well as internationally,
will continue and may increase, which may make it difficult for us to sell any approved product at a price acceptable to us or
any of our future collaborators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition, in some foreign countries,
the proposed pricing for a drug or medical device must be approved before it may be lawfully marketed. The requirements governing
pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict
the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices
of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt
a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. A member
state may require that physicians prescribe the generic version of a drug instead of our approved branded product. There can be
no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any of our products or product candidates. Historically, pharmaceutical products launched
in the European Union do not follow price structures of the United States and generally tend to have significantly lower prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Our financial results will
depend on the acceptance among hospitals, third-party payors and the medical community of our products and product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our future success depends on
the acceptance by our target customers, third-party payors and the medical community that our products and product candidates
are reliable, safe and cost-effective. Many factors may affect the market acceptance and commercial success of our products and
product candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         ability to convince our potential customers of the advantages and economic value our
                                         products and product candidates over existing technologies and products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         relative convenience and ease of our products and product candidates over existing technologies
                                         and products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         introduction of new technologies and competing products that may make our products and
                                         product candidates less attractive for our target customers;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         success in training medical personnel on the proper use of our products and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         willingness of third-party payors to reimburse our target customers that adopt our products
                                         and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         acceptance in the medical community of our products and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         extent and success of our marketing and sales efforts; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">general
                                         economic conditions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>If third-party payors do
not reimburse our customers for the products we sell or if reimbursement levels are set too low for us to sell one or more of
our products at a profit, our ability to sell those products and our results of operations will be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">While Natesto and ProstaScint
are already FDA-approved and generating revenues in the U.S., they may not receive, or continue to receive, physician or hospital
acceptance, or they may not maintain adequate reimbursement from third party payors. Additionally, even if one of our product
candidates is approved and reaches the market, the product may not achieve physician or hospital acceptance, or it may not obtain
adequate reimbursement from third party payors. In the future, we might possibly sell other product candidates to target customers
substantially all of whom receive reimbursement for the health care services they provide to their patients from third-party payors,
such as Medicare, Medicaid, other domestic and foreign government programs, private insurance plans and managed care programs.
Reimbursement decisions by particular third-party payors depend upon a number of factors, including each third-party payor&rsquo;s
determination that use of a product is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">a
                                         covered benefit under its health plan;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">appropriate
                                         and medically necessary for the specific indication;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">cost
                                         effective; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">neither
                                         experimental nor investigational.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Third-party payors may deny reimbursement
for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods,
as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse
for procedures and devices deemed to be experimental.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Obtaining coverage and reimbursement
approval for a product from each government or third-party payor is a time consuming and costly process that could require us
to provide supporting scientific, clinical and cost-effectiveness data for the use of our potential product to each government
or third-party payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement.
In addition, eligibility for coverage does not imply that any product will be covered and reimbursed in all cases or reimbursed
at a rate that allows our potential customers to make a profit or even cover their costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Third-party payors are increasingly
attempting to contain health care costs by limiting both coverage and the level of reimbursement for medical products and services.
Levels of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party
payors may adversely affect the demand for and reimbursement available for any product or product candidate, which in turn, could
negatively impact pricing. If our customers are not adequately reimbursed for our products, they may reduce or discontinue purchases
of our products, which would result in a significant shortfall in achieving revenue expectations and negatively impact our business,
prospects and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Manufacturing risks and
inefficiencies may adversely affect our ability to produce our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">As part of the acquisition of
ProstaScint from Jazz Pharmaceuticals, we terminated the relationship with the third-party manufacturer of ProstaScint. We have
initiated the process of transferring the manufacturing to Biovest International, which we believe is a qualified manufacturer
and with whom we have entered into a Master Services Agreement. Although this contract is currently on hold as we evaluate our
strategic options for the ProstaScint product. In the event that this manufacturing transfer does not occur or we do not find
a replacement manufacturer by the time our current inventory expires, which could adversely impact our continued sales of ProstaScint
or its disposition should we elect to do so, we may not be able to supply sufficient quantities and on a timely basis, while maintaining
product quality, acceptable manufacturing costs and complying with regulatory requirements, such as quality system regulations.
In addition, we expect to engage third parties to manufacture components of the MiOXSYS and RedoxSYS systems. We have an agreement
for supplies of Natesto with Acerus, from whom we license Natesto. We have an agreement with a third party manufacturer for our
Fiera product as well. For any future product, we expect to use third-party manufacturers because we do not have our own manufacturing
capabilities. In determining the required quantities of any product and the manufacturing schedule, we must make significant judgments
and estimates based on inventory levels, current market trends and other related factors. Because of the inherent nature of estimates
and our limited experience in marketing our current products, there could be significant differences between our estimates and
the actual amounts of product we require. If we do not effectively maintain our supply agreements for Natesto and Fiera, we will
face difficulty finding replacement suppliers, which could harm sales of those products. If we do not effectively transition sites
with our manufacturing and development partners to enable to production scale of ProstaScint, or if we do not secure collaborations
with manufacturing and development partners to enable production to scale of the MiOXSYS System, we may not be successful in selling
ProstaScint or in commercializing the MiOXSYS System in the event we receive regulatory approval of the MiOXSYS System. If we
fail in similar endeavors for future products, we may not be successful in establishing or continuing the commercialization of
our products and product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Reliance on third-party manufacturers
entails risks to which we would not be subject if we manufactured these components ourselves, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">reliance
                                         on third parties for regulatory compliance and quality assurance;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">possible
                                         breaches of manufacturing agreements by the third parties because of factors beyond our
                                         control;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">possible
                                         regulatory violations or manufacturing problems experienced by our suppliers; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">possible
                                         termination or non-renewal of agreements by third parties, based on their own business
                                         priorities, at times that are costly or inconvenient for us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Further, if we are unable to secure
the needed financing to fund our internal operations, we may not have adequate resources required to effectively and rapidly transition
our third party manufacturing. We may not be able to meet the demand for our products if one or more of any third-party manufacturers
is unable to supply us with the necessary components that meet our specifications. It may be difficult to find alternate suppliers
for any of our products or product candidates in a timely manner and on terms acceptable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Any third-party manufacturers
we engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience
delays in, our product commercialization as a result of these regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The manufacturing processes and
facilities of third-party manufacturers we engage for our current and any future FDA-approved products are required to comply
with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production,
control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through
periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests
that could cause delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery
of previously unknown problems with the manufacturing processes and facilities of third-party manufacturers we engage, including
the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">administrative
                                         or judicially imposed sanctions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">injunctions
                                         or the imposition of civil penalties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">recall
                                         or seizure of the product in question;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">total
                                         or partial suspension of production or distribution;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         FDA&rsquo;s refusal to grant pending future clearance or pre-market approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">withdrawal
                                         or suspension of marketing clearances or approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">clinical
                                         holds;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">warning
                                         letters;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">refusal
                                         to permit the export of the product in question; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">criminal
                                         prosecution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Any of these actions, in combination
or alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition, a product defect
or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we
initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in
other countries have similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture
that could endanger health. Any recall would divert our management attention and financial resources, expose us to product liability
or other claims, and harm our reputation with customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Our future growth depends,
in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks
and uncertainties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our future profitability will
depend, in part, on our ability to commercialize our products and product candidates in foreign markets for which we intend to
primarily rely on collaboration with third parties. If we commercialize our products or product candidates in foreign markets,
we would be subject to additional risks and uncertainties, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         inability to directly control commercial activities because we are relying on third parties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         burden of complying with complex and changing foreign regulatory, tax, accounting and
                                         legal requirements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">different
                                         medical practices and customs in foreign countries affecting acceptance in the marketplace;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">import
                                         or export licensing requirements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">longer
                                         accounts receivable collection times;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">longer
                                         lead times for shipping;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">language
                                         barriers for technical training;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">reduced
                                         protection of intellectual property rights in some foreign countries, and related prevalence
                                         of generic alternatives to our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">foreign
                                         currency exchange rate fluctuations;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         customers&rsquo; ability to obtain reimbursement for our products in foreign markets;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         interpretation of contractual provisions governed by foreign laws in the event of a contract
                                         dispute.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Foreign sales of our products
or product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability,
trade restrictions and changes in tariffs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We are subject to various
regulations pertaining to the marketing of our approved products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We are subject to various federal
and state laws pertaining to healthcare fraud and abuse, including prohibitions on the offer of payment or acceptance of kickbacks
or other remuneration for the purchase of our products, including inducements to potential patients to request our products and
services. Additionally, any product promotion educational activities, support of continuing medical education programs, and other
interactions with health-care professionals must be conducted in a manner consistent with the FDA regulations and the Anti-Kickback
Statute. The Anti-Kickback Statute prohibits persons or entities from knowingly and willfully soliciting, receiving, offering
or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending,
or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and
Medicaid programs. Violations of the Anti-Kickback Statute can also carry potential federal False Claims Act liability. Additionally,
many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients
for healthcare items or services reimbursed by any third party payer, not only the Medicare and Medicaid programs, and do not
contain identical safe harbors. These and any new regulations or requirements may be difficult and expensive for us to comply
with, may adversely impact the marketing of our existing products or delay introduction of our product candidates, which may have
a material adverse effect on our business, operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Our products and product
candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile
of an approved label, or result in significant negative consequences following marketing approval, if any.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Undesirable side effects caused
by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result
in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Further, if a product candidate
receives marketing approval and we or others identify undesirable side effects caused by the product after the approval, or if
drug abuse is determined to be a significant problem with an approved product, a number of potentially significant negative consequences
could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">regulatory
                                         authorities may withdraw or limit their approval of the product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">regulatory
                                         authorities may require the addition of labeling statements, such as a &ldquo;Black Box
                                         warning&rdquo; or a contraindication;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">we
                                         may be required to change the way the product is distributed or administered, conduct
                                         additional clinical trials or change the labeling of the product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">we
                                         may decide to remove the product from the marketplace;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">we
                                         could be sued and held liable for injury caused to individuals exposed to or taking the
                                         product; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         reputation may suffer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Any of these events could prevent
us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs
of commercializing an affected product or product candidates and significantly impact our ability to successfully commercialize
or maintain sales of our product or product candidates and generate revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Natesto contains, and future
other product candidates may contain, controlled substances, the manufacture, use, sale, importation, exportation, prescribing
and distribution of which are subject to regulation by the DEA.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Natesto, which is approved by
the FDA, is regulated by the DEA as a Schedule III controlled substance. Before any commercialization of any product candidate
that contains a controlled substance, the DEA will need to determine the controlled substance schedule, taking into account the
recommendation of the FDA. This may be a lengthy process that could delay our marketing of a product candidate and could potentially
diminish any regulatory exclusivity periods for which we may be eligible. Natesto is, and our other product candidates may, if
approved, be regulated as &ldquo;controlled substances&rdquo; as defined in the Controlled Substances Act of 1970, or CSA, and
the implementing regulations of the DEA, which establish registration, security, recordkeeping, reporting, storage, distribution,
importation, exportation, inventory, quota and other requirements administered by the DEA. These requirements are applicable to
us, to our third-party manufacturers and to distributors, prescribers and dispensers of our product candidates. The DEA regulates
the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials
used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. A number of
states and foreign countries also independently regulate these drugs as controlled substances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The DEA regulates controlled substances
as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not
be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II
substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such
substances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Natesto is regulated by the DEA
as a Schedule III controlled substance. Consequently, the manufacturing, shipping, storing, selling and using of the products
are subject to a high degree of regulation. Also, distribution, prescribing and dispensing of these drugs are highly regulated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Annual registration is required
for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific
to the particular location, activity and controlled substance schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Because of their restrictive nature,
these laws and regulations could limit commercialization of our product candidates containing controlled substances. Failure to
comply with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and
distribution activities, consent decrees, criminal and civil penalties and state actions, among other consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>If testosterone replacement
therapies are found, or are perceived, to create health risks, our ability to sell Natesto could be materially adversely affected
and our business could be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Recent publications have suggested
potential health risks associated with testosterone replacement therapy, such as increased cardiovascular disease risk, including
increased risk of heart attack or stroke, fluid retention, sleep apnea, breast tenderness or enlargement, increased red blood
cells, development of clinical prostate disease, including prostate cancer, and the suppression of sperm production. Prompted
by these events, the FDA held a T-class Advisory Committee meeting on September 17, 2014 to discuss this topic further. The FDA
has also asked health care professionals and patients to report side effects involving prescription testosterone products to the
agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">At the T-class Advisory Committee
meeting held on September 17, 2014, the Advisory Committee discussed (i) the identification of the appropriate patient population
for whom testosterone replacement therapy should be indicated and (ii) the potential risk of major adverse cardiovascular events,
defined as non-fatal stroke, non-fatal myocardial infarction and cardiovascular death associated with testosterone replacement
therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">At the meeting, the Advisory Committee
voted that the FDA should require sponsors of testosterone products to conduct a post marketing study (e.g. observational study
or controlled clinical trial) to further assess the potential cardiovascular risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">It is possible that the FDA&rsquo;s
evaluation of this topic and further studies on the effects of testosterone replacement therapies could demonstrate the risk of
major adverse cardiovascular events or other health risks or could impose requirements that impact the marketing and sale of Natesto,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">mandate
                                         that certain warnings or precautions be included in our product labeling;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">require
                                         that our product carry a &ldquo;black box warning&rdquo;; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">limit
                                         use of Natesto to certain populations, such as men without specified conditions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Demonstrated testosterone replacement
therapy safety risks, as well as negative publicity about the risks of hormone replacement therapy, including testosterone replacement,
could hurt sales of and impair our ability to successfully relaunch Natesto, which could have a materially adverse impact on our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>FDA action regarding testosterone
replacement therapies could add to the cost of producing and marketing Natesto.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The FDA is requiring post-marketing
safety studies for all testosterone replacement therapies approved in the U.S. to assess long-term cardiovascular events related
to testosterone use. Depending on the total cost and structure of the FDA&rsquo;s proposed safety studies there may be a substantial
cost associated with conducting these studies. Pursuant to our license agreement with Acerus Pharmaceuticals, Acerus is obligated
to reimburse us for the entire cost of any studies required for Natesto by the FDA. However, in the event that Acerus is not able
to reimburse us for the cost of any required safety studies, we may be forced to incur this cost, which could have a material
adverse impact on our business and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Our approved products may
not be accepted by physicians, patients, or the medical community in general.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Even if the medical community
accepts a product as safe and efficacious for its indicated use, physicians may choose to restrict the use of the product if we
or any collaborator is unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors,
our product is preferable to any existing medicines or treatments. We cannot predict the degree of market acceptance of any of
our approved products, which will depend on a number of factors, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         efficacy and safety of the product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         approved labeling for the product and any required warnings;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         advantages and disadvantages of the product compared to alternative treatments;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         and any collaborator&rsquo;s ability to educate the medical community about the safety
                                         and effectiveness of the product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         reimbursement policies of government and third-party payors pertaining to the product;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         market price of our product relative to competing treatments.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We may use hazardous chemicals
and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could
be time consuming and costly.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our research and development processes
may involve the controlled use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risk
of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination
that results from our use or the use by third parties of these materials, and our liability may exceed any insurance coverage
and our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal
of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human
health and safety matters. Compliance with environmental laws and regulations may be expensive and may impair our research and
development efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal
fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve
and maintain compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations
or any changes in the way existing and future laws and regulations are interpreted and enforced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Intellectual
Property Risks Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Our ability to compete may
decline if we do not adequately protect our proprietary rights or if we are barred by the patent rights of others.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our commercial success depends
on obtaining and maintaining proprietary rights to our products and product candidates as well as successfully defending these
rights against third-party challenges. We will only be able to protect our products and product candidates from unauthorized use
by third parties to the extent that valid and enforceable patents, or effectively protected trade secrets, cover them. Our ability
to obtain patent protection for our products and product candidates is uncertain due to a number of factors, including that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">we
                                         may not have been the first to make the inventions covered by pending patent applications
                                         or issued patents;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">we
                                         may not have been the first to file patent applications for our products and product
                                         candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">others
                                         may independently develop identical, similar or alternative products, compositions or
                                         devices and uses thereof;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         disclosures in patent applications may not be sufficient to meet the statutory requirements
                                         for patentability;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">any
                                         or all of our pending patent applications may not result in issued patents;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">we
                                         may not seek or obtain patent protection in countries that may eventually provide us
                                         a significant business opportunity;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">any
                                         patents issued to us may not provide a basis for commercially viable products, may not
                                         provide any competitive advantages, or may be successfully challenged by third parties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         compositions, devices and methods may not be patentable;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">others
                                         may design around our patent claims to produce competitive products which fall outside
                                         of the scope of our patents; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">others
                                         may identify prior art or other bases which could invalidate our patents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Even if we have or obtain patents
covering our products and product candidates, we may still be barred from making, using and selling them because of the patent
rights of others. Others may have filed, and in the future may file, patent applications covering products that are similar or
identical to ours. There are many issued U.S. and foreign patents relating to chemical compounds, therapeutic products, diagnostic
devices, personal care products and devices and some of these relate to our products and product candidates. These could materially
affect our ability to sell our products and develop our product candidates. Because patent applications can take many years to
issue, there may be currently pending applications unknown to us that may later result in issued patents that our products and
product candidates may infringe. These patent applications may have priority over patent applications filed by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Obtaining and maintaining a patent
portfolio entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity
fees, various other governmental fees on patents and/or applications due in several stages over the lifetime of patents and/or
applications, as well as the cost associated with complying with numerous procedural provisions during the patent application
process. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations
in which failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment
or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive
position could suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Legal actions to enforce our patent
rights can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be
unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may
not choose to pursue litigation or other actions against those that have infringed on our patents, or used them without authorization,
due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual
property rights successfully, our competitive position could suffer, which could harm our business, prospects, financial condition
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Pharmaceutical and medical
device patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us,
could negatively impact our patent position.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The patent positions of pharmaceutical
and medical device companies can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth
of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine, and are often
affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The
standards of the United States Patent and Trademark Office, or USPTO, are sometimes uncertain and could change in the future.
Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated
or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be
subject to re-examination proceedings, post-grant review and/or inter partes review in the USPTO. Foreign patents may be subject
to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent
or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application.
In addition, such interference, re-examination, post-grant review, inter partes review and opposition proceedings may be costly.
Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition, changes in or different
interpretations of patent laws in the United States and foreign countries may permit others to use our discoveries or to develop
and commercialize our technology and products and product candidates without providing any compensation to us, or may limit the
number of patents or claims we can obtain. The laws of some countries do not protect intellectual property rights to the same
extent as U.S. laws and those countries may lack adequate rules and procedures for defending our intellectual property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If we fail to obtain and maintain
patent protection and trade secret protection of our products and product candidates, we could lose our competitive advantage
and competition we face would increase, reducing any potential revenues and adversely affecting our ability to attain or maintain
profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Developments in patent law
could have a negative impact on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">From time to time, the United
States Supreme Court, other federal courts, the United States Congress or the USPTO may change the standards of patentability
and any such changes could have a negative impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition, the Leahy-Smith America
Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent
law. These changes include a transition from a &ldquo;first-to-invent&rdquo; system to a &ldquo;first-to-file&rdquo; system, changes
the way issued patents are challenged, and changes the way patent applications are disputed during the examination process. These
changes may favor larger and more established companies that have greater resources to devote to patent application filing and
prosecution. The USPTO has developed regulations and procedures to govern the full implementation of the America Invents Act,
and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file
provisions, became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may
affect our ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact
the America Invents Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents
based on our discoveries and our ability to enforce or defend any patents that may issue from our patent applications, all of
which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>If we are unable to protect
the confidentiality of our trade secrets, our business and competitive position would be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition to patent protection,
because we operate in the highly technical field of discovery and development of therapies and medical devices, we rely in part
on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult
to protect. We expect to enter into confidentiality and intellectual property assignment agreements with our employees, consultants,
outside scientific and commercial collaborators, sponsored researchers, and other advisors. These agreements generally require
that the other party keep confidential and not disclose to third parties all confidential information developed by the party or
made known to the party by us during the course of the party&rsquo;s relationship with us. These agreements also generally provide
that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these
agreements may not be honored and may not effectively assign intellectual property rights to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition to contractual measures,
we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such
measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized
access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant
from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not
provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated
a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside
the United States may be less willing to protect trade secrets. Trade secrets may be independently developed by others in a manner
that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were
to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position
could be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We may not be able to enforce
our intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The laws of some foreign countries
do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered
significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems
of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property
protection, especially those relating to pharmaceuticals and medical devices. This could make it difficult for us to stop the
infringement of some of our patents, if obtained, or the misappropriation of our other intellectual property rights. For example,
many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition,
many countries limit the enforceability of patents against third parties, including government agencies or government contractors.
In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country
basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent
protection in certain countries, and we will not have the benefit of patent protection in such countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Proceedings to enforce our patent
rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our
business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition,
changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate
protection for our technology and the enforcement of intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Third parties may assert
ownership or commercial rights to inventions we develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Third parties may in the future
make claims challenging the inventorship or ownership of our intellectual property. We have or expect to have written agreements
with collaborators that provide for the ownership of intellectual property arising from our collaborations. These agreements provide
that we must negotiate certain commercial rights with collaborators with respect to joint inventions or inventions made by our
collaborators that arise from the results of the collaboration. In some instances, there may not be adequate written provisions
to address clearly the resolution of intellectual property rights that may arise from a collaboration. If we cannot successfully
negotiate sufficient ownership and commercial rights to the inventions that result from our use of a third-party collaborator&rsquo;s
materials where required, or if disputes otherwise arise with respect to the intellectual property developed with the use of a
collaborator&rsquo;s samples, we may be limited in our ability to capitalize on the market potential of these inventions. In addition,
we may face claims by third parties that our agreements with employees, contractors, or consultants obligating them to assign
intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which
could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability
to capture the commercial value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are
not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual
property. Either outcome could have an adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Third parties may assert
that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We might employ individuals who
were previously employed at universities or other biopharmaceutical or medical device companies, including our competitors or
potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or
know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors
have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information,
of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending
any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even
if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management
and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>A dispute concerning the
infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and costly,
and an unfavorable outcome could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">There is significant litigation
in the pharmaceutical and medical device industries regarding patent and other intellectual property rights. While we are not
currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may
be exposed to future litigation by third parties based on claims that our products or product candidates infringe the intellectual
property rights of others. If our development and commercialization activities are found to infringe any such patents, we may
have to pay significant damages or seek licenses to such patents. A patentee could prevent us from using the patented drugs, compositions
or devices. We may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets, or to determine
the scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel or consultants formerly
employed by other companies involved in one or more areas similar to the activities conducted by us. Either we or these individuals
may be subject to allegations of trade secret misappropriation or other similar claims as a result of prior affiliations. If we
become involved in litigation, it could consume a substantial portion of our managerial and financial resources, regardless of
whether we win or lose. We may not be able to afford the costs of litigation. Any adverse ruling or perception of an adverse ruling
in defending ourselves against these claims could have a material adverse impact on our cash position and stock price. Any legal
action against us or our collaborators could lead to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">payment
                                         of damages, potentially treble damages, if we are found to have willfully infringed a
                                         party&rsquo;s patent rights;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">injunctive
                                         or other equitable relief that may effectively block our ability to further develop,
                                         commercialize, and sell products; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">we
                                         or our collaborators having to enter into license arrangements that may not be available
                                         on commercially acceptable terms, if at all, all of which could have a material adverse
                                         impact on our cash position and business, prospects and financial condition. As a result,
                                         we could be prevented from commercializing our products and product candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #000000"><B>Risks
Related to Our Organization, Structure and Operation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We intend to acquire, through
asset purchases or in-licensing, businesses or products, or form strategic alliances, in the future, and we may not realize the
intended benefits of such acquisitions or alliances.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We intend to acquire, through
asset purchases or in-licensing, additional businesses or products, form strategic alliances and/or create joint ventures with
third parties that we believe will complement or augment our existing business. If we acquire businesses or assets with promising
markets or technologies, we may not be able to realize the benefit of acquiring such businesses or assets if we are unable to
successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing,
manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from
realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition or alliance,
we will achieve the expected synergies to justify the transaction. These risks apply to our acquisition of ProstaScint in May
2015, Natesto in April 2016 and Fiera in May 2017. As an example, we acquired Primsol in October 2015, but sold it in March 2017.
Depending on the success or lack thereof of any of our existing or future acquired products and product candidates, we might seek
to out-license, sell or otherwise dispose of any of those products or product candidates, which could adversely impact our operations
if the dispositions triggers a loss, accounting charge or other negative impact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>In fiscal 2017, the great
majority of our net revenue and gross accounts receivable were due to three significant customers, the loss of which could materially
and adversely affect our results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">During fiscal 2017 and fiscal
2016, three customers accounted for 74% and one customer that accounted for 86%, respectively, of our net revenue. At June 30,
2017 and 2016, the same customers accounted for 60% and 69%, respectively, of our gross accounts receivable. Although we expect
to increase revenue and not be as reliant on only a few customers, at least for fiscal 2018, and perhaps beyond, the loss of any
of these customers could have a material adverse effect on our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We will need to develop
and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our
operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">As of June 30, 2017, we had 60
full-time employees, and in connection with being a public company, we expect to continue to increase our number of employees
and the scope of our operations. To manage our anticipated development and expansion, we must continue to implement and improve
our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified
personnel. Also, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities
and devote a substantial amount of time to managing these development activities. Due to our limited resources, we may not be
able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result
in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and
reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may
divert financial resources from other projects, such as the planned expanded commercialization of our approved products and the
development of our product candidates. If our management is unable to effectively manage our expected development and expansion,
our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not
be able to implement our business strategy. Our future financial performance and our ability to expand the market for our approved
products and develop our product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively
manage the future development and expansion of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;<B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We depend on key personnel
and attracting qualified management personnel and our business could be harmed if we lose personnel and cannot attract new personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our success depends to a significant
degree upon the technical and management skills of our directors, officers and key personnel. Any of our directors could resign
from our board at any time and for any reason. Although our executive officers Joshua Disbrow, Jarrett Disbrow and Gregory Gould
have employment agreements, the existence of an employment agreement does not guarantee the retention of the executive officer
for any period of time, and each agreement obligates us to pay the officer lump sum severance of two years of salary if we terminate
him without cause, as defined in the agreement, which could hurt our liquidity. The loss of the services of any of these individuals
would likely have a material adverse effect on us. Our success also will depend upon our ability to attract and retain additional
qualified management, marketing, technical, and sales executives and personnel. We do not maintain key person life insurance for
any of our officers or key personnel. The loss of any of our directors or key executives, or the failure to attract, integrate,
motivate, and retain additional key personnel could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We compete for such personnel,
including directors, against numerous companies, including larger, more established companies with significantly greater financial
resources than we possess. There can be no assurance that we will be successful in attracting or retaining such personnel, and
the failure to do so could have a material adverse effect on our business, prospects, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Product liability and other
lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The risk that we may be sued on
product liability claims is inherent in the development and commercialization of pharmaceutical, medical device and personal care
products and devices. Side effects of, or manufacturing defects in, products that we develop and commercialized could result in
the deterioration of a patient&rsquo;s condition, injury or even death. Once a product is approved for sale and commercialized,
the likelihood of product liability lawsuits increases. Claims may be brought by individuals seeking relief for themselves or
by individuals or groups seeking to represent a class. These lawsuits may divert our management from pursuing our business strategy
and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities
and may be forced to limit or forgo further commercialization of the affected products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We may be subject to legal or
administrative proceedings and litigation other than product liability lawsuits which may be costly to defend and could materially
harm our business, financial condition and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Although we maintain general liability,
clinical trial liability and product liability insurance, this insurance may not fully cover potential liabilities. In addition,
inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential
product or other legal or administrative liability claims could prevent or inhibit the commercial production and sale of any of
our products and product candidates that receive regulatory approval, which could adversely affect our business. Product liability
claims could also harm our reputation, which may adversely affect our collaborators&rsquo; ability to commercialize our products
successfully.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Our internal computer systems,
or those of our third-party contractors or consultants, may fail or suffer security breaches, which could result in a material
disruption of our product development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Despite the implementation of
security measures, our internal computer systems and those of our third-party contractors and consultants are vulnerable to damage
from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While
we do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were
to occur and cause interruptions in our operations, it could result in a loss of clinical trial data for our product candidates
which could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the
data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other
data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary
information, we could incur liabilities and the further development of our product candidates could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Our ability to use our net
operating loss carryforwards and certain other tax attributes may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">As of June 30, 2017, we had federal
net operating loss carryforwards of approximately $42.3 million. The available net operating losses, if not utilized to offset
taxable income in future periods, will begin to expire in 2032 and will completely expire in 2036. Under the Internal Revenue
Code of 1986, as amended (the &ldquo;Code&rdquo;) and the regulations promulgated thereunder, including, without limitation, the
consolidated income tax return regulations, various corporate changes could limit our ability to use our net operating loss carryforwards
and other tax attributes (such as research tax credits) to offset our income. Because Ampio&rsquo;s equity ownership interest
in our company fell to below 80% in January 2016, we were deconsolidated from Ampio&rsquo;s consolidated federal income tax group.
As a result, certain of our net operating loss carryforwards may not be available to us and we may not be able to use them to
offset our U.S. federal taxable income. As a consequence of the deconsolidation, it is possible that certain other tax attributes
and benefits resulting from U.S. federal income tax consolidation may no longer be available to us. Our company and Ampio do not
have a tax sharing agreement that could mitigate the loss of net operating losses and other tax attributes resulting from the
deconsolidation or our incurrence of liability for the taxes of other members of the consolidated group by reason of the joint
and several liability of group members. In addition to the deconsolidation risk, an &ldquo;ownership change&rdquo; (generally
a 50% change (by value) in equity ownership over a three-year period) under Section 382 of the Code could limit our ability to
offset, post-change, our U.S. federal taxable income. Section 382 of the Code imposes an annual limitation on the amount of post-ownership
change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized
built-in losses. We believe that the August 2017 financing created over a 50% change in our equity ownership so our current tax
loss carryforward will be limited in the future. Either the deconsolidation or the ownership change scenario could result in increased
future tax liability to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Our outstanding warrants
may result in dilution to our stockholders and may impede our ability to raise equity capital.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The exercise of some or all of our outstanding warrants to purchase our common stock may dilute the ownership
interests of existing stockholders. In particular, on August 15, 2017, we had outstanding warrants to purchase up to an aggregate
of 6,600,714 shares. Included in these warrants are warrants that we issued in August 2017 to purchase up to an aggregate of 5,919,998
shares of common stock (the August 2017 warrants), with a current exercise price of $3.60 per share, that contain certain price
adjustment and anti-dilution provisions. Until such time as our common stock is listed on any NASDAQ or NYSE exchange, these anti-dilution
provisions may be triggered upon any future issuance by us of securities convertible into shares of our common stock or any rights,
warrants or options to purchase shares of our common stock at a price per share below the then-exercise price of the warrants,
subject to some exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">To the extent that these anti-dilution
provisions are triggered in the future, we would be required to reduce the exercise price of all of the warrants on a full-ratchet
basis, which would have a dilutive effect on our stockholders. In addition, any sales in the public market of the shares of our
common stock issuable upon such exercise could adversely affect prevailing market prices of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Furthermore, the existence of
these August 2017 warrants may encourage short selling by market participants because the anticipated exercise of such warrants
for shares of our common stock could depress the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The anti-dilution provisions of
the August 2017 warrants also may impede our ability to raise equity capital in the future due to the limitation on issuing any
common stock or securities convertible into common stock at a price less than $3.60 per share. On August 22, 2017, the closing
price of our common stock as reported on the OTCQX was $4.00. Should we be unable to list our common stock on any NASDAQ or NYSE
exchange and should our common stock price remain at or near that level, any equity financing in the future may be too onerous
due to the anti-dilution protection afforded the August 2017 warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Several stockholders potentially
own a significant percentage of our stock and could be able to exert significant control over matters subject to stockholder approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At August 15, 2017, eight entities who invested in our August 2017 common and preferred stock and warrant
financing own common and/or preferred stock and warrants that potentially would enable them to beneficially own in excess of 4.99%
or 9.99% of our common stock. The preferred stock and warrants held by these investors contain a provision that prohibits the conversion
or exercise of the preferred stock or warrants should the holder beneficially own in excess of 4.99% or 9.99%, as elected by the
investor, after giving effect to such conversion or exercise. However, the significant ownership potential of these investors,
and the significant investment that they have made in our company, could give these stockholders the ability to influence us through
their ownership positions, even if they are prohibited from converting or exercising their preferred stock or warrants to acquire
more than 4.99% or 9.99% of our common stock at any time. Further, this significant ownership potential may prevent or discourage
unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Restrictions under our August
2017 Securities Purchase Agreement may limit our ability to raise funds and operate our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The August 2017 Securities Purchase
Agreement contains covenants described below that may restrict our ability to finance future operations or capital needs or to
engage in other business activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">For the 24 months following the
Effective Date, as defined in the Securities Purchase Agreement, upon any issuance by us of any common stock or common stock equivalents
for cash consideration or indebtedness or a combination thereof (a &ldquo;Subsequent Financing&rdquo;), each investor in the offering
will have the right to participate in up to an amount of the Subsequent Financing equal to 35% of the Subsequent Financing on
the same terms, conditions and price provided for in the Subsequent Financing.&nbsp;The &ldquo;Effective Date&rdquo; is the earliest
of the date that (a) the initial registration statement registering all of the shares of common stock and the shares of common
stock into which the Series A Preferred Stock is convertible and the warrants (collectively, the &ldquo;Securities&rdquo;) are
exercisable has been declared effective by the SEC, (b) all of the Securities have been sold pursuant to Rule 144 or may be sold
pursuant to Rule 144 without the requirement for our company to be in compliance with the current public information required
under Rule 144 and without volume or manner-of-sale restrictions or (c) following the one year anniversary of August 15, 2017,
all of the Securities may be sold pursuant to an exemption from registration under Section 4(1) of the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), without volume or manner-of-sale restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Until the later of (i) 270 days
after the Effective Date and (ii) 365 days from August 15, 2017, without the consent of investors that purchased at least 51%
of the shares of common stock in the offering, we may not issue, enter into any agreement to issue or announce the issuance or
proposed issuance of any shares of common stock or common stock equivalents, or file any registration statement covering the issuance
or resale of any shares of common stock or common stock equivalents. If the value weighted average price of our common stock exceeds
$1.00 (as adjusted for stock splits, stock dividends and similar corporate events) for five or more consecutive trading days,
this right will terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Until such time as no investor in the August 2017 offering
holds any of the warrants, we are prohibited from effecting or entering into an agreement to affect any issuance by us of our
common stock or common stock equivalents involving a Variable Rate Transaction, as defined in the Securities Purchase Agreement.
&ldquo;Variable Rate Transaction&rdquo; means a transaction in which we (i) issue any debt or equity securities that are convertible
into common stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or
varies with, the trading prices of or quotations for the shares of our common stock at any time after the initial issuance of
such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future
date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
or indirectly related to our business or the market for our common stock or (ii) enter into any transaction under, any agreement,
including, but not limited to, an equity line of credit, an &ldquo;at-the-market&rdquo; offering or similar agreement, whereby
we may issue securities at a future determined price.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The restrictions and covenants
in the August 2017 Securities Purchase Agreement, as well as any future financing agreements that we may enter into, may restrict
our ability to finance our operations, engage in business activities or expand or fully pursue our business strategies. Our ability
to comply with these covenants may be affected by events beyond our control and we may not be able to meet those covenants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Risks Related
to Securities Markets and Investment in our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>There is a limited trading
market for our common stock, which could make it difficult to liquidate an investment in our common stock, in a timely manner.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our common stock is currently
traded on the OTCQX. Because there is a limited public market for our common stock, investors may not be able to liquidate their
investment whenever desired. We cannot assure that we will maintain an active trading market for our common stock and the lack
of an active public trading market could mean that investors may be exposed to increased risk. In addition, if we failed to meet
the criteria set forth in SEC regulations, various requirements would be imposed by law on broker-dealers who sell our securities
to persons other than established customers and accredited investors. Consequently, such regulations may deter broker-dealers
from recommending or selling our common stock, which may further affect its liquidity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our ability to uplist our common
stock to the NASDAQ or NYSE American is subject to us meeting applicable listing criteria.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We intend to apply for our common stock to be listed on the NASDAQ
or NYSE American, each a national securities exchange. Each exchange requires companies desiring to list their common stock to
meet certain listing criteria including total number of stockholders; minimum stock price, total value of public float, and in
some cases total shareholders&rsquo; equity and market capitalization. Our failure to meet such applicable listing criteria could
prevent us from listing our common stock on either exchange. In the event we are unable to uplist our common stock, our common
stock will continue to trade on the OTCQX market, which is generally considered less liquid and more volatile than the either exchange.
Our failure to uplist our common stock could make it more difficult for you to trade our common stock shares, could prevent our
common stock trading on a frequent and liquid basis and could result in the value of our common stock being less than it would
be if we were able to uplist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If we apply and our common stock is accepted for uplisting
on the NASDAQ or NYSE American, our failure to meet the continued listing requirements of such exchange could result in a delisting
of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="margin: 0">If our common stock were to be uplisted on the NASDAQ or NYSE American, and thereafter we fail to satisfy
the continued listing requirements of such exchange, such as the corporate governance requirements or the minimum closing bid price
requirement, the exchange may take steps to delist our common stock. Such a delisting would likely have a negative effect on the
price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event
of a delisting, we anticipate that we would take actions to restore our compliance with applicable exchange requirements, such
as stabilize our market price, improve the liquidity of our common stock, prevent our common stock from dropping below such exchange&rsquo;s
minimum bid price requirement, or prevent future non-compliance with such exchange&rsquo;s listing requirements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>If we fail to comply with
the continued trading standards of the OTCQX U.S. Premier tier, it may result in our common stock moving tiers in the OTC Markets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our common stock is currently
quoted for trading on the OTCQX U.S. Premier tier, and the continued quotation of our common stock on the OTCQX U.S. Premier tier
is subject to our compliance with a number of standards. These standards include the requirement of our common stock to have a
minimum bid price of $1.00 per share as of the close of business for at least one of every thirty consecutive calendar days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Future sales and issuances
of our equity securities or rights to purchase our equity securities, including pursuant to equity incentive plans, would result
in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">To the extent we raise additional
capital by issuing equity securities, our stockholders may experience substantial dilution. We may, as we have in the past, sell
common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine
from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors
may be further diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and
new investors could gain rights superior to existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Pursuant to our 2015 Stock Plan,
our Board of Directors is currently authorized to award up to a total of 3.0 million shares of common stock or options to purchase
shares of common stock to our officers, directors, employees and non-employee consultants. As of June 30, 2017, options to purchase
38,263 shares of common stock issued under our 2015 Stock Plan at a weighted average exercise price of $16.31 per share were outstanding.
In addition, at June 30, 2017, there were outstanding warrants to purchase an aggregate of 286,049 shares of our common stock
at a weighted average exercise price of $50.29. Stockholders will experience dilution in the event that additional shares of common
stock are issued under our 2015 Stock Plan, or options issued under our 2015 Stock Plan are exercised, or any warrants are exercised
for shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Our share price is volatile
and may be influenced by numerous factors, some of which are beyond our control.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The trading price of our common
stock is likely to be highly volatile, and could be subject to wide fluctuations in response to various factors, some of which
are beyond our control. In addition to the factors discussed in this &ldquo;Risk Factors&rdquo; section and elsewhere in this
prospectus, these factors include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         products or product candidates we acquire for commercialization;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">the
                                         products and product candidates we seek to pursue, and our ability to obtain rights to
                                         develop, commercialize and market those product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         decision to initiate a clinical trial, not to initiate a clinical trial or to terminate
                                         an existing clinical trial;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">actual
                                         or anticipated adverse results or delays in our clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         failure to expand the market for our currently approved products or commercialize our
                                         product candidates, if approved;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">unanticipated
                                         serious safety concerns related to the use of any of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">overall
                                         performance of the equity markets and other factors that may be unrelated to our operating
                                         performance or the operating performance of our competitors, including changes in market
                                         valuations of similar companies;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">conditions
                                         or trends in the healthcare, biotechnology and pharmaceutical industries;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">introduction
                                         of new products offered by us or our competitors;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">announcements
                                         of significant acquisitions, strategic partnerships, joint ventures or capital commitments
                                         by us or our competitors;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         ability to maintain an adequate rate of growth and manage such growth;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">issuances
                                         of debt or equity securities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">sales
                                         of our common stock by us or our stockholders in the future, or the perception that such
                                         sales could occur;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">trading
                                         volume of our common stock;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">ineffectiveness
                                         of our internal control over financial reporting or disclosure controls and procedures;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">general
                                         political and economic conditions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">effects
                                         of natural or man-made catastrophic events;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">other
                                         events or factors, many of which are beyond our control;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">adverse
                                         regulatory decisions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">additions
                                         or departures of key scientific or management personnel;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">changes
                                         in laws or regulations applicable to our product candidates, including without limitation
                                         clinical trial requirements for approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">disputes
                                         or other developments relating to patents and other proprietary rights and our ability
                                         to obtain patent protection for our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         dependence on third parties, including CROs and scientific and medical advisors;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">our
                                         ability to uplist our common stock to a national securities exchange;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">failure
                                         to meet or exceed any financial guidance or expectations regarding development milestones
                                         that we may provide to the public;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">actual
                                         or anticipated variations in quarterly operating results; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">failure
                                         to meet or exceed the estimates and projections of the investment community.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition, the stock market
in general, and the stocks of small-cap healthcare, biotechnology and pharmaceutical companies in particular, have experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these
companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual
operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described
in these &ldquo;Risk Factors,&rdquo; could have a dramatic and material adverse impact on the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>FINRA sales practice requirements
may limit a stockholder&rsquo;s ability to buy and sell our stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Financial Industry Regulatory
Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have
reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced
securities to their non institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&rsquo;s
financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated
its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers.
Because these FINRA requirements are applicable to our common stock, they may make it more difficult for broker-dealers to recommend
that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our
common stock and could have an adverse effect on the market for and price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>If securities or industry
analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and any trading
volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Any trading market for our common
stock that may develop will depend in part on the research and reports that securities or industry analysts publish about us or
our business. Securities and industry analysts do not currently, and may never, publish research on us or our business. If no
securities or industry analysts commence coverage of our company, the trading price for our stock could be negatively affected.
If securities or industry analysts initiate coverage, and one or more of those analysts downgrade our stock or publish inaccurate
or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage
of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price
and any trading volume to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We have a substantial number
of shares of authorized but unissued capital stock, and if we issue additional shares of our capital stock in the future, our
existing stockholders will be diluted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Certificate of Incorporation authorize the issuance of
up to 100.0 million shares of our common stock and up to 50.0 million shares of preferred stock with the rights, preferences and
privileges that our Board of Directors may determine from time to time. At the next annual shareholders meeting, we may seek approval
to increase our authorized common shares from 100.0 million common shares authorized to 200.0 million or 300.0 million shares.
As of June 30, 2017, we had 824,831 shares of our common stock issued and outstanding, which represents less than 1% of our total
authorized shares of common stock. In addition to capital raising activities, which we expect to continue to pursue to raise the
funding we will need in order to continue our operations, other possible business and financial uses for our authorized capital
stock include, without limitation, future stock splits, acquiring other companies, businesses or products in exchange for shares
of our capital stock, issuing shares of our capital stock to partners or other collaborators in connection with strategic alliances,
attracting and retaining employees by the issuance of additional securities under our equity compensation plans, or other transactions
and corporate purposes that our Board of Directors deems are in the best interest of our company. Additionally, shares of our
capital stock could be used for anti-takeover purposes or to delay or prevent changes in control or our management. Any future
issuances of shares of our capital stock may not be made on favorable terms or at all, they may not enhance stockholder value,
they may have rights, preferences and privileges that are superior to those of our common stock, and they may have an adverse
effect on our business or the trading price of our common stock. The issuance of any additional shares of our common stock will
reduce the book value per share and may contribute to a reduction in the market price of the outstanding shares of our common
stock. Additionally, any such issuance will reduce the proportionate ownership and voting power of all of our current stockholders.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Future sales and issuances
of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan or otherwise, could result
in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We could need significant additional
capital in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or
other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common
stock, convertible securities or other equity securities in more than one transaction, investors in a prior transaction may be
materially diluted by subsequent sales. Additionally, any such sales may result in material dilution to our existing stockholders,
and new investors could gain rights, preferences and privileges senior to those of holders of our common stock. Further, any future
sales of our common stock by us or resales of our common stock by our existing stockholders could cause the market price of our
common stock to decline. Any future grants of options, warrants or other securities exercisable or convertible into our common
stock, or the exercise or conversion of such shares, and any sales of such shares in the market, could have an adverse effect
on the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Some provisions of our charter
documents and applicable Delaware law may discourage an acquisition of us by others, even if the acquisition may be beneficial
to some of our stockholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Provisions in our Certificate
of Incorporation and Amended and Restated Bylaws, as well as certain provisions of Delaware law, could make it more difficult
for a third-party to acquire us, even if doing so may benefit some of our stockholders. These provisions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><P STYLE="margin: 0">the authorization of 50.0 million shares of &ldquo;blank check&rdquo; preferred stock, the rights, preferences
and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion from time
to time and without stockholder approval;</P>


</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">limiting
                                         the removal of directors by the stockholders;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">allowing
                                         for the creation of a staggered board of directors;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">eliminating
                                         the ability of stockholders to call a special meeting of stockholders; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD><FONT STYLE="color: #000000">establishing
                                         advance notice requirements for nominations for election to the board of directors or
                                         for proposing matters that can be acted upon at stockholder meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">These provisions may frustrate
or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders
to replace members of our board of directors, which is responsible for appointing the members of our management. In addition,
we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging
in any of a broad range of business combinations with an interested stockholder for a period of three years following the date
on which the stockholder became an interested stockholder, unless such transactions are approved by the board of directors. This
provision could have the effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whether
or not it is desired by or beneficial to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Any provision of our Certificate
of Incorporation or Bylaws or of Delaware law that is applicable to us that has the effect of delaying or deterring a change in
control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock in the event
that a potentially beneficial acquisition is discouraged, and could also affect the price that some investors are willing to pay
for our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>The elimination of personal
liability against our directors and officers under Delaware law and the existence of indemnification rights held by our directors,
officers and employees may result in substantial expenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our Certificate of Incorporation
and our Bylaws eliminate the personal liability of our directors and officers to us and our stockholders for damages for breach
of fiduciary duty as a director or officer to the extent permissible under Delaware law. Further, our Certificate of Incorporation
and our Bylaws and individual indemnification agreements we intend to enter with each of our directors and executive officers
provide that we are obligated to indemnify each of our directors or officers to the fullest extent authorized by the Delaware
law and, subject to certain conditions, advance the expenses incurred by any director or officer in defending any action, suit
or proceeding prior to its final disposition. Those indemnification obligations could expose us to substantial expenditures to
cover the cost of settlement or damage awards against our directors or officers, which we may be unable to afford. Further, those
provisions and resulting costs may discourage us or our stockholders from bringing a lawsuit against any of our current or former
directors or officers for breaches of their fiduciary duties, even if such actions might otherwise benefit our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>We do not intend to pay
cash dividends on our capital stock in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We have never declared or paid
any dividends on our common stock and do not anticipate paying any dividends in the foreseeable future. Any future payment of
cash dividends in the future would depend on our financial condition, contractual restrictions, solvency tests imposed by applicable
corporate laws, results of operations, anticipated cash requirements and other factors and will be at the discretion of our Board
of Directors. Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="color: #000000"><A NAME="a_004"></A><B>Item&nbsp;
1B.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Unresolved Staff Comments </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="color: #000000"><A NAME="a_005"></A><B>Item&nbsp;
2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Properties </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On August 19, 2015, Aytu entered
into a 37 month non-cancellable operating lease for new office space effective September 1, 2015. The new lease has initial base
rent of $8,500 per month beginning in October 2015, with the total base rent over the term of the lease of approximately $318,000
which includes rent abatements. We have also opened a 1,333 square foot office in Raleigh, North Carolina for which the lease
runs until July 31, 2018. We believe our current office space is sufficient to meet our current needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We recognize rental expense of
the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments
are classified as liabilities between current deferred rent and long-term deferred rent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="color: #000000"><A NAME="a_006"></A><B>Item&nbsp;3.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Legal
Proceedings </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We are currently not party to
any material legal or administrative proceedings and are not aware of any material pending or threatened legal or administrative
proceedings in which we will become involved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><FONT STYLE="color: #000000"><A NAME="a_007"></A><B>Item&nbsp;
4.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Mine Safety Disclosures </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Not applicable.</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="a_008"></A><B>PART&nbsp;II
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-indent: -55.45pt"><FONT STYLE="color: #000000"><A NAME="a_009"></A><B>Item&nbsp;5.</B>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;Market
for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Market Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our common stock is quoted on
the OTCQX under the symbol &ldquo;AYTU.&rdquo; Prior to December 14, 2015, our common stock was quoted on the OTCQB Market. The
following table sets forth the range of bid and asked closing quotations for our common stock on the OTCQX or OTCQB, for the periods
shown. The quotations represent inter-dealer prices without retail markup, markdown or commission, and may not necessarily represent
actual transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Fiscal Year ended June 30,
    2016</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">High</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Low</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%"><FONT STYLE="color: #000000">First Quarter (ended September 30, 2015)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">1,140.00</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">1,111.20</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">Second Quarter (ended December 31, 2015)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,140.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">753.60</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">Third Quarter (ended March 31, 2016)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">840.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">134.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">Fourth Quarter (ended June 30, 2016)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">146.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">72.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; width: 74%"><FONT STYLE="color: #000000">Fiscal Year ended June
    30, 2017</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 10%"><FONT STYLE="font-size: 10pt; color: #000000"><B>High</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; width: 10%"><FONT STYLE="font-size: 10pt; color: #000000"><B>Low</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left; width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">First Quarter (ended September 30, 2016)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">100.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">60.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">Second Quarter (ended December 31, 2016)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">77.80</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">20.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">Third Quarter (ended March 31, 2017)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">25.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">14.82</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">Fourth Quarter (ended June 30, 2017)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">18.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">10.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On August 21, 2017, the closing
price as reported on the OTCQX of our common stock was $3.80. As of August 21, 2017, there were 570 holders of record of our common
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Equity Compensation Plan Information
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">In
June 2015, our shareholders approved the adoption of a stock and option award plan (the &ldquo;2015 Plan&rdquo;). At the Special
meeting of stockholders on July 26, 2017, the Aytu Stockholders voted to increase the plan to 3.0 million shares. The 2015 Plan
permits grants of equity awards to employees, directors and consultants. The following table displays equity compensation plan
information as of June 30, 2017.</FONT><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">Plan Category</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Number&nbsp;of&nbsp;Securities&nbsp;to<BR>
    be Issued upon Exercise<BR> of Outstanding Options,<BR> Warrants and Rights (a)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Weighted-Average<BR> Exercise
    Price of<BR> Outstanding Options,<BR> Warrants and Rights<BR> (b)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Number&nbsp;of&nbsp;Securities&nbsp;Remaining<BR>
    Available for Issuance under<BR> Equity Compensation Plans<BR> (Excluding Securities Reflected<BR>
    in Column (a)) (c)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left"><FONT STYLE="color: #000000">Equity compensation plans approved by security holders</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">38,263</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">16.31</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">61,737</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Equity compensation plans not approved by security holders</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">32,641</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">44.12</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">70,904</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="color: #000000">29.11</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">61,737</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our private placement of approximately $4.7 million of common stock in 2013, we were obligated
to issue to the placement agent warrants to purchase 444 shares of our common stock. The placement agent warrants have a term of
five years from the date of issuance and an exercise price of $1,087.20. In connection with our private placement of approximately
$5.2 million of convertible notes in July and August 2015, we were obligated to issue to the placement agents warrants for an amount
of shares equal to 8% of the number of shares of our common stock issued upon conversion of the notes and any accrued interest.
The placement agents&rsquo; warrants have a term of five years from the date of issuance of the related notes in July and August
2015, an exercise price equal to 100% of the price per share at which equity securities were sold in our next equity financing,
and provide for cashless exercise. Those warrants were not approved by our stockholders. In connection with the conversions of
the notes in February 2016 and May 2016, which were triggered by an equity financing in January 2016 and our public offering of
common stock and warrants in May 2016, respectively, we issued warrants to the placement agents to purchase an aggregate of 1,115
shares of our common stock at a weighted average exercise price of $156.00 per share, and an aggregate of 1,129 shares of our common
stock at an exercise price of $96.00 per share. In connection with our May 2016 public offering, we issued warrants to purchase
an aggregate of 5,474 shares of common stock at an exercise price of $120.00 to the underwriters of the public offering. In July
2016, we issued warrants to purchase an aggregate of 4,402 shares of common stock at an exercise price of $80.00 to initial investors.
In connection with our November 2016 public offering, we issued warrants to purchase an aggregate of 20,077 shares of common stock
with an exercise price of $15.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: #000000">Dividend
Policy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We have not paid any cash dividends
on our common stock and our Board of Directors presently intends to continue a policy of retaining earnings, if any, for use in
our operations. The declaration and payment of dividends in the future, of which there can be no assurance, will be determined
by the Board of Directors in light of conditions then existing, including earnings, financial condition, capital requirements
and other factors. Delaware law prohibits us from declaring dividends where, if after giving effect to the distribution of the
dividend:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 3%; font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #000000">&middot;</FONT></td>
    <td style="width: 94%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">we would not be able to pay our debts
    as they become due in the usual course of business; or</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 3%; font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #000000">&middot;</FONT></td>
    <td style="width: 94%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">our total assets would be less than
    the sum of our total liabilities plus the amount that would be needed to satisfy the rights of stockholders who have preferential
    rights superior to those receiving the distribution.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Except as set forth above, there
are no restrictions that currently materially limit our ability to pay dividends or which we reasonably believe are likely to
limit materially the future payment of dividends on common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our Board of Directors has the
right to authorize the issuance of preferred stock, without further stockholder approval, the holders of which may have preferences
over the holders of our common stock as to payment of dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-indent: -55.45pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-indent: -55.45pt"><FONT STYLE="color: #000000"><A NAME="a_010"></A><B>Item&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selected
Financial Data </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Not applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-indent: -55.45pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-indent: -55.45pt"><FONT STYLE="color: #000000"><A NAME="a_011"></A><B>Item&nbsp;7.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>You should read the following
discussion and analysis of our financial condition and results of operations together with our financial statements and the related
notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis, including
information with respect to our plans and strategy for our business and related financing, includes forward-looking statements
that involve risks and uncertainties. You should read the &ldquo;Risk Factors&rdquo; section of this Form 10-K for a discussion
of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking
statements contained in the following discussion and analysis. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a commercial-stage specialty pharmaceutical company concentrating
on developing and commercializing products with an initial focus on urological diseases and conditions. We are currently focused
on addressing significant medical needs in the areas of hypogonadism, male infertility, urological cancers and female personal
care.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Through a multi-step reverse triangular merger, on April 16,
2015, Vyrix Pharmaceuticals, Inc. (&ldquo;Vyrix&rdquo;) and Luoxis Diagnostics, Inc. (&ldquo;Luoxis&rdquo;) merged with and into
our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare
market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and Zertane products. On June
8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind
Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stock holder received one share of
common stock for every 12.174 shares outstanding. On June 30, 2016, we effected another reverse stock split in which each common
stock holder received one share of common stock for each 12 shares. Additionally, on August 25, 2017 we completed another reverse
split in which each common stockholder received one share of common stock for each 20 shares then owned. All share and per share
amounts in this Report have been adjusted to reflect the effect of these two reverse stock splits (herein referred to collectively
as the Reverse Stock Splits).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2015, we entered into an asset purchase agreement with
Jazz Pharmaceuticals, Inc., pursuant to which we purchased assets related to Jazz Pharmaceuticals&rsquo; product known as ProstaScint
(capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress
(together, the &ldquo;ProstaScint Business&rdquo;), and assumed certain of Jazz Pharmaceuticals&rsquo; liabilities, including those
related to product approvals and the sale and marketing of ProstaScint. The purchase price consisted of the upfront payment of
$1.0 million. We also paid an additional $500,000 within five days after transfer for the ProstaScint-related product inventory
and $227,000 on September 30, 2015 (which represents a portion of certain FDA fees). We also will pay 8% on net sales made after
October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. Based upon the estimated expiration
date, per our projections we could stop selling this product mid-fiscal 2019, thus, we impaired the non-tangible assets related
to this product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2015, we entered into an asset purchase agreement
with FSC Laboratories, Inc., or FSC. Pursuant to the agreement, we purchased assets related to FSC&rsquo;s product known as Primsol
(trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and
sales assets and materials related solely to Primsol (together, the &ldquo;Primsol Business&rdquo;), and assumed certain of FSC&rsquo;s
liabilities, including those related to the sale and marketing of Primsol arising after the closing. We paid $500,000 at closing
for the Primsol Business and we paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol
Business, for the transfer of the Primsol-related product inventory. We also paid $500,000 on April 1, 2016 and $500,000 on July
1, 2016, and paid $250,000 in November 2016 (together, the &ldquo;Installment Payments&rdquo;), for a total purchase price of $1,892,000.
During fiscal 2017 we sold our Prismol product which was used in the treatment of urinary tract infections.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2016, we entered into a license and supply agreement to acquire the exclusive U.S. rights to Natesto
nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we received on July 1, 2016. We paid Acerus an upfront
fee of $2.0 million upon execution of the agreement. In October 2016 we paid an additional $2.0 million and in January of 2017,
we paid the final upfront payment of $4.0 million. We also purchased on April 28, 2016, an aggregate of 12,245,411 shares of Acerus
common stock for Cdn. $2,535,000 (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately
US $0.16 per share. We also agreed to make various payments based upon certain sales milestones up to an aggregate of $37.5 million
based on net sales of Natesto. During the term of the agreement, we will purchase all of our Natesto product needs from Acerus
at a designated price. In our third fiscal quarter of 2017. We sold all of the shares of common stock of Acerus Pharmaceutics Corporation
that we acquired in April 2016 for approximately $2.0 million as a condition to our licensing of Natesto. Acerus common stock is
traded on the Toronto Stock Exchange. The gross proceeds from the sale of the Acerus shares was approximately $1.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In May 2016, we sold in an underwritten
public offering 78,125 shares of our common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate 78,125
shares of common stock at a combined public offering price of $96.00 per share and related warrant. Each warrant is exercisable
for five years from issuance and has an exercise price equal to $120.00. In addition, we granted the underwriters a 45-day option
to purchase up to an additional 11,719 shares of common stock and/or 11,719 additional warrants. The underwriters elected a partial
exercise of their over-allotment option to purchase 8,542 warrants. The net cash proceeds from the sale of the shares and warrants
were approximately $6.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In July 2016, Aytu issued 50,000
shares of restricted stock to executive officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2016, we entered into a purchase agreement (the &ldquo;Purchase Agreement&rdquo;), together with a
registration rights agreement (the &ldquo;Registration Rights Agreement&rdquo;), with Lincoln Park Capital Fund, LLC (&ldquo;Lincoln
Park&rdquo;), an Illinois limited liability company. Upon signing the Purchase Agreement, Lincoln Park agreed to purchase 6,684
shares of our common stock for $500,000 as an initial purchase under the agreement. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also issued as a commitment fee to Lincoln Park of 2,625 shares of common stock. During fiscal 2017, Lincoln Park purchased 10,000
common shares for $240,000. As part of our August 2017 private placement financing, we terminated the Purchase Agreement, effective
August 16, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On October 27, 2016, we priced
an underwritten public offering of 286,749 shares of our common stock and warrants to purchase up to an aggregate of 286,749 shares
of our common stock at a combined public offering price of&nbsp;$30.00&nbsp;per share and related warrant. The gross proceeds
from the offering to Aytu was $8.6 million, before deducting the underwriting discount and estimated offering expenses payable
by Aytu, but excluding the exercise of any warrants. The Company also granted the representative of the underwriters a 45-day
option to purchase up to an additional 43,013 shares and/or 43,013 additional warrants. The shares of common stock were immediately
separable from the warrants and were issued separately. The warrants are exercisable immediately upon issuance, expire five years
after the date of issuance and have an exercise price of&nbsp;$37.20&nbsp;per share. On November 2, 2016, we completed the public
offering. In connection with the closing, the underwriters purchased a portion of their 45-day option and purchased an additional
14,263 additional warrants at closing. Our net cash proceeds from the offering, after deducting the placement agent fees and the
offering expenses, was $7.6 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On February 28, 2017, we consummated
our warrant tender offer to exercise, at a temporarily reduced exercise price of $15.00 per share, (i) outstanding warrants to
purchase 86,667 shares of our common stock with an exercise price of $120.00 per share, which were originally issued to investors
in our May 2016 financing (the &ldquo;May 2016 Warrants&rdquo;), and (ii) outstanding warrants to purchase 301,013 shares of our
common stock with an exercise price of $37.20 per share, which were originally issued to investors in our October 2016 financing
(the &ldquo;October 2016 Warrants&rdquo; and together with the May 2016 Warrants, the &ldquo;Original Warrants&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The warrant tender offer expired
at 11:59 p.m. Eastern Time on the evening of February 27, 2017 (the &ldquo;Expiration Date&rdquo;). Original warrants to purchase
an aggregate of 149,552 shares of our common stock were tendered and exercised in the warrant tender offer, for aggregate gross
proceeds to our Company of approximately $2.2 million. Original warrants tendered and exercised represent approximately 38.6%
of the original warrants outstanding immediately prior to the Expiration Date. Original warrants that were not tendered and exercised
remain in effect at the pre-tender offer exercise prices of $120.00 per share and $37.20 per share, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Joseph Gunnar &amp; Co., LLC and
Fordham Financial Management, Inc. acted as warrant solicitation agents and received a fee equal to 6% of the aggregate gross
proceeds to our Company, plus reimbursement of approximately $25,000 in out-of-pocket expenses and indemnification against certain
liabilities. We also reduced the exercise prices of an aggregate of 25,541 warrants to purchase shares of our common stock, which
were originally issued as underwriters&rsquo; compensation in the May 2016 and October 2016 financings, from $120.00 per share
and $37.20 per share, respectively, to $15.00 per share. In March, we also reduced the price of the 429 warrants issued to the
bankers that helped us with the Convertible Promissory Notes in fiscal 2016 to an exercise price of $15.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On March 16, 2017, we reduced
the exercise price of outstanding options issued to directors, employees and consultants to purchase an aggregate of 36,834 shares
of our common stock from a weighted average exercise price of $70.60 to $16.40 to incentivize the holders of these options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On March 31, 2017, we entered
into and closed on an Asset Purchase Agreement with Allegis Holdings, LLC (the &ldquo;Purchaser&rdquo;). Pursuant to the agreement,
we sold to the Purchaser all of our assets related to our Primsol product, including certain intellectual property and contracts,
inventory, work in process and all marketing assets and materials related solely to Primsol (together, the &ldquo;Primsol Asset&rdquo;).
We evaluated this transaction and concluded that it is not significant to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On May 5, 2017, we acquired Nuelle,
Inc, or Nuelle, a women&rsquo;s sexual health company. This transaction expanded our product portfolio with the addition of the
Fiera<SUP>&reg;</SUP> personal care device for women. Fiera was recently launched in the U.S. and is a proprietary, revenue-generating
product scientifically proven to enhance physical arousal and sexual desire in the millions of adult women around the world impacted
by changes in sexual desire. This acquisition adds a novel, commercial-stage product in a complementary adjacency readily accessible
by our U.S.-based commercial infrastructure. We purchased Nuelle for 125,000 common shares at closing and future contingent royalty
payment averaging the high single digits and milestone payments dependent on achieving certain annualized sales amounts. Nuelle
was previously a portfolio company of leading venture capital firm New Enterprise Associates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 11, 2017, we entered into a Securities Purchase Agreement
with various investors pursuant to which we agreed to sell Class A and Class B equity units for gross proceeds of approximately
$11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares
of common stock and were sold at a negotiated price of $3.00 per unit. Class B units consist of one (1) share of our newly created
Series A Convertible Preferred Stock (the &ldquo;Series A Preferred Stock&rdquo;) and warrants to purchase one and one-half (1.5)
shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at
a negotiated price of $1,000 per unit to those purchasers who, together with their affiliates and certain related parties, would
beneficially own more than 9.99% of our outstanding common stock following the offering. The offering closed on August 15, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the offering, we issued an aggregate of 3,196,665 shares of our
common stock, 2,250 shares of Series A Preferred Stock and warrants to purchase up to an aggregate of 5,919,998 shares of our common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of the date of this Report, we have financed operations through
a combination of private and public debt and equity financings including net proceeds from the private placements of stock and
convertible notes. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, as of
the date of this Report, we believe we will have sufficient cash to meet our projected operating requirements into the first half
of fiscal 2019, at which point we anticipate nearing or reaching cash-flow breakeven. See &ldquo;Liquidity and Capital Resources.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0">We have only begun to generate material revenues from the commercialization of our product candidates in the
last fiscal year. We have recognized approximately $3.2 million in revenue from Natesto, ProstaScint, Primsol, MiOXSYS and Fiera
sales during fiscal 2017. We have incurred accumulated net losses since our inception, and at June 30, 2017, we had an accumulated
deficit of $69.1 million. Our net loss was $22.5 million for fiscal 2017 and we used $13.8 million in cash from operations during
that year.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Significant Accounting Policies
and Estimates </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Information regarding our Significant
Accounting Policies and Estimates is contained in Note 2 to the Financial Statements.<B><I> </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Newly Issued Accounting
Pronouncements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Information regarding the recently
issued accounting standards (adopted and not adopted as of June 30, 2017) is contained in Note 2 to the Financial Statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Results of Operations&mdash;June
30, 2017 Compared to June&nbsp;30, 2016 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Results of operations for the
year ended June 30, 2017 (&ldquo;fiscal 2017&rdquo;) and the year ended June&nbsp;30, 2016 (&ldquo;fiscal 2016&rdquo;) reflected
losses of approximately $22.5 million and $28.2 million, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Revenue </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><FONT STYLE="color: #000000"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><FONT STYLE="color: #000000"><I>Product and service
revenue</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The total product and service revenue recognized during 2017 was $3.2 million, related to the sales of our
products Natesto, ProstaScint,and Primsol, the MiOXSYS and RedoxSYS Systems, as well as products in the Fiera line. The product
and service revenue in fiscal 2016 was $2.1 million, which was from the ProstaScint and Primsol product lines, as well as the RedoxSYS
and MiOXSYS Systems. The increase in product revenue of over 57% from fiscal 2016 to 2017 is due to our acquisitions and ensuing
sales of the Natesto and Fiera products, which occurred late in fiscal 2016 and late fiscal 2017, respectively, and expanded marketing
of our commercial products.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">As is customary in the pharmaceutical
industry, our gross product sales are subject to a variety of deductions in arriving at reported net product sales. Provisions
for these deductions are recorded concurrently with the recognition of gross product sales revenue and include discounts, chargebacks,
distributor fees, processing fees, as well as allowances for returns and Medicaid rebates. Provision balances relating to estimated
amounts payable to direct customers are netted against accounts receivable and balances relating to indirect customers are included
in accounts payable and accrued liabilities. The provisions recorded to reduce gross product sales and net product sales are as
follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Year
    Ended June 30,</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left"><FONT STYLE="color: #000000">Gross product and service revenue</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">4,694,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">2,657,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">Provisions to reduce gross product sales to
    net product and service sales</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(1,472,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(606,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Net product and service revenue</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">3,222,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">2,051,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Percentage to net sales</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">68.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">77.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><FONT STYLE="color: #000000"><I>License revenue</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">During fiscal 2017 and fiscal
2016, we recognized $0 and $512,000, respectively, in license revenue. In 2012, we received a payment of $500,000 for our license
agreement of our former product candidate Zertane with a Korean pharmaceutical company. This payment was deferred and was being
recognized over 10 years. In 2014, we received a payment of $250,000 for our license agreement of Zertane with a Canadian-based
supplier. This payment was deferred and was being recognized over seven years. At June 30, 2016, Aytu determined that the Zertane
asset has no value as Aytu does not have the resources to complete the necessary clinical trials and bring it to market before
the patents expire. Therefore, the remaining unamortized deferred revenue of $426,000 which was outstanding as of the date it
was determined not to proceed with the clinical trials was recognized as of June 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Expenses </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Cost of Sales </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The cost of sales of $1.4 million
and $1.0 million recognized for fiscal 2017 and fiscal 2016, respectively, are related to the Natesto, ProstaScint and Primsol
products, the MiOXSYS and RedoxSYS Systems, as well as products in the Fiera line. We expect to see cost of sales to continue
to increase in the year ending June 30, 2018 (&ldquo;fiscal 2018&rdquo;) as we expect our sales of our current products to continue
to grow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Research and Development
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Research and development costs
consist of clinical trials and sponsored research, labor, stock-based compensation, sponsored research &ndash; related party and
consultants and other. These costs relate solely to research and development without an allocation of general and administrative
expenses and are summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Clinical trials and sponsored research</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">956,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,278,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Manufacturing tech transfer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,304,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Labor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">427,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sponsored research - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">388,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Consultants and other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,348,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,320,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Comparison of Years Ended June
30, 2017 and 2016 </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Research and development expenses
decreased $5.0 million, or 78.7%, in fiscal 2017 compared to fiscal 2016. This was due primarily to placing the contract for our
manufacturing tech transfer on hold for our ProstaScint product, as well as shifting our focus to our existing commercialized
products. We expect that the research and development expenses will decrease in fiscal 2018 as compared to fiscal 2017 due to
the fact that we will continue to focus on our existing products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>General and Administrative
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">General and administrative expenses
consist of personnel costs for employees in executive, business development and operational functions and director fees; stock-based
compensation; patents and intellectual property; professional fees including legal, auditing, accounting, investor relations,
shareholder expense and printing and filing of SEC reports; occupancy, travel and other including rent, governmental and regulatory
compliance, insurance, and professional subscriptions. These costs are summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: #000000"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%">Labor</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">7,488,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,671,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,227,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">814,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,133,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,630,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Occupancy, travel and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,267,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,086,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Patent costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">168,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">303,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Director fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Management fee - related party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">165,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">308,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,608,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,825,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Comparison of Years Ended June
30, 2017 and 2016 </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">General and administrative costs
increased $8.8 million, or 99.5%, in fiscal 2017 over fiscal 2016. The increase in labor costs, stock-based compensation, and
occupancy, travel and other primarily relates to increased costs related to the increase in commercial department staffing during
fiscal 2017 as compared to fiscal 2016, increased travel expense and stock options granted, as well as the continuing vesting
of stock option awards granted in previous years. We expect general and administrative expenses to remain flat in fiscal 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Impairment of Intangible Assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Impairment of intangible assets
was $1.3 million for fiscal 2017, which was related to the impairment of the ProstaScint product. Impairment of intangible assets
was $7.5 million for fiscal 2016 related to the impairment of the Zertane in process research and development (IPRD).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Amortization of Intangible
Assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Amortization of intangible assets
was $1.7 million and $665,000 for fiscal 2017 and fiscal 2016, respectively. This expense increased due to the acquisition of
the Natesto and Fiera businesses in late fiscal 2016 and late fiscal 2017, respectively, and the corresponding amortization of
their finite-lived intangible assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Net Cash Used in Operating
Activities </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">During fiscal 2017, our operating
activities used $13.8 million in cash. The use of cash was approximately $8.7 million lower than the net loss due primarily to
non-cash charges for asset impairment, stock-based compensation, issuance of restricted stock, depreciation, amortization and
accretion, amortization of prepaid research and development related party, common stock issued to executives, warrants issued
to initial investors, and an increase in accounts payable. These charges were offset by a decrease in accrued compensation, accrued
liabilities, and accounts receivable, a gain on the sale of an asset, and derivative income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">During fiscal 2016, our operating
activities used $10.7 million in cash. The use of cash was approximately $17.5 million lower than the net loss due primarily to
non-cash charges for asset impairment, amortization of the beneficial conversion feature, stock-based compensation, depreciation,
amortization and accretion, unrecognized loss on investment, noncash interest expense, amortization of prepaid research and development
related party, an increase in accounts payable and accrued liabilities and an increase accrued compensation offset by an increase
to inventory and a decrease to deferred revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Net Cash Used in Investing
Activities </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">During fiscal 2017, cash was received
through the sale of Primsol, the sale of our investment in Acerus and the merger with Nuelle, Inc. Cash was used to make additional
required payments for Natesto and Primsol, and to purchase fixed assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">During fiscal 2016, cash was used
to acquire Natesto, our investment in Acerus common stock, Primsol, the purchase of fixed assets as well as the refund of a deposit
for office space.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Net Cash from Financing
Activities </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Net cash of $10.2 million provided
by financing activities during fiscal 2017 was primarily related to our warrant tender offer of $2.2 million offset by issuance
costs of $312,000, our registered public offering of $8.6 million of common stock and warrants offset by cash issuance costs of
$998,000, and the issuance of common stock to Lincoln Park Capital of $740,000 offset by issuance costs of $91,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Net cash of $16.7 million provided
by financing activities during fiscal 2016 was primarily related to our registered public offering of $7.5 million of common stock
and warrants offset by cash issuance costs of $905,000, the issuance of convertible promissory notes which reflects gross proceeds
of $5.2 million offset by the cash portion of the debt issuance costs of $298,000, as well as the $5.0 million stock subscription
payment from Ampio and $200,000 for a sale of stock subscriptions in January 2016 as well as the issuance costs of $30,000 related
to the debt conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Contractual Obligations and
Commitments </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Information regarding our Contractual
Obligations and Commitments is contained in Note 7 to the Financial Statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Liquidity and Capital Resources
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We are a relatively young company
and we have not yet generated substantial revenue as our primary activities are focused on commercializing our approved products,
acquiring products and developing our product candidates, and raising capital. As of June 30, 2017, we had cash, cash equivalents
and restricted cash totaling $878,000 available to fund our operations offset by an aggregate of $3.0 million in accounts payable
and other and accrued liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With the additional capital that we raised in August 2017 of
approximately $11.8 million, we believe we have sufficient resources to fund our operations through fiscal 2018 and into the middle
of fiscal 2019. We believe, if our sales continue to grow as we have projected, this could be sufficient until we reach cash-flow
breakeven and potentially profitability. If necessary, in the future we will evaluate the capital markets from time to time to
determine if we need to raise additional capital in the form of equity, convertible debt or other financing instruments, depending
on market conditions relative to our need for funds at such time. We may seek to raise additional capital at such time as we conclude
that such capital is available on terms that we consider to be in the best interests of our Company and our stockholders.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">At this time, we expect to satisfy our future cash needs through sales revenue related to our current products
and if necessary, private or public sales of our securities or debt financings. We cannot be certain that financing will be available
to us on acceptable terms, or at all. Over the last three years, including recently, volatility in the financial markets has adversely
affected the market capitalizations of many bioscience companies and generally made equity and debt financing more difficult to
obtain. This volatility, coupled with other factors, may limit our access to additional financing.</P>



<P STYLE="margin: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">If we cannot raise adequate additional
capital in the future when we require it, we could be required to delay, reduce the scope of, or eliminate one or more of our
commercialization efforts or our research and development programs. We also may be required to relinquish greater or all rights
to product candidates at less favorable terms than we would otherwise choose. This may lead to impairment or other charges, which
could materially affect our balance sheet and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Going Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The continuation of our business as of June 30, 2017 was dependent
upon us obtaining further financing for our business. With the completion of our financing of $11.8 million in August 2017, we
believe this going concern has been remediated as we believe that we now have enough capital to operate through fiscal 2018 and
into the middle of fiscal 2019 and possibly achieve cash-flow breakeven and profitability with no additional financing, please
see Note 3 for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Off Balance Sheet Arrangements
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We do not have off-balance sheet
arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as &ldquo;variable
interest entities.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Impact of Inflation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In general, we believe that our
operating expenses can be negatively impacted by increases in the cost of clinical trials due to inflation and rising health care
costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><A NAME="a_012"></A><B>Item&nbsp;7A.
&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures about Market Risks </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Not applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.45pt; text-indent: -55.45pt"><A NAME="a_013"></A><FONT STYLE="color: #000000"><B>Item&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements and Supplementary Data </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The financial statements required
by this item are identified in Item&nbsp;(a)(1) of Part IV and begin at page&nbsp;F-1 of this Annual Report on Form 10-K and are
incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><A NAME="a_014"></A><FONT STYLE="color: #000000"><B>Item&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes
in and Disagreements with Accountants on Accounting and Financial Disclosure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><A NAME="a_015"></A><FONT STYLE="color: #000000"><B>Item&nbsp;9A.&nbsp;&nbsp;&nbsp;&nbsp;Controls
and Procedures </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Evaluation of Disclosure Controls
and Procedures </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our management is responsible
for establishing and maintaining adequate &ldquo;disclosure controls and procedures,&rdquo; as such term is defined in Rules&nbsp;13a-15(e)
and 15d-15(e) of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;), that are designed to ensure that information
required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and
reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to
our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding
required disclosure. Our management has concluded that our disclosure controls and procedures were effective as of the end of
the period covered by this Report to provide the reasonable assurance discussed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Management&rsquo;s Annual Report
on Internal Control over Financial Reporting </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f)
under the Exchange Act). Our management assessed the effectiveness of our internal control over financial reporting as of June
30, 2017. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of
the Treadway Commission in <I>Internal Control-Integrated Framework (2013)</I>. Our management has concluded that, as of June
30, 2017, our internal control over financial reporting is effective based on these criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">EKS&amp;H LLLP, the independent
registered public accounting firm that audited our financial statements included in this Annual Report on Form 10-K, was not required
to issue an attestation report on our internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Changes in Internal Control
over Financial Reporting </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">There were no changes in our internal
controls over financial reporting, known to the chief executive officer or the chief financial officer that occurred during the
period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control
over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><A NAME="a_016"></A><B>Item&nbsp;9B.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Other
Information </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="a_017"></A><B>PART
III </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><A NAME="a_018"></A><B>Item&nbsp;10.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Directors
and Executive Officers, and Corporate Governance </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following table sets forth
the names and ages of all of our directors and executive officers as of August 15, 2017. Our Board of Directors is currently comprised
of five members, who are elected annually to serve for one year or until their successor is duly elected and qualified, or until
their earlier resignation or removal. Executive officers serve at the discretion of the Board of Directors and are appointed by
the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Name</B></FONT></td>
    <TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Age</B></FONT></td>
    <TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="width: 59%; font-size: 10pt; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>Position</B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Joshua R. Disbrow</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">42</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="margin: 0">Chairman and Chief Executive Officer</P>


</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Jarrett T. Disbrow</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">42</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Chief Operating Officer</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Gregory A. Gould</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">51</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Chief Financial Officer, Secretary,
    and Treasurer</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Michael Macaluso</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">65</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Director</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Carl C. Dockery</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">54</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Director</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">John A. Donofrio, Jr.</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: center">49</td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Director</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Gary V. Cantrell</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">62</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">Director</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following is a biographical
summary of the experience of our executive officers and directors during the past five years, and an indication of directorships
held by the director in other companies subject to the reporting requirements under the federal securities law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Joshua R. Disbrow &ndash; Chairman
and Chief Executive Officer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Joshua R. Disbrow has been employed
by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Luoxis since January
2013. Mr. Disbrow was also the Chief Operating Officer of Ampio since December 2012. Prior to joining Ampio, he served as the
Vice President of Commercial Operations at Arbor Pharmaceuticals, a specialty pharmaceutical company, from May 2007 through October
2012. He joined Arbor as that company&rsquo;s second full-time employee. Mr. Disbrow led the company&rsquo;s commercial efforts
from inception to the company&rsquo;s acquisition in 2010 and growth to over $127 million in net sales in 2011. By the time Mr.
Disbrow departed Arbor in late 2012, he had led the growth of the commercial organization to comprise over 150 people in sales,
marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent over 17 years
in the pharmaceutical, diagnostic and medical device industries and has held positions of increasing responsibility in sales,
marketing, sales management, commercial operations and commercial strategy. Prior to joining Arbor, Mr. Disbrow served as Regional
Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005 through April
2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience, an in vitro diagnostics company. Mr. Disbrow
holds an MBA from Wake Forest University and BS in Management from North Carolina State University. Mr. Disbrow&rsquo;s experience
in executive management and marketing within the pharmaceutical industry, monetizing company opportunities, and corporate finance
led to the conclusion that he should serve as a director of our Company in light of our business and structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Gary V. Cantrell &ndash; Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Gary Cantrell joined our Board
in July 2016. He has 30 years of experience in the life sciences industry ranging from clinical experience as a respiratory therapist
to his current exclusive consulting role with Mayne Pharma (ASX: MYX) as Business Development Executive focused on acquiring branded
prescription assets for Mayne&rsquo;s U.S. Specialty Brands Division. Mr. Cantrell served as CEO of Yasoo Health Inc., a global
specialty nutritional company from 2007 through June 2016, highlighted by the sale of its majority asset AquADEKs to Actavis in
March 2016. Previously, he was President of The Catevo Group, a U.S.-based healthcare consulting firm. Prior to that, he was Executive
Vice President, Sales and Marketing for TEAMM Pharmaceuticals, an Accentia Biopharmaceuticals company, where he led all commercial
activities for a public specialty pharmaceutical business. His previous 22 years were at GlaxoSmithKline plc where he held progressively
senior management positions in sales, marketing and business development. Mr. Cantrell is a graduate of Wichita State University
and serves as an advisor to several emerging life science companies. He served as a director for Yasoo Health Inc., Yasoo Health
Limited and Flexible Stenting Solutions, Inc., a leading developer of next generation peripheral arterial, venous, neurovascular
and biliary stents, which was sold to Cordis, while a Division of Johnson &amp; Johnson in March 2013. Mr. Cantrell served as
a director of Vyrix Pharmaceuticals from February 2014 to April 2015.Mr. Cantrell&rsquo;s experience in consulting and executive
management within the pharmaceutical industry led to the conclusion that he should serve as a director of our company in light
of our business and structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Carl C. Dockery &ndash; Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Carl Dockery joined our Board
in April 2016. Mr. Dockery is a financial executive with 30 years of experience as an executive in the insurance and reinsurance
industry and more recently in 2006 as the founder and president of a registered investment advisory firm, Alpha Advisors, LLC.
Mr. Dockery&rsquo;s career as an insurance executive began in 1988 as an officer and director of two related and closely held
insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as vice president of Gulf
Insurance Co. Ltd. of Grand Cayman. Familiar with the London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd&rsquo;s
and the London Underwriting Centre brokering various types of reinsurance placements. Mr. Dockery serves as a director of CytoDyn
Inc. (OTCQB: &ldquo;CYDY&rdquo;), a biotechnology company. Mr. Dockery graduated from Southeastern University with a Bachelor
of Arts in Humanities. Mr. Dockery&rsquo;s financial expertise and experience, as well as his experience as a director of a publicly
traded biopharmaceutical company, led to the conclusion that he should serve as a director of our company in light of our business
and structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>John A. Donofrio, Jr. &ndash;
Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000; background-color: white">John
Donofrio </FONT><FONT STYLE="color: #000000">joined our Board in July 2016. He <FONT STYLE="background-color: white">is a Senior
Finance Executive with </FONT>24 years of experience in the pharmaceutical industry across a broad range of areas, including consolidated
financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting,
inventory management, supply chain, transfer pricing, budget and forecast planning, integration of mergers and acquisitions and
business development.<FONT STYLE="background-color: white"> He has served as the </FONT>Chief Financial Officer and Head of North
American Business Development for Merz North America, or Merz, since August 2013. Merz is a specialty healthcare company that
develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada.&nbsp;At
Merz, Mr. Donofrio is accountable for financial performance, cost management, business development and strategic business planning
and analysis for the finance organization in North America. Prior to joining Merz, Mr. Donofrio served as Vice President, Stiefel
Global Finance, U.S. Specialty Business and Puerto Rico for Stiefel, a GlaxoSmithKline plc company from July 2009 to July 2013.
In that role, Mr. Donofrio was responsible for the financial strategy, management reporting, and overall control framework for
the Global Dermatology Business Unit. He was also the Senior Finance Partner accountable for the U.S. Specialty Business Units
of GlaxoSmithKline plc. Mr. Donofrio served as a director of Vyrix Pharmaceuticals from February 2014 to April 2015. Mr. Donofrio
holds a degree in Accounting from North Carolina State University. Mr. Donofrio&rsquo;s financial expertise and experience in
the pharmaceutical industry, led to the conclusion that he should serve as a director of our company in light of our business
and structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Michael Macaluso &ndash; Director</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Michael Macaluso has been a member
of our Board of Directors since April 2015. Mr. Macaluso is also the Chairman and Chief Executive Officer of Ampio. Mr. Macaluso
has been a member of Ampio Pharmaceuticals&rsquo; Board of Directors since March 2010 and Ampio&rsquo;s Chief Executive Officer
since January 2012. Mr. Macaluso served in the roles of president and Chief Executive Officer of Isolagen, Inc. (AMEX: ILE) from
June 2001 until September 2004. Mr. Macaluso also served on the board of directors of Isolagen from June 2001 until April 2005.
From October 1998 until June 2001, Mr. Macaluso was the owner of Page International Communications, a manufacturing business.
Mr. Macaluso was a founder and principal of International Printing and Publishing, a position Mr. Macaluso held from 1989 until
1997, when he sold that business to a private equity firm. Mr. Macaluso&rsquo;s experience in executive management and marketing
within the pharmaceutical industry, monetizing company opportunities, and corporate finance led to the conclusion that he should
serve as a director of our company in light of our business and structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Jarrett T. Disbrow &ndash;
Chief Operating Officer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Jarrett Disbrow has been employed
by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive Officer of Vyrix from November
2013. Mr. Disbrow joined Vyrix from Eurus Pharma LLC, or Eurus Pharma, where he held the position of general manager from 2011
to 2013. Prior to joining Eurus Pharma, Mr. Disbrow was the founder, president and chief executive officer of Arbor Pharmaceuticals,
Inc., or Arbor Pharmaceuticals from 2006 to 2010. Following Arbor Pharmaceuticals&rsquo; acquisition in 2010, Mr. Disbrow remained
with the company as vice president of commercial development. Prior to founding Arbor Pharmaceuticals in 2006, he was head of
marketing for Accentia Biopharmaceuticals, Inc. from 2002 to 2006. Mr. Disbrow began his career with GlaxoWellcome, Inc. (now
GlaxoSmithKline plc) from 1997 to 2001, where he held positions of increasing responsibility in sales and later marketing. Mr.
Disbrow received a BS in business management from North Carolina State University in Raleigh, NC. Mr. Disbrow served on our Board
of Directors from April 2015 to July 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>Gregory A. Gould &ndash; Chief
Financial Officer, Secretary, and Treasurer</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory A. Gould has been our Chief Financial Officer since
April 16, 2015. However, prior to joining Aytu on a full time basis in June 2017, he split his time between Aytu and Ampio Pharmaceuticals,
Inc. from April 2015 until June 2017. Mr. Gould joined Ampio as their Chief Financial Officer, Secretary and Treasurer in June
2014. Prior to joining Ampio, he provided financial and operational consulting services to the biotech industry through his consulting
company, Gould LLC from April 2012 until June 2014. Mr. Gould was Chief Financial Officer, Treasurer and Secretary of SeraCare
from November 2006 until the company was sold to Linden Capital Partners in April 2012. During the period from July 2011 until
April 2012 Mr. Gould also served as the Interim President and Chief Executive Officer of SeraCare Life Sciences. Mr. Gould has
held several other executive positions at publicly traded life sciences companies including the Chief Financial Officer role at
Atrix Laboratories, Inc., an emerging specialty pharmaceutical company focused on advanced drug delivery. During Mr. Gould&rsquo;s
tenure at Atrix he was instrumental in the negotiation and sale of the company to QLT, Inc. (now Novelion Therapeutics, Inc.)
for over $855 million. He also played a critical role in the management of several licensing agreements including the global licensing
agreement with Sanofi-Synthelabo of the Eligard&reg; products. Mr. Gould was the Chief Financial Officer at Colorado MedTech,
Inc., a publicly traded medical device design and manufacturing company where he negotiated the transaction to sell the company
to KRG Capital Partners. Mr. Gould began his career as an auditor with Arthur Andersen, LLP. He currently serves on the board
of directors of CytoDyn, Inc., a publicly traded drug development company pursuing anti-viral agents for the treatment of HIV.
Mr. Gould graduated from the University of Colorado with a BS in Business Administration and is a Certified Public Accountant.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Family Relationships&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Jarrett T. Disbrow, our Chief
Operating Officer, is the brother of Joshua R. Disbrow, our Chief Executive Officer and a director. There are no other family
relationships among or between any of our current or former executive officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Involvement in Certain Legal
Proceedings&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">None of our directors or executive
officers has been involved in any legal proceeding in the past 10 years that would require disclosure under Item 401(f) of Regulation
S-K promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Section 16(a) Beneficial Ownership
Reporting Compliance </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Section&nbsp;16(a) of the Securities
Exchange Act requires our officers and directors and persons who own more than 10% of our outstanding common stock to file reports
of ownership and changes in ownership with the Securities and Exchange Commission.&nbsp;These officers, directors and stockholders
are required by regulations under the Securities Exchange Act to furnish us with copies of all forms they file under Section&nbsp;16(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Based solely on our review of
the copies of forms we have received, we believe that all such required reports have been timely filed, except for the following:
a Form 3 and Form 4 for John Donofrio to report the appointment as a director, the issuance of restricted stock and stock options,
which reports were due on July 15, 2016, and were filed on July 18, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Code of Ethics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The information required by this
Item regarding our Code of Ethics is found in Part I, Item 1, under the caption &ldquo;Code of Ethics.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Board Committees </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our Board has established an Audit
Committee, Compensation Committee and Nominating and Governance Committee.&nbsp;Our Audit Committee consists of Mr. Donofrio (Chair),
Mr. Cantrell and Mr. Dockery.&nbsp;Our Compensation Committee consists of Mr. Cantrell (Chair), Mr. Dockery and Mr. Donofrio.&nbsp;Our
Nominating and Governance Committee consists of Mr. Dockery (Chair), Mr. Cantrell and Mr. Donofrio. The independence of our directors
is discussed in Part III, Item 13 under the caption &ldquo;Director Independence.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Each of the above-referenced committees
operates pursuant to a formal written charter. The charters for these committees, which have been adopted by our Board, contain
a detailed description of the respective committee&rsquo;s duties and responsibilities and are available on our website at <U>http://www.aytubio.com
</U>under the &ldquo;Investor Relations&mdash;Corporate Governance&rdquo; tab.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our Board has determined Mr. Donofrio
qualifies as an audit committee financial expert, as defined in Item&nbsp;407(d)(5) of Regulation S-K promulgated by the SEC.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Stockholder Proposals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our bylaws establish procedures
for stockholder nominations for elections of directors and bringing business before any annual meeting or special meeting of stockholders.
A stockholder entitled to vote in the election of directors may nominate one or more persons for election as directors at a meeting
only if written notice of such stockholder&rsquo;s intent to make such nomination or nominations has been delivered to our Corporate
Secretary at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary of the
prior year&rsquo;s annual meeting. In the event that the date of the annual meeting is more than 30 days before or more than 60
days after the anniversary date of the prior year&rsquo;s annual meeting, the stockholder notice must be given not more than 120
days nor less than the later of 90 days prior to the date of the annual meeting or, if it is later, the 10<SUP>th</SUP> day following
the date on which the date of the annual meeting is first publicly announced or disclosed by us. These notice deadlines are the
same as those required by the SEC&rsquo;s Rule 14a-8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Pursuant to the bylaws, a stockholder&rsquo;s
notice must set forth among other things: (a) as to each person whom the stockholder proposes to nominate for election or reelection
as a director all information relating to such person that is required to be disclosed in solicitations of proxies for election
of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange
Act of 1934, as amended, or the Exchange Act, and the rules and regulations thereunder; and (b) as to any other business that
the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting,
the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the
beneficial owner, if any, on whose behalf the proposal is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">There have been no changes to
these nominating procedures since the adoption of the bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><A NAME="a_019"></A><B>Item&nbsp;11.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Executive
Compensation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Executive Compensation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In accordance with Item 402 of
Regulation S-K promulgated by the SEC, we are required to disclose certain information regarding the makeup of and compensation
for our company&rsquo;s directors and named executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In establishing executive compensation,
our Board is guided by the following goals:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="width: 95%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">compensation should consist
        of a combination of cash and equity awards that are designed to fairly pay the executive officers and directors for work
        required for a company of our size and scope;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">compensation should align
        the executive officers&rsquo; and directors&rsquo; interests with the long-term interests of stockholders; and</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">compensation
    should assist with attracting and retaining qualified executive officers and directors. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Compensation of Directors&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our current compensation package
for non-employee directors, effective July 1, 2017, consists of: an annual cash retainer of $40,000 for the board chair, $25,000
for each other director, $10,000 for each committee chair and $5,000 for each other committee member; a grant of 65,000 restricted
shares of stock upon appointment to the board; and an annual stock option grant of 15,000 shares thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following table provides information
regarding all compensation paid to non-employee directors of Aytu during the fiscal year ended June 30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Name</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Fees Earned&nbsp;or<BR>
    Paid in Cash</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Stock Option<BR> Awards
    (1)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">All Other<BR> Compensation<BR>
    (2)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Total</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="color: #000000">Gary V. Cantrell (3)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">45,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">46,860</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">209,950</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">301,810</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Carl C. Dockery (3)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">45,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">20,840</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">209,950</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">275,790</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">John A. Donofrio Jr. (3)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">45,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">46,860</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">209,950</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">301,810</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Michael E. Macaluso (3)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">25,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">70,331</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">209,950</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">305,281</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #000000">(1)</FONT></TD><TD><FONT STYLE="color: #000000">This column reflects the aggregate
                                         grant date fair value computed in accordance with Financial Accounting Standards Board,
                                         or FASB, issued Accounting Standards Update, or ASC, Topic 718</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #000000">(2)</FONT></TD><TD><FONT STYLE="color: #000000">This column reflects the aggregate
                                         grant date fair value of restricted stock.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #000000">(3)</FONT></TD><TD><FONT STYLE="color: #000000">As of June 30, 2017, the number
                                         of shares underlying options and restricted shares held by each non-employee director
                                         was as follows: 750 options and 3,250 restricted shares for Mr. Cantrell; 334 options
                                         and 3,250 restricted shares for Mr. Dockery; 750 options and 3,250 restricted shares
                                         for Mr. Donofrio; 1,125 options and 3,250 restricted shares for Mr. Macaluso. Gary V.
                                         Cantrell and John A. Donofrio Jr. were each appointed a director in July 2016 and therefore
                                         received no compensation or equity awards from Aytu in the fiscal year ended June 30,
                                         2016.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Executive Officer Compensation&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following table sets forth
all cash compensation earned, as well as certain other compensation paid or accrued for the years ended June 30, 2017 and 2016
to each of the following named executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Name and Principal Position</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Year</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Salary ($)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Bonus ($)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Stock<BR>
 Award ($)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Option<BR>
 Award<BR>
 ($)(1)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Non-Equity<BR>
 Incentive Plan<BR>
 Compensation<BR>

    ($)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Change in<BR>
 Pension Value<BR>
 and<BR>
 Nonqualified<BR>

    Deferred<BR>
 Compensation<BR>
 Earnings ($)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">All Other<BR>
 Compensation ($)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Total ($)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(a)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(b)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(c)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(d)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(e)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(f)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(g)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(h)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(i)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">(j)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Named Executive Officers</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Joshua R. Disbrow</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 19%; font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Chief Executive Officer</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">250,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">614,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">189,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">1,053,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">since December 2012</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">250,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">313,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">559,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,122,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Jarrett T. Disbrow</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Chief Operating Officer, Secretary</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">250,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">533,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">189,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">972,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">and Treasurer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">250,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">288,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">559,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,097,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Gregory A. Gould (2)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Chief Financial Officer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">533,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">79,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">622,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">since June 2014</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">250,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">250,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Jonathan H. McGrael (3)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">VP of Commercial Operations</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">144,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">75,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">452,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">91,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">61,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">(4)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">823,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">140,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">238,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">186,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">13,000</FONT></TD><TD STYLE="text-align: left">(4)</TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">577,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="color: #000000"><SUP>(1)</SUP></FONT></TD><TD><FONT STYLE="color: #000000">Option awards are
                                         reported at fair value at the date of grant. See Item 15 of Part IV, &ldquo;Notes to
                                         the Financial Statements &mdash; Note 11 &mdash; Equity Instruments.&rdquo;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="color: #000000"><SUP>(2)</SUP></FONT></TD><TD><FONT STYLE="color: #000000">Mr. Gould was appointed
                                         to Chief Financial Officer, Secretary and Treasurer full time effective June 16, 2017.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="color: #000000"><SUP>(3)</SUP></FONT></TD><TD><FONT STYLE="color: #000000">Mr. McGrael was hired
                                         in September 2015 and he resigned in March, 2017.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 13.5pt"><FONT STYLE="color: #000000"><SUP>(4)</SUP></FONT></TD><TD><FONT STYLE="color: #000000">Represents reimbursed
                                         relocation expenses and severance.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -13.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our executive officers are reimbursed
by us for any out-of-pocket expenses incurred in connection with activities conducted on our behalf. Executives are reimbursed
for business expenses directly related to Aytu business activities, such as travel, primarily for business development as we grow
and expand our product lines. On average, each executive incurs between $1,000 to $3,000 of out-of-pocket business expenses each
month. The executive management team meets weekly and determines which activities they will work on based upon what we determine
will be the most beneficial to our company and our shareholders. No interest is paid on amounts reimbursed to the executives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="color: #000000"><B>Grants
of Plan-Based Awards&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following table sets forth
certain information regarding grants of plan-based awards to the Named Executive Officers during the year ended June 30, 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Name</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Grant Date</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">All Other Option<BR> Awards:
    Number of<BR> Securities<BR> Underlying Options<BR>
    (#)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Exercise Price<BR> of Option<BR>
    Awards<BR> ($/Share)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Grant Date<BR> Fair Value
    of<BR> Option Awards<BR> ($)(1)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="color: #000000">Named Executive Officers</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Joshua R Disbrow</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%; text-align: center"><FONT STYLE="color: #000000">7/7/2016</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">3,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">16.40</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">188,895</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Jarrett T Disborw</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">7/7/2016</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">3,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">16.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">188,895</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Gregory A Gould</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">7/7/2016</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,250</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">16.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">78,706</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="color: #000000">(1)</FONT></TD><TD><FONT STYLE="color: #000000">The amounts reported
                                         in this column represent the aggregate grant date fair value computed in accordance with
                                         FASB ASC 718, excluding the effect of any estimated forfeitures and may not correspond
                                         to the actual value that will be realized by the named executive officer.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Outstanding Equity Awards at
Fiscal Year-End 2017 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following table contains certain
information concerning unexercised options for the Named Executive Officers as of June 30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="16" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option
    Awards</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Stock
    Awards</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Name</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Number of<BR>
 Securities<BR>
 Underlying<BR>

    Unexercised<BR>
 Options<BR>
 Exercisable (#)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Number of<BR>
 Securities<BR>
 Underlying<BR>

    Unexercised<BR>
 Options<BR>
 Unexercisable<BR>
 (#)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Equity Incentive<BR>
 Plan Awards:<BR>
 Number
    of<BR>
 Securities<BR>
 Underlying<BR>
 Unexercised<BR>
 Unearned<BR>
 Options (#)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Option<BR>
 Exercise<BR>
 Price ($)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Option<BR>
 Expiration<BR>
 Date</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Number of<BR>
 Shares or<BR>
 Units of Stock<BR>

    That Have Not<BR>
 Vested (#)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Market Value<BR>
 of Shares or <BR>
Units
    of Stock<BR>
 That Have Not<BR>
 Vested ($) (1)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Equity<BR>
 Incentie Plan<BR>
 Awards:<BR>
 Number
    of<BR>
 Unearned<BR>
 Shares, Units<BR>
 or Other<BR>
 Rights That<BR>
 Have Not<BR>
 Vested (#)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Equity<BR>
 Incentive<BR>
 Plan Awards:<BR>
 Market
    or<BR>
 Payout Value<BR>
 of Unearned<BR>
 Shares, Units<BR>
 or Other<BR>
 Rights That<BR>
 Have Not<BR>
 Vested ($)</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Named Executive Officers</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; text-align: left"><FONT STYLE="font-size: 8pt">Joshua R. Disbrow</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">834</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">1,666</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">16.40</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">11/11/2025</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">9,500</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">112,100</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Joshua R. Disbrow</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7/7/2026</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Jarrett T. Disbrow</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">834</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,666</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">11/11/2025</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8,250</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">97,350</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Jarrett T. Disbrow</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7/7/2026</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Gregory A. Gould</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,042</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">11/11/2025</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">825</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">97,350</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Gregory A. Gould</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">417</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">833</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7/7/2026</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Jonathan H. McGrael</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">834</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">11/11/2025</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Jonathan H. McGrael</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,167</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16.40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7/7/2026</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">Based on $11.80 per share
which was the closing price of our common stock on OTCQX on June 30, 2017, the last trading day of that fiscal year.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Employment Agreements&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We entered into an employment
agreement with Joshua Disbrow in connection with his employment as our Chief Executive Officer. The agreement is for a term of
24 months beginning on April 16, 2015, subject to termination by us with or without Cause or as a result of officer&rsquo;s disability,
or by the officer with or without Good Reason (as discussed below). Mr. Disbrow is entitled to receive $250,000 in annual salary,
plus a discretionary performance bonus with a target of 125% of his base salary. Mr. Disbrow is also eligible to participate in
the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans. On April 16, 2017, we
extended this agreement for another 24 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We entered into an employment
agreement with Jarrett Disbrow, our Chief Operating Officer, in connection with his employment with us. The agreement is for a
term of 24 months beginning on April 16, 2015, subject to termination by us with or without Cause or as a result of the officer&rsquo;s
disability, or by the officer with or without Good Reason (as discussed below). Mr. Disbrow is entitled to receive $250,000 in
annual salary, plus a discretionary performance bonus with a target of 125% of his base salary. Mr. Disbrow is also eligible to
participate in the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans. On April
16, 2017, we extended this agreement for another 24 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 15, 2017, we entered into an employment agreement with
Gregory A. Gould, effective June 16, 2017, to serve as our Chief Financial Officer. Mr. Gould had been serving as our Chief Financial
Officer on a part-time basis since April 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The agreement is identical to the two-year employment agreement
entered into effective April 16, 2017, with Jarrett Disbrow, our Chief Operating Officer, except for the positon that Mr. Gould
is to occupy. The agreement is for a term of 24 months beginning on June 16, 2017, subject to termination by us with or without
Cause (as defined below) or as a result of Mr. Gould&rsquo;s disability, or by Mr. Gould with or without Good Reason (as defined
below). Mr. Gould is entitled to receive $250,000 in annual salary, plus a discretionary performance bonus with a target of 125%
of his base salary, based on his individual achievements and company performance objectives established by the board or the compensation
committee in consultation with Mr. Gould. Mr. Gould is also eligible to participate in the benefit plans maintained by us from
time to time, subject to the terms and conditions of such plans<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Payments Provided Upon Termination
for Good Reason or Without Cause&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the employment agreements, in the event employment is terminated without Cause by us or the officer
terminates his employment with Good Reason, we will be obligated to pay him any accrued compensation and a lump sum payment equal
to two times his base salary in effect at the date of termination, as well as continued participation in the health and welfare
plans for up to two years. All vested stock options shall remain exercisable from the date of termination until the expiration
date of the applicable award. So long as a Change in Control is not in effect, then all options which are unvested at the date
of termination Without Cause or for Good Reason shall be accelerated as of the date of termination such that the number of option
shares equal to 1/24<SUP>th</SUP> the number of option shares multiplied by the number of full months of such officer&rsquo;s employment
shall be deemed vested and immediately exercisable by the officer. Any unvested options over and above the foregoing shall be cancelled
and of no further force or effect, and shall not be exercisable by such officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&ldquo;Good Reason&rdquo; means,
without the officer&rsquo;s written consent, there is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="width: 95%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">a material
reduction in the officer&rsquo;s overall responsibilities or authority, or scope of duties (it being understood that the occurrence
of a Change in Control shall not, by itself, necessarily constitute a reduction in the officer&rsquo;s responsibilities or authority);</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">a material reduction of
the level of the officer&rsquo;s compensation (excluding any bonuses) (except where there is a general reduction applicable to
the management team generally, provided, however, that in no case may the base salary be reduced below certain specified amounts);
or</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">a material change in the principal
    geographic location at which the officer must perform his services. </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&ldquo;Cause&rdquo;, means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="width: 95%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">conviction of, or entry of a plea
of guilty to, or entry of a plea of nolo contendere with respect to, any crime, other than a traffic violation or a misdemeanor;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">willful malfeasance or
willful misconduct by the officer in connection with his employment;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">gross negligence in performing
any of his duties;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">willful and deliberate
violation of any of our policies;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">unintended but material
breach of any written policy applicable to all employees adopted by us which is not cured to the reasonable satisfaction of the
board;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">unauthorized use or disclosure
of any proprietary information or trade secrets of us or any other party as to which the officer owes an obligation of nondisclosure
as a result of the officer&rsquo;s relationship with us;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">willful and deliberate
breach of his obligations under the employment agreement; or</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">any
    other material breach by officer of any of his obligations which is not cured to the reasonable satisfaction of the board.
    </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Payments Provided Upon a
Change in Control&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In the event of a Change in Control
of us, all stock options, restricted stock and other stock-based grants granted or may be granted in the future by us to the officers
will immediately vest and become exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&ldquo;Change in Control&rdquo;
means: the occurrence of any of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></td>
    <td style="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">the
    acquisition by any individual, entity, or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (the
    &ldquo;Acquiring Person&rdquo;), other than us, or any of our Subsidiaries, of beneficial ownership (within the meaning of
    Rule 13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of the then
    outstanding voting securities of us entitled to vote generally in the election of directors (excluding any issuance of securities
    by us in a transaction or series of transactions made principally for bona fide equity financing purposes); or</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></td>
    <td style="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">the acquisition of us by another entity
    by means of any transaction or series of related transactions to which we are party (including, without limitation, any stock
    acquisition, reorganization, merger or consolidation but excluding any issuance of securities by us in a transaction or series
    of transactions made principally for bona fide equity financing purposes) other than a transaction or series of related transactions
    in which the holders of the voting securities of us outstanding immediately prior to such transaction or series of related
    transactions retain, immediately after such transaction or series of related transactions, as a result of shares in us held
    by such holders prior to such transaction or series of related transactions, at least a majority of the total voting power
    represented by the outstanding voting securities of us or such other surviving or resulting entity (or if we or such other
    surviving or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent); or</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></td>
    <td style="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">the sale or other disposition of all
    or substantially all of the assets of us in one transaction or series of related transactions. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our only obligation to Joshua
Disbrow, Jarrett Disbrow and Gregory A. Gould had a Change in Control occurred as of June 30, 2017, would be the acceleration
of the vesting of all options held by them at that date. On June 30, 2017, the closing price of our common stock was below the
exercise price for all of the options held by Joshua Disbrow, Jarrett Disbrow and Gregory A. Gould and therefore there would have
been no economic benefit to them upon the acceleration of vesting of those options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><A NAME="a_020"></A><B>Item&nbsp;12.
</B>&#9;<B>&nbsp;&nbsp;&nbsp;&nbsp;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following table sets forth
information with respect to the beneficial ownership of our common stock as of August&nbsp;15, 2017 for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 4%; font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="width: 2%; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #000000">&middot;</FONT></td>
    <td style="width: 94%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">each beneficial owner of more than 5%
    of our outstanding common stock;</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #000000">&middot;</FONT></td>
    <td style="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">each of our director and named executive officers;
    and</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt; color: #000000">&middot;</FONT></td>
    <td style="font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">all of our directors and executive officers as a
    group.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute
beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those
securities and include common stock that can be acquired within 60 days of August&nbsp;15, 2017. The percentage ownership information
shown in the table is based upon 4,021,822 shares of common stock outstanding as of August&nbsp;15, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Except as otherwise indicated,
all of the shares reflected in the table are shares of common stock and all persons listed below have sole voting and investment
power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is
not necessarily indicative of beneficial ownership for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In computing the number of shares
of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common
stock subject to options and warrants held by that person that are immediately exercisable or exercisable within 60 days of August&nbsp;15,
2017. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.
Beneficial ownership representing less than 1% is denoted with an asterisk (*). The information in the table below is based on
information known to us or ascertained by us from public filings made by the stockholders. Except as otherwise indicated in the
table below, addresses of the director, executive officers and named beneficial owners are in care of Aytu BioScience, Inc., 373
Inverness Parkway, Suite 206, Englewood, Colorado 80112.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">Name of Beneficial Owner</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Number of Shares Beneficially Owned</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Percentage of Shares Beneficially Owned</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">5% Stockholders:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">G. Nicholas Farwell &amp;
    Gale Farwell TTEE U/A 12-2-98 FBO Farwell Family Trust <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">583,334</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">13.34</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">AIGH Partners LP<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(2)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">453,750</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10.57</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Armistice Capital Master Fund Ltd <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(3)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">405,667</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9.99</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Jeb Partners, L.P. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(4)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">424,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9.99</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Galileo Partners Fund I, L.P. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(5)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">375,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8.83</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Pacific Capital Mgmt LLC <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(6)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">291,663</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.95</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Triple Gate Partners, LP <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(7)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">250,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.99</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Lincoln Park Capital <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(8)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">250,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.99</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Manchester Management Company, LCC <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(9)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">210,331</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.10</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Clifford Disbrow <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(10)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">208,334</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.02</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Sheila Ryan Disbrow <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(11)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">208,334</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.02</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Directors and Named Executive Officers:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Joshua R. Disbrow <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(12)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">243,125</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.86</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Jarrett T. Disbrow <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(13)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">240,219</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.79</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Gregory A. Gould <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(14)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,471</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Michael Macaluso <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(15)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,802</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: left">Carl C. Dockery<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(16)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">45,865</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.14</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal">John Donofrio<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(17)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal">Gary Cantrell<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><SUP>(18)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,521</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">All directors and executive officers as a group (seven persons)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">566,003</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13.22</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt"><FONT STYLE="color: #000000">* Represents beneficial
ownership of less than 1%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 233,334
shares of common stock and 350,000 shares of common stock issuable upon the exercise of warrants exercisable within 60 days of
August 15, 2017.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 181,500
shares of common stock and 272,250 shares of common stock issuable upon the exercise of warrants exercisable within 60 days of
August 15, 2017.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on information
provided in a Schedule 13G filed by Armistice Capital, LLC (&ldquo;Armistice&rdquo;) on August 24, 2017. Includes 366,667 shares
of common stock and 39,000 shares of common stock issuable upon the exercise of warrants exercisable within 60 days of August
15, 2017.&nbsp;&nbsp;Armistice is contractually limited to beneficial ownership of our common shares not to exceed 9.99% and this
limitation has been taken into account in calculating the number of shares shown in the table for Armistice. The table does not
include the following securities held by Armistice: (i) 633,333 shares of common stock underlying shares of Series A Preferred
Stock and (ii) 1,461,000 shares of common stock issuable upon the exercise of warrants.&nbsp;&nbsp;The Managing Member of Armistice
is Steven Boyd and its address is 510 Madison Avenue, 22<SUP>nd</SUP> Floor, New York, New York 10022.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(4)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 200,000
shares of common stock and 224,000 shares of common stock issuable upon the exercise of warrants exercisable within 60 days of
August 15, 2017.&nbsp;&nbsp;Jeb Partners, L.P. is contractually limited to beneficial ownership of our common shares not to exceed
9.99% and this limitation has been taken into account in calculating the number of shares shown in the table for Jeb Partners,
L.P. The table does not include 76,000 shares of common stock issuable upon the exercise of warrants held by Jeb Partners, L.P.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(5)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on information
provided in a Schedule 13G filed by Manchester Management Company, LCC (&ldquo;Manchester&rdquo;) on August 23, 2017.&nbsp;&nbsp;Consists
of 4,206,614 shares held by Manchester and 1,357,341 shares held by the managing member of Manchester, James E. Besser.&nbsp;&nbsp;Manchester&rsquo;s
address is 3 West Hill Place, Boston, Massachusetts 02114.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(6)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 150,000
shares of common stock and 225,000 shares of common stock issuable upon the exercise of warrants exercisable within 60 days of
August 15, 2017.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(7)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 116,665
shares of common stock and 174,998 shares of common stock issuable upon the exercise of warrants exercisable within 60 days of
August 15, 2017.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(8)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 100,000
shares of common stock and 150,000 shares of common stock issuable upon the exercise of warrants exercisable within 60 days of
August 15, 2017.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(9)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 100,000
shares of common stock and 150,000 shares of common stock issuable upon the exercise of warrants exercisable within 60 days of
August 15, 2017.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(10)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 83,334 shares
of common stock and 125,000 shares of common stock issuable upon the exercise of warrants exercisable within 60 days of August
15, 2017.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(11)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 83,334 shares
of common stock and 125,000 shares of common stock issuable upon the exercise of warrants exercisable within 60 days of August
15, 2017.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(12)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of (i)&nbsp;105,344
shares, (ii)&nbsp;9,500 restricted shares (iii) 1,834 vested options to purchase shares of stock, (iv) 1,447 shares issuable upon
the exercise warrants and (v) 125,000 shares issuable upon the exercise of warrants exercisable within 60 days of August 15, 2017.
Does not include 2,328 shares held by an irrevocable trust for estate planning in which Mr. Disbrow is a beneficiary. Mr. Disbrow
does not have or share investment control over the shares held by the trust, Mr. Disbrow is not the trustee of the trust (nor
is any member of Mr. Disbrow&rsquo;s immediate family) and Mr. Disbrow does not have or share the power to revoke the trust. As
such, under Rule 16a-8(b) and related rules, Mr. Disbrow does not have beneficial ownership over the shares purchased and held
by the trust.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(13)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of (i)&nbsp;105,135
shares, (ii)&nbsp;8,230 restricted shares, (iii) 1,834 vested options to purchase shares of common stock and (iv) 125,000 shares
issuable upon the exercise of warrants exercisable within 60 days of August 15, 2017. Does not include 2,328 shares held by an
irrevocable trust for estate planning in which Mr. Disbrow is a beneficiary. Mr. Disbrow does not have or share investment control
over the shares held by the trust, Mr. Disbrow is not the trustee of the trust (nor is any member of Mr. Disbrow&rsquo;s immediate
family) and Mr. Disbrow does not have or share the power to revoke the trust. As such, under Rule 16a-8(b) and related rules,
Mr. Disbrow does not have beneficial ownership over the shares purchased and held by the trust.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(14)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of (i)&nbsp;8,762
shares, (ii)&nbsp;8,250 restricted shares, and (iii)&nbsp;vested options to purchase 1,459 shares of common stock.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(15)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of (i)&nbsp;1,489
shares, (ii)&nbsp;3,250 restricted shares, and (iii)&nbsp;vested options to purchase 2,063 shares of common stock.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(16)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of (i)&nbsp;3,250
restricted shares, (ii)&nbsp;vested options to purchase 750 shares of common stock, and (iii)&nbsp;41,865 shares held by Alpha
Venture Capital Partners, L.P&nbsp;&nbsp;Mr. Dockery is the President of the general partner of Alpha Venture Capital Partners,
L.P. and therefore may be deemed to beneficially own the shares beneficially owned by Alpha Venture Capital Partners, L.P.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(17)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of (i)&nbsp;3,250
restricted shares, and (ii)&nbsp;vested options to purchase 750 shares of common stock.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(18)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consists of (i)&nbsp;3,250
restricted shares, (ii)&nbsp;3,521 shares, and (iii)&nbsp;vested options to purchase 750 shares of common stock.</FONT></TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Information regarding our equity
compensation plans is contained in Part II, Item 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><A NAME="a_021"></A><B>Item&nbsp;13.
</B>&#9;<B>&nbsp;&nbsp;&nbsp;&nbsp;Certain Relationships, Related Transactions, and Director Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>Related
Party Transactions&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We describe below all transactions
and series of similar transactions, other than compensation arrangements, during the last three fiscal years, to which we were
a party or will be a party, in which:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></td>
    <td style="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">the amounts involved exceeded or will
    exceed $120,000; and</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">&bull;</FONT></td>
    <td style="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt; color: #000000">any of our directors, executive officers
    or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will
    have a direct or indirect material interest. </FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Services Agreements&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In January 2013, Luoxis entered
into a services agreement with Ampio whereby Ampio provides corporate overhead services and a shared facility with Luoxis in exchange
for $15,000 per month. The amount can be modified in writing upon the consent of both parties. The agreement may be terminated
at any time by either party. In January 2014, Vyrix entered into a services agreement with Ampio whereby Ampio provides corporate
overhead services to Vyrix in exchange for $7,000 per month. The amount can be modified in writing upon the consent of both parties.
The agreement may be terminated at any time by either party. Both agreements were assigned to us upon the closing of the Merger.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2015, the prior service agreements were canceled and Aytu entered into agreements with Ampio whereby
Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff,
and other miscellaneous overhead expenses. This agreement will be in effect until it is terminated in writing by both parties.
This agreement was amended periodically to reflect the amount of resources used from Ampio, the final amount was $4,000 for the
month of June 2017. This agreement was cancelled in June 2017 and Ampio is no longer considered a related party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Sponsored Research Agreement&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In June 2013, Luoxis entered into
a sponsored research agreement with TRLLC, an entity controlled by Ampio&rsquo;s director and Chief Scientific Officer, Dr. Bar-Or.
The agreement, which was amended in September 2013 and provides for Luoxis to pay $6,000 per month to TRLLC in consideration for
services related to research and development of Luoxis&rsquo; RedoxSYS System. In March 2014, Luoxis also agreed to pay a sum
of $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on
the balance sheet; this amount has been paid in full. This agreement is set to expire March 2019 and cannot be terminated prior
to March 2017. This agreement was cancelled in March 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Review, Approval or Ratification
of Transactions with Related Persons&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="color: #000000">Effective
upon its adoption in July 2016, pursuant to the Audit Committee Charter, the Audit Committee is responsible for reviewing and
approving all related party transactions as defined under Item 404 of Regulation S-K, after reviewing each such transaction for
potential conflicts of interests and other improprieties. Our policies and procedures for review and approval of transactions
with related persons are in writing in our Code of Conduct and Ethics available on our website at <U>http://www.aytubio.com</U>
under the &ldquo;Investor Relations&mdash;Corporate Governance&rdquo; tab.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Prior to the adoption of the Audit
Committee Charter, and due to the small size of our company, we did not have a formal written policy regarding the review of related
party transactions, and relied on our Board of Directors to review, approve or ratify such transactions and identify and prevent
conflicts of interest. Our Board of Directors reviewed any such transaction in light of the particular affiliation and interest
of any involved director, officer or other employee or stockholder and, if applicable, any such person&rsquo;s affiliates or immediate
family members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Director Independence&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Our common stock is not listed
on any exchange. Consequently, no exchange rules regarding director independence are applicable to us. Audit Committee members
must satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, for listed
companies. In order to be considered to be independent for purposes of Rule 10A-3, a member of an audit committee of a listed
company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board
committee: (1) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any
of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Three of our five directors are
independent under the definition of either the NYSE or Nasdaq. The other two directors are not independent under either definition
due to (i) being an executive officer of our Company, in the case of Josh Disbrow, and (ii) the payments we make to Ampio under
the services agreement with Aytu, in the case of Mr. Macaluso.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><A NAME="a_022"></A><B>Item&nbsp;
14.</B>&#9;<B>&nbsp;&nbsp;&nbsp;&nbsp;Principal Accountant Fees and Services </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">EKS&amp;H LLLP has served as our
independent auditor since April 2015, and has been appointed by our Board of Directors to continue as our independent auditor
for the fiscal year ending June 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following table presents aggregate
fees for professional services rendered by our independent registered public accounting firm, EKS&amp;H LLLP, for the audit of
our annual financial statements for the respective periods, all of which were approved by our full Board of Directors for fiscal
2016 and by the Audit Committee for fiscal 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="6" STYLE="text-align: center"><B>Year Ended June 30,</B></TD><TD><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2016</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Audit fees (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">132,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">199,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Audit-related fees (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Tax fees (3)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">Total Fees</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">222,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">311,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #000000"><SUP>(1)</SUP></FONT></TD><TD><FONT STYLE="color: #000000">Audit fees are comprised
                                         of annual audit fees and quarterly review fees.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #000000"><SUP>(2)</SUP></FONT></TD><TD><FONT STYLE="color: #000000">Audit-related fees
                                         for both fiscal year 2016 and 2017 were comprised of fees related to registration statements,
                                         including for our May 2016 public offering and November 2016 public offering, respectively.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #000000"><SUP>(3)</SUP></FONT></TD><TD><FONT STYLE="color: #000000">Tax fees are comprised
                                         of tax compliance, preparation and consultation fees.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="a_023"></A><B>PART&nbsp;IV
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><FONT STYLE="color: #000000"><A NAME="a_024"></A><B>Item&nbsp;
15.</B>&#9;<B>&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Consolidated Financial Statement Schedules </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.7pt; text-indent: -36.7pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36.7pt"><FONT STYLE="color: #000000"><B>(a)(1)</B></FONT></TD><TD><FONT STYLE="color: #000000"><B>Financial Statements
                                         </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><FONT STYLE="color: #000000">The following documents
are filed as part of this Form 10-K, as set forth on the Index to Financial Statements found on page F-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="color: #000000">&bull;</FONT></TD><TD><FONT STYLE="color: #000000">Report of Independent Registered
                                         Public Accounting Firm</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="color: #000000">&bull;</FONT></TD><TD><FONT STYLE="color: #000000">Consolidated Balance Sheets
                                         as of June 30, 2017 and 2016</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="color: #000000">&bull;</FONT></TD><TD><FONT STYLE="color: #000000">Consolidated Statements
                                         of Operations for the years ended June 30, 2017 and 2016</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="color: #000000">&bull;</FONT></TD><TD><FONT STYLE="color: #000000">Consolidated Statements
                                         of Stockholders&rsquo; Equity (Deficit) for the years ended June 30, 2017 and 2016</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="color: #000000">&bull;</FONT></TD><TD><FONT STYLE="color: #000000">Consolidated Statements
                                         of Cash Flows for the years ended June 30, 2017 and 2016</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 30.6pt"></TD><TD STYLE="width: 18.35pt"><FONT STYLE="color: #000000">&bull;</FONT></TD><TD><FONT STYLE="color: #000000">Consolidated Notes to the
                                         Financial Statements</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.7pt; text-indent: -36.7pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36.7pt"><FONT STYLE="color: #000000"><B>(a)(2)</B></FONT></TD><TD><FONT STYLE="color: #000000"><B>Financial Statement
                                         Schedules </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><FONT STYLE="color: #000000">Not Applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.7pt; text-indent: -36.7pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36.7pt"><FONT STYLE="color: #000000"><B>(a)(3)</B></FONT></TD><TD><FONT STYLE="color: #000000"><B>Exhibits </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom; width: 11%"><FONT STYLE="font-size: 10pt; color: #000000"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Description</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 9%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Registrant&rsquo;s</B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt"><B>Form</B></FONT></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 7%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Date</B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt"><B>Filed</B></FONT></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 7%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Exhibit</B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt"><B>Number</B></FONT></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Filed</B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt"><B>Herewith</B></FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">3.1</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Certificate of Incorporation</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">6/09/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">3.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">3.2</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Certificate of Amendment of Certificate of Incorporation effective June
    1, 2016</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">6/02/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">3.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">3.3</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Certificate of Amendment of Certificate of Incorporation, effective June
    30, 2016</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">7/01/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">3.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">3.4</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Certificate of Designation of Preferences, Rights and Limitations of Series
    A Convertible Preferred Stock, filed on August 11, 2017.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8/16/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">3.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">3.5</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Certificate of Amendment of Certificate of Incorporation, effective August
    25, 2017</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8/29/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">3.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">3.6</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Bylaws</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">6/09/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">3.2</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">4.2</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Form of Placement Agent Warrant issued in 2015 Convertible Note Financing</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">7/24/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4.2</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">4.3</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Warrant Agent Agreement, dated May 6, 2016 by and between Aytu BioScience,
    Inc. and VStock Transfer, LLC.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">5/6/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">4.4</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">First Amendment to May 6, 2016 Warrant Agent Agreement between Aytu BioScience,
    Inc. and VStock Transfer LLC.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">S-1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">9/21/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4.5</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">4.5</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Warrant Agent Agreement, dated November 2, 2016 by and between Aytu BioScience,
    Inc. and VStock Transfer, LLC.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">11/2/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">4.6</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Form of Amended and Restated Underwriters&rsquo; Warrant (May 2016 Financing)</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">3/1/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">4.7</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Form of Amended and Restated Underwriters&rsquo; Warrant (October 2016 Financing)</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">3/1/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4.2</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">4.8</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Form of Common Stock Purchase Warrant issued on August 15, 2017.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8/16/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.1&dagger;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Form of Indemnification Agreement, to be entered into between the Registrant
    and its directors and officers</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4/22/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.2#</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Asset Purchase Agreement between the Registrant (as assigned to it by Ampio/Vyrix)
    and Valeant International (Barbados) SRL, effective as of December 2, 2011</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K/A</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">6/08/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.4</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.3#</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Manufacturing and Supply Agreement between the Registrant (as assigned to
    it by Ampio/Vyrix) and Ethypharm S.A., dated September 10, 2012</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K/A</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">6/08/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.5</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.4</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">License, Development and Commercialization Agreement between the Registrant
    (as assigned to it by Ampio/Vyrix) and Daewoong Pharmaceuticals Co., Ltd., effective as of August 23, 2011 (incorporated by
    reference to Exhibit 10.1 of Ampio Pharmaceutical&rsquo;s Form 8-K/A filed October 5, 2011; </FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt">File No. 001-25182)</FONT></FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.5#</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Distribution Agreement between the Registrant (as assigned to it by Ampio/Vyrix)
    and FBM Industria Farmaceutica, Ltda., dated as of </FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt">March&nbsp;1, 2012</FONT></FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K/A</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">6/08/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.7</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.6#</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Distribution and License Agreement between the Registrant (as assigned to
    it by Ampio/Vyrix) and Endo Ventures Limited, dated April 9, 2014</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K/A</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">6/08/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.8</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.7#</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Sponsored Research Agreement between the Registrant (as assigned to it by
    Ampio/Luoxis) and Trauma Research LLC, dated September 1, 2009</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K/A</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">6/08/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.9</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.8#</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Addendum No. 4 to Sponsored Research Agreement between the Registrant (as
    assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated March 17, 2014</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">5/27/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.14</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.9</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Promissory Note issued by Ampio to the Registrant on April 16, 2015</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4/22/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.11</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.10</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Subscription Agreement between the Registrant and Ampio, dated April 16,
    2015</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4/22/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.12</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.11</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Voting Agreement between the Registrant and Ampio, dated April 21, 2015
    (incorporated by reference to Exhibit 10.1 to Ampio&rsquo;s Form 8-K filed April 22, 2015; File No. 001-35182)</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.12</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Asset Purchase Agreement between Jazz Pharmaceuticals, Inc. and Rosewind
    Corporation, dated May&nbsp;20, 2015</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">5/27/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.14</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.13</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Form of Note Purchase Agreement for 2015 Convertible Note Financing</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">7/24/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 11%"><FONT STYLE="font-size: 10pt; color: #000000"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Description</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 9%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Registrant&rsquo;s</B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt"><B>Form</B></FONT></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 7%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Date</B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt"><B>Filed</B></FONT></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 7%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Exhibit</B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt"><B>Number</B></FONT></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Filed</B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font-size: 10pt"><B>Herewith</B></FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.14</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Asset Purchase Agreement, dated October 5, 2015, between Aytu BioScience,
    Inc. and FSC Laboratories, Inc.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10/07/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.18</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.15</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Master Services Agreement between Biovest International, Inc. and Aytu BioScience,
    Inc., entered into on October 8, 2015, and effective October 5, 2015</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10/13/15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.19</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.16</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Form of Subscription Agreement for January 2016 common stock purchases</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">1/20/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.17</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">License and Supply Agreement between the Registrant and Acerus Pharmaceuticals
    Corporation, dated April 22, 2016</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4/25/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.18</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Subscription Agreement between the Registrant and Acerus Pharmaceuticals
    Corporation, dated April 22, 2016</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4/25/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.2</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.19</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">First Amendment, dated May 15, 2016, to Employment Agreement dated September
    16, 2015 between Aytu BioScience, Inc. and Jonathan McGrael</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">5/16/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.20</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Purchase Agreement, dated July 27, 2016, by and between Aytu BioScience,
    Inc. and Lincoln Park Capital Fund, LLC.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">7/28/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.21</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Registration Rights Agreement dated July 27, 2016, by and between Aytu BioScience,
    Inc. and Lincoln Park Capital Fund, LLC.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">7/28/16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.2</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.22&dagger;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Employment Agreement, effective as of April 16, 2017, between Aytu BioScience,
    Inc. and Joshua R. Disbrow.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4/18/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.23&dagger;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Employment Agreement, effective as of April 16, 2017, between Aytu BioScience,
    Inc. and Jarrett T. Disbrow.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4/18/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.2</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.24</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Asset Purchase Agreement, dated March 31, 2017, between Allegis Holdings,
    LLC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and Aytu BioScience, Inc.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">5/11/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.25^</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Merger Agreement, dated May 3, 2017, between Nuelle, Inc. and Aytu BioScience,
    Inc.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.26&dagger;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Employment Agreement, effective as of June, 2017, between Aytu BioScience,
    Inc. and Gregory A. Gould.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">6/19/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">10.27&dagger;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">2015 Stock Option and Incentive Plan, as amended on July 26, 2017.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">7/27/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">10.28</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Securities Purchase Agreement, dated August 11, 2017, between Aytu BioScience,
    Inc. and the investors named therein.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8/16/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.1</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">10.29</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Registration Rights Agreement, dated August 11, 2017, between Aytu BioScience,
    Inc. and the investors named therein.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8-K</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">8/16/17</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">10.2</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">23.1</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Consent of EKS&amp;H LLLP, Independent Registered Public Accounting Firm.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">31.1</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Certificate of the Chief Executive Officer of Aytu BioScience, Inc. pursuant
    to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">31.2</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Certificate of the Chief Financial Officer of Aytu BioScience, Inc. pursuant
    to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">32.1</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Certificate of the Chief Executive Officer and the Chief Financial Officer
    of Aytu BioScience, Inc. pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">X</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-size: 10pt; color: #000000">101</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">XBRL (extensible Business Reporting Language). The following materials from
    Aytu BioScience, Inc.&rsquo;s Annual Report on Form 10-K for the year ended June 30, 2017 formatted in XBRL: (i) the Balance
    Sheets, (ii) the Statements of Operations, (iii) the Statements of Stockholders&rsquo; Equity (Deficit), (iv) the Statements
    of Cash Flows, and (v) the Notes to the Financial Statements.</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">X</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"><FONT STYLE="color: #000000">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 5%; text-align: right"><FONT STYLE="font-size: 10pt; color: #000000">&dagger;</FONT></td>
    <td style="vertical-align: top; width: 1%; padding-left: 4.95pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="width: 94%; padding-left: 4.5pt"><FONT STYLE="font-size: 10pt; color: #000000">Indicates is a management contract
    or compensatory plan or arrangement. </FONT></td></tr>
<tr>
    <td style="vertical-align: top; text-align: right"><FONT STYLE="font-size: 10pt; color: #000000">#</FONT></td>
    <td style="vertical-align: top; padding-left: 4.95pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="padding-left: 4.95pt"><FONT STYLE="font-size: 10pt; color: #000000">The company has received confidential treatment
    of certain portions of this agreement. These portions have been omitted and filed separately with the Securities and Exchange
    Commission pursuant to a confidential treatment request.</FONT></td></tr>
<tr>
    <td style="vertical-align: top; text-align: right"><FONT STYLE="color: #000000">^</FONT></td>
    <td style="vertical-align: top; padding-left: 4.95pt"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <td style="padding-left: 4.95pt"><FONT STYLE="font-size: 10pt; color: #000000">Confidential treatment has been requested with
    respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="a_025"></A><B>SIGNATURES
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Pursuant to the requirements of
Section&nbsp;13 or 15(d) of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="width: 5%"><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD STYLE="width: 45%"><FONT STYLE="color: #000000">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-size: 10pt; color: #000000"><B>AYTU BIOSCIENCE, INC.</B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt; color: #000000">Date: August 31, 2017</FONT></td>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt; color: #000000">By:</FONT></td>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000">/s/ Joshua R. Disbrow</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Joshua R. Disbrow</FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-size: 10pt; color: #000000"><I>Chairman and Chief Executive Officer</I></FONT></td></tr>
<tr style="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></td>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">&nbsp;(Principal Executive Officer)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Pursuant to the requirements of
the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in
the capacities indicated, on August 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%"><FONT STYLE="font-size: 10pt; color: #000000"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 59%; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000"><B>Title</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000">/s/ Joshua R. Disbrow</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Chairman and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Joshua R. Disbrow&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000"><I>(Principal Executive Officer)</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000">/s/ Gregory A. Gould</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Chief Financial Officer </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Gregory A. Gould&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000"><I>(Principal Financial and Accounting Officer)</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000">/s/ Michael Macaluso</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Michael Macaluso</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000">/s/ Carl Dockery&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Carl Dockery</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000">/s/ John Donofrio&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">John Donofrio</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000">/s/ Gary Cantrell</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #000000">Gary Cantrell</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>INDEX TO
THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>AYTU BIOSCIENCE,
INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 10%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: #000000"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="color: #000000"><A HREF="#b_001"><FONT STYLE="font-size: 10pt">Report
    of Independent Registered Public Accounting Firm</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="color: #000000"><A HREF="#b_002"><FONT STYLE="font-size: 10pt">Consolidated
    Balance Sheets</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="color: #000000"><A HREF="#b_003"><FONT STYLE="font-size: 10pt">Consolidated
    Statements of Operations</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="color: #000000"><A HREF="#b_004"><FONT STYLE="font-size: 10pt">Consolidated
    Statements of Stockholders&rsquo; Equity (Deficit)</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="color: #000000"><A HREF="#b_005"><FONT STYLE="font-size: 10pt">Consolidated
    Statements of Cash Flows</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="color: #000000"><A HREF="#b_006"><FONT STYLE="font-size: 10pt">Consolidated
    Notes to the Financial Statements</FONT></A></FONT></TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">F-7</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 89; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="b_001"></A><B>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aytu BioScience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Englewood, Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Aytu BioScience, Inc. (the &ldquo;Company&rdquo;) as of June 30, 2017 and 2016, and the related consolidated
statements of operations, stockholders&rsquo; equity, and cash flows for each of the years then ended. The Company&rsquo;s management
is responsible for these consolidated financial statements. Our responsibility is to express an opinion on these consolidated financial
statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test
basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the financial position of Aytu BioScience, Inc. as of June
30, 2017 and 2016, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting
principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">/s/EKS&amp;H LLLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">August 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Denver, Colorado</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="b_002"></A><B>AYTU
BIOSCIENCE, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Consolidated
Balance Sheets </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>June 30,</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>2017</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>2016</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Assets</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Current assets</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Cash and cash equivalents</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">802,328</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">8,054,190</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Restricted cash</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">75,214</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Accounts receivable, net</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">528,039</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">162,427</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Inventory, net</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,312,221</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">524,707</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Prepaid expenses and other</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">310,760</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">215,558</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Prepaid research and development - related party&nbsp;&nbsp;(Note
    11)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">121,983</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">Investment in Acerus</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">1,041,362</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt"><FONT STYLE="color: #000000">Total current assets</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">3,028,562</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">10,120,227</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Fixed assets, net</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">647,254</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">231,430</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Developed technology, net</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,337,333</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,159,736</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Customer contracts, net</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">77,667</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,353,375</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Trade names, net</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">164,037</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">194,472</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Natesto asset</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">9,231,072</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">10,549,797</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 10pt"><FONT STYLE="color: #000000">Goodwill</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">238,426</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">221,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Patents, net</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">271,278</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">296,611</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Long-term portion of prepaid research and development
    - related party (Note 11)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">213,471</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">Deposits</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">2,888</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">2,888</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt"><FONT STYLE="color: #000000">Total long-term assets</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">11,969,955</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">14,222,780</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Total assets</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">14,998,517</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">24,343,007</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Liabilities and Stockholders' Equity</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Current liabilities</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Accounts payable and other</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2,220,400</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2,322,605</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Accrued liabilities</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">782,536</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,197,106</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Natesto payable</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5,379,675</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Accrued compensation</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">339,704</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,200,930</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Deferred rent</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">6,673</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">4,109</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">Current contingent consideration</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">261,155</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Total current liabilities</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">3,610,468</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">10,104,425</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Contingent consideration</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">7,386,782</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">3,869,122</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Deferred rent</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,451</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">8,215</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">Warrant derivative liability</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">275,992</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt"><FONT STYLE="color: #000000">Total liabilities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">10,998,701</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">14,257,754</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Commitments and contingencies (Note 7)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Stockholders' equity</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Preferred Stock, par value $.0001; 50,000,000
    shares authorized; none issued</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in"><FONT STYLE="color: #000000">Common Stock, par value
    $.0001; 100,000,000 shares authorized; shares issued &nbsp;and outstanding 824,831 in 2017 and 187,098 in 2016</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">82</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">19</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Additional paid-in capital</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">73,069,463</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">56,646,659</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Ampio stock subscription</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">Accumulated deficit</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(69,069,729</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(46,561,425</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt"><FONT STYLE="color: #000000">Total stockholders' equity</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">3,999,816</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">10,085,253</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Total liabilities and stockholders' equity</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">14,998,517</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">24,343,007</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">The accompanying
notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="b_003"></A><B>AYTU
BIOSCIENCE, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Consolidated
Statements of Operations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Year Ended June 30,</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">Revenue</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Product and service revenue</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">3,221,590</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">2,050,838</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">License revenue</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">511,607</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt"><FONT STYLE="color: #000000">Total revenue</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">3,221,590</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">2,562,445</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Operating expenses</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">Cost of sales</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,417,355</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">957,076</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Research and development</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">959,857</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">6,127,772</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Research and development - related party (Note
    11)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">387,960</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">191,991</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Sales, general and administrative</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">17,442,627</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">8,517,592</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Sales, general and administrative - related party
    (Note 11)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">165,131</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">307,704</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Impairment of intangible assets</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,265,125</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">7,500,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">Amortization of intangible
    assets</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">1,708,771</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">664,707</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">Total operating expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">23,346,826</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">24,266,842</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt"><FONT STYLE="color: #000000">Loss from operations</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(20,125,236</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(21,704,397</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Other (expense)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Interest (expense)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(2,534,358</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(5,491,486</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">(Loss) on investment</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(61,519</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(971,629</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">Derivative income (expense)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">212,809</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(12,572</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt"><FONT STYLE="color: #000000">Total other (expense)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(2,383,068</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(6,475,687</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">(22,508,304</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">(28,180,084</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Weighted average
    number of Aytu common shares outstanding</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">466,024</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">87,057</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Basic
    and diluted Aytu net loss per common share</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">(48.30</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">(323.70</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">)</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">The accompanying
notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="b_004"></A><B>AYTU
BIOSCIENCE, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Consolidated
Statements of Stockholders&rsquo; Equity </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp; <FONT STYLE="font-size: 10pt">
</FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>Common Stock</B></FONT></TD><TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="color: #000000"><B>Additional</B><BR>
    <B>paid-in</B></FONT></TD><TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="color: #000000"><B>Ampio</B></FONT></TD><TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="color: #000000"><B>Accumulated</B></FONT></TD><TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="color: #000000"><B>Total</B><BR><B> Stockholders'</B></FONT></TD><TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>Shares</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>Amount</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>capital</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>Stock Subscription</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>Deficit</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>Equity</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Balance - June 30, 2015</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="color: #000000">59,415</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="color: #000000">6</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="color: #000000">38,997,787</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="color: #000000">(5,000,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="color: #000000">(18,381,341</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="color: #000000">15,616,452</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Ampio stock subscription</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5,000,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5,000,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Stock subscription</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,282</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">200,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">200,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Conversion of convertible
    promissory notes and interest to common stock, net of $29,754 conversion costs</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">48,108</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">10,090,844</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">10,090,849</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Issuance of warrants related
    to the convertible promissory notes</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">136,828</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">136,828</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Issuance of common stock,
    net of $1,202,231 in issuance costs</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">78,125</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">8</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">4,237,866</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">4,237,874</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Warrants issued in connection
    with registered financing</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2,059,895</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2,059,895</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Warrants issued in connection
    with registered offering to the placement agents for the over-allotment option</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">20,493</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">20,493</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Adjustment for rounding
    of shares due to stock split</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">168</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Stock-based compensation</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">902,946</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">902,946</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt"><FONT STYLE="color: #000000">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">(28,180,084</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">(28,180,084</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Balance - June 30, 2016</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">187,098</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">19</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">56,646,659</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(46,561,425</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">10,085,253</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Lincoln&nbsp;&nbsp;Park
    stock issuance, net of issuance costs $90,924</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">19,309</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">648,931</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">648,933</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Stock-based compensation</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2,502,092</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2,502,092</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Issuance of restricted
    stock</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">724,608</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">724,613</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Common stock issued to
    executives</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">7,123</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">509,996</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">509,996</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Issurance of warrants
    to initial investors</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">596,434</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">596,434</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Issuance of common stock,
    net of $997,865 in issuance costs</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">286,749</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">29</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">3,671,552</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">3,671,581</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Warrants issued in connection
    with registered offering</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">3,470,646</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">3,470,646</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Warrants issued in connection
    with registered offering to the placement agents for the over-allotment option</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">172,629</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">172,629</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Warrants issued in connection
    with the registered offering to the placement agents, non-cash issuance costs</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">292,630</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">292,630</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Warrant tender offer,
    net of $312,159 in issuance costs</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">149,552</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">15</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,931,108</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,931,123</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Warrant amendments</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">64,690</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">64,690</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Investment in Subsidiary</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">125,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">12</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,837,488</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,837,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Net loss</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(22,508,304</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(22,508,304</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="color: #000000">Balance - June 30,
    2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">824,831</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">82</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">73,069,463</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">(69,069,729</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">3,999,816</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">The accompanying
notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="b_005"></A><B>AYTU
BIOSCIENCE, INC. AND SUBSIDIARY </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Consolidated
Statements of Cash Flows </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Year
    Ended June 30,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Cash flows from operating activities:</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Net loss</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">(22,508,304</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">(28,180,084</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Adjustments to reconcile net loss to cash used
    in operating activities:</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Depreciation, amortization and accretion</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">4,364,680</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">874,789</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Asset impairment</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,265,125</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">7,500,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Stock-based compensation expense</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2,502,092</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">902,946</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Issuance of restricted stock</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">724,613</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Amortization of debt issuance costs</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">182,759</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Amortization of beneficial conversion feature</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">4,943,073</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Noncash interest expense</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">221,024</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Derivative (income) expense</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(212,809</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">12,572</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Amortization of prepaid research and development
    - related party (Note 11)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">335,454</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">121,983</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Loss on investment</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">61,519</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">971,629</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Common stock issued to executives</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">509,996</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Issuance of warrants to initial investors</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">596,434</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Gain on sale of asset</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(428,374</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Warrant amendment</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,507</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile
    net loss to net cash used in operating activities:</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 30pt"><FONT STYLE="color: #000000">(Increase) in accounts receivable</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(355,031</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(5,369</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 30pt"><FONT STYLE="color: #000000">Decrease (increase) in inventory</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">195,427</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(485,265</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 30pt"><FONT STYLE="color: #000000">(Increase) decrease in prepaid expenses and other</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(95,202</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">155,330</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 30pt"><FONT STYLE="color: #000000">Increase in accounts payable and other</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">493,217</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">698,237</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 30pt"><FONT STYLE="color: #000000">(Decrease) increase in accrued liabilities</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(414,570</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">925,232</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 30pt"><FONT STYLE="color: #000000">(Decrease) increase in accrued compensation</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(861,226</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,004,427</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 30pt"><FONT STYLE="color: #000000">(Decrease) increase in deferred rent</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(4,200</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">10,875</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 30pt"><FONT STYLE="color: #000000">(Decrease) in deferred revenue</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(511,607</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">Net cash used in operating activities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(13,829,652</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(10,657,449</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Cash flows used in investing activities:</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Purchases of fixed assets</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(111,608</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(252,932</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Purchase of Natesto assets</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(6,000,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(2,000,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Investment in Acerus</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,071,707</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(2,012,991</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Sale of investment in Acerus cost</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(91,864</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Sales of Primsol assets</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,750,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Purchase of Primsol asset</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(750,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(1,040,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Cash proceed from Nuelle</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">613,309</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Cost related to Nuelle acquisition</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(16,082</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 20pt"><FONT STYLE="color: #000000">Deposits</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">1,998</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">Net cash used in investing activities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(3,534,538</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(5,303,925</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Cash flows from financing activities:</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Issuance of common stock to Lincoln Park</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">739,857</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Costs related to the sale of common stock</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(90,924</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Warrant tender offer</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2,243,282</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Warrant tender offer cost</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(312,159</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Proceeds from convertible promissory notes, net
    (Note 8)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5,175,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Debt issuance costs (Note 8)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(298,322</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Costs related to the conversion of the convertible
    promissory notes to equity</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(29,754</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Ampio stock subscription payment</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5,000,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Registerd offering</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">8,602,499</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">7,520,493</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Registered offering costs</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(997,865</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(904,914</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 20pt"><FONT STYLE="color: #000000">Over-allotment warrants purchased by placement
    agents</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2,852</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 20pt"><FONT STYLE="color: #000000">Sale of stock subscription</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">200,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">Net cash provided by financing activities</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">10,187,542</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">16,662,503</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Net change in cash and cash equivalents</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(7,176,648</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">701,129</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">Cash and cash equivalents at beginning of period</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">8,054,190</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">7,353,061</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Cash and cash equivalents at end of period</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">877,542</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">8,054,190</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Non-cash transactions:</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Issuance of common stock to Nuelle share holders</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,837,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Fixed assets included in accounts payable</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">10,789</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Warrants issued in connection with the equity financing to the placement
    agents</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">292,630</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Warrants amended in connection with warrant tender offer</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">63,182</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Warrant derivative liability related to the issuance of the convertible
    promissory notes (Note 8)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">102,931</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Primsol asset purchase included in primsol payable, $1,250,000 less
    future accretion of $173,000</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,077,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Conversion of convertible promissory notes and interest of $221,000
    to common stock</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5,396,024</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Natesto asset purchase included in Natesto payable, $6,000,000 less
    future accretion of $620,325</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5,379,675</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Warrant derivative liability related to the issuance of the registered
    offering placement agent warrants (Note 8)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">297,317</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Reclassification of liability based warrants to equity presentation
    related to the convertible promissory notes</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">136,828</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Beneficial conversion feature related to convertible promissory
    notes</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">4,943,073</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Debt issuance costs related to notes that converted to equity</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(218,494</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">The accompanying
notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><A NAME="b_006"></A><B>AYTU
BIOSCIENCE, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>Notes to
the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 1 &ndash; Business, Basis
of Presentation, Merger and Business Combinations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Business </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu BioScience, Inc. (&ldquo;Aytu&rdquo;,
the &ldquo;Company&rdquo; or &ldquo;we&rdquo;) was incorporated as Rosewind Corporation on August&nbsp;9, 2002 in the State of
Colorado. Aytu was re-incorporated in the state of Delaware on June&nbsp;8, 2015. Aytu is a commercial-stage specialty healthcare
company concentrating on developing and commercializing products with an initial focus on urological diseases and conditions.
Aytu is currently focused on addressing significant medical needs in the areas of hypogonadism, urological cancers, male infertility,
and sexual wellness and vitality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Basis of Presentation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Through a multi-step reverse triangular
merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (&lsquo;&lsquo;Vyrix&rsquo;&rsquo;) and Luoxis Diagnostics, Inc. (&lsquo;&lsquo;Luoxis&rsquo;&rsquo;)
merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue
the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS
and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law
and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common
stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse
stock split in which each common stockholder received one share of common stock for every 12 shares outstanding; On August 25,
2017, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every
20 shares outstanding (herein referred to collectively as the &ldquo;Reverse Stock Splits&rdquo;). All share and per share amounts
in this report have been adjusted to reflect the effect of these Reverse Stock Splits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Business Combination&mdash;ProstaScint
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: #000000">In May 2015,
Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (&ldquo;Jazz Pharmaceuticals&rdquo;).
Pursuant to the agreement, Aytu purchased assets related to the Jazz Pharmaceuticals&rsquo; product known as ProstaScint<SUP>&reg;
</SUP>(capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work
in progress (together, the &lsquo;&lsquo;ProstaScint Business&rsquo;&rsquo;), and assumed certain of Jazz Pharmaceuticals&rsquo;
liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consists
of the upfront payment of $1.0 million. We also agreed to pay an additional $500,000 which was paid after transfer for the ProstaScint-related
product inventory and $227,000 which was paid September 30, 2015 (which represents a portion of certain FDA fees). We also will
pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million.</FONT><FONT STYLE="color: #000000">
<FONT STYLE="font-size: 10pt">The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2017
at $54,000 using a discounted cash flow. The total fair value consideration for the purchase was $2.4 million.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Company&rsquo;s allocation
on consideration transferred for ProstaScint as of the purchase date May&nbsp;20, 2015 was as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Estimated<BR>
    Fair Value</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left"><FONT STYLE="color: #000000">Tangible assets</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">727,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Intangible assets</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,590,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">Goodwill</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">74,000</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Total assets acquired</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">2,391,000</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Included in the intangible assets
at May 2015 was developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will
be amortized over a ten-year period. Amortization expense of $159,000 was recognized in both fiscal 2017 and 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">At June 30, 2017, the ProstaScint asset was impaired based upon sales projections that we intend to only sell
this product through mid-fiscal 2019, when this product expires. The value for the intangible assets were adjusted to $54,000 for
developed technology, $7,000 for trade names and $0 for customer contracts. The estimated future amortization of ProstaScint after
June 30, 2017 is as follows:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Total ProstaScint</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 75%; text-align: left"><FONT STYLE="color: #000000">2018</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 22%; text-align: right"><FONT STYLE="color: #000000">47,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">2019</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">14,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">2020</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">2021</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">2022</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">Thereafter</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">61,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Business Combination&mdash;Primsol</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In October 2015, Aytu entered
into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (&ldquo;FSC&rdquo;). Pursuant to the agreement, Aytu
purchased assets related to FSC&rsquo;s product known as Primsol&reg; (trimethoprim solution), including certain intellectual
property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol
(together, the &ldquo;Primsol Business&rdquo;), and assumed certain of FSC&rsquo;s liabilities, including those related to the
sale and marketing of Primsol arising after the closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu paid $500,000 at closing
for the purchase of the Primsol Business and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards
the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000
which was paid on April 1, 2016, (b) $500,000 which was paid on July 1, 2016, and (c) $250,000 which was paid in November 2016
(together, the &ldquo;Installment Payments&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Company&rsquo;s allocation
on consideration transferred for Primsol as of the purchase date of October 5, 2015 was as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>Fair Value</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left"><FONT STYLE="color: #000000">&nbsp;Tangible assets</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">182,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;Intangible assets</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,470,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;Goodwill</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">147,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;Total assets acquired</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">1,799,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Included in tangible assets was
$102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets was developed technology of
$520,000, customer contracts of $810,000 and trade names of $140,000, each of which was being amortized over a six-year period.
Amortization expense of $184,000 and $174,000 was recognized in fiscal 2017 and fiscal 2016, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Divestiture &ndash; Primsol</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In March 2017, we entered into
and closed on an Asset Purchase Agreement with Allegis Holdings, LLC (the &ldquo;Purchaser&rdquo;). Pursuant to the agreement,
we sold to the Purchaser all of our assets related to our Primsol product, including certain intellectual property and contracts,
inventory, work in process and all marketing assets and materials related solely to Primsol (together, the &ldquo;Primsol Asset&rdquo;).
We retain any liability associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us $1,750,000
at the closing for the Primsol Asset. We recognized a gain of approximately $428,000 on the sale which is included in sales, general
and administrative expense on our statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We have evaluated this transaction
and concluded that it is not significant to our business and therefore the results are included in continuing operations, as the
criteria to be presented as discontinued operations was not satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>License and Supply Agreement&mdash;Natesto</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In April, 2016, Aytu entered into
and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto&reg; (testosterone) nasal gel from Acerus
Pharmaceuticals Corporation, or Acerus, which rights we acquired effective upon the expiration of the current licensee&rsquo;s
rights, which occurred on June 30, 2016. The licensee&rsquo;s term runs for the greater of eight years or until the expiry of
the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic
product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu
paid Acerus an upfront fee of $2.0 million upon execution of the agreement. In October 2016, we paid an additional $2.0 million.
In January 2017, Aytu paid the final upfront payment of $4.0 million. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aytu
also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5 million (approximately
US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share. These shares were
a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares until after August
29, 2016. During fiscal 2017, Aytu sold all of these shares. The gross proceeds from the sales totaled $1.1 million, the cost
of the sales totaled $92,000, and we recognized a loss on investment of $62,000 and $972,000 during fiscal 2017 and 2016, respectively.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the upfront payments, we must make the following one-time, non-refundable payments to Acerus
within 45 days of the occurrence of the following event (provided that, the maximum aggregate amount payable under such milestone
payments will be $37.5 million):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$2.5 million if net sales during any four consecutive calendar quarter period equal or exceed $25.0 million (the &ldquo;First Milestone&rdquo;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon trial work would no longer make the agreement economically viable for Acerus;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$5.0 million if net sales during any four consecutive calendar quarter period equal or exceed $50.0 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$7.5 million if net sales during any four consecutive calendar quarter period equal or exceed $75.0 milion;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$10.0 million if net sales during any four consecutive calendar quarter period equal or exceed $100.0 million; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">$12.5 million if net sales during any four consecutive calendar quarter period equal or exceed $125.0 million.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of the net identifiable asset acquired totaled $10.5 million which is being amortized over
eight years. The amortization expense for fiscal 2017 was $1.3 million and zero for fiscal 2016. The estimated future amortization
of Natesto after June 30, 2017 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 75%; text-align: center"><FONT STYLE="color: #000000">2018</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 22%; text-align: right"><FONT STYLE="color: #000000">1,319,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">2019</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,319,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">2020</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,319,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">2021</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,319,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">2022</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,319,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">Thereafter</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">2,636,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">9,231,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The contingent consideration was
valued at $3.2 million using a Monte Carlo simulation, as of June 30, 2016. The contingent consideration accretion expense for
fiscal 2017 and 2016 was $228,000, and zero respectively. As of June 30, 2017, the contingent consideration was revalued and increased
to $5.7 million based on increased future estimated sales performance of Natesto using a Monte Carlo simulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Merger/Subsidiary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In May 2017, Aytu Women&rsquo;s
Health, LLC., a wholly-owned subsidiary of Aytu, acquired Nuelle, Inc., or Nuelle, a women&rsquo;s sexual health company. This
transaction expanded our product portfolio with the addition of the Fiera<SUP>&reg;</SUP> personal care device for women.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In the Merger, (i) each share
of Nuelle common stock and each option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred
stock was converted into the right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate
of 125,000 shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, Nuelle preferred stockholders will be entitled to revenue earn-out payments equal to a designated
percentage of net sales on tiers of net sales up to $100.0 million, with an average rate for all tiers in the mid-single digit
range and a maximum aggregate payout of $6.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Nuelle stockholders additionally
will be entitled to milestone earn-out payments of up to a potential aggregate of $24.0 million, upon the attainment by us of
designated net sales thresholds over any sequential four calendar quarter period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The first $1.0 million of earn-out
payments will be paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares
of our common stock. The stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&rsquo;s portion
of the earn-out by the average closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver
notice to the Nuelle stockholders of the earn-out or any public disclosure by us of the earn-out being due and payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In the event that we do not make
all of the required earn-out payments to the Nuelle stockholders before May 3, 2022, and we also close a divestiture before May
3, 2022 of any of the products acquired in the transaction, we will pay the Nuelle stockholders a combination of (i) cash in an
amount equal to 10% of the value of all cash, securities and other property paid to us in the divestiture (cash is to be 60% of
the total consideration), and (ii) shares of our common stock equal to the Nuelle stockholders&rsquo; portion of the divestiture
payment divided by the average closing price of our common stock for the 10 trading days prior to the earlier of the closing date
of the divestiture or the public disclosure of the divestiture (shares of common stock are to be 40% of the total consideration).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In addition to the upfront issuance
of common stock, we must make the following one-time payments to the Nuelle stockholders within 90 days of the occurrence of the
following events (provided that, the maximum aggregate amount payable under such milestone payments will be $24.0 million):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Upon achieving the first occurrence of Net Sales of $10.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.0 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon achieving the first occurrence of Net Sales of $17.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.8 million.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon achieving the first occurrence of Net Sales of $25.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $2.5 million.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Upon achieving the first occurrence of Net Sales of $37.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $3.8 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Upon achieving the first occurrence of Net Sales of $50.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $5.0 million; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9642;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Upon achieving the first occurrence of Net Sales of $100.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $10.0 million.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Company&rsquo;s allocation
on consideration transferred for Nuelle as of the purchase date May&nbsp;5, 2017 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000"><B>Fair Value</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: left"><FONT STYLE="color: #000000">Tangible assets</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">2,061,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Intangible assets</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,540,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">Goodwill</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">238,000</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Total assets acquired</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">3,839,000</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Included in the intangible assets
is developed technology of $1.3 million, customer contracts of $80,000 and trade names of $160,000, each of which will be amortized
over a nine to twelve-year period. Amortization expense of $22,000 and $0 was recognized in fiscal 2017 and 2016, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Future amortization after the
year ended June 30, 2017 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 75%; text-align: left"><FONT STYLE="color: #000000">2018</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 22%; text-align: right"><FONT STYLE="color: #000000">144,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">2019</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">144,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">2020</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">144,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">2021</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">144,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">2022</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">144,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">Thereafter</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">798,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">1,518,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The contingent consideration was
valued at $1.9 million using a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for fiscal
2017 and 2016 was $12,000, and zero respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Additionally, we assumed liabilities
of $47,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #000000"><B>Note
2 &ndash; Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #000000"><B><I>Principals
of Consolidation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #000000">These
consolidated financial statements include the accounts of Aytu and its wholly-owned subsidiary, Aytu Women&rsquo;s Health. All
material intercompany transactions and balances have been eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Cash, Cash Equivalents and
Restricted Cash</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu considers all highly liquid
instruments purchased with an original maturity of three months or less to be cash equivalents. Restricted cash consist primarily
of a certificate of deposit investment account. Aytu&rsquo;s investment policy is to preserve principal and maintain liquidity.
The Company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests.
Periodically, throughout the year, Aytu has maintained balances in excess of federally insured limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Revenue Recognition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><I>License Agreements and Royalties</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Payments received upon signing
of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term
or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and
other projected milestones and are recognized at the time the milestones are achieved. Royalties will be recognized as revenue
when earned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000"><I>Product&nbsp;&amp;
Service Sales</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">The Company
recognizes revenue only when all of the following criteria have been met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.2in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">Persuasive
                                         evidence of an arrangement exists,</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">Delivery
                                         has occurred or services have been performed,</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">The
                                         fee for the arrangement is fixed or determinable, and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in"><FONT STYLE="font-family: Symbol; color: #000000">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #000000">Collectability
                                         is reasonably assured.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: #000000">Persuasive evidence
of an arrangement exists - The Company documents all terms of an arrangement in a written contract by the customer prior to recognizing
revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: #000000">Delivery has
occurred or services have been performed - The Company delivers all products prior to recognizing revenue. Equipment is considered
delivered upon delivery to a customer's designated location.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: #000000">Device sales
are recorded when products are shipped to customers. Drug sales are recorded when the product arrives at the customer&rsquo;s
dock. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided
for in the same period the related sales are recorded and are estimated at the time of sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: #000000">The fee for
the arrangement is fixed or determinable - Prior to recognizing revenue, a customer's fee is either fixed or determinable under
the terms of the written contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: #000000">Collectability
is reasonably assured - The Company determines that collectability is reasonably assured prior to recognizing revenue. Collectability
is assessed on a customer-by-customer basis based on criteria outlined by management. New customers are subject to a credit review
process, which evaluates the customer's financial position and ultimately its ability to pay. The Company does not enter into
arrangements unless collectability is reasonably assured at the outset. Existing customers are subject to ongoing credit evaluations
based on payment history and other factors. If it is determined during the arrangement that collectability is not reasonably assured,
revenue is recognized on a cash basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Estimated Sales Returns
and Allowances</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu records estimated reductions
in revenue for potential returns of products by customers. As a result, management must make estimates of potential future product
returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical
returns, current economic trends and changes in customer demand and acceptance of our products. If management were to make different
judgments or utilize different estimates, material differences in the amount of the Company&rsquo;s reported revenue could result.
As of June 30, 2017 and 2016, we accrued $58,000 and $284,000, respectively, in our estimated returns allowance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Shipping and Handling</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">The Company's
shipping and handling costs are included in cost of goods sold for all periods presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Accounts Receivable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Accounts receivable are recorded
at their net realized value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation
allowance accordingly. As of June 30, 2017 we had an allowance for doubtful accounts of $44,000, and as of June 30, 2016, there
had been an allowance for doubtful accounts of $41,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Concentration of Business Risks</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #000000">The following
counterparties contributed greater than&nbsp;10%&nbsp;of the Company's total revenue during the year ended June 30, 2017 and 2016,
respectively. The revenue from these counterparties as a percentage of total revenue was as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Year
    Ended June 30,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left"><FONT STYLE="color: #000000">Customer A</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">34</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Customer B</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">22</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Customer C</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">18</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Customer D</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">86</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The loss of one or more of the
Company's significant partners or collaborators could have a material adverse effect on its business, operating results or financial
condition. Although the Company is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management
does not believe significant credit risk exists as of&nbsp;June&nbsp;30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #000000">We are
also subject to credit risk from our accounts receivable related to our product sales. Historically, we have not experienced significant
credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would
have a material adverse effect on our financial position, liquidity or results of operations. As of June 30, 2017, three customers
accounted for 60% of gross accounts receivable. As of June 30, 2016, one customer accounted for 69% of gross accounts receivable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Year
    Ended June 30,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left"><FONT STYLE="color: #000000">Customer A</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">25</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Customer B</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">17</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Customer C</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">18</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Customer D</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">69</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Inventories</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Inventories consist of raw materials,
work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in,
first-out basis. Aytu periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise
unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down
to net realizable value in the period that the impairment is first recognized. We currently have a reserve of $311,000 for slow
moving inventory as of June 30, 2017 and $199,000 at June 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Inventory consist of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">June
    30,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left"><FONT STYLE="color: #000000">Raw materials</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">442,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">77,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Work in process</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">442,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Finished goods</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">738,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">647,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">Reserve</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(310,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(199,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">1,312,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">525,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Trading Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000; background-color: white">Trading
securities are carried at fair value with realized and unrealized gains and losses recorded in earnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000; background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Fixed Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Fixed assets are recorded at cost.
After being placed in service, the fixed assets are depreciated using the straight-line method over estimated useful lives. Fixed
assets consist of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">Estimated</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">June
    30,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Useful
    Lives in years</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left"><FONT STYLE="color: #000000">Office equipment, furniture and other</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%; text-align: center"><FONT STYLE="color: #000000">2 - 5</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">405,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">201,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Lab equipment</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">3 - 5</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">111,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">90,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Leasehold improvements</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">3</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">287,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">45,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Manufacturing equipment</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">2 - 5</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">90,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">7,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Less accumulated depreciation and amortization</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(246,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(112,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><FONT STYLE="color: #000000">Fixed assets, net</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">647,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">231,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu recorded the following depreciation
expense in the respective periods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Year
    Ended June 30,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;Depreciation expense</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">134,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">51,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Patents</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Costs of establishing patents,
consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined
by an independent third party appraisal, was $500,000. The Zertane patents were acquired in connection with the 2011 acquisition
of DMI BioSciences by Ampio, the former parent company of Aytu, and were being amortized over the remaining U.S. patent lives
of approximately 11 years, which were to expire in March 2022. In fiscal 2016, we redirected our resources towards our commercial-stage
products and the Company determined that this asset had no further value as the Company did not have the resources to complete
the necessary clinical trials and bring it to market before the patents expired. The remaining fair value of the Zertane patents
were expensed as of June 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The cost of the Luoxis patents
were $380,000 when they were acquired in connection with the 2013 formation of Luoxis and are being amortized over the remaining
U.S. patent lives of approximately 15 years, which expires in March 2028. Patents consist of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">June 30,</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%"><FONT STYLE="color: #000000">Patents</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">880,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">880,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Less accumulated amortization</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(609,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(583,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;Patents, net</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">271,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">297,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu recorded the following amortization
expense in the respective periods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Year Ended June 30,</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;Amortization expense</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">26,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">332,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Future amortization from the year
ended June 30, 2017 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 75%; text-align: center"><FONT STYLE="color: #000000">2018</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 22%; text-align: right"><FONT STYLE="color: #000000">25,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">2019</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">25,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">2020</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">25,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">2021</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">25,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">2022</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">25,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">Thereafter</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">146,000</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="color: #000000">271,000</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Business Combinations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Company accounts for its business
acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;)
Accounting Standards Codification (&ldquo;ASC&rdquo;) 805, &ldquo;Business Combinations&rdquo;, which requires the acquiring entity
in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest
in the acquired business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes
assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling
interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company
recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the
fair value of the identified net assets acquired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Goodwill</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Nuelle, ProstaScint and Primsol&nbsp;purchase price allocations
were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted
up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities
acquired required the use of estimates by management, and were based upon currently available data, as noted below.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Company allocated the excess
of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax
purposes and represents the value placed on entering new markets and expanding market share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Company tests its goodwill
for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing
the carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance
of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other
circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying
value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability
of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to
determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments
in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint
that occurred on May&nbsp;20, 2015, Primsol that occurred on October 5, 2015 and Nuelle that occurred on May 5, 2017. There was
an impairment of $74,000 related to the ProstaScint goodwill for the year ended June 30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Use of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The preparation of financial statements
in accordance with Generally Accepted Accounting Principles in the United States of America (&ldquo;GAAP&rdquo;) requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets
and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting
periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, warrant
valuation, purchase price allocation, valuation of contingent consideration, sales returns and allowances, useful lives of fixed
assets, collectability of accounts receivable, and assumptions in evaluating impairment of definite and indefinite lived assets.
Actual results could differ from these estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Income Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu has been included in the
consolidated tax returns of Ampio, the former parent company of Aytu, for tax years ended on or before December 31, 2015. As of
January 2016, due to the decrease in Ampio&rsquo;s ownership percentage of Aytu stock, Aytu will begin to file tax returns separate
from Ampio. For all consolidated tax return periods, Aytu's taxes were computed and reported on a &quot;separate return&quot;
basis for these financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets
are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities
are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets
and liabilities and their tax bases. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it
is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities
are adjusted for the effects of changes in tax laws and rates on the date of enactment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The amount of income taxes and
related income tax positions taken are subject to audits by federal and state tax authorities. The Company has adopted accounting
guidance for uncertain tax positions which provides that in order to recognize an uncertain tax position, the taxpayer must be
more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is
more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has no material uncertain
tax positions. The Company's policy is to record a liability for the difference between the benefits that are both recognized
and measured pursuant to FASB ASC 740-1 &quot;Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109&quot;
(ASC 740-10) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such
tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports
tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company
has concluded that no significant tax position requires recognition under ASC 740-10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Stock-Based Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu accounts for share based
payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company
determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably
over the period of service using the graded method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Research and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Research and development costs
are expensed as incurred with expenses recorded in the respective period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Income (Loss) Per Common
Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Basic income (loss) per common
share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common
shares outstanding during that period. <FONT STYLE="background-color: white">Diluted net loss per share reflects the potential
of securities that could share in the net loss of Aytu. Basic and diluted loss per share was the same in 2017 and 2016. Although
there were common stock equivalents of 367,312 and 126,239 shares outstanding at June 30, 2017 and 2016, respectively, consisting
of stock options and warrants; they were not included in the calculation of the diluted net loss per share because they would
have been anti-dilutive.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Fair Value of Financial
Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The carrying amounts of financial
instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets
and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent
consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential
future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted
future cash&nbsp;flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Derivative Liability</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu accounts for liability warrants
by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability.
The fair value of the financial instruments and related warrants were calculated using a Monte Carlo based valuation model. We
recorded a derivative expense at the inception of the instrument reflecting the difference between the fair value and cash received.
Changes in the fair value in subsequent periods was recorded as unrealized gain or loss on fair value of debt instruments for
the financial instruments and to derivative income or expense for the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000; background-color: white">The fair
value of the warrants issued to the placement agents in connection with the registered offering were valued using the Black-Scholes
valuation methodology. Changes in the fair value in subsequent periods were recorded to derivative income or expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Adoption of Newly Issued Accounting
Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In November 2016, the Financial
Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2016-18, &quot;Statement
of Cash Flows: Restricted Cash.&quot;&nbsp; The amendments address diversity in practice that exists in the classification and
presentation of changes in restricted cash on the statement of cash flows.&nbsp; ASU 2016-18 is effective for the fiscal year
commencing after December 15, 2017. During fiscal 2017, the Company early adopted this pronouncement, the impact of which was
minimal, which is now shown on the statements of cash flows within cash and cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In August 2016, the FASB issued
ASU 2016-15 &ldquo;Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments,&rdquo; which provides
guidance on the presentation of certain cash receipts and cash payments in the statement of cash flows in order to reduce diversity
in existing practice. ASU 2016-15 is effective for interim and annual periods beginning after December 15, 2017. Early adoption
is permitted. During fiscal 2017, the Company early adopted this standard. The primary cash flow categorization that will impact
the Company will be contingent consideration payments, however, no such payments have been made to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In March 2016, the FASB issued
ASU 2016-09, &ldquo;Compensation &ndash;Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting.&rdquo;
The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The
amendments are expected to impact net income, earnings per share, and the statement of cash flows. Implementation and administration
may present challenges to companies with significant share based payment activities. The amendments are effective for public entities
for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The Company adopted this standard
during fiscal, 2017. Aytu has elected to account for forfeitures as they occur, rather than estimate expected forfeitures. Prior
to adopting this standard, the Company had not estimated any forfeitures, therefore, no adjustments were necessary. Aytu is also
operating at a net operating loss, therefore, there was no tax implication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In July&nbsp;2015, the FASB issued
ASU 2015-11,&nbsp;&ldquo;Simplifying the Measurement of Inventory.&rdquo;&nbsp; ASU&nbsp;2015-11 clarifies that inventory should
be held at the lower of cost or net realizable value.&nbsp; Net realizable value is defined as the estimated selling price, less
the estimated costs to complete, dispose and transport such inventory.&nbsp; ASU 2015-11 was effective for fiscal years and interim
periods beginning after December&nbsp;15, 2016. &nbsp;ASU 2015-11 is required to be applied prospectively.&nbsp; The amendments
in ASU 2015-11 were adopted by the Company during fiscal 2017. The adoption of this standard did not have an impact on the Company&rsquo;s
financial position or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In August 2014, the FASB issued
ASU 2014-15, &ldquo;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an
Entity&rsquo;s Ability to Continue as a Going Concern&rdquo; (&ldquo;ASU 2014-15&rdquo;). ASU 2014-15 is intended to define management&rsquo;s
responsibility to evaluate whether there is substantial doubt about an organization&rsquo;s ability to continue as a going concern
and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December
15, 2016. The Company adopted this standard during fiscal 2017 and has included the required disclosure in the Company&rsquo;s
financial statements (Note 3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Recently Issued Accounting
Pronouncements, Not Adopted as of June 30, 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In May 2017, the FASB issued ASU
No. 2017-09,&nbsp;&ldquo;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&nbsp;(ASU 2017-09).&rdquo;
ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification
accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017,
with early adoption permitted. The Company is currently evaluating the impact of its adoption of this standard on its financial
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In January 2017, the FASB issued
ASU 2017-04, &ldquo;Intangibles - Goodwill and Other (Topic 350).&rdquo; The amendment simplifies the subsequent measurement of
goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual,
or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge
should be recognized for the amount by which the carrying amount exceeds the reporting unit&rsquo;s fair value; however, the loss
recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to
perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment
should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including
interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed
on testing dates after January 1, 2017. The Company does not believe that adoption of this amendment will have a material impact
on its financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In January 2017, the FASB issued
ASU 2017-01, &ldquo;Business Combinations (Topic 805) Clarifying the Definition of a Business.&rdquo; The amendment clarifies
the definition of a business, which is fundamental in the determination of whether transactions should be accounted for as acquisitions
(or disposals) of assets or businesses. This determination is important given the diverging accounting models used for each type
of transaction. The guidance is generally expected to result in fewer transactions qualifying as business combinations. The amendment
is effective prospectively for public business entities for interim and annual periods beginning after December 15, 2017, including
interim periods within those periods. Early adoption is permitted. The Company does not expect an immediate impact on its financial
statements from this codification however, if Aytu seeks to purchase additional assets in the future it could have an impact if
that purchase is accounted for as a business combination or an asset purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In February 2016, the FASB issued
ASU 2016-02, &ldquo;Leases (Topic 842).&rdquo; The new standard establishes a right-of-use (ROU) model that requires a lessee
to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will
be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement.
The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal
years. A modified retrospective transition approach is required for leases for capital and operating leases existing at, or entered
into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients
available. The Company is currently evaluating the impact of its adoption of this standard on its financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In January 2016, the FASB issued
ASU No. 2016-01,<I> Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities</I> <I>(Topic
825)</I>. ASU No. 2016-01 revises the classification and measurement of investments in certain equity investments and the presentation
of certain fair value changes for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in
fair value of many equity investments to be recognized in net income. ASU No. 2016-01 is effective for interim and annual periods
beginning after December 15, 2017, with early adoption permitted. &nbsp;Adopting ASU No. 2016-01 may result in a cumulative effect
adjustment to the consolidated statement of equity retained earnings as of the beginning of the year of adoption. The Company
is currently evaluating the impact of this standard on its financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In May 2014, the FASB issued ASU
2014-09, Topic 606, Revenue from Contracts with Customers (the &quot;New Revenue Standard&quot;). The amendments in this ASU provide
a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition
guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized
to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity
expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty
of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14
which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11,
and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations,
identifying performance obligations, and accounting for licenses of intellectual property. The guidance also requires expanded
disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.
Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes
in judgments, and assets recognized from the costs to obtain or fulfill a contract.&nbsp; The New Revenue Standard is effective
for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is
permitted for interim and annual periods beginning after December 5, 2017. The amendments in this update are to be applied on
a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the
update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019.
We will adopt the standard in our third quarter of fiscal 2018 and preliminarily expect to use the modified prospective method.
However, we are continuing to evaluate the impact of the standard, and our adoption method is subject to change. We currently
do not anticipate these standards to have a material impact on our consolidated financial statements outside of the expanded disclosure
requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000"><B>Note 3
&ndash; Going Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying financial statements, the Company had a net loss of $22.5 million and net
cash used in operations of $13.8 million, for the year ended June 30, 2017. At June 30, 2017, Aytu had $878,000 of cash, cash equivalents
and restricted cash, stockholders&rsquo; equity of $4.0 million and an accumulated deficit of $69.1 million at June 30, 2017.&nbsp;&nbsp;In
addition, the Company is in the early stage of commercialization and has not yet generated any profits. These factors raised substantial
doubt about the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">However,
with the completion of the August 2017 financing of $11.8 million, the Company expects that its current cash resources plus this
additional funding will be sufficient to fund operations through fiscal 2018 and into mid-fiscal 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">The accompanying
financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery
of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue
as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 4 &ndash; License Agreement/Revenue
Recognition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">During 2011, Ampio Pharmaceuticals,
Inc., (&ldquo;Ampio&rdquo;), Aytu&rsquo;s former parent company, entered into a license, development and commercialization agreement
with a major Korean pharmaceutical company which was assigned to Vyrix when it was formed in 2013. The agreement grants the pharmaceutical
company exclusive rights to market Zertane in South Korea for the treatment of premature ejaculation (&ldquo;PE&rdquo;) and for
a combination drug to be developed, utilizing Zertane and an erectile dysfunction drug. Upon signing of the agreement, Ampio received
a $500,000 upfront payment, the net proceeds of which were $418,000 after withholding of Korean tax. The upfront payment was deferred
and was being recognized as license revenue over a ten-year period. Milestone payments of $3.2 million could have been earned
and recognized contingent upon achievement of regulatory approvals and cumulative net sales targets, which could have taken several
years. In addition, Aytu could have earned a royalty based on 25% of net sales, as defined, if the royalty exceeded the transfer
price of the Zertane product. No royalties have been earned to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2014, Vyrix entered into a Distribution and License Agreement (the &ldquo;Paladin Agreement&rdquo;)
with Endo Ventures Limited, which acquired Paladin Labs Inc. (&ldquo;Paladin&rdquo;), whereby Paladin has exclusive rights to market,
sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub Saharan Africa, Colombia and Latin
America. The Paladin Agreement expires on a country by country basis upon the later of 15 years after the first commercial sale
of the product in that country or expiration of market exclusivity for Zertane in that country. Paladin paid $250,000 to Vyrix
upon signing the Paladin Agreement and is obligated to make milestone payments aggregating up to $3.0 million based upon achieving
Canadian and South African product regulatory approval and achieving specific sales goals. The upfront payment was deferred and
was being recognized as license revenue over a seven-year period. In addition, the Paladin Agreement provides that Paladin pay
royalties based on sales volume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="color: #000000">At the end of fiscal 2016, Aytu determined that the Zertane asset had no further
value as Aytu did not have the resources to complete the necessary clinical trials and bring it to market before the patents expire.
The remaining deferred revenue of $426,000 was recognized as of June 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 5 &ndash; Fair Value Considerations
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The carrying amounts of financial
instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets
and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent
consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential
future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted
future cash&nbsp;flows. The valuation policies are determined by the Chief Financial Officer and approved by the Company&rsquo;s
Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Authoritative guidance defines
fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly
transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring
fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most
observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset
or liability developed based on market data obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect
Aytu&rsquo;s assumptions of what market participants would use in pricing the asset or liability developed based on the best information
available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 15%"><FONT STYLE="font-size: 10pt; color: #000000">Level&nbsp;1:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 85%"><FONT STYLE="font-size: 10pt; color: #000000">Inputs that reflect unadjusted
    quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Level&nbsp;2:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">Inputs include quoted prices for similar
    assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or
    indirectly; and</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; color: #000000">Level&nbsp;3:</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt; color: #000000">Unobservable inputs that are supported by
    little or no market activity.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu&rsquo;s assets and liabilities
which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their
fair value measurement. Aytu&rsquo;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in
which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed
below in all periods presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following table presents Aytu&rsquo;s
financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2017 and 2016, by level within
the fair value hierarchy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Fair
    Value Measurements Using</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Level
    1</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Level
    2</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Level
    3</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Total</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline"><FONT STYLE="color: #000000">June 30, 2017</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">ASSETS</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Investment in Acerus</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">LIABILITIES</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Warrant derivative liability</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left"><FONT STYLE="color: #000000">Contingent consideration</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">7,648,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">7,648,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline"><FONT STYLE="color: #000000">June 30, 2016</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">ASSETS</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Investment in Acerus</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,041,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,041,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">LIABILITIES</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Warrant derivative liability</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">276,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">276,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Contingent consideration</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">3,869,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">3,869,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The estimated fair value of the Company&rsquo;s investment, which is classified as Level 1 (quoted price is
available), was $1.0 million as of June 30, 2016. This investment was sold during fiscal 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The warrant derivative liability
was valued using the Black-Scholes valuation methodology because that model embodies all of the relevant assumptions that address
the features underlying these instruments. The warrants related to the warrant derivative liability are not actively traded and
therefore classified as Level 3. Significant assumptions in valuing the warrant derivative liability, based on estimates of the
value of Aytu common stock and various factors regarding the warrants, were as follows as of February 28, 2017, the date when
the derivative instruments converted into equity, and at June 30, 2016:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">February
    28, 2017</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">June
    30, 2016</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline"><FONT STYLE="color: #000000">Warrants:</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; padding-left: 0.25in"><FONT STYLE="color: #000000">Volatility</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">160.7</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">75.0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Equivalent term (years)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">4.18</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">4.84</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Risk-free interest rate</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1.87</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">0.99</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Dividend yield</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">0.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following table sets forth
a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Derivative
    Instruments</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%"><FONT STYLE="color: #000000">Balance as of June 30, 2016</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">276,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Warrant issuances</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Change in fair value included in earnings (February
    28, 2017)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(213,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">Reclassification of warrant
    from liability to equity upon amendment</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(63,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Balance as of June 30, 2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The contingent consideration was
valued using the Monte-Carlo valuation methodology because that model embodies all of the relevant assumptions that address the
features underlying these instruments. Contingent consideration is not actively traded and therefore classified as Level 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2016, we had $3.9 million in contingent consideration.
During fiscal 2017, this balance increased to $7.6 million as a result of $305,000 in accretion, which is included in our interest
expense, as well as an increase of $1.9 million related to our Nuelle merger and adjustments of $1.5 million related to the revaluation
of our ProstaScint and Natesto products.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 6 &ndash; Income Taxes
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">As previously
discussed in Note 2 - Summary of Significant Accounting Policies, the Company has been included in the consolidated tax returns
of Ampio for tax years ending on or before December 31, 2015. Beginning in January 2016, Aytu will file tax returns separate from
Ampio. For all consolidated tax return periods, the Company's taxes have been computed and reported on a &quot;separate return&quot;
basis. Ampio and Aytu did not have a tax sharing agreement for the consolidated return periods. Accordingly, certain tax attributes,
e.g. net operating loss carryforwards, reflected in these financial statements, may or may not be available to Aytu. In January
2016, Ampio's ownership interest in Aytu fell below 80% so that Aytu will no longer be included in the Ampio consolidated tax
return. The deconsolidation resulted in approximately $4.5 million of net operating loss carryforwards originating prior to the
incorporation of Vyrix and Luoxis no longer being available to Aytu. Upon deconsolidation, the deferred tax asset and related
valuation allowance for these pre-incorporation net operating losses have been removed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">Income tax
benefit resulting from applying statutory rates in jurisdictions in which Aytu is taxed (Federal and various states) differs from
the income tax provision (benefit) in the Aytu financial statements. The following table reflects the reconciliation for the respective
periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1pt solid">Year&nbsp;Ended&nbsp;June 30,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Benefit at statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(7,653,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(34.00</TD><TD STYLE="width: 1%; text-align: left">)%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(9,581,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(34.00</TD><TD STYLE="width: 1%; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State income taxes, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(681,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3.02</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(853,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3.03</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">116,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.51</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.03</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest on convertible debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.27</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.90</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in tax rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.05</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,922,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35.19</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,672,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30.77</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Reduction of net operating losses upon deconsolidation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,674,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.94</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.45</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Net income tax provision (benefit)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Deferred income taxes arise from
temporary differences in the recognition of certain items for income tax and financial reporting purposes. The approximate tax
effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective
periods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Deferred tax assets (liabilities):</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Deferred revenue</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Deferred rent</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">3,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">5,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Accrued expenses</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">127,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">445,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Net operating loss carry forward</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">15,435,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">9,202,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="color: #000000">Intangibles</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,559,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">606,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Share-based coompensation</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,362,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">327,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Fixed assets</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">191,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Unrealized loss on investment</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">360,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Capital loss carry forward</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">385,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Contribution carry forward</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">41,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in"><FONT STYLE="color: #000000">Warrant liability</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">75,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">153,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="color: #000000">Inventory</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">174,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">192,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in"><FONT STYLE="color: #000000">Allowance for doubtful
    accounts</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">17,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">15,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Total deferred income tax assets (liabilities)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">19,369,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">11,305,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">Less: Valuation allowance</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(19,369,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(11,305,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Total deferred income tax assets (liabilities)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: #000000">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion
or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the
generation of future taxable income during periods in which those temporary differences become deductible. Management considers
the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning
strategies in making the assessment. The Company believes it is more likely than not it will realize the benefits of these deductible
differences, net of the valuation allowance provided.</FONT><FONT STYLE="color: #000000"> <FONT STYLE="font-size: 10pt">The Company
has federal net operating losses of approximately $42.3 million and $24.8 million as of June 30, 2017 and June 30, 2016, respectively
that, subject to limitation, may be available in future tax years to offset taxable income. The available federal net operating
losses, if not utilized to offset taxable income in future periods, will begin to expire in 2031 through 2036. The Company has
state net operating losses of approximately $32.8 million and $17.3 million as of June 30, 2017 and June 30, 2016, respectively
that, subject to limitation, may be available in future tax years to offset taxable income. The available state net operating
losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2036. Under the provisions
of the Internal Revenue Code, substantial changes in the Company's ownership may result in limitations on the amount of NOL carryforwards
that can be utilized in future years. Net operating loss carryforwards are subject to examination in the year they are utilized
regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance
is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are
utilized. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">As of June 30, 2017 and 2016,
the Company has no liability for gross unrecognized tax benefits or related interest and penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu has made its best estimates
of certain income tax amounts included in the financial statements. Application of the Company's accounting policies and estimates,
however, involves the exercise of judgement and use of assumptions as to future uncertainties and, as a result, could differ from
these estimates. In arriving at its estimates, factors the Company considers include how accurate the estimates or assumptions
have been in the past, how much the estimates or assumptions have changed and how reasonably likely such changes may have a material
impact. Aytu has been historically included in the Ampio consolidated tax return. Under the general statute of limitations, the
Company would not be subject to federal or Colorado income tax examinations for tax years prior to 2013 and 2012, respectively.
However, given the net operating losses generated since inception, all tax years since inception are subject to examination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 7 &ndash; Commitments
and Contingencies </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Commitments and contingencies
are described below and summarized by the following table as of June&nbsp;30, 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Total</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2018</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2019</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2020</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2021</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2022</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Thereafter</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%; text-align: left"><FONT STYLE="color: #000000">Prescription database</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">1,342,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">769,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">573,000</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">Natesto</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">15,000,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">2,500,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5,000,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">7,500,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Manufacturing/commercial supply agreements</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="color: #000000">Office lease</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">175,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">145,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">30,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">16,517,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">914,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">603,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">2,500,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">5,000,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">7,500,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Prescription Database</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In May 2016, Aytu entered into
an agreement with a company that will provide Aytu with prescription database information, whereby Aytu agreed to pay approximately
$1.9 million over three years for access to the database of prescriptions written for Natesto. The payments have been broken down
into quarterly payments, the first of which was made in November 2016, the second payment was made in January 2017 and the third
payment was made in April 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Natesto</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In April 2016, the Company entered
into an agreement with Acerus whereby Aytu agreed to pay $8.0 million for the exclusive U.S. rights to Natesto (see Note 1). The
first payment totaling $2.0 million was paid in April, the second installment payment was paid in October 2016. The final payment
totaling $4.0 million was paid in January 2017. Additionally, Aytu is required to make the first milestone payment of $2.5 million
even if the milestone is not reached and anticipates making the second milestone payment of $5.0 million along with the third
milestone payment of $7.5 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Manufacturing/Commercial
Supply Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In October 2015, Aytu entered
into a Master Services Agreement with Biovest International, Inc. (&ldquo;Biovest&rdquo;). The agreement provides that Aytu may
engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders.
Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing,
processing, quality control testing, release or storage of its products for the ProstaScint product. In September 2016, Aytu entered
into a Commercial Supply Agreement with Grand River Aseptic Manufacturing, Inc. (&ldquo;GRAM&rdquo;). The agreement provides that
Aytu may engage GRAM from time to time to provide services in accordance with mutually agreed upon work orders. As of June 30,
2017, both contracts were on hold as the Company evaluates its strategic options for the ProstaScint product. If the contracts
are not restarted, Aytu does not anticipate any future liability related to either contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Office Lease </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In June 2015, Aytu entered into
a 37 month operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $3,000 a month, with total
base rent over the term of the lease of approximately $112,000. In September 2015, the Company entered into a 37 month operating
lease in Englewood, Colorado. This lease has an initial base rent of $9,000 a month with a total base rent over the term of the
lease of approximately $318,000. The Company recognizes rental expense of the facilities on a straight-line basis over the term
of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current
deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Year Ended June 30,</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; background-color: White"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%; background-color: White"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; background-color: White"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right; background-color: White"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left; background-color: White"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%; background-color: White"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; background-color: White"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right; background-color: White"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left; background-color: White"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Rent expense</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">139,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">120,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 8 &ndash; Convertible
Promissory Notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B></B>During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth
individual investors for the purchase and sale of convertible promissory notes (&ldquo;Notes&rdquo;) with an aggregate principal
amount of $5.2 million. The sale of the Notes was pursuant to a private placement. Debt issuance costs totaled $401,000, which
included the $103,000 fair value of the placement agent warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Notes were an unsecured obligation.
Aytu did not have the right to prepay the Notes prior to the maturity date. Interest accrued on the Notes in the following amounts:
(i)&nbsp;8% simple interest per annum for the first six months and (ii)&nbsp;12% simple interest per annum thereafter if not converted
during the first nine months. Interest accrued, was payable with the principal upon maturity, conversion or acceleration of the
Notes and could have been paid in kind or in cash, in Aytu&rsquo;s sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Placement agents for the offering
sold the institutional portion of the offering of the Notes. Aytu sold the balance of the Notes to individuals and entities with
whom Aytu had an established relationship. For Notes sold by the placement agent, Aytu paid the placement agent 8% of the gross
proceeds of Notes sold by the placement agents and was obligated to issue warrants for an amount of shares equal to 8% of the
gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company
by the private placement agents in the private placement, in addition to a previously paid non-refundable retainer fee of $20,000.
The placement agent warrants have a term of five years from the date of issuance of the related notes in July and August 2015,
an exercise price equal to the conversion price per share at which the Notes are converted into common stock. Change in fair value
is recorded in earnings. Fair value at the grant date was recorded as a debt discount and amortized over the term of the debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The warrants were recorded at
fair value as long-term liabilities on the Balance Sheet and upon conversion were moved to equity classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Upon Aytu&rsquo;s adoption of
ASU 2015-3, the issuance costs associated with the Notes were recorded as a long&ndash;term liability and were presented in the
Balance Sheet as a direct reduction of the carrying amount of the Notes on their inception date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the convertible promissory note agreements,
if Aytu sold equity securities at any time while the Notes were outstanding in a financing transaction that was not a Qualified
Financing (a public offering of Aytu stock resulting in gross proceeds of at least $5.0 million (excluding indebtedness converted
in such financing) prior to the maturity date of the Notes), the holders of the convertible promissory notes had the option, but
not the obligation, to convert the outstanding principal and accrued interest as of the closing of such financings into a number
of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding
principal and accrued interest by the lesser of (a) the lowest cash price per share paid by purchasers of shares in such financing,
or (b) $92.60. As a result of Aytu&rsquo;s sale of common stock on January 20, 2016, the Company was obligated to provide notice
to the above-referenced noteholders of such stock sales. In accordance with the convertible note terms, noteholders had the option
to convert their entire balance (inclusive of accrued but unpaid interest) into a number of shares of Aytu common stock equal
to 120% of the number of shares calculated by dividing such note balance by $156.00, which was the per share purchase price paid
in the equity financing described above. On February 10, 2015, the date of the conversion, an aggregate of $4.1 million of principal
and $143,000 of accrued interest on the Notes converted into an aggregate of 32,830 shares of Aytu&rsquo;s common stock under
the original terms of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">In May 2016, Aytu completed a registered public offering which was considered a Qualified Financing and
all outstanding Notes were automatically converted on the same terms as in the offering. At the insistence of the underwriters
of the offering, all outstanding noteholders had signed lockup agreements which granted them an extra 10% on the conversion, increasing
it to 130% of shares calculated by dividing such Note balance by $96.00, which was the per share purchase price in the registered
offering. On May 6, 2016, the date of conversion, an aggregate of $1.1 million of principal and $78,000 of accrued interest on
the Notes converted into an aggregate of 15,279 shares of Aytu&rsquo;s common stock and 15,279 warrants.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In connection with the conversion
of the Aytu Notes, Aytu was obligated to issue to the placement agents for the convertible note offering warrants for an amount
of shares equal to 8% of the number of shares of Aytu&rsquo;s common stock for the Notes sold by the placement agents issued upon
conversion of the Notes. As a result of the optional note conversion, on February 10, 2016, Aytu issued warrants to the placement
agents to purchase an aggregate of 1,113 shares of common stock at an exercise price of $156.00 per share. As a result of the
second Note conversion, on May 6, 2016, Aytu issued warrants to the placement agents to purchase an aggregate of 1,129 shares
of common stock at an exercise price of $96.00 per share. These warrants are exercisable for five years from the date of issuance
of the related Notes in July and August 2015. The warrants have a cashless exercise feature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Also in connection with the conversion
of the Notes, Aytu recorded a beneficial conversion feature of $4.9 million which was recorded as a debt discount; this amount
represents that carrying amount of the Notes at the date of conversion. The&nbsp;beneficial conversion feature was expensed upon
conversion of the Notes to interest expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 9 &ndash; Common Stock
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Capital Stock </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">At June 30, 2017 and June 30,
2016, Aytu had 824,831 and 187,098 common shares outstanding, respectively, and no preferred shares outstanding at either June
30, 2017 or June 30, 2016. The Company has 100.0&nbsp;million shares of common stock authorized with a par value of $0.0001&nbsp;per
share and 50.0&nbsp;million shares of preferred stock authorized with a par value of $0.0001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In May 2016, Aytu raised gross
proceeds of approximately $7.5 million through a public offering of 78,125 Units. Offering costs totaled $1.2 million resulting
in net proceeds of $6.3 million. Each Unit consisted of one share of Aytu common stock and a warrant to purchase one share of
Aytu common stock. The common stock issued had a relative fair value of $4.2 million. The warrants have an exercise price of $120.00
per share and will expire five years from the date of issuance. These warrants have a relative fair value of $2.1 million. We
also granted the underwriters a 45-day option (the Over-Allotment Option) to purchase up to an additional 11,719 shares of common
stock and/or warrants. The underwriters exercised 8,542 of this over-allotment option for the warrants and paid $2.40 per over-allotment
warrant resulting in proceeds of $20,000. These warrants have the same terms as the warrants sold in the registered offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In July 2016, we entered into
a purchase agreement (the &lsquo;&lsquo;Purchase Agreement&rsquo;&rsquo;), together with a registration rights agreement (the
&lsquo;&lsquo;Registration Rights Agreement&rsquo;&rsquo;), with Lincoln Park Capital Fund, LLC (&lsquo;&lsquo;Lincoln Park&rsquo;&rsquo;).
Upon signing the Purchase Agreement, Lincoln Park agreed to purchase 6,684 shares of our common stock for $500,000 as an initial
purchase under the agreement. We also issued as a commitment fee to Lincoln Park of 2,625 shares of common stock. Between September
2016 and June 2017, Lincoln Park purchased an additional 10,000 shares for $240,000, the issuance costs related to these purchases
totaled $91,000, resulting in net proceeds of $649,000. We terminated the Purchase Agreement effective August 16, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2016, we issued 50,000 shares of restricted stock as compensation to certain executive officers and
directors, which vest in July 2026. This expense is included in sales, general and administrative. For the year ended June 30,
2017, the expense was $725,000. The original fair value of the restricted stock was $3.2 million. As of June 30, 2017, the remaining
unrecognized expense is $2.5 million. During fiscal 2017, one of the Company&rsquo;s executive officers resigned and his restricted
stock vested in full upon this event. This resulted in the Company recognizing the remainder of the expense related to this executive&rsquo;s
restricted stock grant of $430,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In August 2016, we issued an aggregate
of 7,123 shares of common stock as bonuses for performance in 2016 to three executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In November 2016, we raised gross
proceeds of approximately $8.6 million through a public offering of 286,749 Units. Offering costs totaled $1.0 million resulting
in net cash proceeds of $7.6 million. We also issued underwriter warrants in connection with the offering with a fair value of
$293,000, resulting in net proceeds of $7.3 million. Each Unit consisted of one share of Aytu common stock and a warrant to purchase
one share of Aytu common stock. The common stock issued had a relative fair value of $3.7 million and a fair value of $4.4 million.
The investor warrants have an exercise price of $37.20 per share and will expire five years from the date of issuance. These investor
warrants have a relative fair value of $3.5 million and a fair value of $4.2 million. We also granted the underwriters a 45-day
option (the Over-Allotment Option) to purchase up to an additional 43,013 shares of common stock and/or warrants. The underwriters
purchased 14,263 of this Over-Allotment Option for the warrants and paid $0.20 per over-allotment warrant. These warrants have
the same terms as the warrants sold in the registered offering. These warrants have a relative fair value of $173,000, a fair
value of $208,000, and proceeds of $3,000, which was the purchase price per the underwriting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In February 2017, the Company
consummated its warrant tender offer to exercise, at a temporarily reduced exercise price of $15.00 per share, (i) outstanding
warrants to purchase 86,667 shares of common stock with an exercise price of $120.00 per share, which were originally issued to
investors in the Company&rsquo;s May 2016 financing (the &ldquo;May 2016 Warrants&rdquo;), and (ii) outstanding warrants to purchase
301,013 shares of common stock with an exercise price of $37.20 per share, which were originally issued to investors in the Company&rsquo;s
October 2016 financing (the &ldquo;October 2016 Warrants&rdquo; and together with the May 2016 Warrants, the &ldquo;Original Warrants&rdquo;).
Original warrants to purchase an aggregate of 149,552 shares of common stock were tendered and exercised in the warrant tender
offer, for aggregate gross proceeds to the Company of approximately $2.2 million. Original warrants that were not tendered and
exercised remain in effect at the pre-tender offer exercise prices of $120.00 per share and $37.20 per share, respectively (see
Note 11).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In May 2017, we entered into a
Merger Agreement with Nuelle, Inc. and its stockholders, pursuant to which Nuelle would become our wholly owned subsidiary (the
&ldquo;Merger&rdquo;). The Merger closed on May 5, 2017. As part of the Merger, we issued to the Nuelle preferred stockholders
an aggregate of 125,000 shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 10 &ndash; Equity Instruments
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Stock Option Repricing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In March 2017, our Board of Directors
approved a common stock option repricing program whereby all previously granted and unexercised options were repriced on a one-for-one
basis to $16.40 per share which represented the closing price of our common stock as of the date of the repricing. There was no
other modification to the vesting schedule of the previously issued options. As a result, 36,864 unexercised options originally
granted to purchase common stock at prices ranging from $64.60 to $1,111.20 per share were repriced under this program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We treated the repricing as a
modification of the original awards and calculated additional compensation costs for the difference between the fair value of
the modified award and the fair value of the original award on the modification date. The repricing resulted in an incremental
stock-based compensation expense of $34,000. The full expense was recognized during fiscal 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In July 2016, our Board of Directors
approved a common stock option repricing program whereby previously granted and unexercised options held by our then current employees,
consultants and directors with exercise prices above $120.00 per share were repriced on a one-for-one basis to $64.60 per share
which represented the per share fair value of our common stock as of the date of the repricing. There was no other modification
to the vesting schedule of the previously issued options. As a result, 15,803 unexercised options originally granted to purchase
common stock at prices ranging from $134.40 to $362.40 per share were repriced under this program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">We treated the repricing as a
modification of the original awards and calculated additional compensation costs for the difference between the fair value of
the modified award and the fair value of the original award on the modification date. The repricing resulted in an incremental
stock-based compensation expense of $318,000. Expense related to vested shares was expensed on the repricing date and expense
related to unvested shares is being amortized over the remaining vesting period of such stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Options </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">On June&nbsp;1, 2015, Aytu&rsquo;s
stockholders approved the 2015 Stock Option and Incentive Plan (the &ldquo;2015 Plan&rdquo;), which, as amended in November 2016,
provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate
of 100,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by
Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under
the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Pursuant to the 2015 Stock Plan,
100,000 shares of its common stock, are reserved for issuance. The fair value of options granted was calculated using the Black-Scholes
option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of
the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend
yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the
expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is
based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The assumptions
used for the year ended June 30, 2017 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 114; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Year
    Ended June 30,</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&nbsp;<B>2016</B></FONT></TD><TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; text-align: left"><FONT STYLE="color: #000000">Expected volatility</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">178%
                                         - 185%</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 18%; text-align: center"><FONT STYLE="color: #000000">75%</FONT></TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Risk free interest rate</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">0.97%
                                         - 1.88%</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&nbsp;1.16%
                                         - 1.90%</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Expected term (years)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">5.0
                                         -6.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #000000">&nbsp;3.75
                                         - 6.25</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Dividend yield</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">0%</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">0%</FONT></TD><TD STYLE="text-align: left"></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Stock option activity is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Number&nbsp;of<BR>
    Options</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Weighted<BR>
    Average<BR> Exercise&nbsp;Price</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Weighted&nbsp;Average<BR>
    Remaining<BR> Contractual&nbsp;Life&nbsp;in<BR> Years</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">Outstanding&nbsp;June&nbsp;30,&nbsp;2015</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; padding-left: 0.125in"><FONT STYLE="color: #000000">Granted</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">16,340</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">360.20</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="color: #000000">Exercised</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="color: #000000">Forfeited/Cancelled</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(209</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="color: #000000">362.40</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">Outstanding June 30, 2016</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">16,131</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">360.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">9.33</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="color: #000000">Granted</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">23,608</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">18.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="color: #000000">Exercised</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="color: #000000">Forfeited</FONT></TD><TD STYLE="padding-left: 0.125in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(1,408</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">83.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"><FONT STYLE="color: #000000">Cancelled</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(68</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="color: #000000">64.60</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">Outstanding June 30, 2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">38,263</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="color: #000000">16.31</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="color: #000000">8.40</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">Exercisable at June 30, 2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">19,341</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="color: #000000">16.40</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="color: #000000">7.95</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Available for grant at June 30, 2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">61,737</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The following table details the
options outstanding at June 30, 2017 by range of exercise prices:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; border-bottom: Black 1pt solid; text-align: center"><B>Range of Exercise Prices</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Number of Options Outstanding</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Weighted Average Exercise Price</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Weighted Average Remaining
    Contractual Life of Options Outstanding</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Number of Options Exercisable</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Weighted Average Exercise Price</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">14.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">1,500</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">14.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">9.85</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: right">14.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">16.40</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">36,763</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">16.40</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">8.34</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,341</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">16.40</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">38,263</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">16.31</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">8.40</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">19,341</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">16.40</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Stock-based compensation expense
related to the fair value of stock options was included in the statements of operations as research and development expenses and
sales, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant
using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. The following table
summarizes stock-based compensation expense for the years ended June&nbsp;30, 2017 and 2016:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">Year Ended June 30,</FONT></TD><TD NOWRAP STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Research and development expenses</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; text-indent: 10pt"><FONT STYLE="color: #000000">Stock-based compensation</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">89,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Selling, general and administrative expenses</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt"><FONT STYLE="color: #000000">Stock-based compensation</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">2,502,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">814,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">2,502,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">903,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">Unrecognized expense at June 30, 2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">775,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Weighted average remaining years to vest</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1.81</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Warrants </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">A summary of all warrants is as
follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Number
    of <BR> Warrants</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Weighted
    <BR> Average <BR> Exercise Price</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Weighted
    Average <BR> Remaining Contractual<BR> &nbsp;Life in Years</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%"><FONT STYLE="color: #000000">Outstanding June 30, 2015</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">444</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">1,087.20</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 10%; text-align: center"><FONT STYLE="color: #000000">2.92</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Warrants issued to placement agents for convertible
    promissory notes</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,115</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">156.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Warrants issued to investors in connection
    with the registered offering</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">86,667</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">120.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Warrants issued to placement agents for convertible
    promissory notes</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">1,129</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">96.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Warrants issued to placement agents for the
    registered offering</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">5,474</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">120.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Warrants issued to convertible note holders
    who converted May 5, 2016</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">15,279</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="color: #000000">120.00</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">Outstanding June 30, 2016</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">110,108</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">124.02</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">4.71</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Issuance of settlement warrants to initial
    investors</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">4,402</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">80.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Warrants issued to investors in connection
    with the registered offering</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">301,014</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">37.20</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Warrants issued to placement agents for the
    registered offering</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">20,077</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">15.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="color: #000000">Warrants exercised</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">(149,552</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">15.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">Outstanding June 30, 2017</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">286,049</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right"><FONT STYLE="color: #000000">50.29</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: center"><FONT STYLE="color: #000000">4.23</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In connection with our private
placement of approximately $5.2 million of convertible notes in July and August 2015, the Company was obligated to issue to the
placement agents&rsquo; warrants for an amount of shares equal to 8% of the number of shares of our common stock issued upon conversion
of the notes and any accrued interest. The placement agents warrants have a term of five years from the date of issuance of the
related notes in July and August 2015, an exercise price equal to 100% of the price per share at which equity securities were
sold in our next equity financing, and provide for cashless exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In connection with the conversions
of the notes in February 2016 and May 2016, which were triggered by an equity financing in January 2016 and our public offering
of common stock and warrants in May 2016, respectively, we issued warrants to the placement agents to purchase an aggregate of
1,115 shares of our common stock at an exercise price of $156.00 per share, and an aggregate of 1,129 shares of our common stock
at an exercise price of $96.00 per share. These warrants have a fair value of $87,000 and $50,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Also in connection with the conversion
of the notes in May 2016, the noteholders that converted also received 15,279 warrants (see Note 9). These warrants have a term
of five years with an exercise price of $120.00 per share. These warrants are accounted for under equity treatment and have a
fair value of $480,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In connection with our May 2016
public offering, we issued warrants to purchase an aggregate of 5,474 shares of common stock at an exercise price of $120.00 and
a term of five years to the underwriters of the public offering. These warrants are accounted for under liability accounting and
are fair valued at each reporting period (see Note 6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Also in connection with our May
2016 public offering, we issued to investors warrants to purchase an aggregate of 86,667 shares of common stock, which includes
the over-allotment warrants, at an exercise price of $120.00 with a term of five years. These warrants are accounted for under
equity treatment (see Note 10).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Included in the warrant balance
at June 30, 2016 are warrants to purchase of 5,474 shares of common stock issued to the underwriters of our May registered offering.
These warrants were accounted for under liability accounting and were fair valued at each reporting period (see Note 7). On February
28, 2017, these warrants had a fair value of $63,000. Upon the amendment to these warrant agreements, in connection with the closing
of our warrant tender offer, this value was reclassified from liability accounting to equity after we removed any provision in
the amendment that could cause this to be paid in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Included in the warrant balance
at June 30, 2016 are warrants to purchase of 429 shares of common stock issued to the bankers that assisted us with our Notes
(see Note 9). In March 2017, the Company reduced the exercise price of $156.00 to $15.00. This modification resulted in an expense
of $1,500 which was recognized during the quarter ended March 31, 2017 in sales, general and administrative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">During fiscal 2017, Aytu issued
warrants to purchase 4,402 shares of common stock to initial investors of the Company at an exercise price of $80.00 and a term
of five years from July 2016. These warrants generated a non-cash expense of $596,000 for the year ended June 30, 2017, which
is included in sales, general and administrative expense. These warrants are accounted for under equity treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In connection with our November
2016 public offering, we issued to the underwriters of the public offering warrants to purchase an aggregate of 20,077 shares
of common stock at an exercise price of $37.20 and a term of five years. These warrants are accounted for under equity treatment.
In February, we reduced the exercise price of these warrants to $15.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Also in connection with our November
2016 public offering, we issued to investors warrants to purchase an aggregate of 301,014 shares of common stock, which includes
the over-allotment warrants, at an exercise price of $37.20 with a term of five years. These warrants are accounted for under
equity treatment (see Note 10).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In February 2017, the Company
consummated its warrant tender offer to exercise, at a temporarily reduced exercise price of $15.00 per share, (i) outstanding
warrants to purchase 86,667 shares of common stock with an exercise price of $120.00 per share, which were originally issued to
investors in the Company&rsquo;s May 2016 financing (the &ldquo;May 2016 Warrants&rdquo;), and (ii) outstanding warrants to purchase
301,014 shares of common stock with an exercise price of $37.20 per share, which were originally issued to investors in the Company&rsquo;s
October 2016 financing (the &ldquo;October 2016 Warrants&rdquo; and together with the May 2016 Warrants, the &ldquo;Original Warrants&rdquo;).
Original Warrants to purchase an aggregate of 149,552 shares of common stock were tendered and exercised in the warrant tender
offer, for aggregate gross proceeds to the Company of approximately $2.2 million. Original warrants that were not exercised remain
in effect at the pre-tender offer exercise prices of $120.00 per share and $37.20 per share, respectively. The incremental fair
value, which had no book impact, was $178,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">The Company also reduced the exercise
prices of an aggregate of 25,541 warrants to purchase shares of common stock, which were originally issued as underwriters&rsquo;
compensation in the May 2016 and October 2016 financings, from $120.00 per share and $37.20 per share, respectively, to $15.00
per share. The amended warrants related to the May 2016 financing adjusted the accounting for these warrants from liability classification
to equity. The incremental fair value of these warrant modifications, which had no book impact, was $23,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">All warrants were valued using
the Black-Scholes option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding
components of the model, including the selling price or fair market value of the underlying common stock, risk-free interest rate,
volatility, expected dividend yield, and expected life. Changes to the assumptions could cause significant adjustments to valuation.
The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies.
The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of
similar maturity. During fiscal 2017, Aytu modified 175,522 warrants. We used the value of $15.20 per the valuation of our common
stock issued in March 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Significant assumptions in valuing
the warrants issued and modified during the year ended June 30, 2017 were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Year
    Ended June 30,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; text-align: left"><FONT STYLE="color: #000000">Expected volatility</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 18%; text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">156.64%
                                         - 169.22%</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 18%; text-align: center"><FONT STYLE="color: #000000">75%</FONT></TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Risk free interest rate</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">1.63%
                                         - 1.87%</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">1.07
                                         - 1.76%</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Contractual term (years)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">3.46
                                         - 4.67</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: #000000">4.2 -
                                         5.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Dividend yield</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">0%</FONT></TD><TD STYLE="text-align: left"></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="color: #000000">0%</FONT></TD><TD STYLE="text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 11 &ndash; Related Party
Transactions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Services Agreement </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In July 2015, Aytu entered into
an agreement with Ampio, whereby Aytu agreed to pay Ampio a set amount per month for shared overhead, which includes costs related
to the shared corporate staff and other miscellaneous overhead expenses. This agreement was amended in November 2015, April 2016,
July 2016, and again in January 2017 resulting in an amount of $12,000 per month. This agreement was terminated in June 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B><I>Sponsored Research Agreement
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In June 2013, Luoxis entered into
a sponsored research agreement with TRLLC, an entity controlled by Ampio&rsquo;s director and Chief Scientific Officer, Dr.&nbsp;Bar-Or.
The agreement, which was amended in January 2015 and provided for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration
for services related to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed
to pay a sum of $615,000 which was being amortized over the contractual term of 60.5 months and was divided between current and
long-term on the balance sheet; as of September 2014, this amount had been paid in full. This agreement was terminated in March
2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 12 &ndash; Segment Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000; background-color: white">Aytu
manages our Company and aggregated our operational and financial information in accordance with two reportable segments: Aytu
and Aytu Women&rsquo;s Health. The Aytu segment consists of our core male urology products. The Aytu Women&rsquo;s Health segment
contains our women&rsquo;s health platform which consists of sexual wellness platform. Select financial information for these
segments is as follows:</FONT><FONT STYLE="color: #000000"><B> </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="color: #000000">Year
    Ended June 30,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">2017</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="color: #000000">2016</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="color: #000000">Revenue:</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; padding-left: 0.25in"><FONT STYLE="color: #000000">Aytu</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">3,175,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="color: #000000">2,562,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="color: #000000">Aytu Women's Health</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">47,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Consolidated revenue</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">3,222,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">2,562,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Consolidated net loss:</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="color: #000000">Aytu</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(22,349,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">(28,180,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="color: #000000">Aytu Women's Health</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">(159,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">Consolidated net loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">(22,508,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">(28,180,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="color: #000000">Total assets:</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="color: #000000">Aytu</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">11,779,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">24,343,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="color: #000000">Aytu Women's Health</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">3,220,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="color: #000000">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="color: #000000">Total assets</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">14,999,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="color: #000000">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="color: #000000">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="color: #000000">24,343,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="color: #000000">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 13 &ndash; Employee Benefit
Plan </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">Aytu has a 401(k) plan that allows
participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. The Company matches
50% of the first 6% contributed to the plan by employees. In fiscal 2017, the Company&rsquo;s match was $99,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000"><B>Note 14 &ndash; Subsequent
Events </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In July 2017, our stockholders
approved an amendment to our 2015 Stock Option and Incentive Plan to (i) increase the number of authorized shares of common stock
reserved for issuance thereunder from 2.0 million to 3.0 million, (ii) increase the number of shares that may be issued as incentive
stock options from 2.0 million to 3.0 million, (iii) increase the maximum number of shares of common stock (A) underlying stock
options or stock appreciation rights that may be granted to any one individual during any calendar year period, and (B) granted
to any one individual that is intended to qualify as &ldquo;performance-based compensation&rdquo; under Section 162(m) of the
Internal Revenue Code of 1986, as amended, for any performance cycle from 1.0 million to 2.0 million, and (iv) in the event that
we effect a reverse stock split prior to November 14, 2018 (or such other date that is one year after the date of our 2018 annual
meeting of stockholders), immediately after the effective time of such reverse stock split, (A) the maximum number of shares reserved
under the Plan will be automatically increased to 3.0 million, (B) the maximum number of shares that may be issued pursuant to
any type of award will be automatically increased to 3.0 million, (C) the number of shares that may be granted to any one individual
during any one calendar year period as stock options or stock appreciation rights will be automatically increased to 2.0 million,
and (D) the number of shares that may be issued in the form of incentive stock options will be automatically increased</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">to 3.0 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In July 2017, our stockholders
also approved an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio of any whole number
up to 1-for-20, as determined by our board of directors, at any time before November 14, 2018 (or such other date that is one
year after the date of our 2018 annual meeting of stockholders), if and as determined by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">August 11, 2017, our board of
directors approved a reverse stock split in which each common stockholder received one share of common stock for every 20 shares
outstanding, which was effected on August 25, 2017. This adjustment is reflected in this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 11, 2017, we entered into a Securities Purchase Agreement
with various investors pursuant to which we agreed to sell Class A and Class B equity units for gross proceeds of approximately
$11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares
of common stock and were sold at a negotiated price of $3.00 per unit. Class B units consist of one (1) share of our newly created
Series A Convertible Preferred Stock (the &ldquo;Series A Preferred Stock&rdquo;) and warrants to purchase one and one-half (1.5)
shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at
a negotiated price of $1,000.00 per unit to those purchasers who, together with their affiliates and certain related parties,
would beneficially own more than 9.99% of our outstanding common stock following the offering. These Series A Preferred Shares
concert into common shares at $3.00 per share, which when fully exercised will increase the common shares outstanding by 750,000
shares. The offering closed on August 15, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the offering, we issued an aggregate of 3,196,665 shares
of our common stock, 2,250 shares of Series A Preferred Stock and warrants to purchase up to an aggregate of 5,919,998 shares of
our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We incurred certain expenses related to this transaction to
attorneys and underwriters inclusive of a 9% cash fee and warrants to purchase 10% of the aggregate number of shares issued in
the transaction.</P>



<P STYLE="margin: 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">In connection with the closing of the financing, we terminated the<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Purchase Agreement, dated as of July 27, 2016, by and between us and Lincoln Park Capital Fund, LLC. The termination was effective
on August 16, 2017. </FONT>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #000000">&nbsp;&nbsp;&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>2
<FILENAME>v473641_ex10-25.htm
<DESCRIPTION>EXHIBIT 10.25
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><I>EXECUTION VERSION </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.25</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Portions of this exhibit marked [*] are requested
to be treated confidentially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>MERGER AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">among</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>AYTU BIOSCIENCE, INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>NUELLE, INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Aytu
Acquisition Corporation,</B> </FONT><B>INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Aytu
Holdings, LLC</B></FONT><B>,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>EARL BRIGHT, </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>AS REPRESENTATIVE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">dated as of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">May 3,
2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 1.25in; text-align: center; text-indent: -1.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-right: 0.5in"><FONT STYLE="text-transform: uppercase">Article 1. THE MERGERS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="text-transform: uppercase">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 15%; padding-left: 0.25in"><B>Section 1.1</B></TD>
    <TD STYLE="width: 75%; padding-left: 0.125in"><B>The Mergers</B></TD>
    <TD STYLE="width: 10%; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 1.2</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Closing; Effective Time</B></TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 1.3</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Certificate of Incorporation; Bylaws; Directors and Officers</B></TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 1.4</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Surrender and Payment</B></TD>
    <TD STYLE="text-align: right">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 1.5</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Treatment of Dissenting Shares</B></TD>
    <TD STYLE="text-align: right">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 1.6</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>No Further Ownership Rights in Company Stock</B></TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 1.7</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Lost Certificates</B></TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 1.8</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Withholding</B></TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 1.9</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Interest; No Liability</B></TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 1.10</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Adjustments to Prevent Dilution</B></TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 1.11</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Tax Treatment</B></TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding-right: 0.5in"><FONT STYLE="text-transform: uppercase">Article 2. CONDITIONS TO MERGERS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="text-transform: uppercase">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 2.1</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Conditions to All Parties&rsquo; Obligations</B></TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 2.2</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Conditions to Parent&rsquo;s and Merger Subs&rsquo; Obligations</B></TD>
    <TD STYLE="text-align: right">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 2.3</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Conditions to Company&rsquo;s Obligations</B></TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 2.4</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Waiver of Conditions</B></TD>
    <TD STYLE="text-align: right">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding-right: 0.5in"><FONT STYLE="text-transform: uppercase">Article 3. REPRESENTATIONS AND WARRANTIES OF COMPANY</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="text-transform: uppercase">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.1</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Organization and Qualification of Company</B></TD>
    <TD STYLE="text-align: right">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.2</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Authorization</B></TD>
    <TD STYLE="text-align: right">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.3</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Capitalization</B></TD>
    <TD STYLE="text-align: right">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.4</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Subsidiaries</B></TD>
    <TD STYLE="text-align: right">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.5</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>No Conflicts; Consents</B></TD>
    <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.6</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Financial Statements</B></TD>
    <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.7</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Undisclosed Liabilities; Cash on Hand</B></TD>
    <TD STYLE="text-align: right">14</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.8</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Absence of Certain Changes, Events and Conditions</B></TD>
    <TD STYLE="text-align: right">14</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.9</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Material Contracts</B></TD>
    <TD STYLE="text-align: right">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.10</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Title to Tangible Assets; Real Property</B></TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.11</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Condition and Sufficiency of Assets</B></TD>
    <TD STYLE="text-align: right">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.12</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Intellectual Property</B></TD>
    <TD STYLE="text-align: right">19</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.13</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Inventory</B></TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.14</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Accounts Receivable</B></TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.15</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Customers and Suppliers</B></TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.16</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Insurance</B></TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.17</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Legal Proceedings; Governmental Orders</B>.</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.18</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Compliance With Laws; Permits</B></TD>
    <TD STYLE="text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.19</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Environmental Matters</B></TD>
    <TD STYLE="text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.20</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Employee Benefit Matters</B></TD>
    <TD STYLE="text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.21</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Employment Matters</B></TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.22</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Taxes</B></TD>
    <TD STYLE="text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.23</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Books and Records</B></TD>
    <TD STYLE="text-align: right">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.24</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Certain Payments</B></TD>
    <TD STYLE="text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.25</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Privacy and Data Security</B></TD>
    <TD STYLE="text-align: right">30</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">TABLE OF CONTENTS<BR>
(Continued)</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-left: 0.125in; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; width: 15%"><B>Section 3.26</B></TD>
    <TD STYLE="padding-left: 0.125in; width: 75%"><B>Government Grants and Incentives</B></TD>
    <TD STYLE="text-align: right; width: 10%">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.27</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Products Liability</B></TD>
    <TD STYLE="text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.28</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>State Takeover Statutes</B></TD>
    <TD STYLE="text-align: right">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.29</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Related Party Transactions</B></TD>
    <TD STYLE="text-align: right">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 3.30</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Brokers</B></TD>
    <TD STYLE="text-align: right">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-right: 0.5in"><FONT STYLE="text-transform: uppercase">Article 4. REPRESENTATIONS AND WARRANTIES OF PARENT</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="text-transform: uppercase">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.1</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Organization</B></TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.2</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>No Conflicts; Consents</B></TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.3</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>No Stockholder Vote Required</B></TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.4</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Issuance of Parent Shares</B></TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.5</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Brokers</B></TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.6</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Legal Proceedings</B></TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.7</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Merger Sub</B></TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.8</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Second Merger Sub</B></TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.9</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>SEC Filings; Securities Law and Other Matters</B></TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.10</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Compliance with Laws</B></TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 4.11</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Taxes</B></TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding-right: 0.5in"><FONT STYLE="text-transform: uppercase">Article 5. COVENANTS OF THE PARTIES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="text-transform: uppercase">35</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.1</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Conduct of Business Prior to the Closing</B></TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.2</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Access to Information</B></TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.3</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>No Solicitation of Other Bids</B>.</TD>
    <TD STYLE="text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.4</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Notice of Certain Events</B>.</TD>
    <TD STYLE="text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.5</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Financial Statement Preparation</B></TD>
    <TD STYLE="text-align: right">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.6</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Resignations</B></TD>
    <TD STYLE="text-align: right">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.7</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Confidentiality</B></TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.8</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Governmental Approvals and Consents</B></TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.9</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Stockholder Approval</B></TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.10</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Director and Officer Indemnification</B></TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.11</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Closing Conditions</B></TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.12</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Intellectual Property Registrations.</B></TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.13</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Further Assurances</B></TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.14</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Maintenance and Prosecution of Company Intellectual Property</B></TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 5.15</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Compliance with Laws</B>.</TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-right: 0.5in"><FONT STYLE="text-transform: uppercase">Article 6. TERMINATION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="text-transform: uppercase">42</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 6.1</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Termination</B></TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 6.2</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Effect of Termination</B></TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-right: 0.5in"><FONT STYLE="text-transform: uppercase">Article 7. OTHER COVENANTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="text-transform: uppercase">44</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 7.1</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Survival</B></TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 7.2</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Indemnification of Parent</B></TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 7.3</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Indemnification of Company Securityholders</B></TD>
    <TD STYLE="text-align: right">45</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">TABLE OF CONTENTS<BR>
(Continued)</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; width: 15%"><B>Section 7.4</B></TD>
    <TD STYLE="padding-left: 0.125in; width: 75%"><B>Expiration of Claims</B></TD>
    <TD STYLE="text-align: right; width: 10%">46</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 7.5</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Inter-Party Claims</B></TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 7.6</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Third Party Claims</B></TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 7.7</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Limitation</B></TD>
    <TD STYLE="text-align: right">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 7.8</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Tax Matters</B></TD>
    <TD STYLE="text-align: right">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 7.9</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Further Assurances</B></TD>
    <TD STYLE="text-align: right">51</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding-right: 0.5in"><FONT STYLE="text-transform: uppercase">Article 8. REPRESENTATIVE</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="text-transform: uppercase">52</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 8.1</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Representative</B></TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-right: 0.5in"><FONT STYLE="text-transform: uppercase">Article 9. DEFINITIONS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="text-transform: uppercase">54</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 9.1</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Certain Defined Terms</B></TD>
    <TD STYLE="text-align: right">54</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 9.2</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Other Defined Terms</B></TD>
    <TD STYLE="text-align: right">62</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-right: 0.5in"><FONT STYLE="text-transform: uppercase">Article 10. MISCELLANEOUS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="text-transform: uppercase">64</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.1</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Press Releases and Communications</B></TD>
    <TD STYLE="text-align: right">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.2</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Expenses</B></TD>
    <TD STYLE="text-align: right">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.3</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Notices</B></TD>
    <TD STYLE="text-align: right">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.4</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Interpretation</B></TD>
    <TD STYLE="text-align: right">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.5</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Headings</B></TD>
    <TD STYLE="text-align: right">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.6</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Severability</B></TD>
    <TD STYLE="text-align: right">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.7</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Entire Agreement</B></TD>
    <TD STYLE="text-align: right">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.8</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Successors and Assigns</B></TD>
    <TD STYLE="text-align: right">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.9</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>No Third-party Beneficiaries</B></TD>
    <TD STYLE="text-align: right">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.10</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Amendment and Modification; Waiver</B></TD>
    <TD STYLE="text-align: right">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.11</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Governing Law; Submission to Jurisdiction; Waiver of Jury Trial</B>.</TD>
    <TD STYLE="text-align: right">67</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.12</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Specific Performance</B></TD>
    <TD STYLE="text-align: right">67</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><B>Section 10.13</B></TD>
    <TD STYLE="padding-left: 0.125in"><B>Counterparts</B></TD>
    <TD STYLE="text-align: right">67</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 1.25in; text-align: center; text-indent: -1.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 1.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>Annexes, Exhibits and Schedules</U></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: justify">Annex 1:</TD>
    <TD STYLE="width: 88%; text-align: justify">Earnout Calculation</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Exhibit A:</TD>
    <TD STYLE="text-align: justify">Form of Certificate of Incorporation of the Initial
    Surviving Corporation</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Exhibit B:</TD>
    <TD STYLE="text-align: justify">Paying Agent Agreement</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Exhibit C:</TD>
    <TD>Form of Letter of Transmittal</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>MERGER AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Merger Agreement
(this &ldquo;<B>Agreement</B>&rdquo;), dated as of May 3, 2017 (the &ldquo;<B>Agreement Date</B>&rdquo;), is entered into among
NUELLE, INC., a Delaware corporation (&ldquo;<B>Company</B>&rdquo;), AYTU BIOSCIENCE, INC., a Delaware corporation (&ldquo;<B>Parent</B>&rdquo;),
<FONT STYLE="text-transform: uppercase">Aytu Acquisition Corporation,</FONT> INC., a Delaware corporation and wholly-owned Subsidiary
of Parent (&ldquo;<B>Merger Sub</B>&rdquo;), AYTU HOLDINGS, LLC, a Delaware limited liability company and wholly-owned Subsidiary
of Parent (&ldquo;<B>Second Merger Sub</B>&rdquo;, and together with the Merger Sub, the &ldquo;<B>Merger Subs</B>&rdquo;) and,
solely in its capacity as representative of the Company Securityholders, Earl Bright (the &ldquo;<B>Representative</B>&rdquo;).
Capitalized terms used herein (including in the immediately preceding sentence) and not otherwise defined herein shall have the
meanings set forth in Article 9 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors of Parent, Company and Merger Sub believe it is in the best interests of their respective companies for Company
and Merger Sub to combine into a single company through the statutory merger of Merger Sub, a direct wholly-owned subsidiary of
Parent, with and into Company, with Company surviving the merger (the &ldquo;<B>Merger</B>&rdquo;), upon the terms and conditions
set forth in this Agreement and pursuant to the First Certificate of Merger (as defined in Section 1.2);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately
following the Merger, the Initial Surviving Corporation (as defined in Section 1.1) will merge (the &ldquo;<B>Second Merger</B>&rdquo;,
and together with the Merger, the &ldquo;<B>Mergers</B>&rdquo;) with and into Second Merger Sub upon the terms and conditions
set forth in this Agreement and pursuant to the Second Certificate of Merger (as defined in Section 1.2);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
furtherance of the foregoing recitals, the Board of Directors of Company (the &ldquo;<B>Company Board</B>&rdquo;) has unanimously
(a) determined that it is in the best interests of Company and its stockholders (the &ldquo;<B>Stockholders</B>&rdquo;), and declared
it advisable, to enter into this Agreement with Parent and Merger Subs, (b) approved the execution, delivery and performance of
this Agreement and the consummation of the transactions contemplated hereby, including the Mergers, and (c) resolved, subject
to the terms and conditions set forth in this Agreement, to recommend adoption of this Agreement by the Stockholders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors of Parent and Merger Sub, and Parent, in its capacity as the sole stockholder of Merger Sub and the sole member
of Second Merger Sub, have each, upon the terms and subject to the conditions set forth herein, approved and consented to the
Mergers, the execution by Parent and Merger Subs of this Agreement and the consummation of the transactions contemplated hereby
in accordance with the DGCL (as defined in Section 1.1) and the DLLCA (as defined in Section 1.1) as well as all other applicable
Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly
following the execution of this Agreement, in order to induce Parent and Merger Subs to enter into this Agreement, Company shall
use its commercially reasonable efforts to obtain and deliver to Parent an executed Action by Written Consent of the Stockholders
adopting this Agreement, executed by Stockholders holding at least 95% of the outstanding equity securities of the Company (the
&ldquo;<B>Required Stockholder Approval</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
federal income Tax purposes, it is intended that (i) the Merger and the Second Merger constitute an integrated plan described
in Rev. Rul. 2001-46, 2001-2 C.B. 321 (the &ldquo;<B>Integrated Transaction</B>&rdquo;), (ii) the Integrated Transaction shall
qualify as a reorganization under Section 368 of the Code and the Treasury Regulations promulgated thereunder, and (iii) this
Agreement constitutes a plan of reorganization within the meaning of Section 368(a) of the Code; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
parties desire to make certain representations, warranties, covenants and agreements in connection with the Mergers and the transactions
contemplated by this Agreement and also to prescribe certain conditions to the Mergers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and of the representations, warranties, covenants and agreements contained in this Agreement, the parties, intending
to be legally bound, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
1.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B><U>THE MERGERS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Mergers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the terms and subject to the conditions set forth in this Agreement, and in accordance with the Delaware General Corporation Law
(the &ldquo;<B>DGCL</B>&rdquo;), at the Effective Time, (a) Merger Sub will merge with and into Company, and (b) the separate
corporate existence of Merger Sub will cease and Company will continue its corporate existence under the DGCL as the surviving
corporation in the Merger (sometimes referred to herein as the &ldquo;<B>Initial Surviving Corporation</B>&rdquo;). As a result
of the Merger, the Initial Surviving Corporation shall become a wholly-owned Subsidiary of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately
following the consummation of the Merger, upon the terms and subject to the conditions set forth in this Agreement, and in accordance
with the DGCL and the Delaware Limited Liability Company Act (the &ldquo;<B>DLLCA</B>&rdquo;), the Initial Surviving Corporation
will be merged with and into Second Merger Sub pursuant to the Second Certificate of Merger (as defined in Section 1.2). Upon
consummation of the Second Merger, the separate corporate existence of the Initial Surviving Corporation will cease and Second
Merger Sub shall continue as the surviving company (the &ldquo;<B>Surviving Company</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Effective Time (as defined below), the effect of the Mergers shall be as provided in this Agreement and the Certificates of
Merger (as defined below) and as provided by the applicable provisions of the DGCL and DLLCA. Without limiting the generality
of the foregoing, and subject thereto, upon the consummation of the Merger, all the property, rights, privileges and powers of
Company and the Merger Sub shall vest in the Initial Surviving Corporation, and all debts, liabilities, obligations, restrictions,
disabilities and duties of each of those corporations shall become the debts, liabilities, obligations, restrictions, disabilities
and duties of the Initial Surviving Corporation, all as provided under the DGCL, and then upon the consummation of the Second
Merger, all the property, rights, privileges and powers of the Initial Surviving Corporation shall vest in the Surviving Company,
and all debts, liabilities, obligations, restrictions, disabilities and duties of each of those corporations shall become the
debts, liabilities, obligations, restrictions, disabilities and duties of the Surviving Company, all as provided under the DLLCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Closing;
Effective Time</B>. The closing of the Merger, the Second Merger and the other transactions contemplated by this Agreement (the
&ldquo;<B>Closing&rdquo;</B>) shall take place through the remote exchange of electronic copies of executed documents (a) on the
next<FONT STYLE="background-color: yellow"> </FONT>Business Day following the satisfaction or waiver of the conditions to the
Closing set forth in Article 2 below (other than conditions which are to be satisfied or waived on the Closing Date, which conditions
shall be satisfied on the Closing Date), or (b) at such other place or such other date as is mutually agreeable to the parties
hereto. The date of the Closing is herein referred to as the &ldquo;<B>Closing Date.</B>&rdquo; The parties anticipate the Closing
Date will be May 5, 2017. At the Closing, Merger Sub and Company shall cause a certificate of merger (the &ldquo;<B>First Certificate
of Merger&rdquo;</B>) to be executed and filed with the Secretary of State of the State of Delaware in accordance with Section
251 of the DGCL. Also at the Closing, the Second Merger Sub and the Initial Surviving Company shall cause a certificate of merger
to be executed and filed with the Secretary of State of the State of Delaware in accordance with the DLLCA (the &ldquo;<B>Second
Certificate of Merger</B>&rdquo;, and together with the First Certificate of Merger, the &ldquo;<B>Certificates of Merger</B>&rdquo;).
The Mergers shall become effective as of the date and time of such filing or such other time after such filing as the parties
shall agree in the Certificates of Merger (the &ldquo;<B>Effective Time&rdquo;</B>). In the event of a conflict between this Agreement
and the Certificates of Merger, to the extent permitted by applicable Law, this Agreement shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificate
of Incorporation; Bylaws; Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Effective Time, the certificate of incorporation of the Initial Surviving Corporation shall be amended so as to read in its
entirety as set forth in <U>Exhibit A</U>, until thereafter changed or amended as provided therein or by applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Effective Time, the bylaws of the Initial Surviving Corporation shall be the bylaws of Company as in effect immediately prior
to the Effective Time, until thereafter changed or amended or repealed as provided therein, in the certificate of incorporation
of the Initial Surviving Corporation or by applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
and after the Effective Time, Josh Disbrow, Michael Malcaluso, Gary Cantrell, Carl Dockery and John Donofrio, Jr. shall be the
directors, and Josh Disbrow (CEO), Jarrett Disbrow (COO) and Greg Gould (CFO) shall be the officers, of the Initial Surviving
Corporation and Surviving Company until their successors have been duly elected or appointed and qualified or until their earlier
death, resignation or removal or otherwise ceasing to be a director or officer or until their respective successors are duly elected
or appointed and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Effective Time all Convertible Debt and Unpaid Contractual Obligations shall be converted into the right to receive a portion
of the Aggregate Merger Consideration, as set forth in the Distribution Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Effective Time, except as otherwise provided in Section 1.5, each share of Company Preferred Stock outstanding immediately
prior to the Effective Time shall be converted, without any action on the part of holders thereof, into the right to receive a
portion of the Aggregate Merger Consideration, without interest, calculated and distributed in accordance with the Company Charter,
as in effect immediately prior to the Effective Time, and as set forth in the Distribution Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Effective Time, except as otherwise provided in Section 1.5, each share of Company Common Stock outstanding immediately prior
to the Effective Time and each option or Warrant to purchase Company Stock shall be cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Effective Time, each share of common stock of Merger Sub outstanding immediately prior to the Effective Time shall be converted
into and become one share of common stock of the Initial Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
and after the Effective Time, the holders of certificates evidencing ownership of the shares of Company Stock (&ldquo;<B>Company
Stock Certificates</B>&rdquo;) outstanding immediately prior to the Effective Time shall cease to have any rights with respect
to such shares of Company Stock except as otherwise provided for herein or under applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Surrender
and Payment.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the Effective Time, Parent shall appoint VStock Transfer, LLC (the &ldquo;<B>Paying Agent</B>&rdquo;) to act as paying agent
in connection with the consideration to be paid to the Company Securityholders pursuant to a paying agent agreement among Parent,
Representative and Paying Agent in the form attached hereto as <U>Exhibit B</U> (the &ldquo;<B>Paying Agent Agreement</B>&rdquo;).
All of Paying Agent&rsquo;s fees and expenses shall be borne by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
soon as practicable following the date hereof, Company shall, or shall cause the Paying Agent to, send a notice, Letter of Transmittal
in the form attached hereto as <U>Exhibit C</U> (the &ldquo;<B>Letter of Transmittal</B>&rdquo;) and acknowledgements of cancellation
to each Company Securityholder advising such holder of the Mergers and the procedure for surrendering to the Paying Agent such
holder&rsquo;s certificate(s) representing Company Stock or Convertible Debt (collectively, &ldquo;<B>Exchange Documentation</B>&rdquo;)
in exchange for the payment of such portion of the Aggregate Merger Consideration to which the Company Securityholders are entitled
pursuant to Section 1.3. Each Company Securityholder, upon proper surrender of Exchange Documentation to the Paying Agent in accordance
with the instructions in such notice, shall be entitled to receive, in exchange therefor, the payments required by Section 1.3.
Until properly surrendered, such Exchange Documentation shall be deemed for all purposes to evidence only the right to receive
the payments required by Section 1.3. All Parent Shares will be book entry only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
shall deliver to Parent, at least three (3) Business Days prior to the Closing Date, a distribution schedule (the &ldquo;<B>Distribution
Schedule</B>&rdquo;), setting forth Company&rsquo;s calculation of how the Aggregate Merger Consideration shall be allocated among
the Company Securityholders and Creditors with Unpaid Contractual Obligations, in addition to an electronic copy thereof in Microsoft
Excel format. Parent shall be able to rely on, and shall have no liability to any party to this Agreement or to any Company Securityholder,
Company shareholder or Company Creditor for any payment not reflected on the Distribution Schedule. The Distribution Schedule
shall include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
name and address (as listed in the corporate record books of Company);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
allocation of the Aggregate Merger Consideration among the Creditors and Company Securityholders, determined in accordance with
the Company Charter as in effect as of immediately prior to the Effective Time, including the allocation of any cash consideration
and any Parent Shares issuable to each Company Securityholder and the allocation of the Closing Merger Consideration payable to
each Creditor and Company Securityholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Closing, Parent shall deposit the Closing Merger Consideration with the Paying Agent. Promptly after the Effective Time, Parent
shall cause the Paying Agent to deliver to each Company Securityholder who has completed and returned the requisite Exchange Documentation
to the Paying Agent, together with Company Stock Certificates representing outstanding shares of Company Stock or original copies
of the Company&rsquo;s Convertible Debt notes (or an affidavit of lost instrument in form reasonably acceptable to Parent but
without any bond) and any Company Creditors, the Closing Merger Consideration payable to such Company Securityholder or Creditor,
and in any event within three (3) Business Days after return of such documentation to the Paying Agent; provided, however, that
Parent shall cause the Paying Agent to deliver the Closing Merger Consideration on the Closing Date to each Company Securityholder
who at least three (3) Business Days prior to the Closing has completed and returned the requisite Exchange Documentation to the
Paying Agent, together with Company Stock Certificates representing outstanding shares of Company Stock or original copies of
the Company&rsquo;s Convertible Debt notes (or an affidavit of lost instrument in form reasonably acceptable to Parent but without
any bond) and any Company Creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent
shall not be required to pay any amount of the Closing Merger Consideration or any portion of any Earnout Payment to any Company
Securityholder until receipt by the Paying Agent from such Company Securityholder of properly completed and executed Letters of
Transmittal and the applicable Company Stock Certificate or original Convertible Debt note (or an affidavit of lost instrument
in form reasonably acceptable to Parent but without any bond (except as may be required by the Paying Agent)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parent Shares pursuant to the terms of this Agreement will be issued in a transaction exempt from registration under the Securities
Act by reason of Section 4(a)(2) thereof and/or Regulation D promulgated under the Securities Act and may not be re-offered or
resold other than in conformity with the registration requirements of the Securities Act and such other applicable rules and regulations
or pursuant to an exemption therefrom. Until the resale by the Company Securityholders or Creditors of their Parent Shares has
become registered under the Securities Act, or otherwise transferable pursuant to an exemption from such registration otherwise
required thereunder, the Parent Shares issued to the Company Securityholders or Creditors shall be characterized as &ldquo;restricted
securities&rdquo; under the Securities Act and, if certificated, shall bear the following legend (or if held in book entry form,
will be noted with a similar restriction):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&ldquo;THE SHARES OF STOCK REPRESENTED
BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY, AND THE RESALE OF SUCH SHARES HAS NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE RESOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION WITHOUT
AN EXEMPTION UNDER THE SECURITIES ACT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parent agrees to cooperate in a timely manner
with the Company Securityholders or Creditors holding registrable securities to remove any restrictive legends or similar transfer
instructions from the registrable Securities upon the registration of the registrable securities or in the event that the registrable
securities are otherwise transferable pursuant to an exemption from registration otherwise required thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
such times and subject to the terms and conditions set forth in <U>Annex 1</U> hereto, as additional consideration for the Merger,
and subject to the setoff rights of Parent Indemnitees pursuant to Article 7 hereof, after the Effective Time, Parent shall deliver
the Earnout Payments to Paying Agent to distribute to the Company Securityholders and Creditors in accordance with each the Distribution
Allocation. Any such Earnout Payments, including, without limitation, the Accelerated Payment, shall be payable in cash and/or
Parent Shares (valued at the average closing price of Parent Shares as reported on OTC Markets (or such national or foreign securities
exchange on which Parent&rsquo;s shares are listed) for the ten (10) trading days immediately prior to the date of issuance),
pursuant to an allocation of 60% in cash and 40% in Parent Shares, unless otherwise agreed by Parent and the Representative in
writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
surrendered in accordance with this Agreement, each Company Stock Certificate or Convertible Debt note shall represent after the
Effective Time for all purposes only the right to receive payment as provided in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time following the day that is twelve (12) months after the Effective Time, the Parent shall be entitled to require the Paying
Agent to deliver to it any funds (including any earnings received with respect thereto) and Parent Shares that had been made available
to the Paying Agent with respect to the Closing Merger Consideration and that have not been disbursed to Company Securityholders
and thereafter such Company Securityholders shall be entitled to look only to the Parent (subject to abandoned property, escheat
or other similar Laws) and only as general creditors thereof with respect to the applicable portion of Closing Merger Consideration
payable to them, without interest thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment
of Dissenting Shares</B>. Notwithstanding anything in this Agreement to the contrary, Stockholders who have properly demanded
appraisal of their shares of Company Stock (&ldquo;<B>Dissenting Shares</B>&rdquo;) pursuant to, and who comply in all respects
with, the provisions of Section 262 of the DGCL shall not have such shares converted as provided herein, but instead such Stockholders
shall be entitled to such rights (and only such rights) as are granted under Section 262 of the DGCL. At the Effective Time, all
Dissenting Shares shall no longer be outstanding and shall automatically be canceled and extinguished and shall cease to exist,
and except as otherwise provided by Law, each holder of Dissenting Shares shall cease to have any rights with respect thereto
other than the rights granted pursuant to Section 262 of the DGCL. Notwithstanding the foregoing, if any Stockholder shall fail
to validly perfect or shall otherwise waive, withdraw or lose the right to appraisal under Section 262 of the DGCL, or if a court
of competent jurisdiction shall determine that such Stockholders are not entitled to the relief provided by Section 262 of the
DGCL, then the rights of such Stockholders under Section 262 of the DGCL shall cease and such Dissenting Shares shall be deemed
to have been converted at the Effective Time as set forth in Section 1.4(a) or Section 1.4(b), as applicable. Prior to the Closing,
Company shall give Parent prompt written notice of any demands for appraisal with respect to Dissenting Shares (&ldquo;<B>Appraisal
Demands</B>&rdquo;), and Parent shall have the opportunity to participate in all negotiations and proceedings with respect to
such Appraisal Demands, and any settlements with respect thereto shall not be entered into without the prior written consent of
Representative and Parent (such consents not to be unreasonably conditioned, withheld or delayed). From and after the Closing,
the Representative shall be entitled to assume the defense of any Appraisal Demands, whether such Appraisal Demands were commenced
before or after the Closing; <I>provided</I> that Parent shall have the opportunity to participate in all negotiations and proceedings
with respect to such Appraisal Demands, and any settlements with respect thereto shall not be entered into without the prior written
consent of Parent (such consent not to be unreasonably conditioned, withheld or delayed). After the Closing, Parent shall give
the Representative prompt written notice of any Appraisal Demands. Any payments to be made in respect of Dissenting Shares shall
be made by Parent and/or the Surviving Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Further Ownership Rights in Company Stock</B>. The consideration paid in accordance with the terms hereof (shall be deemed to
have been paid in full satisfaction of all rights pertaining to Company Stock (including any rights to receive accrued but unpaid
dividends or any liquidation preference on Company Stock, if any), and, from and after the Effective Time, the Stockholders shall
cease to have any rights with respect to the shares of Company Stock (including any rights to receive any accrued but unpaid dividends
or any liquidation preference on such shares, if any) except as otherwise expressly provided for in this Agreement. At the Effective
Time, the stock transfer books of Company shall be closed, and thereafter there shall be no further registration of transfers
on the records of the Surviving Company of shares of Company Stock. If, after the Effective Time, Company Stock Certificates are
presented to Parent or the Surviving Company for any reason, they shall be canceled and exchanged as provided and in accordance
with this Section 1.6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lost
Certificates</B>. If any Company Stock Certificate or Convertible Debt note shall have been lost, stolen or destroyed, then upon
the making of an affidavit of that fact by the Person claiming such Company Stock Certificate or Convertible Debt note to be lost,
stolen or destroyed, and an indemnity, reasonably satisfactory to Parent, the Surviving Company and their Affiliates, against
any claim that may be made against any of them with respect to such Company Stock Certificate or Convertible Debt note, but without
any bond (except as may be required by the Paying Agent), Parent or the Surviving Company shall pay, or shall cause the Paying
Agent to pay, in exchange for such lost, stolen or destroyed Company Stock Certificate or Convertible Debt note, the applicable
Distribution Allocation as contemplated by this Article 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding</B>.
Parent, Merger Sub, the Company, the Surviving Company, the Paying Agent and the Representative (as applicable) shall be entitled
to deduct and withhold from the amounts payable under this Agreement such amounts as may be required to be deducted and withheld
under the Code, and any other applicable Tax Laws, that are set forth on the Distribution Schedule or that the Parent is entitled
to withhold as set forth in the instructions in the Exchange Documentation. Any such withheld amount shall be timely paid over
to the appropriate Governmental Authority and treated as though it had been paid to the Person in respect of which such withholding
was required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest;
No Liability</B>. All payments made pursuant to this Article 1, whether at the Closing or afterwards, shall be without interest.
None of Parent, Merger Sub or the Surviving Company shall be liable to any Person in respect of any cash or securities delivered
to a public official pursuant to any applicable abandoned property, escheat or similar Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments
to Prevent Dilution</B>. Without limiting the other provisions of this Agreement, in the event that Company changes the number
of shares of Company Stock issued and outstanding prior to the Effective Time as a result of a reclassification, stock split (including
a reverse stock split), stock dividend or distribution, recapitalization, merger, subdivision, issuer tender or exchange offer,
or other similar transaction, the consideration paid in accordance with this Agreement shall be equitably adjusted to reflect
such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax
Treatment</B>. It is intended by the parties hereto that the Integrated Transaction constitute a reorganization within the meaning
of Section 368(a) of the Code. Each of the parties hereto adopts this Agreement as a &ldquo;plan of reorganization&rdquo; within
the meaning of Sections 1.368-2(g) and 1.368-3(a) of the Treasury Regulations. Both prior to and after the Closing, each party&rsquo;s
books and records shall be maintained, and all federal, state and local income Tax Returns and schedules thereto of the parties
hereto shall be filed, in a manner consistent with the Integrated Transaction&rsquo;s being qualified as a merger under Section
368(a)(1)(A) of the Code (and comparable provisions of any applicable state or local laws), except to the extent the Integrated
Transaction is determined in a final administrative or judicial decision not to qualify as a reorganization within the meaning
of Code Section 368(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
2.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B><U>CONDITIONS TO MERGERS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions
to All Parties&rsquo; Obligations</B>. The obligations of Parent, Merger Subs and Company to consummate the transactions contemplated
by this Agreement are subject to the satisfaction or waiver of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no
court or other Governmental Authority shall have issued, enacted, entered, promulgated or enforced any Law or order (whether or
not temporary or final and non-appealable, and that has not been vacated, withdrawn or overturned), restraining, enjoining or
otherwise prohibiting the Merger;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement shall not have been terminated in accordance with Article 6;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Required Stockholder Approval shall have been attained; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall be no Action pending against Parent, Merger Subs or Company or any of their respective Affiliates by any Governmental Authority
in which such Governmental Authority is (i) seeking to enjoin or make illegal, delay or otherwise restrain or prohibit the consummation
of, or to have rescinded, the Merger; or (ii) seeking to impose any criminal sanctions on Parent, Merger Subs or Company in connection
with the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions
to Parent&rsquo;s and Merger Subs&rsquo; Obligations</B>. The obligation of Parent and Merger Subs to consummate the transactions
contemplated by this Agreement is subject to the satisfaction or waiver of the following conditions as of the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
of the representations and warranties of Company contained in Article 3 that is (i) qualified as, to, or by Material Adverse Effect
shall be true and correct in all respects as of the Closing Date as if made anew as of such date (except to the extent any such
representation and warranty expressly relates to an earlier date (in which case as of such earlier date)) and (ii) not qualified
as to or by Material Adverse Effect shall be true and correct as of the Closing Date as if made anew as of such date (except to
the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)),
except where any failure of any such representation and warranty referred to in this clause (ii) to be true and correct has not
had or will not have a Material Adverse Effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
shall have performed in all material respects all of the covenants and agreements under this Agreement that are required to be
performed by it at or prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from
the date of this Agreement, there shall not have occurred any Material Adverse Effect with respect to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;holders
of no more than five percent (5.0%) of the aggregate outstanding Company Common Stock and Company Preferred Stock (calculated
on an as-converted to Company Common Stock basis) as of the Effective Time will have elected to exercise (and will not have withdrawn
or otherwise lost their ability to seek) dissenters&rsquo;, appraisal or similar rights under Delaware law with respect to such
shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
will have delivered to Parent each of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
certificate of Company executed by a duly authorized officer thereof, dated as of the Closing Date, stating that the preconditions
specified in subsections (a) and (b) above as they relate to Company have been satisfied;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;evidence
of Cash on Hand;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
copy of the Paying Agent Agreement duly executed by the Representative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
certificate conforming to the requirements of Treasury Regulations Section 1.1445-2(c)(3);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;certified
copies of the resolutions duly adopted by the Company Board authorizing the execution, delivery and performance of this Agreement,
the Mergers and the other transactions contemplated hereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)
a certified copy of the Company Charter and (B) a certificate of good standing from the Secretary of State of the State of Delaware
dated within five (5) Business Days of the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
resignations, effective as of the Closing, from all Company directors, officers, employees and contractors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an
electronic copy of the true, correct and complete contents of the Dataroom, which shall be delivered promptly after the Closing;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;duly
executed copies of consulting agreements with the following individuals in a form satisfactory to Parent: Karen Long, Leah Millheiser,
Earl Bright, Traci Chu and Mary Beth Kreissler.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions
to Company&rsquo;s Obligations</B>. The obligations of Company to consummate the transactions contemplated by this Agreement are
subject to the satisfaction or waiver of the following conditions as of the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
of the representations and warranties of Parent contained in Article 4 that is (i) qualified as, to, or by Material Adverse Effect
shall be true and correct in all respects as of the Closing Date as if made anew as of such date (except to the extent any such
representation and warranty expressly relates to an earlier date (in which case as of such earlier date)) and (ii) not qualified
as to or by Material Adverse Effect shall be true and correct as of the Closing Date as if made anew as of such date (except to
the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)),
except where any failure of any such representation and warranty referred to in this clause (ii) to be true and correct has not
had or will not have a Material Adverse Effect on Parent&rsquo;s or Merger Sub&rsquo;s ability to perform the transactions contemplated
hereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
of Parent and Merger Subs shall have performed in all material respects all of its respective covenants and agreements under this
Agreement that are required to be performed by it at or prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from
the date of this Agreement, there shall not have occurred any Material Adverse Effect with respect to Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent
shall have delivered to Company each of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
certificate of Parent executed by a duly authorized officer thereof, dated as of the Closing Date, stating that the preconditions
specified in subsections (a) and (b) hereof have been satisfied;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
copy of the Paying Agent Agreement duly executed by Parent and the Paying Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;certified
copies of the resolutions duly adopted by Parent&rsquo;s and Merger Sub&rsquo;s Board of Directors and Parent, in its capacity
as sole Stockholder of Merger Sub and the sole member of Second Merger Sub authorizing the execution, delivery and performance
of this Agreement, the Mergers and the other transactions contemplated hereby; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)
a certified copy of the certificate of incorporation and bylaws of Parent and Merger Subs and (B) a certificate of good standing
or equivalent certificate from the jurisdictions in which Parent and Merger Subs are incorporated, in each case, dated within
five (5) Business Days of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver
of Conditions</B>. All conditions to the Closing will be deemed to have been satisfied or waived from and after the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
3.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B><U>REPRESENTATIONS AND WARRANTIES OF COMPANY</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Except as set forth in
the correspondingly numbered Section of the Company Disclosure Schedules, Company represents and warrants to Parent and Merger
Sub that the statements contained in this Article 3 are true and correct as of the date hereof. Any information, qualifications
or disclosure in one section of the Company Disclosure Schedule shall be deemed to have been disclosed in all other sections of
the Company Disclosure Schedule to the extent the relevance of such information, qualification or disclosure is readily apparent
from the text of such disclosure and the corresponding Section of this Article 3, notwithstanding the omission of an appropriate
cross-reference to such other section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Organization
and Qualification of Company</B>. Company is a corporation duly organized, validly existing and in good standing under the Laws
of the State of Delaware and has full corporate power and authority to own, operate or lease the properties and assets now owned,
operated or leased by it and to carry on its business as it has been and is currently conducted. Section 3.1 of the Company Disclosure
Schedules sets forth each jurisdiction in which Company is licensed or qualified to do business, and Company is duly licensed
or qualified to do business and is in good standing in each jurisdiction in which the properties owned or leased by it or the
operation of its business as currently conducted makes such licensing or qualification necessary, except where the failure to
be so licensed, qualified or in good standing would not have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorization.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
has full corporate power and authority to enter into this Agreement, to carry out its obligations hereunder and to consummate
the transactions contemplated hereby. The execution and delivery by Company of this Agreement, the performance by Company of its
obligations hereunder and the consummation by Company of the transactions contemplated hereby have been duly authorized by all
requisite corporate action on the part of Company. This Agreement has been duly executed and delivered by Company, and this Agreement
constitutes, legal, valid and binding obligations of Company enforceable against Company in accordance with their terms, except
(i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting
enforcement of creditors&rsquo; rights, and (ii) general principles of equity that restrict the availability of equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company Board, at a meeting duly called and held at which all directors of Company were present, duly and unanimously adopted
resolutions (i) determining that the terms of this Agreement, the Mergers and the other transactions contemplated hereby are fair
to and in the best interests of the Stockholders, (ii) approving and declaring advisable this Agreement and the transactions contemplated
hereby, including the Mergers, (iii) directing that this Agreement be submitted to the Stockholders for adoption and approval
and (iv) resolving to recommend that the Stockholders vote in favor of the adoption and approval of this Agreement and the transactions
contemplated hereby, including the Mergers, which resolutions have not been subsequently rescinded, modified or withdrawn in any
way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Required Stockholder Approval is the only approval of the holders of any class or series of Company&rsquo;s capital stock or other
securities required in connection with the consummation of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalization.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
authorized capital stock of Company consists of 65,000,000 shares of Company Common Stock, 29,313,755 shares of Series A Preferred
Stock, and 14,686,245 shares of Series A-1 Preferred Stock. The respective rights, restrictions, privileges and preferences of
Company Preferred Stock are as stated in the Company Charter. Each share of Company Preferred Stock is presently convertible into
Company Common Stock on the basis set forth in the Company Charter and the consummation of the transactions contemplated hereby
will not result in any anti-dilution adjustment or other similar adjustment to the outstanding shares of Company Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Distribution Schedule sets forth a true and complete list of all Company Securityholders and the portion of the Aggregate Merger
Consideration each is to receive. The Company represents and warrants that all Company Securityholders are &ldquo;accredited investors&rdquo;
as such term is defined in Rule 501(a) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of the outstanding shares of Company Stock have been duly authorized and validly issued and are fully paid, non-assessable and,
except as set forth on Section 3.3(c) of the Company Disclosure Schedules, free of preemptive or similar rights. All of the issued
and outstanding shares of Company Stock were issued in compliance with all applicable state and federal Laws concerning the issuance
of securities. Except as set forth on the Distribution Schedule, Company does not have any other equity securities or securities
containing any equity features authorized, issued or outstanding, and there are no agreements, options, warrants or other rights
or arrangements existing or outstanding which provide for the sale or issuance of any of the foregoing by Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsidiaries</B>.
Section 3.4 of the Company Disclosure Schedules lists each of the Subsidiaries of Company as of the date hereof and its place
of organization and sets forth, for each Subsidiary that is not, directly or indirectly, wholly-owned by Company, (x) the number
and type of any capital stock of, or other equity or voting interests in, such Subsidiary that is outstanding as of the date hereof
and (y) the number and type of shares of capital stock of, or other equity or voting interests in, such Subsidiary that, as of
the date hereof, are owned, directly or indirectly, by Company. All of the outstanding shares of capital stock of, or other equity
or voting interests in, each Subsidiary of Company that is owned directly or indirectly by Company have been validly issued, were
issued free of pre-emptive rights and are fully paid and non-assessable, and are free and clear of all Encumbrances, including
any restriction on the right to vote, sell or otherwise dispose of such capital stock or other equity or voting interests, except
for any Encumbrances (x) imposed by applicable securities Laws or (y) arising pursuant to the certificate of incorporation, by-laws
or similar organizational documents of any non-wholly-owned Subsidiary of Company. Except for the capital stock of, or other equity
or voting interests in, its Subsidiaries, Company does not own, directly or indirectly, any capital stock of, or other equity
or voting interests in, any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Conflicts; Consents</B>. The execution, delivery and performance by Company of this Agreement, and the consummation of the transactions
contemplated hereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision
of the Company Charter or the by-laws or other organizational documents of Company; (b) conflict with or result in a violation
or breach in any material respect of any provision of any Law or Governmental Order applicable to Company; (c) except as set forth
in Section 3.5 of the Company Disclosure Schedules, require the consent, notice or other action by any Person under, or to the
Knowledge of Company, (i) conflict with, result in a violation or breach of, constitute a default or an event that, with or without
notice or lapse of time or both, would constitute a default under, or (ii) result in the acceleration of or create in any party
the right to accelerate, terminate, modify or cancel any Material Contract or any material Permit affecting the properties, assets
or business of Company; or (d) result in the creation or imposition of any Encumbrance, other than Permitted Encumbrances, on
any material properties or assets of Company. No consent, approval, Permit, Governmental Order, declaration or filing with, or
notice to, any Governmental Authority is required by or with respect to Company in connection with the execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements</B>. Complete copies of Company&rsquo;s Financial Statements consisting of the unaudited balance sheet of Company as
at December 31 in each of the years 2014, 2015 and 2016 and the related unaudited statements of income and retained earnings,
stockholders&rsquo; equity and cash flow for the years then ended (the &ldquo;<B>Year-End Financial Statements</B>&rdquo;), and
statements consisting of the unaudited balance sheet of Company as at March 31, 2017 and the unaudited related statements of income
and retained earnings, stockholders&rsquo; equity and cash flow for the calendar period then ended (the &ldquo;<B>Interim Financial
Statements</B>&rdquo; and together with the Year-End Financial Statements, the &ldquo;<B>Financial Statements</B>&rdquo;) have
been delivered to Parent. Except as disclosed on Section 3.6 of the Company Disclosure Schedules, the Financial Statements have
been prepared in accordance with GAAP applied on a consistent basis throughout the period involved, subject to normal and recurring
year-end adjustments (the effect of which will not be materially adverse) and the absence of notes. The Financial Statements are
based on the books and records of Company, and fairly present in all material respects the financial condition of Company as of
the respective dates they were prepared and the results of the operations of Company for the periods indicated, subject to normal
and recurring year-end adjustments and the absence of notes. The balance sheet of Company as of December 31, 2016 is referred
to herein as the &ldquo;<B>Balance Sheet</B>&rdquo; and the date thereof as the &ldquo;<B>Balance Sheet Date</B>&rdquo; and the
balance sheet of Company as of March 31, 2017 is referred to herein as the &ldquo;<B>Interim Balance Sheet</B>&rdquo; and the
date thereof as the &ldquo;<B>Interim Balance Sheet Date</B>&rdquo;. Except as set forth on Section 3.6 of the Company Disclosure
Schedules, Company maintains a standard system of accounting established and administered in accordance with GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Undisclosed
Liabilities; Cash on Hand</B>. Company has no Liabilities that would be required to be disclosed, set forth or reserved against
on a balance sheet of Company prepared in accordance with GAAP except (a) those which are adequately reflected or reserved against
in the Interim Balance Sheet as of the Interim Balance Sheet Date, (b) Liabilities incurred in connection with the transactions
contemplated hereby and that are included in the Securityholder Transaction Expenses, (c) those which have been incurred in the
ordinary course of business consistent with past practice since the Interim Balance Sheet Date and (d) Liabilities set forth on
Section 3.7 of the Company Disclosure Schedules. Company has not incurred additional liabilities in excess of $10,000 since the
date of the Interim Balance Sheet. Company represents and warrants that Cash on Hand equals or exceeds $600,000 and aggregate
liabilities of the Company do not exceed $100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Absence
of Certain Changes, Events and Conditions</B>. Except as set forth on Section 3.8 of the Company Disclosure Schedules or in accordance
with Section 5.1(b) hereof, since the Interim Balance Sheet Date, and other than in the ordinary course of business consistent
with past practice, there has not been, with respect to Company, any:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;event,
occurrence or development that has had, or could reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect with respect to Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an
amendment of the Company Charter or the by-laws or other organizational documents of Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;split,
combination or reclassification of any shares of its capital stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issuance,
sale or other disposition of any of its capital stock, or grant of any options, warrants or other rights to purchase or obtain
(including upon conversion, exchange or exercise) any of its capital stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;declaration
or payment of any dividends or distributions on or in respect of any of its capital stock or redemption, purchase or acquisition
of its capital stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;material
change in any method of accounting or accounting practice of Company except as required by GAAP or as disclosed in the notes to
the Financial Statements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;material
change in Company&rsquo;s cash management practices and its policies, practices and procedures with respect to collection of accounts
receivable, establishment of reserves for uncollectible accounts, accrual of accounts receivable, inventory control, prepayment
of expenses, payment of trade accounts payable, accrual of other expenses, deferral of revenue and acceptance of customer deposits;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;entry
into any Contract that would constitute a Material Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;incurrence,
assumption or guarantee of any indebtedness for borrowed money except unsecured current obligations and Liabilities incurred in
the ordinary course of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;transfer,
assignment, sale or other disposition of any of the assets shown or reflected in the Balance Sheet or cancellation of any debts
or entitlements other than in each case in the ordinary course of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;transfer,
assignment or grant of any license or sublicense of any material rights under or with respect to any Intellectual Property other
than, in each case, in connection with a sale of Products in the ordinary course of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;damage,
destruction or loss (whether or not covered by insurance) to its property having a replacement cost in excess of Five Thousand
Dollars ($5,000);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
capital investment in, or any loan to, any other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acceleration,
termination, material modification to or cancellation of any Material Contract to which Company is a party or by which it is bound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
capital expenditures in excess of Five Thousand Dollars ($5,000) individually or Fifteen Thousand Dollars ($15,000) in the aggregate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;imposition
of any material Encumbrance upon any of Company properties, capital stock or assets, tangible or intangible other than Permitted
Encumbrances;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)
grant of any bonuses, whether monetary or otherwise, or increase in any wages, salary, severance, pension or other compensation
or benefits in respect of its employees, officers, directors, independent contractors or consultants, other than as provided for
in any written agreements or required by applicable Law, (ii) change in the terms of employment for any employee, or any termination
of any employees, or (iii) action to accelerate the vesting or payment of any compensation or benefit for any employee, officer,
director, independent contractor or consultant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;adoption,
modification or termination of any: (i) employment, severance, retention or other agreement with any current or former employee,
officer, director, independent contractor or consultant, (ii) material Benefit Plan or (iii) collective bargaining or other agreement
with a Union, in each case whether written or oral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
loan to (or forgiveness of any loan to) any of its stockholders, directors, officers and employees other than the advancement
of expenses in the ordinary course of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;entry
into a new line of business or abandonment or discontinuance of existing lines of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;adoption
of any plan of merger, consolidation, reorganization, liquidation or dissolution or filing of a petition in bankruptcy under any
provisions of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against it under any similar
Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acquisition
by merger or consolidation with, or by purchase of a substantial portion of the assets or stock of, or by any other manner, any
business or any Person or any division thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
for Tax filings and positions in accordance with the Company&rsquo;s prior custom and practice and properly disclosed to Parent,
action by Company to make, change or rescind any Tax election, amend any Tax Return, adopt or change any accounting method in
respect of Taxes, enter into any closing agreement with respect to Taxes, settle any material claim or assessment in respect of
Taxes, or consent to any extension or waiver of the limitation period applicable to any material claim with respect to the collection
or assessment of Taxes; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
Contract to do any of the foregoing, or any action or omission that would result in any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Material
Contracts.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.9(a) of the Company Disclosure Schedules lists each of the following Contracts of Company and all Contracts relating to Intellectual
Property set forth in Section 3.12(d) and Section 3.12(f) of the Company Disclosure Schedules, but excluding Excluded Contracts,
collectively &ldquo;<B>Material Contracts</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
Contract of Company involving aggregate consideration in excess of $5,000 and which, in each case, cannot be cancelled by Company
without penalty or without more than thirty (30) days&rsquo; notice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Contracts that require Company to purchase its total requirements of any product or service from a third party or that contain
&ldquo;take or pay&rdquo; provisions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Contracts that provide for the indemnification by Company of any Person or the assumption of any Tax, environmental or other Liability
of any Person other than Contracts entered into in the ordinary course of business, the principal purpose of which is not the
assumption of Taxes or environmental or other Liabilities of any Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Contracts that relate to the acquisition or disposition of any business, a material amount of stock or assets of any other Person
or any real property (whether by merger, sale of stock, sale of assets or otherwise);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
broker, distributor, dealer, manufacturer&rsquo;s representative, franchise, agency, sales promotion, market research, marketing
consulting and advertising Contracts to which Company is a party involving payments by Company in excess of $10,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
employment agreements, and Contracts with independent contractors or consultants (or similar arrangements) to which Company is
a party, and which, in each case, are not cancellable without material penalty or without more than ninety (90) days&rsquo; notice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
for Contracts relating to trade receivables, all Contracts relating to Indebtedness for borrowed money (including, without limitation,
guarantees of such Indebtedness) of Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Contracts with any Governmental Authority to which Company is a party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Contracts that limit or purport to limit the ability of Company to compete in any line of business or with any Person or in any
geographic area or during any period of time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Contracts with &ldquo;most favored nation&rdquo; or &ldquo;most favored customer&rdquo; provisions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Contracts with rebate, &ldquo;pay for performance&rdquo; or &ldquo;pay for results&rdquo; provisions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
Contracts to which Company is a party that provide for any joint venture, partnership or similar arrangement by Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
Contracts between or among Company on the one hand and Company or any Affiliate of Company (other than Company) on the other hand;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
collective bargaining agreements or Contracts with any Union to which Company is a party; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(xv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
other Contract that is material to Company and not previously disclosed pursuant to this Section 3.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Material Contract is valid and binding on Company in accordance with its terms and is in full force and effect. Neither Company
nor, to Company&rsquo;s Knowledge, any other party thereto is in breach of or default under (or is alleged in writing to be in
breach of or default under), in each case in any material respects, or has provided or received any notice of any intention to
terminate, any Material Contract. To Company&rsquo;s Knowledge, no event or circumstance has occurred that, with notice or lapse
of time or both, would constitute an event of default under any Material Contract or result in a termination thereof or would
cause or permit the acceleration or other changes of any right or obligation or the loss of any material benefit thereunder. Complete
and correct copies of each Material Contract (including all modifications, amendments and supplements thereto and waivers thereunder)
have been made available to Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title
to Tangible Assets; Real Property</B>. Company has good and valid title to all personal property and other tangible assets reflected
in the Financial Statements or acquired after the Interim Balance Sheet Date, other than properties and assets sold or otherwise
disposed of in the ordinary course of business consistent with past practice since the Interim Balance Sheet Date or as set forth
in Section 3.8 of the Company Disclosure Schedules. Company represents and warrants that at Closing, no Contracts involving the
leasing of any Real Property or personal property will be outstanding. All such properties and assets are free and clear of Encumbrances
except for the following, all of which are listed on Section 3.10 of the Company Disclosure Schedules (collectively referred to
as &ldquo;<B>Permitted Encumbrances</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;liens
for Taxes not yet due and payable or being contested in good faith by appropriate procedures and, with respect to any such Taxes,
for which there are adequate accruals or reserves on the Balance Sheet;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;mechanics,
carriers&rsquo;, workmen&rsquo;s, repairmen&rsquo;s or other like liens arising or incurred in the ordinary course of business
consistent with past practice or amounts that are not delinquent and which are not, individually or in the aggregate, material
to the business of Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;easements,
rights of way, zoning ordinances and other similar encumbrances affecting Real Property which are not, individually or in the
aggregate, material to the business of Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other
than with respect to owned Real Property, liens arising under original purchase price conditional sales contracts and equipment
leases with third parties entered into in the ordinary course of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;liens
in favor of customs and revenue authorities arising as a matter of Law to secure payments of customs duties in connection with
the importation of goods;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
Encumbrances against the interest of the landlord or sublandlord of any leased Real Property that are not caused by Company and
do not adversely affect Company&rsquo;s leasehold interest in, or Company&rsquo;s use of, such leased Real Property or otherwise
impair Company&rsquo;s business operations at or relating to such leased Real Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
imperfections of title and non-monetary Encumbrances as do not and will not materially detract from or interfere with the use
of the properties subject thereto or affected thereby, or otherwise materially impair business operations involving such properties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pledges
or deposits to secure obligations under workers&rsquo; compensation Laws or similar legislation; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;non-exclusive
licenses of Intellectual Property granted in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Condition
and Sufficiency of Assets</B>. The furniture, fixtures, machinery, equipment, vehicles and other items of tangible personal property
of Company are structurally sound, are in good operating condition and repair in all material respects, and are materially adequate
for the uses to which they are being put, and none of such furniture, fixtures, machinery, equipment, vehicles and other items
of tangible personal property is in need of maintenance or repairs except for ordinary, routine maintenance and repairs that are
not material in nature or cost. To Company&rsquo;s Knowledge, the furniture, fixtures, machinery, equipment, vehicles, and other
items of tangible personal property currently owned or leased by Company, together with all other properties and assets of Company,
are sufficient for the continued conduct of Company&rsquo;s business after the Closing in substantially the same manner as conducted
prior to the Closing and constitute all of the rights, property and assets necessary in all material respects to conduct the business
of the Company as currently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intellectual
Property</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Intellectual
Property</B>&rdquo; means all of the following and similar intangible property and related proprietary rights, interests and protections,
however arising, pursuant to the Laws of any jurisdiction throughout the world, including such property that is owned by Company
(&ldquo;<B>Company Intellectual Property</B>&rdquo;) and that in which Company holds exclusive or non-exclusive rights or interests
granted by license from other Persons (&ldquo;<B>Licensed Intellectual Property</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;trademarks,
service marks, trade names, brand names, logos, trade dress and other proprietary indicia of goods and services, whether registered
or unregistered (&ldquo;<B>Trademarks</B>&rdquo;), and all registrations and applications for registration of such trademarks,
including intent-to-use applications, all issuances, extensions and renewals of such registrations and applications and the goodwill
connected with the use of and symbolized by any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;internet
domain names, whether or not trademarks, registered in any top-level domain by any authorized private registrar or Governmental
Authority;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;original
works of authorship in any medium of expression, whether or not published, all copyrights (whether registered or unregistered),
all registrations and applications for registration of such copyrights, and all issuances, extensions and renewals of such registrations
and applications;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;confidential
information, formulas, designs, devices, technology, know-how, research and development, inventions, methods, processes, compositions
and other trade secrets, whether or not patentable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;patented
and patentable designs and inventions, all design, plant and utility patents and applications, letters patent, utility models,
inventor&rsquo;s certificates, and provisional applications and all issuances, divisions, continuations, continuations-in-part,
reissues, extensions, reexaminations and renewals of such patents and applications, including the right to claim priority to such
patents and applications, and the right to file such patents and applications under the Patent Laws of the United States, the
International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws
of the country in which any such application is filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.12(b) of the Company Disclosure Schedules lists all Company Intellectual Property that is either (i) subject to any issuance,
registration, application or other filing by, to or with any Governmental Authority or authorized private registrar in any jurisdiction
(collectively, &ldquo;<B>Intellectual Property Registrations</B>&rdquo;), including registered trademarks, domain names and copyrights,
issued and reissued patents and pending applications for any of the foregoing; or (ii) solely with respect to Trademarks, material
to the conduct of the Company&rsquo;s current business or operations. All required filings and fees related to the Intellectual
Property Registrations have been timely filed with and paid to the relevant Governmental Authorities and authorized registrars,
and all Intellectual Property Registrations are in good standing, except in each case for any Intellectual Property Registrations
that were abandoned or permitted to lapse in the ordinary course of business. Company has provided Parent with true and complete
copies of file histories, documents, certificates, office actions, correspondence and other material documents related to all
Intellectual Property Registrations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.12(c) of the Company Disclosure Schedules, Company owns, exclusively or jointly with other Persons,
all right, title and interest in and to Company Intellectual Property material to the conduct of its business or operations as
currently conducted, free and clear of Encumbrances other than Permitted Encumbrances. Without limiting the generality of the
foregoing, Company has entered into binding, written agreements, substantially in the form(s) provided to Parent, with every current
and former employee of Company, and with every current and former independent contractor contributing to the conception or reduction
to practice of Company Intellectual Property, whereby such employees and independent contractors (i) assign to Company any ownership
interest and right they may have in Company Intellectual Property; and (ii) acknowledge Company&rsquo;s exclusive ownership of
all Company Intellectual Property. To Company&rsquo;s Knowledge, Company is in compliance with all legal requirements applicable
to Company Intellectual Property and Company&rsquo;s ownership and use thereof except in any such case where such failure to be
in compliance would not reasonably be expected to have a Material Adverse Effect with respect to Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.12(d) of the Company Disclosure Schedules lists all licenses, sublicenses and other agreements, excluding non-exclusive licenses
to unmodified commercially available software agreements and other agreements entered into in the ordinary course of business,
including without limitation Excluded Contracts, whereby Company is granted rights, interests and authority, whether on an exclusive
or non-exclusive basis, with respect to any Licensed Intellectual Property that is used in or, in Company&rsquo;s reasonable judgment,
necessary for Company&rsquo;s current business or operations. Company has provided Parent with true and complete copies of all
such agreements. All such agreements are valid, binding and enforceable between Company and the other parties thereto, and Company
and, to Company&rsquo;s Knowledge, such other parties are in compliance with the material terms and conditions of such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
Company&rsquo;s Knowledge, the making, using, offering for sale, or selling of any process, machine, article of manufacture, or
composition of matter, including the Products, in each case that is protected by the Company Intellectual Property and the Licensed
Intellectual Property owned, exclusively licensed or used by Company, to the extent such actions are performed by or on behalf
of Company in its conduct of its business as currently conducted, does not infringe, violate or misappropriate the Intellectual
Property of any Person other than Company. Except as set forth in Section 3.12(e) of the Company Disclosure Schedules, Company
has not received any written communication, and no Action has been settled or, to Company&rsquo;s Knowledge, been instituted or
threatened that alleges any such infringement, violation or misappropriation, and none of Company Intellectual Property are subject
to any outstanding Governmental Order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.12(f) of the Company Disclosure Schedules lists all licenses, sublicenses and other agreements pursuant to which Company grants
rights or authority to any Person with respect to any Company Intellectual Property or Licensed Intellectual Property, other than
such licenses, sublicenses or agreements entered into in the ordinary course of business, including without limitation Excluded
Contracts. Company has provided Parent with true and complete copies of all such agreements. All such agreements are valid, binding
and enforceable between Company and the other parties thereto, and Company and, to Company&rsquo;s Knowledge, such other parties
are in compliance with the material terms and conditions of such agreements. Except as set forth in Section 3.12(f) of the Company
Disclosure Schedules, to Company&rsquo;s Knowledge, no Person has infringed, violated or misappropriated, or is infringing, violating
or misappropriating, any Company Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory</B>.
To Company&rsquo;s Knowledge, inventory of Company reflected in the Interim Balance Sheet consists of a quality and quantity usable
and/or salable in the ordinary course of business consistent with past practice, except for obsolete, damaged, defective or slow-moving
items that have been or will be, as applicable, written off or written down to fair market value or for which adequate reserves
have been established in accordance with GAAP applied on a basis consistent with Company&rsquo;s past practices used in preparing
the Financial Statements. Except as set forth in Section 3.13 of the Company Disclosure Schedule, all such inventory is owned
by Company free and clear of all Encumbrances, other than Permitted Encumbrances, and no inventory is held on a consignment basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts
Receivable</B>. The accounts receivable reflected on the Interim Balance Sheet and the accounts receivable arising after the date
thereof (a) have arisen from bona fide transactions entered into by Company involving the sale of goods or the rendering of services
in the ordinary course of business consistent with past practice; (b) constitute only valid, undisputed claims of Company not
subject to claims of set-off or other defenses or counterclaims other than normal cash discounts accrued in the ordinary course
of business consistent with past practice; and (c) subject to a reserve for bad debts shown on the Interim Balance Sheet or, with
respect to accounts receivable arising after the Interim Balance Sheet Date, on the accounting records of the Company, are collectible
in full, less Ten Thousand Dollars ($10,000), within one hundred eighty (180) days after billing. The reserve for bad debts and
provisions for cash discounts and returns shown on the Interim Balance Sheet or, with respect to accounts receivable arising after
the Interim Balance Sheet Date, on the accounting records of Company have been determined in accordance with GAAP, consistently
applied, subject to normal year-end adjustments and the absence of disclosures normally made in footnotes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Customers
and Suppliers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.15(a) of the Company Disclosure Schedules sets forth (i) each customer who has paid aggregate consideration to Company for goods
or services rendered in an amount greater than or equal to $10,000 for each of the two most recent fiscal years (collectively,
the &ldquo;<B>Material Customers</B>&rdquo;); and (ii) the amount of consideration paid by each Material Customer during such
periods. Company has not received any notice, and has no reason to believe, that any of its Material Customers has ceased, or
intends to cease after the Closing, to use its goods or services or to otherwise terminate or materially reduce its relationship
with Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.15(b) of the Company Disclosure Schedules sets forth (i) each supplier to whom Company has paid consideration for goods or services
rendered in an amount greater than or equal to $10,000 for each of the two most recent fiscal years (collectively, the &ldquo;<B>Material
Suppliers</B>&rdquo;); and (ii) the amount of purchases from each Material Supplier during such periods. The Company has not received
any notice, and has no reason to believe, that any of its Material Suppliers has ceased, or intends to cease, to supply goods
or services to Company or to otherwise terminate or materially reduce its relationship with Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance</B>.
Section 3.16 of the Company Disclosure Schedules sets forth a true and complete list, as of the Agreement Date, of all current
policies or binders of fire, liability, product liability, umbrella liability, real and personal property, workers&rsquo; compensation,
vehicular, directors and officers&rsquo; liability, representations and warranties, fiduciary liability and other casualty and
property insurance maintained by Company or its Affiliates and relating to the assets, business, operations, employees, officers
and directors of Company (collectively, the &ldquo;<B>Insurance Policies&rdquo;</B>) and true and complete copies of such Insurance
Policies have been made available to Parent. Such Insurance Policies are in full force and effect. Neither Company nor any of
its Affiliates has received within the past year any written notice of cancellation of, premium increase with respect to, or alteration
of coverage under, any of such Insurance Policies. All premiums due on such Insurance Policies have either been paid or, if due
and payable prior to Closing, will be paid prior to Closing in accordance with the payment terms of each Insurance Policy unless
otherwise agreed with Parent. All such Insurance Policies have not been subject to any lapse in coverage. Except as set forth
on Section 3.16 of the Company Disclosure Schedules, there are no claims related to the business of Company pending under any
such Insurance Policies as to which coverage has been questioned, denied or disputed or in respect of which there is an outstanding
reservation of rights. None of Company or any of its Affiliates is in default under, or has otherwise failed to comply with, in
any material respect, any provision contained in any such Insurance Policy. The Insurance Policies are sufficient for compliance
with all applicable Laws and Material Contracts to which Company is a party or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal
Proceedings; Governmental Orders</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.17(a) of the Company Disclosure Schedules, there are no Actions pending or, to Company&rsquo;s Knowledge,
threatened (a) against or by Company affecting any of its properties or assets (or by or against Company or any Affiliate thereof
and relating to Company); or (b) against or by Company, or any Affiliate of Company that challenges or seeks to prevent, enjoin
or otherwise delay the transactions contemplated by this Agreement. To Company&rsquo;s Knowledge, no event has occurred or circumstances
exist that may give rise to or serve as a basis for any such Action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.17(b) of the Company Disclosure Schedules, there are no outstanding Governmental Orders and no unsatisfied
judgments, penalties or awards against or directly affecting Company or any of its properties or assets. Company is in compliance
with the terms of each Governmental Order set forth in Section 3.17(b) of the Company Disclosure Schedules. To Company&rsquo;s
Knowledge, no event has occurred or circumstances exist that may give rise to or serve as a basis for any such Governmental Order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
With Laws; Permits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.18(a) of the Company Disclosure Schedules, Company has complied for the past three (3) years, and is
now complying, in all material respects with all Laws applicable to it or its business, properties or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
material Permits required for Company to conduct its business have been obtained by it and are valid and in full force and effect.
All fees and charges with respect to such Permits as of the date hereof have been paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Environmental
Matters.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
is currently, and has been, in material compliance with all Environmental Laws and has not, and Company has not, received from
any Person any: (i) Environmental Notice or Environmental Claim; or (ii) written request for information pursuant to Environmental
Law, which, in each case, either remains pending or unresolved, or is the source of ongoing obligations or requirements as of
the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
has obtained and is in material compliance with all Environmental Permits (each of which is disclosed in Section 3.19(b) of the
Company Disclosure Schedules) necessary for the operation of its business and all such Environmental Permits are in full force
and effect and shall be maintained in full force and effect by Company through the Closing Date in accordance with Environmental
Law. With respect to any such Environmental Permits, Company will use commercially reasonable efforts to facilitate the transferability
of the same, and Company has not received any Environmental Notice or written communication regarding any material adverse change
in the status or terms and conditions of any such Environmental Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Knowledge of Company, no real property currently or formerly owned, operated or leased by Company is listed on, or has been
proposed for listing on, the National Priorities List (or CERCLIS) under CERCLA, or any similar state list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Knowledge of Company, there has been no Release of Hazardous Materials in contravention of Environmental Law with respect
to the business or assets of Company or any real property currently or formerly owned, operated or leased by Company. Company
has not received an Environmental Notice that any real property currently or formerly owned, operated or leased in connection
with the business of Company (including soils, groundwater, surface water, buildings and other structure located on any such real
property) has been contaminated with any Hazardous Material which would reasonably be expected to result in an Environmental Claim
against, or a violation of Environmental Law or term of any Environmental Permit by, Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.19(e) of the Company Disclosure Schedules contains a complete and accurate list of all aboveground or active underground storage
tanks owned or operated by Company. To the Knowledge of Company, there are no abandoned underground tanks on its leased Real Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.19(f) of the Company Disclosure Schedules contains a complete and accurate list of all off-site Hazardous Materials treatment,
storage, or disposal facilities or locations used by Company and any predecessors as to which Company may retain liability, and,
to the Knowledge of Company, none of these facilities or locations has been placed or proposed for placement on the National Priorities
List (or CERCLIS) under CERCLA, or any similar state list. Company has not received any Environmental Notice regarding potential
liabilities with respect to such off-site Hazardous Materials treatment, storage, or disposal facilities or locations used by
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
has provided or otherwise made available to Parent and listed in Section 3.19(g) of the Company Disclosure Schedules: (i) any
and all environmental reports, studies, audits, records, sampling data, site assessments, risk assessments, economic models and
other similar documents with respect to the business or assets of Company or any currently or formerly owned, operated or leased
real property which are in the possession or control of Company related to compliance with Environmental Laws, Environmental Claims
or an Environmental Notice or the Release of Hazardous Materials; and (ii) any and all material documents concerning planned or
anticipated capital expenditures required to reduce, offset, limit or otherwise control pollution and/or emissions, manage waste
or otherwise ensure compliance with current or future Environmental Laws (including, without limitation, costs of remediation,
pollution control equipment and operational changes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything in this Agreement to the contrary, the representations and warranties in Sections 3.19(a) through 3.19(g) above contain
Company&rsquo;s sole representations and warranties with respect to the compliance of Company or its business, properties or assets
with Environmental Laws or Permits, the presence of or liability for Hazardous Materials, or the existence of Environmental Claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
Benefit Matters.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.20(a) of the Company Disclosure Schedules contains a true and complete list of each pension, benefit, retirement, compensation,
profit-sharing, deferred compensation, incentive, performance award, phantom equity, stock or stock-based, change in control,
retention, severance, vacation, paid time off, fringe-benefit and other similar agreement, plan, policy, program or arrangement
(and any amendments thereto), in each case whether or not reduced to writing and whether funded or unfunded, including each &ldquo;employee
benefit plan&rdquo; within the meaning of Section 3(3) of ERISA, whether or not Tax-qualified and whether or not subject to ERISA,
which is or has been maintained, sponsored, contributed to, or required to be contributed to by Company or an ERISA Affiliate
for the benefit of any current or former employee, officer, director, retiree, independent contractor or consultant of Company
or an ERISA Affiliate or any spouse or dependent of such individual, or under which Company or an ERISA Affiliate has or may have
any Liability, or with respect to which Parent or any of its Affiliates would reasonably be expected to have any Liability, contingent
or otherwise other than offer letters entered into in the ordinary course (as listed on Section 3.20(a) of the Company Disclosure
Schedules, each, a &ldquo;<B>Benefit Plan</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each Benefit Plan, Company has made available to Parent accurate, current and complete copies of each of the following:
(i) where the Benefit Plan has been reduced to writing, the plan document together with all amendments; (ii) where the Benefit
Plan has not been reduced to writing, a written summary of all material plan terms; (iii) where applicable, copies of any trust
agreements or other funding arrangements, custodial agreements, insurance policies and contracts, administration agreements and
similar agreements, and investment management or investment advisory agreements, now in effect; (iv) copies of any summary plan
descriptions, summaries of material modifications, employee handbooks and any other written communications (or a description of
any oral communications) relating to any Benefit Plan; (v) in the case of any Benefit Plan that is intended to be qualified under
Section 401(a) of the Code, a copy of the most recent determination, opinion or advisory letter from the Internal Revenue Service;
(vi) in the case of any Benefit Plan for which a Form 5500 is required to be filed, a copy of the most recently filed Form 5500,
with schedules attached; (vii) actuarial valuations and reports related to any Benefit Plans with respect to the two most recently
completed plan years; and (viii) copies of material notices, letters or other correspondence from the Internal Revenue Service,
Department of Labor or Pension Benefit Guaranty Corporation relating to the Benefit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.20(c) of the Company Disclosure Schedules, each Benefit Plan (other than any multiemployer plan within
the meaning of Section 3(37) of ERISA (each a &ldquo;<B>Multiemployer Plan</B>&rdquo;)) has been established, administered and
maintained in accordance with its terms and in material compliance with all applicable Laws (including ERISA and the Code). Each
Benefit Plan that is intended to be qualified under Section 401(a) of the Code (a &ldquo;<B>Qualified Benefit Plan</B>&rdquo;)
is so qualified and has received a favorable and current determination letter from the Internal Revenue Service, or with respect
to a prototype plan, can rely on an opinion letter from the Internal Revenue Service to the prototype plan sponsor, to the effect
that such Qualified Benefit Plan is so qualified and that the plan and the trust related thereto are exempt from federal income
Taxes under Sections 401(a) and 501(a), respectively, of the Code, and nothing has occurred that would reasonably be expected
to cause the revocation of such determination letter from the Internal Revenue Service or the unavailability of reliance on such
opinion letter from the Internal Revenue Service, as applicable, nor has such revocation or unavailability been threatened. Nothing
has occurred with respect to any Benefit Plan that has subjected or would reasonably be expected to subject Company or, with respect
to any period on or after the Closing Date, Parent or any of its Affiliates, to a penalty under Section 502 of ERISA or to a Tax
or penalty under Section 4975 of the Code. Except as set forth in Section 3.20(c) of the Company Disclosure Schedules, all benefits,
contributions and premiums relating to each Benefit Plan have been timely paid in accordance with the terms of such Benefit Plan
and all applicable Laws and accounting principles, and all benefits accrued under any unfunded Benefit Plan have been paid, accrued
or otherwise adequately reserved to the extent required by, and in accordance with, GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
Company nor any of its ERISA Affiliates has (i) incurred or reasonably expects to incur, either directly or indirectly, any material
Liability under Title I or Title IV of ERISA or related provisions of the Code or foreign Law relating to employee benefit plans;
(ii) failed to timely pay premiums to the Pension Benefit Guaranty Corporation; (iii) withdrawn from any Benefit Plan; or (iv)
engaged in any transaction which would give rise to liability under Section 4069 or Section 4212(c) of ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each Benefit Plan (i) except as set forth in Section 3.20(e) of the Company Disclosure Schedules, no such plan is a
Multiemployer Plan, and all contributions required to be paid by Company or its ERISA Affiliates have been timely paid to the
applicable Multiemployer Plan; (ii) no such plan is a &ldquo;multiple employer plan&rdquo; within the meaning of Section 413(c)
of the Code or a &ldquo;multiple employer welfare arrangement&rdquo; (as defined in Section 3(40) of ERISA); (iii) no Action has
been initiated by the Pension Benefit Guaranty Corporation to terminate any such plan or to appoint a trustee for any such plan;
(iv) no such plan is subject to the minimum funding standards of Section 302 of ERISA or Section 412 of the Code; and (v) no &ldquo;reportable
event,&rdquo; as defined in Section 4043 of ERISA, has occurred with respect to any such plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.20(f) of the Company Disclosure Schedules and required by applicable Law, no provision of any Benefit
Plan or collective bargaining agreement could reasonably be expected to result in any limitation on Parent or any of its Affiliates
from amending or terminating any Benefit Plan. Company has no commitment or obligation and has not made any representations to
any employee, officer, director, independent contractor or consultant, whether or not legally binding, to adopt, amend or modify
any Benefit Plan or any collective bargaining agreement, in connection with the consummation of the transactions contemplated
by this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.20(g) of the Company Disclosure Schedules and other than as required under Section 601 et. seq. of ERISA
or other applicable Law, no Benefit Plan provides post-termination or retiree welfare benefits to any individual for any reason,
and neither Company nor any of its ERISA Affiliates has any Liability to provide post-termination or retiree welfare benefits
to any individual or ever represented, promised or contracted to any individual that such individual would be provided with post-termination
or retiree welfare benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.20(h) of the Company Disclosure Schedules, there is no pending or threatened Action relating to a Benefit
Plan (other than routine claims for benefits), and no Benefit Plan has within the three (3) years prior to the date hereof been
the subject of an examination or audit by a Governmental Authority or the subject of an application or filing under or is a participant
in, an amnesty, voluntary compliance, self-correction or similar program sponsored by any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
has been no amendment to, announcement by Company or any of its Affiliates relating to, or change in employee participation or
coverage under, any Benefit Plan or collective bargaining agreement that would increase the annual expense of maintaining such
plan above the level of the expense incurred for the most recently completed fiscal year with respect to any director, officer,
employee, independent contractor or consultant, as applicable. Neither Company, nor any of its Affiliates has any commitment or
obligation or has made any representations to any director, officer, employee, independent contractor or consultant, whether or
not legally binding, to adopt, amend or modify any Benefit Plan or any collective bargaining agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Benefit Plan that is subject to Section 409A of the Code has been operated in material compliance with such section and all applicable
regulatory guidance (including notices, rulings and proposed and final regulations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
individual who is classified by Company as an independent contractor has been properly classified for purposes of participation
and benefit accrual under each Benefit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.20(l) of the Company Disclosure Schedules, neither the execution of this Agreement nor any of the transactions
contemplated by this Agreement will (either alone or upon the occurrence of any additional or subsequent events): (i) entitle
any current or former director, officer, employee, independent contractor or consultant of Company to severance pay or any other
payment; (ii) accelerate the time of payment, funding or vesting, or increase the amount of compensation due to any such individual;
(iii) limit or restrict the right of Company to merge, amend or terminate any Benefit Plan; (iv) increase the amount payable under
or result in any other material obligation pursuant to any Benefit Plan; or (v) result in a &ldquo;parachute payment&rdquo; within
the meaning of Section 280G of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employment
Matters.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
represents and warrants that at Closing, it will have no employees and all such arrangements have been terminated without further
liability to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
is currently under no duty to bargain with any union, works council or labor organization (collectively, a &ldquo;<B>Union</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
is, and has been, in all material respects, in compliance with all applicable Laws pertaining to employment and employment practices,
including all Laws relating to labor relations, equal employment opportunities, fair employment practices, employment discrimination,
harassment, retaliation, reasonable accommodation, disability rights or benefits, immigration, wages, hours, overtime compensation,
child labor, hiring, promotion and termination of employees, working conditions, meal and break periods, privacy, health and safety,
workers&rsquo; compensation, leaves of absence and unemployment insurance. All individuals characterized and treated by Company
as independent contractors or consultants are properly treated as independent contractors under all applicable Laws. All employees
classified as exempt under the Fair Labor Standards Act and state and local wage and hour laws are properly classified. There
are no Actions against Company pending, or to Company&rsquo;s Knowledge, threatened to be brought or filed, by or with any Governmental
Authority or arbitrator in connection with the employment of any current or former applicant, employee, consultant or independent
contractor of Company, including, without limitation, any claim relating to unfair labor practices, employment discrimination,
harassment, retaliation, equal pay, wages and hours or any other employment -related matter arising under applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
has complied in all material respects with the WARN Act, if applicable, and it has no plans to undertake any action in the future
that would trigger the WARN Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes</B>.
Except as set forth in Section 3.22 of the Company Disclosure Schedules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
material Tax Returns required to be filed on or before the Closing Date by Company have been, or will be, filed (taking into account
any valid extensions). Such Tax Returns are, or will be, true, complete and correct in all material respects; <I>provided, however</I>,
that regardless of any information or items reported on any Tax Returns, Company makes no representation regarding the amount
of any net operating losses that are available to it or have been reported by the Company for any federal, state or other Tax
purposes, and Company makes no representation regarding any limitation on use of its net operating losses that might apply either
before or after the Closing Date under Code Section 382 or any other applicable limitations under any Tax laws, rules or regulations.
All material Taxes due and owing by Company on or before the Closing Date (whether or not shown on any Tax Return) have been,
or will be, paid before the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
has withheld and paid each Tax required to have been withheld and paid in connection with amounts paid or owing to any employee,
independent contractor, creditor, customer, shareholder or other party, and complied with all information reporting and backup
withholding provisions of applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
written claim has been made by any taxing authority in any jurisdiction where Company does not file Tax Returns that it is, or
may be, subject to Tax by that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
extensions or waivers of statutes of limitations have been given or requested with respect to the collection or assessment of
any Taxes of Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
amount of Company&rsquo;s Liability for unpaid Taxes for all periods ending on or before the Balance Sheet Date has been properly
and accurately accrued on the Balance Sheet in accordance with GAAP and consistent with past custom and practice. The Company
does not have any Liability for unpaid Taxes since the Balance Sheet Date outside of the ordinary course of business; <I>provided,
however</I>, that no representation is made under this Agreement with respect to any Tax liability or other costs that might arise
or accrue to Company or any other Person or entity by reason of, or in connection with, any election by or on behalf of Company
pursuant to Section 338 of the Code with respect to the consummation of the Mergers or any other transactions contemplated by
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
deficiencies asserted, or assessments made, against Company as a result of any examinations by any taxing authority have been
fully paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
is not a party to any Action by any taxing authority. To Company&rsquo;s Knowledge, there are no written pending or threatened
Actions by any taxing authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no Encumbrances for Taxes, other than Permitted Encumbrances, upon the assets of Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
is not a party to, or bound by, any Tax indemnity, Tax-sharing or Tax allocation agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
is not a party to, or bound by, any closing agreement or offer in compromise with any taxing authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
private letter rulings, technical advice memoranda or similar agreement or rulings have been requested, entered into or issued
by any taxing authority with respect to Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
has not been a member of an affiliated, combined, consolidated or unitary Tax group for Tax purposes. Company has no Liability
for Taxes of any Person (other than Company) under Treasury Regulations Section 1.1502-6 (or any corresponding provision of state,
local or foreign Law), as a transferee or successor, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.22(m) of the Company Disclosure Schedules, Company has not agreed to make, nor is it required to make,
any adjustment under Section 481(a) of the Code or any comparable provision of state, local or foreign Tax Laws by reason of a
change in accounting method or otherwise. Company will not be required to include any item of income in, or exclude any item of
deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any installment
sale or open transaction disposition made prior to the Closing or prepaid amount received outside of the ordinary course of business
prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
is not a &ldquo;foreign person&rdquo; as that term is used in Treasury Regulations Section 1.1445-2. Company is not, nor has it
been, a &ldquo;United States real property holding corporation&rdquo; (as defined in Section 897(c)(2) of the Code) during the
applicable period specified in Section 897(c)(1)(A)(ii) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
has not been a &ldquo;distributing corporation&rdquo; or a &ldquo;controlled corporation&rdquo; in connection with a distribution
described in Section 355 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
is not, and has not been, a party to a &ldquo;reportable transaction&rdquo; within the meaning of Section 6707A(c)(1) of the Code
and Treasury Regulations Section 1.6011-4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the assets of Company is property that Company is required to treat as being owned by any other person pursuant to the so-called
&ldquo;safe harbor lease&rdquo; provisions of former Section 168(f)(8) of the Internal Revenue Code of 1954, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Books
and Records</B>. The minute books and stock record books of Company, all of which have been made available to Parent, are complete
(except for such redactions as are necessary to maintain privilege prior to Closing) and correct and have been maintained in accordance
with sound business practices. The minute books of Company contain accurate and complete records of all meetings, and actions
taken by written consent of, the stockholders, the Company Board and any committees thereof (other than records of committee meetings
where such committee took no formal action), and no meeting, or action taken by written consent, of any such stockholders, the
Company Board or committee thereof has been held for which minutes have not been prepared and are not contained in such minute
books. At the Closing, all of those books and records will be in the possession or control of Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
Payments</B>. Neither Company nor, to Company&rsquo;s Knowledge, any director, officer, employee, or other Person associated with
or acting on behalf of it, has, directly or indirectly, in violation of any Law made any contribution, gift, bribe, rebate, payoff,
influence payment, kickback, or other payment to any Person, private or public, regardless of form, whether in money, property,
or services (a) to obtain favorable treatment in securing business for Company, (b) to pay for favorable treatment for business
secured by Company or (c) to obtain special concessions or for special concessions already obtained, for or in respect of Company.
Without limiting the generality of the foregoing, Company (including any of its directors, officers, employees or other Persons
associated with or acting on its behalf) has not, directly or indirectly, taken any action which would cause it to be in violation
of the U.S. Foreign Corrupt Practices Act, as amended, or any rules or regulations thereunder (the &ldquo;<B>FCPA&rdquo;</B>),
including by offering or conveying, directly or indirectly (such as through an agent), anything of value to obtain or retain business
or to obtain any improper advantage, including any bribe, rebate, payoff, influence payment, kickback or other similar unlawful
payment to a foreign government official, candidate for office, or political party or official of a political party. Company has
conducted its business in compliance with the FCPA in all respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Privacy
and Data Security</B>. Company has made available true and correct copies of all written privacy policies adopted by Company in
connection with its operations. Company (i) has complied in all material respects with all applicable privacy laws and other laws
regarding the disclosure of data, (ii) has not violated its applicable privacy policies in any material respect and (iii) has
taken commercially reasonable steps to protect and maintain the confidential nature of the personal information provided to Company
in accordance with its applicable privacy policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government
Grants and Incentives</B>. Section 3.26 of the Company Disclosure Schedules provides a complete list of all pending and outstanding
grants, incentives, benefits, qualifications and subsidies from any Governmental Authority, granted to Company within the last
three (3) years (collectively, &ldquo;<B>Government Grants&rdquo;</B>). Company does not have any Liability whatsoever with respect
to royalties or other payments relating to, arising out of or in connection with such Government Grants. Company is in material
compliance with all of the terms, conditions and requirements of the Government Grants and has fulfilled in all material respects
the undertakings relating thereto. Neither Company nor any of its agents, contractors, vendors, licensors or otherwise has developed
any Company Intellectual Property through the application of any financing made available by any Government Grants, and no Company
Intellectual Property is subject to any assignment, grant-back, license or other right of any Governmental Authority as a result
of any Government Grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Products
Liability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
claim is pending or, to Company&rsquo;s Knowledge, threatened in connection with the product liability of any Products, and no
Governmental Authority has commenced or, to Company&rsquo;s Knowledge, threatened to initiate any Action or requested the recall
of any Product, or commenced or, to Company&rsquo;s Knowledge, threatened in writing to initiate any Action to enjoin the production
of any Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth on Section 3.27 of the Company Disclosure Schedules, no customer of Company has delivered any written complaint or
written allegation of any quality, design, engineering or safety issue with respect to any Product that would reasonably be expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State
Takeover Statutes. </B>No &ldquo;moratorium,&rdquo; &ldquo;fair price,&rdquo; &ldquo;business combination,&rdquo; &ldquo;control
share acquisition&rdquo; or similar provision of any state anti-takeover Law is, or at the Effective Time will be, applicable
to this Agreement, the Mergers or any of the other transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related
Party Transactions</B>. Except as set forth in Section 3.29 of the Disclosures Schedules and other than Contracts entered into
in connection with bona fide financings, no present or former director, executive officer, stockholder, partner, member, employee
or Affiliate of Company, nor any of such Person&rsquo;s Affiliates or immediate family members (each of the foregoing, a &ldquo;<B>Related
Party&rdquo;</B>), is a party to any Contract with Company that is of a type that would be required to be disclosed pursuant to
Item 404 of Regulation S-K (an &ldquo;<B>Affiliate Transaction&rdquo;</B>) if the Company Stock was publicly traded. To Company&rsquo;s
Knowledge, no Related Party of Company owns, directly or indirectly, on an individual or joint basis, any interest in (other than
ownership of two percent (2%) or less of the outstanding voting stock of a publicly-traded entity), or serves as an officer or
director or in another similar capacity of, any supplier or other independent contractor of Company, or, except for those Contracts
set forth in Section 3.29 of the Company Disclosure Schedules or any Material Contract entered into in connection with bona fide
financings, any organization which has a Material Contract with Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 3.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Brokers</B>.
Except for Torreya Capital, a division of Financial West Investment Group, Inc. (the &ldquo;<B>Company&rsquo;s Investment Banker&rdquo;</B>),
no broker, finder or investment banker is entitled to any brokerage, finder&rsquo;s or other fee or commission in connection with
the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Company. The Company represents
and warrants it will pay, or otherwise make accommodation on the Distribution Schedule for, any amounts due to the Company&rsquo;s
Investment Banker at or prior to Closing and further represent and warrant that any such amount is excluded from the definition
of &ldquo;Cash on Hand&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
4.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B><U>REPRESENTATIONS AND WARRANTIES OF PARENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Parent represents and
warrants to Company that the statements contained in this Article 4 are true and correct as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Organization</B>.
Parent is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware. Parent
has full corporate power and authority to enter into this Agreement, to carry out its obligations hereunder and to consummate
the transactions contemplated hereby. The execution and delivery by Parent of this Agreement, the performance by Parent of its
obligations hereunder and the consummation by Parent of the transactions contemplated hereby have been duly authorized by all
requisite corporate action on the part of Parent. This Agreement has been duly executed and delivered by Parent and Merger Subs,
and this Agreement constitutes legal, valid and binding obligations of Parent and Merger Subs, as applicable, enforceable against
Parent and Merger Subs in accordance with their terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization,
moratorium or other laws of general application affecting enforcement of creditors&rsquo; rights, and (ii) general principles
of equity that restrict the availability of equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Conflicts; Consents</B>. The execution, delivery and performance by Parent of this Agreement, and the consummation of the transactions
contemplated hereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision
of the certificate of incorporation, by-laws or other organizational documents of Parent; (b) conflict with or result in a violation
or breach of any provision of any Law or Governmental Order applicable to Parent; or (c) require the consent, notice or other
action by or to any Person pursuant to, or result in any breach or violation of or constitute a default under, any Contract to
which Parent or any of its Affiliates is a party. Except for (i) applicable requirements of the Exchange Act, including the filing
of any Current Report on Form 8-K required to be filed in connection with the Mergers, (ii) any filings required under state securities
Laws, (iii) any filings required by OTC Markets (or such national or foreign securities exchange on which Parent&rsquo;s shares
are listed) and (iv) the filing of the Certificate of Merger with the Secretary of State of the State of Delaware, in each case,
which have or will be made, neither Parent nor Merger Subs are required to submit any notice, report or other filing with any
Governmental Authority in connection with the execution, delivery or performance by any of them of this Agreement or the consummation
of the transactions contemplated hereby. Other than as stated above, no consent, approval or authorization of any governmental
or regulatory authority or any other party or Person is required to be obtained by Parent or Merger Subs in connection with its
execution, delivery and performance of this Agreement or the consummation of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Stockholder Vote Required</B>. No vote or other action of the stockholders of Parent is required pursuant to any applicable Law,
the governing documents of Parent or otherwise in order for the Parent to consummate the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuance
of Parent Shares</B>. The issuance and delivery of Parent Shares in accordance with this Agreement has been duly authorized by
all necessary corporate action on the part of Parent and, when issued as contemplated hereby, such Parent Shares shall be duly
and validly issued, fully paid and nonassessable. Such Parent Shares, when so issued and delivered in accordance with the provisions
of this Agreement, shall be free and clear of all Encumbrances, other than restrictions on transfer created by applicable securities
Laws and will not have been issued in violation of applicable Laws, applicable OTC Markets rules or regulations, or any preemptive
rights or rights of first refusal or similar rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Brokers</B>.
No broker, finder or investment banker is entitled to any brokerage, finder&rsquo;s or other fee or commission in connection with
the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal
Proceedings</B>. There are no Actions pending or, to Parent&rsquo;s knowledge, threatened against or by Parent or any Affiliate
of Parent or any of their respective properties or any of their respective officers or directors (in their capacities as such)
that would challenge or would reasonably be expected to prevent, enjoin or otherwise delay the transactions contemplated by this
Agreement. No event has occurred or circumstances exist that may give rise or serve as a basis for any such Action. There is no
Governmental Order against Parent or any Affiliate of Parent, or any of their respective directors or officers (in their capacities
as such), that could prevent, enjoin, or materially alter or delay the consummation of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Merger
Sub. </B>Merger Sub was organized solely for the purpose of entering into this Agreement and consummating the transactions contemplated
hereby and has not engaged in any activities or business, and has incurred no liabilities or obligations whatsoever, in each case,
other than those incident to its organization and the execution of this Agreement and the consummation of the transactions contemplated
hereby. Merger Sub is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware.
Merger Sub has full corporate power and authority to enter into this Agreement, to carry out its obligations hereunder and to
consummate the transactions contemplated hereby. The execution and delivery by Merger Sub of this Agreement, the performance by
Merger Sub of its obligations hereunder and the consummation by Merger Sub of the transactions contemplated hereby have been duly
authorized by all requisite action on the part of Merger Sub.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Second
Merger Sub</B>. Second Merger Sub was organized solely for the purpose of entering into this Agreement and the Second Merger and
consummating the transactions contemplated hereby and has not engaged in any activities or business, and has incurred no liabilities
or obligations whatsoever, in each case, other than those incident to its organization and the execution of this Agreement or
the Second Certificate of Merger and the consummation of the transactions contemplated hereby. Second Merger Sub is a limited
liability company duly organized, validly existing and in good standing under the Laws of the State of Delaware. Second Merger
Sub has full power and authority to enter into this Agreement and the Second Certificate of Merger, to carry out its obligations
hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Second
Merger Sub of this Agreement and the Second Certificate of Merger, the performance by Second Merger Sub of its obligations hereunder
and thereunder and the consummation by Second Merger Sub of the transactions contemplated hereby and thereby have been duly authorized
by all requisite action on the part of Second Merger Sub. Second Merger Sub is an entity disregarded as separate from Parent for
U.S. federal tax purposes and neither Parent nor Second Merger Sub intends to take any action inconsistent with such treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SEC
Filings; Securities Law and Other Matters.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent
has filed all forms, reports, statements and documents required to be filed with the SEC for the twenty-four (24) month period
preceding the Closing (collectively, the &ldquo;<B>Parent SEC Reports</B>&rdquo;), each of which has complied in all material
respects with the applicable requirements of the Securities Act and the Exchange Act, and the rules and regulations of the SEC
promulgated thereunder, as applicable, and applicable to the Parent SEC Reports. None of the Parent SEC Reports contained as of
their respective dates, and as of the date of the last amendment thereof, if amended after filing, any untrue statement of a material
fact or omitted or omits to state a material fact required to be stated or incorporated by reference therein or necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of the financial statements included in the Parent SEC Reports, in each case, including any related notes thereto, as filed with
the SEC (collectively, the &ldquo;<B>Parent Financial Statements</B>&rdquo;), have been prepared in accordance with GAAP applied
on a consistent basis throughout the periods involved and fairly present the consolidated financial position of Parent and its
Subsidiaries at the respective date thereof and the consolidated results of its operations and changes in cash flows for the periods
indicated (except, in each case as may be indicated in the notes thereto and subject, in the case of the unaudited statements,
to normal, year-end adjustments and the absence of footnotes otherwise required by GAAP). To the knowledge of Parent, there are
no circumstances that would require Parent to restate any of the Parent Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no material liabilities of Parent or any of its Subsidiaries, taken as a whole, of any kind whatsoever, whether or not accrued
and whether or not contingent or absolute, other than (i) liabilities disclosed in Parent&rsquo;s consolidated balance sheet (the
&ldquo;<B>Parent Balance Sheet</B>&rdquo;) as of March 31, 2017 (the &ldquo;<B>Parent Balance Sheet Date</B>&rdquo;), included
in Parent&rsquo;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017; (ii) liabilities incurred by or on behalf
of Parent in connection with this Agreement and the transactions contemplated hereby; (iii) liabilities disclosed in Parent SEC
Report filed since the filing of the Parent Balance Sheet and (iv) liabilities incurred in the ordinary course of business since
the Parent Balance Sheet Date, none of which, individually or in the aggregate, would reasonably be expected to result in a Material
Adverse Effect with respect to Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
of Parent common stock are registered pursuant to Section 12(b) of the Exchange Act and are listed on the OTC Markets and Parent
has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of its shares under
the Exchange Act or delisting its shares from the OTC Markets, nor has Parent received any notification that the SEC or the OTC
Markets is contemplating terminating such registration or listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
the Parent Balance Sheet Date, and other than in the ordinary course of business consistent with past practice, there has not
been, with respect to Parent, any event, occurrence or development that has had, or could reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with Laws</B>. Except as has not had and would reasonably be expected to have, individually or in the aggregate, Material Adverse
Effect with respect to Parent and its Subsidiaries, taken as a whole, Parent and each of its Subsidiaries is, and since December&nbsp;31,
2014 has been, in compliance with all Laws applicable to it or its business, properties or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes</B>.
There are no material Taxes due and payable by Parent or any of its Subsidiaries which have not been duly paid. Parent and each
of its Subsidiaries has duly filed all material Tax Returns required to have been filed by them and there are in effect no waivers
of applicable statutes of limitations with respect to the collection or assessment of Taxes for any year. Parent is not aware
of any fact or circumstance that would reasonably be expected to prevent the Integrated Transaction from qualifying as a &ldquo;reorganization&rdquo;
within the meaning of Section 368(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
5.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B><U>COVENANTS OF THE PARTIES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conduct
of Business Prior to the Closing.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the period from the date of this Agreement until the Closing or the earlier termination of this Agreement pursuant to Section
6.1 hereof, except with the prior written consent of Parent (which consent shall not be unreasonably withheld or delayed), Company
shall (i) except as set forth in Section 5.1(b) of the Company Disclosure Schedules, carry on its business according to its ordinary
course of business and substantially in the same manner as heretofore conducted; provided that, the foregoing notwithstanding,
Company may use all available cash to repay any Indebtedness or Securityholder Transaction Expenses prior to Closing, (ii) use
commercially reasonable efforts to preserve and protect its material assets, properties, organization (including key officers
and employees), goodwill and business relationships, (iii) cause all transactions with third parties to take place on arm&rsquo;s
length terms, (iv) maintain insurance coverage on such terms and in such amounts substantially as maintained on the date hereof,
and (v) comply in all material respects with all applicable Laws, orders, codes, licenses, regulations and ordinances of any Governmental
Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the period from the date of this Agreement until the Closing or the earlier termination of this Agreement pursuant to Section
6.1 hereof, except as otherwise expressly provided for by this Agreement or consented to in writing by Parent (which consent will
not be unreasonably withheld or delayed) or as set forth on Section 5.1(b) of the Company Disclosure Schedules, Company shall
not:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cause
or permit any amendments to the Company Charter or any of Company&rsquo;s organizational documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;incur
or commit to incur any Indebtedness in excess of $10,000, or guarantee any Indebtedness of others;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;declare
or pay any dividend or make any other distributions (whether in cash, shares or property) in respect of any of its shares, or
split, combine, reclassify any of its shares or issue or authorize the issuance of any other securities in respect of, in lieu
of or in substitution for its shares, or repurchase or otherwise acquire, directly or indirectly, any of its shares, other than
(A) the issuance of shares of Company Stock pursuant to the exercise in accordance with their terms of options or Warrants outstanding
as of the Agreement Date, or (B) the repurchase of Company Common Stock from former employees, non-employee directors and consultants
in accordance with agreements providing for the repurchase of shares in connection with any termination of service as in effect
on the Agreement Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except
as contemplated by this Agreement or the acceleration of options prior to the Closing, accelerate, amend, or change the period
of exercisability or vesting of any options, Warrants or any other rights to purchase securities or authorize cash payments in
exchange for any such options, Warrants or other rights to purchase securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sell,
lease, license or otherwise dispose of or encumber any of its properties or assets that are material, individually or in the aggregate,
to its business, taken as a whole, other than in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;enter
into, terminate or amend, in a manner that will materially and adversely affect the business of Company, any agreement that is,
or would be if existing on the date of this Agreement, a Material Contract, other than in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;make
any capital expenditures, capital additions or capital improvements, in excess of $10,000 in the aggregate, except those that
are made in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reduce
the amount of any insurance coverage provided by existing insurance policies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amend
any benefit plan of Company or adopt any plan that would constitute a benefit plan except in order to comply with applicable Law,
or hire any new employee, pay any discretionary bonus, special remuneration or special noncash benefit, or increase the benefits,
salaries or wage rates of its employees (except with respect to payments and benefits made pursuant to written agreements outstanding
on the date of this Agreement);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;grant
or pay any severance or termination pay or benefits (A) to any director or officer or (B) to any other employee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;commence
a lawsuit other than (A) for the routine collection of bills, (B) in such cases where Company in good faith determines that failure
to commence suit would result in the material impairment of Company&rsquo;s business, provided that it consults with Parent prior
to the filing of such a suit, or (C) in connection with a breach of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acquire
or agree to acquire by merging with, or by purchasing a material portion of the shares or assets of, or by any other manner, any
business or any corporation, partnership, association or other business organization or division thereof or otherwise acquire
or agree to acquire any assets that, in any such of the foregoing cases, are material individually or in the aggregate, to its
business, taken as a whole;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other
than in the ordinary course of business or as may be required by applicable Law, make or change any material election in respect
of material Taxes, adopt or change any material accounting method in respect of Taxes, enter into any closing agreement with respect
to Taxes, settle any material claim or assessment in respect of Taxes, or consent to any extension or waiver of the limitation
period applicable to any material claim with respect to the collection or assessment of Taxes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;revalue
any of its assets, including writing down the value of inventory or writing off notes or accounts receivable other than in the
ordinary course of business or as required by changes in GAAP; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(xv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;take
or agree in writing or otherwise to take, any of the actions described in Section 5.1(b)(i) through (xiv) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Access
to Information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until the Closing, Company shall, and shall cause Company to, (i) afford Parent and its Agents reasonable access
during normal business hours to and the right to inspect all of the Real Property, properties, assets, premises, books and records,
Contracts and other documents and data related to Company, except that the right to inspect the Real Property does not extend
to the right to conduct sampling of the soil, groundwater, and/or air of the Real Property without Company&rsquo;s prior written
consent; (ii) furnish Parent and its Agents with such financial, operating and other data and information related to Company as
Parent or any of its Agents may reasonably request; and (iii) instruct the Agents of Company and Company to cooperate with Parent
in its investigation of Company; provided, that such access shall be at Parent&rsquo;s sole expense; <I>provided</I>, <I>however</I>,
that Company shall not be required to provide Parent or its Agents with access to any files, books, records or information where
such access would (A) waive any privileges or protections under applicable Law, (B) violate any Law concerning privacy rights
applicable to employees, (C) violate the terms of any nondisclosure or similar Contract with any third party (<I>provided</I>,
that in each case, Company shall use its commercially reasonable efforts to provide Parent with access to such information to
the fullest extent practicable without risking loss of privilege or protections under such Law, privacy right or Contract, including,
for example, providing for such information to be reviewed by counsel for Parent on terms reasonably acceptable to counsel for
Company) or (D) violate any Law, including but not limited to any antitrust Law as interpreted in the reasonable discretion of
counsel to Company. Any investigation pursuant to this Section 5.2 shall be conducted in such manner as not to interfere unreasonably
with the conduct of the business of Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
a period of seven (7) years from and after the Closing, Parent will make or cause to be made available (including by electronic
means, to the extent available) to the Representative all books, records, Tax Returns and documents of the Surviving Company (and
the assistance of employees responsible for such books, records and documents or whose participation is reasonably necessary or
desirable in connection therewith) as may be reasonably necessary for (i) investigating, settling, preparing for the defense or
prosecution of, defending or prosecuting any Third Party Claim or (ii) such other purposes for which access to such documents
is reasonably necessary for the Representative to conduct its duties hereunder; <I>provided</I>, <I>however</I>, that any such
access or furnishing of information shall be during Parent&rsquo;s normal business hours, under the supervision of Parent&rsquo;s
personnel and in such a manner as not to interfere with the normal operations of Parent or Surviving Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Solicitation of Other Bids</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the earlier of the Closing or termination of this Agreement, Company shall not, and shall not authorize or permit any of its
Affiliates or any of its or their Agents to, directly or indirectly, (i) encourage, solicit, facilitate, initiate or continue
inquiries regarding an Acquisition Proposal; (ii) enter into discussions or negotiations with, or provide any information to,
any Person concerning a possible Acquisition Proposal; or (iii) enter into any agreements or other instruments (whether or not
binding) regarding an Acquisition Proposal. Company shall immediately cease and cause to be terminated, and shall cause its Affiliates
and all of its and their Agents to immediately cease and cause to be terminated, all existing discussions or negotiations with
any Persons conducted heretofore with respect to, or that could lead to, an Acquisition Proposal. For purposes hereof, &ldquo;<B>Acquisition
Proposal</B>&rdquo; shall mean any inquiry, proposal or offer from any Person (other than Parent or any of its Affiliates) concerning
(A) a merger, consolidation, liquidation, recapitalization, share exchange or other business combination transaction involving
Company; (B) the issuance or acquisition of shares of capital stock or other equity securities of Company (other than (x) the
issuance of shares of Company Stock pursuant to the exercise in accordance with their terms of options or Warrants outstanding
as of the Agreement Date, or (y) the repurchase of Company Common Stock from former employees, non-employee directors and consultants
in accordance with agreements providing for the repurchase of shares in connection with any termination of service as in effect
on the Agreement Date); or (C) the sale, lease, exchange or other disposition of any significant portion of Company&rsquo;s properties
or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the other obligations under this Section 5.3, Company shall promptly (and in any event within three (3) Business Days
after receipt thereof by Company) advise Parent in writing of any Acquisition Proposal, any request for information with respect
to any Acquisition Proposal, or any inquiry with respect to an Acquisition Proposal, the material terms and conditions of such
request, Acquisition Proposal or inquiry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
agrees that the rights and remedies for noncompliance with this Section 5.3 shall include having such provision specifically enforced
by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach shall cause
irreparable injury to Parent and that money damages would not provide an adequate remedy to Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
of Certain Events</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until the Closing, Company shall promptly notify Parent, and Parent shall promptly notify Company, in writing
of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
fact, circumstance, event or action the existence, occurrence or taking of which (A) has had, or could reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect with respect to such notifying party, or (B) has resulted
in, or would reasonably be expected to result in, the failure of any of the conditions set forth in Section 2.2 or 2.3, as applicable,
to be satisfied;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
written notice or other communication from any Person alleging that the consent of such Person is or may be required in connection
with the transactions contemplated by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
notice or other communication from any Governmental Authority in connection with the transactions contemplated by this Agreement;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
Actions commenced or, to Company&rsquo;s Knowledge or Parent&rsquo;s knowledge, as applicable, threatened against, relating to
or involving or otherwise affecting such notifying party that, if pending on the date of this Agreement, would have been required
to have been disclosed pursuant to Section 3.17 or Section 4.7 or that relates to the consummation of the transactions contemplated
by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
delivery of any notice pursuant to Section 5.4(a) (each, a &ldquo;<B>Disclosure Update</B>&rdquo;) shall amend, modify and supplement
the Company Disclosure Schedules or Parent Disclosure Schedules, as applicable, delivered upon the execution of this Agreement
for all purposes hereunder but only (1) to the extent such Disclosure Update does not disclose facts, events or circumstances
describing a previously undisclosed Material Adverse Effect on the Company or Parent, as applicable, or (2) if such Disclosure
Update discloses facts, events or circumstances that first occurred after the date of this Agreement and the Closing occurs. For
the avoidance of doubt, any disclosure in any such Disclosure Update shall not be deemed to have cured any inaccuracy or breach
of any representation or warranty made and effective as of the date of this Agreement, including for purposes of the indemnification
or termination rights contained in this Agreement or of determining whether or not the conditions set forth in Section 2.2 have
been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statement Preparation</B>. Company shall use its commercially reasonable efforts prior to Closing to prepare, or assist Parent
in causing to be prepared, as promptly as practicable, and in any event no later than seventy (75) days following the Closing
Date, any financial statements that Parent is required to file pursuant to Form 8-K, Rule 3-05 or Article 11 of Regulation S-X
under the 1934 Act, and shall use its commercially reasonable efforts to obtain the consents of its auditor(s) with respect thereto
as may be required by applicable SEC regulations. Company represents and warrants that it has secured the cooperation of its finance
staff to assist Parent with getting audited financial statements for each of 2014, 2015 and 2016. All costs and expenses associated
with this Section 5.5, including reasonable compensation for services provided by Company&rsquo;s finance staff and auditors,
shall be paid by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Resignations</B>.
Company shall deliver to Parent written resignations, effective as of the Closing Date, of the officers, directors, employees
and contractors of Company prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality</B>.
The parties hereto acknowledge that Parent and Company have entered into a confidentiality agreement, dated February 27, 2017,
which shall continue in full force and effect in accordance with its terms (the &ldquo;<B>Confidentiality Agreement&rdquo;</B>).
Without limiting the terms of the Confidentiality Agreement, except for disclosures required to obtain any consent or approval
of any Person (including Company Securityholders) or other disclosures approved by the other party, neither the Company nor Parent
shall disclose the terms of this Agreement or the terms of any of the transactions contemplated hereby to any other Person, other
than to the directors, officers, employees, agents, attorneys, consultants or representatives of such Person in connection with
any of the foregoing to assist such Person in complying with its obligations under this Agreement. Notwithstanding the foregoing,
this Section 5.7 shall not prohibit any such Person from making any disclosure which is, upon the advice of counsel, (a) required
to avoid a violation of applicable Law by such party or (b) required by rule or regulation of any securities exchange or market
on which the securities of any party or its Affiliates are listed or quoted, and in each such case the party required to make
such disclosure shall do so only to the limited extent necessary to comply with such Law, regulation, rule or obligation and shall,
to the extent practicable, give advance notice thereof to the other party hereto and an opportunity to comment on any such disclosure
and oppose the need therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governmental
Approvals and Consents.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
party hereto shall, as promptly as possible, (i) make, or cause or be made, all filings and submissions required under any Law
applicable to such party or any of its Affiliates; and (ii) use reasonable best efforts to obtain, or cause to be obtained, all
consents, authorizations, orders and approvals from all Governmental Authorities that may be or become necessary for its execution
and delivery of this Agreement and the performance of its obligations pursuant to this Agreement. Each party shall cooperate fully
with the other party and its Affiliates in promptly seeking to obtain all such consents, authorizations, orders and approvals.
The parties hereto shall not willfully take any action that will have the effect of delaying, impairing or impeding the receipt
of any required consents, authorizations, orders and approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any consent, approval or authorization necessary to preserve any right or benefit under any Material Contract to which Company
is a party is not obtained prior to the Closing, Company shall, subsequent to the Closing, cooperate with Parent and Company in
attempting to obtain such consent, approval or authorization as promptly thereafter as practicable. If such consent, approval
or authorization cannot be obtained, Company shall use its reasonable best efforts to provide Company with the rights and benefits
of the affected Material Contract for the term thereof, and, if Company provides such rights and benefits, Parent shall assume
all obligations and burdens thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder
Approval</B>. Promptly after execution of this Agreement, Company shall solicit the written consent to this Agreement and the
transactions contemplated hereby by the requisite number of Stockholders necessary to obtain the Required Stockholder Approval.
Company shall provide the Stockholders with such Disclosure Materials as shall be required by applicable Law. Company shall submit
to Parent the form of any written notice and other Disclosure Materials to be transmitted to the Stockholders pursuant to this
Section 5.9 prior to delivery thereof to the Stockholders. Company shall include in such Disclosure Materials such information
relating to the Parent and the Parent Shares as Parent may reasonably request in writing prior to such delivery in connection
with the potential issuance of Parent Shares pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director
and Officer Indemnification.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
a period of six (6) years from and after the Closing Date, Parent agrees to indemnify (including advancement of expenses) and
hold harmless, and shall cause the Surviving Company to indemnify (including advancement of expenses) and hold harmless, all past
and present officers and directors of Company to the same extent such persons are indemnified by Company as of the date of this
Agreement pursuant to Company&rsquo;s organizational documents, any applicable employment agreements and indemnification agreements
and to the fullest extent under applicable Law for acts or omissions which occurred at or prior to the Effective Time. The Surviving
Company&rsquo;s organizational documents shall contain provisions with respect to indemnification and exculpation that are at
least as favorable to the past and present officers and directors of Company as those provisions contained in Company Charter
and Company bylaws in effect on the date hereof, and such provisions shall not be amended, repealed or otherwise modified for
a period of six (6) years in any manner that would adversely affect the rights of the past and present officers and directors
of Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent
or the Surviving Company shall maintain in effect for a period of six (6) years from and after the Effective Time, an officers&rsquo;
and directors&rsquo; liability insurance policy and a fiduciary liability policy with respect to acts or omissions occurring at
or prior to the Effective Time covering each past and present officer and member of the Company Board who is currently covered
by Company&rsquo;s officers&rsquo; and directors&rsquo; liability insurance policy. The cost of obtaining such &ldquo;tail&rdquo;
insurance policies shall be paid by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Parent, the Surviving Company or any of Parent&rsquo;s or Surviving Company&rsquo;s successors or assigns (i) consolidates with
or merges into any other person and shall not be the continuing or surviving corporation or entity of such consolidation or merger
or (ii) transfers or conveys all or substantially all of its properties and assets to any person, then, and in each such case,
to the extent necessary, proper provision shall be made so that the successors and assigns of Parent or the Surviving Company,
as the case may be, shall assume the obligations set forth in this Section 5.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
provisions of this Section 5.10 are intended for the benefit of, and shall be enforceable by, all past and present officers and
directors of Company and his or her heirs and representatives. The rights of all past and present officers and directors of Company
under this Section 5.10 are in addition to, and not in substitution for, any other rights to indemnification or contribution that
any such person may have by contract, applicable Law or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Closing
Conditions</B>. From the date hereof until the Closing, each party hereto shall use reasonable best efforts to take such actions
as are necessary to expeditiously satisfy the closing conditions set forth in Article 2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intellectual
Property Registrations. </B>Prior to Closing, the Company will direct its current intellectual property counsel to forward all
correspondence regarding Intellectual Property Registrations to Parent&rsquo;s intellectual property counsel, Sheridan Ross P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further
Assurances</B>. Following the Closing, each of the parties hereto shall, and shall cause their respective Affiliates to, execute
and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably
required to carry out the provisions hereof and give effect to the Mergers or any other acts or transactions contemplated by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintenance
and Prosecution of Company Intellectual Property</B>. During the period between the Effective Time and the Earnout Termination
Date, Parent shall, at its own cost and expense, maintain all Company Intellectual Property in effect as of the date hereof and
subject to protection under the Laws of the United States, including but not limited to paying any applicable filing fees, and
shall prosecute any United States Patent Applications included in the Company Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with Laws</B>. From and after the Closing, Parent will be in material compliance with all Healthcare Laws applicable to Parent
and its products, including without limitation the Products (collectively, the &ldquo;<B>Seller Products</B>&rdquo;). The design,
manufacture, testing, and distribution of the Seller Products by or on behalf of Parent will be conducted in material compliance
with all applicable Healthcare Laws. Parent will be in material compliance with FDA&rsquo;s establishment registration and product
listing requirements to the extent required by applicable Healthcare Laws. Parent will hold such Permits of the applicable government
or government agencies required for the conduct of its business as will be conducted, including, without limitation, those Permits
necessary based on the scope of its activities to permit such activities related to the design, development, pre-clinical and
clinical testing, manufacture, labeling, sale, shipment, distribution and promotion of products in jurisdictions where it will
conduct such activities with respect to each Seller Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
6.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B><U>TERMINATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination</B>.
This Agreement may be terminated at any time prior to the Closing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
the mutual written consent of Company and Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
Parent by written notice to Company if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent
is not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in or failure to perform
any representation, warranty, covenant or agreement made by Company pursuant to this Agreement that would give rise to the failure
of any of the conditions specified in Section 2.2(a) or (b) and such breach, inaccuracy or failure has not been cured by Company
within twenty-one (21) days of Company&rsquo;s receipt of written notice of such breach from Parent; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
of the conditions set forth in Section 2.2 shall not have been, or if it becomes apparent that any of such conditions will not
be, fulfilled by May 31, 2017, unless such failure shall be due to the failure of Parent to perform or comply with any of the
covenants, agreements or conditions hereof to be performed or complied with by it prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
Company by written notice to Parent if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
is not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in or failure to perform
any representation, warranty, covenant or agreement made by Parent or Merger Sub pursuant to this Agreement that would give rise
to the failure of any of the conditions specified in Section 2.3(a) or (b) and such breach, inaccuracy or failure has not been
cured by Parent within twenty-one (21) days of Parent&rsquo;s receipt of written notice of such breach from Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
of the conditions set forth in Section 2.3 shall not have been, or if it becomes apparent that any of such conditions will not
be, fulfilled by May 31, 2017, unless such failure shall be due to the failure of Company to perform or comply with any of the
covenants, agreements or conditions hereof to be performed or complied with by it prior to the Closing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by
Parent or Company by written notice to the other party in the event that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall be any Law that makes consummation of the transactions contemplated by this Agreement illegal or otherwise prohibited;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
Governmental Authority shall have issued a Governmental Order restraining or enjoining the transactions contemplated by this Agreement,
and such Governmental Order shall have become final and non-appealable; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
of the conditions set forth in Section 2.1 shall not have been, or if it becomes apparent that any of such conditions will not
be, fulfilled by May 31, 2017, unless such failure shall be due to the failure of the notifying party to perform or comply with
any of the covenants, agreements or conditions hereof to be performed or complied with by it prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The party desiring to terminate
this Agreement pursuant to this Section 6.1 (other than pursuant to Section 6.1(a)) shall give a notice of such termination to
the other party setting forth a brief description of the basis on which such party is terminating this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect
of Termination</B>. In the event of the termination of this Agreement in accordance with this Article 6, this Agreement shall
forthwith become void and there shall be no liability on the part of any party hereto except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as
set forth in this Article 6 (Termination), and Section 5.7 (Confidentiality) and Article 10 (Miscellaneous) hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
nothing herein shall relieve any party hereto from liability for any willful breach of any provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
7.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B><U>OTHER COVENANTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival</B>.
The representations and warranties contained in Article 3 and Article 4 shall survive the Closing for twelve months. The indemnity
contained in Section 7.2(a)(iv) shall survive until the expiration of the applicable statute of limitations plus sixty (60) days.
All other covenants and agreements of the parties contained herein shall survive the Closing indefinitely or for the period explicitly
specified therein. The period ending on each such termination date described in this Section 7.1 is referred to as the &ldquo;<B>Survival
Period</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification
of Parent.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
and after the Closing (but subject to the terms and conditions of this Article 7), each Company Securityholder, based upon and
limited to each such Company Securityholder&rsquo;s Distribution Allocation, shall, in each case, severally but not jointly, indemnify
and hold the Parent Indemnitees (as defined below) harmless from and against any and all losses, liabilities, claims, suits, actions,
obligations, deficiencies, demands, awards, judgments, damages, interest, fines, penalties, costs and expenses (including reasonable
costs of investigation and defense and reasonable attorneys&rsquo; and other professionals&rsquo; reasonable fees and expenses)
whether or not involving a Third Party Claim, but specifically excluding consequential, special, incidental, indirect, exemplary
or punitive damages (including diminution of value, loss of future revenue, lost profits or lost business opportunity as consequential
or indirect damages) except to the extent actually awarded in a Third Party Claim (hereinafter individually a &ldquo;<B>Loss</B>&rdquo;
and collectively &ldquo;<B>Losses</B>&rdquo;) suffered or incurred by Parent, its Affiliates or any of their respective officers,
directors, managers, employees, stockholders, members, partners, agents, representatives or successors and assigns (the &ldquo;<B>Parent
Indemnitees</B>&rdquo;) attributable to, or arising or resulting from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
fraud of Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
fraud of any Company Securityholder (but each Company Securityholder&rsquo;s liability shall be limited to Losses caused by its
own fraud);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
breach of any covenant of Company contained in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
proceeding in respect of any Dissenting Shares and any payments required to be made by Parent or the Surviving Company to any
Person that was a holder of Company Stock immediately prior to the Effective Time in respect of such Person&rsquo;s Dissenting
Shares, to the extent that such payments exceed the portion of the final Aggregate Merger Consideration to which such Person would
have been entitled pursuant to this Agreement in respect of such Dissenting Shares if such Person had not exercised appraisal
or dissenting rights in respect thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
Pre-Closing Tax Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
parties hereto acknowledge and agree that the Representative (solely in its capacity as the Representative) is a party to this
Agreement solely to perform certain administrative functions in connection with the consummation of the transactions contemplated
hereby. Accordingly, the parties hereto acknowledge and agree that other than any liability which any Company Securityholder may
have hereunder, Representative shall have no additional liability to, and shall not be liable for any Losses of, any party hereto
or to any Parent Indemnitee in connection with any obligations of the Representative under this Agreement or otherwise in respect
of this Agreement or the transactions contemplated hereby, except to the extent such Losses are a result of gross negligence or
willful misconduct by the Representative in connection with the performance of its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Losses
that may be recovered pursuant to Section 7.2 shall take account of and be reduced by (i) any amounts recovered by the Parent
Indemnitees or the Surviving Company pursuant to any indemnification by or indemnification agreement with any third party, (ii)
any refund, credit or reduction in Tax realized by such Parent Indemnitees or their Affiliates arising from the incurrence or
payment of such indemnifiable Losses (based upon the maximum marginal federal, state or local tax rate applicable to such Persons),
and (iii) the amount of any insurance proceeds, contribution payments or reimbursements actually received or receivable by the
Parent Indemnitees in respect thereof (each Person named and source identified in clauses (i) through (iii), a &ldquo;<B>Collateral
Source</B>&rdquo;). The Parent Indemnitees shall use commercially reasonable efforts to seek recovery from all Collateral Sources;
<I>it being understood that</I> the reasonable costs and expenses of exercising such efforts shall be deemed Losses. If the amount
to be netted hereunder from any payment required under Section 7.2 is determined after payment the set off of any Earnout Payment
of any amount otherwise required to be paid to a Parent Indemnitee under this Article 7, the Parent Indemnitees shall repay to
the Company Securityholders, promptly after such determination, any amount that the Company Securityholders would not have had
to pay pursuant to this Section 7.2(c) had such determination been made at the time of such payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amounts
payable by any Company Securityholder to Parent pursuant to this Section 7.2 shall, to the extent reasonably practicable, be satisfied
by returning to Parent an amount of Parent Shares equal to (x) the dollar value of such Company Securityholder&rsquo;s indemnification
obligation under this Section 7.2 divided by (y) the dollar value per Parent Share used to determine the amount of Parent Shares
to be issued to such Company Securityholder pursuant to this Agreement, determined as if the Parent Shares having the highest
dollar value per Parent Share were returned first. Notwithstanding anything to the contrary contained herein, in no event shall
any Company Securityholder be liable under 7.2(a)(iv) for any amounts in excess of the consideration actually received by such
Company Securityholder hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
payments under this Section 7.2 shall be treated by the parties as an adjustment to the proceeds received by the Company Securityholders
pursuant to Article 1, to the extent permitted by applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification
of Company Securityholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
and after the Closing (but subject to the provisions of this Article 7), Parent shall indemnify and hold each Company Securityholder,
each Company Securityholder&rsquo;s Affiliates and each of their respective officers, directors, managers, employees, stockholders,
members, partners, agents, representatives, successors and assigns (the &ldquo;<B>Securityholder Indemnitees</B>&rdquo;) harmless
from and against, and pay to the applicable Securityholder Indemnitees the amount of, any and all Losses based upon, attributable
to or resulting from (a) the fraud, criminal activity, or intentional misconduct of the Parent or Merger Sub, (b) any breach of
any covenant of Parent or Merger Sub contained in this Agreement, including, without limitation, <U>Annex 1</U> hereof, and (c)
any design, sale, manufacture and any other activities primarily associated with Parent Products. All payments under this Section
7.3 shall be treated by the parties as an adjustment to the proceeds received by the Company Securityholders pursuant to Article
1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary set forth in this Agreement or otherwise, from and after the Closing (but subject to the terms and conditions
of this Article 7), any indemnification of the Securityholder Indemnitees for which the Parent is liable hereunder shall be paid
promptly to the Company Securityholders pursuant to the Distribution Schedule and any such payments shall be payable pursuant
to an allocation of 60% in cash and 40% in Parent Shares (valued at the average closing price of Parent Shares as reported on
OTC Markets (or such national or foreign securities exchange on which Parent&rsquo;s shares are listed) for the ten (10) trading
days immediately prior to the date of issuance), unless otherwise agreed by Parent and the Representative in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expiration
of Claims</B>. The ability of any Parent Indemnitee or Securityholder Indemnitee to receive indemnification pursuant to Section
7.2 or Section 7.3, respectively, shall terminate upon expiration of the applicable Survival Period (as set forth in Section 7.1),
unless such Parent Indemnitee or Securityholder Indemnitee, as applicable, has made, in good faith, a proper claim (as described
in Sections 7.5(a) and 7.6(a) below) for indemnification pursuant to Section 7.2 or Section 7.3, respectively, subject to the
terms and conditions of this Article 7, prior to such termination date, as applicable. If a Parent Indemnitee or an Securityholder
Indemnitee has made, in good faith, a proper claim for indemnification pursuant to Section 7.2 or Section 7.3, respectively, prior
to such termination date, then such claim, if then unresolved, shall not be extinguished by the passage of the deadlines set forth
in Section 7.1 (it being understood that any and all Losses arising after the expiration of the Survival Period shall be recoverable
(subject to the limitations set forth herein) only upon notice specifically with respect to such Losses properly given prior to
the expiration of the Survival Period in accordance with this Article 7).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inter-Party
Claims.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order for a Parent Indemnitee or Securityholder Indemnitee to be entitled to seek any indemnification provided for under this
Agreement (such party, the &ldquo;<B>Claiming Party</B>&rdquo;), such Claiming Party must notify the other party or parties from
whom such indemnification is sought (the &ldquo;<B>Defending Party</B>&rdquo;), in writing promptly after the Claiming Party becomes
aware of the occurrence of the event giving rise to such Claiming Party&rsquo;s claim for indemnification, specifying in reasonable
detail the basis and, if available, the amount of Loss with respect to, such claim (each, a &ldquo;<B>Demand</B>&rdquo;); provided,
that failure to give such notification shall not affect the indemnification provided hereunder except to the extent the Defending
Party is materially prejudiced as a result of such failure or the indemnification obligations are materially increased as a result
of such failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
receipt of a Demand by the Defending Party, such Defending Party shall have thirty (30) days (the &ldquo;<B>Indemnity Notice Period</B>&rdquo;),
to review and respond by written notice to such Demand (the &ldquo;<B>Return Notice</B>&rdquo;) to the Claiming Party. If the
Return Notice does not contest the Demand, or if no Return Notice is delivered to the Claiming Party by the expiration of the
Indemnity Notice Period, then, (i) with respect to a Demand made by Parent, payment shall be made in the order and priority set
forth in Section 7.2, and (ii) with respect to a Demand made by the Securityholder Indemnified Parties, payment shall be made
in accordance with Section 7.3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Return Notice given by the Defending Party disputes the claim or claims asserted in a Demand or the amount of Losses thereof
(a &ldquo;<B>Disputed Claim</B>&rdquo;), then the Claiming Party and the Defending Parties shall make a reasonable good faith
effort to resolve their differences for a period of thirty (30) days following the receipt by the Claiming Party of the Return
Notice asserting a Disputed Claim. If the Claiming Party and the Defending Party are unable to resolve the Disputed Claims through
negotiations prior to the expiration of such thirty (30) day period, such Disputed Claims shall, subject to the terms of this
Agreement, be resolved by litigation in an appropriate court of competent jurisdiction. The Claiming Party shall have the burden
of proof in establishing the amount of Losses it has suffered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
Party Claims.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order for a Claiming Party to seek any indemnification provided for under this Agreement in respect of a claim or demand made
by any third party Person against the Claiming Party (a &ldquo;<B>Third Party Claim</B>&rdquo;), such Claiming Party must notify
the Defending Party in writing, specifying in reasonable detail the basis and, if available, the amount of Losses with respect
to the Third Party Claim promptly after receipt by such Claiming Party of notice of the Third Party Claim (a &ldquo;<B>Notice
of Third Party Claim</B>&rdquo;); <I>provided</I> that failure to give such notification on a timely basis shall not affect the
indemnification provided hereunder except to the extent the Defending Party is materially prejudiced as a result of such failure
or the indemnification obligations are materially increased as a result of such failure. Such Notice of Third Party Claim shall
be accompanied by copies of all relevant documentation with respect to such Third Party Claim, including any summons, complaint
or other pleading that may have been served, any written demand or any other document or instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Third Party Claim is made against a Claiming Party, the Defending Party shall, at its expense, be entitled to participate in
the defense thereof and, if it so chooses, to assume the defense thereof with counsel selected by the Defending Party and reasonably
satisfactory to the Claiming Party (i) if within thirty (30) days of the receipt of the Notice of Third Party Claim, the Defending
Party gives notice to the Claiming Party stating the Defending Party&rsquo;s intention to do so and acknowledging that the Defending
Party shall indemnify the Claiming Party from and against all Losses (to the extent finally determined to be required by, and
subject to any applicable limits provided in, this Article 7), that the Claiming Party suffers from the Third Party Claim, or
(ii) if the Defending Party does not assume the defense of a Third Party Claim pursuant to clause (i) of this sentence, at any
time that the Defending Party reasonably believes that the Claiming Party has ceased to actively and diligently prosecute the
defense of such Third Party Claim. Should a Defending Party so elect to assume the defense of a Third Party Claim, the Defending
Party shall under no circumstances be liable to the Claiming Party for legal expenses subsequently incurred by the Claiming Party
in connection with the defense thereof; <I>provided</I>, that in the case that (A) there exists or is reasonably likely to exist
a conflict of interest that would make it unethical under applicable rules of professional responsibility for the same counsel
to represent both the Claiming Party and the Defending Party, (B) the Defending Party fails to actively and diligently prosecute
the defense of such Third Party Claim, (C) such Third Party Claim relates to or otherwise arises in connection with any criminal
or material regulatory enforcement action, or (D) such Third Party Claim is reasonably likely to result in an injunction or other
equitable relief against the Claiming Party or, in the reasonable discretion of the Claiming Party, result in a Loss in excess
of the dollar amount available for indemnification pursuant to this Article 7 (the scenarios described in clauses (A) &ndash;
(D) are collectively referred to as &ldquo;<B>Conflicts</B>&rdquo;), then the Defending Party shall be liable to the Claiming
Party for reasonable legal expenses of one legal counsel selected by the Claiming Party and reasonably satisfactory to the Defending
Party subsequently incurred by the Claiming Party in connection with the defense thereof (to the extent finally determined to
be required by, and subject to any applicable limits provided in this Article 7). If the Defending Party assumes such defense,
the Claiming Party shall have the right to participate in the defense thereof and to employ counsel, at its own expense, separate
from the counsel employed by the Defending Party, it being understood, however, that the Defending Party shall control such defense
so long as the Third Party Claim does not involve a Conflict, in which case the Claiming Party shall control such defense. If
the Defending Party chooses to defend any Third Party Claim, then all the parties shall cooperate in the defense or prosecution
of such Third Party Claim, including by retaining and, upon the Defending Party&rsquo;s request, providing to the Defending Party
all records and information which are reasonably relevant to such Third Party Claim, and making employees available on a mutually
convenient basis to provide additional information and explanation of any material provided hereunder. If the Defending Party
assumes the defense of any Third Party Claim, the Defending Party shall obtain the prior written consent of the Claiming Party
(which shall not be unreasonably conditioned, withheld or delayed) before entering into any settlement or consenting to the entry
of a judgment with respect to such claim unless such settlement or judgment (1) involves no finding or admission of any violation
of Law or the rights of any Person and has no effect on any other claims that may be made against the Claiming Party, and (2)
expressly and unconditionally provides a full and general release of the Claiming Party from all liabilities and obligations with
respect to such claim. If the Claiming Party assumes the defense of any Third Party Claim, then the Claiming Party shall obtain
the prior written consent of the Defending Party (which shall not be unreasonably conditioned, withheld or delayed) before entering
into any settlement or consenting to the entry of a judgment with respect to such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Solely for purposes of calculating indemnifiable
Losses hereunder (but not for purposes of determining whether a breach of any representation, warranty, covenant or agreement
has occurred), any materiality or Material Adverse Effect qualifications in the representations, warranties, covenants and agreements
shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation</B>.
Each of the parties understands, acknowledges and agrees that this Article 7 shall be the sole and exclusive remedy for claims
made after the Effective Time with respect to the subject matter of this Agreement or the transactions contemplated hereby, and
that the parties hereto shall have no other remedy or recourse with respect to any such claims other than pursuant to, and subject
to the terms and conditions of, this Article 7, except for claims of or arising out of fraud, in which case each Company Securityholder
shall be liable on a several but not joint basis for its pro rata portion of its Distribution Allocation of such losses in an
aggregate amount not to exceed such Company Securityholder&rsquo;s Distribution Allocation of the Aggregate Merger Consideration
actually paid and/or issued or otherwise deemed earned under the terms of this Agreement. The parties hereto acknowledge and agree
that no party hereto may avoid such limitation on liability by (x) seeking damages for breach of contract, tort or pursuant to
any other theory of liability, all of which are hereby waived or (y) asserting or threatening any claim against any Person (other
than a Company Securityholder in a claim pursuant to Article 7) that is not a party (or a successor to a party) for breaches of
the representations, warranties and covenants contained in this Agreement. PARENT, ON BEHALF OF ITSELF AND EACH OF THE PARENT
INDEMNITEES EXPRESSLY WAIVES ALL RIGHTS AFFORDED BY ANY STATUTE WHICH LIMITS THE EFFECT OF A RELEASE WITH RESPECT TO UNKNOWN CLAIMS.
EACH OF THE PARENT INDEMNITEES UNDERSTANDS THE SIGNIFICANCE OF THIS RELEASE OF UNKNOWN CLAIMS AND WAIVER OF STATUTORY PROTECTION
AGAINST A RELEASE OF UNKNOWN CLAIMS. EACH PARENT INDEMNITEE ACKNOWLEDGES AND AGREES THAT THIS WAIVER IS AN ESSENTIAL AND MATERIAL
TERM OF THIS AGREEMENT. Notwithstanding anything to the contrary in this Agreement, no term or provision of this Agreement shall
limit any potential claims or remedies based on fraud and nothing herein shall limit any claim that a Company Securityholder may
have as a stockholder of Parent whether or not the Company Securityholder&rsquo;s status as a stockholder of Parent arose out
of the receipt of the Parent Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax
Matters.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Responsibility
for Filing Tax Returns</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent
shall prepare or cause to be prepared and timely file or cause to be timely filed all Tax Returns for the Company and the Surviving
Company that have not yet been filed as of the Closing Date, in a manner consistent with past practice, except as otherwise required
by applicable Law. Parent shall deliver to Representative all income Tax Returns for any Pre-Closing Tax Periods (including Tax
Returns for Straddle Periods) that are to be filed after the Closing Date for review and comment no less than fifteen (15) days
before the applicable due date. Except to the extent that an amendment or election would not result in an increase in liabilities
for a Pre-Closing Tax Period, Parent shall not, without the Representative&rsquo;s prior written consent, cause or permit the
Surviving Company to (i) amend any Tax Return that relates in whole or in part to any Pre-Closing Tax Period or (ii) make any
election that has retroactive effect to any Pre-Closing Tax Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
to the extent that such refund is attributable to the carryback of a Tax attribute attributable to a Post-Closing Tax Period,
the Company Securityholders shall be entitled to any Tax refunds that are received by Parent or the Surviving Company, and any
amounts credited against Taxes to which Parent or the Surviving Company become entitled in any Post-Closing Tax Period of Company,
that relate to any Pre-Closing Tax Period, including Taxes paid with respect to a Pre-Closing Tax Period of Company. Parent shall
pay or cause to be paid over to the Company Securityholders (in accordance with each Company Securityholder&rsquo;s Distribution
Allocation) any such refund or the amount of any such credit within twenty (20) days after receipt of such refund or after becoming
entitled to such credit against Taxes. Any payment under this Section 7.8(a) shall be considered a purchase price adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Cooperation</B>.
The parties shall reasonably cooperate with each other to provide each other with such assistance as may be reasonably requested
by them in connection with the preparation of any Tax Returns, any Tax audit or other examination in connection with an administrative
or judicial proceeding involving a taxing authority relating to Taxes, and the enforcement of the provisions of this Section 7.8(b).
Such cooperation shall include, including upon Representative&rsquo;s request, providing records and information that are reasonably
relevant to any such matters and making employees available on a mutually convenient basis to provide additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Transfer
Taxes</B>. Parent, on the one hand, and the Company Securityholders, on the other hand, will each pay fifty percent (50%) of any
real property transfer or gains tax, stamp tax, stock transfer tax, or other similar Tax imposed on the Surviving Company or any
Company Securityholder as a result of the transactions contemplated by this Agreement (collectively, &ldquo;<B>Transfer Taxes</B>&rdquo;),
and any penalties or interest with respect to the Transfer Taxes. Parent shall file all necessary Tax Returns and other documentation
with respect to Transfer Taxes (except to the extent such Tax Returns are required by Law to be filed by a Company Securityholder),
and Representative agrees to cooperate with Parent in the filing of any such Tax Returns, including promptly supplying any information
in its possession that is reasonably necessary to complete such returns. Each party shall use commercially reasonable efforts
to minimize any applicable Transfer Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Reorganization</B>.
Each of Company and Parent will report the Mergers as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the
Code. Neither Company nor Parent shall take or cause to be taken any action that could prevent the Mergers from qualifying as
a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Code, including by paying or issuing any consideration
pursuant to this Agreement that would result in the aggregate consideration paid in Parent Shares pursuant to this Agreement,
including pursuant to Annex 1, being less than forty percent (40%) by value of the overall aggregate consideration paid pursuant
to this Agreement (provided that the value of any Parent Shares shall be determined solely for this purpose as the average of
the high and low trading values of Parent Shares for the day immediately before the date on which the applicable portion of such
aggregate consideration is issued or paid).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax
Covenants of Parent and Second Merger Sub.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent,
either directly or through a member of Parent&rsquo;s &ldquo;qualified group&rdquo; within the meaning of Treasury Regulations
Section 1.368-1(d)(4)(ii) (the &ldquo;<B>Qualified Group</B>&rdquo;), will continue at least one significant historic business
line of Company, or use at least a significant portion of the historic business assets of Company in a business, in each case
within the meaning of Treasury Regulations Section 1.368-1(d), except that the historic business assets of Company may be transferred
(i) to a corporation that is another member of Parent&rsquo;s Qualified Group, or (ii) to an entity subject to federal income
Tax as a partnership if (A) one or more members of Parent&rsquo;s Qualified Group have active and substantial management functions
as a partner with respect to such historic business or historic business assets of Company, or (B) members of Parent&rsquo;s Qualified
Group in the aggregate own an interest in the partnership representing a significant interest in the historic business or historic
business assets of Company, in each case within the meaning of Treasury Regulations Section 1.368-1(d)(4)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Mergers, Parent will not reacquire, and will not permit any Person that is a &ldquo;related person&rdquo;
(as defined in Treasury Regulations Section 1.368-1(e)(4)) to Parent to acquire, any Parent Shares issued in connection with the
Mergers, in exchange for any consideration other than Parent Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent
will not sell or otherwise dispose, and will not cause or permit Surviving Company or any of Parent&rsquo;s other Affiliates to
sell or otherwise dispose, of any of the assets of Company acquired in the Mergers, except for dispositions made in the ordinary
course of business or transfers described in Section 368(a)(2)(C) of the Code or described and permitted in Treasury Regulations
Section 1.368-2(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 7.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further
Assurances</B>. From time to time, as and when requested by any party and at such requesting party&rsquo;s expense, any other
party shall execute and deliver, or cause to be executed and delivered, all such documents and instruments and shall take, or
cause to be taken, all such further or other actions as the requesting party may reasonably deem necessary or desirable to evidence
and effectuate the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
8.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B><U>REPRESENTATIVE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representative.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective
upon and by virtue of the Required Stockholder Approval and his, her or its acceptance of the consideration payable under the
terms and conditions of this Agreement, and without any further act of any of the Company Securityholders, each Company Securityholder
hereby appoints the Representative as his, her or its attorney-in-fact and agent for and on behalf of such Company Securityholder
for purposes of this Agreement and any other agreements and documents executed or delivered in connection with this Agreement.
The Representative shall take such actions to be taken by the Representative under this Agreement and any other agreements and
documents executed or delivered in connection with this Agreement and such other actions on behalf of such Company Securityholder
as it may deem necessary or appropriate in connection with or to consummate the transactions contemplated hereby or thereby, including,
without limitation, (i) accepting service of process on the Company Securityholders, (ii) executing and delivering this Agreement,
and any other ancillary documents and negotiating and executing such amendments, modifications, waivers or changes thereto as
to which the Representative, in its sole discretion, shall have consented (provided that any waiver or amendment that shall adversely
and disproportionately affect the rights or obligations of any Company Securityholder as compared to other Company Securityholders
shall require the prior written consent of such Company Securityholder), (iii) receiving or providing notices on behalf of the
Company Securityholders with respect to any matter or Actions arising out of or relating to this Agreement, or the transactions
contemplated hereby, (iv) taking all actions and making all filings on behalf of such Company Securityholders with any Governmental
Authority or other Person necessary to effect the consummation of the transactions contemplated by this Agreement, (v) agreeing
to, negotiating, entering into settlements and compromises of, complying with orders of courts with respect to, and otherwise
administering and handling any claims under this Agreement on behalf of such Company Securityholders, (vi) interpreting all terms
of this Agreement; (vii) instituting, prosecuting and/or defending lawsuits; (viii) in connection with any of the foregoing actions,
engaging and hiring accountants, auditors, appraisers, legal counsel and other legal and financial experts as may be necessary
and appropriate properly to discharge the Representative&rsquo;s duties and obligations hereunder and (ix) taking all other actions
that are either necessary or appropriate in the judgment of the Representative for the accomplishment of the foregoing or contemplated
by the terms of this Agreement. The Representative hereby accepts such appointment. The appointment of the Representative as each
Company Securityholder&rsquo;s attorney-in-fact revokes any power of attorney heretofore granted that authorized any other Person
to represent such Company Securityholder with regard to this Agreement and any other agreements or documents executed or delivered
in connection with this Agreement. The Representative is the sole and exclusive representative of each of the Company Securityholders
for any purpose provided for by this Agreement. Representative shall be bound by the same confidentiality restrictions binding
Company pursuant to Section 5.7 provided, however, that the Representative shall use commercially reasonable efforts based on
contact information available to the Representative to keep the Company Securityholders reasonably informed with respect to actions
of Representative pursuant to the authority granted Representative under this Agreement which actions have a material impact on
the amounts payable to the Company Securityholders. Each Company Securityholder shall promptly provide written notice to the Representative
of any change of address of such Company Securityholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
decision, act, consent or instruction of the Representative hereunder shall constitute a decision, act, consent or instruction
of all Company Securityholders and shall be final, binding and conclusive upon each such Company Securityholder, and Parent and
the Surviving Company may rely upon any such decision, act, consent or instruction of the Representative as being the decision,
act, consent or instruction of each and every such Company Securityholder. Parent, the Surviving Company shall be relieved from
any liability to any Person for any acts done by them in accordance with such decision, act, consent or instruction of the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
Company Securityholders have entered into a letter agreement with the Representative to provide direction to the Representative
in connection with the performance of its services under this Agreement (such Company Securityholders, included their individual
representatives, hereinafter referred to as the &ldquo;<B>Advisory Group</B>&rdquo;). Neither the Representative and its members,
managers, directors, officers, contractors, agents and employees) nor any member of the Advisory Group (collectively, the &ldquo;<B>Representative
Group</B>&rdquo;) shall incur liability with respect to any action taken or suffered by any Company Securityholder in reliance
upon any notice, direction, instruction, consent, statement or other document believed by such Representative to be genuine and
to have been signed by such Company Securityholder (and shall have no responsibility to determine the authenticity thereof), nor
for any other action or inaction, except the gross negligence, bad faith or willful misconduct of the Representative Group. In
all questions arising under this Agreement, the Representative may rely on the advice of outside counsel, and the Representative
shall not be liable to any Company Securityholder for anything done, omitted or suffered in good faith by Representative based
on such advice. No provision of this Agreement shall require the Representative to expend or risk its own funds or otherwise incur
any financial liability in the exercise or performance of any of its powers, rights, duties or privileges under this Agreement
on behalf of any Company Securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Company Securityholder shall severally, but not jointly (based on such Company Securityholder&rsquo;s Distribution Allocation),
indemnify the Representative Group and hold the Representative Group harmless against any loss, liability or expense incurred
without gross negligence, bad faith or willful misconduct on the part of the Representative Group and arising out of or in connection
with the acceptance or administration of the Representative&rsquo;s duties hereunder, including the reasonable fees and expenses
of any legal counsel or other advisors reasonably retained by the Representative. Notwithstanding the foregoing, the Representative&rsquo;s
standard hourly rates and all out-of-pocket fees and expenses incurred by the Representative in performing its duties shall be
borne by the Company Securityholders paid in accordance with their respective Distribution Allocations of such fees and expenses
out of any Earnout Payment otherwise distributable to the Company Securityholders, and, thereafter, directly from the Company
Securityholders, in accordance with their respective Distribution Allocations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time Stockholders representing at least a majority of the equity securities of the Company outstanding immediately prior to
the Effective Time may, by written consent, appoint another Person as Representative. Notice together with a copy of the written
consent appointing such Person and bearing the signatures of such Stockholders must be delivered to Parent not less than ten (10)
days prior to such appointment. Such appointment shall be effective upon the later of the date indicated in the consent or the
date ten (10) days after such consent is received by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that the Representative becomes unable or unwilling to continue in his or its capacity as the Representative, or if
the Representative resigns as a Representative, Stockholders representing at least a majority of the equity securities of the
Company outstanding immediately prior to the Effective Time may, by written consent, appoint a new representative as the Representative.
Notice and a copy of the written consent appointing such new representative and bearing the signatures of such Stockholders must
be delivered to Parent. Such appointment shall be effective upon the later of the date indicated in the consent or the date ten
(10) days after such consent is received by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
immunities and rights to indemnification shall survive the resignation or removal of Representative or any member of the Advisory
Group and the Closing and/or any termination of this Agreement. The Representative shall be entitled to: (i) rely upon the Distribution
Schedule, (ii) rely upon any signature believed by it to be genuine, and (iii) reasonably assume that a signatory has proper authorization
to sign on behalf of the applicable Company Securityholder or other party. The grant of authority provided for herein (A) is coupled
with an interest and shall be irrevocable and survive the death, incompetency, bankruptcy or liquidation of any Company Securityholder,
(B) shall survive the delivery of an assignment by any Company Securityholder of the whole or any fraction of his, her or its
interest in any post-Closing consideration and (C) shall survive the consummation of the Mergers. The provisions of this Section
8.1 shall be binding upon the executors, heirs, legal representatives, successors and assigns of each Company Securityholder,
and any references in this Agreement to any Company Securityholder or the Company Securityholders shall mean and include the successors
to such Company Securityholder&rsquo;s rights hereunder, whether pursuant to testamentary disposition, the laws of descent and
distribution or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
9.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B><U>DEFINITIONS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
Defined Terms</B>. The following terms have the meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Action</B>&rdquo;
means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation,
citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether
at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by,
or is under common control with, such Person. The term &ldquo;control&rdquo; (including the terms &ldquo;controlled by&rdquo;
and &ldquo;under common control with&rdquo;) means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agents</B>&rdquo;
means, with respect to any Person, any and all directors, officers, employees, consultants, financial advisors, counsel, accountants
and other agents of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Aggregate Merger
Consideration</B>&rdquo; means, collectively, the rights of the Company Securityholders to receive (i) the Closing Merger Consideration,
(ii) the Earnout Payments, if any, and (iii) any amounts payable under Sections 7.3 and 7.8(a)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
means any day except Saturday, Sunday or any other day on which commercial banks located in New York, New York are authorized
or required by Law to be closed for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Cash on Hand</B>&rdquo;
means, with respect to Company, as of the close of business on the Closing Date all unrestricted cash, cash equivalents and freely
marketable securities but not including any restricted cash (including all cash posted to support letters of credit, performance
bonds or other similar obligations or deposits with third parties, including landlords), in each case determined in accordance
with GAAP and expressed in United States dollars. For the avoidance of doubt, Cash on Hand shall be calculated net of issued but
uncleared checks and drafts and shall include checks, other wire transfers and drafts deposited or available for deposit for the
account of Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>CERCLA</B>&rdquo;
means the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended by the Superfund Amendments
and Reauthorization Act of 1986, 42 U.S.C. &sect;&sect; 9601 et seq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing Merger
Consideration</B>&rdquo; means an amount equal to 2,500,000 Parent Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Code</B>&rdquo;
means the Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company Charter</B>&rdquo;
means the Amended and Restated Certificate of Incorporation of Company, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company Common
Stock</B>&rdquo; means Company&rsquo;s Common Stock, par value $0.001 share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company Disclosure
Schedules</B>&rdquo; means the Company Disclosure Schedules delivered by Company to Parent concurrently with the execution and
delivery of this Agreement as modified by any Disclosure Updates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company Preferred
Stock</B>&rdquo; means the Company&rsquo;s Series A Preferred Stock and the Company&rsquo;s Series A-1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company Securityholders</B>&rdquo;
means collectively, the holders of Preferred Stock and Convertible Debt of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company Stock</B>&rdquo;
means Company Preferred Stock and Company Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company&rsquo;s
Knowledge</B>&rdquo; or &ldquo;<B>Knowledge of Company</B>&rdquo; or any other similar knowledge qualification, means the actual
knowledge of Earl Bright and Karen Long.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Contracts</B>&rdquo;
means all contracts, leases, deeds, mortgages, licenses, instruments, notes, commitments, undertakings, indentures, joint ventures
and all other agreements, commitments and legally binding arrangements, whether written or oral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Convertible
Debt</B>&rdquo; means those certain Secured Convertible Promissory Notes issued pursuant to that certain Note Purchase Agreement
dated March 30, 2016, as well as that certain Convertible Promissory Note dated as of September 27, 2012 issued to ExploraMed
NC6, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company Creditor</B>&rdquo;
shall mean ExploraMed NC6, LLC and Torreya Capital Partners, each as related to the Unpaid Contractual Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Dataroom</B>&rdquo;
means the electronic dataroom hosted by SecureDocs.com at <U>https://nuelle.securedocs.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disclosure Materials</B>&rdquo;
means the documents, materials and notices prepared or to be prepared by Company pursuant to the DGCL or otherwise in connection
with obtaining the approval by the Stockholders of this Agreement and the Merger or notifying any Company Securityholders of the
approval of the Agreement and the Merger and the availability of appraisal rights under the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Distribution
Allocation</B>&rdquo; means the allocation of Parent Shares or cash a Company Securityholder will receive at Closing or as part
of an Earnout Payment pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Dollars or $</B>&rdquo;
means the lawful currency of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Earnout Payments</B>&rdquo;
means any amounts payable to Company Securityholders pursuant to <U>Annex 1</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Earnout Termination
Date</B>&rdquo; means the last date on which any Earnout Payments may become due and payable to the Company Securityholders in
accordance with <U>Annex 1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Encumbrance</B>&rdquo;
means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option,
security interest, mortgage, easement, encroachment, right of way, right of first refusal, or restriction of any kind, including
any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Environmental
Claim</B>&rdquo; means any Action, Governmental Order, lien, fine, penalty, or, as to each, any settlement or judgment arising
therefrom, by or from any Person alleging liability of whatever kind or nature (including liability or responsibility for the
costs of enforcement proceedings, investigations, cleanup, governmental response, removal or remediation, natural resources damages,
property damages, personal injuries, medical monitoring, penalties, contribution, indemnification and injunctive relief) arising
out of, based on or resulting from: (a) the presence, Release of, or exposure to, any Hazardous Materials; or (b) any actual or
alleged non-compliance with any Environmental Law or term or condition of any Environmental Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Environmental
Law</B>&rdquo; means any applicable Law, and any Governmental Order or binding agreement with any Governmental Authority: (a)
relating to pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, human
health or safety, or the environment (including ambient air, soil, surface water or groundwater, or subsurface strata); or (b)
concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse,
treatment, generation, discharge, transportation, processing, production, disposal or remediation of any Hazardous Materials.
The term &ldquo;<B>Environmental Law</B>&rdquo; includes, without limitation, the following (including their implementing regulations
and any state analogs): the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended by the Superfund
Amendments and Reauthorization Act of 1986, 42 U.S.C. &sect;&sect; 9601 et seq.; the Solid Waste Disposal Act, as amended by the
Resource Conservation and Recovery Act of 1976, as amended by the Hazardous and Solid Waste Amendments of 1984, 42 U.S.C. &sect;&sect;
6901 et seq.; the Federal Water Pollution Control Act of 1972, as amended by the Clean Water Act of 1977, 33 U.S.C. &sect;&sect;
1251 et seq.; the Toxic Substances Control Act of 1976, as amended, 15 U.S.C. &sect;&sect; 2601 et seq.; the Emergency Planning
and Community Right-to-Know Act of 1986, 42 U.S.C. &sect;&sect; 11001 et seq.; the Clean Air Act of 1966, as amended by the Clean
Air Act Amendments of 1990, 42 U.S.C. &sect;&sect; 7401 et seq.; and the Occupational Safety and Health Act of 1970, as amended,
29 U.S.C. &sect;&sect; 651 et seq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Environmental
Notice</B>&rdquo; means any written directive, notice of violation or infraction, or notice respecting any Environmental Claim
relating to actual or alleged non-compliance with any Environmental Law or any term or condition of any Environmental Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Environmental
Permit</B>&rdquo; means any Permit, letter, clearance, consent, waiver, closure, exemption, decision or other action required
under or issued, granted, given, authorized by or made pursuant to Environmental Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ERISA</B>&rdquo;
means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ERISA Affiliate</B>&rdquo;
means, with respect to any Person, any other Person that, together with such first Person, would be treated as a single employer
within the meaning of Section 414(b), (c), (m) or (o) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange Act</B>&rdquo;
means the Securities Exchange Act of 1934, as amended, or any successor federal statute thereto and the rules and regulations
of the SEC promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded Contracts</B>&rdquo;
means (i) non-exclusive Contracts concerning &ldquo;off-the-shelf&rdquo; or similar software that is available on commercially
reasonable terms, (ii) standard non-disclosure, confidentiality and material transfer Contracts, in each case entered into in
the ordinary course of business, (iii) Contracts that have expired on their own terms or were terminated, and (iv) purchase orders
and associated terms and conditions for which the underlying goods or services have been delivered or received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GAAP</B>&rdquo;
means, with respect to any Person, United States generally accepted accounting principles in effect from time to time, as consistently
applied by such Person across its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental
Authority</B>&rdquo; means any federal, state, local or foreign government or political subdivision thereof, or any agency or
instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory
authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority
have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental
Order</B>&rdquo; means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any
Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Hazardous Materials</B>&rdquo;
means: (a) any material, substance, chemical, waste, product, derivative, compound, mixture, solid, liquid, mineral or gas, in
each case, whether naturally occurring or manmade, that is hazardous, acutely hazardous, toxic, infectious, or words of similar
import or regulatory effect under Environmental Laws; and (b) any petroleum or petroleum-derived products, radioactive materials
or wastes, asbestos in any form, lead or lead-containing materials, urea formaldehyde foam insulation, and polychlorinated biphenyls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Healthcare Laws</B>&rdquo;
means, to the extent related to the conduct of a Person&rsquo;s business as of the date hereof, Federal, state, and foreign Laws
in jurisdictions where such Person operates relating to health care products and services, including (each as amended from time
to time): the FDCA, Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act), the
federal Anti-Kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), the Stark Anti-Self-Referral Law (42 U.S.C. &sect;&sect; 1395nn),
the Anti-Inducement Law (42 U.S.C. &sect; 1320a-7a(a)(5)), the civil False Claims Act (31 U.S.C. &sect;&sect; 3729 et seq.), the
administrative False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), the Health Insurance Portability and Accountability Act of 1996
(42 U.S.C. &sect; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C.
&sect;&sect; 17921 et seq.) and the exclusion laws (42 U.S.C. &sect; 1320a-7), the Affordable Care Act (Public Law 111-148), all
regulations or guidance promulgated pursuant to such Laws, and any other federal, or state Law that regulates the design, development,
testing, studying, manufacturing, processing, storing, importing or exporting, licensing, labeling or packaging, advertising,
distributing or marketing of medical device products, or that is related to kickbacks, patient or program charges, recordkeeping,
claims process, documentation requirements, medical necessity, referrals, the hiring of employees or acquisition of services or
supplies from those who have been excluded from government health care programs, quality, safety, privacy, security, licensure,
accreditation or any other aspect of providing health care services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indebtedness</B>&rdquo;
means, with respect to any Person, without duplication: (a) the principal, accreted value, accrued and unpaid interest, fees and
prepayment premiums or penalties, unpaid fees or expenses and other monetary obligations in respect of (i) indebtedness of such
Person for borrowed money and (ii) indebtedness evidenced by notes, debentures, bonds, or other similar instruments for the payment
of which such Person is liable; (b) all obligations of such Person for the reimbursement of any obligor on any letter of credit,
banker&rsquo;s acceptance or similar credit transaction; (c) all obligations of such Person under capital leases; and (d) all
obligations of the type referred to in clauses (a) through (c) of any Persons for the payment of which such Person is responsible
or liable as obligor, guarantor or surety, including guarantees of such obligations (but solely to the extent of such responsibility
or liability).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Law</B>&rdquo;
means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement
or rule of law of any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Liability</B>&rdquo;
means, with respect to any Person, any liability or obligation of that Person of any kind, character or description, whether known
or unknown, absolute or contingent, accrued or unaccrued, asserted or unasserted, disputed or undisputed, liquidated or unliquidated,
secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Material Adverse
Effect</B>&rdquo; means, with respect to a party, any change, effect, event, occurrence or development, which individually or
in the aggregate, with all other changes, effects, events and developments, that has or would reasonably expected to have a material
adverse effect (a) on the ability of Company to consummate the transactions contemplated by this Agreement or perform its obligations
under this Agreement; provided, that any effect on Company&rsquo;s ability to consummate the transactions contemplated by this
Agreement or perform its obligations under this Agreement, to the extent resulting from Parent&rsquo;s or Merger Sub&rsquo;s material
breach or failure to consummate the Closing on or before the date for Closing set forth in Section 1.2 (assuming all conditions
to such obligations have been satisfied or duly waived) for any reason shall not be considered a &ldquo;Material Adverse Effect&rdquo;
under this subsection (a), or (b) upon the business, assets, liabilities, financial condition, or operating results of such party,
except any adverse effect related to or resulting from (i) general business or economic conditions affecting the economy or the
industry or markets in which such party operates; (ii) any natural disaster, or national or international political or social
conditions, including the engagement by the United States in hostilities or the escalation thereof, whether or not pursuant to
the declaration of a national emergency or war, or the occurrence or the escalation of any military or terrorist attack upon the
United States, or any of its territories, possessions, or diplomatic or consular offices or upon any military installation, equipment
or personnel of the United States; (iii) financial, banking, or securities markets (including any disruption thereof and any decline
in the price of any security or any market index); (iv) changes in GAAP or other similar accounting requirements in foreign countries
which are not specific to the affected party, (v) changes in Laws, rules, regulations, orders, or other binding directives issued
by any Governmental Authority, (vi) the taking of any action explicitly contemplated by this Agreement, the other agreements contemplated
hereby or at the request of the affected party other party hereto or the announcement of this Agreement, or the other agreements
contemplated hereby or the transactions contemplated hereby or thereby, (vii) the negotiation, execution, announcement or pendency
of this Agreement or the transactions contemplated hereby or any communication by Parent or any of its Affiliates of its plans
or intentions (including with respect to employees) with respect to any of the business of such party, including losses or threatened
losses of, or any adverse change in the relationship with employees, customers, suppliers, distributors, financing sources, joint
venture partners, licensors, licensees, or others having relationships with such party, (viii) any adverse change in or effect
on the business of such party that is cured by or on behalf of such party before the earlier of the Closing Date and the date
on which this Agreement is terminated pursuant to Article 6, or (ix) any failure to meet internal projections relating to such
party (it being understood that the underlying causes of, or factors contributing to, the failure to meet such projections may
be taken into account in determining whether a Material Adverse Effect has occurred), but only in the case of (i), (ii) or (iii),
to the extent such change or effect does not disproportionately affect such party relative to other industry participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>OTC Markets</B>&rdquo;
means OTC Market Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Parent Disclosure
Schedules</B>&rdquo; means the Parent Disclosure Schedules delivered by Parent to Company concurrently with the execution and
delivery of this Agreement as modified by any Disclosure Updates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Parent Product</B>&rdquo;
means any product that Parent has manufactured, distributed, marketed or sold, or is manufacturing, distributing, marketing or
selling and any products currently under preclinical or clinical development by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Parent Shares</B>&rdquo;
means shares of common stock, par value $0.0001 per share, of Parent. All references to a number of Parent Shares shall be subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting
the Parent Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permits</B>&rdquo;
means all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights
obtained, or required to be obtained, from Governmental Authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated
organization, trust, association or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Pre-Closing
Tax Liability</B>&rdquo; means all unpaid Taxes of Company for all taxable periods ending on or before the Closing Date and, for
any Straddle Period, the Straddle Period Prorated Taxes for the portion of any such taxable period up to and including the Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Post-Closing
Tax Period</B>&rdquo; means any taxable period ending after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Pre-Closing
Tax Period</B>&rdquo; means any taxable period ending on or before the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Preferred Stockholders</B>&rdquo;
means collectively, the holders of Company Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Products</B>&rdquo;
means any product that Company has manufactured, distributed, marketed or sold, or is manufacturing, distributing, marketing or
selling, and/or any products currently under preclinical or clinical development by Company at Closing, including in each case
any modifications or improvements thereto, including but not limited to Fiera&reg; personal care devices, Sofsense&trade; rings,
chargers, and including improvements, derivatives, and the like.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Real Property</B>&rdquo;
means the real property owned, leased or subleased by Company, together with all buildings, structures and facilities located
thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Release</B>&rdquo;
means any actual release, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching,
dumping, abandonment, disposing or allowing to escape or migrate into or through the environment (including, without limitation,
ambient air (indoor or outdoor), surface water, groundwater, land surface or subsurface strata or within any building, structure,
facility or fixture), including the abandonment or discarding of barrels, containers and other closed receptacles containing any
Hazardous Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SEC</B>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities Act</B>&rdquo;
means the Securities Act of 1933, as amended, or any successor federal statute thereto and the rules and regulations of the SEC
promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securityholder
Transaction Expenses</B>&rdquo; means, without duplication, all (i) unpaid third party fees and expenses, including any fees expenses
payable to counsel, accountants, investment bankers and consultants, payable by Company arising from, incurred in connection with
or incident to this Agreement, the Merger and the transactions contemplated hereby, including the drafting, negotiation, execution
and delivery of this Agreement and all of the other agreements and documents contemplated hereby, and (ii) fifty percent (50%)
of any Transfer Taxes; provided, for the avoidance of doubt, that Securityholder Transaction Expenses shall not include any severance,
change of control or other similar payments, including accrued vacation and accrued bonuses and other similar compensation paid
or payable in connection with the termination of any employee of the Company in connection with or as a result of the Merger and
the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Stockholder</B>&rdquo;
means a holder of Company Stock immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Straddle Period</B>&rdquo;
means any Tax period that includes but does not end on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Straddle Period
Prorated Taxes</B>&rdquo; as of the Closing Date means (a) for any (i) income, payroll or other Taxes measured by net income or
receipts, (ii) Taxes imposed in connection with the sale, transfer, or assignment of property, or (iii) Taxes required to be withheld,
the liability for Taxes that would arise upon a deemed &ldquo;closing of the books&rdquo; on the Closing Date if the Closing Date
is not otherwise the last day of a taxable period (provided that any deduction or allowance for depreciation or amortization shall
be allocated on a per diem basis), and (b) for any other Taxes, including ad valorem Taxes or other Taxes determined with respect
to a period of time, the portion of such Taxes that are accrued on the Closing Date based on the applicable number of days in
the taxable period arising on or before the Closing Date as compared to the total taxable days in the applicable taxable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsidiary</B>&rdquo;
means, with respect to any Person, any corporation, partnership, association, limited liability company, unlimited liability company
or other business entity of which (a) if a corporation, a majority of the total voting power of shares of stock entitled (without
regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time
owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination
thereof, or (b) if a partnership, association, limited liability company, or other business entity, a majority of the partnership
or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by that Person or one
or more Subsidiaries of that Person or a combination thereof. For purposes hereof, a Person or Persons shall be deemed to have
a majority ownership interest in a partnership, association, limited liability company, or other business entity if such Person
or Persons are allocated a majority of partnership, association, limited liability company, or other business entity gains or
losses or otherwise control the managing director, managing member, general partner or other managing Person of such partnership,
association, limited liability company, or other business entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Unpaid Contractual
Obligations</B>&rdquo; means those amounts due to each of ExploraMed NC6, LLC under than certain Business Services Agreement dated
September 27, 2012 and Torreya Capital Partners under that certain Engagement Letter dated July 27, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tax</B>&rdquo;
or &ldquo;<B>Taxes</B>&rdquo; means (a) any federal, provincial, territorial, state, municipal, school board, school, local or
non-U.S. taxes, like charges, levies, like fees or assessments imposed by any Governmental Authority, including income, gross
receipts, business, capital, capital gains, goods and services, provincial sales, registration, value added, escheat, excise (including
medical device excise), severance, premium, windfall profit, customs, duties, land transfer, personal property, employment, payroll,
license, employee, capital stock, franchise, profits, withholding, social security, unemployment, health, employment insurance,
governmental pension plan premiums or contributions, disability, real property, ad valorem/personal property, stamp, occupation,
sales, use, transfer, value added, alternative minimum, estimated or other similar tax, and (b) any interest, penalty or addition
thereto imposed by any Governmental Authority whether disputed or not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tax Return</B>&rdquo;
means any return, declaration, report, claim for refund, information return or statement or other document relating to Taxes that
is filed or required to be filed with a Governmental Authority responsible for Tax administration, including any schedule or attachment
thereto, and including any amendment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Treasury Regulations</B>&rdquo;
means the final or temporary regulations promulgated under the Code, as such regulations may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>WARN Act</B>&rdquo;
means the federal Worker Adjustment and Retraining Notification Act of 1988, and similar state, local and foreign laws related
to plant closings, relocations, mass layoffs and employment losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Warrant Holder</B>&rdquo;
means a holder of one or more Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Warrants</B>&rdquo;
means warrants issued by Company to purchase Company Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
Defined Terms</B>. The following terms have the meanings defined for such terms in the Sections set forth below</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Term</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 58%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Section</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Accelerated Payment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Annex 1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Acquisition Proposal</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 5.3(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Advisory Group</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 8.1(c)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Affiliate Transaction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.29</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Preamble</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Agreement Date</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Preamble</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Appraisal Demands</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.5</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Balance Sheet</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.6</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Balance Sheet Date</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.6</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Benefit Plan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.20(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Certificates of Merger</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.2</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Claiming Party</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 7.5(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Closing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.2</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Closing Date</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.2</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Preamble</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Company Board</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Recitals</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Company Intellectual Property</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.12(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Company&rsquo;s Investment Bank</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.30</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Conflicts</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 7.6(b)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Defending Party</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 7.5(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dissenting Shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.5</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Distribution Schedule</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.4(c)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Divestiture Consideration</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Annex 1</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%"><FONT STYLE="font-size: 10pt"><B>Term</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 58%"><FONT STYLE="font-size: 10pt"><B>Section</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Earnout Accounting Firm</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Annex 1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Earnout Objection Statement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Annex 1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Earnout Payments</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 9.1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Earnout Share Amount</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Annex 1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Earnout Statement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Annex 1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Effective Time</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.2</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">FCPA</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.24</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Financial Statements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.6</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">First Certificate of Merger</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.2</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Government Grants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.26</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Initial Surviving Corporation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Insurance Policies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.16</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Integrated Transaction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Recitals</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Intellectual Property</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.12(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Intellectual Property Registrations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.12(b)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Interim Balance Sheet</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.6</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Interim Balance Sheet Date</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.6</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Interim Financial Statements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.6</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Letters of Transmittal</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.4(b)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Licensed Intellectual Property</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.12(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Loss or Losses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 7.2(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Material Contracts</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.9(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Material Customers</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.15(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Material Suppliers</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.15(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Merger</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Recitals</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Merger Sub</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Preamble</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Mergers</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Recitals</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Milestone Payment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Annex 1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Multiemployer Plan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.20(c)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Parent</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Preamble</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Parent Balance Sheet</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 4.9(c)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Parent Balance Sheet Date</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 4.9(c)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Parent Financial Statements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 4.9(b)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Parent Indemnitees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 7.2(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Parent SEC Reports</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 4.9(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Paying Agent</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.4(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Paying Agent Agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.4(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Permitted Encumbrances</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.10</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Qualified Benefit Plan</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.20(c)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Related Party</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.29</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Representative</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Preamble</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Representative Group</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 8.1(c)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Required Stockholder Approval</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Recitals</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Revenue Earnout Payments</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Annex 1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Second Certificate of Merger</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 1.2</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Second Merger</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Recitals</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Second Merger Sub</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Recitals</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Securityholder Indemnitees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 7.3</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Seller Products</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 5.15</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Stockholders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Recitals</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%"><FONT STYLE="font-size: 10pt"><B>Term</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 58%"><FONT STYLE="font-size: 10pt"><B>Section</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Surviving Company</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 58%"><FONT STYLE="font-size: 10pt">Section 1.1(b)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Third Party Claim</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 7.6(a)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Trademarks</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.12(a)(i)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Transfer Taxes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 7.8(c)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Union</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.21(b)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Year-End Financial Statements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 3.6</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
10.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B><U>MISCELLANEOUS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press
Releases and Communications</B>. Prior to issuing any press release relating to this Agreement, Parent will submit such press
release to Representative for its consent, which will not be unreasonably withheld; <I>provided</I> that Parent shall use its
best efforts to exclude any financial deal terms from any such press release or public filing. Company and the Representative
shall not, without the prior written consent of Parent, issue any press release or otherwise make any public statements with respect
to this Agreement or the transactions contemplated; <I>provided, however,</I> that the foregoing will not restrict or prohibit
Company from making any announcement to its employees, customers and other business relations with the prior approval of Parent,
such approval not to be unreasonably withheld or delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses</B>.
Except as otherwise expressly provided herein, all costs and expenses, including, without limitation, fees and disbursements of
counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby
shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices</B>.
All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be
deemed to have been given (a) when delivered by hand; (b) two (2) Business Days following deposit with a nationally recognized
overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission)
if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the
recipient or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid.
Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as
shall be specified in a notice given in accordance with this Section 10.3):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">If to Parent or Merger Sub:</FONT></TD>
    <TD STYLE="width: 65%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aytu BioScience, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">373 Inverness Parkway, Suite 206</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Englewood, CO 80112</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">E-mail:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attention:</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">with a copy to:</FONT></TD>
    <TD STYLE="width: 65%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Wyrick Robbins Yates &amp; Ponton LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4101 Lake Boone Trail, Suite 300</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Raleigh, NC 27607</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Facsimile: (919) 781-4865</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">E-mail: dmannheim@wyrick.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attention: W. David Mannheim and Zachary R. Bishop</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">If to Representative:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">with a copy to:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">If to Company:</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Nuelle, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2570 W. El Camino Real</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Suite 310</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mountain View, CA 94040</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Facsimile:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">E-mail: ebright@nuelle.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attention: Earl Bright</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">with a copy to:</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Wilson Sonsini Goodrich &amp; Rosati P.C.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">650 Page Mill Road</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Palo Alto, CA 94304</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">E-mail: poettinger@wsgr.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attention: Philip Oettinger</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interpretation</B>.
For purposes of this Agreement, (a) the words &ldquo;include,&rdquo; &ldquo;includes&rdquo; and &ldquo;including&rdquo; shall
be deemed to be followed by the words &ldquo;without limitation&rdquo;; (b) the word &ldquo;or&rdquo; is not exclusive; (c) the
words &ldquo;herein,&rdquo; &ldquo;hereof,&rdquo; &ldquo;hereby,&rdquo; &ldquo;hereto&rdquo; and &ldquo;hereunder&rdquo; refer
to this Agreement as a whole; (d) the word &ldquo;will&rdquo; shall be construed in the imperative having the same meaning as
the word &ldquo;shall&rdquo;; (e) the word &ldquo;day&rdquo;, &ldquo;quarter&rdquo; or &ldquo;year&rdquo; means a calendar day,
quarter or year (except where a fiscal day, quarter or year is expressly referenced); (f) the word &ldquo;notice&rdquo; requires
notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications
contemplated under this Agreement; (g) provisions that require that a party or the parties &ldquo;agree,&rdquo; &ldquo;consent&rdquo;
or &ldquo;approve&rdquo; or the like shall require that such agreement, consent or approval be specific and in writing, whether
by written agreement, letter, approved minutes or otherwise; (h) words of any gender include the other gender; and (i) words using
the singular or plural number also include the plural or singular number, respectively. Unless the context otherwise requires,
references herein: (x) to Articles, Sections, Company Disclosure Schedules, Parent Disclosure Schedules and Exhibits mean the
Articles and Sections of, and Company Disclosure Schedules, Parent Disclosure Schedules and Exhibits attached to, this Agreement;
(y) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented
and modified from time to time to the extent permitted by the provisions thereof and (z) to a statute means such statute as amended
from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement shall
be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an
instrument or causing any instrument to be drafted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headings</B>.
The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.
If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality
or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such
term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable,
the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as
closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally
contemplated to the greatest extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement</B>. This Agreement (including the Exhibits and Schedules hereto) constitute the sole and entire agreement of the parties
to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous
understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between
the statements in the body of this Agreement, the Exhibits, Company Disclosure Schedules (other than an exception expressly set
forth as such in the Company Disclosure Schedules) Parent Disclosure Schedules (other than an exception expressly set forth as
such in the Parent Disclosure Schedules), and other Schedules hereto, the statements in the body of this Agreement will control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Successors
and Assigns</B>. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
successors and permitted assigns. Neither party may assign its rights or obligations hereunder without the prior written consent
of the other party, which consent shall not be unreasonably withheld or delayed. No assignment shall relieve the assigning party
of any of its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Third-party Beneficiaries</B>. Except as provided in Article 7 or Section 5.10, this Agreement is for the sole benefit of the
parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or
shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment
and Modification; Waiver</B>. This Agreement may only be amended, modified or supplemented by an agreement in writing signed by
each party hereto; provided that after the Effective Time, Parent and the Representative may cause this Agreement to be amended
by execution of an instrument in writing signed on behalf of Parent and the Representative. No waiver by any party of any of the
provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any
party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such
written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to
exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed
as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any
other or further exercise thereof or the exercise of any other right, remedy, power or privilege.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law; Submission to Jurisdiction; Waiver of Jury Trial</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect
to any choice or conflict of law provision or rule (whether of the State of Delaware any other jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ANY
LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY
MAY BE INSTITUTED IN THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA OR THE COURTS OF THE STATE OF DELAWARE IN EACH CASE LOCATED
IN THE CITY OF RALEIGH, COUNTY OF WAKE, AND EACH PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS IN ANY
SUCH SUIT, ACTION OR PROCEEDING. SERVICE OF PROCESS, SUMMONS, NOTICE OR OTHER DOCUMENT BY MAIL TO SUCH PARTY&rsquo;S ADDRESS SET
FORTH HEREIN SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY SUIT, ACTION OR OTHER PROCEEDING BROUGHT IN ANY SUCH COURT. THE PARTIES
IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR ANY PROCEEDING IN SUCH COURTS
AND IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY
SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY TO THIS
AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT
SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED
THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO
THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.11(C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific
Performance</B>. The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in
accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition
to any other remedy to which they are entitled at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Section 10.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</B>.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be
deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic
transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">NUELLE, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Karen Long</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Karen Long</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President and CEO</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PARENT:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">AYTU BIOSCIENCE, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Joshua Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Joshua Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>MERGER SUB:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">AYTU ACQUISITION CORPORATION, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Joshua Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Joshua Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>SECOND MERGER SUB:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">AYTU HOLDINGS, LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Joshua Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Joshua Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>REPRESENTATIVE:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Earl Bright, solely in his capacity as the Representative</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Earl Bright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Earl Bright</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Representative</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Annex
1.</B></FONT><BR>
<FONT STYLE="text-transform: uppercase"><B>EARNOUT CALCULATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>A.</B></TD><TD STYLE="text-align: justify"><B>Certain Defined Terms.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Bundled Product</B>&rdquo;
means a Company Product and other products that are not such Company Product either (a) packaged together for sale or shipment
as a single unit or (b) sold together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commercially
Reasonable Best Efforts</B>&rdquo; shall mean, for the purposes of this Annex 1, with respect to the efforts and resources to
be expended, or considerations to be undertaken, by Parent such reasonable, good faith best efforts and resources as a device
company of a similar size and with similar revenues as Parent would normally use to accomplish a similar objective, activity or
decision under similar circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company Product</B>&rdquo;
means (i) any product that incorporates any portion of Company Intellectual Property existing as of the Closing or Licensed Intellectual
Property existing as of the Closing, and that is being acquired by Parent through the Merger, but for any ownership or license
thereof, would infringe a Valid Claim with respect to any Company Intellectual Property existing as of the Closing or Licensed
Intellectual Property existing as of the Closing, and/or (ii) any Product that is being acquired by Parent through the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Divestiture</B>&rdquo;
(and other correlative terms) shall mean any transaction in which any Company Product or any intellectual property or regulatory
assets related to the same are divested or transferred by any means, directly or indirectly, including by way of merger, consolidation,
asset acquisition or sale, license, sublicense, purchase, sale, assignment or other similar transfer; <I>provided, however,</I>
that a Divestiture shall not include (i) any transfer to a member of Parent Group, or (ii) sales of any Company Product in the
ordinary course of business of Parent or the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Earnout Period</B>&rdquo;
means the period from the date hereof until all of the payments have been made pursuant to Sections B and C below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Earnout Year</B>&rdquo;
means each of the twelve months periods commencing on June 1 of the Earnout Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Licensee</B>&rdquo;
means, with respect to Parent Group, any licensee of a member of Parent Group, any sublicensee of any such licensee (ad infinitim),
and any distributor of a member of Parent Group or any such licensee or sublicensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Net Sales</B>&rdquo;
means gross amounts invoiced, deemed invoiced or otherwise received for sales of Company Products by Parent Group and any Licensees
(each, a &ldquo;<B>Selling Party</B>&rdquo;), less the sum of the following, solely to the extent related to the sale of such
Company Products: (1) sales, value added, use, excise, and similar taxes; (2) amounts allowed or credited on returns of Company
Products; (3) freight, shipping, handling, and insurance charges; (4) import or export duties, tariffs, or similar charges incurred
with respect to the import or export of Company Products into or out of any country; (5) any coupons, discounts or rebates; and
(6) third party licensing fees. Such amounts shall be determined from the books and records of the Selling Party maintained in
accordance with GAAP as consistently applied by the Selling Party across its operations. Parent shall cause each Licensee to maintain
all necessary books and records and to provide reports and otherwise grant access to such books and records to Parent and its
Agents in order for Parent to satisfy its record maintenance and reporting obligations hereunder. Company Products are considered
&ldquo;sold&rdquo; when billed out or invoiced or, in the event such Company Products are not billed out or invoiced, Products
are considered &ldquo;deemed invoiced&rdquo; when the consideration for sale of the Company Products is received or when the Product
is shipped to any third party, with or without consideration. If a sale, transfer or other disposition of Company Products involves
consideration other than cash or is not at arm&rsquo;s length, then the Net Sales from such sale, transfer or other disposition
shall be the arm&rsquo;s length fair market value, which generally will mean the Selling Party&rsquo;s Per Unit Average Selling
Price. Whenever any Company Product is sold as part of a Bundled Product, the &ldquo;Net Sales&rdquo; for such Company Product
resulting from such sale of such Bundled Product shall be the product of (i) the number of units of such Bundled Product sold
by one or more members of Parent Group and any Licensees multiplied by (ii) the Per Unit Average Selling Price of such Company
Product. For the avoidance of doubt, Net Sales does not include sales of products of Parent, any Affiliate of Parent, or of any
other party that are not Company Products, as such term is defined above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Parent Group</B>&rdquo;
means Parent and its direct and indirect Subsidiaries and Affiliates including, after the Effective Time, the Surviving Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Parent Trading
Price at Date of Accelerated Payment</B>&rdquo; means the mean of the average of the closing price of Parent Shares as reported
on OTC Markets (or such national or foreign securities exchange on which Parent&rsquo;s shares are listed) for the ten (10) trading
days immediately prior to the earlier of (i) the date of closing of the Divestiture or (ii) any public announcement relating to
the Divestiture (subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization
affecting the Parent Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Parent Trading
Price at Delivery of Earnout Statement</B>&rdquo; means the mean of the average of the closing price prices of Parent Shares as
reported on OTC Markets (or such national or foreign securities exchange on which Parent&rsquo;s shares are listed) for the ten
(10) trading days immediately prior to the earlier of (i) the date of Parent&rsquo;s delivery of an Earnout Statement reflecting
the amount of any Revenue Earnout Payment or Milestone Payment (as defined below), or (ii) any public announcement by Parent Group
that it owes any Revenue Earnout Payment or Milestone Payment (subject to adjustment in the event of any stock dividend, stock
split, combination or other similar recapitalization affecting the Parent Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Per Unit
Average Selling Price</B>&rdquo; means, with respect to a Company Product in a given Earnout Year, an amount equal to the
greater of (1) the price per unit at which the Company sold such Company Product immediately preceding the Closing Date, and
(2) the quotient of (x) the total amount of annual Net Sales of such Company Product, not including any such Company Products
that are sold as a Bundled Product, divided by (y) the total number of units of such Company Products sold during such year,
not including any such Company Products that are sold as a Bundled Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Valid Claim</B>&rdquo;
means a claim of any pending patent application or any issued, unexpired United States or granted foreign patent that has not
been dedicated to the public, disclaimed, abandoned or held invalid or unenforceable by a court or other body of competent jurisdiction
from which no further appeal can be taken, and that has not been explicitly disclaimed, or admitted in writing to be invalid or
unenforceable or of a scope not covering a particular technology, product, services, process, or method through reissue, disclaimer
or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>B.</B></TD><TD STYLE="text-align: justify"><B>Revenue Earnout Payments</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the Earnout Period, Parent shall pay
the Company Securityholders an amount equal to the following (the &ldquo;<B>Revenue Earnout Payments</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">[*]% of Net Sales of Company Products
for cumulative Net Sales between $0 and $[*] (this payment to be made in Parent Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">[*]% of Net Sales of Company Products
for cumulative Net Sales between $[*] and $[*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">[*]% of Net Sales of Company Products
for cumulative Net Sales between $[*] and $[*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">[*]% of Net Sales of Company Products
for cumulative Net Sales between $[*] and $[*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">[*]% of Net Sales of Company Products
for cumulative Net Sales between $[*] and $[*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the payments set forth in this Section
B above: (i) will be made for the preceding twelve month period ended June 30; and (ii) are due and payable within 90 days of
June 30.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>C.</B></TD><TD STYLE="text-align: justify"><B>Milestone Earnout Payments</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the amounts payable under B
above, during the Earnout Period, Parent shall pay the Company Securityholders an amount equal to the following (each a &ldquo;<B>Milestone
Payment</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Upon achieving the first occurrence
of Net Sales of $[*] over any sequential four calendar quarter period, Parent will make a one-time payment to the Company Securityholders
of an amount equal to $[*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Upon achieving the first occurrence
of Net Sales of $[*] over any sequential four calendar quarter period, Parent will make a one-time payment to the Company Securityholders
of an amount equal to $[*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Upon achieving the first occurrence
of Net Sales of $[*] over any sequential four calendar quarter period, Parent will make a one-time payment to the Company Securityholders
of an amount equal to $[*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Upon achieving the first occurrence
of Net Sales of $[*] over any sequential four calendar quarter period, Parent will make a one-time payment to the Company Securityholders
of an amount equal to $[*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Upon achieving the first occurrence
of Net Sales of $[*] over any sequential four calendar quarter period, Parent will make a one-time payment to the Company Securityholders
of an amount equal to $[*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Upon achieving the first occurrence
of Net Sales of $[*] over any sequential four calendar quarter period, Parent will make a one-time payment to the Company Securityholders
of an amount equal to $[*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the payments set forth in this Section
C above are due and payable within 90 days of achieving the applicable milestone. For clarity, the Milestone Payments set forth
above are one-time payments only, but if more than one milestone event occurs in any sequential four calendar quarter period,
all corresponding Milestone Payments for such milestone events so occurring in such period shall be due as described in this Annex
1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For example, if Net Sales reach $[*] for the
sequential four calendar quarters ending December 31, 2018 (and no previous Milestone Payments have been made), Parent will make
a Milestone Payment to the Company Securityholders in an amount equal to $[*], which will be paid on or before March 31, 2019,
but no additional Milestone Payments will be payable to the Company Securityholders unless and until Net Sales reaches $[*] over
any sequential four calendar quarter period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>D.</B></TD><TD STYLE="text-align: justify"><B>Reporting</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parent shall provide the Representative (1)
within ninety (90) days after the end of each calendar year, a written report indicating, on a product-by-product basis, Parent&rsquo;s
calculation of Net Sales of Company Products and each component thereof, including total gross invoiced amounts and amounts deducted
by category from gross invoiced amounts to calculate Net Sales, and (2) as soon as reasonably practicable following the due date
for Parent Group&rsquo;s release of earnings for each Earnout Year, but no later than ten (10) Business Days after such release,
Parent&rsquo;s calculation of the applicable Revenue Earnout Payment or Milestone Payment, if any, and information and data reflecting
and demonstrating the Net Sales for such Earnout Year. All such amounts shall be expressed in U.S. dollars, and such reports shall
include the rates of exchange used to convert to U.S. dollars from the currency in which such sales were made or payments received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>E.</B></TD><TD STYLE="text-align: justify"><B>Payment</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On or before the tenth (10<SUP>th</SUP>) Business
Day following the date on which the Representative accepts Parent&rsquo;s calculation of the Revenue Earnout Payments or Milestone
Payment (either by delivering written notice of acceptance to Parent or deemed acceptance under Section F below) or the Revenue
Earnout Payment or Milestone Payment is finally determined under Section F below, Parent shall (i) pay to the Paying Agent, who
shall in turn pay to each Company Securityholder such Company Securityholder&rsquo;s Distribution Allocation of the cash portion
of such Revenue Earnout Payment or Milestone Payment, by wire transfer of immediately available funds, and (ii) deliver to each
Company Securityholder a number of Parent Shares (rounded to the nearest share) equal to (A) such Company Securityholder&rsquo;s
Distribution Allocation of the Parent Share portion of such Revenue Earnout Payment or Milestone Payment <U>divided by</U> (B)
the Parent Trading Price at Delivery of Earnout Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the extent payment of any Accelerated Payment
(as defined below), Revenue Earnout Payment or Milestone Payment in cash would disqualify the Mergers from being a reorganization
under Section 368 of the Code and the Treasury Regulations promulgated thereunder as determined pursuant to the second sentence
of Section 7.8(d), each party hereto agrees to such payment will be made in Parent Shares at the Parent Trading Price at Date
of Accelerated Payment or Parent Trading Price at Delivery of Earnout Statement, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>F.</B></TD><TD STYLE="text-align: justify"><B>Objections</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parent shall, and shall cause its Parent Group
to, keep complete, true and accurate books of account and records showing the derivation of the amounts of all Revenue Earnout
Payments or Milestone Payments, including, without limitation, on a product-by-product basis, Parent&rsquo;s calculation of Net
Sales and each component thereof, including total gross invoiced amounts and amounts deducted by category from gross invoiced
amounts to calculate Net Sales. Parent shall,<B> </B>and shall cause the Parent Group to provide Representative and its Agents
with reasonable access during normal business hours to the books, records (including work papers, schedules, memoranda and other
documents), supporting data and employees of Parent Group to the extent reasonably necessary to verify any Revenue Earnout Payment
or Milestone Payment. If the Representative has any objections to the statements described in Section D above (each, an &ldquo;<B>Earnout
Statement</B>&rdquo;), the Representative shall deliver to Parent a statement setting forth, in reasonable detail, its objections
thereto (each, an &ldquo;<B>Earnout Objection Statement</B>&rdquo;). If an Earnout Objection Statement is not delivered to Parent
within thirty (30) days after delivery of an Earnout Statement, such Earnout Statement as prepared by Parent shall be deemed irrevocably
accepted by the Representative on behalf of the Company Securityholders and be final, binding and non-appealable by the parties
and the Company Securityholders. The Representative and Parent shall negotiate in good faith to resolve the objections raised
in any Earnout Objection Statement, but if they do not reach a final resolution within thirty (30) days after the delivery of
an Earnout Objection Statement to Parent, any unresolved disputes shall be submitted to an independent national accounting firm
mutually selected by Parent and the Representative (the &ldquo;<B>Earnout Accounting Firm</B>&rdquo;). In the event any such dispute
is submitted to the Earnout Accounting Firm, each party shall be permitted to submit a statement setting forth its calculation
of the applicable Revenue Earnout Payment or Milestone Payment, together with such supporting documentation as it deems appropriate,
to the Earnout Accounting Firm. The Representative and Parent shall use their respective commercially reasonable efforts to cause
the Earnout Accounting Firm to resolve such dispute as soon as practicable, but in any event within thirty (30) days after the
date on which the Earnout Accounting Firm receives the applicable statements prepared by the Representative and Parent. The calculation
of any Revenue Earnout Payment or Milestone Payment as finally determined by the Earnout Accounting Firm (which such determination
shall be made in a manner consistent with the terms of this Agreement and shall not, for any Revenue Earnout Payment or Milestone
Payment, be less than the amount set forth in the applicable Earnout Statement nor exceed the amount set forth in the applicable
Earnout Objection Statement) shall be final, binding and non-appealable among the parties. Each party shall bear its own costs
and expenses in connection with the resolution of such dispute by the Earnout Accounting Firm. All costs and expenses of the Earnout
Accounting Firm, if any, shall be paid by the parties proportionately based on the difference of each party&rsquo;s calculation
of the applicable Revenue Earnout Payment or Milestone Payment as compared to the final determination of the Earnout Accounting
Firm. For example, if Parent proposes a Revenue Earnout Payment or Milestone Payment of $100, the Representative proposes a Revenue
Earnout Payment or Milestone Payment of $200, and the final determination of the Earnout Accounting Firm is $160, then 60% of
the costs of the Earnout Accounting Firm&rsquo;s review would be borne by Parent and 40% of such costs would be borne by the Representative
(on behalf of the Company Securityholders). Notwithstanding the foregoing, in the event that the Earnout Accounting Firm determines
that the actual amount of any Revenue Earnout Payment or Milestone Payment exceeds Parent&rsquo;s determination of such Revenue
Earnout Payment or Milestone Payment by five percent (5%) or more, then Parent shall pay all costs and expenses of the Earnout
Accounting Firm and Representative (with respect to its resolution of the corresponding dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Divestiture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Parent (a) does not make all of the payments to the Company Securityholders under Sections B or C of this <U>Annex 1</U> before
May 3, 2022, and (b) closes a Divestiture before May 3, 2022, Parent shall make the Accelerated Payment (as defined below) to
the Company Securityholders. Parent shall pay and deliver to the Paying Agent, who shall in turn (i) pay to each Company Securityholder
such Company Securityholder&rsquo;s Distribution Allocation of the cash portion of such Accelerated Payment, by wire transfer
of immediately available funds, and/or (ii) deliver to each Company Securityholder a number of Parent Shares (rounded to the nearest
share) equal to (A) such Company Securityholder&rsquo;s Distribution Allocation of the Parent Share portion of such Accelerated
Payment <U>divided by</U> (B) the Parent Trading Price at Date of Accelerated Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;<B>Accelerated Payment</B>&rdquo; means an amount equal
to ten percent (10%) of the Divestiture Consideration (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;<B>Divestiture Consideration</B>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>in
the case of an asset sale or license (or sublicense) transaction</U>, the sum of all cash and the fair market value of all securities
or other property payable to Parent Group in consideration of the transaction at any time, less all current and long-term liabilities
(but not contingent liabilities) of Parent Group that are not discharged or assumed by the buyer or licensee (or its affiliates)
in connection with the transaction; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>in
the case of a merger or stock sale</U>, the sum of all cash, and the fair market value of all securities and other property payable
to the stockholders of Parent Group (and any option holders or warrant holders) in return for their stock (or options or warrants)
in Parent Group at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The valuation of any securities
or other property shall be determined by reference to the operative transaction agreement for a respective merger, stock sale
or asset sale, provided that, if no such valuation is readily determinable from such operative transaction agreement, then for
securities for which there is an active public market;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
traded on a securities exchange or the NASDAQ Stock Market, the value shall be deemed to be the average of the closing prices
of the securities on such exchange or market over the 10 day period ending three days prior to the closing of such transaction;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
actively traded over-the-counter, the value shall be deemed to be the average of the closing bid prices over the 10 day period
ending three days prior to the closing of such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The method of valuation
of securities subject to investment letters or other similar restrictions on free marketability shall take into account an appropriate
discount from the market value as determined pursuant to clause (a) or (b) above so as to reflect the approximate fair market
value thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For securities for which
there is no active public market, the value shall be the fair market value thereof as either (i) determined in good faith by the
Board of Directors of Parent, (ii) approved by the Representative, such approval not to be unreasonably withheld, or (iii) determined
by a third party appraiser appointed and paid for by the Parent Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the closing of the Divestiture, all Revenue Earnout Payments and Milestone Payments shall immediately cease, and the provisions
of Sections B and C above shall be thereafter null and void and of no effect, and no more Earnout Payments of Milestone Payments
will be paid, except for those that are due and payable prior to the closing of the Divestiture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>I.</B></TD><TD STYLE="text-align: justify"><B>Miscellaneous.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
payments required pursuant to this <U>Annex 1</U> shall be deemed to be adjustments for Tax purposes to the aggregate consideration
paid by Parent pursuant to this Agreement (in the case of Parent, in respect of the shares in the Surviving Company held by Parent
as a result of the Mergers), unless otherwise required by applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent
shall, and shall cause its Affiliates to, make an appropriate number of sales calls on not less than 75% of the clinicians identified
in <U>Attachment A</U> to this <U>Annex 1</U> for a period of no less than eighteen months, commencing on the Closing Date, and
use Commercially Reasonable Best Efforts to sell the Company Products, which includes, without limitation, Parent engaging an
appropriately incentivized sales force for the Company Products for a period of no less than eighteen months, commencing on the
Closing Date. Notwithstanding the foregoing, the obligation of Parent to use, or cause its Affiliates to use, such Commercially
Reasonable Best Efforts shall not be deemed a guarantee or assurance of any kind that any Net Sales will be earned. Except as
specifically provided in this paragraph, from and after the Effective Time, all decisions and efforts with respect to the operation
or conduct of business of the Surviving Company shall be in Parent&rsquo;s sole and absolute discretion without any express or
implied warranty or covenant of any kind to any Stockholder or anyone else. The parties acknowledge and agree that Parent and
its Affiliates owe no fiduciary duty to the Company, the Surviving Company or the Stockholders with respect any payment under
this Annex A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time following the day that is eighteen months after any Earnout Payment is due hereunder, the Surviving Company shall be
entitled to require the Paying Agent to deliver to it any funds (including any earnings received with respect thereto) and any
Parent Shares that had been made available to the Paying Agent with respect to such Earnout Payment and that have not been disbursed
to Company Securityholders and thereafter such Company Securityholders shall be entitled to look only to Parent and the Surviving
Company (subject to abandoned property, escheat or other similar Laws) and only as general creditors thereof with respect to the
applicable portion of the Earnout Payment payable to them, without any interest thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATE OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>AYTU ACQUISITION CORPORATION, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">FIRST:</TD><TD>The name of the corporation is Aytu Acquisition Corporation, Inc.
                                         (the &ldquo;<B><I>Corporation</I></B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">SECOND:</TD><TD>The address of the Corporation&rsquo;s registered office in the
                                         State of Delaware is 3500 South DuPont Highway, in the City of Dover, Kent County, Delaware
                                         19901. The name of its registered agent at such address is Incorporating Services, Ltd.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">THIRD:</TD><TD>The purpose of the Corporation is to engage in any lawful act
                                         or activity for which corporations may be organized under the General Corporation Law
                                         of Delaware.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">FOURTH:</TD><TD>The total number of shares that the Corporation shall have authority
                                         to issue is two million (2,000,000) shares, $0.0001 par value per share. The Corporation
                                         is authorized to issue one class of stock to be designated Common Stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left">FIFTH:</TD><TD STYLE="text-align: justify">The name and mailing address of the incorporator are as
follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Zachary
R. Bishop</P></TD>
    <TD STYLE="width: 65%">4101 Lake Boone Trail, Suite 300</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Raleigh, NC 27607</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left">SIXTH:</TD><TD STYLE="text-align: justify">Unless and except that the bylaws of the Corporation shall
so require, the election of directors of the Corporation need not be by written ballot.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">SEVENTH:</TD><TD>To the fullest extent permitted by the Delaware General Corporation
                                         Law as the same exists or as may hereafter be amended, no present or former director
                                         of the Corporation shall be personally liable to the Corporation or its stockholders
                                         for monetary damages for breach of fiduciary duty as a director. Neither any amendment
                                         nor repeal of this Article, nor the adoption of any provision of this Certificate of
                                         Incorporation inconsistent with this Article, shall eliminate or reduce the effect of
                                         this Article in respect of any matter occurring, or any cause of action, suit or claim
                                         that, but for this Article, would accrue or arise, prior to such amendment, repeal or
                                         adoption of an inconsistent provision.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">EIGHTH:</TD><TD>The Corporation shall have the power to indemnify any person
                                         who was or is a party or is threatened to be made a party to, or testifies in, any threatened,
                                         pending or completed action, suit or proceeding, whether civil, criminal, administrative
                                         or investigative in nature, by reason of the fact such person is or was a director, officer
                                         or employee or agent of the Corporation, or is or was serving at the request of the Corporation
                                         as a director, officer, employee or agent of another corporation, partnership, joint
                                         venture, employee benefit plan, trust or other enterprise, against expenses (including
                                         attorney&rsquo;s fees), judgments, fines and amounts paid in settlement actually and
                                         reasonably incurred by such person in connection with such action, suit or proceeding
                                         to the full extent permitted by law, and the Corporation may adopt bylaws or enter into
                                         agreements with any such person for the purpose of providing for such indemnification.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">&nbsp;</P>

<!-- Field: Page; Sequence: 82; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">NINTH:</TD><TD>The Corporation reserves the right at any time, and from time
                                         to time, to amend, alter, change or repeal any provision contained in this Certificate
                                         of Incorporation, and other provisions authorized by the laws of the State of Delaware
                                         at the time in force may be added or inserted, in the manner now or hereafter prescribed
                                         by law; and all rights, preferences and privileges of whatsoever nature conferred upon
                                         stockholders, directors or any other persons whomsoever by and pursuant to this Certificate
                                         of Incorporation in its present form or as hereafter amended are granted subject to the
                                         rights reserved in this Article.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left">TENTH:</TD><TD STYLE="text-align: justify">In furtherance and not in limitation of the powers conferred
by the laws of the State of Delaware, the Board of Directors of the Corporation is expressly authorized to make, alter and repeal
the bylaws of the Corporation, subject to the power of the stockholders of the Corporation to alter or repeal any bylaw whether
adopted by them or otherwise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">The undersigned incorporator hereby acknowledges that
the foregoing Certificate of Incorporation is his act and deed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dated: May ___, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">                                                                                                                                          <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"></TD><TD STYLE="text-align: justify; width: 50%">Zachary R. Bishop, Incorporator</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Paying Agent Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PAYING AGENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Paying Agent Agreement
(this &ldquo;<B>Agreement</B>&rdquo;) is entered into as of ________, 2017, by and among AYTU BIOSCIENCE, INC., a Delaware corporation
(&ldquo;<B>Parent</B>&rdquo;), EARL BRIGHT (the &ldquo;<B>Representative</B>&rdquo;), and <FONT STYLE="text-transform: uppercase">VStock
Transfer, LLC,</FONT> a California limited liability company (the &ldquo;<B>Paying Agent</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to a Merger Agreement dated as of May ___, 2017 (the &ldquo;<B>Merger Agreement</B>&rdquo;), by and among Parent, Nuelle, Inc.,
a Delaware corporation (&ldquo;<B>Company</B>&rdquo;), AYTU ACQUISITION CORPORATION, INC., a Delaware corporation (&ldquo;<B>Merger
Sub</B>&rdquo;), AYTU HOLDINGS, LLC, a Delaware limited liability company (&ldquo;<B>Second Merger Sub</B>&rdquo;), and the Representative,
Merger Sub will merge with and into Company, leaving Company as the initial surviving corporation (the &ldquo;<B>Initial</B> <B>Surviving
Corporation</B>&rdquo;). The Initial Surviving Corporation will then merge with and into Second Merger Sub, leaving Second Merger
Sub as the surviving company (the &ldquo;<B>Surviving Company</B>&rdquo;). Capitalized terms used but not expressly defined in
this Agreement shall have the meanings ascribed to them in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Merger Agreement describes an amount of shares of Parent common stock (the &ldquo;<B>Paying Agency Shares</B>&rdquo;) which Parent
is required to deliver to the Paying Agent at the Closing for further distribution to the Company Securityholders and Creditors
(each a &ldquo;<B>Payee</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Annex
1</U> of the Merger Agreement describes an amount of shares of Parent common stock (the &ldquo;<B>Paying Agency Earnout Shares</B>&rdquo;)
and amounts of cash (the &ldquo;<B>Paying Agency Earnout Fund</B>&rdquo;) that Parent may be required to deliver to the Paying
Agent for further distribution to the Payees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Annex
1</U> of the Merger Agreement additionally describes an amount of shares of Parent common stock (the &ldquo;<B>Paying Agency Acceleration
Shares</B>&rdquo;) and amounts of cash (the &ldquo;<B>Paying Agency Acceleration Fund</B>&rdquo;) that Parent may be required
to deliver to the Paying Agent for further distribution to the Payees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through
this Agreement, Parent and the Representative desire to appoint the Paying Agent as the &ldquo;Paying Agent&rdquo; under the Merger
Agreement, and the Paying Agent desires to accept such appointment and to distribute the Paying Agency Shares, Paying Agency Earnout
Shares, Paying Agency Earnout Fund, Paying Agency Acceleration Shares and Paying Agency Acceleration Fund and other materials
discussed herein to the Payees pursuant to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">NOW, THEREFORE, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
11.<FONT STYLE="font-size: 10pt"><U>Appointment of Paying Agent. Paying Agent hereby accepts appointment by Parent and the Representative
as the &ldquo;Paying Agent&rdquo; under the Merger Agreement and, in such capacity, shall be authorized as the Paying Agent to
act on behalf of the Surviving Company and Parent for the purpose of delivering the portion of the Aggregate Merger Consideration
to be paid to Company Creditors as well as in exchange for shares of the Company&rsquo;s stock and Convertible Debt (the &ldquo;Company
Securities&rdquo;) and pay the same to the Payees upon satisfaction of the conditions set forth herein. Paying Agent hereby acknowledges
that its duties, liabilities and rights as Paying Agent are as set forth herein and in the Letter of Transmittal. </U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 85; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
12.<FONT STYLE="font-size: 10pt"><U>Receipt of Company Securities and Related Materials. In connection with the receipt of Company
Securities and related materials:</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 12.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Documents
To Be Received</FONT></B><FONT STYLE="font-size: 10pt">. With respect to an exchange of Company Securities, the Paying Agent shall
receive (i) a Letter of Transmittal (or facsimiles thereof), properly executed in accordance with the instructions therein, (ii)
subject to Section 3(i) hereof, a Company stock certificate(s) or convertible note (the &ldquo;<B>Certificate(s)</B>&rdquo;) from
the Payees listed on the Distribution Schedule attached hereto as <U>Exhibit A</U> representing the Company Securities, and (iii)
all other instruments and communications submitted to the Paying Agent in connection with the exchange of the Certificate(s),
and the Paying Agent shall preserve the same, and upon request will deliver a copy of the same to Parent or otherwise disposed
of them in accordance with the written instructions of the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Examination
of Documents</FONT></B><FONT STYLE="font-size: 10pt">. The Paying Agent shall examine the Letters of Transmittal and Certificate(s)
and other documents received to ascertain whether: (i) the Letters of Transmittal and/or other documents appear to the Paying
Agent to have been completed and executed in accordance with the instructions set forth in the Letter of Transmittal and (ii)
the Certificate(s) appear to be properly surrendered and are in proper form for transfer in accordance with the instructions set
forth in the Letter of Transmittal. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 12.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Irregularities
in Documents</FONT></B><FONT STYLE="font-size: 10pt">. In the event the Paying Agent determines that any Letter of Transmittal
or other document has been improperly completed or executed, that any of the Certificate(s) are not in proper form, or some other
irregularity exists, the Paying Agent shall follow its regular procedures to attempt to cause such irregularity to be corrected.
As to any irregular item that the Paying Agent cannot resolve through its regular procedures, the Paying Agent shall consult with
Parent and the Representative for instructions. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 12.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Tax
Documents</FONT></B><FONT STYLE="font-size: 10pt">. To the extent not included with the materials submitted with the Letter of
Transmittal, the Paying Agent shall request and obtain from each Payee, before issuing any payment hereunder, tax identification
numbers by means of a completed appropriate IRS Form W-9 or original W-8 and other forms and documents that the Paying Agent may
reasonably request. The parties hereto understand that if such tax reporting documentation is not so certified to the Paying Agent,
the Paying Agent may be required by the Internal Revenue Code of 1986, as amended, to withhold a portion of any interest and other
earnings, if any, on the Paying Agency Earnout Fund and Paying Agency Acceleration Fund. To the extent that the Paying Agent becomes
liable for the payment of any taxes in respect of income derived from the investment of funds held or payments made hereunder,
the Parent and the Representative (solely on behalf of the Payees and not in its individual capacity) agree, jointly and severally,
to indemnify the Paying Agent (and its officers, directors, employees, agents, attorneys and affiliates) (the &ldquo;<B>Paying
Agent Indemnitees</B>&rdquo;) for, and hold the Paying Agent Indemnitees harmless against any taxes, additions for late payment,
interest, penalties and other expenses that may be assessed against the Paying Agent Indemnitees, unless any such tax, addition
for late payment, interest, penalties and other expenses shall arise out of or be caused by the actions or failure to act of the
Paying Agent Indemnitees. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
13.<FONT STYLE="font-size: 10pt"><U>Disbursement of Paying Agency Shares, Paying Agency Earnout Shares, Paying Agency Earnout
Fund, Paying Agency Acceleration Shares and Paying Agency Acceleration Fund.</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 13.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Deposit
of Paying Agency Shares. </FONT></B><FONT STYLE="font-size: 10pt">On the Closing Date, Parent will deliver issuance instructions
to the Paying Agent with respect to the Paying Agency Shares, and will deposit with the Paying Agent, or cause a third party to
deposit, in electronic or book-entry form evidence of the Paying Agency Shares. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 13.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Disbursement
of Paying Agency Shares to Payees</FONT></B><FONT STYLE="font-size: 10pt">.<B> </B>The Paying Agent agrees, promptly after notice
from Parent of the closing of the transaction contemplated by the Merger Agreement (which such notice may be by e-mail) (the &ldquo;<B>Effective
Time</B>&rdquo;), to deliver, to each Payee who has completed a Letter of Transmittal and returned it to the Paying Agent, together
with Certificates representing outstanding Company Securities (or an affidavit of lost stock certificate in form reasonably acceptable
to Parent and Paying Agent), that portion of the Paying Agency Shares payable to such Payee promptly after receipt of such documentation
but in any event within three (3) Business Days thereafter. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 13.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Deposit
of Paying Agency Earnout Shares and Paying Agency Earnout Fund. </FONT></B><FONT STYLE="font-size: 10pt">If Revenue Earnout Payments
or Milestone Payments are required by <U>Annex 1</U> of the Merger Agreement, Parent will deliver issuance instructions to the
Paying Agent with respect to the Paying Agency Earnout Shares, and will deposit with the Paying Agent in a special account immediately
available funds the portion of the Paying Agency Earnout Fund and will deposit with the Paying Agent, or cause a third party to
deposit, in electronic or book-entry form evidence of the portion of the Paying Agency Earnout Shares collectively equal to such
Revenue Earnout Payment or Milestone Payment; provided that Parent shall provide to the Paying Agent and the Representative no
later than forty-eight (48) hours prior to making such deposit notice of, and a disbursement schedule for, the Revenue Earnout
Payment or Milestone Payment. The funds on deposit in the Paying Agency Earnout Fund shall remain uninvested. The wire transfer
instructions for the transfer of all funds to be delivered to the Paying Agent hereunder are: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">VStock Transfer, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">ABA No.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Acct No.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Attention:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">As the Paying Agent for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify; text-indent: -2.5in">For further credit
to account number:&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 13.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Disbursement
of Paying Agency Earnout Shares and Paying Agency Earnout Fund to Payees</FONT></B><FONT STYLE="font-size: 10pt">.<B> </B>Subject
to any applicable withholding or backup withholding requirements of Section 5 hereof, the Paying Agent agrees to make the appropriate
payment to each Payee of such Payee&rsquo;s portion of the Paying Agency Earnout Shares and Paying Agency Earnout Fund as set
forth on a disbursement schedule provided by Parent and approved by the Representative in writing on the terms and conditions
set forth herein, and in no event later than three (3) Business Days, after receiving all proper documentation from such Payee
as described herein and approval of the Representative in writing. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 13.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Deposit
of Paying Agency Acceleration Shares and Paying Agency Acceleration Fund. </FONT></B><FONT STYLE="font-size: 10pt">If and only
if Parent delivers to Representative written notice of a proposed Divestiture occurring on or before May 3, 2022 in accordance
with the terms and conditions of <U>Annex 1</U> of the Merger Agreement, then on or before the later of (a) closing of a Divestiture
and (b) May 3, 2022, Parent will deliver issuance instructions to the Paying Agent with respect to the Paying Agency Acceleration
Shares, will deposit with the Paying Agent in a special account immediately available funds the Paying Agency Acceleration Fund
and will deposit with the Paying Agent, or cause a third party to deposit, in electronic or book-entry form evidence of the Paying
Agency Acceleration Shares; provided that Parent shall provide to the Paying Agent and the Representative no later than forty-eight
(48) hours prior to making such deposit notice of, and a disbursement schedule for, the Accelerated Payment. The funds on deposit
in the Paying Agency Earnout Fund shall remain uninvested. The wire transfer instructions for the transfer of all funds to be
delivered to the Paying Agent hereunder are: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">VStock Transfer, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">ABA No.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Acct No.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Attention:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">As the Paying Agent for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify; text-indent: -2.5in">For further credit
to account number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 13.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Disbursement
of Paying Agency Acceleration Shares and Paying Agency Acceleration Fund to Payees</FONT></B><FONT STYLE="font-size: 10pt">. Subject
to any applicable withholding or backup withholding requirements of Section 5 hereof, the Paying Agent agrees to make the appropriate
payment to each Payee of such Payee&rsquo;s portion of the Paying Agency Acceleration Shares and Paying Agency Acceleration Fund
as set forth on a disbursement schedule provided by Parent and approved by the Representative in writing on the terms and conditions
set forth herein, and in no event later than three (3) Business Days, after receiving all proper documentation from such Payee
as described herein and approval of the Representative in writing. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 13.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Delivery
and Cancellation of Certificate(s)</FONT></B><FONT STYLE="font-size: 10pt">. A Payee will not receive any consideration for his,
her or its shares of Company Securities unless and until such Payee delivers the Letter of Transmittal or a facsimile thereof,
duly completed and signed, to the Paying Agent, together with the Certificate(s) representing such Company Securities and any
required accompanying evidences of authority in form satisfactory to the Paying Agent, who may request direction from the Parent
as to whether or not such documentation and evidences of authority are deemed satisfactory. If the Certificate(s) have been lost,
destroyed or wrongfully taken, the Payee will not receive any consideration for his, her or its Company Securities unless and
until such Payee delivers the documents referred to in Section 3(i). Upon making payment for Company Securities, the Paying Agent
shall physically cancel the Certificate(s) and retain them on behalf of the Surviving Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 13.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Payment
in Another Name</FONT></B><FONT STYLE="font-size: 10pt">.<B> </B>If payment is to be made by the Paying Agent to a person other
than the person in whose name a surrendered Certificate(s) is/are registered, the Paying Agent shall make no payment until the
Certificate(s) so surrendered has/have been properly endorsed (or otherwise put in proper form for transfer), including, without
limitation, a Medallion Signature Guaranty if necessary, and the person requesting such payment has paid any transfer or other
taxes or governmental charges required by reason of such payment in a name other than that of the registered holder of the Certificate(s)
or has established to the Paying Agent&rsquo;s reasonable satisfaction that such tax or charge either has been paid or is not
payable. Any tax information with respect to such payment which the Paying Agent is required to report pursuant to Section 5 of
this Agreement shall list the registered holder of the Certificate(s) as the payee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 13.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Lost,
Stolen or Mutilated Certificates.</FONT></B><FONT STYLE="font-size: 10pt"> In the event a Payee claims a Certificate has been
lost, stolen or destroyed, the Paying Agent shall mail to such Payee documentation and instructions necessary to be completed
in order to effectively surrender the Company Securities represented by such Certificate, including instructions relating to the
payment to secure an indemnity/surety bond. Upon its receipt of such items (in lieu of surrender of the lost, stolen or destroyed
Certificate), accompanied by a duly executed Letter of Transmittal, the Paying Agent shall promptly make payment to the related
holder in accordance with Sections 3(b), 3(d) and 3(f) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
14.<FONT STYLE="font-size: 10pt"><U>Information and Reports.</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 14.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Monthly
Report</FONT></B><FONT STYLE="font-size: 10pt">. Upon written request, the Paying Agent shall deliver to the Representative and
Parent, at the addresses listed in Section 12(b) hereof, and to such other persons as the Representative or Parent may designate,
a monthly report of the items presented for exchange. Each such report shall include: the number of shares of Company stock or
Convertible Debt and, Paying Agency Earnout Shares, Paying Agency Acceleration Shares and cash paid in exchange therefore (previous
period, current period and total). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 14.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Maintaining
Records</FONT></B><FONT STYLE="font-size: 10pt">. The Paying Agent shall keep and maintain complete and accurate ledgers showing
all shares of Company stock and Convertible Debt. The Paying Agent is authorized to cooperate with and furnish information to
any organization or its legal representatives designated from time to time by the Representative or Parent in any manner reasonably
requested by either of them in connection with the Mergers and share exchange pursuant thereto. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
15.<FONT STYLE="font-size: 10pt"><U>Tax Reporting. </U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 15.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">The
Paying Agent shall prepare and mail to each Payee, other than Payee who demonstrate their status as nonresident aliens in accordance
with United States Treasury Regulations, a Form 1099-B reporting any cash payments, in accordance with United States Treasury
Regulations; the Paying Agent shall also prepare and electronically file copies of such Forms 1099-B with the Internal Revenue
Service, in accordance with United States Treasury Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 15.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">If
the Paying Agent has not received notice from the surrendering Payee of that Payee&rsquo;s certified Taxpayer Identification Number,
the Paying Agent shall deduct and withhold backup withholding tax from any cash payment made pursuant to Internal Revenue Code
regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 15.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">Upon
Paying Agent&rsquo;s request, Company agrees to consult with Paying Agent regarding Paying Agency&rsquo;s tax inquiries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
16.<FONT STYLE="font-size: 10pt"><U>Delivery of Paying Agency Shares, , Paying Agency Earnout Shares, Paying Agency Earnout Fund,
Paying Agency Acceleration Shares and Paying Agency Acceleration Fund. All distributions of Paying Agency Shares, Paying Agency
Earnout Shares and Paying Agency Acceleration Shares shall be made directly to the Payees in accordance with the disbursement
schedule as set forth on Exhibit A. The transfer of such Paying Agency Shares, Paying Agency Earnout Shares and Paying Agency
Acceleration Shares shall be evidenced in electronic or book-entry form and not by delivery of stock certificates. All payments
from the, Paying Agency Earnout Fund and Paying Agency Acceleration Fund shall be made by wire transfer of immediately available
funds to the account designated by the receiving Payee in the applicable Letter of Transmittal (provided that wire instructions
have been included in the applicable Letter of Transmittal). </U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
17.<FONT STYLE="font-size: 10pt"><U>Compensation. Parent agrees to pay upon demand the fees of the Paying Agent and the reasonable
expenses and disbursements incurred by the Paying Agent under this Agreement as set forth on Exhibit B.</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
18.<FONT STYLE="font-size: 10pt"><U>Duties of the Paying Agent. In the execution of its duties hereunder, the Paying Agent:</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 18.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">shall
have no duties or obligations other than those specifically set forth herein, all of which are ministerial and non-fiduciary in
nature, or as may be subsequently agreed to in writing by the Paying Agent, the Representative and Parent, and no implied duties
or obligations shall be read into this Agreement against the Paying Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 18.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">shall
not be regarded as making any representation as to, and shall have no responsibility for the validity, sufficiency, value or genuineness
of any Certificate(s), and the Paying Agent shall not be required to make any representations as to the validity, sufficiency,
value or genuineness of the Mergers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 18.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">shall
not be obligated to expend any of its own funds or to take any legal action hereunder which might in the Paying Agent&rsquo;s
sole judgment require it to risk the Paying Agent&rsquo;s own funds or incur any liability;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 18.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">may
rely on and be protected in acting in reliance upon any stock certificate, stock power, affidavit, instrument, opinion, notice,
letter, facsimile transmission, telex, telegram, electronic transmission or other document or security delivered to the Paying
Agent and believed by the Paying Agent in good faith to be genuine and to have been signed by the proper party or parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 18.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">may
rely on and be protected in acting in reliance upon the written instructions of the Representative, Parent or any other employee
or representative designated by either of the Representative or Parent in accordance with this Agreement with respect to any matter
relating to the Paying Agent&rsquo;s actions hereunder;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 18.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">shall
have no obligation to make any payment as the Paying Agent unless Parent shall have provided the necessary available funds to
make such payments;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 18.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">shall
not be liable or responsible for any failure of the Representative, Parent or the Surviving Company to comply with any of their
respective obligations relating to the Mergers, including, without limitation, obligations under applicable securities laws;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 18.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">shall
not be liable for any error in judgment made or action taken or omitted by Paying Agent in good faith in the course of performance
or administration under this Agreement. The Paying Agent shall not be liable for any action taken or omitted by it in good faith
except to the extent that a court of competent jurisdiction determines that the Paying Agent&rsquo;s gross negligence or willful
misconduct in breach of this Agreement was the sole cause of any loss to Parent. Under no circumstances shall the Paying Agent
be liable for special, indirect, incidental, punitive or consequential loss or damage of any kind (including, without limitation,
lost profits), even if Paying Agent has been advised in advance of the possibility of such loss or damage;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 18.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">may
consult with counsel satisfactory to it (including in-house counsel) and shall be held harmless in relying on the advice or opinion
of such counsel in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with such
advice or opinion of such counsel; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 18.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">is
authorized, in its sole discretion, to comply with final orders issued or process entered by any court with respect to the Paying
Agency Shares, Paying Agency Earnout Shares, Paying Agency Earnout Fund, Paying Agency Acceleration Shares and Paying Agency Acceleration
Fund or this Agreement, without determination by the Paying Agent of such court&rsquo;s jurisdiction in the matter. If any portion
of the Paying Agency Shares, Paying Agency Earnout Shares, Paying Agency Earnout Fund, Paying Agency Acceleration Shares or Paying
Agency Acceleration Fund is at any time attached, garnished or levied upon under any court order, or in case the payment, assignment,
transfer, conveyance or delivery of any such property shall be stayed or enjoined by any court order, or in case any order, judgment
or decree shall be made or entered by any court affecting such property or any part thereof, then and in any such event, the Paying
Agent is authorized, in its sole discretion, to rely upon and comply with any such order, writ, judgment or decree which it is
advised by legal counsel selected by it is binding upon it without the need for appeal or other action; and if the Paying Agent
complies with any such order, writ, judgment or decree, it shall not be liable to any of the parties hereto or to any other person
or entity by reason of such compliance even though such order, writ, judgment or decree may be subsequently reversed, modified,
annulled, set aside or vacated. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">The provisions of this
Section 8 shall survive the termination of this Agreement or the resignation or removal of the Paying Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
19.<FONT STYLE="font-size: 10pt"><U>Indemnification of Paying Agent. From and at all times after the date of this Agreement, Parent
and Representative (solely on behalf of the Payees and not in its individual capacity), jointly and severally, shall, to the fullest
extent permitted by law, indemnify and hold harmless each Paying Agent Indemnitee against any and all actions, claims (whether
or not valid), losses, damages, liabilities, penalties, costs and expenses of any kind or nature (including without limitation
reasonable attorneys' fees, costs and expenses) incurred by or asserted against any of the Paying Agent Indemnitees, whether direct,
indirect or consequential, as a result of or arising from or in any way relating to any claim, demand, suit, action or proceeding
(including any inquiry or investigation) by any person, including without limitation Parent, Representative and any Payee, whether
threatened or initiated, asserting a claim for any legal or equitable remedy against any person under any statute or regulation,
including, but not limited to, any federal or state securities laws, or under any common law or equitable cause or otherwise,
arising from or in connection with the negotiation, preparation, execution, performance or failure of performance in connection
with this Agreement or any transactions contemplated herein, whether or not any such Paying Agent Indemnitee is a party to any
such action, proceeding, suit or the target of any such inquiry or investigation; provided, however, that no Paying Agent Indemnitee
shall have the right to be indemnified hereunder for any liability finally determined by a court of competent jurisdiction, subject
to no further appeal, to have resulted solely from the gross negligence or willful misconduct of such Paying Agent Indemnitee
in breach of this Agreement. Parent and Representative (solely on behalf of the Payees and not in its individual capacity) further
agree, jointly and severally, to indemnify each Paying Agent Indemnitee for all costs, including without limitation reasonable
attorney&rsquo;s fees, incurred by such Paying Agent Indemnitee in connection with the enforcement of Parent&rsquo;s and Representative&rsquo;s
indemnification obligations hereunder. The provisions of this Section 9 shall survive the termination of this Agreement or the
resignation or removal of the Paying Agent.</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
20.<FONT STYLE="font-size: 10pt"><U>Termination of Agreement. This Agreement shall terminate either:</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 20.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">upon
the exchange of all shares of Company Securities and distribution in full of the Paying Agency Shares, Paying Agency Earnout Shares,
Paying Agency Earnout Fund, Paying Agency Acceleration Shares and Paying Agency Acceleration Fund;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 20.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">following
the date that no further Revenue Earnout Payment, Milestone Payment, or Accelerated Payment can become due and payable by Parent,
upon the distribution of all amounts remaining of the Paying Agency Shares, Paying Agency Earnout Shares, Paying Agency Earnout
Fund, Paying Agency Acceleration Shares and Paying Agency Acceleration Fund in accordance with the provisions of Sections 3(b),
3(d) and 3(f) hereof; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 20.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">at
the option of the Representative and Parent, on the one hand, or the Paying Agent, on the other hand, with thirty (30) days&rsquo;
prior written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Upon any termination of this Agreement pursuant to subsection (c) of this Section 10, the Paying Agent shall
promptly deliver to Parent any Certificate(s), funds or other property not permitted to be retained by the Paying Agent. After
such time, any party entitled to such Certificate(s), funds or property shall look solely to Parent, not to the Paying Agent or
Representative, and any liability of the Paying Agent with respect thereto shall cease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
21.<FONT STYLE="font-size: 10pt"><U>Force Majeure. No party shall be liable to any other, or held in breach of this Agreement,
if prevented, hindered, or delayed in performance or observance of any provision contained herein by reason of act of God, riots,
acts of war, acts of terrorism, epidemics, governmental action or judicial order, earthquakes, or similar cause (including, but
not limited to, mechanical, electronic or communications interruptions, disruptions or failures).</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Article
22.<FONT STYLE="font-size: 10pt"><U>Miscellaneous.</U></FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Governing
Law; Jurisdiction</FONT></B><FONT STYLE="font-size: 10pt">. This Agreement will be construed under and governed by the laws of
the State of New York without regard to the conflicts of law principles of any jurisdiction. Except as otherwise provided in the
Merger Agreement, each of the parties submits to the jurisdiction of any state or federal court sitting in New York, New York,
in any action or proceeding arising out of or relating to this Agreement and agrees that all claims in respect of the action or
proceeding may be heard and determined in any such court. Each party also agrees not to bring any action or proceeding arising
out of or relating to this Agreement in any other court. Each of the parties waives any defense of inconvenient forum to the maintenance
of any action or proceeding so brought and waives any bond, surety, or other security that might be required of any other party
with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notices</FONT></B><FONT STYLE="font-size: 10pt">.
All notices required or permitted to be given under this Agreement will be in writing and will be deemed given (i) when delivered
in person, (ii) on the next business day after being deposited with a nationally recognized overnight courier service addressed
as set forth below or (iii) upon dispatch if sent by facsimile with telephonic confirmation of receipt from the intended recipient
to the facsimile number set forth below (or to such other respective addresses as may be designated by notice given in accordance
with the provisions of this Section, except that any notice of change of address will not be deemed given until actually received
by the party to whom directed):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 179.4pt; text-align: justify; text-indent: -107.4pt">&nbsp;</P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 179.4pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 179.4pt; text-align: justify; text-indent: -107.4pt">If to Representative:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1in">Earl Bright</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1in">2570 W. El Camino
Real</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1in">Suite 310</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1in">Mountain View,
CA 94040</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1in">Attention: Earl
Bright</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in; text-align: justify; text-indent: -1in">E-mail: <U>ebright@nuelle.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Wilson Sonsini Goodrich &amp; Rosati P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">650 Page Mill Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Palo Alto, CA 94304</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">E-mail: poettinger@wsgr.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Attention: Philip Oettinger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 179.4pt; text-align: justify; text-indent: -107.4pt">If to Parent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt">Aytu BioScience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt">373 Inverness Parkway, Suite 206</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt">Englewood, CO 80112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt">E-mail:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt">Attention:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">with a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Wyrick Robbins Yates &amp; Ponton
LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">4101 Lake Boone Trail, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Raleigh, NC 27607</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Facsimile: (919) 781-4865</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">E-mail: dmannheim@wyrick.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Attention: David Mannheim</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">If to the Paying Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">VStock Transfer, LLC, a California
limited liability company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">Attention:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Entire
Agreement</FONT></B><FONT STYLE="font-size: 10pt">. This Agreement supersedes all prior agreements between the parties with respect
to the subject matter of this Agreement. This Agreement constitutes a complete and exclusive statement of the terms of the agreement
between the parties with respect to its subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Amendments
and Waivers</FONT></B><FONT STYLE="font-size: 10pt">. This Agreement may not be amended, modified, altered or supplemented without
the prior written consent of all parties to the Agreement. No failure or delay by any party to exercise any right or remedy under
this Agreement will constitute as a waiver of such right or remedy. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section
22.5&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Severability of Invalid
Provision</FONT></B><FONT STYLE="font-size: 10pt">. If any provision of this Agreement is held invalid or unenforceable by
any court of competent jurisdiction, the other provisions of this Agreement will remain in full force and effect. Any
provision of this Agreement held invalid or unenforceable only in part or degree will remain in full force and effect to the
extent not held invalid or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Successors
and Assigns</FONT></B><FONT STYLE="font-size: 10pt">. This Agreement is enforceable by, and inures to the benefit of, the parties
to this Agreement and their respective successors and assigns. Neither this Agreement nor any right, interest or obligation under
this Agreement may be assigned by any party to this Agreement without the prior written consent of the other parties hereto and
any attempt to do so will be void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Status
of Parties</FONT></B><FONT STYLE="font-size: 10pt">. The relationship of the parties to each other in the execution and performance
of this Agreement shall be that of independent contractors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Rules
of Construction</FONT></B><FONT STYLE="font-size: 10pt">. Section headings contained in this Agreement are inserted only as a
matter of convenience and in no way define, limit, extend or describe the scope of this Agreement or the intent of any of the
provisions of this Agreement. This Agreement has been negotiated on behalf of the parties with the advice of legal counsel and
no general rule of contract construction requiring an agreement to be more stringently construed against the drafter or proponent
of any particular provision may be applied in the construction or interpretation of this Agreement. Unless otherwise expressly
provided, the word &ldquo;including&rdquo; does not limit the preceding words or terms. Except as otherwise indicated, all references
in this Agreement to &ldquo;Sections&rdquo; and &ldquo;Exhibits&rdquo; are intended to refer to Sections of this Agreement and
Exhibits to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Counterparts</FONT></B><FONT STYLE="font-size: 10pt">.
This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of this Agreement
and all of which, when taken together, will be deemed to constitute one and the same agreement. The exchange of copies of this
Agreement and of signature pages by facsimile transmission will constitute effective execution and delivery of this Agreement
as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by
facsimile will be deemed to be their original signatures for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Cumulative
Remedies</FONT></B><FONT STYLE="font-size: 10pt">. The powers, rights, privileges and remedies provided in this Agreement are
cumulative and not exclusive or alternative and are in addition to any and all other powers, rights, privileges and remedies granted
by law, rule, regulation or instrument. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Further
Assurances</FONT></B><FONT STYLE="font-size: 10pt">. Each of the parties shall execute and deliver such additional instruments
and other documents and shall take such further actions as may be necessary or appropriate to effectuate, carry out and comply
with all of the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Patriot
Act</FONT></B><FONT STYLE="font-size: 10pt">. To help the government fight the funding of terrorism and money laundering activities,
Federal law requires all financial institutions to obtain, verify and record information that identifies each person who opens
an account. For a non-individual person such as a business entity, a charity, a Trust or other legal entity the Paying Agent will
ask for documentation to verify its formation and existence as a legal entity. The Paying Agent may also ask to see financial
statements, licenses, identification and authorization documents from individuals claiming authority to represent the entity or
other relevant documentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><B>Section 22.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Third
Party Beneficiaries.</FONT></B><FONT STYLE="font-size: 10pt"> This Agreement is not intended to be for the benefit of or to be
enforceable by any third party; and no third party shall be entitled to claim that it is a third party beneficiary hereof. Neither
party shall make any commitments with third parties that are binding on the other party without the other party&rsquo;s prior
written consent. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">IN WITNESS WHEREOF, this Agreement has been
duly executed by the parties hereto as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PAYING AGENT:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase">VStock Transfer, LLC, </FONT><FONT STYLE="font-size: 10pt">a California limited liability company</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PARENT:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">AYTU BIOSCIENCE, INC.,<B> </B>a Delaware corporation</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>REPRESENTATIVE:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">EARL BRIGHT</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><I>[Signature page of
Paying Agent Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in">&nbsp;</P>

<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Distribution Schedule</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As provided to Paying Agent on ___________,
2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Exhibit B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Schedule of Fees for Services as</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Paying Agent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Exhibit C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form of Letter of Transmittal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>LETTER OF
TRANSMITTAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>for Securities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>NUELLE, INC</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><I>The Paying Agent for the Merger is: </I>VStock
Transfer, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>DELIVERY INSTRUCTIONS</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">VStock Transfer, LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Attn: _____</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">18 Lafayette Place</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Woodmere, NY 11598</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>For information please email info@vstock.com or call (212) 828-8436</I></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>THE INSTRUCTIONS ACCOMPANYING
THIS LETTER OF TRANSMITTAL SHOULD BE READ CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED. IF CERTIFICATES ARE REGISTERED
IN DIFFERENT NAMES, A SEPARATE LETTER OF TRANSMITTAL MUST BE SUBMITTED FOR EACH DIFFERENT REGISTERED HOLDER. SEE INSTRUCTION 4.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with
the merger (the &ldquo;<B>Merger</B>&rdquo;) of Aytu Acquisition Corporation, Inc. (&ldquo;<B>Merger Sub</B>&rdquo;), a
wholly owned subsidiary of Aytu Bioscience, Inc. (&ldquo;<B>Buyer</B>&rdquo;), with and into Nuelle, Inc. (the
&ldquo;<B>Company</B>&rdquo;), and immediately following the Merger, the surviving corporation&rsquo;s merger with and into
Aytu Holdings, LLC, a wholly-owned subsidiary of Buyer (&ldquo;<B>Second Merger Sub</B>&rdquo;), all in accordance with that
certain Merger Agreement dated as of May ___, 2017 (the &ldquo;<B>Merger Agreement</B>&rdquo;), by and among Buyer, Merger
Sub, Second Merger Sub, the Company, and Earl Bright as &ldquo;Representative,&rdquo; the undersigned herewith surrenders the
below described Secured Convertible Promissory Notes of the Company, Securities of Company Common Stock, par value $.001 per
share, and/or Securities of Company Preferred Stock, par value $.001 per share (collectively, the
&ldquo;<B>Securities</B>&rdquo;), as applicable, and the certificate(s) (the
&ldquo;<B>Certificate(s)</B>&rdquo;) representing such Securities (collectively, the Certificate(s) are referred to herein as
the &ldquo;<B>Exchange Documentation</B>&rdquo;) to be exchanged for the consideration payable pursuant to the Merger
Agreement, without interest (and subject to applicable withholding and other adjustments) as contemplated by the Merger
Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>By delivery of this
Letter of Transmittal to VStock Transfer, LLC (the &ldquo;Paying Agent&rdquo;), the undersigned hereby (i) forever waives all
appraisal rights under applicable Delaware law, (ii) withdraws all written objections to the Merger and/or demands for appraisal,
if any, with respect to the Securities owned by the undersigned, (iii) appoints and irrevocably constitutes, effective as of the
date of the Merger Agreement, Earl Bright as the Representative (and any successor Representative appointed in accordance with
the terms of the Merger Agreement), with all power and authority set forth in and contemplated by the Merger Agreement, (iv) acknowledges
and agrees that the Securities (and the Exchange Documentation representing such Securities, where applicable) will be cancelled
as of the Effective Time in exchange for the consideration payable pursuant to the terms of the Merger Agreement, (v) acknowledges
that the undersigned shall be bound by all actions taken by the Representative in connection with or related to the matters set
forth in or reasonably contemplated by the Merger Agreement, including, without limitation, Section 8.1 thereof, and hereby adopts,
ratifies, confirms and approves in all respects all such actions, and (v) acknowledges, agrees and confirms that, by his, her
or its execution of this Letter of Transmittal, the undersigned hereby accepts that portion of the Aggregate Merger Consideration
to which he, she or it is entitled under the Merger Agreement subject to, from and after the Closing, the indemnification obligations,
and related limitations on such indemnification obligations, of a &ldquo;Company Securityholder&rdquo; under the Merger Agreement
for his, her or its applicable share of any Losses under Article VII of the Merger Agreement, including, among other things, that
except in the event of fraud, the undersigned&rsquo;s indemnification obligations shall be limited as described in Section 7.2(b)
of the Merger Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 99; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Letter of Transmittal
should be completed and returned to the Paying Agent by all Company Securityholders surrendering Securities with all other documents
required by this Letter of Transmittal to be delivered to the Paying Agent in exchange for the Merger Consideration payable in
respect of such Securities. The undersigned understands that surrender is not made in acceptable form until the receipt by the
Paying Agent of this Letter of Transmittal duly completed and signed, and of the appropriate Exchange Documentation, together
with all accompanying evidences of authority in form satisfactory to Buyer (which may delegate power in whole or in part to the
Paying Agent). All questions as to validity, form and eligibility of any surrender of Securities hereby will be determined by
Buyer (which may delegate power in whole or in part to the Paying Agent) and such determination shall be final and binding. The
undersigned understands that payment for surrendered Securities delivered to the Paying Agent will be made as promptly as practicable
after the later of the Closing Date or the surrender of the Securities is made in acceptable form. The undersigned understands
that by surrendering the Securities, the undersigned also surrenders Securities that may be issued, acquired or granted to the
undersigned after the Securities are surrendered and prior to the closing of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">By signing this Letter
of Transmittal, (i) the undersigned acknowledges and agrees that the Representative shall not have any liability to the Stockholders,
Buyer, Merger Sub, Second Merger Sub, the Company or their respective affiliates for any act done or omitted under the Merger
Agreement or under any other related agreement as Representative (except in the case of willful misconduct or fraud), and (ii)
the undersigned agrees to indemnify, hold harmless and defend the Representative from and against all losses arising out of or
in connection with (A) the Representative&rsquo;s actions taken, or omissions to act, arising out of, in connection with, or otherwise
with respect to the Merger Agreement, and (B) actions taken with respect to the Merger Agreement believed by the Representative
to be within the scope of its authority; provided that such Losses do not arise out of the willful misconduct or fraud of the
Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">By signing this Letter
of Transmittal the undersigned hereby represents and warrants to Buyer, Merger Sub, Second Merger Sub, the Company and Paying
Agent that (a) the undersigned has received a copy of the Merger Agreement and understands the terms, conditions and transactions
(including any obligations of the Company Securityholders or payments that may be adjusted, offset or made from the Aggregate
Merger Consideration) described therein, (b) the undersigned has full power, authority, and legal capacity to execute and deliver
this Letter of Transmittal and to consummate the transactions contemplated by this Letter of Transmittal and the Merger Agreement,
(c) this Letter of Transmittal has been duly executed and delivered and constitutes a legal, valid, and binding obligation of
the undersigned, enforceable in accordance with its terms, (d) the undersigned is the record and beneficial owner of the Securities
shown in the box on page four of this Letter of Transmittal, free and clear of all encumbrances or other obligations under any
contract to sell, dispose or transfer such Securities (other than pursuant to the Merger Agreement), and possesses full legal
right, power, and authority to deliver and surrender all right, title, and interest in and to such Securities (and the Exchange
Documentation representing such Securities, where applicable), for cancellation at the Effective Time pursuant to the terms of
the Merger Agreement, without the consent of any third party that has not also executed this Letter of Transmittal, and (e) the
undersigned has no, and has no right or obligation to acquire any, other Securities or other securities of any type or nature
of the Company. The undersigned hereby understands, acknowledges and agrees that all of the representations, warranties and agreements
contained in this Letter of Transmittal shall survive the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Letter of Transmittal
shall be governed by and construed in accordance with the internal substantive laws of the State of North Carolina applicable
to contracts executed in and to be performed in that state, without regard to the conflicts of laws principles thereof to the
extent the same would require the application of the laws of another jurisdiction. No authority herein conferred or agreed to
be conferred shall be affected by, and all such authority shall survive, the death or incapacity of the undersigned. All obligations
of the undersigned hereunder shall be binding upon the heirs, executors, administrators, legal representatives, successors and
assigns of the undersigned. The surrender of the Securities hereby made is irrevocable. The undersigned will, upon request, execute
and deliver any additional documents reasonably deemed appropriate or necessary by Buyer or Paying Agent in connection with the
surrender of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For and in consideration
of the right to receive the applicable portion of the Aggregate Merger Consideration, the undersigned hereby releases, acquits
and forever discharges Buyer, the Company, each of Buyer&rsquo;s and the Company&rsquo;s respective subsidiaries and affiliates
and each of Buyer&rsquo;s, the Company&rsquo;s and Buyer&rsquo;s and the Company&rsquo;s respective subsidiaries&rsquo; and affiliates&rsquo;
present, former and future officers, directors, attorneys, agents, representatives, trustees, affiliates and employees and each
of their respective heirs, executors, administrators, successors and assigns (each, a &ldquo;<B>Released Party</B>&rdquo;), of
and from any and all manner of action or actions, cause or causes of action, demands, rights, damages, debts, dues, sums of money,
accounts, reckonings, costs, expenses, responsibilities, covenants, contracts, controversies, agreements and claims whatsoever,
whether known or unknown, of every name and nature, both in law and in equity (each, a &ldquo;<B>Claim</B>&rdquo;), which the
undersigned or any of the undersigned&rsquo;s heirs, executors, administrators, successors or assigns (collectively, &ldquo;<B>Releasing
Party</B>&rdquo;) ever had, now has, or which the undersigned or the undersigned&rsquo;s heirs, executors, administrators, successors
or assigns hereafter may have or shall have against the Company or any other Released Party arising out of any matters, causes,
acts, conduct, claims, circumstances or events occurring or failing to occur or conditions existing at or prior to the Effective
Time; provided, however, that the foregoing release shall not cover or otherwise in any way affect (i) the right to receive the
payments due to the undersigned pursuant to or any other rights of the undersigned arising under the Merger Agreement and any
document contemplated by the Merger Agreement, whether as of the date hereof or following the date hereof, (ii) if the undersigned
is a present or former employee or consultant of Company, rights to earned but unpaid cash compensation, including any bonuses,
or unreimbursed business expenses incurred as of the Effective Time and reimbursable pursuant to the Company&rsquo;s business
expense policy, (iii)&nbsp;unreimbursed claims under employee health, welfare and pension plans, consistent with the terms of
coverage, and (iv)&nbsp;rights of indemnification, advance of expenses, reimbursement and other coverage for liability pursuant
to the Company Charter, the Company&rsquo;s Bylaws and any indemnification agreement with the Company or any directors&rsquo;
and officers&rsquo; liability insurance policy. Neither the undersigned nor any of the undersigned&rsquo;s heirs, executors, administrators,
successors or assigns has heretofore assigned, and shall not hereafter sue any Released Party upon, any Claim released, acquitted
or discharged or purported to be released, acquitted or discharged under this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>The undersigned acknowledges
and agrees that, as set forth in Section 1.4(f) of the Merger Agreement, at Closing the Parent Securities to be issued pursuant
to the Merger Agreement will not be registered under the Securities Act, or under any state securities laws. Under the Securities
Act, such securities will be not be eligible for transfer except in accordance with applicable law and the provisions of the Merger
Agreement. Prior to transfer, such Securities must be (i)&nbsp;registered under the Securities Act or (ii) otherwise be eligible
to be transferred without restriction in accordance with Rule 144 or another exemption from registration under the Securities
Act.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please issue the payment
to which the undersigned is entitled in the name set forth and deliver such payment by the method set forth, unless otherwise
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>PLEASE CAREFULLY READ THE ACCOMPANYING<BR>

INSTRUCTIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DO NOT USE WHITEOUT OR CORRECTION TAPE &ndash;
DO NOT CROSS OUT INCORRECT<BR>
 INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONTACT VSTOCK TRANSFER, LLC, TEL _____
FOR ADDITIONAL COPIES OF THE<BR>
 LETTER OF TRANSMITTAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="9" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>DESCRIPTION OF CERTIFICATES AND SURRENDERED SECURITIES</B></FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Name(s) and Address </B><BR>
<B>of Registered </B><BR>
<B>Holder(s)</B><BR>
<B>(Please fill in, exactly </B><BR>
<B>as name(s)<BR>
appear(s) on Share <BR>
Certificate(s))</B></P></TD>
    <TD NOWRAP STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="7" NOWRAP>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Security Position(s) Surrendered (Attach additional signed list if necessary)</B></FONT></TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 20%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Type of Interest </B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt; text-align: center; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; width: 25%; border-bottom: Black 1pt solid; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Class/Series of Share(s)/Notes<BR>
(e.g.,
Common Stock, Series A<BR>
 Preferred Stock or Series A-1 <BR>
Preferred Stock)</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt; text-align: center; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 15%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Certificate<BR>
 Number(s) </B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt; text-align: center; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; width: 18%; border-bottom: Black 1pt solid; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Check Box if<BR>
 Lost/Misplaced</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><SUP>(See Instruction 10)</SUP></B></P></TD>
    <TD NOWRAP STYLE="width: 1%; padding-bottom: 1pt; text-align: center; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; width: 18%; border-bottom: Black 1pt solid; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number of Securities </B><BR>
<B>or Principal Amount </B><BR>
<B>Represented by <BR>
Certificate(s) </B></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>COMPLETE <U>ONLY ONE</U> OF THE PAYMENT INSTRUCTION
SECTIONS BELOW</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%; border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><u>CHECK PAYMENT INSTRUCTIONS</u></b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">If you wish to have cash consideration
        to be issued to you in the Merger (as defined herein) sent by <b>check</b>, please complete the remainder of this Letter of Transmittal
        and provide mailing address instructions below.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Address <u>____________________________________________________________________________________</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">City, State, Zip _______________________________________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Country ____________________________________________________________________________________</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%; border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><u>WIRE PAYMENT INSTRUCTIONS</u></b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">If you wish to have cash consideration
        to be issued to you in the Merger (as defined herein) sent by <b>wire transfer</b>, please complete the remainder of this Letter
        of Transmittal and provide wire instructions below or include such instructions herewith. <b><i>For international wires, please
        provide the SWIFT code (BIC) in the Fedwire ABA Number field and the complete IBAN in the Account Number field, if available.</i></b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Bank Name _________________________________________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Fedwire ABA Number* ________________________________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Account Name** <U>____________________________________________________________________________</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Account Number ____________________________________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">FFC Account Name (if applicable) <u>________________________________________________________________</u></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">FFC Account Number (if applicable) ________________________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Bank Contact/Telephone Number ________________________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">*Please provide valid Fedwire ABA (Check validity
        here: http://www.fedwiredirectory.frb.org/search.cfm)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">**Please provide the name on the account not
        the type of account</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(If wire is to be issued to an account in a
        name other than that set forth in the description of Securities surrendered box above, See Instructions 3, 4, 5 and 7)</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%; border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><u>SPECIAL PAYMENT/DELIVERY INSTRUCTIONS</u></b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(See Instructions 3, 4, 5, 7 and 11)</b></P></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify"><b>If you wish to have cash consideration
        to be issued in a name other than that of the registered holder and sent by check, please complete the remainder of this Letter
        of Transmittal and provide the payment instructions below.</b>***</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Payee Name  _______________________________________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Address  __________________________________________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">City, State, Zip  _____________________________________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Country __________________________________________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt">Tax Identification Number**** <u>________________________________________________________________</u></P></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">***Requires signature guarantee. See Instruction
        No. 3 to this Letter of Transmittal.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">****Fill in Taxpayer Identification Number of
        Payee. See Instruction 11 to this Letter of Transmittal.</P></td></tr>
</table>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="width: 100%; border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-decoration: underline; text-align: center"><font style="font-size: 10pt"><b><u>IMPORTANT &ndash; COMPANY SECURITYHOLDER SIGNATURE PAGE</u></b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><font style="font-size: 10pt">Must be signed by registered holder(s) exactly as name(s) appear(s) on stock certificate(s), a security position listing or by person(s) authorized to become registered holder(s) by certificates and documents transmitted herewith. Signature below certifies that no language alterations have been made in any way to this form of Letter of Transmittal. If signature is by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, please set forth full title. See Instruction 4. (For information concerning signature guarantees see Instruction 3.)</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><font style="font-size: 10pt">Dated ________________________&nbsp;&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><font style="font-size: 10pt">Sign
    Here&nbsp;&nbsp;X<u> ______________________________________________________________________________</u></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>(Signature(s) of Owner(s))</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name(s)
 _________________________________________________________________________________</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>(Please Print)</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Capacity
 _________________________________________________________________________________</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><font style="font-size: 10pt"><b>(See Instruction 4)</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Address
 _________________________________________________________________________________</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Area
Code &amp; Telephone No. _____________________________</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Email
Address  _______________________________________________________________________________</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><b>(Complete the attached Form W-9. See instruction 11.)</b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top; background-color: black">
    <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: white">STOP &ndash; CAREFULLY REVIEW
        INSTRUCTION 3 PRIOR TO COMPLETING REMAINDER OF PAGE</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: white">Securities need not be endorsed
        and transfer powers and signature guarantees are unnecessary unless (a) the Securities are registered in a name other than that
        of the person surrendering the Securities or (b) such registered holder completes the Special Payment/Delivery Instructions or
        requests payment to a name other than the registered holder.</P></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-left: black 1.5pt solid; border-right: black 1.5pt solid; text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURE GUARANTEE </U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-left: black 1.5pt solid; border-right: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(This section should be completed by the individual applying the MSG Stamp)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-left: black 1.5pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 45%; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Apply
    Medallion Signature Guarantee Stamp Here) &nbsp;</B></FONT></TD>
    <TD STYLE="width: 5%; border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signature ____________________________</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name ________________________________________</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-right: Black 1pt solid; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Please Print)</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; text-indent: 99pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title _________________________________________</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-right: Black 1pt solid; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Please Print)</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; text-indent: 99pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Firm __________________________________</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Area Code &amp; Telephone No. _______________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: black 1.5pt solid; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address ______________________________________</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>INSTRUCTIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify"><I>Delivery of Letter of Transmittal and Surrender of Exchange
Documentation</I>. This Letter of Transmittal, filled in and signed, must be used in connection with the delivery and surrender
of the Exchange Documentation. A Letter of Transmittal and Exchange Documentation must be received by Paying Agent in satisfactory
form in order to make an effective surrender. Delivery of the Exchange Documentation and other documents, as applicable, shall
be effected, and the risk of loss and title to the Exchange Documentation shall pass, only upon proper surrender of the Exchange
Documentation to Paying Agent. The method of surrender of the Exchange Documentation and other documents is at the election and
risk of the holder. If such surrender is by mail, registered mail with return receipt requested, properly insured, is recommended.
Surrender may be made by mail, by hand or by overnight courier to VStock Transfer, LLC, as Paying Agent, at one of the addresses
shown above. Upon surrender of the Exchange Documentation, any Securities issued subsequent to such surrender and prior to the
closing of the Merger shall be deemed to be surrendered for payment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify"><I>Terms of Conversion of the Securities</I>. Each Equity
Interest (as shown in the box on the second page of this Letter of Transmittal) will be converted at the Effective Time of the
Merger into the right to receive the consideration payable pursuant to the Merger Agreement, without interest (and subject to
applicable withholding contemplated by the Merger Agreement).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify"><I>Guarantee of Signature</I>. Securities need not be endorsed
and transfer powers and signature guarantees are unnecessary unless (a) the Securities are registered in a name other than that
of the person surrendering the Securities or (b) such registered holder completes the Special Payment/Delivery Instructions or
requests payment to a name other than the registered holder. In the case of (a) above, any such Securities must be duly endorsed
or accompanied by a properly executed transfer power with the signature on the endorsement or transfer power and on the Letter
of Transmittal guaranteed by a participant in the Security Transfer Agents Medallion Program, the New York Stock Exchange Medallion
Signature Guarantee Program or the Stock Exchange Medallion Program (each, an &ldquo;Eligible Institution&rdquo;). In the case
of (b) above, only the signature on the Letter of Transmittal should be similarly guaranteed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify"><I>Signatures on Letter of Transmittal and Endorsements</I>.
If this Letter of Transmittal is signed by the registered holder(s) of the Securities surrendered hereby, the signature(s) must
correspond with the name(s) as written on the face of the Exchange Documentation, without alteration, enlargement or any change
whatsoever. If any of the Securities surrendered hereby are registered in different names, it will be necessary to complete, sign
and submit as many separate Letters of Transmittal as there are different registrations of Exchange Documentation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">If any of the Securities surrendered
hereby are held of record by two or more joint owners, all such owners must sign this Letter of Transmittal. If this Letter of
Transmittal or any Exchange Documentation or transfer power is signed by a trustee, executor, administrator, guardian, attorney-in-fact,
officer of a corporation or other person acting in a fiduciary or representative capacity, such person should so indicate when
signing, and proper evidence satisfactory to the Company of the authority of such person so to act must be submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">If this Letter of Transmittal is
signed by the registered holder(s) of the Securities listed and surrendered hereby, no endorsements of Exchange Documentation
or separate transfer powers, as applicable, are required unless payment is to be issued in the name of a person other than the
registered holder(s). Signatures on any such Exchange Documentation or transfer powers, as applicable, must be guaranteed by an
Eligible Institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">If this Letter of Transmittal is
signed by a person other than the registered holder(s) of the Securities listed and surrendered hereby, the Securities must be
endorsed or accompanied by appropriate transfer powers, in either case signed exactly as the name(s) of the registered holder(s)
appear(s) on the Equity Documentation. Signature(s) on any such Exchange Documentation or transfer powers must be guaranteed by
an Eligible Institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify"><I>Transfer Taxes</I>. The registered holder(s) of the
Securities surrendered hereby will bear liability for any state stock transfer taxes applicable to the delivery of checks in payment
for surrendered Securities; provided, however, that if any such check is to be issued to any person(s) other than the registered
holder(s) of the surrendered Securities, it shall be a condition of the issuance and delivery of such check that the amount of
any stock transfer taxes (whether imposed on the registered holder(s) or such person(s)) payable on account of the transfer (or
transfers) of the surrendered Securities shall be delivered to Paying Agent or satisfactory evidence of the payment of such taxes
or nonapplicability thereof shall be submitted to Paying Agent before such check will be issued.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">6.</TD><TD STYLE="text-align: justify"><I>Validity of Surrender, Irregularities</I>. All questions
as to validity, form and eligibility of any surrender of Exchange Documentation hereby will be determined by Buyer (which may
delegate power in whole or in part to Paying Agent), and such determination shall be final and binding. Buyer reserves the right
to waive any irregularities or defects in the surrender of any Exchange Documentation and its interpretations of the terms and
conditions of the Merger Agreement and of this Letter of Transmittal (including these instructions) with respect to such irregularities
or defects shall be final and binding. A surrender will not be deemed to have been made until all irregularities have been cured
or waived. Parties entitled to payment may be contacted by Buyer or Paying Agent and requested to provide any missing or incomplete
information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">7.</TD><TD STYLE="text-align: justify"><I>Special Payment and Delivery Instructions</I>. Indicate
the name and address to which payment for the Securities is to be sent if different from the name and/or address of the person(s)
signing this Letter of Transmittal.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">8.</TD><TD STYLE="text-align: justify"><I>Requests for Information or Additional Copies</I>. Information
and additional copies of this Letter of Transmittal may be obtained by contacting Vstock Transfer, LLC at _____.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">9.</TD><TD STYLE="text-align: justify"><I>Inadequate Space</I>. If the space provided on this
Letter of Transmittal is inadequate, the Share certificate numbers, if applicable, and number of Securities should be listed on
a separate signed schedule affixed hereto.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">10.</TD><TD STYLE="text-align: justify"><I>Letter of Transmittal Required; Surrender of Exchange
Documentation; Lost Exchange Documentation</I>. You will not receive any cash for your Securities unless and until you deliver
this Letter of Transmittal duly completed and signed to Paying Agent, together, as applicable, with the Exchange Documentation
and any required accompanying evidences of authority in form satisfactory to the Buyer. If any Exchange Documentation has been
lost or destroyed, such fact should be indicated on the face of this Letter of Transmittal</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">11.</TD><TD STYLE="text-align: justify"><I>Form W-9.</I> Each holder surrendering Securities for
payment is required to provide Paying Agent with a correct Taxpayer Identification Number (&ldquo;TIN&rdquo;) and certain other
information on a Form W-9, or an appropriate IRS Form W-8. For more information, see &ldquo;Important Tax Information&rdquo; below.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>Important Tax Information:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In order to avoid backup
withholding of United States federal income tax, United States federal income tax law generally requires that if your Securities
are accepted for payment, you or your assignee (in either case, the &ldquo;Payee&rdquo;) must provide the Paying Agent (the &ldquo;Payor&rdquo;)
with the Payee&rsquo;s correct Taxpayer Identification Number (&ldquo;TIN&rdquo;), which, in the case of a Payee who is an individual,
is the Payee&rsquo;s social security number. If the Payor is not provided with the correct TIN or an adequate basis for an exemption,
the Payee may be subject to a $50 penalty imposed by the Internal Revenue Service (&ldquo;IRS&rdquo;) and backup withholding of
a portion (currently 28%) of the gross proceeds received pursuant to the Merger. Backup withholding is not an additional tax.
Rather, the tax liability of a person subject to backup withholding will be reduced by the amount withheld. If withholding results
in an overpayment of taxes, a refund may generally be obtained from the IRS provided that the required information is timely furnished
to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To prevent backup withholding,
each Payee must provide such Payee&rsquo;s correct TIN by completing the Form W-9 set forth herein, certifying that (i)&nbsp;the
TIN provided is correct, (ii)&nbsp;(a)&nbsp;the Payee is exempt from backup withholding, (b)&nbsp;the Payee has not been notified
by the IRS that such Payee is subject to backup withholding as a result of a failure to report all interest or dividends, or (c)&nbsp;the
IRS has notified the payee that such Payee is no longer subject to backup withholding, and (iii)&nbsp;the Payee is a U.S. Person
(including a U.S. resident alien).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain Payees (including,
among others, certain corporations and certain foreign individuals) are not subject to these backup withholding and reporting
requirements. To prevent possible erroneous backup withholding, an exempt Payee that is a U.S. person should check the &ldquo;Exempt
payee&rdquo; box on the Form W-9. In order for a nonresident alien individual or foreign entity to establish its exemption from
backup withholding, such person must submit an appropriate and properly completed Form W-8BEN, W-8ECI, W-8EXP or W-8IMY, as the
case may be, signed under penalties of perjury attesting to such exempt status. Such forms may be obtained from the Paying Agent
or the IRS at its Internet website: www.irs.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>PAYEES ARE URGED TO CONSULT THEIR TAX
ADVISOR REGARDING BACKUP WITHHOLDING. FAILURE TO COMPLETE AND RETURN THE FORM W-9 MAY RESULT IN BACKUP WITHHOLDING OF A PORTION
(CURRENTLY 28%) OF ANY PAYMENTS MADE TO YOU PURSUANT TO THE MERGER. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 107; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>v473641_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference
in Aytu BioScience, Inc.&rsquo;s Registration Statements on Form S-8 (File No. 333-205462) and Form S-1 (File Nos. 333-207421,
333-205414, 333-209874, 333-210144, 333-212100, and 333-213738) of our report dated August 31, 2017, relating to the consolidated
financial statements that appear in this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">/s/ EKS&amp;H LLLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">August 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Denver, Colorado</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>v473641_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Joshua R. Disbrow, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(1)</TD><TD>I have reviewed this annual report on Form 10-K for the year ended June 30, 2017 of Aytu BioScience, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(2)</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(3)</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(4)</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(d)</TD><TD>Disclosed in the report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of the annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(5)</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or
persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Dated: August 31, 2017</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Joshua R. Disbrow</FONT></TD>
    <TD>
</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Joshua R. Disbrow</FONT></TD>
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer (Principal Executive Officer)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>v473641_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECTION 302 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Gregory A. Gould, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(1)</TD><TD>I have reviewed this annual report on Form 10-K for the year ended June 30, 2017 of Aytu BioScience, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(2)</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(3)</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(4)</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(d)</TD><TD>Disclosed in the report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of the annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(5)</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 79.5pt"></TD><TD STYLE="width: 24.5pt">(b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Dated: August 31, 2017</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Gregory A. Gould</FONT></TD>
    <TD>
</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Gregory A. Gould</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>v473641_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PURSUANT TO 18 U.S. C. SECTION 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AS ADOPTED PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the annual report on Form 10-K of Aytu BioScience,
Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended June 30, 2017, as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), each of Joshua R. Disbrow, Chief Executive Officer (Principal Executive Officer),
and Gregory A. Gould, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), of the Company, certify,
pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to his
knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(1)</TD><TD>The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(2)</TD><TD>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Dated: August 31, 2017</FONT></TD>
    <TD STYLE="width: 50%; padding-left: 0.1in; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Joshua R. Disbrow&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.1in; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Joshua R. Disbrow</FONT></TD>
    <TD STYLE="padding-left: 0.1in; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer (Principal Executive Officer)</FONT></TD>
    <TD STYLE="padding-left: 0.1in; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Gregory A. Gould&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.1in; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Gregory A. Gould</FONT></TD>
    <TD STYLE="padding-left: 0.1in; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</FONT></TD>
    <TD STYLE="padding-left: 0.1in; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>v473641_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v473641_img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!= &/ P$1  (1 0,1 ?_$ ,X  0  !@,!
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M+F'2BAQ]_P#M_;D'F3_\,^]19H_YD[3],F@OIBVA4;1&X5S!.TXJ[HHLD?\
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M3'YUA827IDN=(<+LB3(E.*>DO.N'HXI]U94KD>IZ<9WSM_1[71K>.U:T!T3
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M*\[;ST9;4B.ZMA]E:5QY32E(?BN!:%^ZPM)_ X%(20>I! XR/5[.QU:W\B8
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M2#^X^G]N7"Z.:EOS'X*?#5L[IS\I'W+>I^T#LKCVM>7M1>?4H0KNBNH3?/\
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M%=U07NN25P[^DMZ24T>UR-:UTNO?0KG@CVY;32E!)Z$CD9LW3]SZ+J3<T$S
MT]2/N)6"7FCZG9$B6"0GL'XT4HY'VIY(20 M!40I0'/:%<\ 'D_=E]CGLI9C
M"RXAS 5KFP^Q6>9US!%YS[>?+6GRBOVJ)X22"0./O']HX)Y&4S]0T]EQ],9X
ML_6N"GLAO)+?ZAMO-D_U<?M7OK:JTNI"(=-665O,<*0B+65\N>^KN(2#V167
M2!R?4\#+=J.Y-&TR,R7$["T="/OHJZQTK4K]P9%!(">H_"JS*\2_M]_)3RP_
M&7_I!.C4D@H5^M[RK].;4PH%2G6*I*'K.1P!T_RDCGCJ/4:QUWUMVO86TK+<
M3ONP*-RAA%>I\?!9]I'I9N74IXVQF%C7'B\N Z\FE;?_ (]?MG^)/$4F#L6Z
MN+\G;A"[7V'[AE+6MP)([5<P:?\ S"\MI2?P.25.J YX YSG?=/JQKNX*PQ.
M=%:FHZN/W#V>]= ;5]+[/2&A^J".6X 'RU(^("V/Q*]N&VAF.VRPRVA+;;3"
M/:9;;0"&VFV$ -MI0GT[0/X9JISL[B^0ESCU6U[:"VM&9(&Y6E>SVSTXX^G/
MK_/*3R UV:/!1ETA.!%%V@<#@Y/%:>+BF//BHYZB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M0/H?X80<5P]00>0#]1R"/X$=0<B7KFYA1>5R.#V%"OZ3U[@%%0X(Y45<DGGZ
MCK@NDIX#0J4R"W!)F:"",*\E3-QH6G[,E0V/6-?O0IM3*Q;5$"P);4>5)"I3
M#BT@_<<G0ZGJUF08)9&@='$?8507&BZ1=?U(8W>P+&SRI\9/CM5:1N.SCPEX
MUEV&OZW?WD)$K7&4QW9,.KE2DM2D17(Y<:<6R >"" >G7+]I.Z-Q27PB;=SM
M<XM'SDFE5CFL[7T"+3RXV\>!)X*WWQ:\&?'[RAX&\5^4;7P/XJK+_=]/K+ZT
MC5.M-IKX\J6E94U#;ENR74-(2@#\2B2>N3-4W#KL&H/;]5/X74!SFOO4>CZ!
MH,^G-_(CQ;T]GW+,VA\>:)J[3;&N:EKM&EI(;;54TU? <2@<<)]V-';=4!Q]
M5'+#<:QK%W7S9I75XYGDU]AP5XMM%T6WPCAC!!Y-"JU,3M<2M*^$]_*DA(3R
M."".Y/"CS]Y(^[+5DN'2B21V Y*],9;L;EC8 1SHO8$A/4<_VD_[R<J5ZN6$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(N/:,]JO:E0* ?J?[<\))[%"]H>*.7+M
M ' Z81H#>"M;YG2/_2?R<.I'^@=K]3SQ_P#@-CZ?V9<-(C'ZK"_',Z1H/=F'
MXJUZ\ [2W5 5D?@:HJ^'OQ[Y^GC2A'3[D.^O]N3=WL%MK^I6T=?+M[ES6UXD
M  X]3CV*7MV-K=-CIS;][EE\$)]?YY9VBK0:G@KL(V UHN7'\?\ AD5%&HYZ
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$5KO,__ .U'DW_] [7_ /D-
MCESTC_J5O_ZK?]X*U:[_ -+=WJQWP+__ *>_'S_^-*+_ .JYDW>W_P"3ZS__
M *W_ .ZU-O\ _38^[[W+,(>@RRL^0=P5U3(D3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB816N\S_P#[4>3?_P! [7_^0V.7/2/^I6__ *K?]X*U:[_T
MMW>K'? O_P#I[\?/_P"-*+_ZKF3=[?\ Y/K/_P#K?_NM3;__ $V/N^]RS"'H
M,LK/D'<%=4R)$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")S@8\%X2!B5Q*T@$E0X
M'4Y[E*@,L8%210+B76TCN4M('IR3P.3Z#K]3GA\/%3&?F#,S$% \T>.%IZG@
M=>.3]G7('R,C +R #P49C>.(*XN2&6AW..)0GU)4>T #U))] ,FL8Z058*A4
MDUU;V_\ 6>UO>K+>7]JU>5X[\@TS&S:ZJVL--V.OA5Z[RK9E29LJGG,1XS;3
MTML^Z\\XE*0>.2<NFEQOBOX9) 1&V1I)/  .&*L6LZKILNG.CCFC,E>%<59_
MX6V=3J?QC\*:9L=U15.UZ_H5/67>OOWE0Y9U=@PESWH<MB--?]M]OGJ.3DS=
MC'7NX=4N;0>9;S7+G,<.#@6M%1V8)HVJZ;;:?&R>:-KZ<">TK,=N5'=2%MOM
M+3VA7<E:2GM(Y"NX'CMXZ\Y9A&]C1F!% K]'=6TW])[75Z%<OS#'/'NIYX!Z
M'GD'T(X]0><IVW,#I1"UP\T\N:J7-<QGF.%&=5R]YH@$.)(5SVD$$'CUX(Y'
M3(W2QM=E<0'+QK2\9FXA<PH*]"#_  R9Q%>2$$<5'"\3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A%UE7173G@\?[\AD.1M0H6>,D'D5T>^@I7_A[4\GNY ]/0'CA2A]@R36
MYE8?*^>F![4E\B(?FD!JQ5\[_,7P9X#9=A;?M+<S:$LA^/I]$E%E?O ]$%R.
MA19B-D_U*=4DI3U(S*MM;#W)N"7\F-SQ0&I!:TUZ.I0^Q8AKV\M*T6 Y9&YQ
MR!!/VK4#Y7_=:\N;._*A^+M?I_']45.-L6-FPC8-@4V>B7#[BT5L11X!"$MN
MI2<Z/VOZ"V['F?7W%\604;P =WAPX?%:!W/ZQZB\"/333Q8TIP]RP0W3Y#>;
MO(DER3N?E/=K<+2H"+^KO1822H\E,:OA&'$C-*^H3Q_#-G:=Z6;4TP'RXVXF
MIK4_:XK6][Z@;AU"I<]W[>Q6FD6$^7^*1/L7U>I,BPE/J4?KW!Q2D_WG,BCV
M?MQC<HCCIW#\58)=R:[F^=QP_;DN#,V;&<2[%E2HSG/*EL2Y,91/T),5U@D_
MSR/^TMN?\./_ &0I?]R:[2F=_P"WL5T=3\[^9=%=]S4?)^ZTB04E4>-L-D^P
MYV$'L6U)=+:VU<<%)Y21T/3+)K'I7M6_A+'QMRNQPJ,?8X+(M*]0=PVLH(>Z
MH_;HLZ?%7[J/FW5'8D/R154GD:G:+:')28Z:*_0RGIRB1!'Y*0^ !_6TGGZJ
M.:BW%Z#V$S'/T1QCG:W!M*YC7J7$C#HMHZ)ZPWT$S#JAS6@/BX##V <Z+;QX
M#^;'@OSVJ+6Z_L*:';7VU+7J&RENNN XV$^ZF(21%LDI*AVEH]Q^PYH+<7IW
MKFV9 _4('9,3F:"X4',D##VK=F@>H>CZ\ RU>T'H2.:R_9E,$N$+)">WDA"B
M.O/V _B^[U^[,0+PYV2A!'9U6=-80/,S!P=\%ZTJ"N>.>!QP?H>1SR#]>/\
M?A>KEA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A%Q[C_P!D_P!V>T4O.:\"I/9W%?4Q)DVSD-0H
M,-IR3+F276F8L:.TE2G7Y+[BTH990 >5'/&Q/NG^5&"3P]O<I5Q<0V$)N)G#
M+Q6BWY>?N43;5=IXZ^/DIZN@-.2*^W\@D!+DY+0*'6M3:/<AF*$__P#4KJY_
M@SI+TX]'I=1;'JVJOC9'&0[RG,KF Y'B#7MX+G+?_JGY?FV&GQR9G-+0\.
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M7O\ CMXZVEK5?E/\?[>$SK_E_8]/H5T6GVLVLC2K6PI)#UB_517S+5',T0W
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MIE.9+DRED;? .?[%1%EN&>9*152N7?5E<E:[&P@0&@"0Y-EL14@#U[@\I''
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M/Z#&@ 'D!P529ZK@F$3"+K65 C@\?;_MP<EOD#"*\%+>'DC(:+K*E?\ :/\
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MGU*Q+63L874 K6F-,H(J3R/%;@VEZJ7=M=06EP287/ -<*5PK4C !?1KXO\
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M,"UC=G>T#A0US<.OS8KICTTWZV*%FF2GQR48VO4X#G[ENX0XDI"RL%) 7SU
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M"):<71ZRE%W>NA7^82]8/AJ#&">.WA(<XYYZYJ'</^8NWFMI=*L( 9Y!1KN
M&(/2O =BVSHWH)=PRQ:E>3'(TU+>->7"I'-;:/"_Q*\)^ 8[1T74HXNEM@3=
MFMNRTOY;A3PM0G2&R(*5J )1&0RGIZ'USGO<?J%KVKRF*YFD,!/R-<0SVBN/
MM6]-O[ T+2X@]L3?J*<:"M?<LG8S?M)*1QQP#SQPHD\\E9Y)4K[_ %S'B\2@
M2"E2LMC;Y9,0^1O!>K/%-3")A$PBZ)!(;Y2.O<CZ\#CN'/=_W>/7)4V;)1O$
MD#XIPJ>@)]R^9W]S?S8]Y,\ZKT:ME)_TYXI954,AI7N-O;)+#3US(<0/\OWH
M)"6$GU'"OMSK[T1VN[3+%NL2M(,HK4].7PQHN1?5O=#=9OG:6TU$9I1:WP /
MPCH$\I ^@1ZC[NXDDG.BVMB-PV1E,Q&"TR&L^B>R3@#]JS ^/NFZ19Z?L)W2
M9IT:5Y'LWM U<;9[IDQULTLZ4]9ZVIF',3'LE74F$T5.EE!0TI/?PLYJ'?5W
MJ\.MQFQ\S(PYG9:8X@4-7# "OO!Y+-MO6^G.TIWFEH)'/_!596>*=$T_1M@?
MVK4K.9#=TW1)=OY$E7T94!^TMMVAU^R:_J]4ZR3"G4$$**GVRMU24J*SP1F,
M/W7N>VUAT#C6%KR&M:#4^!Q\1K0@X$< **_LV[HL^G1SU >YM3PZ]**H*#XR
M^-6]F=TVW%CL,B(=?K[NPH;Z982J21MLBTGT]FU&AE$*-20-61%_.S)"W&DR
MC[90.[*'4]_;H(C?8M#BY^-0:96TS#$C'-4"G+JIUGM31"Q^=XP:??RY*U$3
MQ7XL73UU*Z;2#?2=&OMSF;F[L"#7,3*GR ]J0K6J 1VXO:]4M>^MQ3B7N\I*
M!V<Y=!O'<IN:Y0+7S S+E=FJ6AU<U:=G"GM5!_:^E9?G&:E>2K&N\&^.?]3;
MU"OM%WFGA:D8477*"JGV6S[#O52Y9*BR=RA)JTUD@QH3+:#VQ/=C@/CW5>G-
MGU/>FZHK6.A8]SY20YO@ :*4::N^;'&ON4Z';FD1R9JBE*=?;P[%Z=$\?>-=
MPT+;_'B(\.DF6?EK87]8V/;H<"JV:!3:C35%S84UQ+5_G1!(HWYJ&6.C:I+2
M/KSDVXUW<#)/JIGRB$0MYN+?&X@>$$XUH*]%$W3-)>,C0W.3V<O8K@5U#XJW
M+>+"X=J]8JJ56J>)9&M4D=FFK::RV*QJ[-NF9LDEE,EDV<R,T9333K;;CKG^
M?RD\92VM[KS+:1TDDV9LL@!)-:9A7GC3D>BJ6V6C-H*-%0#RZ<>'-4QK-#73
MFM15YWU?5-4E.-;XKR-)13T6KV,'QS 9C*H;>/74R&H\:T9V=:F*YYMOWY$<
MJ')2 K)L%WK%K X6LTLP+@&YG%_B-:C-7AAPY*8ZWT=SJN#0>P4^Y3)N*Y21
M=A?F^.M,H*35[2TNG+%_5M5O]!W36V[*#'K:O]8<0[<:OL;5,I#<$\K1)9D*
M>4GWCW9+N[_5?JH3]=>%CXFT;GE\)Q+C3AEK0"G#@J)]II&)RMP=QH*?8NN-
M6T;NZ;KX]TS1H;=#K/\ I_6ZWR([KVL;8_5L3:^PN)4C<84\*DR*&VD3FF5S
MHKC4F(F,@=W;SERN]1UAK[.:6[O' 2@F,ODH\UHUH)PIQJ'<:]BD36VDB)_E
M!N?+A@/P6O:;&5"E2X0=:D(B3)\=,AD$M/\ MRU@N)!Z-@J'X4IZ)1TY.;MT
MM]R6>.M%K351&UWY*]5%>6>LW-5L=/+7!MZ*QA6]7+;/#L:= ?1(C26U#@\M
M+;Z_:"1Z9*UW2X=7L)K245!8<%.T+5;G2M1CN@2 '!?6'J_GMG9OB79^?:QJ
M,_-@>(MCW&7$;6%,MW^L:M8SY]>L\<)]FQKE(/W'. ]1T!^G;TBT)S2/.OXX
MNVDDC6@^XKN/3-Q?J.SIM8K5T%I(_P!K(W.^Y8!_N^^1%0M:\9^+XLGL_7;>
M=L]NPE1_%$IT-QH")"4GM#9FR2I'/JI&;7]"=$9>ZC+?S9@Z*F7H<23QQZ+5
MOKEJ\MO;,T]E"R08GF*K1'T(Z9V%)<ON;A@> T1].>'.JY@L8Q:6[XQXFR\2
M>([J8>]5CI>G+W%[8V46":[_ $_J-[M2G%Q7)29*:1A#WY(AM:/8_,E?'NJ/
M:CZY;=3UING-#LH=5P;[S2O<%<K:P9<&E2KD-_'3?SK*;MQF$JWF;#J>MU.I
MP9T"SO9$[;(TZ='_ %:+#F.+U\QH,,.]L@<.MN!0(X(S"[OU*L[2Y;"]H\DY
MJOQ#?#3Y22 [CRX$4600;2?.PN8YU13##G[%Y'?CMY6C3GX4NFJ8:(]0U?.V
M<W:*2)1IJEVB:<OIO'Y":M:DV#K;:D^X%-K6 1U!-S'J-MWZ3ZG._-B,N7Q5
M J?#7-PQ[E2_VM=^9D[*_M@IM*^-V[U,RCKKR70P[+8*38;F)5P;ZBL;* F@
M4^U);N6%VD)N"RR['5[CP6ML#H#W=,M3/4&RO'RN@8<K",2"*]V./L5QMMER
M3/#7O(!Z4K]B\GE'P!L_C>UE0F9<;8ZZLUD[':7\9R!%J&$Q51HMI#8FMV4^
M.X_!L+".V$N+:==2LJ"!Z9.V[O>SU><Q7@$)S.#0*U-,Q;4.H02!6E%0ZQM2
MXT\TMRY_#C[.@4E8\$>2),/5Y\.JK[.)M]C IJ:16WU1(BJM;.$].@Q9LM,H
MMUQD,-DCW@G@(5E1#ZBZ3()3(<GE<:@C#J*GQ#M%5[_:5]A0$YNG^&"GU-\:
MO)EG=557(;UZ# M)59$:V3_5&O2**0[9VBZM+%5,%HVU;V<9R+([X3*B^2WP
M!DFX]1["*,OB:7$ ^&A#J@$XCBT'J<%*?M:]:VHXU'[<%X:SPE-M*+R7=M[!
M#CKT.TLZNIK9$1Y,O<W*%+TB^<JN'%!E-57L&0OOY)1T'/KE(/4D&:*/R 62
M#$BIRX5%<:<<.2JF;/N71E]3F'[=%*&?"6_.R8,)4>@BRY=.F_D1)NUT,.73
M4Y99E"=LD:1+;7KC+T66PMDRNT/>\A((4>,O#_4#1H[22=Q.=C@!1I+7'HT_
MQ$$&H'"AKP5L?MK5/-#(V@MIB<</@NVR\%^2:6\@:_:4K#4^SB7,^&F-<4\Q
MAZ#KT?\ .W$M$QF>8ZFV(2T.MCD>\%'M/3(+'U$T6[MW3EX&4M!IU<: 8GK[
MN:K7;/U1K:Y3FIV_@JEF?&;R@B7*;@UL%Z$S^<<:E6%WK]=+_*0I$>"[-F5@
MMY3T.$FQ?#!?*E(#I">.2 ;9<^IUA;O+*-+AQI4TZ# \:8TXTJ>2ELVEJKA4
MLH/V[%9G9]9O-+O[#6]D@KK+FIE*CS8;_;^$E"'65MNH4MMUIUM?(4.A^F9]
MH&L6&N6OG.?ES,JW+2APPXJR7NG7UA)0M&!QK7\%*X5A*J)\.X@.N1YU;,C6
M,)YH\.,2X3S<F,\V?7N:>:21_#*;6X?U#2WZ=,/R\O$<?P46G3NL=39J$/\
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M>\?@J=UE8NXPQ^Y<DUD%)Y$9@$^I##0)_CP@9%FN_P#CR^]>?0V/_!C]RBJ
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M-:0VE*5KS[E4EQ\C]DN["+:SM;UMNVC56U4+SZ%6[HD4FTJ=7/@ICHF^Q_\
M(.R%.LNIX<6EP GIERT_TYM;2YDM#*7Q-:VF%,:',?FYU&'*G:JC^Y;^%]0V
MA_;L79L7G>WV_P =[#HSM>C]?W#>X6P.JAQTNQXE? A18J:B M8<DO/6-PPV
MZMI7*24@=>,I]-V7:VFM.E!_*;$X ?Z1KB<>F'9C3BI%QN"^NV^)OBK7]L%Z
MY/R;W)4.IKG];HXTFDV'7+R4MYW8'/<M-1J)E' 0FFFVKM93QW&G%!YB%&8[
ME$D]3EGMO3KSI)I'SM,<C2&#(*M!()J[-5_#FO?[ONP  VA'[=%)]:^0%U1Z
MWJVK3]2U+9*O3]B9V2C3<+MHRXNR1+2YN&;50K9C;BI"'+AY/LNDM%*4GCD#
M([GT^9)>^;!,8W/-'$C-5N4-( +L#@,>2B9NR[?2-S:C]CT752?)#>M<2RU3
M*JH-4[;;/=W5*U'2FOVJ7M*51+,V@E>])0PF"MN.A*'$?@'V97W'III4SFW3
MS()6-:!1[@/":BK0ZA[>O!2_[VOHCY(IEJ>0YX=%U/>=I$^5<V%AH.DR7;_7
M&-;VQ#TC8VD[37PT0$079(:O0:N6Q(K4.-R(?85%!2OH2,M=QL.>]L;DMN?
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M#.&\53MC:]Q>\ D]5QX_GS]O4>G'H>@Z9Z35_F'Y^O-30UHP 5SO#6YL>/\
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M90%1ZRHLT75@VBPBOQJNP5.D*4T^VVE96ON[NN; DVIJET^T=(98_)B(=D-
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M>Y!!XS(-Q^I-[<6]N^VAR/+PYY:TR#(,:##@[ $X$5P5@T3:++61YDF#FX@
MD DGG[%(:+P!J<JJBKO]HV.#/J[5^K\B2HE7'9KM$D,6$VKBMRJ^2R=@FINE
M1&RF;$_,QX[C@[U(3ELE]6+Z!SHXK,&(1DMKF#BZE0*4P;PJ>/'!7$[4MGR
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MK]/=!L6+ <:8J&7-4BB"!ZGC^SZ]!_OR3<M+[61C<9"V@',FHP'5>-S?41.
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MX-:_F/O_ 'KS)\B^0$BU2-YW$B\(-R%[+;!-H5,HA<SP9*TRG&(P/85 A(Z
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M<*6.G;SR!ZQ;_P#U-GZ%9.J(Y"Z0CL&#?;Q/N75/I/L8VDLFJ7C:,?  WOS
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M \]<BKA1>!@!KC51SQ1)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7%:
MM/:>>.0>AX/0\_\ #(7-#Q0U437%IJ.*Z5QFU]%%?')/'(XYX(YZ@^G.>3,;
M. '_ ,)J**5%&(7N>TFKN-<5K/\ GU\*8GG*C1O^@L-QO*U!$2VVP?;;3M]9
M%)<;IG'0E';9-)[ORSBB0>>U7 /(W#Z;^I&I;7=^ER.C.E22 DN;4MY&AJ*
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M8>3Y;N&:AX*MD\[,,ORU'W+@G[_<X^O=QQ_=E!#Y_P#!YM%-F\O+^9EHN?\
MD_=S_?\ W],K3]9E_BX\E0'Z#-CDK10/M?7_ (?\,E_\Y_\ ,47_ "/_ ,M<
M.G=^#O[>.O'';W??DB7ZO,*^=[%/B^DR')Y=*KN//;]?^.5,/DT_-^;_ $E+
MES4_*K[%#I]>/OY]?Y_?D9^F]GP4YGFY!7H.]>CIT_NR:RF7P\% >/BXKED2
']3")A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>v473641_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v473641_img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ D #I P$1  (1 0,1 ?_$ +(    %!0$!
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M6IH1<I\IIAP!J4VAAZ%-E24PWICJ5-*I)K;KJSP D1Y!W(A=9>Q?ZBO=CMY
M@6_*L)DYGCCSP8AHCS@F8PV&PHOQIKP0[(Z2B M"F&'JC_AJ!!T5*%UR[/\
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MY4^Y:K*N9;X361O1HL:*Q,EOVXW7@\ZXKK14/1U-L+HOJ%#:II+J*-Y:XU%
MIY_/-JMHHYY(KAPE;4:0<*4_E(:X?J1]FW(:V['8\X7?'9;D2!!R&SLV&$_T
MG8X5,?GIGSE,P78[CBVU!M:@IHAQ+8(5J"3<(A].:H/_ "1M$A$<<5PUYRU
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M2N6ZH5*$"I2^6^B# ]O_ "_PJS/R-8OMG738)>V;CMC#H3\,EF.?J2>WB/\
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M8,CMOV_E++LK!,,D.EV<^7'\9LSJR_="X;F\5.0E$NW$O+ZZO%WD>5:G2&"
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M" !FND/Z/=P$7NKW?[L0FD!_'L:C8?%FI06RS/R0EM3+6]$NJ2]R.VX UO\
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M-XQ]\+(*GFIT)A\<0D<J*2E0&Q&HP]S1044\45&G56M5,GME[@NV<Q+(@WV
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M.*LN@-]$!Q?#J!"32G4(4 $JIZ&@&G/D+G@QBD=/U5N-L#XZD>^J<''.YZQ
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9*4_>=M'<=T15&^G1ZJ^\?^71W'=$57__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>v473641_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v473641_img3.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"#0%N P$1  (1 0,1 ?_$ *\  0 !! ,! 0$
M       )!@<("@$"!0,$"P$!                     !    8" @ $ @4'
M! @/"@45 0(#! 4&  <1""$2$PDQ%$%1(A4687&!,B,7&)&AL<'PT4(DM]<X
M"G(S=96U-G8G-W<H>)@9.>'Q4F)T);9(6%ES-%?'*9*RPD.SM#5%566%I6:&
MID=GAXBX21$!                     /_:  P# 0 "$0,1 #\ W]B$(D0J
M:9")ID*!2$(4"$(4/ "E*4 *4H!] 8'(CQQX"(B/  ''/\XA@?(5R 8I.0\Y
MP$2I^<@*& O'F\A1-R;R\^/T!@?4!Y !^OZ\#G ^:J22Z:B*Z::R*I#$525(
M51-0A@X,10AP$IR& >! 0X' %43\WI$,3S%* B0HEY(4? O) 'S%*/'AX<8'
M83?4 CP/C]']/Q' Z)KI*&.0BA#'2-Y%2%.4QDS\ 8"J%*(B0PE$!X'@>!P/
MIR'/'U_#^3G Y$>/$?  \1$?HP/@1TW43]9-=)1$!, K)JIG2#R"('Y4*82A
MY#!P/CX#\<#Z <!#D/$/ >0$!^(<\AX^(<?3@=3+I$.1,YR%.H82I$,<I3*F
M !,)4RF$#',4H<B ? ,#ZX# XY#^3Q'Z/ ?^]@=$UDUBE.D<BA#>)3IF*<@A
MR(<@<@F*/B''QP/I@,!@<<_V#X?S#X^&!S@,!@,!@,!@.?'CZOZ\#YBBB*I5
MQ23%<B9TB+"F452)',4QTRJ<><I#F3*(@ \"(!]6!SZA/,!/,4#&#S%*(@!C
M!X<B4OZP@'/B/T8'P.Q9*.DWJC-J=XB7R).SMT3.DB?;#RIN#$%4A>%#> "
M?:'Z\#]7/]G]>!T]0G(E\Q>0'@0Y >!^H>/$/TX'? 8# 8# ^:JJ:)!45.1-
M,OZRBARD(4/_ !CG$"A@=P'D 'ZPY^@?C^;D,#G 8# XY#CG^W]?'P^/QP.<
M#!_W(G\K&=%.T;^$>23"6:ZIG%(]]$O';"3;.?4:E3.S>1XE>-E>1X\Z0@<
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M$).@UEY+7ZI5 D2JVB92SZP>3&R1J;AHYJ21SR;QDK!\*BO(^0Y7/!BCZ1^
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MRI ,!S<" X'*W:CLO3X[8^\[!)1]QU'1=T.]:/M;P5'!K9&4*ZAFK2(GTIM
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M2D$Y1$#"J(8$B.!XLTM"-XQ^O8U8Q"$21.:26F3M$HI-MR '%\H_$&94!$0
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M$ ^H/0U]L'3^UDIE;7<U3[<G0YR4ILL,,$:[&MS$>8[22B3$(43L"@9,Q!
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M )P:N"I<"8#'\Z9.1Y*'.![I;GJ&*BHV13M6MHV#!P[)#OTYNL-(H'1%/EY
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M7!Q6HJJC%75&*BANQ2F;[#M9)&29;$<%>VV+FI/[Q,\EXV1D4RNO26,8I'
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M>4H@51<P&' E/*' <!SX"/Q'G^SG YP& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P/S.V31^V<LGK9%VS>(+-G;5RF59NY;.$S)+
MH+HJ 9-5%9(XE,4P" @/ X'EUVLU^HP<;6:S$,8.OPS<&D5$1R)6["/; <ZA
M4&K<OV$4BG.(@4/ .?# ]OR%^K^<?[>!T$H@(^4. _(/'Y?K^L<#@"B7CPX*
M4>>/H#GX^ ?G\,"G*_4JQ5?O8M:@XV$^_IAY8IH6#=-NI*S<@8!>2C]0OVW+
MMP)  3'$1 H  <  !@*_3:Q55II>M0$7!*V267GIY2+:(M?O6:<D(1S*O2I
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MRD4Z1.*1/LD, _7@9PX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# X,'(" ?V>.!@=VPZQVK;&S^O&Y]>/$FETT]/6B!
METE908E1YK;94"M7;4XBWHD.BC/U\52/60' 2G53X^K L? >T#U#UY":GE-;
MT]] ;;TC<T]D5O<<>K%--HW.U-59!VX;7FUGC1&6CK&X?"1X!B$\Q>!Y#C R
M7Z2]<9CKOK>W%N)XQ;9NW=J7G<NS%X=05XTEENDF=P2+9.!X%TWAXU)! %1
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MC@?0#!QR(@'CP/CX<_0'\F!VP& P& P& P& P& P& P& P& P& P& P& P&
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MB <ZC@OB/'_VQU@9X 8H_ 0'QX\!#X_5^? YP& P& P& P& P& P& P& P&
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ML/&MJA"0K0[-9*%*Y.94BBHJJFX,!>  )&0'GXAQ@<X# 8# 8# 8# 8# 8#
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MM=?%^\TPJL9(IJ% 1_OP?!+QYP-@(!$H<<"(!](\A]/U"'A@=P'D.<#G 8#
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M?1Z#1I<E4;'IS:'=Y&Q*K+%=PTRILNNQNQ6J\2Y "'249$G#(*HF+\2>;GZ
M"6=SKFI[10]YBN7%G(.XUGL:-M#3[LG)NO/FT[5.KU+FX"0;2D!(1LDB=A)L
MTE0*54"'$O!RF+R AFA[;^O*QK[I5UW1K24J VO5M)N]A=S<_.661E+/9JS&
M2$W*.)&??R+T5'KQ03B0#E2+S]DH8&<N P& P& P& P& P& P& P& P& P&
MP,:>XLGL6#ZL=@);4C6:>[+9:MMRU):UM$SBP*S_ -UK@R"$1*4QE)4IC<H
M <^H <>.!JO:H'7]&V]UKL'6WJI[@FKNTTOL_7ZNS=C;2G[2]JM]J+UT@QVX
MXM<--6R60D(1T=958IR,P*@H #R'AP&PS[J<&\L'3JY,&5C@8@A;51%WE<LD
MX_K,-L]FE:8_U=5.YN+(>08!=SB#0#)E-YA-P8/*(X&/7M"U=U7%NTI!K%,T
M<T2V9#11NJ-(NDA>HO3#^-KZ!74@I+OTTD2*7/U0=%(R+\J8I>>1-@31"/ "
M/ CQ] ?'^K C?W9[CE%TYV5;==E*3)6-6,A(Z=OUK:V>O1851M,Q[^2C$H^N
MR:R4C:%A:1RAW!6YBBCR4.#"/&!9R+]V1K,5.2<MNN-\1V8^L=08:XU>YMU4
M3>7ZK7V*EK!5[DG/"J$7 ,W,'"+K+MW/[9 _E(/B8,#,Q?M5I^7ZM0^_[E;(
M/5=(V/3'2L6YV#.14"DUEY.+E$TZZL_>.$&2\J5PQ63(0AN5A3'R .!K8=8U
MDY?OE[+3PB@*I5OI[+LFQS<&\R5PJ-TEQ49B41*5NJ6&**@_W9O*(<A@95=2
M8N*L#_J!!S<"I:8:7Z:>XC&RE630*JO8F#O=L(FYA4$C@(*+2*)A13#@?VAP
M^K CH]E3N[LO96B?=5Z?WW6LK!(ZZU;O_;<78YU9XG:HIL^ICN@(4>X-7Z22
MCB2B8RN-"_,E #&4*8#A]HH@&W1U!_R4NMO'_P A>K..?]Q4+@8(]9NOFE:+
M[H'=^UU#6]8K]B8:ZT%),9:.9"@Y9R&Q8VY/KR\;<'$B3BTO6*2KPP  JG3
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MUA^'B("'/Q^@?$.<#ZX# LMM[L7H?09(0^ZMO4#59+(9Z6 />++&5XLP:.!
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MX:;MAVNUNN&Y%G[UQ0+6E?8QG/N=)BYE##^$[W4P6_O9@H<$I)N;S-A$2B7
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MKCL2'HL_LEU48EQ-'IU8<1C2<E&+$HKR L5I=PU8 HT9D.J)3G 3 00+R80
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M!@,!@<<ASQSX_P!@X'. P..0YX_L\<#G 8# 8# XY#GC^H<#D0YP.O@7Q$>
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M_/6H0UU;PDYJQ6&1M1HYN:>2B5 UK^TCDY,5"HC]*8 .!5_\#.VO_>(]S?\
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M !$TTR% I2@   !P&!]\"@YS5NMK-:Z[>[%0JA.76HE<EJULEJ[$R%BKI7@
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M$)68J/@J[$QT%!Q+5%E%PT.R;1T7',VY 30:L6+1))LU;I$*  0A0*&!ZP@
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M E# E0P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MBW:M6R!"(MVZ") *0A"@4I0  #C _=@,!@,!@,!@,!@,!@<"/Y!'CZN/[?.
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M>//&!DAU>[_1>_Y?9+*VZX?:@C*G32;4JTS+V./GD;=J->2EHM*W.4(YNFI
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MVB^N\6YUF2,L^RXV!I+-@UN=8:2L(WB-T*P\Z]M,,^V$5"$(OZ\=8I%9P4K
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M@/ \?$,#9%K:22->@DT4DT4R0\:!$T4R))D#Y-#P(FF!2%#\@  8'MX# 8#
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MSFUNL^I-PPO8UY3$M5J]:KY+66Q-XB3)',I!ML$ZBE35MMCC@\WWHF@7TE#
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MN+]8Y1)PR5(]25&E:WILZIZ:R!U&W*'D-YP-R8.! O!@P,]=V% U^[B^8WF
MWND>WZ'!?B7RQVH/#\^!@,\?=R^MW^<O.9!XK!430/9DT:R<O0005I]PUG(M
M6;"/1?K% _W1L*7N\21(BI_1.X>(E+R8..0V"_;*X_<EMH/'DO;WM< @(<"
M_OCL8\#^7@<"1;G 8# 8# 8# 8# 8$-/OTV_\+>VWM>-3*19SL"X:IU^@U.4
MIQ=)6'8$&20#R'(<GE1C4%3F$?@4@C\<#5R]T]EK[H]M;9N_=)Z@9LK59ZCU
M.IEP2B(;T:.YKMXU7!WJXNY=5L3R5VT35@JC4[1TD! 4.*H&YY ,#9UTQO=#
ML]V ]L'?[>K2M(0VMU,W7:DZI-F(>1AQ=LZ4!T%%B 0KANH=+U&ZH 'JHF*;
M@.<#)GHM]K9W?\!\0_C%MG_HK6,"14 X\ P& P&!U.(E(<P%$XE(80(7CS&$
M $0*'/AR;X8'\SSW!Y[M?[GO=_MW0K/K>1TC6M0WFM-YMLJSG7$= -ZU(CKO
M7I[VMZR$:J]M*4[\VW6\@^ \I%\O(X$F7L\-.[_73=/N1]-NT=Q0-"5/KE<'
M2<+8'A)62MEBJ=5<P%?FZ%.$*J+Z,84XR"CQN93U46RR(B0/C@3G."@;K-[.
M/(<\;AZZB'Z:+*<8$X@  <\?3\<#G 8# 8# 8# 8# 8# X'^O]'Z<#5@[F7C
M==R[:[TTF\D+;K*NO[FQG;'?:SUY@)YOK?K52J.C-R^Q('8CZMR"TU;[S8A^
M[CH>=PL4$BD(0GQ$)LO;:G+[8NF6F)?8S1XWL#J(DS-',M6&M*F9RLI3+].K
M62;JS-HP;0\S/01$'+A,J"7"B@B)0' PS_ZMGL"?<K9HIMC21.M\=V@7[4M'
MB5#G"]DC6EVY,^6KCBV@]"O!'F.<6HNBAZQV'E3$OA@3:D$PF^T' CSR'U>(
MCQS]/&!B#WIZT2/:_KY-ZJA):)B; G8:K<:\I8?O(*X^F*C+HRS6(L*D,HG+
M(PLIZ8HKG;#ZQ2FY !P(Q(KVG-_(GJD9([FH"M:M[>MI;Q0!C:9&0KK.F767
MO-=K^GWDB8RJT0DXDBLS#)&(8B2?F*'FYY#*SIWT.OND[!L=[NNU4F]5Z1UH
MWT52(BI,IA@#[5K.:F9D7EW%\*('L;\)HR"I&H^B4J?F*;DV!JG[YT? ::]P
M'M1IBC66[J:UU3MNCWFOT6;F6\I Q"UYK%%,[ETVI&+9PF[CG\F#-FX,H/IM
M.$A PCYQ"=K=P %][B<?^](]OT1'P^)H[4 #_)@7?[S4B#OO:'L/&S<#,V!2
M"]LFPWBKMJRGZEK87FD;H:V:G3E3$ %5*P1$]'(*("GP8WVB^(&$!#$7_-GN
M_M[[8:B[!ZKV-0U8>W:JV;-7Z9NJ0J(M[-);=GY:>DXZ4CUB >-L,?)I*^J0
MHB4P"/@40XP);-\;R[8U'N1U^T3J^.T(XUENF#MD\ZF+NI>R7>$;ZR1BY.[H
M)-H9%2'<+2\;*D)%B)@*FN0WK_9XP)%\!@,!@,!@,!@,""'WT#&M>L]/:J2\
MIB/W^V-J3!3^)"1>IM7S<PS4],!$QCFL#UH4H\<%$>><#&_?D%!V;7WN+QUB
MB(R<CU=)>VH<S"78(/FGF/ P"*AO3<$4(10S=PH3S  #Y3B'P' Q,3[MT#H%
M[P?7?I-86EKM6HZ9%S%1U)(,6BBLCK!GV885V4BM<G;N!,K/5"E3;0P,EVXB
M9%DY!+C]C@;!?10?]\_W  ^D.XMLY#Z0YJM9XY#\H8$BO(<\<^/U?V?# YP&
M P.IC%(4QC" %(43&$?@4H!R(C^0 # T^:;87&P8?WAMJN4P FQ^S>@GT0MQ
MY57-7K.XI2HUEP53@#F1<0\*F<.!$HB/A@5][D-B)J'5GN<=G*]'3"FU]#=D
M-9O*!+03(79D&5\U)$TVZ0%H,0BBA*/8:O(K)/N0$A5R-S@ "4!P*\Z:=Q*W
MW(Z2^U;<86"4JDGK;N'K'3%I@G4@U>F).4BJR+;[P9F3."P1\LS6361!4I3^
M(_$ YP-HPH\\_#@!X\/R"(#SX_DP.1\WT!S]?]G(8&/$SVPZYU[;#;1DWN.C
M1NW7CEBR::\<RGDL[AU)D(I'II1X)F,871%"B7QX\0Y' R(P& P& P& P& P
M.IN0#P#GQ^''/AP.!%9VWT#0:M9I?;JG?[:'2QSL2000G&ZM_IBM LTBW;(M
MC!%U/9C61C8]T=JB7U 8BF03 !C%YP,B.GNHM?TFJOM@4KL#L#LXML4C(KW:
M]VV"C=V,FUA#KMT6=8;1 (5>#C6S@Z@"DQ1(7S#]H1XP-;A6_P!UKGNN2]!E
MM[TM24G=^UMX&RH[?EGE3(LV%F7>M-?N=9-F:C!O+!!+A"J1HB5H0P L8WF$
M,#</+^O^DW]>!]1#GP' XX#CCZ,#J< \A@^CRC_;P-'KM!&*R7NQ^Z_(G/Q'
MTO5W6N?4*"1U%!>RM_T= E%N! #U509+J )!'Q 0$ YP)"K[N.I7C979QE#Q
M]W:_C7W(>CMPJ[RQT"VU>,F8"KS.KZ9-.V4G.1;1HL+6PQBR)2>8JBA2@<@&
M*/.!+4B0IO=:>>8 ,'\!@EX'Q#@V]F &Y ? >0#C\V!&SH#6]BT?KZ[=WM!5
MH%['K;M1VKK_ &"UQ7&23<=Q:")NNPN)+T&#4$DG5WU>0%)*%.!?4.B"[;GR
MG*7 STN5]J6T^\/MQ['H<TUL-.NFGNSUCKTRR,4[=]%2E-ICEHKR'(IJ !Q*
MHF/!DE"&*8 , A@2C8# 8# 8# 8# 8$$7N8>G;]Q;88K%]1GIGVY-XV;RE.?
ME&<VA=JG7V#DY>/( _=-7>ID'X_;'Z!' L'N'DM)]Q0W'A^Y#VTN!X\/"$K0
M^''ASS@7Y[O]3--=@>Z75G\3:XBY38+[J[O5]6KG$$2A+U'W*E1=7D]<S$3:
M6WHNVDS6IU<3,5SF$$/5,'Z@B&!';_F_?=3M_:^V7<'K;W$@6<+/RMOG;F2=
MM4:A5+=,;0KJC.NV*O,$$2-XVS.?PZR;/G0-R^JF!O6X\BF!-5WF'=S??/3>
M)UGV0V/J"M;>VH\US=*W4H:CR+!_'QU:E;2642<66 DW[:277CB-C^504_0,
M80(!@\V!)RU\[5HBDNY,X,W0226>.?334<&23*F=ROY 21(HN8OG-Y2E+YC>
M <<8'ZDETER^9)5)4 '@124(H4!^KDAC!S@?0P")1 /B(" ?GX\/I# AY[D]
M@^U^E.PJE?KVT-21NCWO7O=.['<+,:PE']TCVNHJZBY=P*%F2MK=@X=65X[*
M""XM"_+"4 %-3G BWK]"4UCUU[3T]R@JVDVFM?;IEYPC@WJ.5)VSV!2R2SET
M;Q_;N7,J)C>/ #@2?5J(BYM?WDHF9C6,O%O)DJ;N.DFJ+UDZ3+H!NJ4J[9P0
MZ*GD4(!B\AR4Q0$/$ ' U^^^OME[LV51_::W%TVO-6TM+7FOZ1UM,13!_*TI
MJ&TD(/[WIVSY$:ZDHTD7K./079N%S(B[ GE+R<!\ V@M%]S"1TM5>O?;6OR.
M@>Q;:*CX-HI;WZ+O7FZ7\:T39KV75NRDR(P=@4F5D#.#1S@6TFB8XE,B(AR(
M2'E. \\B <?V<_FP(T;A7:ZM[J^J)!:OP2\@/4'8ST7ZT1'J/OG6NR*PFV=_
M-G;BX%T@D(D(H)O.0@B4! !$,"3+ 8# 8# 8# 8# X,(@'@'/C@:^'O6RM(H
M][ZT;&M,YUS</(UC>J^E0.P^I[UN.%GF4TI'<RT16J;'R'W6\CG)"D%ZJ &^
MWZ9.1'C DE]N*UPEVZAZJLM?C=<1,4_)._*L=3TN;U]0$10FGC=0*[5;$DA+
MQ;4QTAY*LF4QS\CP&!"-1[SLC6W=N8@*K<;,UZH6WM--1P;0E^J5 F=:H[-F
MK$965U?'[)<R2UV:*N)A(Z!)8Z)DTW?(%  X' VGB_K?3\3?$>1^GZ?' ^V
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M2%MJFV-=S];EMN=;0CYJ+MT&\8.#DWYKE\=$BB3T1^93:-CJ'2,!3D(0PF
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MMBF1XV/8L#NWD@9DR9LA?R"H+R#XS1N1 7;Y<I$RKNW/D\ZAP*'F4,(\ '
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M/7N]7:K;5J&E7\(BW77V)<:\>V-89B*P%<)0E:!9!*:M#_D$6""IA2.N</,
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M@6LTUURT7UXCY:)T9JBC:IC)YV@]F8^D0+2"9R#ILF*:*[ANT*1(RB9!$ X
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MBB)3 )1$,#+-FS;1[5NQ9((-63-NBU9M6R1$$&S9N0$D&Z"28 1-%%(H%*4
M   .,"@-JZ>U?O&I.J%N"AU?9%)>N6;UU5K?$MIJ$</8]4%F3I9@[*=$Z[54
M/,F80Y*;Q#QP+)1W0_IQ$S=.LD9ULU RL&OTVB%+FV].CR2M:08NSR#-"(?
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M_NJ^[(GU?W?_ '/\A(?<7G_#OW?]U>0_WM]T>;^]_D?)YOF?1^QQSY\#JO\
MNI]!7YK]W_RORD-ZWS(5P4/D/5+^&_7]00+\GZO_ ,2\WV/-QZ?CQ@?OB_W>
M?B::^XOP;^,?1;?B'[G^X_Q/\MP'RGWU\E_YU^7X_P!+]?[/U8&-E2_AT_B:
MWE]Q"I^\KY#6G[V DBLAHWXF]!]^"!;FDC E^\'[H\_((AZGROD\>>,#M8 Z
M[?Q5ZB&3%3]Z7X8V)^[0K(L>-%^^/.S_ !R*9V9P)^\?[K\OJ <OK?)>;D<#
6,C 8# 8# 8# 8# 8# 8# 8# 8'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>v473641_img4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v473641_img4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!NP)7 P$1  (1 0,1 ?_$ /@  0 " @(# 0$
M       '" 8)! 4! @,*"P$!  $% 0$!              $" P0%!@<("1
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MP[[MQM3K*[S<JHZ^PZ2;5/92>E7370G;NN>FMVN8=G;[\[E[/=]6H^%=4O\
MII.%]W(R@G:C;FN1RNJ"<FHJK:3[3?O*[0_&-.M#N:Z+UQU;R3SBNQ,55K=<
MYV2C:HS0D;9.$@J5!6"61KU4CG2;B3D%$2,V"*A3K*$*/7*LO<,3!Y?B9<KE
M6B2;;2U;HDW1=KX+M+W4G673O22M/?;[M2O\[A&-N[=G*-M*5R?):A.2A;BU
M*<VE&"=9-(H9M+FT%Q](%PQX[:VV/;(O3U]UW+[OL-AH5 L,RUVTXD6<&\U/
M6B6]S29B-)JJ0CI%1[,2D6N1LB8Q&KUXS/T -/?W1W=YQ<*Q-K%G;=QN*;Y^
M'(J\K]AIUE):+1-JIYYN_7T<[YC['TSM>7?ALV1CO*G*S8N2CD\T5+'AXSM2
MBK#7M7)P:BJ\MR<&M)+])+=MF5X_"RDZXVA=M3)[MYHZUU#>;'KYQ",[0O1[
M-5;VYE&$<]GX.Q1[-8SJ-05(H9JIVG2#R"'4!R=ZN7X?#6K-R=OQ<F,).-*\
MK4JK5/[AL?FMN&[8CV#;]JR\C"6X;]8Q;MRRXJYX5RW><E%SC.*=8IIN+U7
ME^R;ITCP0J>O:AR Y#[&L3K9%ILL;2+?MQNK=+A8YELQ&=<5L'>MZ#$QR2;-
MF )1Z2C))1=10B)#K+'*4<BYE8NU6X6\R]-N<FHN?M-NE:>S%=G#0WN5OVP?
M+K"QL+J7<\N[+*O7%:NY*=VY.27,X5L68Q22HH)Q3;:BG*32.[J/.GB]>-J1
MVEH#8ZP[&E%2QS:%EZ9>ZXT3M/M<2MR^OGL_8:U&5Z.V>RK2P/7-97=)SK9
MIQ4:E$A@"NWNN#=OK&A/^N>E&I+6G-RU:HITU<:\R[C(POF'TCN&\0V'&RI?
MM2>BC*U>MKQ.3Q'9<YVXP5]0]J5AR5V*K6"HSB,.>_%*4V38M2QFT#2-ZK3F
M]QJ\6PIE^>M)RP:PC%I?85/I,VUJZT+?[S3F#<YGT'".'\LB<.SS<3B!1A;M
MM\KSQXW*W4Y*B4M7%5E&+I24H]L8U?D*+?S'Z-O;K=V6SEN>XV7=3BK5YJ<[
M$7*];M35MPO7;:7MVK4IW$].6KH4#T3Z1&R;_P")D+MNW;GAN.EO;<QXK3SZ
MQDX\WNPUNU5R2VI(P=,UO&1%B(Z33L&P*P@@S?S#9TJ%>?F.+I-JH7P@TV)O
M-S+VY9-Z[&Q=^*Y*^')IKQ&HQ2?X4HT3=?9EQ2X'G73WS-R.I>CK>\Y><MLS
M%O4,>4_@KTX7(2NM6[,8S3]J[!*,[L6_!=>?D?"<^+?*9Q"QWI&]A<C]IG;Z
MWT!S:VG1H.<LA40847743":]+ UEB2+8 [<MB3$\9-LF)'#I9=R! $QC%#,S
M!SW".;>S;G]1:RII-\(Q2C1*B[WIQ>IO.C^L96;75.Y]4Y=-JVSJ#(LPG/A:
ML1A9Y()156N:=(JCDW*FK+TZ2W[JKD15GUOU/9%IV,AYU_5Y]C*0-BJ-GK%D
MC2HJNX*TTZWQ4%:JU*%:ND5R(O6:!U6RZ:Q ,FH0P[7%R[&9;=S'=8IT=4TT
MUV--)I^=<#T3I_J39NJ,.6=LUUW+,+CMS4H3M7+<XTK"Y:NQA<MRHTTIQ3<6
MI*J:9K?J;/;7(3TA7.;6LGR<Y :VUWH!'B\\H-,U3.T6#A"GV#K=S8+4C,^V
M+7ML?OD)&3B"GZ$71$H+J@ ^N+V::VLC+WC*LROWH6;7A<L8N*7M1JZUBWJU
MWGE>'#>NI_F;U#M%W=MSQ-LVQ8#LV\:=J$?Z^PYW%/Q+-QM.4>QQXRUX4NI"
M<W>,UA@M562(V-YW#;KW'.:"UJ\]J]O1]L6UJW(6&+F:QX*\$FXC :/JL^)Y
MX[*@R4\'J18P'()ME#=<"<+<XW*QNW7;CH]9IM./#LY7QTT/0+'7W2N3CX>5
M9R6[&?G2Q+#\*ZN?(@YQE"CA6*K"24Y\L'I23JJ]37^?G$>S;FD./\9N&+3V
MQ&W^QZK7K4K!VJ#;K;'JID@EJ4PL4S!,:S)V,2*"=LU;O%%7J::AVX*%(80I
MAN^W3R7AJZOB%-PHTU[2XQ3:HW35)/5:HL8OS(Z,S-]GTU9S8_MF&1.PX2A=
M@O&MM*5M7)05N4ZOV4I-SH^6M&?&)](#Q-GKI:=?06SUYJVU1E?'BL7%478;
M\+.?5R2RNQHK7+UK5%6&S[#2A;G3D8VO*R3YLL'AF2[_ %N1'>-NG<E9A<K<
MCS:)2=>3WE'3VG'M4:M,IL_,GHW(S[VV6,J4\VQ&[)QC9OOQ/ 5;T;#5NF1.
MW^'"R[DT]*5*.:,]()9]]^CL+R*NVXH+C;L".W#'46T;&0T)=;52V!'6\6M8
MKD!!5">\]]L9[M4WC.*<R+)X[1AY)XJ=8456RB*>LQMWGE;/\9=N*Q=5U1<O
M#DX_I$DDGQYE2-4W1OR4//.G/F7F=2_*_P#BC/SH;7N<,U6KE]8=VY:BGE*$
M(PM3YN?Q+;C;G.,I*U.4G)Q<&H[ E^;?&)MNXG'=;9S<FU#V9"CA%^URW&KY
M;\ZC FVVOE+T6!&C)7U>$$'I(8TB$B9J(*@EV" YMOVI@+*^#\1?$<W+2CIS
M4KR\U.7FIKRUK36AZ9+K[I2'4"Z8EE4WAW5:Y?#N\GBM<RL^-R>#XKC[7A\_
M/RZTH=-5^?O$>W[C?Z"AMPQ0;6C[W:=7J5J5A+3 HN=B4U0B<]2XVP3<&PK<
MK9$B'%5!HV=JK.T"'40*H0AC!3#=]NN9/PD;J^(YW"C37M1XQ3:HWVT3U6JT
M+&'\R.B\_?)].8^;']L0R+EAPE"Y!>-:=)VU.<%;E.O",9-R57&J1 _/2W6A
M;D)Z.'1K.P3$%0MQ\DI^:V*C7I%W#2UC;Z6HCS9%2K;F59K)K%K#VULFZTDV
M* &=D;)D Y  >[#W>[<^-P<1-JS=OOFHZ-\D'-*O=S)57:<]\Q<O+N=2],=/
MPNW+>W9NYSG>4).,I_"V_&MVW):^&[E'./&7+'5:UIWRFY1\@Z5#^FU7JNU;
M)"+<=(/BBYT@HS)$B;6Z]XI$=(VU2!\>,6 YIU\J91;SGSCH8?6=H>3-;N6?
MFVK.ZRM7)1E9C;\.E/8K&KI5=K[ZG#]4]8=282Z]^%R[D/V6MM^%I3^I\:W%
MW>73\-MMUKY*$T&7W#O_ )]V?2#CDQOG5&O*MPET=MEI%Z?FJ1 K/+S;K=:(
M2=EI-S9Z#<17\]9,TA[" D4#I@(>3J&92>3E[S/$=^[;L1Q+<TH.*]J4I)MU
MB^Q(W\OVWU)\P[FPRW;<L+;;6Q8V0EC3M0;NSN2C*4G<LW:U7<EJ<BNQFW=X
M^D,Y?Z3?\I^16O\ 7.@M<<5Y6E06M;!08<'DE?*=-.+6]L:\]KBS*2*TN\KZ
M:Y_!\V*"BRO: %,4I)MQR<K>LG%ED7H6+-NRXJ+BM9*56ZQ=:T&-9WKJ'YE;
MUL%S>-TQ=LVW&P)6HV)V8\SNV6[CN<]BY7F<:^SRZREV42\P%PV)3N4_I5]2
MT_8%CB*Y!ZAU3R-IZ[Y9&Q/J'L"]4BWENH4\LVF[81L+.!26JY&BJ#A)H].=
M5,.T?"Q"[>M[CN&-;G)6XVH78]KC*2GS4KP3Y5IV,G'S-SP.J^L-HP<F[#&A
MAV,VVVU-V;UVS/Q?"YZJ,9^&GRM249>TE30OGL*W[/C;]Q3CJJG!+UNZVV;9
M;!/*6)_%/WC%OJ2X3Z:#2/:U*<0D0;+1QGQ .[9"=XU02$035453V]ZY?5W'
M5NG)*3YJNGX#?<Z]_%:I'H6YYV[VMRV:UAJV\3(O35[FG*,FEC79T45;FI4<
M>=5E&LHQCP;DK.YG'7C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!^
M<WT*3[B'"5:,2D+E7X[E_.;2Y$0S>F/=C6Q&QO*ZK>K!*I AK%Q80JQ?%K,4
M1R5T2,*N9%,R@*"(G$>,Z8>WQMKFDEN+N753F=:<S_!K3@JUH?+OR%N=#XV+
M"-S(M1ZXN969%6G?N<[@[DI:6'/P_<CS<WAUHFZ\2O5<K=Y6X(TB\UNQRE @
M].^F2V+M+8^P6M?7LY=:4*(W!>HIYLR4J!VKEK8X&DRTTS?.TW*9FR*"1EU.
MA$C&+@X]N]^R(W8-PC;W2Y.4J5Y8^+/V^7M2JGKI34YYXV?<^7V-N.%>ECXV
M!UM+(OWXP\16+4+TX2ORMT:G&S.4934E2*3<J*+I(T;$5+7,KQVY8-=U[!VK
MHY7TFNR-I;LWA=M<N=;TE"2MVA)/7+;8-4K4$W<1QM,/+(R(1.S&2;QGC._$
M(H*)O&->4(6;EG<8W;ES$_:$IW)RBXQUM.%8Q2IX?-3VO=JZIFUM6\#:7MG6
M'QU_,V!]4WK^3F7+"LVE*[C.TLB$(52QG).*OTC"LOQ?:)HW3=-;W-/@3RHU
MAI.<TOQZJ7I$;K<-@6M[2&%9:3C*UUVUTUOR*EH2N^=2Z%-V=9E$E$YN3;-U
MSH*).78)(JI*'RLRY:O/"W"Q:E:PX9TI2;BE5.,X^(TM>6<FO:>M&FZ(WV];
MCL^7;V#J_:<"Y@=,V^I+ER[<=I6U/Q$X?&RC"LE:OS5?%N1BVJ2G2,HMUEW1
M#S)K#Z1FX-X:7?5_5?I8.&.V[Z[C(M_*+P.N*1 T-_;K8:-CF[J3D(ZO1ZOG
M#KS5%91)N4ZHE["',779,)NYGW%&3A#<\><M'I&,;;E+RI=M*\'W'+]00N+(
MZCSHQG+&PNK-NR+[C%R=NS;2=R;C%.34(R4I43:C[5.74[7D/3TIOD9SMUWM
M/D9L/5U Y?V_BQ=-/4;6&HD=MW#D74FM?K2,%+:NG7:!'T2E0+;6?$E2Q[A)
M&+9CYTY,DFH0YKV;;KEYEK(O7+=G)G:<(PAXDKBI%)QTJN62]JFD5[3:6I3U
M/@1R^JNH-KW;=,C$V[>[N!=QK-C&C?N9UN,(N$L>XZ27@SMUGRR7)'65$XUV
MG>F.;K!Z,'E8V3!=RL2B55,/6&7<*F3V)20,8Q4_$$Z@]HB;IU^2.;[J5/\
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M:2C/7>L>6V^ V/;E8B0\UJ*>PIC==1JLM9F39JJ]@XJ8LL@@V4=*I$:,U7!
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M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!Q4V+%)0%4F;5-4!$053;HD4
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M+O.[>DO>N7&DN:3=6]$DEP2X)59(&7C9# & , 8 P!@# & , 8 P!@# & ,
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M^?M46YSJL0;7#74NV!-7URC=)%<! %NP@&>*;!HB2BJ*ESJQ%4%EFZR9IZ,
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M]^M5^OT7]$X ^$6@^_6J_7^+^BL ?"+0??K5?K_%_16 /A%H/OUJOU_B_HK
M'PBT'WZU7Z_Q?T5@#X1:#[]:K]?XOZ*P!\(M!]^M5^O\7]%8!Z*;)UXB05%K
MS44DP$A145L42F0#*'*DF43G=E*!E%#@4H=>HF$ #RC@'O\ ")0??K5?K]%_
M16 /A%H/OUJOU_B_HK 'PBT'WZU7Z_Q?T5@#X1:#[]:K]?XOZ*P!\(M!]^M5
M^O\ %_16 /A%H/OUJOU_B_HK .QB[;5IMR+.&L<)*NRI&6,VCI1D\7!$@E*9
M44FZRAP3*8X (].@"(8!7+^U%X$FZC9'5%YC31.UJSK:Q*N%(DY8%K>U*FWH
MUA=$1<G,Y7GG%XC14CD>]PS0\Y44/_F_:H!:".E(R7;G=Q,BQDVJ;MZP4<Q[
MMN];D?1KM:/D69UFRBB973!^V4063$>])5,Q# !BB  <[ & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8!5W;FYMK:ZEVZ$3K*F3$5+2JD)5DI"\WY>[6
MQXTBU)F1>1%(UMI39[HL0Q8HJF456<)JI^"<RB1""F90"5M3W"W7BIHSUSI!
MJ))K.G"2,7YY-N4W;1(2E(_20M%5H]JCR'5[T_!D8EDN)DQ.0IT3I*G X]%U
M;&TFZ;;NS91L,CM>S0DZ_08L2L&S1" JL576::I 67,\DW*S1PY<N>J95C+A
M_)E,4QU .]UU[DVG^\[+]T\Q@&;X P!@# & , 8!7C4 ?^JW*#^[LVG]?[O_
M *.:]P"P^ , 8 P!@%1^0  (.NH /K?F0S>[7V%$N/H-.&Y"$\1YZTO\+^"'
M[/\ >SO,#W46F:4>,B20<J^40@DF C82]1 A>H_^()+U?)G=[RW^Q</\G^:C
M2;?^\,G\K[[-]VERE\5GZTO\'Y ?W<\ZW#@;J!N,TAY(L.G_ & ?,9P6X^_Z
M2^N+)[S6E0P!@# & 5WOH!_:.X\#T#J%5WMT'Y(=66N^O3^_D]A/86(R"!@#
M & , 8 P"O/)T '6T1U !_\ 5[1 ^7R^IN6C], L-@# & , 8 P!@$9[=]P[
MC[)*#]WU9P"3, 8 P!@# & , J%!:%V;'2U,D)2ZT.61@-\; V_8TO:C8T5+
M6WN3>490Z3@R]Q>)H3M)CIQ=O'**E<MD4VD?X::8- !0#-^,8 &MICH  'PO
M;W'R?W=RWC_\< ZNP<N]'5)_)Q]KLJ];5BH+D#95U9AD+9LM#<9'%=1VX\:J
M@J?QRPJ%G;.4B@ &7; H< #L$,VEO9\Z]%2LQYJRM1T?;?YO#7IY6O(Z%EW[
M<723II)_F\?NF"->=6KY#S\D52ML2CHSB'94UDV@*P@YV9(24_JRL/V-+&1N
M3%NBI6IS<]>0D%)I2';E\],9!1<B*QB7WL.5&G/.REJY.LO824Y)RI%^\K<V
MN7F>FJ544?%0?!2\G#7@M-?*N-#L@YPZ7%!A* WNXUAY"1<JO;2UYN:#BI&1
MB"V9Q5)%(LJ,[[8X:HE6E78-V2[$&C90B+E9UX;<]/["S:N%;?BJ37+75I/E
MYEI2CE2*JTZO5):D_$V^.M*<?O>>FI\GW.+443\*$G,0U_B:)J&6KD'<MH/X
M>"1HB4G;+W&4&!2C'!;,>PRC5Z_E4WGG:<=YDG'%,J=8IP!(9CL69/PHPE;E
MD7DW&";YZ1@YNOLT5$J4K6NE.T/)MKF;KRQ=&^S5T[SOD^7^L9&]VB@5:(NU
MT?T*<V/ [ F:W&0AZ]276JH"A3UQ6FGDQ8X=X[29#L>-9$3CF[YT=]XR?A 5
M(RF6_P!CY4<>&1=<(1N1@X*3=9>(YJ-*)K7D;U:5*:ZD_$0<G&-6U6ODI2O;
MY4=3 <U=871CKF8UW6MA[%@=FVZD4Z$GZK%UCV*8/M@ZDK6[:[(S*D];H-PE
M#J4"R@NNJV2='0<,W+<Y 5*D5:NYLF58E=ADRMV[EJ$I-2<JM0N2M-*D7KSQ
MHJTJFGPK2%D0DDX)M2:6E.U)]_<=A8N753K[NW-4M;;;L'M6VS&Z49N(*(IA
MT;C?G5?=6F48U0LK>XER=A6(-FHL_=2*<<B(AV-A<'];E-O9[UQ0;NV8\]EW
M=7+V85Y4Y4@]9-T257WT)>1%5TDZ2IV:OCIKV'0RO//C_!L'5BEI"R1]%194
M]XTV&YAD$JG*!;Y/5<:"#7ND0L+0]<)NJN.9)1['M&Y&S\PH*.#H.$TJX;!N
M$Y*W!1>162Y*^TN57'W4]KPIJ-&W5:I55:7E6DJNO)IKV:T^M&>2O*77+>"N
M\S66-IV&XH>[6/'F4@*4QB%IA]M1X:L)K0$6I8IVN0ADHI:UH)O'#EZV2041
M7+U$4P[L>&U9+N6X77"VKEAWDY-T5M<VKHI/7E=$DZU16[\*-JKI+ET[]/K.
M ;E_I8[>759RDO(N(?3FOMWJ1S.*Z/W50VC+R,#26C4CMRU0+/2DO'@DJBNH
MB@R*Z;JN5D4%04RK]CYU8\R24KT[5:Z<T$G+T)/BJMT:2;5"/B+=/]E2]#X'
MP#EI3DWMC:2% VS#(TFD5^YWJ0F*W!,6U.6LUEGJG$U"5;'M1I9_:%Y>LO>A
MHQL_BCMDRN"/3HJHG4G]D7G&+C<LR<[CC%*3?-RQ4G)>S11I)>\U*NG+5,>/
M'6JEHJOR5=*<>/FT\IQ[CS0T?0YZ2K-EDIUE-1\ELZ'19A#]YIB3U'!:^LUQ
M9PHBZ*#Y=&#V2Q<-R^M%<B+GIT\'UU5G9,[(MJ[:47!J#K7@KCG&+?=K!I]V
MG>)9%J+Y76NOT4;^Z2C0MR1-]I]HO:%6N=:K-;D[4R;O;.R@T%+.PJ#N08R5
MAKC2&L,VZ-#.'<6N1OY\1B[4[.X4"E,41Q,C"GCWH8[G"5V2BZ1;]ERHTG5+
M755I5>4KA<4XN5&HJO'MH2_F&7!@# & , 8 P!@# *-\R7%0LM9B8EW9=;Q;
MZFWB,&56O48DJZBW,]4IU:.;U^9D=;[4C8:2D8\YC+&&&<"X8@JB"S<YP,($
MX\:D$VVD*$@A)U68;ILI0K:2I;%6/KKEM[/RPMQ:HJQ%=!9VFB($>.$HV-;N
MGI55D6;5)0B"8$YX!A&N_<FT_P!YV7[IYC ,WP!@# & , 8 P"O&H?C5Y/\
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M@# & 5(W_P"HZ_B_,AF]VOL*)<?0:<=Q_/'GRW[>=Y@>ZBTS2GQD_2JY0_9
M7[H)+.[WG]RX?Y/\U&DV_P#>&3^5]]F^S2_SQG\K^[GG6X&Z@;BM(?2L/\@'
MS&<%N/O^DOKBR>\UI4, 8 P!@%>+[^D;QY^Q7>O^I:[R>PGL+#Y! P!@# &
M, 8!7GDY\6\1^-[1'YY:/@%AL 8 P!@# & , C/;ON'<?9)0ON^K. 29@# &
M , 8 P!@# -).^O2::T]'IJ.LM[%2K!LN^;)V[R-=URGP,@RA$6\'!;JMS:3
MG9N=D$723)N#MZ1%NDF@LJNH!_(0I!-FLW+<[>W**E%RN2X)::+M;/)OFI\W
M=F^5N/C/.L7LO<,OF=NU;:C[,**<Y3E512<DDJ-R?8DFRDW_ #,%8_5&L_Y5
MH7[T\U/\31^Q?YW\AXI_F\VK^X\K^T6_^6/^9@K'ZHUG_*M"_>GC^)H_8O\
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MKW-5S<>67Q"4&W%R2CHI3Y%TT7H^XSFO8>[0K%Q*OYN_7&D-ZTU5B"R3,*'
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M2^41'U R'**XM(HG<A;CS7)*,5VMT7TF#2>Y]/0H'-,[8UK$E3Z^(:3O=78
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MP1[^_KW=XF\O7KUZY;M>_P#[,O\ =9@]/M_M&;[?@LW_ /99!_4)SU$_8H8
MP!@# & , 8 P"$=P,E[$6OQ$3LJI4I>.FCN;&RL+&"FC24!*04M"NDF["6<)
M@UE&R4KYPS.J15H=4@%<(KH&.D8#(M/0R==UU7H%"V1]U:PPR\8QGHI**28>
MQS*=DV\="(%A2D8'&K,4TXLZ@ "BJC,QU0!4QP "3, PC7?N3:?[SLOW3S&
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MC6!$P+U H$*U;)%*!0,/3IZG7+JA"/NI+T&SLXV-CQ4+%N$(K@HQ22]21D(
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MW9'WJX ^%&N?4O8'Y+=D?>K@#X4:Y]2]@?DMV1]ZN /A1KGU+V!^2W9'WJX
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MY5N58UC6W&[-.#KS5;5O7@I5I14+<HV[#32JI0:U[VEKV=_H-=P!T  ZB/0
M#J/JCT^2/J>4<Z,Q#S@$MZ2]V\G^*3D/_P#MYVGF%N'_ &Z__7L?^_;+EKWW
M^3+_ '6?V1,^-#T$8 P!@# & , 8 P"@W(VD[JV!='$7[!;%EM;Q1F;JK,-<
M--3NX:5\]KQH^;->T[[N?64Q(21)!\\238^:NXD&96RP&,Y%4J0%C^.]3DJ-
MIRG5.4I=4UXO#$FT&]0IE?K%4A8F*5LDPZA#*UJDJN:=!V"1AW"#J7;12SB.
M3EEW(-UE4NU0P$U8!A&N_<FT_P!YV7[IYC ,WP!@# & , 8 P"O&H?C5Y/\
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M\1^-[1'YY:/@%AL 8 P!@# & , C/;ON'<?9)0ON^K. 29@# & , 8 P!@#
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M%O$?C>T1^>6CX!8; & , 8 P!@# (SV[[AW'V24+[OJS@$F8 P!@# & , 8
MP"H>GMDT/6.H9.<V!:X:IQ:^Y=[-6[J7=E;^=.1W'>#> T1 #N':H%\HE3(8
M0#RCY,O6;%[(ER6(N4J=A$FHZO@9!_;,XP?ACJ_^)+_T9F5^RMP^RE]'UE'B
MV^\?VS.,'X8ZO_B2_P#1F/V5N'V4OH^L>+;[Q_;,XP?ACJ_^)+_T9C]E;A]E
M+Z/K'BV^\?VS.,'X8ZO_ (DO_1F/V5N'V4OH^L>+;[Q_;,XP?ACJ_P#B2_\
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M,;$E<W[.Q<*''EYO%N^;DA77SLW?[0\1OX6W<N/OIRQ];^HD_P"!_P!.9RI
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M68]AY9^\>L8QPS=3T)YL^/'BW0+%&<>9$(4C<H !+V 81KOW)M/]YV7[IYC
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MNQ%8@Y& ID56JW+319:Y2457WD! MIQ_[7:G/0,:M[(R+M<[A!9R<B7G)"%
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MZ,@U;I%,)SAEJ[ONV-)6KL9^U&M.$4FFV_,A\+?B_:C)5X:<7W(_2YG'&0,
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M2B[#)>AS):%DX&0<1,Y$O8>4:"0KJ.E&2S%\W%0A52 LU<II+)]Z9P,'4/*
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M)+S):+0R+^PQQ0_ U ?7.R_TWE7P&']FOI^LR/X(Z5_4K?KG_2']ACBA^!J
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MU&MV<E%)<6VZ)>EEA-E\:9:ALG+F!M4'LEU7[\WU1?(ZL1$VT7J&QWJ15(V
M*:6:-_9]A)K HW0?(%(F9TD*0D*8Q>N3=Q96U[+4FI<KHGI+NUX^<Z#<^FKN
M!!RQ[MO)E;R%8NJ$9)V[S6D?:2YU)U2DM.94IP/K>^,4U4&2IXBUURZRU?O5
M?UALB'B&,HP-K^^VA-$82)=2,F@DSG8MR[,HT-(-A*BF[1%,2^N*(KF)*"TD
MI24E&278WP\_G*L[IB_B0;M7;=Z[;OPL7HQ4EX5V=.6+<E246ZQYUHI*AR)K
MC ]C[O7*O$W:!G(*;>[(C9"Y#"2T.TK;[3Q%3[-)*1,AT=&9UXI"^ [(J#5[
MXA>ATP[A"98K4U%23B^;6CTY?>T\GTE5[IB=O.MXMJ]"=B<KR=SEE%0>/^FY
MHO6D.R5>65>*(%IL)'V*XU>!<BJ$?-V.'BEU4B$0=>92$DW:J*$ P+%07,@J
M(@ ]X$-^STS&A%2FHO@V:'#L6\C,M6)?HYW8Q?8Z-I>ADI-=-.+Q+PY*2C%P
M[>:A:X_4CI60D'"$5(V"$F95HS3D%&;ERNTD5H)9NW,H)SE<G(500*<ALO*R
M[DER42:7TU^HVD=FEFWH+"4(1G"#I)M\KE&4DJT;:;BTJZUI71HZCX$K 687
M@UY& 0D$[4QJ*#40EUWKV1?P!+*55M',X=R^*BUBU"^.FJ1-PBN8$C)]W7I3
MX$N;EJJUIV]U2S^Q,A7G8E*VKBNJVE[3;;CSU246](\4TFGI2HMNN6%5K\@=
MVW42L,0VIZ$B0'17#1.6D;#LB&G2)]I (HB U)N"0@/0O0PAU[_),[2A%U]Y
M4]=9)_<)R]MMXN/)S5,B"MIZU7,YWHR]']6J>GO(?\-/_ )_BA_T98-/1=P\
M-/\ P"?XH?\ 1@47</#3_P  G^*'_1@47</#3_P"?XH?]&!1=QG.O91_#3DH
MK&.E61Y"B[*AGW@&%,KN,E->V=J^9."E$ 6;K)'\I3=0[@ ?5 ,N6FU)T[8R
M7_A9G[;<N6;\W:;CS8]Z+IVQE9FFGWIGZ\L[(^N1@# & , 8 P!@&KWA^^?/
M-JK(6"PV.0N#2NV$;5&OK3J:T1;69]D62,B*,K6-XVZVS'@O ,1-RK7FOB%]
M<N#8P@F($[<G0V1:W=<H=9U;MF2B_9<TR;8&OG.K7T4BBVK\AW1DK&7#;^L)
MEHX5?*^$40*L@8?#,4YC&,1,";="UA]3M3U2OR:=W1D6OLVZ?([%DHB4MB#N
M6L<O+KH/'$#9KE#MX]%1^)8YHWE'J;&-!!L"G5(0 "7\ PC7?N3:?[SLOW3S
M& 9O@# & , KWR6Y5\?>'^MI#;/(S:%:UC2V7>DV=3;H32D_(E)WI0E5@&A7
M$U9YUR(@";1D@LL/7J( 4!,&PVW:]PW?)6)MMJ5V^^Q<$N^3X12[6VD6KUZU
M8AXEZ2C#RGYD;IZ1GT@/I?-BRG'ST>M(M/&_C\"@M+ON*=4/";-D*VZ.")Y*
MSVAEYTTT_#/D ,9",BCN[/($$2E51*)RA<W#-VW8[KV_:7:W'J*.D[GO8F,_
M)^L7%_Z:?9-H\*W[YD;]U1NMSH_Y5VHW]Q@^7(SI_P#;8BX.LN%RZNR$:^FC
MIO&]'[Z+[07 FMD>UUF6_;LF6B@73<UD9IJ3[YP],*TDPK*2QG)ZU!+N#"*A
M2**/'H^O=KK'$.W06<:2O2S,N<K^XW-9W)NLGY%^+%<$EHEH=GT+\M=HZ,Y]
MQNSGG]59%7D9M[VKUQO5QC6OAV^Z$>*]YOLM+J'XU>3_ .,VG_F<U[F6>CEA
M\ 8 P!@'63,U#UV-=S,]*1\-$L4C+/)*4=H,639(H"(G6<N3IHIAT#Y(^7Y&
M51A*<E&";D^Q!NFK-57('E%%7(LP.H8P+!7XT3)3&T;*<:YKB*,0.BGF\E)"
MU/,+)B ]"I]O?T]:!\Z7#QEA6O%SYQMI=C:K3R]Q:YI7)<MI<S-/E\OCRWJR
MA*HM+[%E#)N$W%M2;J0M+B#F()#^PYG1$#/5$C#ZP>U,!'RAURN>\W<Z$L78
M;%R_=<6O$]VW#3BI/BUV>4RH8<;35S-DHJON\6_1]TA (-%\PU.SB("1@)\K
M>R(7^Q(O)!)U,++6N05CW:BJY2MTU&M? B111$Y>OK#>N+TS@-EQK^9NUK%L
MSG;O.35R49\LN5-\[YJZZ=U:E-OJGIW,O7<+%R\>[E06D$^[C2JI*CX\K="Y
M6N]*Z*55;N[VL23+U*94UJN3DK<W[(*H>>M$3E_ZI@'.[S=EZ=Q7S7[G//ON
M7JO[J^X8=[J+&QX_U^3C6E^5"/W6;'M46[T>.JFI!=,-*M)9%,HH@SIQ+1+>
M, %Z"W7)#RRWG!N@^4A^X1SE,N]LMF7+CNUI^*J_6:3)Z\Z=M2<;NX6Y2[HN
M4GZ.5.I8EMSCTRFF#+76N=QW,H !44*/J*919"!0Z)@'GB45VD$/WO1,?[V8
MOQ]GA;C.7FB_Y#7/KS:[KIAV,[(E_J6)_P ZARQY.[TG2@%)X;[27!41\!W>
M)^MTIJ8O7H4ZJ3@[UVEU]7H).O\ >Q\5D2_1V)^EI$?Q-OE__LMGRG7@[LX6
MU]+;1X]MG/FQ 8(_5&C->I*?O%;1=I>S/4 $?WXIUU,S50P%_@B!?+^QCGW"
M7"%N*\K;^X/B^O,C]'B8./%_CW93:_,5#R36G.2?ZEL'(S6M.;J '<G1-7DD
MER /[XI7%E7!3J7Y E.7KCPL^7O7817DC]86V];W],C<<:S'_P JQ5^N;/4.
M(NP)DW6\<N]^3J1Q[EV5?D(JE,CB( !@2)%H.7#<G[ %4Q\'<E^DO7&O)1#^
M$]PO/_K=WSYQ?%0<;:]'*FUZR)K+POTPPW;IRM39[[>HVV06UW\X:[7ZQ2[M
MTXK36G*Q78Z;NH]5NBFI++"H0@@1;J4#@8"@&2MNQWK/FD_+)E<>@M@D^?*^
M)OS[[EZ;^XT6O@.(_&>LF*>(TGK\BA0 /%?03>75-T\H"=27\^,<>O[/7+L<
M/%CPA'U&QQ^DNFL76SA8Z?E@I?[U29H>FU"O)E2@*K6X-(@ !$H>#C(Q,@!Z
M@%(R:H%* ?W R_&$(^ZDO,C=6</$QU2Q:MP2_%C&/W$C),J,@8 P!@# *\\G
M/BWB/QO:(_/+1\ L-@# & , 8 P!@$9[=]P[C[)*%]WU9P"3, 8 P!@# & ,
M 8!^<3EJV:/'6I&<A))0S!U=N1S9[+KMG3U"*:+<BK>FXD5F;$BKUVDR2,*A
MDT2F5.!>A0$1#-%NZ3O6TW1<O'TGBGS4C">Z8$+DE"#M23DTVHIS56TM71:T
M6K[#K]Z:@UM :XX]2&OKI!R=QL%!(=C'URD71E.;>E7=R/&H6%DNM'D*P?-"
MJ@BF@]%-VJ*8%3*/4F8N18M1M6W:DG-Q[$ZR=>)S6^[/MN/MNWW-OOVY9ES'
MT4+5Q2R).YRJ:;6C7!*7M.FG8=C6(:5?\<DZ_5$IG7%WKG*#6\)LY:QK/9)]
M/W:7$T;3)A-NN5D[JQ:5)&.=U&G16476 %!7[B@GDPC)XW+"L;BNQ4J]K?!^
M2G<5XMF[<Z<^'Q.?&S;>Z68WG-N3G<E[-N5'1P\-ZRA1U>O-54)?Y!RT>C5^
M1LO0&;BN3VN^3VMY+:[J3<*RC#:%H9-U48:8B6 .@"GQ#.UM'#Q6- SD%BK%
M$'!.PJ9;V2TH796])1NQYO\ 6?9YM=::FXZ@NVUB[C>P(NW?Q]SLRON3YE?F
ME[,HJO\ 5Q5Q.3AK6J]I4HL=I-G0W; 38M(<NN&MRLEMH,.Z3E%K/+C9=G ;
M<'(.>B7;E"*\S:K56E(1T:SZ?YH65 BRKE(ZW;3"7CQ>G*I-I:UUE[4WZE1>
M?M,;"R8[WCSY(?#1O7;EJ+YG.7/>_P"HRY1;Y:+P[:A"/X//1N2;*<WBFHTF
MVZ[D-;O; ]97JL5#8U!1F&[ ;;'>S<D]:1D3+!%@:)>2[:5B#=#MRE14(<GK
M0'N#,*Y#PYQ=JM)).->.OFTKH<?G8:P<O'N;;*Y*%^U;O6E)+Q%S-I1ER^RY
M*4>S1IH[N ;[DF+26/CE6]:4L5GHM$>.HP("-@8AQ&SD;(U-%%O&KE9-8"/E
M"H.$UD/\S74[2@H<ZA2FJCXSG1:5:6E*<:KT?07K$=YO97AVVK3N7;5IN/)&
M$6I1=NB3HH*5&FO9;TJVZ'UA(C93JR5XD&W9M6\M889T[4=P=3CJJUF;:+FD
M+I-8SSGV,EJL>)3%-0A2@D9$PF5(0#E4.C&ZY+E[6NQ4J]/50FQ:W*63;5A1
MC&=R+=80C!2N5MND:TE#ET?93BE5-X_8$=GV-VZ9KME9AI9YV7BFKLR%?1\^
M<P4]/V ZKE=HX,TAP8*OI!=-515-L1DHOX:AFQ#&+3+Q9-KBF_)V-OZ_17L+
M&0MSR9N$ESPNW)13I!5<93GJTZ1I6;3;247*C<4=2YU/:&S.)-YFN[E)Z.C)
M*.CF)HU8C0CR=L\&X;S[H9,OL,NV/6%E@%4@)@EWBJ9(J9C92[,TEWM??:U[
MN!9EM65&$'1N[<C%I*CI64XM2?-[+7(WKI2M:)'(KFIYYU.5!*W-'M:JUAMD
M?6Y&<*>-<O(E-Q/N*ZZ=K10/3/6B2<FQ<()+.$DVZBR)@*8_3H,QLR<HJ::@
MW2NFFM"K&VJ_._966I6L6Y=4'+1N-9N#?+6J]I-)M)-IT;(K5*0BJI$SBJF1
M50B:HD%,54RG,5-04Q$PIBH0 'MZCV]>G7+1JW1-I:JI\\@@R>H?3AQ]C%Z^
MX:QY7;][T2_W69>%^F?_ .E=_P#:F?L"SLSZ\& , 8 P!@# (DW;<KC1:&O.
M46MN[+/'FZY$@DTK4]=!A8Z8F6<?*69Q4*LX9V.RLZ^R7.X5:,ED5SD*(@<H
M%' *;<=H^5BMS0@+:KE%8]_!7 $[(KJKD-K6OZN["QKE-M7F&YKU<*A&M;4)
MQ8IL*^TC%4$4  1%L7P@ G/DW?'5,A8BR>R]LH1:G<XPC"P)NM6$JUF6G*S.
M(&0?1][VA0$)5E&>,<I45G*"Q)$J2I&[E),5" 23QYDVLUIZG2[.PS-J0DTY
MM^$Y/2-9E7[I5U9)A9P@F[I]AME>"+CG)SMF**$F_,V8HHHJKJ+)J&$":, P
MC7?N3:?[SLOW3S& 9O@# /@Y<MF39P\>.$&C-H@JY=.G*J:#9LV03,JNX<+J
MF(DB@BD03'.80*4H"(CTR4FW1:M@T%\K_39P97=^U;Z/:M5GD+=Z"DLAM7DI
M<)@U;X9\>.HBD+NZ[0(8B-\LB9RG*U@X,ZRSUP4$TCJG[D1["STUC;9AK>>L
M+_P.V4K&''(N^2%M^ZG^-+U'/[OU%M^T85W.R;MNUAV(UN7;DN6U!>67:WP4
M8UDWHDV:L>-7HQ>0?I/-KMN3/*O;>Q;M0#.#"7>VP(0:Q*72.!43+USBEIAV
MC[":CUBH/5,DZ\;'D'1>JA">)WIDY[=.KL[?,9[1T[:>U=*/22B_Z_(7?<N>
M]1]R=/.>,1AU3\WKG_2SR-K^7LJJ60T[>7G1[L>#7_3X\OM&N>:X=J7ZZ]':
M'U-QOUW"ZLTQ2HFCTN$(/@QT8D(N'[U0"^=S$W)+F5D)N;?G+W+NW*BBR@]
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M7+:[;DEI_LKM\_ K_JO7.KN..V[3J#T>-=?<XO22VD5DN17/W?[]6[0FH%I
M3IS$G8;HJ#Z,B'"3@5 :5F#'R>M1<*.C$%$>,ZBZWW3?)+:=MC"&);TC:MKE
ML6EWRI[\O*ZNOJ/*MZZWRK^ZW.DOEM:AN/5:TR,J=7BX2=?:O7%I*:?NV8:M
MZ/5<KW!\0N %*XXS,ON/8EIEN07+"](=^P^0E^33<SISN$R%<U^A1ZGBH4BG
MM@#PD6S804.B  H?L[4B:3#VZWC2=^XW<S)>]-\?,NY>8Z/HSY=X/3%Z>][E
M>GN76.0OZ_-O).;TUA9CPLVEP4(]FC;5$M@>;$]%& , ]%%$T4U%55")))$,
MHJJH8I$TTR%$QU%#F$"D(0H"(B(] #'$&J.Y<XM8Z"O7(ATU%&Z2EFOU>?0*
MK"39MZJ+>.UG38!XY?6(IG)3^:S$8LB*#9)=4YDQ#UOD'-C' =NU\1GSC8QN
M^7%^:/%D1<KDN2RG*?D^LJ\5YS9YY.45X>&5K^L7#H%$)VV)2--U8V;E4,'C
M1=<3$]HV$JF0?6J+=41'_! >N8[W:-M.WLMJG_G755_[,>S_ $T,CX6W;US)
MUE^)'[[+VZ:]&]IZC.(^Q[6>O-[75CX2K-:W,V[.C0"R8D.4*WK]H<\*U*D8
MO0%'/G)S  #ZT<USL.[<\?,G*]??;+7U+@BJ63)1\.RE;M]RX^EFP4YXR$CC
M**'8Q$1%M.ICG,W81T>Q:I^J)A%)LT:MTB?]4A"A\@,OZ):Z)&).<81=RXTH
MI5;;HDN]ME'K+R=NVW)Q_KOB)7FUK=M%Q8V3==B250UA3S"(E6&+4%,3VR51
M#J)") 9(3!U JI>HA@2R[EZ3M8:J^V3]U?6</D]39N[7Y;?TC;5V:=)Y,ZJQ
M;_)^TDNY:><D?3O%6JZ\FE-B7>8D=N[FD !22V1<0!RX8JB B9K5(M0ZS2N1
MZ77M3!+JJ!0Z <I1[<NV,.%J7BW&YWW^$_O+L-CL_2V+MU][CFSEE[S+WKUS
M5KR6X\(+NIKY>PX&_P#U'7\7YD,ZC:NPZ:7'T&G'<?SQY\M^WG>8'NHM,TI\
M9/TJN4/V0%^Z"2SN]Y_<N'^3_-1I-O\ WAD_E??9OLTO\\9_*_NYYUN!NH&X
MK2'TK#_(!\QG!;C[_I+ZXLGO-:5# & , 8!7B^_I&\>?L5WK_J6N\GL)["P^
M00, 8 P!@# & 5YY.?%O$?C>T1^>6CX!8; & , 8 P!@# (SV[[AW'V24+[O
MJS@$F8 P!@# & , 8!\S))&$IC)IF,0_BD,8A1$BO89/Q"B(=2G\,PEZAY>@
MB& 5]XQ_%O+_ (WM[_GEO& 6&P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & :]>2VP]EAL-O78!.UT9E25VTI VF KN[IQ:W>SM:5:R:JPZZT?MZD.(
M)FI)JM"M)'PY)"08BY(1-,4%%0+4:!F+//:DJ4I<6]D0L*Y9I-XI;2>#-R2#
M2Q2[.-G%6RE;ISYBPL$6@B]9-WD5'2#=DX23=H)N2*EP#3C_ ,1RQY6/_1WR
M:7%XM^60+LBLGWDUUC[*#<7.G0CIP),A$H+_ .^N*X6R#'#*IM.IS-.OB +<
M%L[WY<RVF/4D7NWAT\.7A<].7Q:JE:Z5IS<M>VG;0UF[^/\ "/P*\56G&G^E
M*^0_.AZ#/A_%;AAMI;?](ZTV"CP&XV-F5NU[5MXVVYUC0<ENQ[("$Q)FHDXX
M:15X+"P3$H*MTTE6ZC]=%$R:ZB@I#W?S(ZEP]BM1EM%VQ:W6ZFKMV"@[D;26
MBYUK%R;TI[32T.=AD86VX5W<]^NQL;1CQYG*[+EMKRNO'N2[71)-L_2.RM/(
MGTFC-O0>.3"P<-O1VQJ)8)YMAK")T_;.^:TT'S,U<TS6TT6Q=?:Z=M$O!"0%
M-,RB!A*7KZ]J'S5._F[U-NVYV\)OVIOW[G?2O!/M;XGGCW'JOYM2^'V!W]G^
M73TGEM.&7FQU3CC1='8LR7_%DN:2X+C$VVZ X[:<XP:YB-5Z0I$32*A$D*<Z
M#%,59*;D1(4CJ=LLPN*DE8)Y^8O<LZ=***&'R )2 4H;;'QK&+:5FQ%1@OI\
MK?:SUOIWIK9.E-KM[-L&/#'P+:X1XR?;.<G[4YRXN4FV^\FO+YO1@'@Q@* F
M,(%*4!,8QA  * !U$1$?(  & 4>W]SYT?I!N^8MYAO>;8U[DO8B!>H#%,G0A
MT(E+6#^59(J <>@HMP<N0'R"F YGV\":M?$9<HV,7\:>E?,N+*4W.7):3E/N
M10A;^WASN5_S2/5T[IUZ/4DC9&\I6*Z\8J#W$4CZUU);+R8Z?E(L[\-@(^H)
M>HY0]RM6?8VBU67VUU?3"'WW0O\ @0AKE2J_Q(_?E]18/B=P:TW2-@[84N\>
M3<%RUK<*Y"05INS-)9DR)(4"JVEPM&5,%%H!BJE)3:I45#)K+)I%* ' 0$1U
MT[<K]WXC+G*]D=\M:>9<$O,5RR)*/AV4K=ON7WWQ9M4(0J92D(4I"$*!"$(
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M?;6Y]I-%[2=S6[$$T[4VM,R\;%O(6%.1)NI#*KIN4Y14C@Y%6_A% OI@# &
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MPHOWWW-Z>3M)RTKQDU_II=W8B'D;QLR9[E+'M&YK>RUMEEU0_ER-W*WB%AV
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M]RX?Y/\ -1I-O_>&3^5]]F^S2_SQG\K^[GG6X&Z@;BM(?2L/\@'S&<%N/O\
MI+ZXLGO-:5# & , 8!7B^_I&\>?L5WK_ *EKO)[">PL/D$# & , 8 P!@%>>
M3GQ;Q'XWM$?GEH^ 6&P!@# & , 8 P",]N^X=Q]DE"^[ZLX!)F , 8 P!@#
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M#Y&NV:M6N)W+=ZV+:QDKUNJL'NG7M'K$8[FZ3-&KCRP1U[CY'S(KQ5LW7,5
MY02;IJODVJZI3>(!8+0$U*V#4=2E9N50G9)<)Q!><:VF*N;2:(PLDQ'M9=G8
MH9JR8NV<DT:D622\(B[1,Y6Z_5=)01 J;S3TI#<X=9RU$U-L&M+;"TU>_.G3
M)1ZJM#(3Z+24AI6IV%RR2<#'27:"I2G JHMW* D4*4#&$N+F8[R;7)%TDG5&
M3BWUCW.:2K%JC(<]&KP>MF@Y&U;9V<\KCBQS\:I5JW Q!QEA@&S"8<IS,FYE
M56R"1'[YPQ*DF5MW%!OW=Y^I^P+.#B7,;FE-ZR25%Y.\O9F5"^E&"=$ZU9MX
MS8& , 8!4S;G*R J$_\ !EJV">[FW4\ R36D50Y5V,"?][Y]=IY/O95]@V.(
M"J0QO&  ]<"8#W9AWLR$)>%:7/?[EV>=]ARF[=58^)D?LS:X2S-Z?"U;U4?+
M=EP@EV]OFXF&5'BU9MC3\?LSEM8VVP[*T5![7=5Q8JI:IHAA$%$DB1G<4EFD
MT/(51=R!DSB7R^*'0V40Q)W9*[F/FGV1_!7H[3#Q.E\G<;\=RZLN+(R4ZPL1
M_06O]G\.2[7+3SEX4$$&J*+9LBDW;MTB(H-T$R)(H(I% B:2*28%(FDF0H 4
MI0   .@9GI)*BX';1BHI1BDHI4278?7!)7C4/QJ\G_QFT_\ ,YKW +#X P!@
M# & 5(W_ .HZ_B_,AF]VOL*)<?0:<=Q_/'GRW[>=Y@>ZBTS2GQD_2JY0_9 7
M[H)+.[WG]RX?Y/\ -1I-O_>&3^5]]F^S2_SQG\K^[GG6X&Z@;BM(?2L/\@'S
M&<%N/O\ I+ZXLGO-:5# & , 8!7B^_I&\>?L5WK_ *EKO)[">PL/D$# & ,
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MV;%G'CRVE3[K\[.KVG9=LV3'^'VZTH)^])ZSF^^4GJW]'<D2G[1.1_ZP=/\
MR%(?UDY>T-MH/:)R/_6#I_Y"D/ZR<:#0>T3D?^L'3_R%(?UDXT&A"&L:=O=?
M8W(5".W;5F#]IL&K)3;Y73J+U*9>GU;25V[QLS&^MPB4T(Y5%N*7B..\Z(J]
MQ>\2%:#0F_VB<C_U@Z?^0I#^LG&@T'M$Y'_K!T_\A2']9.-!H/:)R/\ U@Z?
M^0I#^LG&@T'M$Y'_ *P=/_(4A_63C0:#VB<C_P!8.G_D*0_K)QH-"M>ZJKO%
ML5<);<U5E  @ ;P-/MHX3!VA_""ZO!Z_W>HYN-NC=?Z.2CZ*_?10Z5]!JPVH
MPM2)W02-FCY#IW=PH5I)AW?(\G24<=N=EA6<]Q3C?@O_ .'7^<BVW'N^DU+<
M?'E==<C^1#2$@7L//M9LI9V;=SIYAG-+>S;\H*M(4\>R)#$!4#'[ 77\ANWK
MY.N=ENN-O4=IQ97,RU*TXZ)6$FO97%^(Z^I&HPI6'G9"A!J:EJ^:M=7V4T-S
M^IXR[+J-0C;A%QXCV]HKU!*0 OJ].O69;]V<+FVLY>]>@]/LZ?SF;:+CV+Z3
M:5J2H;[=1H>QN[ZE&I^" ]BFEVSXW3UOD\7V]M#9QF<IJ7MM-U[J%Y4J3'[1
M.1_ZP=/_ "%(?UDY@:%6@]HG(_\ 6#I_Y"D/ZR<:#0>T3D?^L'3_ ,A2']9.
M-!H/:)R/_6#I_P"0I#^LG&@T'M$Y'_K!T_\ (4A_63C0:$'W*G;W2WMH]J[W
M;5W<RZK>XSQ$L33J+9M$H-V=&]DT7$6%^5"3/)%51\,XK(^;BB/D4[^A0TH3
MA[1.1_ZP=/\ R%(?UDXT&@]HG(_]8.G_ )"D/ZR<:#0>T3D?^L'3_P A2']9
M.-!H/:)R/_6#I_Y"D/ZR<:#0>T3D?^L'3_R%(?UDXT&@]HG(_P#6#I_Y"D/Z
MR<:#0>T3D?\ K!T_\A2']9.-!H0AR"IV^&E"C%9O=M7F69MGZ<03:-M.HQ*J
M<@XVI44(M^+L+\^[THR242<'0\,/.")"EWI]_>#0:$WC1.1_4>G(*G]/D?\
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MW:(-':CUPN1 R?@G5.0&>W#78NL3*/\ 5NIX#44;74VLA:UO@TY%-=T2**[
M\/51/*LY*'AYM"(8-F#6+1505=I,A:I-#)H@!< O]@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & 5FY.6+0]4K],GM]/'4?!M+FS;PCMLI-)(ED)5D\B'
M[:;-#'3!6JOH9^NC*(NA%HLS.<JI3$$0P"3-/AKTM!C0U8"(4L):W Q%OXXH
MFE@N,^%K.0R_45 4M@/A[TQ% _7N1$4A(. 2;@&#Z[$ J;41$  )*S"(B/0
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MXMXC\;VB/SRT? +#8 P!@# & , 8!&>W?<.X^R2A?=]6< DS & , 8 P!@#
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M"B7'T&G'<?SQY\M^WG>8'NHM,TI\9/TJN4/V0%^Z"2SN]Y_<N'^3_-1I-O\
MWAD_E??9OLTO\\9_*_NYYUN!NH&XK2'TK#_(!\QG!;C[_I+ZXLGO-:5# & ,
M 8!7B^_I&\>?L5WK_J6N\GL)["P^00, 8 P!@# & 5YY.?%O$?C>T1^>6CX!
M8; & , 8 P!@# (SV[[AW'V24+[OJS@$F8 P!@# & , 8 P"CM3@I6R\=K'"
M1*5;54?[VVBB_&V+/@@V\.;D):/9=ZZCV4W7"SYV+#O6)'+OFS9Z<@)J&$!
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M736UHK'DT7WGK6(9-P!9-H<%EV:CA0"[N , 8 P!@# & , 8 P!@# & , 8
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MHT@:Q%,X:*06<*NEB,V214DQ7<KF,JNN?IW',(^N,(CY/4P#)L 8 P!@# &
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M)&LG*34M$94T^PYI:G3%WI\3<8:!DF3H9%VU?QSR0?,6B2:0F<R$"FP/YZD
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MM/JEJ%H# ;-6H*PBQ!?SD&0S46UDA: Y\)#S@&PN>SO["=_;U[0Z], R7 &
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M9I:P25291<&W(^BGJ[2V7"-J;:24-+L&J;9(B+U63125[%G\6S6=-2JMR&5
M#D07*K2DI7%IR0N<;$.8N#J4Q8HOPY61/&&MT)#SK1O%NVD5X-M08M)Q SIS
M%@Y1:D,!UQ1+UZ 6(070=((NFJR3ELY237;N$%"+(+H+$!1%9%9,3)JI*IF
MQ3%$0, ]0\F ?7 & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!&['<&K
MI..J$NRO=:6B[\QF).G/_9)%)I/QU?9G?SCYDLL*9/-8AHF)W)SB0J/D P@8
M0 0,C7N=/;32=;<VNM-[$LA)ND8%>=BTIE5M"-X]W,N$XM1T5\="(:2S15T<
M""5!-RD8XE*H01 Z2?VKK>K'GT[%=:[#'JT?5)2P%?R*" Q;.]2LE!TL[CN-
MT\:U3$.Y:L$2]RSI=/L3*8QB@8#(%K;56[5-\XLU?08JE*=)XM,QJ350AA>
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M8+QK<@@!S.4%"B >&<0 [FX;@U?0'D@PNMYKE9>15:+<9%O,2";11I63RZ,
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MC%&?&\V;N9*.C4(YS+-8MHA%Q#F7\ A".))&*:))'$H%2(!0(D0B8%* &3X
MP!@# /111-%,ZRRA$DDB&4554,4B::9 $QSG.80*0A"AU$1'H 8![X!\TU4E
M?$\)5-3PE#)*^&<I_#5* "9)3M$>Q0H&#J4?*'7 /I@# & , 8 P!@# & ,
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M+F:K"+E42@<X%G, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!T=GDUH2MV&9;$2
M4<1$'+2:":_=X"BS!@X=)$6[#$/X1CI !N@@/3U!# *),.36TQ;P%AE%Z"E7
M9':VM(*3CV-0GW$NVH]BXK);YM+5@[/>RHNK0,^H+=@Y,W*W39%[5&RRIO%
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MHIS,0,+*N(%VF_@UY*+8OEH9\B=%1%[%*ND%3Q[M)1NF8JB(D.4Q"B ]2AT
MZ!QK#6CN0:RSO7E'<RK%&8;LI-Q4X%:09H6%^$K/HM7BC SENE-R90<NRD,
M.5P\13N/Y< SG & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M'M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M[#_NNW .RP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
), 8 P!@# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>v473641_img5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v473641_img5.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!+P'S P$1  (1 0,1 ?_$ .H  0 " @(# 0$
M       '" 8)! 4" PH!"P$!  $% 0$!              4! @,$!@<("1
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MD<YJC4_U21&A3_OZ3B&G-'641"'(1HY;&.NC[TJV(J0P[L_*8T4_NYWDV%V
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M/*V_I"Q&X +>VJ^UUMMUKLQ\3.%. T[8W(+RJY*XYP3"/??-:/SE41;]GM0
MSAO,V^6#KN]FNK4[5W&P=N>KN=TJM6E;(-JZ[;'ID^VFZO&5>S0]@J-PRV#B
MW$['W"5@;; !4$K$];RC$C-195=\W% C@J2ID;3GROR6/#$&]VEA=C< $$%
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MGNM';2QW]U9'#:T4N7ZUU*K5@,J:Y^$.L%G&]KU%!=*:+*-$8])TJ"C94Z)
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M7Y_Z(V=KY#1:D1--[5Q<GG;%\.C4]0L$AH+=K68>[P_Q,<_[.5Q9.P*"><P
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M;M6K9 A$6[=!(@%(0A0*4H    !R3  %AH!7?QQI$BQ1*%C4   6  T  &@
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MR;M<^8O)J2@%$5"NW1P>MA-4TK-/A16W.]'T/N;HN1N86P97/RG6B+S&T4N
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M=//V& JL4ZGK/.1%<A&)2&>S$[),XF+:%54(BD+E^_6;M4/564*0OF.'F,8
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MFO=Q5U.*5X**)I$,HJ<B:9 $QU%#%(0A0_"8QS"!2@'[8\50D*+L; 4]1/U
M2\Y/5$@J GY@]04P$"B<">/F\@&$ \?P>(\4N+[;^U7GQ5:\ 4()S)@<@J$*
M0YTP, G(103@F8Q 'S%*<4S> C[!\H^'X.*I<7M?45Y\56G%*<4IQ2G%*<4I
MQ2G%*<4IQ2M;&A1M)>Y3VJMEG+#!JC>=[,UVG34LN+>SKMV.5VLD55@537;2
M<A6V="3</$8LQA:>[H@]33!4B;@L;($,,KO;S;N 3U^B;#Y+:VZ>->1\I%QT
MG"\WFYGE_70EY".)V-I"%QI-L?4,T8AW.(_HV'F ;@&KRO'8[8*"E(0 S$-:
M)R@V^WH6%:&H9225GKU9-C[T)%\U<VAC TNDQRNI&C9)T@K(S/A[BHV:J"+M
M0B3)FC]FX+*QO8=0-OKL![5CU/2PZTY'NSGN,#XOF1S9&+/*'*0^U)''[J=Q
M!D"11*<GRY&4R2_JRB'](1RF&][2ZE KSFTU=-S?+@6(K,LUJ"90HD2GO=UR
MQ(IF3B863M#US!5I!9=1P= @.SG%,A2>4@!D3%MMQ[1L-.GME?3KH/GK)'W-
MW"\WNKS0A\G(V1L(OU*C-EQNA8^82D8+%B!N)L +"N'A'8[>],OV<QLG%LWU
M?- 4M#1)"(@H")IXO;;0+#;G$ZSE9>WC;6LXUFHELS90[1D_1.P<&666$Y#F
M3I!DY$LB@CV;"]@+:@F]R;WN+ 6.E6=M=V=S<QR>)#,BMB^5")V5$6*\L$DI
M<,TOFAPZJJ1*C@H2S-<$C]TS:='IFI[8PHB](KK&I$T_1[&HM4?E"7NI,HPS
MJ[9HN'DI$)=F5NYEC7EQ'.9 4E5D(M- B)"JHD4XEGE25Q'M &XG3KM5#Z?7
M:_HIR_<'+8'-<C%QIQHHX/>)Y+Q;FF]VP^.D56;<+%O.9&>Q(C"A0"H-2WV5
MUG4:!/LT:!,UB+CXC*;=I$LSGZXO.'GI*!NV<5J(A1=HS$8>)A'*5N<F>J)%
M4=& B?HG2,!A'/E32QM:,@ (6U%[V(%NO376IWN[G.9XO)4<9)"D4>%+.P>,
MOO9)8(U2X==J$2MO(NW3:1K44CO^^A>ZM0X9LG;W5:MLO$W.78UZJQ419(6.
MVE',GLC:'DW;(CYE>YUXZK]H2))(+O9%$$/3\IBIJ8?>,CS%C74AB#H+$;MN
MMR+::Z7N:A/[3]S?64/&P 3O#.RRL$C59$7+&.6D+RKY5H[NHC#EW&VUB >N
MK_8S;KS8&54B;)7H0EQL]"7@KR.=&/!_,^UU7L,]>*T*(D[6>6G&0+8NU6:O
MYLC%R9VZ<@HR*W!),M%R9Y&V @7(L;:6(?H+Z_1ZFWCI6'%[K[BY++7!@FBC
M&1-"4F\CV/*DCSB3"K2;G%\12KS!&W,]XPFT#*KWV/TPE"P>[U^7IM66NO6G
M0^P5HA'T.:8&PRE#K^1V=O2JVNZF&*T='R9+B^2=. ([=),BBHF!5$P.%TF3
M*(XY%*@F(N1Z;!38?.?L5N\EW;S XOC.2Q9,>%LCB)\V1"N[>T*8L@AC)8%5
M;S7#-9F":C47KWO=NV!:3MK*-LE914LR^@(4I@O#P[5W5%,Y[#16'IP\"ZEI
M9E&VVVWR.?G<Q[>55:MAFS(-@4(W4,):F>8D@$:WMITL^VP])/A?Q]572=Q\
M\TT\<,T(,QG$2E%!C,&<N'L0LP66692619"J^=M2X0FV!'T.WZ%:\\DT9FO5
MR65U+K$YM<O4ZLZCG%I:+OMXBINF32,U+/)!JR:.8 $/3,NZ!FZ!P"*KE(Y%
M38_,>1U-P#N2]AU^E<&_R?8]=1AY7/Y7-Q)EDBBG.;QYD:*,J9 3FJ\3AV+
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MLV%ILLS<.PVSX6\E)E[%6.3BJJ[81= :21V,?[VA\I^=(JXMC>7F-,F9B";
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M!&LQGU*E&R<A$RQ&\A5H1X@64@&*$9!R().&*A/?8>-;)MVROAYT$$RID$"
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MU1BQ3,H<L%&M[9%2OI,"%332\14*7P5\PJ5+_%*<4K1C_>/O^$3V-_K+A/\
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MC18TQ''Y)P" .EY"QD47%]K*&#$]2JVMXU3#C7%=G7]*GF_:M8_*#T^6HO\
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MXL.63 C27.6)C&C-L5W"DHK/M;8K-8%MK;0;[3:U:*N]_<_XG^-W7)8BEX1
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MWEU@[A/O*6X@YES(QTA$6.(FETE CE80C802)C?MON&>*6!\:0F3%9=TN2'
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M)NV3D5(E"/43-*X'"\I@\ID,T>4V(7 5DG50T8EC,0 8E[1Q@B3<5+J&%G+
MUKRY,$N.@!C$EM05)L=IW=-/:/T;7L2.EJT;I^()D 0, ^0OB!S 8X#Y0]AS
M![#&#]D?V1YZ&>M0]>7%*<4IQ2OHO_NU?^UGOW_MV2_M*JG/+/BS_N3&_P#5
M?^6U3W;_ /M+_P";^Z*^T#G@==;3BE.*4XI3BE.*4XI5*-<[=Q^3ZP.9S7S+
MCD)2<R&NP5BE+ _]%G*Z)+22#YE:F;6,'Y+D%X^.].&;%5,9\^<M$Q-_C0 B
MI6>=PE2(8#9UU/,":%GRE902)J+'!-+6Z,H?R(HD465/Y2CX$(4QS#[  1$
MXH.M9'*VK/Y605DAF-3C5UTD$EDX:LZO%M5?=P,5-0[9M62I"MY#>43>'B(
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MCC7U(JCU5G/UMTO]NV_=QHWT4Y.USE1E4-1J"-^UMP<UG]-Y,5(Z($S^_J*
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M*68G6^TOH #ZE]5<;\0>U?B[\0NS\[@(\GB>'&5" $B;(GE:S!C&^3^A6-7
MVL4A<D$CH373?"WZDW+$.J;JC[M)UK06&@6@MZAZ.N VRJ5*&79Q8L8Q(DXT
M%FLY<2$>#]0B2!4$'!@$GBH!CCD[8XG,XC ./F.&=GW  W"BP%@?7U-M*O\
M[O/PT[I^%W9#\%W7EQSYLN6TJQ1NTD6.A55\M'8"^XJ78*H4%M+FY.U%NU;-
M"G(U;H-B*KKNE2-TDT2J.72QW#IP<J92@==RNH8ZAQ_&.<PB(B(B/.CKWFO?
MQ2G%*T8_WC[_ (1/8W^LN$_VYY[SN_AM_P 7XWXLO^B>HSF/]@?Y5_=%?S+N
M?3M<;3BE;!_A946E:3W@S&G:'4Z_=ZE(T/LD]D*U:8II-0;UY7^L6QV."=.H
MU\FJV67AY^):O6QC%$473=-0O@8@"'/=U3SXW!RS8[LDPDA 938@&>,'4>D$
M@^HD5M82J^2JN 5LVA_%-;6OB-=6>NF=_"[SO=,ORFHU>]V-I\+^K72S,H.*
M92Y;[.]/K[H^F+P"K5FFY80N@0]LJDA+J%4 9:>;.5ERF42*<W)]M\KR61W3
M)@94KOCK[\RJ22-@R$1+^DH5D"_@H0!UK>S((4PA*B@.?+!/KVDGY[B_I-31
MG.<=$+33OAW]<+[B^)6G8-)ZKY-V:B&%-RAY4-!BWN9=<.Q.IZ!.=BM4:$BV
MFO4S=+15:XV8U]!9XNFG%2/OONX.$3GT<G*Y^&;DN2QYYTPXLN2$EI R$/-#
M&@ACU,;1*SDN0![2[;V-943%810LJF0QAM!8Z*Q.X^(:PT]1O4:57$<8>;1I
M>39?URP8V\=M\#Z4:/G[+;,FMDWU@;6;=^JMAU';\6RJSU:-FUNK.M6FTSOS
MCI[WU$F4?&0*[-$Z94T4S;,N=FK@Q9F5DY'N&'D9*.8I%$^V*<)%+(K$>?&J
MC9(.I9P3>Y-6+%&9&C1%\V14(W [?:4D@$?1).H]%JQ,?JRR3JEN"\'UJZLV
M*9J7P;^C?8N%M&@X/3KG:VNPZKJU>QF]6T9^21*^,\F*M/KN1, E4^6"IO1.
M8Y/*.;_6LOEH ^5EJC\SE0E4E95\N.,R*MAIHP _%]GI5GL1P/9$)&.C7*@F
MY(!/S'YZGIEAO4-HT6M-HQ7'FS'I=U\ZC=N;M'&SR'C(:_T'3?AB724LU?V*
MR?)QHV58:7V3J=;2C%78.5V%BE5W1&RZCPY@T&SN8)\J*>;=FY&1CJ=Y)1TS
M5"F,7N"D+/NM8%% N M9O*Q[;F5;1HCG3J#&;W^5@/LGUUK6^,[ Y/1])Q;.
MLK2ZTUEO6<FS.4F\QQC!Y;,-2H\E=,+QJUO'>YZ2>#C:QL3RXRTHZDHA2-<N
MS12*RR3CTU5!*/3=ER9<^-/DY?O3%IG >24.C!99%_1)<M&%  ;<!N(!%P*T
M^1$:NJ)L%E&@6Q%U!]H]#?PMTK2YSM:CJ<4JQ'7;_/%K_DF+_ASGFM)^N'XG
MW:J_ZD?C_<JX%>9Q4C8(".GI?YO04A.P["<L ,UI$8"%>R39M+3OR<W$'$C\
MCQZJCGW=,046]+R%]I@YCE9TB9XUW2!20M[;B!H+^%SI?PZUA4 L QLM]3Z!
MZ:N!C>!YEIFC;AFM=NJMTK$;-YG6,TV%.KRD*[/&6SL;FF>J7QK1I&4:+).)
M&J6%R4K!\N !ZWM,F;RG+!Y_)9>)B8^7+'Y<Q61I(MP(NL$C[-X!Z,HU \/&
MMJ*&.21XU-UNH#6MU<"]OD/0U*DMTFSQRMBD+7]&FXA>Y8U:-EN-JN,?6X6/
M)"R5PS^(SE@Q:/+>2,9RS"-TQ@$RB#L16%JO[@#M=1NBII)W!E*,B26)6$<Z
MQ(JEB;A7+DD+<@F,[#;2XW;0"1E;#2Z*K$$H6)-AXBWCZQ?[5]*QU?I#6 >7
M9D39QCB468H-7D7\]4VR7RE8['3ZG>[&:OUN)L<I<IV#CH&X($8J-&"SH[A!
M4SY%D@*:ALP[AFVQM[O?S%=@ QT569%W,5" EE-[D"Q&TL;U:<-06&_Z) U'
MB0";"]R+'33Y;5WS/H]4K'4H51A?)>D6F#C=+0OSF_1D-'1SVR16MV*B4-O%
MQR=I<NDT!CH WRBV9>_2"QU$U&:#DHJ"3$W<,\4[!HUDA8Q[-A)(4QJ[W.WT
MM[)-EZAB-*N&&C(/:LPO>_IW$#Q^?Q]%5F[3Y=!8UJ,?GT "BB<1FV='FGZJ
M"C4TS;%X A;7.$:J/7_NS:5G$5E4"%4\OH"0?(F(B0LOP^9)GX9R9.K2O8>A
M=WLCH.@L#Z_36MDQK%+Y:^"B_K-M35<.2M8*D?+JUGMJL4I':9I)LJK[2E7.
M;CK*2IRET-(V^%@W#ZHTT(:(60=I?/*9338^^"<$6?J>HI^*'-3,FRH8E?$A
M\Z4R("NX)92;,]SI[(UMU/05DC6-F(D;:MB;VOJ!H/LG2]6BR;+LBM_7:G)6
MI.(B-+UCL%)Y12K$V;V5_=6\B$SUT;M%T6J+A"G*T:NUB[61601<'1?.9)S'
ME2$4RG,G#YV9G0<I(8=S8D&*)'6ZA+6G_P ;>S(@6UP%#7]>S%%$\"[M)&DV
M@ZW_ 'OV+ $W]=J]T/TXA+36'MLK6B3XQZ""<NU:3=+8MW[F"E- N>>0)#!%
MV>1;EGPD<ZE7+] ACH(-UF0)*K'.N"*3G9(9A!+$N\FQLYL"$1SU4>S9U /4
MD-<"PN&('3>K&WR>L@>/70W^Q6&=M<#A^NZ^04YF\"8GI&CV&;MUB(T<,$)R
M1<7F:-"G;,UWST$DHNJJLFAQ*"7F<(J^)1\ 4/GX3DI.4$\[#;$)%"K>]AL%
M];#JUSXZ$?)5F5"L&Q!JVTW/IU/W*J'R<K5IQ2G%*DBG5K/)FG:K-6[2C4NV
M5. @)#,:>6IRE@#5IZ0L*,=-UXTRQ629TXL'!'._][=@=)7R>F4!-S4GERH\
MB&."'S('9A(VX+Y8"W#6.KW/LV&OC61%C*,6:S@"PM](WZ7\--:O!8^JN7U_
M%J1HD\WO$<L\ZJV.^.Y*$"&=-[#J'CF>@P$HE%.YMNY:0T32-6&'>D5.0'+J
M*(N1$A3G'G/1<SF2\A)BQ&,@9BI8W&V/](A%P.I>/<+= Q%ZW&QHQ$'-Q^C)
M^4Z$?:-C\E=I<.C.:M)N^SD5J%@A*'!6+5E8>MJPU:GM$^9^>N[Q#(&&*&ZM
M5E'RM@HJY5'COW:.48.D#HKJNRKM4[(.XLLQQ1O"K9++'=KLJ;G"'KL.FUQH
M+L""" MB:OA1@LP8A 3II>POZ_2/DMXWTKTN^F-%>1=;I,%9GK*^O)&%KL_8
MIJ$,JSD+W&V[LY"3L=45$K01%G69B QE19%%TR._<2#5DDGZ(NEP"J\_DAWR
M)$!Q@"RJ#T0KCE2WLZL&E%R#8*6)O84.(A 0$A^A-O&[WMKTLORWMZ:K3M_7
MJ&RBD4V[PVAM+:VN4U)-V,49&%0E4:XHXL(UF><MH:P3JC S]A7C"X3= @0Z
MJY#,3NVY3K%EN/Y23-R),>2(H8U%SK;=[.X:J+V+:6OT]K:=*UIH%B0.&O<_
M:UL>I]'WKUN/_NU?^UGOW_MV2_M*JG.$^+/^Y,;_ -5_Y;5+=O\ ^TO_ )O[
MHK[0.>!UUM.*4XI3BE.*4XI3BE8B_P! HD5*J04I=*I'3:3F&9JP[^PQ+233
M>6(RY8!H=@X=INBN9LS53W1,2^=QY#>0#> \4J%NWO\ J&L7];<D_M>HO%!U
MJR_%*<4IQ2G%*@C9=!G8I2%S+-Q;.-:T%-RG!G<)BX8TRNMC$2G=$L"1/$2Q
MD$FJ!&J9_#WV0.D@7Q 3^'!=Z=Q9^(T/:_;)1N\.1#>5N%TQH5L)<R8#_)Q
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M4I0\ \PC[.24,&/CC;!&B+_!4#]P5W''<3Q/$1>1Q.)BXL/X,,21C[(15O\
M9K <]Z>9K$:7LKZ!M6NUR97EJTG+6"OZ1+P\]8??JU'3"Q[!+,$T'LNH#YT<
MX"L<WX0_9#QXCQ\>)VEBC19'^D0H!/RD=:IB</Q&!E39^#B8T.=D&\LD<2(\
MA&OMLH#-KK[1.NO6IK_1AA_MC[)??A</W_F:]25Z?HPP_P!L?9+[\+A^_P#%
MZ7I^C##_ &Q]DOOPN'[_ ,7I>H+NT7C-,E#5EONG:*]7GQ$B>?YMKUWNUO\
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MP2-1C@C+M*!'+KD9N33";PCHARMDSQ:B8G!8G@"E;5>*5HQ_O'W_  B>QO\
M67"?[<\]YW?PV_XOQOQ9?]$]1G,?[ _RK^Z*_F7<^G:XVO8FBNL(@@@NN)0
M3 @@JN)0'\ G!(AQ* ^'X1]G!('4TKF1;-@\DHEM,KR+"#>RC!I+24;&C*/V
MD2J\02EW<7&G6:I2TBQCSJ*)-?62!90I2"<@&\P6NS*I*6,@!(!-@3X7/@"?
M&VE5%KZ]*^E>2^+GT]+J,#J>=95K&,VG#'?<.LY0H=D&AP<Q3=RZJI8QE4Q#
M4:9585/%(XF@TN!EIJHF:2S!-1XX62=NP]=$WF:]H<S[JV)DRPSQ3C':3780
MT4_F2 L+M(=C.JR74Z $#0U,'/Q]X=%967?;QT9;#3H-0"1K]FJ(*?$PMCOJ
M[UYQN>L<XM:3]Q]-[!=O/#*\\8Q%WKTU?L)N].+29-M!-%ZY.,7F>2:CME )
MP*7B=%)054C^4L\.V(1RN3FQJOE>Y)#C_I')4A)5;<+Z@AUL7W^)T-:OOA,*
M1DF_F%GT&NJD6]'3PM5HNUWQ .GG:B2[39UI.G]GKSEVP:93^R^<6*'Z\Y9F
M%XK5QS9MOL?5.KLK 0TM(MEZ6HUU]JY-HKU.4F#>ZK).8]3S)+$B^)[>YGB5
MQ,G&BQ8\J&)H7!FD=65_*+3@D#VOT9'DC:NH(;J*SSY>/.71V<HS!A[(!!&Z
MRV]&OTNOJK5UNFV9OL&'_#TRI UNBE>MF1:#FFW2IJVFZ0BU+QV0O&EFD:@F
M,DD2RIQ])LY#>1P9@"CY,R B4O[ISJ<#!R<//Y'+.P^]3(\0W==L*I9M/9NR
M^%]-?56E+(DD42:^PI!^RQ.GV#6T?9_B-]*-UT+%K%58WM%U#5PO==P>4K2<
M<3B=&GT<PNV3UZIT69IN>VE>+I-0K)K5GL6[MF:"D[:/&DH\(C(JE47*/*X7
M;?.8&-/'*<7,$\$09)+H-ZR%F#.MV9MKL(YM""JW46%;LF7C2NI&^/:[6(UT
M(L+ Z 7 NOK.M:G.].I8WM_:K3M)Z\TMS3,ILOS.2K$.I2(+/GDU(0=#KD%;
M[NM0ZD=S!5IWH=PBI&=69M3J$14?F 3"(&'G7<%BYN#Q,6-R+A\M=VX[BX +
ML57>VK;%(6Y]%:&5)'+.SPBT9M;2W@+FPZ7.M5'\IO+YQ(<">H*7J"0X)^L!
M?.*/J"7R>L!/QO)X^;R^WP\.2]8*_.*58CKM_GBU_P DQ?\ #G/-:3]</Q/N
MU5_U(_'^Y5M8Z1?P\C'3$2]=1LK$/V4K%23%8[9['2<:Y2>Q\@R<I"55N\9/
M$"*I*%$#$4(!@'Q#EK*KJ4< HP((/0@Z$'U$5@!(-QU%67QS2-8G;+MBA*=:
M]]F]EI;MKJAE[=?6%ME(I&WU^XR,R]MM6F&%A=N9:7A4&B[9998LH1R+0J*J
MBB9!B<_$PHXL<%TQHX) 8_90J#M90 K J+ D@@#;;=< &MF*25G<V+LZ^UJ;
M]0>HUZZ>OI7963M=9G#ZOK2>59U RL%,9%>F)?DZQ18B]RMW(/\ -YEM&J2K
M=)HS3SJ;0KR)B$,@I!(MU$O!3R*\LAX6$*P2:5D994.JG20 .+VU.\%SX[R0
M=-*JV2UP2J@@J?'][T^UI\E=I5.].K4R)/&P;.MMA2=TUV9=-U/MFJB],4(W
MCBS,4RF&S";;N(%NV8F0= =$ID/>2D%=0P\LF[<PIWWR%R+/^"?I=;$BXUN;
MC76W055<R5!86\/M>G[&E5KTF[N]+T&Y:$_C&$*\N=AD+ O#Q:CM:-BS/U?.
M6/8K2"SA^LV:)@!"G64.J8 \3&$1'DMB8ZXF+'BJ2RQJ%N;7-O$VTU]5:\CF
M20R$6)-ZPGFQ5E.*5D]2NMQH,FYFZ-:[%39E["3=:=R]8EWT')N*]9&"D788
M51]'+-W0QLU&K'0<I 8"K)&$IO$!YAGQX,E!'D(LD88, P!&Y3=38^(.H]!J
MY7=#N0D&UM--#UJPF=]CM:QO)X6 @*Q6$<[DKA8G;*?FZVV>.YF_Q%@R"^KE
MCK0KY9:/)6'U J:KB*9K(L7J/A[VFJ*X&3C,KBL+/S6EE=_>A&H*AK (5E35
M>AW!Y+,02#T(MKGCR)8H@H \NYUMU/LGKZK+H/LUSK'W3T>=H;#/#QE?90L4
ME4T8<JDC8Y).*^8%ZJUYJPQL1(RZL,W68C363)X<$!6D$0.JL?U3 );(NW\2
M+).4"QD;=?11?>C(UR!?7>2-;*; :55LR1D\O2PMZ? @C]P?+5<]"<2JU_NR
M]CABUBR/;;.OY^MF.MYX2;E9)S(R$7Y'2R[HGH.W)P*50YC@7V>(^')7%"#&
MC$3;X@BA6](  !^:M=[[SN%FN;CT&NEE(:6A%&24O'.XU62B(J?CR.TA2,\A
M)QFG(0TJW 1'U&4FQ5*JB</8<A@'F1)$D!*$$!BIMX$&Q'R@]:H05Z^(O]@U
MUG+ZI3BE9/"W:YUJ$M];K=LL5?@+_&,8:\PT/+/8^,N$1%R!):-B[*R:K)(3
M4<QE$RN$T%P.F54/-X<PR8^/-(DLJ*TD1)0D E218E3X$C2X\*N#NH*J2%8:
M^OY:L2\[>WJ4J[.D2]/SF4J,73PH47"N*^9J8M6^9%6I)F,[+Q+F-G+>Y%&C
M0SLKJ2<KN$5&1D$CD:KJ)<BUX/&28Y"/*)R^\G=^^WL]P#<+]-A90 ;W.H!K
M/[TY780NVUNGA8#7Q/0=?W*],;V^T^'A;?$1;2OL5+W5(.IV63;H.P=/&U;R
MUKD\,^115<*M&CIG#1;%[Y2$](\BS*<Q13.HF8_!8<DD;N6/ENS*-+#=)YA'
MI-R2/Q3;K8T&7( 0+>T+'["[?O?9K ]JWJZ;NXIKJXE034I=;3KS C5_,NVR
MGBFQ2=O&S*4D'C.#1=$C$/!FQ30;)B03>!C&\0VN/XW'XX2"#I(^XZ >FPN
M";7.IN:LFF>8@MX"WC4(\D*PU]%_]VK_ -K/?O\ V[)?VE53GEGQ9_W)C?\
MJO\ RVJ>[?\ ]I?_ #?W17V@<\#KK:<4IQ2G%*<4K6W\2OY=LV3PF;5R@R%V
MDYBSP]E,BGETSHS;W*NG>J C'.F+-S&5>QI3:L>HFN\'RKLQ<(D(('.JBI5\
M<X(_2SVAI2L6>#DTZ95R2,*HQC(Q2'?D@V)7D6I&PIU(>//'N ,D*#0QFR0D
M\J0B0"\4K,^*56?M[_J&L7];,E_M>HO%!UJS'%*<4K@2DI'0D:_F)=ZVC8J+
M9N)"1D'BI$&C)DT2.NY=.%CB!$D4$2"8QA]@ ',&5E8^%C29F6ZQXL2%W=B
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M9U]X[GHNFZA7I672:L2NB@V=$.9NJJ/HDC4X;*@\[8I*[KJ!(1N5LAY)%%V
M4M&RJ2;:@Z@:G.<J-BN[K;6XZ$(%!Z:V()T^:IDRS8NL&A[[F32.J5:C*U!/
MYLD&A9*%5XN$HU1<4QLZF%Y\SPA64RQ83#=Z9<RHR+A BQG*8>@F<Z>AF8/,
M8O&S,SN9F OM=B7;>;;;:@D6M]$&UCJ0#FCFQI)UL %!TN +"VOW?36G$O\
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MFU\IT@YH,W"/=FL>JTSL)<F53V2LQE[7C(BOLB=>[&DY>^O-**#(M# @(JN
M)&-WL/=\6>?"3SVF=6&\$1B-H5+1L4N2?.2PLO0ZZ"LHX[VW1)#M"@C3J2&-
MCKT]D^FJ[X9T.H5XT;X;*3_LK=-8K/Q%,]WFM6*1IR5OH;C+);(:ZX8P=%=O
MK4M\MW^"H=SCVA'[ 4640\-$@FP7]V,DN$CG\]D8^-R97%2&7C9(F ;:_F"0
MW+ +HA=2;&Y8;O:%[BL46*C-#[983!AI<6L-!KUL?L::5%%)Z81UAT#+W+?M
M+?:M<-.L>8)16M3M+ML*C*/M.P6*UZS-8*RP=@L%W>W*JL;&BE(*+D19*1[]
ML4[GWAT" ;<_-M'CR@XD;PQ*]XPRFP24QK=2 H5B-+7-P=+"]8TQP76SD,2-
M;'Q%SZ[BM7Y9V:5A2P'R_*KUPTF:=+!IR\H>M*S2C<6AK"C"KJI,1E'#,?3!
MV=N1V9 WD,(!XEYU/EH'\S:/,M:]ANMUM?K:_A>UZT[FUKZ5U_+JI5B.NW^>
M+7_),7_#G/-:3]</Q/NU5_U(_'^Y5P*\TB']A@&%@E5(&OOIV'93\\BR4DEH
M.#=R+9O,324:D(*R*L3'**N"MR"!UQ3 @>TP<QRLZQ,T0W2A20+VN0-!?PN=
M+^'6L*@%@&-EOJ?0*MIG-0RV)=]Q9*LN:3LU9R?/2R>36_4J3=F$58T%MAHU
M6:3Q*17G"TU$V>QUR77;,4WI_=&KER!W!TB!YR0N5/F.N DPDQYII;2+&Z$K
M^B=B-[:%58 M;4@6%ZV8TC!F*[75%]DL#K[0%[#Q(]-6>ANFF%4B0S9U99?0
M+^6Q=A/JXD63Z"AH=@-8K-'U8]^(JTC[0L=9VXL]/2<0JOJI"9-(B;D4O54
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MQ83Z)[$E?&QX9,L>9',[R$1Z,KM"Q5!N]DCR5L26ZMITK)]9@.[*FC* ->A
M87.FOTCZ/"JD=3._&?9):/AN%OU2L;& Z %[83SF9AEV\XYU.=VQ.Q6*GP"4
M25!DK3V",\X;1CQ^)Y(44UA= W,5,4N3'+\!D9D7)>[NIDY#R!8Z>6(]JL;_
M +XVNP&E^E_&L$&4D;0[P;1;C\M^@]7RUKK;[3LR%<CJDEK>H-ZK%2#*8BJJ
MCH%L)7(B6CF:<?'2,9#)RQ8QE(1L<D1L@NDD11)N0J9! @ 4.C.%A&4S>3%Y
MI%BVQ;D'4@FUR"=2/3K6IYDFW;N;;\IJ-2E H 4H 4I0 I2E     /    ]@
M  <V:LK]XI5B.NW^>+7_ "3%_P .<\UI/UP_$^[57_4C\?[E6HXK!6456[W6
MB.WLA1[A:J8_DHY6(DGU3L,O7'<A$N%$EEXI\YAW;-9Y&K+($.=!03)&.0HB
M7Q* AAFQ\?)4)D1I(H-P&4, ?2+@V/KJY7=#="02/ VKV_/^^>;S_/>X>?UC
MN?/\YYOS>\*.5WBCCS>_>(+J.W2JIC_]85%#F$?$QA&GNN-^SC_)'R>CT"U-
M[^D_/7*^LS208LXP-#O01L=.-;/'1P6^P^XQ]E8QR40QL3%I\H^@TG642B1J
MB[3*5PFV("13@0 +RGNF)N+^5'O*[2=JW*DW*DVU!.I'2^O6J^9):VYK7OU/
M7T_+7$;WR],X1_66EVM[6MRK>):2E>;6::0@Y-I OEI2":R$2D]*P>-X63<*
M.6A%$S%;.#F43 IQ$W+CC8S2"9HXS,I)#%1<$BQL;7%QH?2-#5-[VVW.T^%]
M-*X_SRN'IR2/SLL_I3,J2=ETOG!+>G*SB;QK(IS,F3WSROY9.08H+E<J^=8%
MT4U -YB%$'N\%P=B75;#V1H+$6&F@L2+#2Q(IO?74ZF_6NB=.G+YTY>O7+AX
M]>.%G;QX[64<NG;IPH99PY=.%C'6<.%UCB<YSF$QS"(B(B/,H 4!5 "@6 \
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M&^C7'UGQO\YQ_P"-3\ZGNN3^SD_)/WJ!UR[$!^#K[N@>T1]F/:*'M'VB/_\
MK7X1'CZSXW^<X_\ &I^=3W7)_9R?DG[U/T<^Q'ZOVZ_<]HWT:X^L^-_G./\
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M"LF)"6QYLB!E66*.&.55\M15YH30;-W%8E#-7D_G6 &5%G9[T<OR/HE]=(%
MDO2ZDS$5'%2AVZAQ0?RYA]Y5$#)L_ OBOSZ+RN(P_AW,1S2Q9?=@%XX/IX\
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M^:G:C[9LC^Y:>_\ 57E*II3YJ=J/MFR/[EI[_P!5>*:4^:G:C[9LC^Y:>_\
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M,!0YCCRQ&GEE;KM ^V3?IZZY;M7XTX_;_;\?;6=Q2YG&KQ\>.]Y%5B\>5D9
MF7=&ZJ5$Y"*RL!(BN21[-9):/BC0-DLU;E Q*Q,8FM&ML"B/UCP[NTNZ#H/7
M:JX/<&"LFM0_D)*ZF5HT7+,)0(XS-OX.$%&*H*$,G5LP%A[)L+^/@5 /AUT_
MP5N9WQQQ<W.AG^K)EQX?-0?ZPAE,&1Q\6#,I8P;!->"*6.7R]B^VK1-N!'ND
M/BB49S.U*YEZT2DY=J3?*;8*Q-Z'M,M?SURO5&P'?KA6'\U636.MV^TU\XQT
MA[J])7? PK(Q::O@;E3F*2&V>T".IOT]'HOT]'JJ^;XX<6^7C\D.%DEY/%RH
M9(GR,QY_+CBDW'RF>/S(Y98_T<FUQCZ[E@#:U7SL#WB^M>HP<)G=,L^46)*X
M4VWV:VH7T\@^<N,QRU3&<Z;TXT/$5Y[40;4)8Y)@WKN?E-Z852 W)XI#BER-
MZ@*"IN"3?T"PMZ-.M<CW;\3OK[CXL7B,:? S!D0RR2B?<Q.-B^YXXAV)&T5H
M"1-[3>8YW#8/9J$L-[%/L3@-C8M:^6Q6#3SX^_CIN2?B+:$FLFV>M[$F^EV)
MT5'-@1GGM>!LL0'#<X"J*@G,/L'''+Y886N6M]HWKFNU^\)>V<3D8HX?.R\[
MW0J[-HCXN9'EAG6UY [1[2-RG7=<UL0BOBS5J)N,Q+A@-NF:O+E1DODJP;4+
MR9865U=;Q99Q:+<-J0UKD16U8S1)!LT8M8Y)4'*;=PZ7<G!45=H9H!N%-OE]
M9/H]=>O0?'S"Q^0DR/JG(DPI+-LDS+NLAFGD<J1"(TCVY$BHBQ@[@CNSG=NK
M7UC[RP?7W*;-C;_+IRQU:P7&^3"<O WB/@+7'530*A"UJ4@F[J6J5CAPGF#J
MG0KEM)&:&3 B;Q([8?72.AAAR!$AC*W4D^.NH^0^@5QG9/Q/Q>TN!G[=EP99
ML&;(G?>DZQRK%/$D;("T4B;U,,++)L(L)%*>VI6>93XGN8V!^><G^M-T?VAZ
MK+,%K:OV'FI>U5>M2*%B;.&E$LMEJ,S-I*6-"4:EFXF:6EZJ]*W4*G%I%5,
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M+WM,Y=)*(8_5I9)2M3=<K&KW7,G5QF]R=6:5C%9R>/4 DFS%PB9RY0=E\%#
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ME;;0UG:]5JY0FS8[6JRK.?=S-OEWI_=Q"3?1HQ;6'AF"1#J@5$5G*QE"E$1
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M2Q@CF[E-1)!-15R@W0134K+.X2?JX#9TO452]6T92EZJ!_272]36Z,3U4%/
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MJ4^K(/M!T_\ .TWY#Q2GU9!]H.G_ )VF_(>*4^K(/M!T_P#.TWY#Q2HTJ.>
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MO$<IM&1:[=>OW?#6N@Q^V>\<R2'M7,QWB.5F1^9*[>:5\I'5-]I65$A5I0"
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MXTNHV'/*S98=K27$358!G9*[-)).*LH0L*\>,4E442#Y4T\R\C)YOO+1(TP
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MZJV;:>JVCQ6O,NJS34)E9> :YZ&ET^V('JM_51C=#HEMISJ*<1<HTFQC").
M3-YFLG'.#(*?BJ" ZF(TV)()A%O;3;N!T/4$6UO;YQI7&=E9G</9?+)SD?"C
M,G)00^?%*/+F]F>&2(J58/;:UM5D1MIT-=!I_=:]ZUUDS;K1,TZD1\-0IB&E
MW%\B"S);1;VU64T-6E1DDR<R"\%&-JZ&IS("HT1(J]]9,51_<B\MES9)<5<4
MA0JD&XO<VO;U:;C\M:G,_$+DN;[/Q.T,B#'2#%D5C,N_S)1'Y_E*P+%%">\2
MZJ 7N-W053CFG7 UG>=_YXEOY*:?PU;DOQGT'^45E_R'^/\ <J:8R2D(:2C9
MF)>.(Z6AY!C+14BT.*3N/DXQTD^CW[54/:DY9/$"*IF_[)R@/),$@W'6D,TN
M-,F3CL4R(W#*PT*LI!5@? @@$>L5+%0VVR5_1IS5;.Q::==YYPZF'4]>7;]_
M*_.Q9^C*$LB\B547#\73I$4))FKXMI6+778J^5%81"]9"'+M[3'T^FI_C^Y<
MS$YB7G<Y5S>3E)<O.69O-+!O,+7NUR-LB'V98F:)K*U9\MVDF7&<VF@K4*II
MO;;3*+29:XL',JSF7L=03TA*'6E&BBCMH^,A%9['-FZ*0M4&QE':XE64<?N5
MWG'85L+D 7^2WWJE6[YR7X>?BFQ,<29&-!"\RE@[+!Y(0L+D-98(U4#:JWD:
MS,_LR%7^^&B0$A&.B5.O/&#&X72TN8%24FFL._1MUFM%R1BCHM#)J).(.RW!
MZJF_.99=5N8J'D2#U#J7C)8&]AU/WZE\3XI\QB3)(,>%HDR)I3'N<(PEDEF"
MV'0I),Y#FY*V6RZEJ,A[ \/P_P#3S6KR\:"OWE:K3BE914;M<*!)NINCV>;J
M4P^@YJM.Y6OOUXR06K]C8GC9Z(%VV,1<C.6CU#(K 42B8@^P0'V\JK,INI(-
M;W'\GR/$SMD\9/+CY+1/&7C8JQCD7;(EQK9UT/JJ4:'V%N.=T*4SR 910PLW
M$:O"3)G9#KGD&6K0-,AG(F14*=)LZK#BCM7;%='TUQ.JLB<_HJG*:]965=@Z
M6/V[?>J<XKN[D>(XI^(Q%C]VECRD>^NX94<*'3H#&8%9&6S:LI.UB#)5G[GZ
M!:[G4KK(P,0H_J=ME;8FV7DI-V@_-9:\]@;9 ^*@)EBH*;^6'ZQ$VI$U&GO7
ME*<ZA/6/>9V+!B-0?^^IG.^)'+9_)8_)S11F;'R'EL68AO,C:.5/X*/O<@(
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M4]]&>/J_)_@_/_@I_P!*GQ#_ )UQGY<O\G3_ '#O<[_2/%/SJGOHSQ]7Y/\
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MY!Q2YKH+)7L2IT<G+6RO9C7(M5_'Q:<A-PE8C69Y&5=)LH]F#AVT22%=VY5
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2\4IQ2G%*<4IQ2G%*<4IQ2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>v473641_img6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v473641_img6.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"W )$ P$1  (1 0,1 ?_$ +@  0 !! ,! 0$
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M-3"FFDE*4&3O5I\OHD%*A<;VE@E-:D]#H(,[,/,I::FI8, >8L)D[[R^J@%
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MVV4JW\I9"%!8##+KL3Y&N.-E82C,,)]^':W8<$F\6)L61R.SYF3R0J9VB/\
M.^"+B1Y H/.%P?Q-GM:#$;6#GF>_C$L8QV1NY3&HGN$Y4YMRC'K_ (ZRJ'G,
M4>RGMY.(W61+SBXN7,-GN/I:5<MV(M=LA%VY>W#S3@_:ZCH/4?.G;-E7*64=
MP,]$3^-Q]MRYVD7';]"LR:9!3\9DKTUF,BB<E!;6KJ#!);R1I)\HK?"FE>Q2
MF@PT=HW(2N7\;R%67X2.,AF?!G*^66/N,V<X^?>#..OD.*B8)X*1"+Q>?>MK
M6]??N-MTR65M);4'-R0[?$>U;,L;QOM>A;C(L:N;K@S.N9<KR%UA,FEB;L^2
M8?DN.BV(;?:>8+J/=SBW5<><E"2&'-A4=M0U;&]BO(%O@+.,*S?#F9N)[6^"
M>'(R_5:3-]&_:#PMRE?<G6\U>6ZF;.Z=Q&6NS;6YVD7B4*<.P$)J'?,]FO)=
M[YF0S^5X$C,<JMN[B5SEJ&9R!./VN5=Q^,8WC>/V6-*O;9R1N8#$[;'&Q=/7
M(:??W%:&@?9 58SV395C'+7'&>,N<(3EK&87P' YED&78(YDO(..27!V+KQU
M^TXCOY%A<?$1V;'R'%WCQ8NXY;)<:0XMP>6'8=Z?9]R%W(SZ)+%I?B]49<\7
MW>!>X<GQL_(NX7.',(_*FN0./TQB+FPL\JOK*T,<_<NMI>99"%(6H!32@RZ6
M[6LGF,]GLE=R& ;BI[N<L>:EL(]_]_9Q9GMV^Q>ZAMWNI87.JF%F[0-PM_=>
MGF!?0A=[3NW#E3A;)+B2Y%R7 )VPA^#^*>#<4^2K7(;6\O(7BJ2RYR/R')6I
MM!9:EYB.R%GS6K9Q3+3S:TIJFBB&-1?;CSNVQW4<7R4KQ(UPUW&9)SED]ED5
MA>9B_P G8Y>\JX];Q,8S=0C\3;XK<6L7<L[W]EWO4C\4DGH&(PG:!SK=X1S$
MUF&:<3V_(.83/;3D6#/8Y9Y9<X78R';A:8VS&V>4,R:;>;=LLGN<90;A=JHK
M91<J* 2V L,OA>TK+(?GW,^4V+7@LQF>S4SGDOD%WA%S+\Q1>4S_ !;98#?8
M9CF77UKY$5@K,Y9_%$WK6R_6TZY:EH(6I9#%6.RO/FL"M,4.6X@;^U[>.UKA
MU=TD3'NRYW@GE)[.LBE4CW%#HB9N.<#-E5/F^=^J)2GKH.PR;MAYZMLMQR?P
MB5XDG(6*[IN5>XV1Q/.9++HNPDKS*8:SA^/2NYQ^%DW'97!G'[^]+2DBW7>>
M[+2L^6=!WUIVG9PUF R:XR3%4L#F+NEY(7;I,J71'<\\>KQ#'H]"S9I1[Y#2
M+GF7AKL+/ZD5JZ:#QUG_ !9E7%>?<%\.PTTF:R69CNQ*$S?'6^/\QOK?)5\!
M9E)"\S#CWD!E28"TAX>);NG9^WE&6W[5AFV6CK<= ^G_ "3Q#.9?SQPIRO8R
MD5:PG&.'\T8Y+1UT+DR<A><F1F*6$2]'^6PNV2Q'N0#A?\Q:%$.)V@]=!XKM
M^PSE:RXXXLX_CL]X_;9;X)P_@'F2]O8[(+ESY=P_DH\CVV0<<EM#"'I:Y7=W
M=@IF12RTE+Z']Q+6Q8;[ENV/+I#%^7()O(,;1=<@]W.%]P<6^HR0;L,8QG)^
M+9VZA+W;;>8<@N+7 [EM 0%6^^X;W+ W4#'+[LYR&>N[FSF<H@D04QD?>A=R
MQLVY!<BU"]S]NJS@462'+=FV<D\>8<6;Q*UI;*A1M2O'08YA?:#R_;O8SD6?
MYAQQ>Y5#\O=N62WC&)V>16L"K ^W;$9K$K'W54NEZ_7E^4_&5W;S:@FTMB0T
MEU81O4&)RO85F+MOQ;=69X$R;),6@N4L'FWN5L$NL[A(3'\_YCON4XW,,#B+
MNV3;/9K!6M\[9+MKU#5H^7R2[M0 L/9G.'"U[RIE';[)M7,(('BODJ4RS*XR
M89?69['I3C/-\$N(F/98MGF#<//92VM8=+;990M-:D AXND.P[D)_'>%K%4C
MP7F\_P 48;R#PS97O+F%2.>PUAQ=+YK&S?'.60L)?6WN;O(V#8Y#-6+EO<4C
M[KS55>2E*=P;AF^U3D/*.?Y+D*5RCCB,Q$8QG>,64YB>,7\#RCDF,YE@:\0B
M^/\ D%-BXQBN3XQ@DL^Y+1]V\';WS4M,I2PE"U.!IW'NQSG$8-FD%E6=\4?,
M(X\[5\'XZO("-RWX(I?:QEMYD<'?9O:WWEWC:<O2&$70L%$VJEN!O>$(*PW1
MD_;?R_<3'<)?8_*\+3<)SI*<9YK)8;R1BTKDV/7<_B^,P.'YI@^0-K8=2O"L
MCB(%NXL)*W;$G87O7REH3H-[<'<89CPWP+CG'#F0QN1YCC<)/-QTC=F8<QBT
MDI&^EI2"@;55_<7>1KP_%_B#,?;>:ZY=FPM4U._IH-OX?\T_+, ,Y5!+S(0\
M?\T*Q<7PQQ4][NV)0P8D_P!T1%>^!7D!_P"M\NF_KH,ET#0- T#0- T#0- T
M#0- T#0- T#0- T#0- T#0- T#0- T#0- T'DGF;DG*N,>4(&7DLULXOAR*X
MFY3Y,SN ML"$_DUTSQI>86T\U#3#,NU=M_$[;+E*\ENS>=\RV0E%?,50,H'<
M]@"9:7Q[X%R+\>AH/XH85&$R;\I)235IC-]?8=#VEL7G+_,8BRS**>O+041;
MMWJ5+< ;?\H,"8[PL6.42UJWA.>W>(VO&^!9E:SMG .7$I=9+G'*F1<2,\??
M %7+=TSD,?E4,FV=2?JP]YM5^6V'%!W<;WD<42F.RF0L1/(S*K!R#:L<?O<'
MD;3)\F7/2F10=L,7B'G$KEO=)G$96VN?;;\E4>\LU:\M:PQ7..]SC>*Q[/K_
M  V$RW,IC$,&ELU@FV(.ZC\>S9R(PK#>0+B#@LC?(87),8EGD9>/I4A):9=7
M3<IM20&Y<^[A^.^+&<<7GKDW .9+!VTW86[D/<7;S:'\GPG#UQ]T+)5PA$K;
M3F?QZ76DJ7M9+KNXH:4=!J5/=?$RV78Y"X=$2^7Q66<A_((N;:#O(MW$"U@W
M(&3?,,J_?WP8FXB2O<&7[NNV0UY=FM3IWG8% XO[E'N3.W3*,^M+-Z,Y+PGB
M2VRO(8>=Q^]A+ 9!)<=N9C!2MC:./N^^X?-K07+5U#Q+C*5)5M6-!K[@WO.D
M,LPB:SGD+&)/9 X-PW>3V-8%C5_D$SC><9#BF5RW*UK?I9N%CX#C$ABMRXV^
MX6@FT; !<==;0H-G67=UB5F]RO<S^,95:06"<AQF%X[)0T6N=>SB+O>*87EV
M]RJ-LK=T7#,7!XO?W5[=%83Y5@PAP;G'?)2$9IW>XK&LNG"\,SG/%VG)& X
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M2<PQ?&:V3JX]Z&B)Z'CXUR183=H5=W*K.045K2M 6JAH*:#,+KNCXHL<UO\
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M;FXI$@6F^2W\.>=F:F]LUJ7$#$DA+&X!\O5*T;!4-9Y=VEO3V3\LY)#9?CL
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M@U(P%Q>7DBY$X>PPRB\6]9MA3CJ+=#KA4 ]<#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T#0- T#0- T#0<._-T+5_W%#"[SR7O=$73KK-JNZ\M0MD
M7+S#;SS5NM\I"U(0M24DD GH0^5L+]Y#<0O&,Y,\P8+"XWRN]9]QDAQWAN&2
M69Y)A&7CMYO,PC)2)O>097#(%B,R7(7\ E+FVLF[>X4BQ;0M:@ZL-$,J;^\_
MX)AK+(\PSAC(L1X]BH?C--K(2&/SS>8)S/,I_E^ RO$YK"'[!J^@S@*N'[ZY
MO'UK4%6X6L [4!P/6HYRB+WGR"X2B$Q=XJ]XFN>5I2:5,M-/6]K?3EO#8?%P
M\8E"G)=^=M;64O7E!21:VEDE:@0ZD@-_4! KUZ#QZ^CZ=!.@:!H&@:!H&@:!
MH&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!
MH&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H/GK/_=E]M>1Y$G)[Y?(
MS4FF(Y+A2+7,E(M2QRK?\H2&273;+T:^JSOK=WF&<3:+MU-(2EUCSD/JMF2D
M)O/NT.W>0AX^+OI3E2]N[&\A99[)+S-F[O(I3((/(^0LC9R23N[J&>M'9J\5
MRI.V;[C=NT@V5Z$H0VXTRZ@-^27:IPI(\]X3W,'%1:<QX'CTOBD3E%C?WML+
M^ EX40'P^=L$/^YRJ(J-4XBR4M 5;EYPU45= ]&#H /4-!.@:!H&@:!H&@:!
MH&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!
MH&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:#H,JN[F.QG(9*S<\J\CH*
M7OK1TI2L-W-K'W#["RA8*%A#K8)!!!'0C08Y9XWD=Q:6EPOD7* MZUMW5A,=
MAP3O<:0M92#C*B 5'PJ::#D_*F0=?^L;*NIKUC\.Z=*4'\F/#00,4R 4_P"L
M?*_"AK88:03Z_P EQ0Z <4R BGVC94.H-4V&' ]/$?DP>AT$G%,@((/(V5BO
M@4V&' C_ /1<@Z ,4R'^L;*3^&/P[_HQH'RKD/\ 6-E/\'X=_P!&-!!Q3(-U
M1R-E8J*;388<4_A'\EZ@Z!\J9 2#]H^54!K06&&@'Z#_ "8/302<4R __9&R
ML?@L,-'Y_P#)<Z!\JY#_ %C93_!^'?\ 1C00,4R "GVCY434FJK##3X^C\EQ
MX:"?E3(!X<C97^;88<?_ *F!H'RKD/\ 6-E/\'X=_P!&- ^5,@/CR-E7YEAA
MP_\ J8.@'%,@((^T;*A7P(L,.J/S?E@U.@#%,A_K&RD_AC\._P"C&@?*F0#_
M .R-E?YMAAI_^I<:"/E3(-Q4.1LJ (IM]PPXI'TC^3%:Z!\IY 2">1LKH/0F
MPPX _0?Y,'03\JY!_6-E/\'X=_T8T#Y5R'^L;*?X/P[_ *,:"!BF0)33[1LK
M)K^,JPPXG\'Y+C03\J9 "3]HV5]36AL,-('3P'\EQH(^5,@/CR-E7@1TL,-'
MCZ?R8/AH'RID!%/M'ROH1U%AAH/3QK_)<^.@GY4R"O\ ]<;*J=>@L,-'CZ3_
M "8\1H(&)Y *?]8^5F@H:V&&FOTG^2XZZ!\J9#4_]8V5=36AC\.Z=*4'\F/#
M0/E/(.G_ %CY9T21_@.&]2?T7Y+^(]&@?*F0$4^T?*^A'46&&@]/&O\ )<^.
M@GY4R G_ .N-E7@1TL,-'CZ?R7/4: ,4R'^L;*3^&/P[_HQH'RKD/]8V4_P?
MAW_1C00<4R#=4<C96*BFTV&'%/X1_)>H.@LOX],VJ$KN.3,D92MUMALNV>%-
M!QYY00RR@N8TD+>=60E*1U4HT&@O?*F0'QY&RL?@L,-'Y_\ )<Z"?E7(?ZQL
MI_@_#O\ HQH+#V.3-FR7;GDS)66DK2%/W%IA33:2ZM+;:2MS&4(25N+"4BO5
M1 '4Z"_\J9!Z.1LK_-L,./\ <^5QH'RKD/\ 6-E/\'X=_P!&- ^5,@/CR-E7
MYEAAP_\ J8.@'%,@((^T;*A44!%AAP(^G\F#70!BF0_UC92?PQ^'?]&- ^5,
M@'_V1LK_ #;##3_]2XT$'%,@W%0Y&RH @#:;##2!](_DO7KH'RID!()Y&RN@
M] L,-%?H/\ER::"?E7(/ZQLI_@_#O^C&@?*N0_UC93_!^'?]&-! Q3( *?:-
ME9-:DJL,./YE!BX &@#%,@%?^L;*S4UZV&&D#IX#^2XT#Y4R ^/(V5>!Z"PP
MX>/I_)CT:!\IY 0!]H^5]*=188:":>-?Y+GQT$_*F05_^N-E5.O06&&CQ])_
MDQXC0=3>660X_*XDI6:3DQ;2>0B)O;&2LL;0P[;N0LU?;TNQT'8733S;]B@@
MI< I4$&N@V<!0 >H4T$Z!H&@:!H&@:!H&@:!H&@:!H&@:#%\W_(O+_\ ->?_
M .2;O0=U&?O;'_\ J-I_B[>@YV@:!H&@:!H&@:!H&@:!H&@:#X^_>NY0W"3/
M9="3N>\XX+QYF'.>4PW(J^WV8SN-Y"FH%CC'(I"SCXVTX[;NLEEU-S-NP[Y+
M-O<*2E*EA'0D!>R/OK=[?\MQ+B#!N.<CY$X;XHQGM;L.6^4>4,_E[;EJ'LNY
M?(/E;CJ[5 Y#!NRN6Y#&I+-U.&0N;.Z072C:74J #0V*\F\EN9%Q(P[R/F]R
MQ>??2<Z<<7J7,JG'6;_CV)QOD-<7@UPE=[];A\>[8M+8C5%5HVII*@W4#0;=
MQ;N[SC!X][ N ^*\FYDY5Y,[M>[C%(C'N8.;G_<V;#@]:Y[,783*;O'[U<'#
M7K18M<=@_*]WLU/!M;^P%>@JR[NXRC@CECO@YGS>'RI41QOVM]HV8V'"4SEB
M188OG>?WN;15W JNF7+Z B;Q<]>6MM*R-JTMM;=L7"5)2@:#U9VM]TN3]T/%
MO,M[;P.%X_RMQ3E^5\97;&$9S:<D\<2F4VN+1V0XQ.8OFC%C&,R\%?MSMLES
MS&6RT\VZ@F@T'R4XGY1YQXVX+[JY:5YZ[B6N[_#^T'-LQY:[>.X/W^/5C_)<
M5?/..]P_!>42%K(8X,%A8M:K>UC8E#UA=.-LASR5JJ ]'7'=[E_%]GC?+6>X
MME\SRWB_W7%]W#3./)Y@NKCB;)!$9MBL<V[)8G:8[:V@SO*$23=\Y-MHWV++
MSED&W$CS"&8X7]Y-SC=\F0^%\@=MF&XW VG//#'!6>Y)C_,-QD-U#R7<3B%A
MF?%TOCL2]AL>F:MK2-D6TS'FOVQ:<5M9WT) 3D7?]E_(N$91B%GA5MAM_F?'
M/WBUK997!Y/)?%<7ONTUY>+P4K&*]PMEID<D<OQ>*6'&U6+C0#97^, ZB0[\
M>1NV#M.[/LWF<"A.0\8E>V?AK-^4N0,[YFAL9S*>NY:-Q&'E(CC[&Y1,KD_)
M/(A$LY+W9<#-LJW2:OEU5 &"\V]RG+MC-?>0VG)MAFZN'.)\Y[56\!/&?,8P
M;,L?;S2]X_\ AUA!RT?BR[Z+L,Q1*?%9E+CC^P>9844ETNI#T5"_>&9T[W7N
M<%3'#$$SQF[W.9/VLQG)$?GS]QE*\Q@^*K3E.QE[_"WX%NW:A;B,6ZP^ZB_4
MXETIVH("CH.Z[2>_/D/N1YBBL(R'AO'<!P3/.(LXYIXOR:QSRXR7(9C%<2Y8
M^RVV9R6#$#&6<#)7ETR[=+;:N+A ;4V HG> 'SEYL[ILNQWF/NHXA:SWF6VR
M9_[Q[M2L,*?B$<A/8?CO']XUQFC)\.3FMB@XKBD?/E^Y+T*Y=,>_>>KZI8<.
M@^A%O]XKDC_<'.<=N</QMOQ&.5.<^ <1Y'3FJWLFE.8>!^.'.1LCMI?"T0C;
M4=B$M;6[UI:73=ZZ_P"<@*6VE)T&OX7[Q7N/R3ASMDY&A^V7C]&1]TTAF"N/
M\6D>9;UBS9QC#^*Y?D2\R2:F6,-N/A;U\_!7+-O8!E]XL^65K0XHH0'!Q/[U
MW*'N/.0^1.0^ +'%K&Q[6<-[I^*HF"Y(;R2^RW&<PS97&=EC>47#F.1EOC<V
M,S+9)9%TVFR<W$^8"D!W=[]XSS6Q'1.$([?<&/<4WW6L]K&4X&]RK?# K&8E
MN*[OE3'LIC,Y:Q%=R]%WD0EM#[3M@'&W&W G<=F@PS._O>W\;X?X'Y'A.(L7
M5,<E<*9_SUG..9KRO'8<Q XEQAEC6&Y'C>!2MS$/C.LZF99%RN)L=EL7V+?<
MLA2J /0'=U/6>?\ *OW8["'+M["L][C$YO<PCK[S%K)N0/"F8YMACTJQ;NI;
MO%PDPEB[:;65M"Y:2HA12-!XP[?I:>S?GGOWD,;Y,[H)[N<P?E/NL@^$<0DL
MDY+O>V6QCX_&K2SP6-?M)!ESBAG(XZ>E2NVL7;IMYBC;@:"0#H-$.\D9OA?9
M!WF72.YONGL>=L.X.XAF^6.%^>#D\3ROQ#RU=9E#VV9\E<=9B7K>X5Q_G3A>
MM[*VB%KCFFV1M4G?Y9#8F3\TL]R&*_>]7UO-<EWW'^*=JO"\]@^/9[8YQA=W
MB67XWQ;E.17$_ XCE"(R2QVZN,K@;:^3>-6[7OKK*70MQ/70?>WA.3D)OAKB
M2;EKQ^0E9CC' I23OKE9<N;Z1O\ %8FZO+RX</X[]S<.J6L^E1.@V?H&@:!H
M&@:!H&@:!H&@:!H&@PK+Z>_8)4T_EK;^H5/R[DE!U]?AH,UT#0- T#0- T#0
M- T#0- T#0- T#08OF_Y%Y?_ )KS_P#R3=Z#NHS][8__ -1M/\7;T'.T#0-
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MMVPGVR0&SM T#0- T#0-!P3^5''O^>"O_=?)=!Z.T#0- T#0- T#0- T#0-
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MK'3$??7*VF\7R/>ZABV?<<4T@*!4JE!70>K!U /KT#0- T#0- T#0- T#0-
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M-HWMI1[N2I.X@U4D*>+:23^-[) \/3H#-I;!"E*:82G<M6Y#+:T"NWHL+:"
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ME(W;5>(]&@;G-Q;0XZ"VAQPEQ)=-4!L5W*4V5+JE1**^->GK"4MNEKVB 4+
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MK^KF8IZ_F+#?'U?OYH'NN=>GCB9'X<APW^/= %KGE*GC>9K4C:,BPTG\/[^
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M+';=SUFW+/,^<0?$606D+G/>/]V]RKC]G<OP#%TQ@W$>,QC7)-VZPQ*N-,#
MGTJM[IM))4X@A@.IHHAYTY!XHY=X*XIP[)L@Q#%K?*HC/?O5+Q?&N9<DXE@>
M03G'?.<-D%[8<B8JN7N';'(&,;@VF;V]L&E&^7:7(2E 630/8W+'!^6\^_=6
M]HW%^*X9=YP]?QW99(Y-C32V;-Q_!86^P6_S1^Y]ZN[!3=M:8ZV^MU*%I>V
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MC+#XC&UY&VIV(D,C>F\7O@NTMWGG&V&2ZH!"DE0?8X=>O]_0- T#0- T#0-
MT#0- T#0- T#0- T&%9<%>_8+M J,U8)J2 $_+N2!1Z>)VGIZ*Z#-= T#0-
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MY]YIV,Y%>0$E/6V33%_B\F)G&[V1XQNKRY@I?RBRB2C'7U*79WB6U=%H(4"
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MH.W=2O3\/IZ_@T$JJ#M)213<*  >/4?A!T$"I(3[(!J:T'2G4D]*G0*GH.A
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MDD!5>I23T\!T50Z"25T!  7N]I*A4#J?2.A)3U&@]R_=N%7]L[B'V=P*\O\
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M-GIO5"RHVG<D#V1:5-2L&OA0Z"M$#D"T[A SW@=](64]DCJ0?VK^E!/X- 3
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M-^ZM$+)]S*4 HH>I].@Y7VSY=5-8#%@%A)2?B$R=P5T%$BT*BO=4;?&@KX:
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MTTI0"MH4H 6G4(4?P4H? Z"G[9\NHM1Q_& A'4J]_F543M*MQVVI\2* >DZ
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M*-A:@EQ 7T(](-10"F@NM!P(3L4DJ075J2ZE25*6*$+-&VT A *D@A23ZO2
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M=;\91;D7*6_N_+.'8WS5(S;%LMF\>;=8#B[52/K$!]?G$H;<4W;K)6OS][M
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M#0<IM*E^8I2-JVUI*5;0H@K]A+9 43OV*-0H UZ^&@E:4[G/:4H.(4LEUUL
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M/O,*D!TMH)3U416E =!W;B GS4J6E:F4!T[$5^L&W<V G8C>3T512A4"F@Y
M;6ZK>:DAH(*7E;5.^:% GVJ*_&*:$#V!6F@G8_M89#:ZH0MSS2M0945?H>JZ
M- )03T2DDD5/4:"RL.A712EJH"@44T-Q&Y!*@D**6CT*E [?IK305-@(<25_
MJRD44M"5.E1+?0;D(VN>S[-2*>.X:"DIWI)Z*"25!:F$)2@)31KS4I_'*:D
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MD;UT37:-QHG=X[17I7TZ '' "D.+ ( ("E $)&U((K0@)%!]&@U+S#P9Q'W
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MH,!;XJ@6D--MR^7I0RVEII'S/)42VA(0A/5SJ$I2!UKH*OLN@Z$?&,NZ^/\
M*:1!_/"] '%L&$A(F,OH/7D\B2>M>I*]!)XO@S6LMEHJ".F32(/4@UZ+'7IH
M'V70=2?B^7&M?')I'IN%#3V^E!H'V7P@Z?%<LZ>O)I&OYO7QT#[+X0@CXMEH
M!%/9R:1']T*!T$#BZ$2D)$OEI _39-(G^Z5$Z!]ET)6OQC+Z_P"<TC_>WTT$
M_9?"'_??+1U\1DTB"?P^T- ^RZ#%*2V6F@IUR:1IXDU/M'KH'V7PG_"^6I_\
M7)I#K^'VAH!XN@ST,MEOB#49-(U-#7K[0\?3H'V80G_"N5_TED?^_H('%T&
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MJ!S?(;V2N<0<MHS/K/CC,&^/,SM^,KMZ^1\RR$+GS[,.674V:GKY]L-;VR7
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M\]F/[N-Y,!_=.@S;0- T#0- T#0- T#0- T#0- T#0-!B^;_ )%Y?_FO/_\
M)-WH.ZC/WMC_ /U&T_Q=O0<[0- T#0- T#0- T#0- T#0- T#0- T'Y"^;^V
M3DWD-G[S#D?$I=5GPK(\Y]UKO<Q&"^;;>OKCM^Q")Y%X+9M;5UY#[S<GEL\^
MQ>^[-J/N["0X0FA(;)Y*3,S7<IP):2O(N$\<3T9P)]W-?]OD_FDER@O+T7+T
MP'<YAN$\1P2ROXW)W<QNT_#<E7=-EJVL5MJ=4EH*(#L,?Y-Q7)>\GE.4X_L[
M#"Y'*,(^\D@.3HJ[Y0S;,.9)NXP6!2U#R7*\),M6F-XAC;<I8JN<0CK N&RC
MB1O*>N@]1?="PT=AW)\ECV-&]L83*NP?LIY1GXQ<Q+25G*Y_E%AFK4]E[K<G
M>W81+2[5LVAU;80"AM(I0  .R[O. L+X'S4RO%#&:9UE=[&<S]T.2<?9/D#L
MUAN,<=\89 US?D.,0L-&QC$HS#<K=Q5S .7*+EZ[=4U;/LVZFDBF@]E=O//F
M9]P?:7SUE.;S&&95>XP_RYA,;G/'L7>0V'YS#1>!VDK;SL1'W<O/^4&+F;>L
M72W>/MJ=LU'<%[T)#XG=OD'S#B,%P;,1O)\_G>3SOW,_<5D'#<(QB^/0LGQT
MZTO&%0V-X_=P;;4ADSK,DMIQBZOBN[+B$I!Z[=!C/',#C<KVL9#81&?X%E.!
M9ESK]V=&97@G%^0<HS$)C&5S$_9V/(#F0Y3E3%A;JSW/[>Z0O);*+N7/<[Y%
M'MA4@D-K\"0F(\,\B8!G./1F8MNVG+GWL'&LQ88CE63NY#+\4<.XQ*2>#<=0
M:;R4O6+5>,.,;H93;9-G<J#@)7H/.$4[BO(W:Y]X'#X3$P#O'5OV]]GO,<=@
MV <A<@<G6>-Y0<PD+C+IS+9W)$6<I)<JQ^/)=3E2FF?=%W5LI135NJ0]5<B2
M6"'O5@W\"R-Q_-X_FK[MF-[.FXG),BOE2';'*XS=GE96&6YOWF)[C^]95<F=
MNGA< T3YZPJE0XF-7?!3G;#WYSEQE^6GO>=XF[Z%<V0#<_F#KB,7C^6IZWQR
M_P"0XM\OX[$2\7&,QC>.K=6Q=>X*<]U"V2J@>I,\XGQR!F.U;A;#HV9^5<W^
M[X[PI24Q1G(<EOW<ORV?POB22?DI)^YEGI*4FY":O5NH<6[O2MQ26RE)*=!B
MKGR2S]P!Y>#7%D[;VO!.$(RL65_>7OPS/;'-L33G]E**NWWGXN4B,@;N$WEK
M]6BT<0I*4(0D !V7W@_*7&W"?*F0<M\8<O9+QIW:V/ 7&2++C;(\4BLNX;[O
ML">RNY9@N-HZ'EK.\?GLLC;^]NZO1#K%W9(N&UJ2M%5)#S5W1<@XI=YM]Y#P
M>[*1MOS?S;W _=\JXWXI:?2]E^17<7:\6RV0?!8=I*[M^RQQBV>]Y?2GR[=+
M?ME.@^O';HH/?>(?>+OM4<9;QWL^LW'6R%MHO&..<S6];+<02A-RVAU*E()W
M@+!(ZC0?1[0- T#0- T#0- T#0- T#0- T#0- T&%9>2+[!*4ZYJP#7U?+F2
M5_-IH,UT#0- T#0- T#0- T#0- T#0- T#08MG*DIPK+RHA*1B^0%2U$!*0(
MF[)*B: ) %2? :#HHWD[C9,='I5R%@P(LK0$?-L!T(8;K_OAH.;]I_&O]8>#
M?TM@/XPT#[3^-?ZP\&_I; ?QAH'VG\:_UAX-_2V _C#0/M/XU_K#P;^EL!_&
M&@?:?QK_ %AX-_2V _C#0/M/XU_K#P;^EL!_&&@?:?QK_6'@W]+8#^,- ^T_
MC7^L/!OZ6P'\8:!]I_&O]8>#?TM@/XPT#[3^-?ZP\&_I; ?QAH'VG\:_UAX-
M_2V _C#0/M/XU_K#P;^EL!_&&@?:?QK_ %AX-_2V _C#0/M/XU_K#P;^EL!_
M&&@?:?QK_6'@W]+8#^,- ^T_C7^L/!OZ6P'\8:!]I_&O]8>#?TM@/XPT#[3^
M-?ZP\&_I; ?QAH.E&5<))M)BP3DG%B;#(7[RYG[(3&)"TG+B0:2S?W$Q;"X\
MF3?OF4A#RWDK4ZD *)&@I7E'"#EU#WJ\BXJ7>XZR;;'[M<OB*KJ"MU-)84Q#
MW!N"[&,J80$%+!0DH %*:#CF:X%7(7,J9;B)<K>"\%Y)&_PU4A="1M4V4@+F
M\\TW+XOK-"67MRCYK0"%52*:#DQF5<)0CPN(;(^*XFX3&V,,'HR8Q*P>$1&>
M8(V*#EK<-+$;'AU7D,5\IK<=J14Z#FKSSB)R^,FO,^.%R1LEQID%Y%C*KXQS
MCHN'(\W9O"^;);XWEK=Y97UI7KH+5EFG#<9&)A8W+.,X^&0T\PB)LI[%K2,2
MS<%9N&4V#%TW:I:?+JBM(116XUK4Z#AV.2<&1CT=<1L]Q/'OP\8N$B'K&4P^
MT>BX9QQ#KD1'.6[[:[&,6ZTE1MVBEHJ2"4U T%EJ;X$M[ Q;$OQ"S&&4$X8Y
MJ_PQNP,TFX%VF8-FAU-N91-V Z+C;YH<&[=7KH+S&2<&6K]O=6T_Q/;W5I>2
MDA:7+$IA[3]K?S@(F[ZW>;?2XS>3 )]Z=20NX_UPJT%,;D/!,/[T8B<XEBC?
M6YL[WX;)X=8^^6A=N'C:W7NS[7O%N7KIU>Q=4[G%FE5&H5,Y)P9;745?V\]Q
M/;WT%8JC(2\9E,/:NH>-6 E<?%7"'TO1]BI(H6F2ALCT:"E>0\$NKG7')SB5
MQ>4-!C)EKD\.6O(F$LFW2S.J4^3+M!@E 3<>8-AIX=-!S1F?#0O(Z0&6<9"0
MB+-^/B;X3N*^^1=A<AA-S8QUS[UYUE9W";5H+::4E"PVFH.T4#HYR0[?\CQ3
M(<&FICB60P[+;.7L,GQFXE\4^"SUI/MNMS34G8MW:&+HR8>47E*!6M1W$[NN
M@JL9+@".L,7B[68XF38818V,;AS+DQBERK&;&-M&K"QMX5ZZNWGX]-M9L(;2
M6E)4$I J=!?$QP",A.6B5X>&5D4.3"^PL9"1Y89H9KS?B1'D@(_5/Q13PT'
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M(ITJ.N@NE":UV-U'@=B:=/"HV^K0"VWZ$-G\"!X^D> \#H*0TCQ*6U;A7HD
MI()!!!2#4^/7P]&@J4AO<:AD$  @H!/X3TI4CU=- 4A"5@%+-"V%44E/6IIM
MJE-$H]->BOHIH'E-&E V:]![(H3]"J4\!^#0-C92FJ6BKKN"4"B3Z *IW>'C
M7K70 VC: 4MD@GP0*D'P)Z4_.T -HV@E#>TU*"4C<>M"F@'0 ^OKH'EMC]"T
M*]#N2GK^#V3UKH'EM]2$-=*?C(!%*]3T'2@]?30-C8"J(16AV^P@@GT ]#[)
M]--!'EM_I6R?2 D=#^:-!/EH_2MD>  0/$=%$U2%=:?@]6@@(3O35#-*F@V"
MI_  *G;XZ""V@J"0EL$DD$H30T%:>% #^?ZM!5Y3704;-:#=L%"?#]+TZZ 6
MVS^A:)!I[*4^CPK[(%:: 6V_#:V:>!V **?05)I3Z*CIH(*$$GZMO;TVC8*I
M]8K3J*^OKH+3K;6P_5I!VJHO:FC9VFA(-*U/307@VS1*2AI>TU55/M;NM:T(
MZ?1H(#2* ^6WM_UJB4U*0:?6 BM>F@I#+:0=C*3U3T%#X]%=%#H$) ]-3H)6
MAL)6H,M@@!2E=$IHCQ_& ":CKH-Q91V_<M8;@$/RAD^!7\3A$XF*79S#EQ&N
M+MVI^W>N\>?F(MB\<E8&WGK=E2[-R\893<@>P345#30-JJA*62@JK50 *?9'
MLD52:T54TK309=B^"S^9VV4W&-Q7Q.VPG&+[-,F6T_:,B+QJ*N+2VO91Q3[S
M7O"+=^^:26VM[BBOHDT.@MW>&S-EAT1GUQ9V3>*SLW)8W&R'Q"-=?>E8BVMK
MV_MUQB+E<G;--,7C:DONLH:<*B$*5M- Q?\ :H\L!+%72-H((4X"#T;W5!43
MT]%#H,JM<'G;S"YSD*TBDOXAC,_"8S-RXN+4-V$U/V][=P]DNU+PO''+NWCG
ME;DMEL;**4"0-!M.\[5^;H[ X?DR[P!SY+G++'9..EK>:@+NX$3E4@B-QZ4O
MXMB37+Q\5)2"T,IN'[=MI+IVK4-!W5OV=]PUY995>6W&C]PWA603^+3UJQ.8
MP95.18K8,2V01D;%_%TR$Y<1<?<I><39-W +9J*@'0:CS#C7+<"M<3N\K@51
M-OF^-6^48ZM]22;F,NGGV&U*2?;;N4EG>IM75*%I/@K08.&FOT2$J^D) K]/
M2@ZZ"/+;\/+13T^RFM/H)%:Z"%--FE$(INZC8GVDT((J!4'0060'$(2VUM*%
M+&X%2@?8H?9H"FJ2*'KH*RVS^A;2/P@'^_4:"@,H%:H03N-#M ]C=4 BE*C0
M5%MLUHVCJH$>RGP](\-!DV'83D.?9-#X7A<'<Y!D^07PL8B(LTM&XN[E3;CR
MD(<>6VRVRTRTMQQQU:$-MI4I1 &@[7DGC#,N(LC^4N0X#Y<FW8VQF;1#EU&R
M%E?Q4B%FTD8R5C;F\C)2P?4VI =8=<2E:5)KN!&@P%7NB4*J&@I(/3<C\9/@
M*$]*FGJ\?7H,LDL'R",Q#%L^D(H,XKF<E/0>-2Z7K13<G*8PN/1.6[=LV\JZ
M;-D91BJG$)0H+JDD T"SF6'2^ Y+)8CE=E;Q^0Q2;3WNS8OXV1:;$A9VTA:E
M%]%W5W8W'F6UR@GRW%;%$I-%=-!C"G+3>02R-B%%T)"21L719Z^TE23T(Z:#
M:3/#&?O95A6&" M&)[D''HC*\1M9":@8ZVEH"?M;B\B)$RE_?V\99(O&+590
MBX>:<W424[B 0V!/=I'/&-3=W 2N!-,S$;>8C8R5C;Y%BT@Y8WF>3;F.8M9W
MHL)BY19W<I+M*:#;FQ38HM>UM040POE;@?D[A.ZBK;DK$7,?,Y\2$5>-2,--
MQ5X]%7"+:5L&I*#OY&Q3)1;ZTI?MU+2\UN&Y(!T&I?*9(55 K2B=H I7QK0#
MU:"?+;.^K:*[A^@3ZB33IX:"D-(!4"A!3N -4C<.G@DT\-![G^[;;1_;/X@#
M:&T[5Y>LE)HL_P C9M*MQV]4DGHD'0?K-T#0- T#0- T#0- T#0- T#0- T#
M08)RDD+XRY%214*P3+DGP\%8_( ^/3P.@_$,T/JD#QVI0A5?6$C\_P#O:"Y4
MFM:>/2@I44\3]-?S- %0D!8"3576E 034 ?2!H(_1T ZJJ5*J.I!2D$C\91]
MK\S03T"@HTZ>SUH/'H "?$^H: 1T)- $D$[C0>/K/AH%!2@ ":$!(IM )K0#
MPI70 /9W"E%'J0:U-/$D>)IH%/&@J0:';0D=*T5ZC]&@$4--I43170#V?13K
MZ330"/01Z0:'UCP/X1H J4U(*2H$+2?I]!(JE6X: .B0G;MV] >E%"@H13P
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MO/Z18I_'6@D=@W=N:)^R.[H3Z,BQ0D>M2J35:=-!ZR[&NU/G_B3NGXJS+D/
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M*(K^'04'F/C@':,@=) 42/@615&VF[I\)K[->N@G[8N.-N[YB72H_P!X\BZ
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M94)?\O8XH!S?50<2]XA?1P$ CV@.@&@NMJ54)JMQ1+3;@;*E( 00I"'%A.X
M4H3M62"$^G02Z5/.+05(" 5%H=6P 1[2PA2TK05*! 220JHITT%"%NI2M12E
M+=0HK+CH]GRTA!(KN2D*"@55H"-!<92XI(;=VEU#H(3M6II="5N*ZGH4MD)_
M'4.O@:=0Q_+%MM8[-MHV (A[\ 4\I2]MLI14LMN44G;[233\SI30=X5(MVTM
M-E:SY+3J]^UP%2FAL94L[T+KO!\.I&@NK4[Y)91M+B4N+"-Y< 622X'U4*T$
M-] "$T/4=-!#:UAQ*6W"'5!*4@E2O8"E*^K;!KM;;6*GVE$#T'P""A"%E2@E
M2-I!=;W)60"Z4E32DE6^C:O:6D$@"A%-!#>]:O)6E0JEH'RR5NH;VJ2EY(6C
M:E0*.E3U3U)--!5Y24I+;@<HA2?,-5+<\K<ZE='$+W%6]("J$@4/3IT"ROS%
M+4"K;M(0M)\QIQS80D!D(W*;<HF@)W&IVGH-!=*EU91[ :30O@*2A6Y*JJ]K
M=L6E)/J30CU'03[;@4E1318:*&]U$T*O8]H+"G#L50GK^+50'706T(\MTH:2
MNJFT>RM:W/;=%4I0LEQIM2T))H3N_O:"\X6W&VVWE*\H.%Q6PU35:_,;2XT"
M5I4:BIZ4V^K05ON)*$E]2O+^K4X6DJ9:.XH*MQ" JJR:@]25?03H.+0E)*2%
M4*6@5 ;$I2ESS$J!*J[@E54I*0G:#6N@J45!JCI;8V^4A.[:NKB0 G8M% %H
M 22#U(J-V@H2"A56W$+6M2=I;\U+:VG*)2=KP(:IO/4CI7PH*Z"X&W"1Y@"$
M>8X\@I"2XV 5I7M61]:TBI&[TU\:4&@QYX[<I@04J4W\*G=NZCB2MMV%]AM"
M:-%7M4(KZ=!D"-Q=>1L6AP!U!!<]E:E*3]6ENA0D)H34&M"/7H+B$*]@@%"4
MN,G<M0637S$J<%"D_6J/M)I04ZUZ:"E!;;(*%#W@$M VZ5$U=6I(42%T<"4A
M?4[B!UH.M H2CZWS4GRB4-HJ%);<+B4;0IO> 5)V)'XJ14^.@J65>E8=!W$!
MQMQ*PXX3YBG"E120 .A (3^#04MJ0%[22TMCJD!7M$AM 0%K2!5!4L!154CP
M-:Z"KS"BV"WEAGJZ@H*$%)*TI6I 31: XT?0H]":IKUH!#1>#NQE*Q1OJJF]
M+CKE%JJ=JU[Z 5  !Z5Z'0$*3L?H6E*]D.*62JB=R5A"VB5!)14>T!2J? 5T
M%55**6@FJD!=4K2CVZ@J "TK"E.)+8H:JVD#I7P"YYGL)6XXMW<IH*5YG4D>
M9Y35 5(4&TJ H$II4BAT%+SH=0DJ6E>U;I2VI)2$! 'GNH2 @I\I0J%D$UW'
MQ%=!0S4;%!2W:(2MUYL#:VD.*:2A-$J5Y@'LJ4=JB.I.@EULN*>#:%J*W'%J
M0L'VVPHJJ%H4T2%;OQ4DD> -.F@M!71'U:FQMVA"U;RXPVMI"5MA9;4JKAHF
MOI\370;"XE4H<JX&VL5_=^2]I;R7G ZG%YU3B5'<M060H$BII6GHT'TDT#0-
M T#0- T#0- T#0- T#0- T#08AR"#\B9H4TJ,2R7QJ1^\M]2H'B-U-!\O(Y*
M?<+$D(;2[9V9"ZH9?^KM6VG%&FXI\O=T)-3T&@YFX%(<4D40ES<DI6I>QSS
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M5+2A6U.U#*"5)"2RDJJ@U-5>@Z"$*4GV2VE3;Q"5!0="E%2A5;CB440=U H
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M[50&P.+"#ROQ^OS6R@S5^4AM(;2I:L9FVS2A\216@ !*B /'0?2'0- T#0-
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M!(^8@E(VI3\QR- FH)!&^AKZ?H--!/V*X3TJO)32E"<FDR>@VCKYGH3T_!H
MX6PFFTJR,H"MVWYDD:5K7].>M?[N@I'">#I45)5DH)H2?F:3 )2 $D)#FU)
M2/#U:"K[%<(J37(]QW#=\R2-:*ZD5W ]"/7H,;RWAC";;$LE<;.1U:A9)]*7
M,EDW$%QJT=4@*2M9JV2.J?"A.@R!OA3!E,M5^9 %-,$I3DLBE%4H2I-$!6T
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MUV;#3J?5H*SSG>A2P>/[M!2DJ0#E,0L.46$J%$VX*!0U%:$]/IH%L<[W2EJ
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MY.N,MY$X]AW,3N8=!R*[N_>WYBPO@E5MC,^?*-O:MI62L.=% T21UT'N?0-
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M!6D(6TM84GW>I()6&UE!!K3_ .Y'B?$+/EE;(;HA"%ES>$!!56OU1WJ22''
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M>NZBJTH/3H-@\2KV\J8 TO\ '5.R*]R4%(<V8Q/IW[ FJ22JI!Z>G0?270-
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MHD$"AJFHZ$Z#O@2A+/XSH##-$A(:!*D):*FU^8ZGS0HT2I2CX]*:#DJ0=K;
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M\G,2@Y!R#%LBE6YM-C6QNL3XPP;BBS9LO<F&_P!J7,1@5M=.5"E&Y><H0DI
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M]?7075E*4-OI0EQ(6I1]G>E6](7Y:VU* &Y'5)ZD=*TT%*GET_P<);=HF@
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MC&OYO0?C7]Z;#Q'@?\'\=!'ROC7\W8+PI^]-AX=.G^#^'305?+.-_P WX/\
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MQ;):0NJ6P@A06E*@'*3V\<2-Q3$.QAM@Q96MNJVM_+O9<7B&U1]G&$_$_?\
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MKF\O7KD(LF4;6FTK2VCK1(KH.2_Q!QX_81$8O&+'W"#D)>3C;=+UZTAB[GY
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MGHR+C<:D;J]O;YNUO2BVBW68>X6W=I;;4;E;:2;2V<\UW:V:D.MF^?./,;Y
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MN39M<TQ>,,A?R;J)%G$I"YE;:UDX!JPDG!<7F1/)?D9Z380Y<N+!-LBON:F
MI;:@ML]GV2VD'?Q=CFV'L7MS<6<U;3#N#O7U[9RB<1E<6N<;0;R:=87Q]:IO
MPY96!;*F-R_:J 2&/([%+Y*(QA7(5KY5M!7T?>OLQ<Q:73\M><?XIAB9A:K/
M(+<R3EHYB39;3>J?!M+EUI6X[5:#),A[-)#),*XMQA><Q./W.!/YT]*C'\6+
M4)+M9ME:<C^'1\<])>9%V$(S<7;%NDK<)+^\_BE*@R"$[2/@<YCLK;9-$A&.
MY? Y=;N-XTAF36_&VG&,=(6OOR+W>!>QW')92Y^.&[]:%;D)HH.^CNW6?CG.
M4T,9-CK=MR/R='<A)+,!>,OV)A\^&>V3-^$289E)*X>><LKBYHWNMFF-J04&
MH9%QWPKDV$\E\EYY<9)CM\QR,Y9J?8M,>NK27LDV]WDDOL?DW9.X1*)M)3(/
M)M0XT$MV+(;IN)5H//S/9'DC]S%N3F?XO+MMW\S?2KCF&.I> D&Y]CW."85+
MKL(B.E!D*W+^W2WY2UL-I0 D= [)OL?+%K;V=OFT<S;6L396-O;MXNA#+-_9
MXVS#"88;%^$V]ZN1:-Z%H 6ETUW;R5:#L8_LVO;*X\U668W<(8NY&^96]B;]
MQ>7=]-0^:8]?WU[>7LS=NVMS8P^7[+469MV"JW2IQLK*EJ!)=G$G(RN:WZLR
MQYAG))6,7"LV^'BW.-0UIB\]C;R8]%O),V[$]Y$NTE-VVA)=:M_K0M2JH#(N
M,NU*\P+,L7S&\RV,DKO'''&T,VD [9>99FRFH]SR'G9*Y<MKN93?LW4BH51=
M7R7'"/:% P=[LDEMD#86/(UA'0T7>9G+/6MEBXMKLS638NN$MI.VO6)!M=6)
M#R[M]EP%IYQL+(\RBP&68SVA*Q[%^5L9<RYB1;Y(C\8L??KNQDKA=NF*<L;J
M6;O(Z[E[F(>M+J\8>\A#;"'$MOE+KC@  "YQSVFWN"Y?C657.4P4V[B<I$74
M:ES&5M7EY;6\!ED-(.7]\[(W"DRMNC*2U'O-)2+:SMDLJ"PJJ0P2_P"QJ1D)
M>9E%\A6UFF6NN0WVK>*C9B+3&/9C:,M6<S:^XSS#3^0^8T47[SR'&;EE71H*
M%2&QL>[3U0MCD3+>4VUA>9)Q-E/&=S<PUA(M.62LCBL8L;>_MKN_EKV1N+:!
MN(-]=JT\ZHH%T0VIH520P%/9'+6\)(Q4;R%&1J9=S$%W-JWCE[>6T>(QR3NL
ML7$R%_.W$VS=9%)KC[E#GGI+1C_*(++I;2%^9[/<[DHBX@V>3<=MH]*(*WLJ
M8G?JO/=H],$W?>9>.3SR[*YW8Y;/6SMLEMQM9<;4I3:SH.JD^Q>1=5D'PO-X
M)#%[9,6<182>/2ES#M,-9-?S+ME*0EK/6D3<V5VQ=I==*6O.^((\U"T(4IM0
M=_S/VO9!D<H,D@)6R>F%X;QK@$2JUAFD2]DYC\\&IR8DI6[DV6',:7B\C?%=
MHE"GP\Y[!62!H-LYGV_W<L[F$KB<O"Q,SDV18;(V:I>-DKZ-CH+%<-9Q!,0N
MSM)2T\Y91YMRTXCR5!:TH<WH3H+W#7 DQP_-S<E;9N]D-KE=G9V^16TE9%E2
M;B"O)U..7<)[LZANR+$%(VUG<I=#Y>]VWI4D%*$!Z8'@*]3303H&@:!H&@:!
MH&@:!H&@:!H&@:!H&@:!H&@^1'/6 36>0F:VN*8O\<Y+@>Y3GRYCKM$.F1E(
M&2ENV_)E89?,W"TAR.5?QZH=%F]YK04^&$(4%A- TE!89&(F.+9R,QNXY"^:
M,[E(N%Q>Z[9\CXYXQNL<E+_!8_-KKCRQN)N6E>+<IPRXBG9>XO) ,1^1VC5\
MPIIQ*T[@Z#&^*K:QP>#PZ4X^S+'\W9@K:=R"?P_C6\<G(OMHN.V&WQZ\A(ZX
M>B;>#D6[/DYPN7&,K?+]U?MNK\A2W*D)N<!D;F)@<\?P#$\2Q]F-P>WS#*H_
MMURW)\+R/&&LM[FHZ)R,<,KN[++&(>>O[R%DD1!?+4*]=VCGE-L--!(9==<3
MP>*8X].<G<9Y=F5M+OY7B+\A)\>2LSD\EG">VSBN#X;OY2"C3D;T7=6\LB8M
M+%]#[UM%S5PXHW*'27M!V69\0Y1!P%QD]MAYL<UF9KDY_F;*G\ D<S7D>.X[
MS-P3(WQRJ!CWK*0SS'V(6-D;AF,1<@7UJBZ#"5>8X%!ZQ[:XI,9DW 3$9<W]
MRE'#_/,C?KN<-N..&$8?D'+>)R&#,VV!7TK,R6+0GGFY^"V=Q<*=9L$E*DMD
M%M(>-[;BJ#PQOC69RWB26NN,[^&@I_G"'LL"EIUS*)][-NX6.QB5R> L(N]O
M,FDXB>GHAT*<;<=M&56SIHRVC:&*8[B%K!G&&)?C'*,AQ8<<\'S_ #O#9+Q-
MD*<MQ7"L;'!S$O$6TU',W=OR?Q]EL)$$OXU<,7$G'7L/?;6TMNN)4'I_@/$\
MG:X2[B8_%,6R3#WYSA:?L^/(V9BI"!O[4W>8]PEQCM@TU(H8<L[MN/E+)8:)
M2ME#S5=H*=!Y9O(#$\FNI!SBG&)+ N([O+9;%X.(_L[9+ELE%\D2G%O 3<2O
M&,(-_B5SQYFE^_&R*X[(KPMV;+K;ZRI*7M[@>MN4L3GK?MEP25D++(K.UP?N
M,Y,R#,+BRQZ9F)R$Q;)\CYEP]>;,XY"L/3DHS"/9K:R:DV;3KBK9*G6PH *T
M'L_M9L'+#A+#DJO)V_9O42DK97N2P<IC<U=1\G+7EW87%]!3BU3$67[1Q#C;
M5R$.^4M)4A).T!Z&T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
M T#0- T#0- T#0-!! /B ?P@'^_H)T#0- T#0- T#0- T#0- T#0- T#0- T
M#0- T#08E'87 QF6Y#FEG9JMIW*8Z%C9Y]JX>%M*-8^J]$1<W5AN]T,E9VU\
MICWD)#JV$H;42EM 2&6;4]>@]K\;H.M/"OKT"@]0\:^'I]?X= H!U %2:DT\
M30"OX:#0* &H KZZ=?&OC^$Z!0>H>@>'J\/SJZ#%H[#(&,RG(LT8M%*R3*+&
M$BY:2??>N%JC,=3>?"8ZS;>4INPL;=Z1N'E-LA*7'WUN*JHUT&54_P"__P!S
M^]H(VI-.@Z&HZ>!->H]1Z^.@X$M%1\Y&R$/+6;%_&2MA>1DC97"2IF[CY"W<
MM;VU= (46KBW=4A0!!(/CH,%XNXFPWAZ NL;PFTDF(Z^DWYB_N)S()S*IF0D
M'K>UL4O7\[DE_)R]VFUC+"WM6$./*0Q;,-MH 2D#0;)H*@T%1X&@J.E.GYF@
MF@]6@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@
M:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@
M:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H/$?<?R)S!BV<)M.-I5^SCH
M#B'),]GFW[/&[C'VF8^4=L'[^77)I,VY>,,)3\/9LO84^%%\>7H*++O+CKN]
M3'LX+*J??S'),2BFKJ68C[R=;QPO6#DY8M7=DS9VM@[/,IMW';FX8LVTW#*D
M/NJ66TADV%=T"\T^>$V.#W/F8/@HR9]QJ=;1'RL\BUMKJ[Q2RD):/B&$/V[E
MVA@OKJ&7VW4/);*4>8&"([U67IB&B+7C>:E/C600>.V\A$3#ES8B_NXE4O.4
M==A[-/DQ+(*&EK\M"WFUMW"K982E0=SROW3/X[E.8\88Q&VB<I@'<=2UD%S+
M!,?;L7Q1>S*'F;F)+#L]:V 2+:Q0Z[Y_GI*W&30$-3M]WV<W\C.7MM9QUA#.
MW-[-6=D]*1EY<1&%(X[?R&U1;OB&059FN180XNWNBY:L*<4P5.42O0;(C.\^
MPOKV.MUX>NWC'S++D)N^R6VMTQL=8OPUA'7=[;M1JT-WEU>S*%7K 6#8M)*@
M7:I20Y>/=Q4[F/'F3\A1"TV#5OR;Q=$6$0[Y;[MAC\W<878Y#8J=N[&SN74R
M5Q=2"F'GV$/(0ZDA*5("0'2I[V_=BXB7XV<M'+6^M?>F[+,[>_<,4\J?;??C
MVUPEDN0ED/P*DLV0"2\%U*T[2"'(:[N)><^!O1F,P<#'VTWB#N92,WE8N;)C
M'\CNLI;4S%7%K#AMRY:L(!MUVX44(8N5K8"5%!60Z>S[SYG*G<5L\7PFUC'9
MV?PFSNY";GW3;,6TER1:X=DUFU9*AK>\;\N/4MVTN'4M*4XI*5LMG097F/<-
M)\4<B9TSEDY;Y%&KOXNWQ'$HI<0JU9B0Y#6TB$7\:Q>Y'9YM%+N;E^]L))E-
MK<6CK%PR^TTT\ &!6?=9R:+Z Q-G$&)?)?GB)MLIG';]5KCK\3D$]-JLL:@'
M!#VR&[]40+&VM[@^:I%V'4O@>RXX&R9KN=O$8_QMR#C\$J_@,XC,M<L,>N9:
MWM%2:V,XPG$X*5>F_A]T8]AMJ:N'BRAMS<%)!)("@&$8CWASCZ+IF8Q9B6E)
MK(Y96/-,S]O&LV<1*9_+8GA<3<-B)6JMM%PCKLC=%3NV[4AM'F>8-@<NZ[XK
M*+5D"YG!39LQ3\DS&>1E9O7YOX3?0K=\PU:L0)>8D%14R+AEI*705,N!Q:&T
MEW06<>[OYJ/C(![+\?9E928B;F;OVX23M;.-CX^WS?(\6MFHU#]BN0OIVX#=
MAYUHXH)#;=PZA0\M25AL]WN=]VP/"<VO\0-N[DTI(V$E$,9';O\ PMJ,E(Z)
MN'(V]7'LIG[Q=Q+VZD6WEVZE-!Y6X%JB@X+'=:RKC3%.0[S#';7X]E]YC,M$
M)R2V<5#IL4^=<75C?*L&43-Q[LZA2;;RV%*5O&ZB*J#6TAWX1]G;VEQ9X!<R
MJ;JYN(U";'(77';J4N)B=BH)V(L5029*6A+U$%YUS<I80MA%PWL:<"@2&U&N
M7<KO.>.-8-#[D1A65<6HR67@9 1*[FPF)"(R.>:9NW 3)^^VK$(D)N&%JCVV
MV7FW!YSS*M!KNQ[X;.67?)C\)2[;VZ?<K22^9E,65W+R$K,Q\"X%7D#:O-8]
M>VD0JY<O5MU;"QL:<00X0YC7=C-8C@G#EW/XC=YQ.YMQM@>2R\A!2+-L7IK*
M7W[5UBSCV8QYM=LL1MTZEZK+._RD':E:EH#AX)W895=S+&)3V%7$O/7^;NP:
MIJWE$1V.QUMD7+$UB.,62%IAP+DQF-V:7']BG7W+MAQM5$K2[H-@0'<3,)Y,
MO^.LBA[&Y<ON6LMPV$D(V_-N['X_%VD,8-=U'7%L').1>N[MU5WY:PEFV*7*
MJ'L@,9;[RH^\7F"8W$D72<,F<GBI!]S*46-O)?!EXTQ$W..^^P[3LNW(NY1;
MJNTH2$V3"''DJ?2$[@JD^[V[MI2_A+# K*3EK":LH4IMLZM51;KKD/.WLG<?
M$[>%NT>[LWL$M%F0W6[86EWZNA00ZI?>_%6K$X_?84[:F&=PUIJU^9/>KR4>
MR2RC;R78M&;:&=V7$4B04JU"REJ[9MW75N6Z$*T%D=Z!E61:,8/)14D_),H:
M>M,@B[YM,3;7&,7$K(-B\CFVGO<K',HEM]LH!#M^0A1#:5J#*^,>[1OD?+H+
M%CA;\,Y)NREO>W R-B^5:N6V.3F61YC;3X?:W$JS<1$$47*_JC;W+R4 .)]K
M0=;>=X+EK&VM^,&LKIV1QR)R"QM+3.[%UQOYFNUIQZPDTLQ*WK!X1S2UR(*5
M+LKHMLA+@<2YH,9E>\N4O+5N%ML01B^02,4FY1(C);.=8B+QVS1D-H#9KBK4
M2%BY!M+1<O\ U:;:X6A-%((<T'.N.\2=0]*3S7'=V<9MK$6\1#O7]PQD4W,7
M>81L+&WR$")6JQBC%7I\\.(4AJZ3^.IE27B&T<Q[E!BW(9P%O#79.Z>:P]=I
M<#(K>T6%Y+(0%O=F\LF[*[5;LQMG.AQI:%O>^/,+93L)"]!@L1WA/2[,,58"
M(6XR=N.1C3>198U$LRUQ*3-K8LJ<6J(7=P\?81MVBXNWKIEAU"E --.M[G4A
MT.1=V$Y'99&[8@V\!'Y#*0TQ&L3,5?.RL8Q-<@89;RT7<_"TNNR:9_%F[M-H
MEQ3;ML  X"5@AR[WO*=@;UF&N<+7*W L\?N6)1_*;*-$E9W,/&R,W>75LB&]
MTL).W=DDHM;1DK1=E*SN:  T',Y7[FLBQ29Y&PC'(H/ST<_,1,%D$G)V%M9P
MLNU@MIDT<?A;47=.R%@H!]:G'RIQ#H2-CC9  <O^US=>[3C=G@BKQ_'O9<=N
M<K9M_>VWI_",:BE/.,0;K;$A<W>8AV\9V 68MR*++B0 QC(.\R75'1<7!8E&
MQN;3=B9!AJ_GWI.'AV;::QAQ7Q2X:AK1OW65Q>9>6R[N#@NV% -EI!=T%ZV[
MV&FHB4N_DN_ES"7 3=7#L_'V=R_9VC%W?S5V[;VL4+6W>M;-MM-BT*"^5O*B
MT$*40^@"35(/7J >M*]1Z:=*Z"= T#0- T#0- T#0- T#0- T#0- T#0- T#
M0- T#0- T#0- T#0-!TE_P#+GG7?Q/X)Y_P:X]^]_P#<?.^7_,/O?O?O'M_!
MO-KYF_ZC=X]=!A"/L3]Y;\O[+/>_B=[Y6SY2]Y^,?#F?B/E[?K?B?PGR_/I]
M;[MMW>Q30<F+^Q_RK_X+]FWD_*['Q/X7\K^5\E;KCW;W_P!T]CY7W>;L\S]J
M5WT].@X+?V&^8WY7V4>;NQ?RO+^4/,W[7/DKR]OM;MN_X73K2OD>G0<V6^Q[
MXU=_'?LU^8OB,'[]\6^5_C7Q;:[\M>]^^?M[XCLW^X[_ *VF[RO3H.(U]B'N
M5UY/V5?#OB-Q[[Y7RC[E\6]\/O7O6SZCXC[_ %\S?];YWC[6@[%G[)O+OO=_
ML[\KXA*?$O)^6O+^*^9:?&_?MGL_$/-\CWKS/K-WE^9UVZ"[!?99\*_DS]G_
M ,$\J'_>+Y=^%>1YCGP#][_VIY7G;_<_1NKY?6N@PW)_L1^;.-/C7RE\P_--
MS\D^5\*\GYD^7<@\OWCROJO>_AGOON7F>U[U^I?6:#*K3[)/A ]S^SGX']1_
M@ORS\)K\;O?=OU']IU^8_>?+_P#ZWS*?6[M!8L/L9]PM/A?V8_#/=+?W'W#Y
M5]P]Q]]1[I[I[O\ M?W3XEM\O9['GTI[5-!,S]C7Q.6^8?LR^,^^0GQWXS\J
M_$_B&W^3?Q;W[]M>^;?\!\[VZ?J6@IF?LSK)4^4/C'P=OS_AOR[\S_#_ (A<
M?"?A^[]M>;\R5]QK['Q'\7ZRN@XV"?9E]GV!? O@_P G_*T/\G_&_=/>O@_E
M1WN^_P"(_MCWWWCR/>:^W[UMW>W30=NC[*O?;/R_L^^(^XO^X;/ESWWX;\9:
M]Y]SV_7^X_,&S?L^K]\VU^LIH.'*?8U[M<_&OLQ]S]X_;?Q3Y5]V]Z\^T_PG
MWOZKWCWKR/QO:\SR_3MT'*>^RCWBU]X^SSWKXO<^Y>=\M^\?'MLE[Y[KO^L^
M+[??/-V?74\[=^CT'-N?LY]UA??/DGW+XN/EWWGX%[K\>\A_;\%\WZKXO[MY
ME/(^N\O=Z*Z#$<C^R#XGQQ\7^5_RLD?D?9\*^"?-_P  D-^RG[G_ !GX9YWN
MW^O>;39[5-!I^4_LX_:MAGOWRUO^5<N^6O=_E#[-/)V3GS;N\O\ :_OWNGO?
MOVW]J;O+]Y^O\G0>EVOD;XQ%>7\J?,/R^OX+L^#_ !GY7JSYOPO;^W?@&[9N
M\G]K5V_1H,7M_L0^%WGNOV5?!/+N_B'N_P H_"_)_;_OWOGE_M3RZ>]>;OZ?
MJN[]'H.UO?LL^#1_Q'[/_E[W&$^%>^_+OP;X9[ZU\M_#_/\ VC[C\0V>X^7]
M7YVWRO:IH*Q]E_QJWV_(7S'Y:?=-OR]\;\KXR_L]VI^W_+^8?-IMZ>^[J?6U
MT'(5]G7S'9;_ )+^;O?;SX=O^!_,GQ+X5;^_^Y[OW4]^^!^5YVSZSW39N^KI
MH,>'V'[W*?93YGOV4^;3Y1W_ !+W%'SKYGZ+W[X;M^*5^L\BGG^S30<V-^R#
MSG/A'V;>?^X_F_#?ECSJ?"'/E_S/=?;_ 'AW^YU_W)7R_JZZ#7.-?V<OBO*/
MNGR![W]H.._/7Q[X![M\X?*F.?*GNOQ/ZGW?X'[K\.\OV//\[R?;\S0=HO[(
M_M,L-_PKX]\G3/PW][/E#X?\;Q3Y@\OR?W.^:/>O@?G^9]?[K[KM]G;H,3OO
ML>^WOCOR=OSI\$R'Y'^#? _E?WGX/,_&MGN/[H?&OESS_-V?M;RO(\WZSR-!
MM.R^Q/S6_</LL]Y\N1\OW/Y2\[R_C5O\8V>1[?E_,7E>\TZ>^[-_UM-!C"_L
M$^T^1]X^2_G?[-F?>_>_@ON7R+\3D?>?*\[]J[?,K[]MZ^Z^[^=]7Y6@R=[[
M$O<+KWC[*_AGO,E[]YWRE[A[W\1C_C'O6_\ :_O/Q;W7WG?[7O'E;_;V:#KX
MC[)/M.SGR/@/VB^Y8)\Q>_\ N'OOP[8_\F?#/>?K_<_/KY?E>Q[U2GUF@O'[
M!/=GZ_9#[G\+N/>:_)GNWP;XU^VO/_UKX7\Q_JF[ZKWWQ^MT'>7?V4^\Q_OW
MV>^^?$V_A7O?RW[S\9]XE/*^'^=];\3][]]V^7];YGGTZ^9H-,\\_87\%QOY
MW]W^$?..-^;\L_+_ )7O/G)^$?,GF?6?!O>/+V^1^W-VWW?VJZ#>E_\ 9Y[U
M=_%ODOW_ ,]?Q#W_ .!^]>]?#QYOO?O/UWG_  O\;?[7N_C[&@X]K]F&R2]R
M^0_+^)7WQCW7Y>V?&/?X_P")?$O)]GXE\4]T\_S?K?>/*W^WLT' NOL>^(L^
M^?9I\6^"W?N_O7RO\1^7-C'OWD^;^V?@OE^7YNWZC;MW=*:"];?9+^W/<_LZ
M_P 'L/?_ ';Y:_P7W>]^&>^>5_N?W3WGR-_L^7YFSINT&Q= T#0- T#0- T#
-0- T#0- T#0- T'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>v473641_img7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v473641_img7.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ G #J P$1  (1 0,1 ?_$ +D    & @,!
M      ,$!08("0('  $*"P$!  ,! 0$!              $#! (%!@<0  $#
M @0#!00%!P@'!0D   $" P01!0 A!@<Q01)182(3"'&!,A21H<$C%?"QT>%"
M4@GQ8G*2TC-3%H*R0Y,D5!=C@S1$)7.S9(0U528G"A$! 0 ! P($! ,&!P
M      $1(3$$40)!$@,489$3!7&!%?"A,E(T%K'!\2)"(P;_V@ , P$  A$#
M$0 _ /2&&IPGR@)DY7_'2C02GP*%]>5/,.,ST,'C;D7!);!DS%9G_P R^>)_
M]H<&6[GO ;E?M29*AE_YA[+N^/C@@\8;4H=-9$@U(_VSOT?%QQJFSHZXB) I
M5Y\U/^*Y_:.> <49#] 2X^:$?[5?]KCE@%ADOE("EO&IRHXK+N.>9P"DT7@C
M)3U:YU<5R'MXXA04&B_X5EQP 'AUJ^BM< ?0DY^-SE^VKO[\ 8;2<_&YR_;5
MW]^ ,H"S6JW5<."B*<?YV $JY_BK_K*_M8#E7/\ %7_65_:P'**/%QP]GB4/
MMP&*E.BE%N*]BC^G  ^,<''!7CXE'[< "ZXX$K'F+R ->I7/WX DI#AX*>'&
MOC5^G 8%#B>*WA_WBOTX D[YIKXGO$*?WBN7^EWX!+=0]11#CP! ']XOE7^=
M@$R4A[Q?>/</\5?]K -J6B0FOWS^8_Q7!P_TC@&M-;D_\Q(X'_:N?V\ RYK,
MTJ44R968ID^]]9Z\ Q;FS,HLB3,/_P T_E3E4.4XX#7UT9GGKI+G"G_Q<CZ_
MO!3 :YNS5Q'72;<.'_.21[C]Z*#&=)E^1=/^?G_WW5_XN3P_WO' 2V1;NB?*
M5T%(^;DY'/JJ^YP[#B%N:=MN@CJ22":4-![??GB$'I AT->GCRI^6>-4DPZ.
MJ%%X>'F/R]N)#DC1<@>DY'E^7' +33033IJ.DU/?V>^N 4FFR*9_"2?I_DQ"
MG-*C8%0>0Y4[:X(&VTT2G^<HCAPP!K &, 82M!K1=.& P\Q'[PP'1>;3Q5QP
M&/GM_O8 )4M*J55P[,OMP "IS:#0*]N0_3@ 4OA_IH:@UH0,LOKY8 TE(6D*
M-<^%#3G3/ =+8"J4"C2O/A6F *N-%)HE"N\UP!!YH54GH5F!V?IP"5(8IUU2
MHY#O_.< B28WQ>$\, W9<3JKD10>W\N& :4R HUJDIRY\^'YL SKE;*]7W:O
M%D/=QK]. 8D^U)!4I22 K+/GW' ,.ZV;J*ATGGQ'Z,\,0,[\(_[,_P!YU<#P
M[.'ZL48_Q2E/^'D2Y)#1SE/U_P!ZOAECFK#D@P$BE$T//G]'?C3),.CNAP^G
MI\/Y?IQ(<,>.$A*E)H!Q/9^O &5/ALD)73 &T2TI2!YB>W@<0IU#BZ,HXN)-
M>X\O=WX(&1>6:5#@S]OZ, 9;OC(K11/]$$T_EP HO;5"5K\L#FXI*13M\2A@
M"CVK[/'J9%ZMK%.(>N$5H@=I"W@:'V8!%E[J:*BC[[5-H2H$U2W,0^KER8\P
MG ($G>[0;/P7Q<FG_*0IK@4<LA5I-< W)?J#TDWU!AB^2BCDB&AH*KR!=D)4
M.',8!MR?43#5UHAZ=N*@>'S4^,S3OHA#ISYX!M3O41>$)66;#;(K9 \<NXNN
M 4/%12EI(^D# (]J]2ZGYX:NC5BEQ4J'S";//)G1DE0"G"RMYY#G2#P5TBO/
M/ 2TTIJ"V:BML6[VB:W.@2D@M.M'-*A4+;>16K3S2LE).84#RH2&QF$]24)X
M5ZOJ). &\M7*JNW+A@"JF"JE$K^G]> *.,HRK6N?/V8!.?8ZJ^!6>7T8!)DQ
MOB\)X8!'DQOB\)X8! F0"JM.0YC]?=@&M-MB5\4J32O'G]!Y8!F3[52GW9-:
M\?=@&3<[07%+ 00:#/\ +G@&M^#?]G^UV'A]'ZL4:_O2D1\BOYE[P'.0_P#^
M\5W<<:,1<7X<#IZ>_N_*IP#@8A]*4GI)I^7TX K>'Y3#*@P "4CI',D_L\@2
M:<\!3SNO_%FVUVYW/N>A8NC-6:JT]8;HY8[[N7"E0F=+P;M$=,:88T)M,J[7
M&SVV2"T]-2D-]2%%(* %'+;<N4@XOJROU\@P[I8;;I=VV7*,S,M\Y-SFW%F3
M%D-I=8?96P&&EH<0JH(QI57<7>]1NOGZ],NP0AQJS:BX$<_BER'!7O(]N 0I
M7J+U$"I,_<>WPL@5AIZR0U(J?A ">L*]AP!%&\]QO"NF-J_5M\4NH\NSLWZZ
M>;7DENS0G@ONZ< HQYVL;R 8VA]U;N%9!V3I^^0VU5[7;\NVH17^=TX!;BZ.
MW9ED*B[62HZ36CE^U+I:VE SS6ABZW1_Z$DX!PL;6[RR2D*B;=6))(K\UJ&^
M7=8'"BVH.G8K9<IR#JA_.P#DB;*;@KZ?G]Q=,V^O%-HT7/F.([DR+IJ9#;Q[
MRP@=V,V:IU+[7I[5(HJ[[GZWF#,K1:K=IBR,E/,@ILUQEMI%.(>RP,B\[:79
M?3[:GM4:MNJDMI*E*U1NE+M;&0^)UB)<;%&"3S!;K3@,/KP_-J._:_\ 1=HY
MF4W*UIL8Q< R\F*I^1)W$F,22D^4XN*J7=9#PZLU(\"U< H9'#4RV'HB_P#I
MZ]2>CKY;MJKGIY<C3<R*Q)N.GM,'3%YT_?#'4N!=DVN7 M\YVT35=0^\"XTI
MGK:*CQPU,FYMON-J79364W3FJ67! 2\P-0VME2G&'H[Y4F'JC3WFYOQ9#8*D
M\U)2MES[QLXTKEH.GKS;[U AW6V3&9UNG,-R8<MA06R\T\CJ"D*' @FBDFA2
MH$$5& ="4E20I()K7W9TP 'E*/%"CV9TP!9R+P\*N?/V8 NY%X>%7/G[, G/
MQ.H@]*@,\OHI7/ );\0I\-%$D9FOY5P"4]!7X_ > ^W (TFV<?NSP[< V9EF
M4JM$*-,C[^ P#4FZ?4:]39/*OV8!&_RT?\$_UL1B#<0MZ ^X>DFK[OT]:N[C
M]6.EY49@@)24H.1->?\ (< =$4(X@YX#1GJ,U.YH;9G=+5T599E6#0>I;A">
M"NE3$Y-IDLPG4G/Q(E/)([\.3I,SHISK7S$-R?5=NH]ZFM27[2>I9S&GM(WI
MG3-JTJM];NFKPQ\XINZIO=LJ8MP-T#+P6\X%.()!201BWB\;,S=49^3TT>A;
M=V'>;%;=#.2%IL6H;6]JO;@27RMZVA)3_FS03BUFJG]-SU*7'23U*C*R%!BJ
M[BVG:*#M_*UQ'M>O]*V#4$34[<2VVB=J"&U<F['?HJGEQ8C34OKBLQ=0-.J;
M"@@*3+;;%?O,0)VNZ)TW8(!D::L6E-,*MY1,D2H.C;1(<5#B5>FL)CQHK4A2
MWHZ"$J02ZDCPU.6,]M4HYN^N'8:/(4BS:AU]JSRUN(%OTMMO?W6%+*E>$JD6
MR E:VU&G5U@5R)P^O!BKU@7&ZC_\1].N]^H$J!\J1<;99],PW*_ HNSK@^ZE
MLC,DH%,4>^XN=]5OM[C.H%6^GJDO *=/^G+36GVE4\I_6FXOF.M'DIR%9[8V
MH4'[KN//OW?AYQEIG!Y6^+@6<O7K4O50[J/930[:_B3;=,WC4DMGL6'[K</)
M=7_W8Q1_</!ZH_3>Z^-(\S0/J.O%5:E]4&K(K1S5'T9IG36FT))^/H>;@.RD
M)4#EXR1C)_<7I_ _3+UIJ3?3I$N/4=7[I;RZQ"LW$7C<.^M1G*YJ!B09,:.$
M$\@D8S?KW)SI(TSB63!/:]-&R4%?FJT+ N3Z:*^9O3\V[R'% ?$ZY<)$CS%$
M]HQD_5>5G9/M"LC;C0-I0&[9H_3D%**D?+6>"V1F"*%+/4"#WXGWWJ7_ )7Y
MU'EFV(UAJ"UZFVWU?;-Y]HF66-8:>9,2^:;0!&M6X&DNOS)VFKJVTE*%2DH3
MUPGZ>8Q(2DI- 0?0^V_<_;7_ ++;^*CD29V3?6YHGU4[7V77FAI:8E[9:E_A
M4B:GR)VG[TQ15[T/JV.@AUIH2T^4\DI!;6$2&J@#J^KES,]6')K; ;]7#:W4
M$G1&N6ID73YN*X-SA20MR5I"]%:$N24H2#YD![K"E]'@<94'V^(*M*U:[;9T
M:;'9?CR&I$=]MMYA]E:'&7F74)6V\RXA2D.-.I4"DI)!& 6NAOL5]/Z\!@8X
M3Q2H>_ %S'">*5#WX HY%X>%7/G[, GN1>'A5SY^S  .1O#3I5G@$J1$H2*$
M]0^BGOSP"2]"^/CP'+V]^ 19%O0KJ\)R'T\<O=@$_P##4?NJ^@8!U%FC[I\M
M63B^?:I7#LQ*\<;92!0I*:<,QG]'/ #K0 A7/+*HX?GQ"FVY0H]>"UH]*V_7
MD'[Q6V]\2FE110#"LLQR!QGY%OE0^5!%D?\ [ OSKY <D:XDNN*S_P#N%R"@
M>VBCCT.-=AZ!_2WJ.XVIFPVVVS/E9WS4#4NBIA5T,P-86YI(3#6M5.B'J:'U
MPWTG)14E7$8ZY.^@]#6@=66W<_0]GU5 0['1=HH3<(J5*:FV6^0W W<()57S
M(T^T7%LEM62DE*5@\,919OLKN YK[2R1='D'5FGW6K5J9"0$?,R VI<"^LMU
MRBWZ*GSA0=*'P\W7P8S7=2V$G3MG@*=7$M5MBE:UNJ<8@QF2XXXOJ6I1;;22
M237/GCXW[WZ7J<;ESF7N[O)/#-Q\GK?;O5[+?]TEOX,78R0:5%.U( !X94'"
MF/&\_==<W7XO8Q.D^1(>B(S"05=/?DJII09<J8R6W*,TFO1NBM$DTX4-.KAP
M[QCG$Z1!&E ^.J>D$"H[>//EC3B=&"VY-2=G7^CS]V)1FF;.)\69^'M]F.G%
MMSN:DQ8/54@43S/LQVY(GX?<KBHH@6VX3%*H$HAPY$E1/+^Y;4FN-'']+E9S
MB,MU)6WNW>^&T^Z3.N-OM$72Z:/UG.APMT=$2WX-EB36DD-QM:6<723&8C:D
MLJ5>,$@2V.IM53TD?6_;._E]^G+F.U3A)O?7:56LHG^:]+QD?YSM$;RG(J>E
MG_-=I92M8M+JE^ 7:(GJ5 =5P42RL^6NJ/4RHI$],?J11IE^'H'6<Y:=-2)'
MRMBNLSK9=TU.^94P[:;DE^CS$!,D*:6%45#>J" DE(TKEIL.8EQ*5)6E:3F%
M"A!!%0H$$@I4D@@C(@U& 5?,JE*LS6O$\*&F #J3Q). "\L<B??G_)@"BFT#
MD36O/]6 +.-I(H:Y\.[]. 3W$5%*YFN=.'\N (/,H\?L'VX!(>8 2I121495
M[L 4^77V'Z/UX \JOFO437[Q?^LK$KQQ ZB$\*Y8A1=W3R.E"LZ\L!#OU@VT
M7?8/>6W$%?S.@;^D(_>Z(H=4/ZK9QGY/\(^4%JF.JS;GZZ@*!0JUZONA0#E0
ML7EX*5W !TCVXW\53JNQ]/DI5VT78I;;JDR&&(RFW&E=*VWFTA:'$K&:5H6
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MQHW4DMT%MY"Z?+6*?**NFA2>F&ZHT(HTH_!CI>LPB2^J@)H1Q!' UY5SXC/
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MZP@LAG3UWE*"#J:$PF@A2'"?_K<-H9$T,EI((JL45TO6&Q)?53,"G=^84[<
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MCS&O#)8(KU4"SU)/ I4,97):\I/\[Z3@,E(00*5';7,8 ' %W&U94JKC7ZL
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MNW "' #!(_;)/9^5< (E/57.E/?^C 9>6.9/NRP'/*3VJ_K' =>0/W%_E[\
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M@.8#F Y@.BH)XUSP /AYJZ>SOP ?F)Y&OLP&> !4GIIG6N QP!? <P!? %\
M7P&.,Z195.M=.OXCPIVG&A PCIZTTZJUYTP!A/%7M^TX =OG[OMP!AOG[OMP
M F $;Y^[[< )@!&^?N^W "BO*ONK@._'_.^O 9HKG6O+C7OP&> Y@.8#F Y@
M,5=673[^'VX %SS,O?\ N]V **\WK->%,JT[3P[L!G&_8ZNU5:_Z7' &,!@Y
F\"O9@ %UZ%4K6G+  X#!=<J5Y\*]V "P!;%/S2+X?,!?[S'(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>v473641_img8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v473641_img8.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Y@"9 P$1  (1 0,1 ?_$ )\   (" @(# 0
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M^.,SZ<8 ^$3_ )?88 -(#TB6"=\CT^WW0#-*DF?A]A@(_#(&X'_T[O3M@(_
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M@N9;)V#JY2@'Y?/W?G 04D R..'#&7* 72WN!GSV0"D. ]@@'THW#'?.4O5
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M=YE+#WP%?E\_=^<!D>7S]WYP'K- @K>!Z9I$L98#'CZ(#V5*0H 3E+PC\_;
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M)2#B9P"\L<3OX?A '0.?N_" .@<_=^$!*0X#V" \/;TGPF6!GLY'ELP@/,
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M';4TE,IA(:6Y<7&_CBI5.DI2XT%]1D"#C/IG$[I=H@V@2&'AEACLY;9X0%T
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MVKZJ9G=?LTF:QL^JA+&? R],0R(?IF?U3V<H @" ( @" ("P^*73C+[#;Z(
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MSC?29:QTS:.59KQGYODC*OR[^]J[9XM&FE!VMZS)S575+%%Y=;E9^@MZ'7G
M NONE2ZW;J2C2D*4M2W4D)V#9'5'?US'G;X$]5HCP[/+Y6_;?=>T+LAT,T"S
M-\*G.&5\OOW'. M[R'Z-O,V8*IRYW&F9>; :J54WFH:==0 EY]"UB945*=-+
M4KBV[D<AG4L@A()G_=CALW$3C89"9C%(/L)^^ R$IGTR5-1E@1*1EQE 3"""
M#AM^VZ L/+; ,)/3,D?8RX0 4D 'C ,)GLX8^F9_I 1@,B ( G/; 07L]?\
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MA 1" #A,G[<H * 3C,'[<H!="=DYGE+9SVXP$X!#Q]25 I!2<9RQV2Q'. >
M$L9[MXES(WP"Z1,JWX"7V]$ X @" ( @" <SR]@_" 4 0! $ 0!]I[SZ3 $
M>WUF?O, R<-@]0Q]T!$3QF,-T!(;]GKG[I0"@" ( @" ( @" ( @" ( @" (
M @" 8)&R /ZX^CE * ( @" ( @" ( @" ( @" ( @" 8Y2]>R #S '(;(!>J
<?+#^I&P0![?7M]?. ( @" ( @" ( @" (#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>v473641_img9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v473641_img9.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ ^P)A P$1  (1 0,1 ?_$ -D  0  !P$! 0$
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MG<CE5LH1?<4P)[UK==&8RS4>22*J[!Z5,-'S'=HBHH'))&X$I/\ P+.=1_\
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M6(W-NH"T*L0"+I4#K5HNDV@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MC5FNN28D9!+H2BZEI(&E@G0CX>O6G-H.4T7ENW,Q?JO-[Q<*L -!<$GQ\;5
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M/_J$+]DC?J45KGQ-DN!5U0J* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#RK[D]MSDNYO.YZ
MPI:9O*\O( 400$N2E*T%[@"]4^6YGS]^I+YEQ7+7AH7[B_!H.+D1G5L@^F1:
MZ;7/G?J+5EP2YJEN4G3B=.85R&S'*1MLFPV@Z#30=+&U7]"U1+@:I[G2X;D-
M;:FT;71L)-AMU-S;2Y-53[C'NJL_&AR+F945IT,0VPE*;ZW!5?Q'M%:[+R$O
M=IJ9^)&22K6A+ARRE((64]-!<7\ZUALC(&IIVI%[WOK:]K"_XJK5K@"XM24N
M6*38C:+=+GQ-B/*JUEWLHXQ>K2,@AS_1(Z7N1?RMUJ_&3TU,24=71&41^3*C
MHMO"A\)O>WEIXUDJXK;YDRRUS:-$$SFMTJ!.A !!)(.A! -2^;:X%J=E.E-#
M7>5SSD@J4WN;N?S5J'CYT=]S]ZI6&,FM>)C:LADP;IE.6)) ).@ZC6Y)JSS3
MYN+XESE2T[B?^^<K8?I"1T_.\^NIO5WF?>4HN)4-93(J(W+)%E7&XCI]-5K+
ML;&C+@S)FN]7%!)V_#?I?V]>M785Y=>)"7$O+*7 -RW"0HC3<3H";^-K&]37
M$B^#\BO1*2R+DW5T.E]/#ZJN2E&"YE0QO?EHZE-(S-A\!M;0VTZ:$].M8\[T
MI4IH3A:<^.E"WMS'7G=^\V5<7-_'W^=6^:3XLR(6XQC1I,PKEL"1,:<](?$;
MZ#KH+$@C07\*Q;ZFZ*-=2Y'E@TTDJ,U_C>+94R$D!:05@E5_RW^&U6(8MSF[
M?O+US)CRZT^XW?QKC\MI*2Y>]CK?4?C)K=6;$;<>"J8%^]SM<KT-QXMM3+:0
M24J &AU)M8?3TK+7 PWQ+W]X<\Z/@1(OO*_(?A]%17$J1"0HW)\/(VJ5$"%3
MX/4E/MO^+36FG@*LI')C2!]K6QM>X%_Y:ME54H'LHE 4=Z>A%B-/LWJE43I4
M]!L<;X^"?.'%/UL(-:]\38K@5E4*B@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * XOY@&V^6\
MD59-U9F<3<#J7E5>4HI)$&G4L0?CHV?I6Q8))&]/AU\:DI1;HN)3E94*Y7 Q
M[+B=[92+DDJMMOH;GITJLFH\1RLYP[D\\:GN&-!<+B ;K4#?:H7^%-M +GVU
MBW<CDE2/"A=LX_/+U)<.!IEAUQUSU'"2HW5J;V!U K69$O4=5QJ9^BT7!%U9
M>M8C4V&ECU_.^H5"+HP7-B221MUU5X^733V5<YD5JBZLR=1N^'VB^BOH\ZJG
M7@5+DB2Y?X5>/E_2]IJI!SC1JNI-7(< -U>7@3X^RIQBU(QFRE62Y]I2NM^I
M'77H>E7E%O@1YD4RF=_4V]A2;:>VI<DNXBVFR<W&MMU201T(\;: >PU=6B(E
M2F,HG4  =?AO[NE52KHN);E)-47$G-Q+J&@.A_-(Z5=MQ<:U()%P0SL1:P'M
M&AT]]7"1$ITBP'N.A/LH"F4IVYVE1O8"]SUMYU;DU-4CQ*Q=&0-0UO+LK=<=
M!M)N3YG6^M0Y)%7.$>+,CA8FUMP23<:%)]]ZDK4WJBS.^^:D?A*UW#M.;@I"
M?JMT]AZUD1A-4,5WKK='P*Z)AF6[*0A/@+;=+>.A%JO\K*-HR-AA#:1L2+]%
M:6]GC:I)4(EP90JW3W:CI?7\=2*$X@CK5*HJ?-^W7Z/'^2E4"G<D*O\ "= 3
MTT_'46Z@I7''"+I*KW&A)/X^E4!0K0^Y8*N+'30F_P!1TJ+3:H3JB?&QAD&S
MFZYO<!*A86/30^%6N27<5YD>BV/&V!"3_1B1A]3*!6(^)L5P*NJ%10"@% *
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M8W%K6]_E4X2E*5'P*-<VCX':D+^IQ/V9C]4FL)\6;>/PKR*FJ%10"@% * 4
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M/EI5&J F)1T)\#<@CR/0^^J UWW)[M<$[4PFI7+\PW&D2D[X.(C['LG,05;
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MS;=)U\#I^!H8K;:U9W) _J,/]DC_ *E%:F7Q/S.AC\*\BKJA44 H!0"@% *
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MQ^I,?+Q[[M>[FX-_T;\=.92:4HM/CRRBTXO@]::IEKY1VDRD,K<CHD1W!\0
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M=U7PIWG3X?3B;C"$.9N*:4?>^S0U_P @Y[Q^25(Y#RME#SB4)^Z8&.,C-90
MFZ59!YUB"EQ"AU1ZR?(FN[VSZ?YF99]3=LJ,(]L8*KKV:H]1V3Z2[WGQAF9'
M]&RU[OO*M/%<48HF;VMR_JER1S%]?I?II3F9@0DH0 E(4\W&Q12VWMU45+MY
MFNGL=!;#!)7I3N->/*_OXG9V?I'8QYQC=N2N7)?;2GC]IJ =HNSW+L\8/"^8
M\J3G' $K:@S/[T)0T5J79V- QKSR6D+4;*7Z: G3=:MM;^G>U9C?RD;T()?$
MTW]Y?RN@]EVJ'S%R=QY"XP4J>6GB;K3\AB'\%+R@^9?@>)RS,20]&P?+L%*A
M(E2FF5.1\=(F<>SN>F8Y3[EFRZY#(03N4FP-<]N7TWN8S?RUUMOA5TKW5[O'
MN/+<K=-PQ-P^5P=LS;MMW*<U'3EK\4:Z2TU7><.(P'+\-DW(F8Q,^!*;D*87
M:[T=10H@^C)94XVZP-OPN7LM-B.M<!N>R9NWP:OVVFN+6J]J/;=LV#=<>U9N
M9EK^A>C6-&I/P4DM8M]S.L^SG8;NEW@R$;$<-XKF<]+=6 Y]T86F+%:"DA3V
M0R#H3"@,HW74MY:$VO8USF'M>X;E?]# MRE=EHG2B7F^"-/UEU#TAT/M]S,Z
MLR8XD8)M1YUZS:[(VHMSDN%7332O$_1Y\H'RAXOY=,&K+Y^3%S7<;*Q4LS94
M,ES&8&*M/Z;'XYY:4N3)3O1Z1M2DBZ4#:2I7M71'0-CIV<\_<6KNXW%IV^F^
M],_-7ZY?7B]]4;L=BV>#QNE+>K?YKLX?"Y1XZ^/ [-=3M5>UMU^GD.GY:](5
M>UZ]_P#$^=N=.%/S4+%R;E/'^$\?R/*.4Y2/A\%B(ZI,Z=)-DH3\0;9:1HM^
M3)< 0TVD%2UFP\2,7.S+6W8LLS)I&$/YM*^*7;]AE[9M&X;WFV]LVVV[N1>D
MH^[KR)\9-]G*>$WS0_-3R3O7*GXO#..8GA..=<_<^##@3]X]$_#/S!0L-RIT
MD>!NA@':C2ZE?.W4O66;U#DRQ^9QVZNB_F\UX?Q/N3Z=?2[:^A[=I9<%D[U)
M1<KDN,/!/MXU^P\C^=]RY06<#C&YTO.9"0U#B0(;:E3'9JU%#++49 W+=*E$
M >6ITK21LVU;4E\'^A[]:MV(<MSF]R''O^SO-C]INV,[B/W^?R\MR^4Y$(5+
M:+J'FL0TZGU_W:W)"MCSR[A3RD:>HD)!(2"<2]%S:Y>"+6[;JL^W'&L-QL1:
M:\?^)D/*L[C\<PZAN5Z3NQ905&P;L=$J4+_"!U/A4>21/;L:YS0G."E"OL\7
MW)=YOCY:NWSF!F1NX?<*'$3C98BR,/A,@'OO>0"93,M$J>RTXR]%@/EE)]$J
M2Z\V=0A*KF[C9E_;LB.19Y/5CPYE7V/L.<ZW6%O^/<V7&=R,VTIS@Z+RK^:O
MAP/;WM'\V>'RV8@X;E\A#./E+9B,R(,*'#:AI^%EE+,>,E"$,L@@)1J   *[
M_9_J)N<\Q0W"4?2=$DM(Z::'S;UA]$,&.S7<C9[<H7HK3ME7M;\WJ=S+<A+=
MD)@3XF38COEC[Y#<#C2U>DS(2E0!467@Q(05H.J"JQKVO"S;&?C1RL=\UM_O
M/E;.PLG;9O&S(N%]55'\6FE6N[Q/@( 5?^B:S#6/@=RP/ZC#_98_ZE%:F7Q/
MS.AC\*\BJJA44 H!0"@% * 4 H!0"@% * 4 H!0$"CT'O)JCU6G$>7$_,K_S
M%OS<Y+B/;+A'R?<)RAC9/NJTCGG=PQ'RB0.WF$R7H\7XK(+2P4,<OY3$7(D)
M4!NC8K8;H?-][L>!\Q<=^7P1_>?>'^$?TLAOG4N1]2MSM<^#M5R-K%B]*Y4J
M2=U5I56K>G_:N+M1^-L0U1W%J60H[];&X%S< J(W*)/C7K&))>BH]RH?M/L4
MH6L=6Y.K3;<OYF]7[.!T7VJQK4B;'<=+?I)V*^T%*N3H;C3QTJSF7Y05(FYS
MMQ<+2LVWJCUY[(<-QLN/$)9;(.T 6NH7 ()O8G=8V\+^%<1GY$XUYN)X%U=N
MV9&3C*5=.'[:';$+M7A<G!=@3H+$R'-C/P9D=QH>A*9D-EF3%<WI%T.,N*2>
MNE:I9-Z,E<MRY91=?/P/(<OJ>_BWHW+<N6Y&2=?Y::I^T\A>X_ IWRW_ -^>
MS.;*(V/[>\D3\S_RL\DR3H;8DQ,=+8C]W.TC<ETI3OY!Q9TR&HP/QR\>-+NB
M_18V3'+MOE5)78\MSPBO>>OFWHJ]NA[/L>Z7.J<K#ZIVA2N2S+<=LW2W!2E*
M-RXY2Q,QQ2?-Z4N:":K17:MJ,6>AN6[7X+F/&,/RG%L(,#D.'Q^=A+4C1<;*
MPF9L=0(*A9*'1IKJ+5J;>=<QKCM2T473V</N.&Q>HLW;\^]MMR2E>Q[L[;U7
M&$W'[J4/-;YC^QR6\=-=1%"'&PM2'6FS\+B25[U*0C<+$D7T&I'A>NBVG<N>
MEJXZ*3/:>D>I[=R4;.0U*VWK'^9:UA_]?PZ]^IZ&?\OE\_&7[<=Y)_R.]RLR
MX]P?N7)R.5[3NY"0HHXKW(C,/3,AQZ&IU=FL9SF!&6I+21M&481L&Z2X3I>J
M]M4;OSEA5_F\%V,^#O\ Y"?H7AYF!;^K?35AK<\6W%9U&O?QY45N7_:QFXVV
M^V#TJHH_9_7$GY""@% * 4!C.6R"GU.X^*I00FR)LAM121?4Q65BQ]0C[9!^
M$:=>@%O0H(;#2$!" -H'B -.H/LH#77.^=L<1CMQ8J$2LU):+K+3ES'@1A<?
M?IVT@E*B"&F@07% DD)!-4;2XE4JG'\ON_S+,\R1Q3MQP9ONOW8FP7,H'.1Y
M5.#X'P+CR9/W(<DY5ES&F-XF [/"F8D6+'DS9KK:TQV%):><;M2]^7NZLDG1
M:EMY#\M/S?=Q"9G,/F2[8\6=<)7^Z.%]KN49N%#0H7$=C*YGFV >>#?3<(;.
MX:V'2CM7>#G1=Q+F1B''?X=W.'>88#E'<OYL>=<IPW',OC\\QQ#A'!\)P!F;
M.Q4UG(0QD>43,URW.-1$R&$^H(@BNK1H'4DDU6-E6GSN=5W:CF39Z3N)6HJ<
M4D$+4H[DD%!-R38@J%OIJZI*7 D43C6Z^W3IY6^JJEN46WH2HLN9C9'JPGE-
MJU]1M1*H[P!U2MM7PW]O4>!%4*<K6IM'#95O+PDRD#8XE:F)#6I]*0V!O2">
MJ2% @^1H1+M0"@% * 4!YK=QV2>?\S(O\7(\H=$^<A7MUK:6G_3CY&ON3I<D
MJ=IA@:4#>Y_Z)_GJ9;<JJA$&E]1NN/$ _EO0@530.EQTT)MU('6@*D:V)_I&
MX/O&OTT!,*0>AL/(=+_70K1O@1+4Q#8<E2WFH\9M.YV1(6AIEH#^DXM03=1.
M@\:C=E''AZE]QC;['4E8C\U<5K&4IS?AH:([@=\XO'XTR/Q&(SF)\=O<N<^X
MA$=E)-BY%A+*7)I"02E2]J#;HKQXO>.K[-F#Q]L][)I\5:?92G9YGHNQ_3R>
M=<A<W>L(U^"E=.QUJN/=0X<YQS/+\PDOY#,N2<A.;;7L6^XY(2A8W+1'1$#B
M&HS"D[B A"+*M;V^6;CGYVXW'+-FW+FK1/M/<]CV?$V-*W@VX^FURZJNG#]Q
MI3-,Q)2X4U*'<>^A>UPL'[LE025*2XELK6E2]1<D:&_LK =NW\44U<[Z^T[#
M$2A*5N23M-:+A0RZ#->A+@SY#7[U8-EO/RVON\U#*2&O2$F,L.*9-K:J3M4;
M[>JADVKO).*4:][+4K7J2G9K6,U\+54_!FH_G@5B<CV<B]RLGFV$X/M[(9.)
MY3D]IY=P>3D'D(1QF>\N2)O(N(\L6$^BP/4DPY8"QN25+K89F-DYSLPQZ2LR
ME1JFL?&O:;?Z?8>5E;_<V;&LQM;A=C50BJ6YVH_$_P!,HKCQYGW'B8Q\P4C/
M)FQN+07,'QR0^Y(G/R'?^*<CEJ*0J;.V )CL+7\34-NS30-R%+*EJ[';<6QM
M%MVL>,?5;]Z35:]_E74^R>C^E]LVS$C?A#GN533?9W::^PPO$=Z.#9#DV2XO
MF^2O\/S#*TMQ,CRC%36.,3U.)O?]\0E39,%C>;>N[%+'BI:4@JK;V\Z*DHUI
M!NG^AZ-C;[AW)2QKC7K0JU%*FBX_\"7W!;S2<TSQWF$C/8D8Q<3)G"Q,FC]S
M9F+.B-2\3E_7QSS\+/8;(07TOQ)#+KD=]E84VH@FLRY&_:R8N^N6FL=>-:/V
M<*<38X<MLWB$,RQ.4H1<E[KIK6C3?>FFFFJIIIFVN#<]:@-1L5 <$#'H"$_<
MX(3!BN'X4I2Y'C!M+I!'584?;77;=G7;TU9E<FK4U2D72E.W[2N3@8EM>Y;C
M)UXS7,_*NFAW]VCEHR;L1M*T@+(6L;KM#>F]B!\)246OXWZUT_\ M=Z:2Y>>
M"[>VG>SRKJ[=;F!:E&Q/ENJM&DE2E:)+N7F>@O'NRO#N;Q&6,SBH4Q1 2IU#
M:0^ N^XAQ%E'[7T7K0;EA*VG!V[;@_YHU1\\[E]3^HM@O.>#DW'[R;4G5/OT
M[#NSL?CN2=D\.UQF$M?).W+04N+AEQH;6>X\%+*W7,;DVDQUYF'91_U:<IQQ
M-[-/(%D5SF+<6W7%&$+,8.M>6%&^[77AJ?,GU)VC8_J-N5S?[-J.-U2T^::G
M<G"X_P!5N4^6+T?PT6NJ.Q\7E,=FX360Q<MN9%>N M 4E;;B;!R.^RX$O1Y+
M)-EMK2%)/45N(?UO>LI4[=>'VGR_NNV;AM.2\;=+=NQDK113TEW26FG-Q[>)
M9.9<KXYP7C^0Y5R[+QL)@<5'7)F3Y:MJ D6"6([85ZLF4^NR&VFP5K4;#SK#
MS\W#V_'G=W"<;4(P;I)\KDDJTCWU["6R[)NO4.X1VG9+5R]N<I)>Y%RC"KHI
M2EPHN+\C\_'S6_-_DN\^6DX^(N3A>"8N0Z,%AO53^F%BV,IEO244/Y.8VDD:
M%+*"$(TN5?.G5/5&?U1D-2G)8-I\L$M-/'O/T)^F_P!*=L^GVRVLFY"+ZBO1
MK<FXUY6^*2J^.G:>9/-NZXQ41]K'2#O<4IEQT+NXA:B1T!*KFP"=+^0K18V%
M&,>9ND$=Y<2NW>=ZW>V7X&QNR7:UZ"EOGW*HWK<VSC"OW>PY<_W8Q4E.XM#?
MTS60:5N>/5E)#8(^,*AE7U&;M6_A7:8^1*XI*W"6BX^)L?GDQ&&B_>6I.R4V
M=KS!(W2+)LD)20H!Q"A;<5>)!J$9UHC+Q,:=^Y'T]=5^\QGMMP69GGF>;<IB
MK^Y?>%/\?Q,D>HU-<2Y<9*2A82AW&QW$_HTJ^%]P7U0!NCD<WI^[QJ;K<,V6
M'CO"QFE=DJ2?'W7Q7F^\Z(RV?D%MI#LA:P!N&W0_$H@$:FVHOK6+&%V6K.=L
M6X652U[MM=^K]IEG ,-S7GG(\)Q3A*91S6<FLQ(SS&XO-D*O(>9<6"EKT$I*
MUO+!:CMI4X;[ D[K9.FLW?,^%NRFX?N^TY'K3KG Z7VJ_/(G%W&E2/?H?H>[
M7\!B]L>"X+AL>?)RS^/9=D9;,2WW9$G+YN>XJ3E<DZZ^MQ]29$I9#>]16&DI
M!UKZ;V;;;&S;<L"TJM<7XGY[]1]09/4>^7M[RDE>N1<:+@H]GVT,\5]E7N/Y
M*V)H'P.YX']1A?LD?]2BM2^+\SH(_"O(JZH2% * 4 H!0"@% * 4 H!0"@%
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M0=,]3;QTCOF'ONPWG8W/$I/U%^>47\+\)1;BV]*-U/YVWS/_ "X=P_DP[_\
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MG?@@STI@2U&P0D.K"XS]SU4U(M?R2HU4OF?Y& ,CBG&0I/WR ?O,0J 6E8;
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MQ[2/_P!-  N=3J2>G47OI0%6AA%]?.]@#I]'D;4!/LD?"+)M?H+WZ >/A[Z
M^#Q-QY 6^@W\* B2BXTT%];>= 30 -!0'V@% * 4 H!0"@/Q=_.GR$1?FL^8
MV*Z^X$H[P<YV)"A^;E70$V OM%]/*OGSJ"%S_?,MKA\Q/]Y]M=%I?^D=L_\
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MH_\ YA0$VYL3<D6 /2_4^&IUO0$'X=3]'D* ^W-[W/AH![=.E 1;5'V>.O\
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M0I7V0==NMM/M:ZT!4M)_,\; 6U\!8^V@)A-AT)L   +FW0:"A)3DE1$E1O\
MCM_EH7E"+57Q9/8UW>RUOI)O0C.,5&J*M)'57AHGZ>O3W4+)&% Z _EH"*@%
M * AL;DWMT ]WC0!-[?%J;GZO"@(J C40K;;\+VH#[?:FU_B'\]_'V4!"2/S
M?&^[\#0$- 0+OM)!M8&_U>Z@/J0  ?$@4!](!M?PZ4!\5]E7N/Y*!\#O;'_U
M"#^QQOU**U+XOS.@C\*\BLJA(4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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ML>I]] ^!WC _J,+]DC?J45J7Q?F=!'X5Y%75"0H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M.5N4]H.99CD><RD/]T_=,AE)<R-ZL]QMWTGG5+1ZB!$4$KL=1<UFPOVXP476
MJ1KKN/?E-N-.5LL'^!O.O+"_^).?V.I_,VO'V%GY*_X>TG#LASBP_P#Z7H/_
M &B[_8ZI\S;\?V^T?)7_ -/M_ 'L?S<Z']S?^(N_V.GS-OQ_;[1\E?\ T^W\
M"8GLES5(L!AN@_\ :+OA_P#Q*?,V_$?)7_T^W\ .R?-[:_N:]_\ W@YTT_\
M4Z?,V_$?)7_T^W\ KLGS?\W]S :]<@Y]'_4S3YFWXCY*_P#I]OX =D^;VU_<
MQ/\ W@Y_8Z?,V_$?)7_T^W\"/_!;G &G[F]G_$'/['3YFUXCY*_^GV_@??\
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
K% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>v473641_img10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v473641_img10.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ LP#M P$1  (1 0,1 ?_$ +    $$ P$! 0
M       %!@<( @,$ 0D* 0$  P$! 0$!             0(#! 4&!P@0  (!
M P,"! ,$!@<( @(#  $" Q$$!0 A$C$&05$3!V$B%'&!,@B1L4(C%1:AP=%2
M,U:6\&*BTD/3)-;A<O&"8S1$$0 " 0($! 0% @4$ P       0(1 R$Q$@1!
M41,%82(R!G&!D3,40B.AL5(5!_#!T7*"0R3_V@ , P$  A$#$0 _ /W\: -
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MN0!UW.,3@+KV%Y!?VEO>6T@E@NH8[B!^G*&90\;$4%#0[CJ#4:P).S0!H T
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MFOV"GA]^IA!QS-*#FP!5;66!MJQMX;#EM0:F<=2P#.!))A<PJLG )*4JM:D
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M#,E0HM?WC(14$^JK@JXH=='3?@8ZD?2'LGM*Q[?L88(8A%Z2*H55"T"@!0*
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M!T&@#0!H#PJ*'8?HT!RR6R25+@$4W% ?OW'70"'>]O65[7FB^0'!:4_0=]]
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MBT?Y:I1)?=R!0[!;3$KTH.1GR)\2*UW.K$%R.=  5;8#R\O_ +: /4']UO\
MA_YM 'J#^ZW_  _\V@#U!_=;_A_YM 'J#^ZW_#_S: \YK_</Z%_YM !D7Q5M
MO@O_ #: U_4Q+'ZM#QI78+7]'+6BMR<M&%2BNV'#JZX='^JN'U-HD7P%*_\
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M(!_F7OE=N@[RS9 ^]K@DZ ]_D&W_ ,S=\_ZQS7_?T ?R#;_YF[Y_UCFO^_H
M_D&W_P S=\_ZQS7_ '] '\@V_P#F;OG_ %CFO^_H _D&W_S-WS_K'-?]_0'A
M[$MU!'\Q]\/4&E>\LV#TZ"ER!^G0?S*BXKWKQ?<^?N8NR.QOS(=^=AX[NN3L
M>\]S>V,U'+VS-G;/)28;,3X;'Y+N>Q[G[F[<P&4BDAOLE98^:TB:&0JTBQL1
M[5[L_0V2ZEZW&^\=.KS+X\GX'W5_V5^!8@^^=V[5M.]W=L[Z[=<HI*VH=1*<
MTM%NY<AC;M3DISPHL4/_  GN;[3W';=WW5W'[D]Q]@X:#OOO#V[M[KOCW*;
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M%QDK4[DI6HN+E/32#BG'7*CKYI9N<M^-/&G]-/[=<6%? ^7P^1[J &@#0!H
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L@#0!H T!SZ - ;(_'[OZ] ;- &@#0!H T : - &@#0!H T : - &@#0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>17
<FILENAME>aytu-20170630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 2.0 on 30-Aug-2017 [07:46:22] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:aytu="http://www.aytubio.com/20170630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="aytu-20170630.xsd" />

<!--Context Section-->
  <xbrli:context id="P02_01_2016To02_10_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-02-01</xbrli:startDate>

      <xbrli:endDate>2016-02-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2017To02_28_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-02-01</xbrli:startDate>

      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_06_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2014To06_30_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>

      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2015To08_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-08-01</xbrli:startDate>

      <xbrli:endDate>2015-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_15_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-08-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2016To11_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-11-01</xbrli:startDate>

      <xbrli:endDate>2016-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn05_20_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-05-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_20_2015_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_JazzPharmaceuticalsIncMemberusgaapBusinessAcquisitionAxis_ProstaScintMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:JazzPharmaceuticalsIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">aytu:ProstaScintMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-05-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_20_2015_CustomerContractsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_JazzPharmaceuticalsIncMemberusgaapBusinessAcquisitionAxis_ProstaScintMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:JazzPharmaceuticalsIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">aytu:ProstaScintMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-05-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_20_2015_JazzPharmaceuticalsIncMemberusgaapBusinessAcquisitionAxis_ProstaScintMemberusgaapProductOrServiceAxis_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:JazzPharmaceuticalsIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">aytu:ProstaScintMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-05-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_02_2015To10_31_2015_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-10-02</xbrli:startDate>

      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_02_2015To10_31_2015_PaidOnApril12016MemberusgaapStatementScenarioAxis_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">aytu:PaidOnApril12016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-10-02</xbrli:startDate>

      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_02_2015To10_31_2015_NoLaterThanSeptember302016MemberusgaapStatementScenarioAxis_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">aytu:NoLaterThanSeptember302016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-10-02</xbrli:startDate>

      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_02_2015To10_31_2015_NoLaterThanJuly012016MemberusgaapStatementScenarioAxis_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">aytu:NoLaterThanJuly012016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-10-02</xbrli:startDate>

      <xbrli:endDate>2015-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_05_2015_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-10-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_CustomerContractsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2016To04_28_2016_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>

      <xbrli:endDate>2016-04-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_28_2016_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-04-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ZertanePatentsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ZertanePatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_OrpMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">aytu:OrpMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_OrpMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">aytu:OrpMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_StockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">aytu:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ManufacturingFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_ManufacturingFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_AmpioMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:AmpioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_AmpioMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:AmpioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2014To04_30_2014_VyrixPharmaceuticalsIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>

      <xbrli:endDate>2014-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2014_VyrixPharmaceuticalsIncMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:VyrixPharmaceuticalsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_AmpioPharmaceuticalsMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:AmpioPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2015_AmpioPharmaceuticalsMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:AmpioPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ManufacturingAgreementMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:ManufacturingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_PrescriptionDatabaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:PrescriptionDatabaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:NatestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_PrescriptionDatabaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:PrescriptionDatabaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2015_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_30_2015_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2015To06_30_2015_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-06-01</xbrli:startDate>

      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2015To08_31_2015_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-08-01</xbrli:startDate>

      <xbrli:endDate>2015-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aytu:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aytu:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2015To02_10_2015_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aytu:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-02-01</xbrli:startDate>

      <xbrli:endDate>2015-02-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aytu:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_06_2016_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aytu:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2015_LuoxisDiagnosticsMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LuoxisDiagnosticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LuoxisDiagnosticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LuoxisDiagnosticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LuoxisDiagnosticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LuoxisDiagnosticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2016To02_29_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-02-01</xbrli:startDate>

      <xbrli:endDate>2016-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_31_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_29_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_31_2016_ConvertiblePromissoryNotesMay2016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:ConvertiblePromissoryNotesMay2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_ConvertiblePromissoryNotesMay2016MemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:ConvertiblePromissoryNotesMay2016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_31_2016_InvestorsWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:InvestorsWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P06_01_2013To06_30_2013_AfterAmendmentMemberusgaapRelatedPartyTransactionAxis_AmpioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ScenarioPlanMemberusgaapStatementScenarioAxis_SecondInstallmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aytu:AmpioMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">aytu:SecondInstallmentMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:AfterAmendmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-06-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2014To03_31_2014_AmpioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FirstInstallmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_ScenarioPlanMemberusgaapStatementScenarioAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aytu:AmpioMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">aytu:FirstInstallmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-03-01</xbrli:startDate>

      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2014_AmpioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ScenarioPlanMemberusgaapStatementScenarioAxis_SecondInstallmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aytu:AmpioMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">aytu:SecondInstallmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_05_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-05-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2015To05_31_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-05-01</xbrli:startDate>

      <xbrli:endDate>2015-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LuoxisDiagnosticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LuoxisDiagnosticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LuoxisDiagnosticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LuoxisDiagnosticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_31_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_31_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2014To06_30_2015_LuoxisDiagnosticsMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LuoxisDiagnosticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>

      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To01_31_2017_ThirdUpfrontMemberusgaapBusinessCombinationSeparatelyRecognizedTransactionsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">aytu:ThirdUpfrontMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_28_2016_NatestoMemberusgaapBusinessAcquisitionAxis_SecondUpfrontMemberusgaapBusinessCombinationSeparatelyRecognizedTransactionsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">aytu:SecondUpfrontMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-04-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2016To04_28_2016_FirstMilestoneMemberusgaapTypeOfArrangementAxis_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:FirstMilestoneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>

      <xbrli:endDate>2016-04-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2016To04_28_2016_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis_SecondMilestoneMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SecondMilestoneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>

      <xbrli:endDate>2016-04-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2016To04_28_2016_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis_ThirdMilestoneMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:ThirdMilestoneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>

      <xbrli:endDate>2016-04-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2016To04_28_2016_ForthMilestoneMemberusgaapTypeOfArrangementAxis_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:ForthMilestoneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>

      <xbrli:endDate>2016-04-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2016To04_28_2016_FifthMilestoneMemberusgaapTypeOfArrangementAxis_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:FifthMilestoneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>

      <xbrli:endDate>2016-04-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_MinimumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_MaximumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_MinimumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_MaximumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_MinimumMemberusgaapRangeAxis_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_MaximumMemberusgaapRangeAxis_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ManufacturingFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ManufacturingFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ZertanePatentsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">aytu:ZertanePatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_31_2016_EmployeeStockOptionMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_31_2016_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_31_2016_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_TwoThousandFifteenStockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2017To02_28_2017_WarrantMemberusgaapFinancialInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-02-01</xbrli:startDate>

      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_WarrantMemberusgaapFinancialInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2017_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_BankersWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:BankersWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2017_BankersWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:BankersWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2017_BankersWarrantsMemberusgaapClassOfWarrantOrRightAxis_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:BankersWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To03_31_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_AmpioPharmaceuticalsMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:AmpioPharmaceuticalsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2016To11_30_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-11-01</xbrli:startDate>

      <xbrli:endDate>2016-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2016To11_30_2016_OverAllotmentWarrantsMemberaytuOverAllotmentWarrantsAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:PlacementAgentWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="aytu:OverAllotmentWarrantsAxis">aytu:OverAllotmentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-11-01</xbrli:startDate>

      <xbrli:endDate>2016-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2017_May2016WarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:May2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2017_October2016WarrantsMemberusgaapClassOfWarrantOrRightAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:October2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2017_BankersWarrantsMemberusgaapClassOfWarrantOrRightAxis_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aytu:BankersWarrantsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2017_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2016_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:NatestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2016To10_31_2016_FirstInstallmentMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:NatestoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:FirstInstallmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-10-01</xbrli:startDate>

      <xbrli:endDate>2016-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To01_31_2017_FirstInstallmentMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:NatestoMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:FirstInstallmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_20_2016_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aytu:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-01-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2016To05_31_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-05-01</xbrli:startDate>

      <xbrli:endDate>2016-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_31_2016_LincolnParkCapitalFundLlcPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:LincolnParkCapitalFundLlcPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2016To06_30_2017_LincolnParkCapitalFundLlcPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:LincolnParkCapitalFundLlcPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-10-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_LincolnParkCapitalFundLlcPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:LincolnParkCapitalFundLlcPurchaseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_31_2016_DirectorMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2016To08_31_2016_ExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-08-01</xbrli:startDate>

      <xbrli:endDate>2016-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2016To11_30_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-11-01</xbrli:startDate>

      <xbrli:endDate>2016-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2016To11_30_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-11-01</xbrli:startDate>

      <xbrli:endDate>2016-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_30_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_30_2016_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_30_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_30_2016_OverAllotmentWarrantsMemberusgaapDebtInstrumentAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aytu:OverAllotmentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2017_May2016WarrantsMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:May2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_28_2017_October2016WarrantsMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:October2016WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_05_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2015_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2015_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_LincolnparkMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:LincolnparkMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_AytuBioscienceIncMemberusgaapStatementBusinessSegmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_AytuWomensHealthMemberusgaapStatementBusinessSegmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_AytuBioscienceIncMemberusgaapStatementBusinessSegmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_AytuWomensHealthMemberusgaapStatementBusinessSegmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_AytuBioscienceIncMemberusgaapStatementBusinessSegmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2016_AytuWomensHealthMemberusgaapStatementBusinessSegmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_AytuBioscienceIncMemberusgaapStatementBusinessSegmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_AytuWomensHealthMemberusgaapStatementBusinessSegmentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_FirstMilestoneMemberusgaapTypeOfArrangementAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:FirstMilestoneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_SecondMilestoneMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SecondMilestoneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_ThirdMilestoneMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:ThirdMilestoneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_ForthMilestoneMemberusgaapTypeOfArrangementAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:ForthMilestoneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_FifthMilestoneMemberusgaapTypeOfArrangementAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:FifthMilestoneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_NuelleIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2017_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2017_CustomerContractsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_MinimumMemberusgaapRangeAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_MaximumMemberusgaapRangeAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2016To10_31_2016_NatestoMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-10-01</xbrli:startDate>

      <xbrli:endDate>2016-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_31_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_31_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_11_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_11_2017_ClassUnitsMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:ClassUnitsMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_11_2017_ClassBUnitsMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:ClassBUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_11_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_11_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_11_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-08-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_CustomerOneMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_CustomerTwoMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_CustomerThreeMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_CustomerFourMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_CustomerOneMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_CustomerTwoMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_CustomerThreeMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_CustomerFourMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerOneMemberusgaapConcentrationRiskByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerTwoMemberusgaapConcentrationRiskByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerThreeMemberusgaapConcentrationRiskByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerFourMemberusgaapConcentrationRiskByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerOneMemberusgaapConcentrationRiskByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerTwoMemberusgaapConcentrationRiskByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerThreeMemberusgaapConcentrationRiskByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerFourMemberusgaapConcentrationRiskByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_CustomerConcentrationRiskMemberusgaapConcentrationRiskByBenchmarkAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_CustomerConcentrationRiskMemberusgaapConcentrationRiskByBenchmarkAxis_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To01_31_2017_AmpioPharmaceuticalsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aytu:AmpioPharmaceuticalsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_CustomerConcentrationRiskMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_CustomerFourMemberusgaapConcentrationRiskByBenchmarkAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">aytu:CustomerFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aytu:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ProstaScintMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">aytu:ProstaScintMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2015To06_30_2016_ProstaScintMemberusgaapProductOrServiceAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">aytu:ProstaScintMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>

      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To06_30_2017_CustomerContractsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2017-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_SixthMilestoneMemberusgaapTypeOfArrangementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SixthMilestoneMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-05-01</xbrli:startDate>

      <xbrli:endDate>2017-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_15_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-08-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_15_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-08-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2017To08_11_2017_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-08-01</xbrli:startDate>

      <xbrli:endDate>2017-08-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn08_11_2017_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-08-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="CAD">
    <xbrli:measure>iso4217:CAD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="CAD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:CAD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P07_01_2016To06_30_2017" id="Factid_1">10-K</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P07_01_2016To06_30_2017" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P07_01_2016To06_30_2017" id="Factid_3">2017-06-30</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P07_01_2016To06_30_2017" id="Factid_4">2017</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P07_01_2016To06_30_2017" id="Factid_5">FY</dei:DocumentFiscalPeriodFocus>

  <dei:EntityRegistrantName contextRef="P07_01_2016To06_30_2017" id="Factid_6">AYTU BIOSCIENCE, INC</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P07_01_2016To06_30_2017" id="Factid_7">0001385818</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P07_01_2016To06_30_2017" id="Factid_8">--06-30</dei:CurrentFiscalYearEndDate>

  <dei:EntityWellKnownSeasonedIssuer contextRef="P07_01_2016To06_30_2017" id="Factid_9">No</dei:EntityWellKnownSeasonedIssuer>

  <dei:EntityVoluntaryFilers contextRef="P07_01_2016To06_30_2017" id="Factid_10">No</dei:EntityVoluntaryFilers>

  <dei:EntityCurrentReportingStatus contextRef="P07_01_2016To06_30_2017" id="Factid_11">Yes</dei:EntityCurrentReportingStatus>

  <dei:EntityFilerCategory contextRef="P07_01_2016To06_30_2017" id="Factid_12">Smaller Reporting Company</dei:EntityFilerCategory>

  <dei:EntityPublicFloat contextRef="PAsOn12_31_2016" id="Factid_13" unitRef="USD" decimals="-5">10500000</dei:EntityPublicFloat>

  <dei:TradingSymbol contextRef="P07_01_2016To06_30_2017" id="Factid_14">AYTU</dei:TradingSymbol>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn06_30_2017" id="Factid_15" unitRef="USD" decimals="0">528039</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:AccountsReceivableNetCurrent contextRef="PAsOn06_30_2016" id="Factid_16" unitRef="USD" decimals="0">162427</us-gaap:AccountsReceivableNetCurrent>

  <us-gaap:InventoryNet contextRef="PAsOn06_30_2017" id="Factid_17" unitRef="USD" decimals="0">1312221</us-gaap:InventoryNet>

  <us-gaap:InventoryNet contextRef="PAsOn06_30_2016" id="Factid_18" unitRef="USD" decimals="0">524707</us-gaap:InventoryNet>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn06_30_2017" id="Factid_19" unitRef="USD" decimals="0">310760</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn06_30_2016" id="Factid_20" unitRef="USD" decimals="0">215558</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <aytu:PrepaidResearchAndDevelopmentRelatedParty contextRef="PAsOn06_30_2017" id="Factid_21" unitRef="USD" decimals="0">0</aytu:PrepaidResearchAndDevelopmentRelatedParty>

  <aytu:PrepaidResearchAndDevelopmentRelatedParty contextRef="PAsOn06_30_2016" id="Factid_22" unitRef="USD" decimals="0">121983</aytu:PrepaidResearchAndDevelopmentRelatedParty>

  <us-gaap:AssetsCurrent contextRef="PAsOn06_30_2017" id="Factid_23" unitRef="USD" decimals="0">3028562</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn06_30_2016" id="Factid_24" unitRef="USD" decimals="0">10120227</us-gaap:AssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn06_30_2017" id="Factid_25" unitRef="USD" decimals="0">647254</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn06_30_2016" id="Factid_26" unitRef="USD" decimals="0">231430</us-gaap:PropertyPlantAndEquipmentNet>

  <aytu:CoreAndDevelopedTechnologyNet contextRef="PAsOn06_30_2017" id="Factid_27" unitRef="USD" decimals="0">1337333</aytu:CoreAndDevelopedTechnologyNet>

  <aytu:CoreAndDevelopedTechnologyNet contextRef="PAsOn06_30_2016" id="Factid_28" unitRef="USD" decimals="0">1159736</aytu:CoreAndDevelopedTechnologyNet>

  <us-gaap:IndefiniteLivedContractualRights contextRef="PAsOn06_30_2017" id="Factid_29" unitRef="USD" decimals="0">77667</us-gaap:IndefiniteLivedContractualRights>

  <us-gaap:IndefiniteLivedContractualRights contextRef="PAsOn06_30_2016" id="Factid_30" unitRef="USD" decimals="0">1353375</us-gaap:IndefiniteLivedContractualRights>

  <us-gaap:IndefiniteLivedTradeNames contextRef="PAsOn06_30_2017" id="Factid_31" unitRef="USD" decimals="0">164037</us-gaap:IndefiniteLivedTradeNames>

  <us-gaap:IndefiniteLivedTradeNames contextRef="PAsOn06_30_2016" id="Factid_32" unitRef="USD" decimals="0">194472</us-gaap:IndefiniteLivedTradeNames>

  <us-gaap:Goodwill contextRef="PAsOn06_30_2017" id="Factid_33" unitRef="USD" decimals="0">238426</us-gaap:Goodwill>

  <us-gaap:Goodwill contextRef="PAsOn06_30_2016" id="Factid_34" unitRef="USD" decimals="0">221000</us-gaap:Goodwill>

  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="PAsOn06_30_2017" id="Factid_35" unitRef="USD" decimals="0">271278</us-gaap:FiniteLivedIntangibleAssetsNet>

  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="PAsOn06_30_2016" id="Factid_36" unitRef="USD" decimals="0">296611</us-gaap:FiniteLivedIntangibleAssetsNet>

  <aytu:PrepaidResearchAndDevelopmentRelatedPartyNoncurrent contextRef="PAsOn06_30_2017" id="Factid_37" unitRef="USD" decimals="0">0</aytu:PrepaidResearchAndDevelopmentRelatedPartyNoncurrent>

  <aytu:PrepaidResearchAndDevelopmentRelatedPartyNoncurrent contextRef="PAsOn06_30_2016" id="Factid_38" unitRef="USD" decimals="0">213471</aytu:PrepaidResearchAndDevelopmentRelatedPartyNoncurrent>

  <us-gaap:DepositsAssetsNoncurrent contextRef="PAsOn06_30_2017" id="Factid_39" unitRef="USD" decimals="0">2888</us-gaap:DepositsAssetsNoncurrent>

  <us-gaap:DepositsAssetsNoncurrent contextRef="PAsOn06_30_2016" id="Factid_40" unitRef="USD" decimals="0">2888</us-gaap:DepositsAssetsNoncurrent>

  <us-gaap:Assets contextRef="PAsOn06_30_2017" id="Factid_41" unitRef="USD" decimals="0">14998517</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn06_30_2016" id="Factid_42" unitRef="USD" decimals="0">24343007</us-gaap:Assets>

  <aytu:AccruedCompensationCurrent contextRef="PAsOn06_30_2017" id="Factid_43" unitRef="USD" decimals="0">339704</aytu:AccruedCompensationCurrent>

  <aytu:AccruedCompensationCurrent contextRef="PAsOn06_30_2016" id="Factid_44" unitRef="USD" decimals="0">1200930</aytu:AccruedCompensationCurrent>

  <us-gaap:DeferredRentCreditNoncurrent contextRef="PAsOn06_30_2017" id="Factid_45" unitRef="USD" decimals="0">1451</us-gaap:DeferredRentCreditNoncurrent>

  <us-gaap:DeferredRentCreditNoncurrent contextRef="PAsOn06_30_2016" id="Factid_46" unitRef="USD" decimals="0">8215</us-gaap:DeferredRentCreditNoncurrent>

  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="PAsOn06_30_2017" id="Factid_47" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>

  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="PAsOn06_30_2016" id="Factid_48" unitRef="USD" decimals="0">275992</us-gaap:DerivativeLiabilitiesNoncurrent>

  <us-gaap:Liabilities contextRef="PAsOn06_30_2017" id="Factid_49" unitRef="USD" decimals="0">10998701</us-gaap:Liabilities>

  <us-gaap:Liabilities contextRef="PAsOn06_30_2016" id="Factid_50" unitRef="USD" decimals="0">14257754</us-gaap:Liabilities>

  <us-gaap:PreferredStockValue contextRef="PAsOn06_30_2017" id="Factid_51" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn06_30_2016" id="Factid_52" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn06_30_2017" id="Factid_53" unitRef="USD" decimals="0">82</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn06_30_2016" id="Factid_54" unitRef="USD" decimals="0">19</us-gaap:CommonStockValue>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn06_30_2017" id="Factid_55" unitRef="USD" decimals="0">73069463</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="PAsOn06_30_2016" id="Factid_56" unitRef="USD" decimals="0">56646659</us-gaap:AdditionalPaidInCapitalCommonStock>

  <us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock contextRef="PAsOn06_30_2017" id="Factid_57" unitRef="USD" decimals="0">0</us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock>

  <us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock contextRef="PAsOn06_30_2016" id="Factid_58" unitRef="USD" decimals="0">0</us-gaap:ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn06_30_2017" id="Factid_59" unitRef="USD" decimals="0">-69069729</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn06_30_2016" id="Factid_60" unitRef="USD" decimals="0">-46561425</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2017" id="Factid_61" unitRef="USD" decimals="0">3999816</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2016" id="Factid_62" unitRef="USD" decimals="0">10085253</us-gaap:StockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn06_30_2017" id="Factid_63" unitRef="USD" decimals="0">14998517</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn06_30_2016" id="Factid_64" unitRef="USD" decimals="0">24343007</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn06_30_2016" id="Factid_65" unitRef="USD" decimals="0">8054190</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn06_30_2017" id="Factid_66" unitRef="USD" decimals="0">802328</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn06_30_2017" id="Factid_67" unitRef="USD" decimals="0">9231072</us-gaap:OtherAssetsNoncurrent>

  <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn06_30_2016" id="Factid_68" unitRef="USD" decimals="0">10549797</us-gaap:OtherAssetsNoncurrent>

  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="PAsOn06_30_2017" id="Factid_69" unitRef="USD" decimals="0">0</us-gaap:AccountsPayableRelatedPartiesCurrent>

  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="PAsOn06_30_2016" id="Factid_70" unitRef="USD" decimals="0">5379675</us-gaap:AccountsPayableRelatedPartiesCurrent>

  <us-gaap:AccruedRentCurrent contextRef="PAsOn06_30_2017" id="Factid_71" unitRef="USD" decimals="0">6673</us-gaap:AccruedRentCurrent>

  <us-gaap:AccruedRentCurrent contextRef="PAsOn06_30_2016" id="Factid_72" unitRef="USD" decimals="0">4109</us-gaap:AccruedRentCurrent>

  <us-gaap:ShortTermInvestments contextRef="PAsOn06_30_2017" id="Factid_73" unitRef="USD" decimals="0">0</us-gaap:ShortTermInvestments>

  <us-gaap:ShortTermInvestments contextRef="PAsOn06_30_2016" id="Factid_74" unitRef="USD" decimals="0">1041362</us-gaap:ShortTermInvestments>

  <aytu:ProductsAndServicesRevenue contextRef="P07_01_2016To06_30_2017" id="Factid_75" unitRef="USD" decimals="0">3221590</aytu:ProductsAndServicesRevenue>

  <aytu:ProductsAndServicesRevenue contextRef="P07_01_2015To06_30_2016" id="Factid_76" unitRef="USD" decimals="0">2050838</aytu:ProductsAndServicesRevenue>

  <us-gaap:LicensesRevenue contextRef="P07_01_2016To06_30_2017" id="Factid_77" unitRef="USD" decimals="0">0</us-gaap:LicensesRevenue>

  <us-gaap:LicensesRevenue contextRef="P07_01_2015To06_30_2016" id="Factid_78" unitRef="USD" decimals="0">511607</us-gaap:LicensesRevenue>

  <us-gaap:Revenues contextRef="P07_01_2016To06_30_2017" id="Factid_79" unitRef="USD" decimals="0">3221590</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P07_01_2015To06_30_2016" id="Factid_80" unitRef="USD" decimals="0">2562445</us-gaap:Revenues>

  <us-gaap:CostOfRevenue contextRef="P07_01_2016To06_30_2017" id="Factid_81" unitRef="USD" decimals="0">1417355</us-gaap:CostOfRevenue>

  <us-gaap:CostOfRevenue contextRef="P07_01_2015To06_30_2016" id="Factid_82" unitRef="USD" decimals="0">957076</us-gaap:CostOfRevenue>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2016To06_30_2017" id="Factid_83" unitRef="USD" decimals="0">959857</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P07_01_2015To06_30_2016" id="Factid_84" unitRef="USD" decimals="0">6127772</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P07_01_2015To06_30_2016" id="Factid_85" unitRef="USD_per_Share" decimals="2">-323.70</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P07_01_2016To06_30_2017" id="Factid_86" unitRef="USD_per_Share" decimals="2">-48.30</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2015To06_30_2016" id="Factid_87" unitRef="USD" decimals="0">-28180084</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2016To06_30_2017" id="Factid_88" unitRef="USD" decimals="0">-22508304</us-gaap:NetIncomeLoss>

  <us-gaap:NonoperatingIncomeExpense contextRef="P07_01_2015To06_30_2016" id="Factid_89" unitRef="USD" decimals="0">-6475687</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P07_01_2016To06_30_2017" id="Factid_90" unitRef="USD" decimals="0">-2383068</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:InterestExpense contextRef="P07_01_2015To06_30_2016" id="Factid_91" unitRef="USD" decimals="0">5491486</us-gaap:InterestExpense>

  <us-gaap:InterestExpense contextRef="P07_01_2016To06_30_2017" id="Factid_92" unitRef="USD" decimals="0">2534358</us-gaap:InterestExpense>

  <us-gaap:OperatingIncomeLoss contextRef="P07_01_2015To06_30_2016" id="Factid_93" unitRef="USD" decimals="0">-21704397</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P07_01_2016To06_30_2017" id="Factid_94" unitRef="USD" decimals="0">-20125236</us-gaap:OperatingIncomeLoss>

  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="P07_01_2015To06_30_2016" id="Factid_95" unitRef="USD" decimals="0">8517592</us-gaap:SellingGeneralAndAdministrativeExpense>

  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="P07_01_2016To06_30_2017" id="Factid_96" unitRef="USD" decimals="0">17442627</us-gaap:SellingGeneralAndAdministrativeExpense>

  <aytu:ResearchAndDevelopmentRelatedParty contextRef="P07_01_2015To06_30_2016" id="Factid_97" unitRef="USD" decimals="0">191991</aytu:ResearchAndDevelopmentRelatedParty>

  <aytu:ResearchAndDevelopmentRelatedParty contextRef="P07_01_2016To06_30_2017" id="Factid_98" unitRef="USD" decimals="0">387960</aytu:ResearchAndDevelopmentRelatedParty>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P07_01_2016To06_30_2017" id="Factid_99" unitRef="shares" decimals="INF">466024</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P07_01_2015To06_30_2016" id="Factid_100" unitRef="shares" decimals="INF">87057</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:OperatingExpenses contextRef="P07_01_2016To06_30_2017" id="Factid_101" unitRef="USD" decimals="0">23346826</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P07_01_2015To06_30_2016" id="Factid_102" unitRef="USD" decimals="0">24266842</us-gaap:OperatingExpenses>

  <us-gaap:CostsAndExpensesRelatedParty contextRef="P07_01_2016To06_30_2017" id="Factid_103" unitRef="USD" decimals="0">165131</us-gaap:CostsAndExpensesRelatedParty>

  <us-gaap:CostsAndExpensesRelatedParty contextRef="P07_01_2015To06_30_2016" id="Factid_104" unitRef="USD" decimals="0">307704</us-gaap:CostsAndExpensesRelatedParty>

  <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="P07_01_2016To06_30_2017" id="Factid_105" unitRef="USD" decimals="0">1265125</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>

  <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="P07_01_2015To06_30_2016" id="Factid_106" unitRef="USD" decimals="0">7500000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017" id="Factid_107" unitRef="USD" decimals="0">1708771</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2015To06_30_2016" id="Factid_108" unitRef="USD" decimals="0">664707</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:IncreaseDecreaseInInventories contextRef="P07_01_2016To06_30_2017" id="Factid_109" unitRef="USD" decimals="0">-195427</us-gaap:IncreaseDecreaseInInventories>

  <us-gaap:IncreaseDecreaseInInventories contextRef="P07_01_2015To06_30_2016" id="Factid_110" unitRef="USD" decimals="0">485265</us-gaap:IncreaseDecreaseInInventories>

  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="P07_01_2016To06_30_2017" id="Factid_111" unitRef="USD" decimals="0">95202</us-gaap:IncreaseDecreaseInPrepaidExpense>

  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="P07_01_2015To06_30_2016" id="Factid_112" unitRef="USD" decimals="0">-155330</us-gaap:IncreaseDecreaseInPrepaidExpense>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P07_01_2016To06_30_2017" id="Factid_113" unitRef="USD" decimals="0">493217</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="P07_01_2015To06_30_2016" id="Factid_114" unitRef="USD" decimals="0">698237</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>

  <aytu:IncreaseDecreaseInAccruedCompensation contextRef="P07_01_2016To06_30_2017" id="Factid_115" unitRef="USD" decimals="0">-861226</aytu:IncreaseDecreaseInAccruedCompensation>

  <aytu:IncreaseDecreaseInAccruedCompensation contextRef="P07_01_2015To06_30_2016" id="Factid_116" unitRef="USD" decimals="0">1004427</aytu:IncreaseDecreaseInAccruedCompensation>

  <us-gaap:IncreaseDecreaseInPrepaidRent contextRef="P07_01_2016To06_30_2017" id="Factid_117" unitRef="USD" decimals="0">4200</us-gaap:IncreaseDecreaseInPrepaidRent>

  <us-gaap:IncreaseDecreaseInPrepaidRent contextRef="P07_01_2015To06_30_2016" id="Factid_118" unitRef="USD" decimals="0">-10875</us-gaap:IncreaseDecreaseInPrepaidRent>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P07_01_2016To06_30_2017" id="Factid_119" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P07_01_2015To06_30_2016" id="Factid_120" unitRef="USD" decimals="0">-511607</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <aytu:PaymentsForDepositsInvestingActivities contextRef="P07_01_2016To06_30_2017" id="Factid_121" unitRef="USD" decimals="0">0</aytu:PaymentsForDepositsInvestingActivities>

  <aytu:PaymentsForDepositsInvestingActivities contextRef="P07_01_2015To06_30_2016" id="Factid_122" unitRef="USD" decimals="0">-1998</aytu:PaymentsForDepositsInvestingActivities>

  <us-gaap:ProceedsFromContributionsFromParent contextRef="P07_01_2016To06_30_2017" id="Factid_123" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromContributionsFromParent>

  <us-gaap:ProceedsFromContributionsFromParent contextRef="P07_01_2015To06_30_2016" id="Factid_124" unitRef="USD" decimals="0">5000000</us-gaap:ProceedsFromContributionsFromParent>

  <us-gaap:AmortizationOfFinancingCosts contextRef="P07_01_2016To06_30_2017" id="Factid_125" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfFinancingCosts>

  <us-gaap:AmortizationOfFinancingCosts contextRef="P07_01_2015To06_30_2016" id="Factid_126" unitRef="USD" decimals="0">182759</us-gaap:AmortizationOfFinancingCosts>

  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="P07_01_2016To06_30_2017" id="Factid_127" unitRef="USD" decimals="0">212809</us-gaap:DerivativeGainLossOnDerivativeNet>

  <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="P07_01_2015To06_30_2016" id="Factid_128" unitRef="USD" decimals="0">-12572</us-gaap:DerivativeGainLossOnDerivativeNet>

  <aytu:WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes contextRef="P07_01_2016To06_30_2017" id="Factid_129" unitRef="USD" decimals="0">0</aytu:WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes>

  <aytu:WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes contextRef="P07_01_2015To06_30_2016" id="Factid_130" unitRef="USD" decimals="0">102931</aytu:WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes>

  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="P07_01_2016To06_30_2017" id="Factid_131" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfDebtIssuanceCosts>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P07_01_2016To06_30_2017" id="Factid_132" unitRef="USD" decimals="0">-13829652</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P07_01_2015To06_30_2016" id="Factid_133" unitRef="USD" decimals="0">-10657449</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P07_01_2016To06_30_2017" id="Factid_134" unitRef="USD" decimals="0">111608</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P07_01_2015To06_30_2016" id="Factid_135" unitRef="USD" decimals="0">252932</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P07_01_2016To06_30_2017" id="Factid_136" unitRef="USD" decimals="0">-3534538</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P07_01_2015To06_30_2016" id="Factid_137" unitRef="USD" decimals="0">-5303925</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P07_01_2016To06_30_2017" id="Factid_138" unitRef="USD" decimals="0">10187542</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P07_01_2015To06_30_2016" id="Factid_139" unitRef="USD" decimals="0">16662503</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P07_01_2016To06_30_2017" id="Factid_140" unitRef="USD" decimals="0">-7176648</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P07_01_2015To06_30_2016" id="Factid_141" unitRef="USD" decimals="0">701129</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="PAsOn06_30_2016" id="Factid_142" unitRef="USD" decimals="0">8054190</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="PAsOn06_30_2015" id="Factid_143" unitRef="USD" decimals="0">7353061</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="PAsOn06_30_2017" id="Factid_144" unitRef="USD" decimals="0">877542</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>

  <aytu:AmortizationOfBeneficialConversionFeature contextRef="P07_01_2016To06_30_2017" id="Factid_145" unitRef="USD" decimals="0">0</aytu:AmortizationOfBeneficialConversionFeature>

  <aytu:AmortizationOfBeneficialConversionFeature contextRef="P07_01_2015To06_30_2016" id="Factid_146" unitRef="USD" decimals="0">4943073</aytu:AmortizationOfBeneficialConversionFeature>

  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="P07_01_2016To06_30_2017" id="Factid_147" unitRef="USD" decimals="0">355031</us-gaap:IncreaseDecreaseInAccountsReceivable>

  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="P07_01_2015To06_30_2016" id="Factid_148" unitRef="USD" decimals="0">5369</us-gaap:IncreaseDecreaseInAccountsReceivable>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P07_01_2016To06_30_2017" id="Factid_149" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="P07_01_2015To06_30_2016" id="Factid_150" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>

  <us-gaap:PaymentsOfDebtRestructuringCosts contextRef="P07_01_2016To06_30_2017" id="Factid_151" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfDebtRestructuringCosts>

  <us-gaap:PaymentsOfDebtRestructuringCosts contextRef="P07_01_2015To06_30_2016" id="Factid_152" unitRef="USD" decimals="0">29754</us-gaap:PaymentsOfDebtRestructuringCosts>

  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="P07_01_2015To06_30_2016" id="Factid_153" unitRef="USD" decimals="0">298322</us-gaap:PaymentsOfDebtIssuanceCosts>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P07_01_2016To06_30_2017" id="Factid_154" unitRef="USD" decimals="0">0</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="P07_01_2015To06_30_2016" id="Factid_155" unitRef="USD" decimals="0">5396024</us-gaap:DebtConversionConvertedInstrumentAmount1>

  <aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote contextRef="P07_01_2016To06_30_2017" id="Factid_156" unitRef="USD" decimals="0">0</aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote>

  <aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote contextRef="P07_01_2015To06_30_2016" id="Factid_157" unitRef="USD" decimals="0">136828</aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote>

  <aytu:DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion contextRef="P07_01_2016To06_30_2017" id="Factid_158" unitRef="USD" decimals="0">0</aytu:DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion>

  <aytu:DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion contextRef="P07_01_2015To06_30_2016" id="Factid_159" unitRef="USD" decimals="0">4943073</aytu:DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion>

  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="P07_01_2016To06_30_2017" id="Factid_160" unitRef="USD" decimals="0">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>

  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="P07_01_2015To06_30_2016" id="Factid_161" unitRef="USD" decimals="0">218494</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2016To06_30_2017" id="Factid_162" unitRef="USD" decimals="0">2502092</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P07_01_2015To06_30_2016" id="Factid_163" unitRef="USD" decimals="0">902946</us-gaap:ShareBasedCompensation>

  <us-gaap:DepreciationDepletionAndAmortization contextRef="P07_01_2016To06_30_2017" id="Factid_164" unitRef="USD" decimals="0">4364680</us-gaap:DepreciationDepletionAndAmortization>

  <us-gaap:DepreciationDepletionAndAmortization contextRef="P07_01_2015To06_30_2016" id="Factid_165" unitRef="USD" decimals="0">874789</us-gaap:DepreciationDepletionAndAmortization>

  <aytu:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties contextRef="P07_01_2016To06_30_2017" id="Factid_166" unitRef="USD" decimals="0">335454</aytu:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties>

  <aytu:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties contextRef="P07_01_2015To06_30_2016" id="Factid_167" unitRef="USD" decimals="0">121983</aytu:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties>

  <aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayable contextRef="P07_01_2016To06_30_2017" id="Factid_168" unitRef="USD" decimals="0">0</aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayable>

  <aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayable contextRef="P07_01_2015To06_30_2016" id="Factid_169" unitRef="USD" decimals="0">1077000</aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayable>

  <us-gaap:AssetImpairmentCharges contextRef="P07_01_2016To06_30_2017" id="Factid_170" unitRef="USD" decimals="0">1265125</us-gaap:AssetImpairmentCharges>

  <us-gaap:AssetImpairmentCharges contextRef="P07_01_2015To06_30_2016" id="Factid_171" unitRef="USD" decimals="0">7500000</us-gaap:AssetImpairmentCharges>

  <us-gaap:OtherNoncashExpense contextRef="P07_01_2016To06_30_2017" id="Factid_172" unitRef="USD" decimals="0">0</us-gaap:OtherNoncashExpense>

  <us-gaap:OtherNoncashExpense contextRef="P07_01_2015To06_30_2016" id="Factid_173" unitRef="USD" decimals="0">221024</us-gaap:OtherNoncashExpense>

  <us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="P07_01_2016To06_30_2017" id="Factid_174" unitRef="USD" decimals="0">750000</us-gaap:PaymentsToAcquireOtherProductiveAssets>

  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="P07_01_2016To06_30_2017" id="Factid_175" unitRef="USD" decimals="0">6000000</us-gaap:PaymentsToAcquireIntangibleAssets>

  <us-gaap:PaymentsForProceedsFromLongtermInvestments contextRef="P07_01_2016To06_30_2017" id="Factid_176" unitRef="USD" decimals="0">-1071707</us-gaap:PaymentsForProceedsFromLongtermInvestments>

  <aytu:NatestoBusinessPurchaseIncludedInNatestoPayable contextRef="P07_01_2016To06_30_2017" id="Factid_177" unitRef="USD" decimals="0">0</aytu:NatestoBusinessPurchaseIncludedInNatestoPayable>

  <aytu:NatestoBusinessPurchaseIncludedInNatestoPayable contextRef="P07_01_2015To06_30_2016" id="Factid_178" unitRef="USD" decimals="0">5379675</aytu:NatestoBusinessPurchaseIncludedInNatestoPayable>

  <aytu:WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants contextRef="P07_01_2016To06_30_2017" id="Factid_179" unitRef="USD" decimals="0">0</aytu:WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants>

  <aytu:WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants contextRef="P07_01_2015To06_30_2016" id="Factid_180" unitRef="USD" decimals="0">297317</aytu:WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants>

  <aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets contextRef="PAsOn05_20_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_181" unitRef="USD" decimals="0">727000</aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>

  <us-gaap:Goodwill contextRef="PAsOn05_20_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_182" unitRef="USD" decimals="0">74000</us-gaap:Goodwill>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="PAsOn05_20_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_183" unitRef="USD" decimals="0">2391000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="PAsOn05_20_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_184" unitRef="USD" decimals="0">1590000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>

  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="PAsOn05_20_2015_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_JazzPharmaceuticalsIncMemberusgaapBusinessAcquisitionAxis_ProstaScintMemberusgaapProductOrServiceAxis" id="Factid_185" unitRef="USD" decimals="0">790000</us-gaap:FiniteLivedIntangibleAssetsGross>

  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="PAsOn05_20_2015_CustomerContractsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_JazzPharmaceuticalsIncMemberusgaapBusinessAcquisitionAxis_ProstaScintMemberusgaapProductOrServiceAxis" id="Factid_186" unitRef="USD" decimals="0">720000</us-gaap:FiniteLivedIntangibleAssetsGross>

  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="PAsOn05_20_2015_JazzPharmaceuticalsIncMemberusgaapBusinessAcquisitionAxis_ProstaScintMemberusgaapProductOrServiceAxis_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_187" unitRef="USD" decimals="0">80000</us-gaap:FiniteLivedIntangibleAssetsGross>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="PAsOn06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_188" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>

  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="P10_02_2015To10_31_2015_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_189" unitRef="USD" decimals="0">500000</us-gaap:PaymentsToAcquireBusinessesGross>

  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="P10_02_2015To10_31_2015_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_190" unitRef="USD" decimals="0">142000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>

  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="P10_02_2015To10_31_2015_PaidOnApril12016MemberusgaapStatementScenarioAxis_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_191" unitRef="USD" decimals="0">500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>

  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="P10_02_2015To10_31_2015_NoLaterThanSeptember302016MemberusgaapStatementScenarioAxis_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_192" unitRef="USD" decimals="0">250000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>

  <aytu:BusinessCombinationConsiderationTransferredInventory contextRef="P10_02_2015To10_31_2015_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_193" unitRef="USD" decimals="0">102000</aytu:BusinessCombinationConsiderationTransferredInventory>

  <aytu:BusinessCombinationConsiderationTransferredProductInventory contextRef="P10_02_2015To10_31_2015_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_194" unitRef="USD" decimals="0">40000</aytu:BusinessCombinationConsiderationTransferredProductInventory>

  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="P10_02_2015To10_31_2015_NoLaterThanJuly012016MemberusgaapStatementScenarioAxis_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_195" unitRef="USD" decimals="0">500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>

  <aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets contextRef="PAsOn10_05_2015_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_196" unitRef="USD" decimals="0">182000</aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="PAsOn10_05_2015_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_197" unitRef="USD" decimals="0">1470000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>

  <us-gaap:Goodwill contextRef="PAsOn10_05_2015_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_198" unitRef="USD" decimals="0">147000</us-gaap:Goodwill>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="PAsOn10_05_2015_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_199" unitRef="USD" decimals="0">1799000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_200" unitRef="USD" decimals="0">520000</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017_CustomerContractsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_201" unitRef="USD" decimals="0">810000</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_202" unitRef="USD" decimals="0">140000</us-gaap:AmortizationOfIntangibleAssets>

  <aytu:BusinessCombinationConsiderationTransferredWorkInProcessInventory contextRef="P07_01_2016To06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_203" unitRef="USD" decimals="0">80000</aytu:BusinessCombinationConsiderationTransferredWorkInProcessInventory>

  <aytu:BusinessCombinationConsiderationTransferredInventory contextRef="P07_01_2016To06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_204" unitRef="USD" decimals="0">102000</aytu:BusinessCombinationConsiderationTransferredInventory>

  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="P04_01_2016To04_28_2016_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_205" unitRef="USD" decimals="-5">2000000</us-gaap:PaymentsToAcquireBusinessesGross>

  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="P04_01_2016To04_28_2016_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_206" unitRef="shares" decimals="INF">12245411</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>

  <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="PAsOn04_28_2016_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_207" unitRef="CAD" decimals="-5">2500000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>

  <us-gaap:BusinessAcquisitionSharePrice contextRef="PAsOn04_28_2016_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_208" unitRef="CAD_per_Share" decimals="3">0.207</us-gaap:BusinessAcquisitionSharePrice>

  <aytu:OneTimeNonrefundablePayments contextRef="P04_01_2016To04_28_2016_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_209" unitRef="USD" decimals="-6">0</aytu:OneTimeNonrefundablePayments>

  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="PAsOn06_30_2017_ZertanePatentsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_210" unitRef="USD" decimals="0">500000</us-gaap:FiniteLivedIntangibleAssetsGross>

  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="PAsOn06_30_2017_OrpMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_211" unitRef="USD" decimals="0">380000</us-gaap:FiniteLivedIntangibleAssetsGross>

  <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="P07_01_2016To06_30_2017_OrpMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_212">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>

  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="PAsOn06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_213" unitRef="USD" decimals="0">880000</us-gaap:FiniteLivedIntangibleAssetsGross>

  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="PAsOn06_30_2016_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_214" unitRef="USD" decimals="0">880000</us-gaap:FiniteLivedIntangibleAssetsGross>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_215" unitRef="USD" decimals="0">609000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="PAsOn06_30_2016_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_216" unitRef="USD" decimals="0">583000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>

  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="PAsOn06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_217" unitRef="USD" decimals="0">271000</us-gaap:FiniteLivedIntangibleAssetsNet>

  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="PAsOn06_30_2016_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_218" unitRef="USD" decimals="0">297000</us-gaap:FiniteLivedIntangibleAssetsNet>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P07_01_2016To06_30_2017_StockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_219" unitRef="shares" decimals="INF">367312</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P07_01_2015To06_30_2016_WarrantMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" id="Factid_220" unitRef="shares" decimals="INF">126239</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn06_30_2017_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_221" unitRef="USD" decimals="0">405000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn06_30_2017_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_222" unitRef="USD" decimals="0">111000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn06_30_2016_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_223" unitRef="USD" decimals="0">90000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn06_30_2017_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_224" unitRef="USD" decimals="0">287000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn06_30_2016_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_225" unitRef="USD" decimals="0">45000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn06_30_2017_ManufacturingFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_226" unitRef="USD" decimals="0">90000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn06_30_2016_ManufacturingFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_227" unitRef="USD" decimals="0">7000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn06_30_2016_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_228" unitRef="USD" decimals="0">201000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn06_30_2017" id="Factid_229" unitRef="USD" decimals="0">246000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn06_30_2016" id="Factid_230" unitRef="USD" decimals="0">112000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:Depreciation contextRef="P07_01_2016To06_30_2017" id="Factid_231" unitRef="USD" decimals="0">134000</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P07_01_2015To06_30_2016" id="Factid_232" unitRef="USD" decimals="0">51000</us-gaap:Depreciation>

  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="PAsOn06_30_2017" id="Factid_233" unitRef="USD" decimals="0">44000</us-gaap:AllowanceForDoubtfulAccountsReceivable>

  <aytu:PotentialMilestonePaymentsReceivable contextRef="PAsOn06_30_2017_AmpioMemberdeiLegalEntityAxis" id="Factid_234" unitRef="USD" decimals="-5">3200000</aytu:PotentialMilestonePaymentsReceivable>

  <aytu:PercentageOfRoyaltyRateOfNetSales contextRef="P07_01_2016To06_30_2017_AmpioMemberdeiLegalEntityAxis" id="Factid_235" unitRef="pure" decimals="2">0.25</aytu:PercentageOfRoyaltyRateOfNetSales>

  <us-gaap:DeferredRevenue contextRef="PAsOn06_30_2017_AmpioMemberdeiLegalEntityAxis" id="Factid_236" unitRef="USD" decimals="0">500000</us-gaap:DeferredRevenue>

  <us-gaap:ProceedsFromLicenseFeesReceived contextRef="P07_01_2016To06_30_2017_AmpioMemberdeiLegalEntityAxis" id="Factid_237" unitRef="USD" decimals="0">418000</us-gaap:ProceedsFromLicenseFeesReceived>

  <aytu:AgreementExpirationPeriod contextRef="P04_01_2014To04_30_2014_VyrixPharmaceuticalsIncMemberdeiLegalEntityAxis" id="Factid_238">P15Y</aytu:AgreementExpirationPeriod>

  <us-gaap:DeferredRevenue contextRef="PAsOn04_30_2014_VyrixPharmaceuticalsIncMemberdeiLegalEntityAxis" id="Factid_239" unitRef="USD" decimals="0">250000</us-gaap:DeferredRevenue>

  <aytu:PotentialMilestonePaymentsReceivable contextRef="PAsOn04_30_2014_VyrixPharmaceuticalsIncMemberdeiLegalEntityAxis" id="Factid_240" unitRef="USD" decimals="-5">3000000</aytu:PotentialMilestonePaymentsReceivable>

  <us-gaap:DeferredRevenue contextRef="PAsOn06_30_2016" id="Factid_241" unitRef="USD" decimals="0">426000</us-gaap:DeferredRevenue>

  <us-gaap:InvestmentsFairValueDisclosure contextRef="PAsOn06_30_2017" id="Factid_242" unitRef="USD" decimals="0">0</us-gaap:InvestmentsFairValueDisclosure>

  <us-gaap:InvestmentsFairValueDisclosure contextRef="PAsOn06_30_2017_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_243" unitRef="USD" decimals="0">0</us-gaap:InvestmentsFairValueDisclosure>

  <us-gaap:InvestmentsFairValueDisclosure contextRef="PAsOn06_30_2017_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_244" unitRef="USD" decimals="0">0</us-gaap:InvestmentsFairValueDisclosure>

  <us-gaap:InvestmentsFairValueDisclosure contextRef="PAsOn06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_245" unitRef="USD" decimals="0">0</us-gaap:InvestmentsFairValueDisclosure>

  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="PAsOn06_30_2017_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_246" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>

  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="PAsOn06_30_2017_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_247" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>

  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="PAsOn06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_248" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>

  <us-gaap:InvestmentsFairValueDisclosure contextRef="PAsOn06_30_2016" id="Factid_249" unitRef="USD" decimals="0">1041000</us-gaap:InvestmentsFairValueDisclosure>

  <us-gaap:InvestmentsFairValueDisclosure contextRef="PAsOn06_30_2016_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_250" unitRef="USD" decimals="0">1041000</us-gaap:InvestmentsFairValueDisclosure>

  <us-gaap:InvestmentsFairValueDisclosure contextRef="PAsOn06_30_2016_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_251" unitRef="USD" decimals="0">0</us-gaap:InvestmentsFairValueDisclosure>

  <us-gaap:InvestmentsFairValueDisclosure contextRef="PAsOn06_30_2016_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_252" unitRef="USD" decimals="0">0</us-gaap:InvestmentsFairValueDisclosure>

  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="PAsOn06_30_2016_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_253" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>

  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="PAsOn06_30_2016_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_254" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesNoncurrent>

  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="PAsOn06_30_2016_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_255" unitRef="USD" decimals="0">276000</us-gaap:DerivativeLiabilitiesNoncurrent>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="PAsOn06_30_2017_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_256" unitRef="USD" decimals="0">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="PAsOn06_30_2017_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_257" unitRef="USD" decimals="0">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="PAsOn06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_258" unitRef="USD" decimals="0">7648000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="PAsOn06_30_2016_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_259" unitRef="USD" decimals="0">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="PAsOn06_30_2016_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_260" unitRef="USD" decimals="0">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="PAsOn06_30_2016_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_261" unitRef="USD" decimals="0">3869000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn06_30_2016_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_262" unitRef="USD" decimals="0">276000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="P07_01_2016To06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_263" unitRef="USD" decimals="0">-213000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_264" unitRef="USD" decimals="0">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>

  <aytu:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances contextRef="P07_01_2016To06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_265" unitRef="USD" decimals="0">0</aytu:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 contextRef="P07_01_2016To06_30_2017_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_266" unitRef="USD" decimals="0">63000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P07_01_2016To06_30_2017" id="Factid_267" unitRef="pure" decimals="4">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P07_01_2015To06_30_2016" id="Factid_268" unitRef="pure" decimals="4">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="P07_01_2016To06_30_2017" id="Factid_269" unitRef="pure" decimals="4">-0.0302</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="P07_01_2015To06_30_2016" id="Factid_270" unitRef="pure" decimals="4">-0.0303</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="P07_01_2016To06_30_2017" id="Factid_271" unitRef="pure" decimals="4">0.0051</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>

  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="P07_01_2015To06_30_2016" id="Factid_272" unitRef="pure" decimals="4">0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>

  <aytu:EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt contextRef="P07_01_2016To06_30_2017" id="Factid_273" unitRef="pure" decimals="2">0.00</aytu:EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt>

  <aytu:EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt contextRef="P07_01_2015To06_30_2016" id="Factid_274" unitRef="pure" decimals="4">0.0027</aytu:EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P07_01_2016To06_30_2017" id="Factid_275" unitRef="pure" decimals="4">0.3519</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P07_01_2015To06_30_2016" id="Factid_276" unitRef="pure" decimals="4">0.3077</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary contextRef="P07_01_2016To06_30_2017" id="Factid_277" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>

  <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary contextRef="P07_01_2015To06_30_2016" id="Factid_278" unitRef="pure" decimals="4">0.0594</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>

  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="P07_01_2016To06_30_2017" id="Factid_279" unitRef="pure" decimals="4">0.0045</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>

  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="P07_01_2015To06_30_2016" id="Factid_280" unitRef="pure" decimals="4">0.0002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P07_01_2016To06_30_2017" id="Factid_281" unitRef="pure" decimals="0">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P07_01_2015To06_30_2016" id="Factid_282" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="P07_01_2016To06_30_2017" id="Factid_283" unitRef="USD" decimals="0">-7653000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>

  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="P07_01_2015To06_30_2016" id="Factid_284" unitRef="USD" decimals="0">-9581000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>

  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="P07_01_2016To06_30_2017" id="Factid_285" unitRef="USD" decimals="0">-681000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="P07_01_2015To06_30_2016" id="Factid_286" unitRef="USD" decimals="0">-853000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="P07_01_2016To06_30_2017" id="Factid_287" unitRef="USD" decimals="0">116000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>

  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="P07_01_2015To06_30_2016" id="Factid_288" unitRef="USD" decimals="0">7000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>

  <aytu:EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt contextRef="P07_01_2016To06_30_2017" id="Factid_289" unitRef="USD" decimals="0">0</aytu:EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt>

  <aytu:EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt contextRef="P07_01_2015To06_30_2016" id="Factid_290" unitRef="USD" decimals="0">75000</aytu:EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt>

  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P07_01_2016To06_30_2017" id="Factid_291" unitRef="USD" decimals="0">7922000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P07_01_2015To06_30_2016" id="Factid_292" unitRef="USD" decimals="0">8672000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary contextRef="P07_01_2016To06_30_2017" id="Factid_293" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>

  <us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary contextRef="P07_01_2015To06_30_2016" id="Factid_294" unitRef="USD" decimals="0">-1674000</us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>

  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="P07_01_2016To06_30_2017" id="Factid_295" unitRef="USD" decimals="0">100000</us-gaap:IncomeTaxReconciliationOtherAdjustments>

  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="P07_01_2015To06_30_2016" id="Factid_296" unitRef="USD" decimals="0">6000</us-gaap:IncomeTaxReconciliationOtherAdjustments>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P07_01_2016To06_30_2017" id="Factid_297" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P07_01_2015To06_30_2016" id="Factid_298" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:DeferredTaxAssetsGrossCurrent contextRef="PAsOn06_30_2017" id="Factid_299" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsGrossCurrent>

  <us-gaap:DeferredTaxAssetsGrossCurrent contextRef="PAsOn06_30_2016" id="Factid_300" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsGrossCurrent>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="PAsOn06_30_2017" id="Factid_301" unitRef="USD" decimals="0">3000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="PAsOn06_30_2016" id="Factid_302" unitRef="USD" decimals="0">5000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn06_30_2017" id="Factid_303" unitRef="USD" decimals="0">15435000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn06_30_2016" id="Factid_304" unitRef="USD" decimals="0">9202000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="PAsOn06_30_2017" id="Factid_305" unitRef="USD" decimals="0">1559000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>

  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="PAsOn06_30_2016" id="Factid_306" unitRef="USD" decimals="0">606000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="PAsOn06_30_2017" id="Factid_307" unitRef="USD" decimals="0">1362000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="PAsOn06_30_2016" id="Factid_308" unitRef="USD" decimals="0">327000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>

  <us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities contextRef="PAsOn06_30_2017" id="Factid_309" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities>

  <us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities contextRef="PAsOn06_30_2016" id="Factid_310" unitRef="USD" decimals="0">360000</us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities>

  <us-gaap:DeferredTaxAssetsDerivativeInstruments contextRef="PAsOn06_30_2017" id="Factid_311" unitRef="USD" decimals="0">75000</us-gaap:DeferredTaxAssetsDerivativeInstruments>

  <us-gaap:DeferredTaxAssetsDerivativeInstruments contextRef="PAsOn06_30_2016" id="Factid_312" unitRef="USD" decimals="0">153000</us-gaap:DeferredTaxAssetsDerivativeInstruments>

  <us-gaap:DeferredTaxAssetsInventory contextRef="PAsOn06_30_2017" id="Factid_313" unitRef="USD" decimals="0">174000</us-gaap:DeferredTaxAssetsInventory>

  <us-gaap:DeferredTaxAssetsInventory contextRef="PAsOn06_30_2016" id="Factid_314" unitRef="USD" decimals="0">192000</us-gaap:DeferredTaxAssetsInventory>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses contextRef="PAsOn06_30_2017" id="Factid_315" unitRef="USD" decimals="0">17000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses contextRef="PAsOn06_30_2016" id="Factid_316" unitRef="USD" decimals="0">15000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn06_30_2017" id="Factid_317" unitRef="USD" decimals="0">19369000</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn06_30_2016" id="Factid_318" unitRef="USD" decimals="0">11305000</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn06_30_2017" id="Factid_319" unitRef="USD" decimals="0">19369000</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn06_30_2016" id="Factid_320" unitRef="USD" decimals="0">11305000</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="PAsOn06_30_2017" id="Factid_321" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>

  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="PAsOn06_30_2016" id="Factid_322" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="PAsOn06_30_2017" id="Factid_323" unitRef="USD" decimals="0">127000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="PAsOn06_30_2016" id="Factid_324" unitRef="USD" decimals="0">445000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn06_30_2016_AmpioPharmaceuticalsMemberdeiLegalEntityAxis" id="Factid_325" unitRef="USD" decimals="-5">42300000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn06_30_2015_AmpioPharmaceuticalsMemberdeiLegalEntityAxis" id="Factid_326" unitRef="USD" decimals="-5">24800000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:ContractualObligation contextRef="PAsOn06_30_2017_ManufacturingAgreementMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_327" unitRef="USD" decimals="0">0</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligation contextRef="PAsOn06_30_2017_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_328" unitRef="USD" decimals="0">175000</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligationDueInFifthYear contextRef="PAsOn06_30_2017_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_329" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInFifthYear>

  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="PAsOn06_30_2017_ManufacturingAgreementMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_330" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueAfterFifthYear>

  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="PAsOn06_30_2017_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_331" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueAfterFifthYear>

  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="PAsOn06_30_2017_ManufacturingAgreementMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_332" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInNextTwelveMonths>

  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="PAsOn06_30_2017_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_333" unitRef="USD" decimals="0">145000</us-gaap:ContractualObligationDueInNextTwelveMonths>

  <us-gaap:ContractualObligationDueInSecondYear contextRef="PAsOn06_30_2017_ManufacturingAgreementMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_334" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInSecondYear>

  <us-gaap:ContractualObligationDueInSecondYear contextRef="PAsOn06_30_2017_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_335" unitRef="USD" decimals="0">30000</us-gaap:ContractualObligationDueInSecondYear>

  <us-gaap:ContractualObligationDueInThirdYear contextRef="PAsOn06_30_2017_ManufacturingAgreementMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_336" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInThirdYear>

  <us-gaap:ContractualObligationDueInThirdYear contextRef="PAsOn06_30_2017_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_337" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInThirdYear>

  <us-gaap:ContractualObligationDueInFourthYear contextRef="PAsOn06_30_2017_ManufacturingAgreementMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_338" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInFourthYear>

  <us-gaap:ContractualObligationDueInFourthYear contextRef="PAsOn06_30_2017_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_339" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInFourthYear>

  <us-gaap:ContractualObligationDueInFifthYear contextRef="PAsOn06_30_2017_ManufacturingAgreementMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_340" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInFifthYear>

  <us-gaap:ContractualObligation contextRef="PAsOn06_30_2017_PrescriptionDatabaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_341" unitRef="USD" decimals="0">1342000</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligation contextRef="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_342" unitRef="USD" decimals="0">15000000</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="PAsOn06_30_2017_PrescriptionDatabaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_343" unitRef="USD" decimals="0">769000</us-gaap:ContractualObligationDueInNextTwelveMonths>

  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_344" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInNextTwelveMonths>

  <us-gaap:ContractualObligationDueInSecondYear contextRef="PAsOn06_30_2017_PrescriptionDatabaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_345" unitRef="USD" decimals="0">573000</us-gaap:ContractualObligationDueInSecondYear>

  <us-gaap:ContractualObligationDueInSecondYear contextRef="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_346" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInSecondYear>

  <us-gaap:ContractualObligationDueInThirdYear contextRef="PAsOn06_30_2017_PrescriptionDatabaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_347" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInThirdYear>

  <us-gaap:ContractualObligationDueInThirdYear contextRef="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_348" unitRef="USD" decimals="0">2500000</us-gaap:ContractualObligationDueInThirdYear>

  <us-gaap:ContractualObligationDueInFourthYear contextRef="PAsOn06_30_2017_PrescriptionDatabaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_349" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInFourthYear>

  <us-gaap:ContractualObligationDueInFourthYear contextRef="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_350" unitRef="USD" decimals="0">5000000</us-gaap:ContractualObligationDueInFourthYear>

  <us-gaap:ContractualObligationDueInFifthYear contextRef="PAsOn06_30_2017_PrescriptionDatabaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_351" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInFifthYear>

  <us-gaap:ContractualObligationDueInFifthYear contextRef="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_352" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInFifthYear>

  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="PAsOn06_30_2017_PrescriptionDatabaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_353" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueAfterFifthYear>

  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_354" unitRef="USD" decimals="0">7500000</us-gaap:ContractualObligationDueAfterFifthYear>

  <us-gaap:ContractualObligation contextRef="PAsOn05_31_2016_PrescriptionDatabaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_355" unitRef="USD" decimals="-5">1900000</us-gaap:ContractualObligation>

  <aytu:OperatingLeasesMonthlyBaseRentInitialYear contextRef="PAsOn06_30_2015_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_356" unitRef="USD" decimals="0">3000</aytu:OperatingLeasesMonthlyBaseRentInitialYear>

  <aytu:OperatingLeasesMonthlyBaseRentInitialYear contextRef="PAsOn09_30_2015_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_357" unitRef="USD" decimals="0">9000</aytu:OperatingLeasesMonthlyBaseRentInitialYear>

  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="P06_01_2015To06_30_2015_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_358">P37M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>

  <us-gaap:LeaseAndRentalExpense contextRef="P06_01_2015To06_30_2015_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_359" unitRef="USD" decimals="0">112000</us-gaap:LeaseAndRentalExpense>

  <us-gaap:LeaseAndRentalExpense contextRef="P08_01_2015To08_31_2015_OfficeLeaseMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_360" unitRef="USD" decimals="0">318000</us-gaap:LeaseAndRentalExpense>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P07_01_2016To06_30_2017" id="Factid_361" unitRef="USD" decimals="0">139000</us-gaap:OperatingLeasesRentExpenseNet>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P07_01_2015To06_30_2016" id="Factid_362" unitRef="USD" decimals="0">120000</us-gaap:OperatingLeasesRentExpenseNet>

  <us-gaap:DebtInstrumentFaceAmount contextRef="PAsOn08_31_2015" id="Factid_363" unitRef="USD" decimals="-5">5200000</us-gaap:DebtInstrumentFaceAmount>

  <us-gaap:UnamortizedDebtIssuanceExpense contextRef="PAsOn08_31_2015" id="Factid_364" unitRef="USD" decimals="0">401000</us-gaap:UnamortizedDebtIssuanceExpense>

  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="PAsOn08_31_2015" id="Factid_365" unitRef="USD" decimals="0">103000</us-gaap:DerivativeLiabilitiesNoncurrent>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn06_30_2017_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis_MinimumMemberusgaapRangeAxis" id="Factid_366" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn06_30_2017_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis_MaximumMemberusgaapRangeAxis" id="Factid_367" unitRef="pure" decimals="2">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <aytu:PlacementAgentsCashFeePercentage contextRef="P07_01_2016To06_30_2017" id="Factid_368" unitRef="pure" decimals="2">0.08</aytu:PlacementAgentsCashFeePercentage>

  <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="P07_01_2016To06_30_2017" id="Factid_369" unitRef="USD" decimals="0">20000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>

  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="P02_01_2015To02_10_2015_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_370" unitRef="USD" decimals="-5">4100000</us-gaap:DebtConversionOriginalDebtAmount1>

  <aytu:DebtConversionAccruedInterestAmount contextRef="P02_01_2015To02_10_2015_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_371" unitRef="USD" decimals="0">143000</aytu:DebtConversionAccruedInterestAmount>

  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="P02_01_2015To02_10_2015_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_372" unitRef="shares" decimals="INF">32830</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>

  <us-gaap:ProceedsFromConvertibleDebt contextRef="P07_01_2016To06_30_2017_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_373" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromConvertibleDebt>

  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="P05_01_2016To05_06_2016_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_374" unitRef="USD" decimals="-5">1100000</us-gaap:DebtConversionOriginalDebtAmount1>

  <aytu:DebtConversionAccruedInterestAmount contextRef="P05_01_2016To05_06_2016_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_375" unitRef="USD" decimals="0">78000</aytu:DebtConversionAccruedInterestAmount>

  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="P05_01_2016To05_06_2016_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_376" unitRef="shares" decimals="INF">15279</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>

  <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="P05_01_2016To05_06_2016_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_377" unitRef="shares" decimals="INF">15279</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>

  <aytu:WarrantsIssuedToPurchaseOfCommonStock contextRef="P02_01_2016To02_10_2016" id="Factid_378" unitRef="shares" decimals="INF">1113</aytu:WarrantsIssuedToPurchaseOfCommonStock>

  <aytu:WarrantsExercisePricePerShare contextRef="P02_01_2016To02_10_2016" id="Factid_379" unitRef="USD_per_Share" decimals="2">156.00</aytu:WarrantsExercisePricePerShare>

  <aytu:WarrantsIssuedToPurchaseOfCommonStock contextRef="P05_01_2016To05_06_2016" id="Factid_380" unitRef="shares" decimals="INF">1129</aytu:WarrantsIssuedToPurchaseOfCommonStock>

  <aytu:WarrantsExercisePricePerShare contextRef="P05_01_2016To05_06_2016" id="Factid_381" unitRef="USD_per_Share" decimals="2">96.00</aytu:WarrantsExercisePricePerShare>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P07_01_2016To06_30_2017_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_382" unitRef="USD" decimals="-5">4900000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn06_30_2015_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_383" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_384" unitRef="shares" decimals="INF">16340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_385" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_386" unitRef="shares" decimals="INF">209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_387" unitRef="shares" decimals="INF">19341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_388" unitRef="USD_per_Share" decimals="1">360.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn06_30_2015_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_389" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_390" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_391" unitRef="USD_per_Share" decimals="1">362.4</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_392" unitRef="USD_per_Share" decimals="1">16.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant contextRef="PAsOn06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_393" unitRef="shares" decimals="INF">61737</aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_394">P7Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_395" unitRef="shares" decimals="INF">16131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_396" unitRef="USD_per_Share" decimals="1">360.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_397">P9Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <aytu:UnrecognizedShareBasedCompensationExpenses contextRef="P07_01_2016To06_30_2017" id="Factid_398" unitRef="USD" decimals="0">775000</aytu:UnrecognizedShareBasedCompensationExpenses>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P07_01_2016To06_30_2017" id="Factid_399">P1Y9M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>

  <aytu:ShareBasedCompensationShareWarrantsOutstanding contextRef="PAsOn06_30_2017" id="Factid_400" unitRef="shares" decimals="INF">286049</aytu:ShareBasedCompensationShareWarrantsOutstanding>

  <aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="PAsOn06_30_2017" id="Factid_401" unitRef="USD_per_Share" decimals="2">50.29</aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>

  <aytu:ShareBasedCompensationShareWarrantsOutstanding contextRef="PAsOn06_30_2016" id="Factid_402" unitRef="shares" decimals="INF">110108</aytu:ShareBasedCompensationShareWarrantsOutstanding>

  <aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="PAsOn06_30_2016" id="Factid_403" unitRef="USD_per_Share" decimals="2">124.02</aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>

  <aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm contextRef="P07_01_2016To06_30_2017" id="Factid_404">P4Y2M23D</aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering contextRef="P07_01_2016To06_30_2017" id="Factid_405" unitRef="shares" decimals="INF">301014</aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering contextRef="P07_01_2016To06_30_2017" id="Factid_406" unitRef="shares" decimals="INF">20077</aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice contextRef="P07_01_2016To06_30_2017" id="Factid_407" unitRef="USD_per_Share" decimals="1">37.2</aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice contextRef="P07_01_2016To06_30_2017" id="Factid_408" unitRef="USD_per_Share" decimals="0">15</aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice>

  <aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm contextRef="P07_01_2014To06_30_2015" id="Factid_409">P4Y8M16D</aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes contextRef="P07_01_2015To06_30_2016" id="Factid_410" unitRef="shares" decimals="INF">1115</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice contextRef="P07_01_2015To06_30_2016" id="Factid_411" unitRef="USD_per_Share" decimals="0">156</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo contextRef="P07_01_2015To06_30_2016" id="Factid_412" unitRef="shares" decimals="INF">1129</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders contextRef="P07_01_2015To06_30_2016" id="Factid_413" unitRef="shares" decimals="INF">15279</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice contextRef="P07_01_2015To06_30_2016" id="Factid_414" unitRef="USD_per_Share" decimals="0">96</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice contextRef="P07_01_2015To06_30_2016" id="Factid_415" unitRef="USD_per_Share" decimals="0">120</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice>

  <aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm contextRef="P07_01_2015To06_30_2016" id="Factid_416">P2Y11M1D</aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm>

  <aytu:ShareBasedCompensationShareWarrantsOutstanding contextRef="PAsOn06_30_2015" id="Factid_417" unitRef="shares" decimals="INF">444</aytu:ShareBasedCompensationShareWarrantsOutstanding>

  <aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="PAsOn06_30_2015" id="Factid_418" unitRef="USD_per_Share" decimals="2">1087.20</aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>

  <aytu:PlacementAgentsCashFeePercentage contextRef="P08_01_2015To08_31_2015" id="Factid_419" unitRef="pure" decimals="2">0.08</aytu:PlacementAgentsCashFeePercentage>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes contextRef="P02_01_2016To02_29_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_420" unitRef="shares" decimals="INF">1115</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice contextRef="P02_01_2016To02_29_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_421" unitRef="USD_per_Share" decimals="2">156.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo contextRef="P05_01_2016To05_31_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_422" unitRef="shares" decimals="INF">1129</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice contextRef="P05_01_2016To05_31_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_423" unitRef="USD_per_Share" decimals="2">96.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice>

  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="PAsOn02_29_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_424" unitRef="USD" decimals="0">87000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>

  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="PAsOn05_31_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_425" unitRef="USD" decimals="0">50000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders contextRef="P05_01_2016To05_31_2016_ConvertiblePromissoryNotesMay2016MemberusgaapDebtInstrumentAxis" id="Factid_426" unitRef="shares" decimals="INF">15279</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice contextRef="P05_01_2016To05_31_2016_ConvertiblePromissoryNotesMay2016MemberusgaapDebtInstrumentAxis" id="Factid_427" unitRef="USD_per_Share" decimals="2">120.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice>

  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="PAsOn05_31_2016_ConvertiblePromissoryNotesMay2016MemberusgaapDebtInstrumentAxis" id="Factid_428" unitRef="USD" decimals="0">480000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering contextRef="P05_01_2016To05_31_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_429" unitRef="shares" decimals="INF">5474</aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice contextRef="P05_01_2016To05_31_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_430" unitRef="USD_per_Share" decimals="2">120.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering contextRef="P05_01_2016To05_31_2016_InvestorsWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_431" unitRef="shares" decimals="INF">86667</aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice contextRef="P05_01_2016To05_31_2016_InvestorsWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_432" unitRef="USD_per_Share" decimals="2">120.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice>

  <aytu:OperatingLeaseMonthlyRentalPayment contextRef="P06_01_2013To06_30_2013_AfterAmendmentMemberusgaapRelatedPartyTransactionAxis_AmpioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ScenarioPlanMemberusgaapStatementScenarioAxis_SecondInstallmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis" id="Factid_433" unitRef="USD" decimals="0">6000</aytu:OperatingLeaseMonthlyRentalPayment>

  <aytu:PrepaidExpensesAmortizationPeriod contextRef="P03_01_2014To03_31_2014_AmpioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FirstInstallmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis_ScenarioPlanMemberusgaapStatementScenarioAxis" id="Factid_434">P60M15D</aytu:PrepaidExpensesAmortizationPeriod>

  <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNet contextRef="PAsOn03_31_2014_AmpioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ScenarioPlanMemberusgaapStatementScenarioAxis_SecondInstallmentMemberusgaapPurchaseCommitmentExcludingLongtermCommitmentAxis" id="Factid_435" unitRef="USD" decimals="0">615000</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNet>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn06_30_2016" id="Factid_436" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn06_30_2017" id="Factid_437" unitRef="USD" xsi:nil="true" />

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn06_30_2017" id="Factid_438" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn06_30_2016" id="Factid_439" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn06_30_2017" id="Factid_440" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn06_30_2016" id="Factid_441" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn06_30_2017" id="Factid_442" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn06_30_2016" id="Factid_443" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn06_30_2017" id="Factid_444" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn06_30_2016" id="Factid_445" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn06_30_2017" id="Factid_446" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn06_30_2016" id="Factid_447" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn06_30_2017" id="Factid_448" unitRef="shares" decimals="INF">824831</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn06_30_2017" id="Factid_449" unitRef="shares" decimals="INF">824831</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn06_30_2016" id="Factid_450" unitRef="shares" decimals="INF">187098</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn06_30_2016" id="Factid_451" unitRef="shares" decimals="INF">187098</us-gaap:CommonStockSharesOutstanding>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn08_15_2017" id="Factid_452" unitRef="shares" decimals="INF">4021822</dei:EntityCommonStockSharesOutstanding>

  <us-gaap:GainLossOnInvestments contextRef="P07_01_2016To06_30_2017" id="Factid_453" unitRef="USD" decimals="0">-61519</us-gaap:GainLossOnInvestments>

  <us-gaap:GainLossOnInvestments contextRef="P07_01_2015To06_30_2016" id="Factid_454" unitRef="USD" decimals="0">-971629</us-gaap:GainLossOnInvestments>

  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="P07_01_2016To06_30_2017" id="Factid_455" unitRef="USD" decimals="0">-414570</us-gaap:IncreaseDecreaseInAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="P07_01_2015To06_30_2016" id="Factid_456" unitRef="USD" decimals="0">925232</us-gaap:IncreaseDecreaseInAccruedLiabilities>

  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="P07_01_2015To06_30_2016" id="Factid_457" unitRef="USD" decimals="0">2000000</us-gaap:PaymentsToAcquireIntangibleAssets>

  <us-gaap:PaymentsForProceedsFromLongtermInvestments contextRef="P07_01_2015To06_30_2016" id="Factid_458" unitRef="USD" decimals="0">2012991</us-gaap:PaymentsForProceedsFromLongtermInvestments>

  <us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="P07_01_2015To06_30_2016" id="Factid_459" unitRef="USD" decimals="0">1040000</us-gaap:PaymentsToAcquireOtherProductiveAssets>

  <aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayableGross contextRef="P07_01_2016To06_30_2017" id="Factid_460" unitRef="USD" decimals="0">1250000</aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayableGross>

  <aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayableGross contextRef="P07_01_2015To06_30_2016" id="Factid_461" unitRef="USD" decimals="0">1250000</aytu:PrimsolBusinessPurchaseIncludedInPrimsolPayableGross>

  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="P07_01_2016To06_30_2017" id="Factid_462" unitRef="USD" decimals="0">221000</us-gaap:DebtConversionOriginalDebtAmount1>

  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="P07_01_2015To06_30_2016" id="Factid_463" unitRef="USD" decimals="0">221000</us-gaap:DebtConversionOriginalDebtAmount1>

  <us-gaap:StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount contextRef="P07_01_2016To06_30_2017" id="Factid_464" unitRef="USD" decimals="0">173000</us-gaap:StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount>

  <us-gaap:StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount contextRef="P07_01_2015To06_30_2016" id="Factid_465" unitRef="USD" decimals="0">173000</us-gaap:StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount>

  <us-gaap:SubsequentEventsTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_466">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note 14 &amp;#150; Subsequent Events&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;In July 2017, our stockholders approved an amendment to our 2015 Stock Option and Incentive Plan to (i) increase the number of authorized shares of common stock reserved for issuance thereunder from 2.0 million to 3.0 million, (ii) increase the number of shares that may be issued as incentive stock options from 2.0 million to 3.0 million, (iii) increase the maximum number of shares of common stock (A) underlying stock options or stock appreciation rights that may be granted to any one individual during any calendar year period, and (B) granted to any one individual that is intended to qualify as &amp;#8220;performance-based compensation&amp;#8221; under Section 162(m) of the Internal Revenue Code of 1986, as amended, for any performance cycle from 1.0 million to 2.0 million, and (iv) in the event that we effect a reverse stock split prior to November 14, 2018 (or such other date that is one year after the date of our 2018 annual meeting of stockholders), immediately after the effective time of such reverse stock split, (A) the maximum number of shares reserved under the Plan will be automatically increased to 3.0 million, (B) the maximum number of shares that may be issued pursuant to any type of award will be automatically increased to 3.0 million, (C) the number of shares that may be granted to any one individual during any one calendar year period as stock options or stock appreciation rights will be automatically increased to 2.0 million, and (D) the number of shares that may be issued in the form of incentive stock options will be automatically increased to 3.0 million.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In July 2017, our stockholders also approved an amendment to our Certificate of Incorporation to effect a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;reverse stock split at a ratio of any whole number up to 1-for-20&lt;/font&gt;, as determined by our board of directors, at any time before November 14, 2018 (or such other date that is one year after the date of our 2018 annual meeting of stockholders), if and as determined by our board of directors.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;August 11, 2017, our board of directors approved a reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding, which was effected on August 25, 2017. This adjustment is reflected in this Annual Report.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On August 11, 2017, we entered into a Securities Purchase Agreement with various investors pursuant to which we agreed to sell Class A and Class B equity units for gross proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11.8&lt;/font&gt; million. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares of common stock and were sold at a negotiated price of $3.00 per unit.&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Class B units consist of one (1) share of our newly created Series A Convertible Preferred Stock (the &amp;#8220;Series A Preferred Stock&amp;#8221;) and warrants to purchase one and one-half (1.5) shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at a negotiated price of $1,000.00 per unit to those purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding common stock following the offering.&lt;/font&gt; These Series A Preferred Shares concert into common shares at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.00&lt;/font&gt; per share, which when fully exercised will increase the common shares outstanding by &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 750,000&lt;/font&gt; shares. The offering closed on August 15, 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In the offering, we issued an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 3,196,665&lt;/font&gt; shares of our common stock, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,250&lt;/font&gt; shares of Series A Preferred Stock and warrants to purchase up to an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,919,998&lt;/font&gt; shares of our common stock.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px"&gt; We incurred certain expenses related to this transaction to attorneys and underwriters inclusive of a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9&lt;/font&gt;% cash fee and warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10&lt;/font&gt;% of the aggregate number of shares issued in the transaction.&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In connection with the closing of the financing, we terminated the Purchase Agreement, dated as of July 27, 2016, by and between us and Lincoln Park Capital Fund, LLC. The termination was effective on August 16, 2017.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>

  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_467">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/b&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/b&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/b&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note 13 &amp;#150; Employee Benefit Plan&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu has a 401(k) plan that allows participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The Company matches 50% of the first 6% contributed to the plan by employees.&lt;/font&gt; In fiscal 2017, the Company&amp;#8217;s match was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;99,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>

  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P07_01_2016To06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_468">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The Company&amp;#8217;s allocation on consideration transferred for ProstaScint as of the purchase date May&amp;#160;20, 2015 was as follows: &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Tangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;727,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,590,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;74,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,391,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>

  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P07_01_2016To06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_469">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The estimated future amortization of ProstaScint after June 30, 2017 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 40%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&amp;#160;ProstaScint&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;47,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;14,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>

  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P07_01_2016To06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_470">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; The Company&amp;#8217;s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 was as follows: &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Tangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;182,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,470,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;147,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,799,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>

  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P07_01_2016To06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_471">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s allocation on consideration transferred for Nuelle as of the purchase date May&amp;#160;5, 2017 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fair&amp;#160;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Tangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,061,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,540,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;238,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,839,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>

  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_472">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Future amortization after the year ended June 30, 2017 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;798,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,518,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>

  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="PAsOn06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_473" unitRef="USD" decimals="0">61000</us-gaap:FiniteLivedIntangibleAssetsNet>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="PAsOn06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_474" unitRef="USD" decimals="0">47000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="PAsOn06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_475" unitRef="USD" decimals="0">14000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="PAsOn06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_476" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="PAsOn06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_477" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="PAsOn06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_478" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>

  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_479">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note 11 &amp;#150; Related Party Transactions&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Services Agreement&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In July 2015, Aytu entered into an agreement with Ampio, whereby Aytu agreed to pay Ampio a set amount per month for shared overhead, which includes costs related to the shared corporate staff and other miscellaneous overhead expenses. This agreement was amended in November 2015, April 2016, July 2016, and again in January 2017 resulting in an amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;12,000&lt;/font&gt; per month. This agreement was terminated in June 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Sponsored Research Agreement&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&amp;#8217;s director and Chief Scientific Officer, Dr.&amp;#160;Bar-Or. The agreement, which was amended in January 2015 and provided for Luoxis (now Aytu) to pay $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6,000&lt;/font&gt; per month to TRLLC in consideration for services related to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;615,000&lt;/font&gt; which was being amortized over the contractual term of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 60.5&lt;/font&gt; months and was divided between current and long-term on the balance sheet; as of September 2014, this amount had been paid in full. This agreement was terminated in March 2017.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_480">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Note&amp;#160;10 &amp;#150; Equity Instruments&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Stock Option Repricing&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In March 2017, our Board of Directors approved a common stock option repricing program whereby all previously granted and unexercised options were repriced on a one-for-one basis to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;16.40&lt;/font&gt; per share which represented the closing price of our common stock as of the date of the repricing. There was no other modification to the vesting schedule of the previously issued options. As a result, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 36,864&lt;/font&gt; unexercised options originally granted to purchase common stock at prices ranging from $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;64.60&lt;/font&gt; to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,111.20&lt;/font&gt; per share were repriced under this program.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;We treated the repricing as a modification of the original awards and calculated additional compensation costs for the difference between the fair value of the modified award and the fair value of the original award on the modification date. The repricing resulted in an incremental stock-based compensation expense of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;34,000&lt;/font&gt;. The full expense was recognized during fiscal 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In July 2016, our &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;Board of Directors approved a common stock option repricing program whereby previously granted and unexercised options held by our then current employees, consultants and directors with exercise prices above $120.00 per share were repriced on a one-for-one basis to $64.60 per share&lt;/font&gt; which represented the per share fair value of our common stock as of the date of the repricing. There was no other modification to the vesting schedule of the previously issued options. As a result, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 15,803&lt;/font&gt; unexercised options originally granted to purchase common stock at prices ranging from $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;134.40&lt;/font&gt; to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;362.40&lt;/font&gt; per share were repriced under this program.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;We treated the repricing as a modification of the original awards and calculated additional compensation costs for the difference between the fair value of the modified award and the fair value of the original award on the modification date. The repricing resulted in an incremental stock-based compensation expense of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;318,000&lt;/font&gt;. Expense related to vested shares was expensed on the repricing date and expense related to unvested shares is being amortized over the remaining vesting period of such stock options.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Options&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;On June&amp;#160;1, 2015, Aytu&amp;#8217;s stockholders approved the 2015 Stock Option and Incentive Plan (the &amp;#8220;2015 Plan&amp;#8221;), which, as amended in November 2016, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 100,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Pursuant to the 2015 Stock Plan, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100,000&lt;/font&gt; shares of its common stock, are reserved for issuance. The fair value of options granted was calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; The assumptions used for the year ended June 30, 2017 are as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;178% - 185%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;75%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0.97% - 1.88%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.16% - 1.90%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Expected term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.0 -6.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3.75 - 6.25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Stock option activity is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Weighted&lt;br/&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Remaining&lt;br/&gt; Contractual&amp;#160;Life&amp;#160;in&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Outstanding June 30, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;16,340&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;360.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Forfeited/Cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(209)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;362.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Outstanding June 30, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;16,131&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;360.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;9.33&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;23,608&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;18.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(1,408)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;83.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(68)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;64.60&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Outstanding June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;38,263&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;16.31&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;8.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Exercisable at June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;19,341&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;16.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;7.95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Available for grant at June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;61,737&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The following table details the options outstanding at June 30, 2017 by range of exercise prices:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="WIDTH: 86%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Weighted Average Remaining Contractual&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Range&amp;#160;of&amp;#160;Exercise&amp;#160;Prices&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Number of Options Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted Average Exercise Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Life of Options Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Number of Options Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted Average Exercise Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;14.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;14.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;9.85&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;14.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;16.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;36,763&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;16.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;8.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;19,341&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;16.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;38,263&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;16.31&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;8.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;19,341&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;16.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and sales, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table summarizes stock-based compensation expense for the years ended June&amp;#160;30, 2017 and 2016:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;89,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Selling, general and administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;2,502,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;814,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;2,502,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;903,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Unrecognized expense at June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;775,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Weighted average remaining years to vest&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;1.81&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Warrants&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of all warrants is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Remaining&amp;#160;Contractual&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Life&amp;#160;in&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Outstanding June 30, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;444&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,087.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.92&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to placement agents for convertible promissory notes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,115&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;156.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to investors in connection with the registered offering&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;86,667&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;120.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to placement agents for convertible promissory notes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,129&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;96.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to placement agents for the registered offering&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,474&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;120.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to convertible note holders who converted May 5, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15,279&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;120.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Outstanding June 30, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;110,108&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;124.02&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.71&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Issuance of settlement warrants to initial investors&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,402&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;80.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to investors in connection with the registered offering&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;301,014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;37.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to placement agents for the registered offering&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;20,077&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(149,552)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Outstanding June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;286,049&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;50.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.23&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In connection with our private placement of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.2&lt;/font&gt; million of convertible notes in July and August 2015, the Company was obligated to issue to the placement agents&amp;#8217; warrants for an amount of shares equal to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8&lt;/font&gt;% of the number of shares of our common stock issued upon conversion of the notes and any accrued interest. The placement agents warrants have a term of five years from the date of issuance of the related notes in July and August 2015, an exercise price equal to 100% of the price per share at which equity securities were sold in our next equity financing, and provide for cashless exercise.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In connection with the conversions of the notes in February 2016 and May 2016, which were triggered by an equity financing in January 2016 and our public offering of common stock and warrants in May 2016, respectively, we issued warrants to the placement agents to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,115&lt;/font&gt; shares of our common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;156.00&lt;/font&gt; per share, and an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,129&lt;/font&gt; shares of our common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;96.00&lt;/font&gt; per share. These warrants have a fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;87,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;50,000&lt;/font&gt;, respectively.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Also in connection with the conversion of the notes in May 2016, the noteholders that converted also received &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 15,279&lt;/font&gt; warrants (see Note 9). These warrants have a term of five years with an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;120.00&lt;/font&gt; per share. These warrants are accounted for under equity treatment and have a fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;480,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In connection with our May 2016 public offering, we issued warrants to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,474&lt;/font&gt; shares of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;120.00&lt;/font&gt; and a term of five years to the underwriters of the public offering. These warrants are accounted for under liability accounting and are fair valued at each reporting period (see Note 6).&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Also in connection with our May 2016 public offering, we issued to investors warrants to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 86,667&lt;/font&gt; shares of common stock, which includes the over-allotment warrants, at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;120.00&lt;/font&gt; with a term of five years. These warrants are accounted for under equity treatment (see Note 10).&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Included in the warrant balance at June 30, 2016 are warrants to purchase of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,474&lt;/font&gt; shares of common stock issued to the underwriters of our May registered offering. These warrants were accounted for under liability accounting and were fair valued at each reporting period (see Note 7). On February 28, 2017, these warrants had a fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;63,000&lt;/font&gt;. Upon the amendment to these warrant agreements, in connection with the closing of our warrant tender offer, this value was reclassified from liability accounting to equity after we removed any provision in the amendment that could cause this to be paid in cash.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Included in the warrant balance at June 30, 2016 are warrants to purchase of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 429&lt;/font&gt; shares of common stock issued to the bankers that assisted us with our Notes (see Note 9). In March 2017, the Company reduced the exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;156.00&lt;/font&gt; to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15.00&lt;/font&gt;. This modification resulted in an expense of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,500&lt;/font&gt; which was recognized during the quarter ended March 31, 2017 in sales, general and administrative.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;During fiscal 2017, Aytu issued warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4,402&lt;/font&gt; shares of common stock to initial investors of the Company at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;80.00&lt;/font&gt; and a term of five years from July 2016. These warrants generated a non-cash expense of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;596,000&lt;/font&gt; for the year ended June 30, 2017, which is included in sales, general and administrative expense. These warrants are accounted for under equity treatment.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In connection with our November 2016 public offering, we issued to the underwriters of the public offering warrants to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 20,077&lt;/font&gt; shares of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;37.20&lt;/font&gt; and a term of five years. These warrants are accounted for under equity treatment. In February, we reduced the exercise price of these warrants to $15.00.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Also in connection with our November 2016 public offering, we issued to investors warrants to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 301,014&lt;/font&gt; shares of common stock, which includes the over-allotment warrants, at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;37.20&lt;/font&gt; with a term of five years. These warrants are accounted for under equity treatment (see Note 10).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2017, the Company consummated its warrant tender offer to exercise, at a temporarily reduced exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15.00&lt;/font&gt; per share, (i) outstanding warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 86,667&lt;/font&gt; shares of common stock with an exercise price of $120.00 per share, which were originally issued to investors in the Company&amp;#8217;s May 2016 financing (the &amp;#8220;May 2016 Warrants&amp;#8221;), and (ii) outstanding warrants to purchase 301,014 shares of common stock with an exercise price of $37.20 per share, which were originally issued to investors in the Company&amp;#8217;s October 2016 financing (the &amp;#8220;October 2016 Warrants&amp;#8221; and together with the May 2016 Warrants, the &amp;#8220;Original Warrants&amp;#8221;). Original Warrants to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 149,552&lt;/font&gt; shares of common stock were tendered and exercised in the warrant tender offer, for aggregate gross proceeds to the Company of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.2&lt;/font&gt; million. Original warrants that were not exercised remain in effect at the pre-tender offer exercise prices of $120.00 per share and $37.20 per share, respectively. The incremental fair value, which had no book impact, was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;178,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company also reduced the exercise prices of an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 25,541&lt;/font&gt; warrants to purchase shares of common stock, which were originally issued as underwriters&amp;#8217; compensation in the May 2016 and October 2016 financings, from $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;120.00&lt;/font&gt; per share and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;37.20&lt;/font&gt; per share, respectively, to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15.00&lt;/font&gt; per share. The amended warrants related to the May 2016 financing adjusted the accounting for these warrants from liability classification to equity. The incremental fair value of these warrant modifications, which had no book impact, was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;23,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;All warrants were valued using the Black-Scholes option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the selling price or fair market value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and expected life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. During fiscal 2017, Aytu modified &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 175,522&lt;/font&gt; warrants. We used the value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15.20&lt;/font&gt; per the valuation of our common stock issued in March 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Significant assumptions in valuing the warrants issued and modified during the year ended June 30, 2017 were as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="30%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;156.64% - 169.22%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;75%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;1.63% - 1.87%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;1.07 - 1.76%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Contractual term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;3.46 - 4.67&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;4.2 - 5.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>

  <aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets contextRef="PAsOn05_05_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_481" unitRef="USD" decimals="0">2061000</aytu:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="PAsOn05_05_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_482" unitRef="USD" decimals="0">1540000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>

  <us-gaap:Goodwill contextRef="PAsOn05_05_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_483" unitRef="USD" decimals="0">238000</us-gaap:Goodwill>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="PAsOn05_05_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_484" unitRef="USD" decimals="0">3839000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="PAsOn06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_485" unitRef="USD" decimals="0">144000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="PAsOn06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_486" unitRef="USD" decimals="0">144000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="PAsOn06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_487" unitRef="USD" decimals="0">144000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="PAsOn06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_488" unitRef="USD" decimals="0">144000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="PAsOn06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_489" unitRef="USD" decimals="0">144000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="PAsOn06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_490" unitRef="USD" decimals="0">798000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>

  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="PAsOn06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_491" unitRef="USD" decimals="0">1518000</us-gaap:FiniteLivedIntangibleAssetsNet>

  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_492">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The assumptions used for the year ended June 30, 2017 are as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="27%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;178% - 185%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;75%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0.97% - 1.88%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1.16% - 1.90%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Expected term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;5.0 -6.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;3.75 - 6.25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_493">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Stock option activity is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Weighted&lt;br/&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Remaining&lt;br/&gt; Contractual&amp;#160;Life&amp;#160;in&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Outstanding June 30, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;16,340&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;360.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Forfeited/Cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(209)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;362.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Outstanding June 30, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;16,131&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;360.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;9.33&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;23,608&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;18.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(1,408)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;83.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(68)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;64.60&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Outstanding June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;38,263&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;16.31&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;8.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Exercisable at June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;19,341&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;16.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;7.95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"&gt; &lt;div&gt;Available for grant at June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;61,737&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_494">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The following table details the options outstanding at June 30, 2017 by range of exercise prices:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="WIDTH: 86%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Weighted Average Remaining Contractual&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div&gt;Range&amp;#160;of&amp;#160;Exercise&amp;#160;Prices&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Number of Options Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted Average Exercise Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"&gt; &lt;div&gt;Life of Options Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Number of Options Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div&gt;Weighted Average Exercise Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;14.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;1,500&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;14.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;9.85&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;14.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;16.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;36,763&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;16.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;8.34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;19,341&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;16.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;38,263&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;16.31&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"&gt; &lt;div&gt;8.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;19,341&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;16.40&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>

  <us-gaap:StockholdersEquityReverseStockSplit contextRef="P07_01_2016To06_30_2017" id="Factid_495">On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding; On August 25, 2017, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding (herein referred to collectively as the Reverse Stock Splits). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.</us-gaap:StockholdersEquityReverseStockSplit>

  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_496">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The following table summarizes stock-based compensation expense for the years ended June&amp;#160;30, 2017 and 2016:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;89,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Selling, general and administrative expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;2,502,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;814,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;2,502,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;903,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Unrecognized expense at June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;775,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Weighted average remaining years to vest&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;1.81&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>

  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_497">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;A summary of all warrants is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Weighted&amp;#160;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Remaining&amp;#160;Contractual&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Exercise&amp;#160;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Life&amp;#160;in&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Outstanding June 30, 2015&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;444&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,087.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.92&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to placement agents for convertible promissory notes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,115&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;156.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to investors in connection with the registered offering&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;86,667&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;120.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to placement agents for convertible promissory notes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,129&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;96.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to placement agents for the registered offering&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,474&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;120.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to convertible note holders who converted May 5, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15,279&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;120.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Outstanding June 30, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;110,108&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;124.02&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.71&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Issuance of settlement warrants to initial investors&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,402&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;80.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to investors in connection with the registered offering&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;301,014&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;37.20&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants issued to placement agents for the registered offering&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;20,077&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrants exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(149,552)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Outstanding June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;286,049&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;50.29&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.23&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>

  <aytu:ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_498">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Significant assumptions in valuing the warrants issued and modified during the year ended June 30, 2017 were as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="30%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;156.64% - 169.22%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;75%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;1.63% - 1.87%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;1.07 - 1.76%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Contractual term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;3.46 - 4.67&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;4.2 - 5.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div&gt;0%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock>

  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="P05_01_2015To05_31_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_499" unitRef="USD" decimals="-5">1000000</us-gaap:PaymentsToAcquireBusinessesGross>

  <aytu:BusinessCombinationConsiderationTransferredProductInventory contextRef="P05_01_2015To05_31_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_500" unitRef="USD" decimals="0">500000</aytu:BusinessCombinationConsiderationTransferredProductInventory>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="PAsOn05_31_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_501" unitRef="USD" decimals="0">227000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>

  <aytu:BusinessCombinationContingentConsiderationPercentage contextRef="P05_01_2015To05_31_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_502" unitRef="pure" decimals="2">0.08</aytu:BusinessCombinationContingentConsiderationPercentage>

  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="P05_01_2015To05_31_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_503" unitRef="USD" decimals="-5">2500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>

  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="P05_01_2015To05_31_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_504" unitRef="USD" decimals="0">664000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="PAsOn05_31_2015_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_505" unitRef="USD" decimals="-5">2400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis_MinimumMemberusgaapRangeAxis" id="Factid_506" unitRef="pure" decimals="2">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis_MaximumMemberusgaapRangeAxis" id="Factid_507" unitRef="pure" decimals="2">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_508" unitRef="pure" decimals="2">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_509" unitRef="pure" decimals="4">0.0097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_510" unitRef="pure" decimals="4">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_511" unitRef="pure" decimals="4">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_512" unitRef="pure" decimals="4">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_513" unitRef="USD" decimals="0">184000</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2015To06_30_2016_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_514" unitRef="USD" decimals="0">174000</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis_MinimumMemberusgaapRangeAxis" id="Factid_515">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis_MaximumMemberusgaapRangeAxis" id="Factid_516">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis_MinimumMemberusgaapRangeAxis" id="Factid_517">P3Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis_MaximumMemberusgaapRangeAxis" id="Factid_518">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_519" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P07_01_2015To06_30_2016_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_520" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="P03_01_2017To03_31_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_521" unitRef="USD" decimals="0">1750000</us-gaap:ProceedsFromDivestitureOfBusinesses>

  <us-gaap:GainLossOnSaleOfBusiness contextRef="P03_01_2017To03_31_2017_PrimsolBusinessMemberusgaapBusinessAcquisitionAxis_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_522" unitRef="USD" decimals="0">428000</us-gaap:GainLossOnSaleOfBusiness>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_523">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_524" unitRef="shares" decimals="INF">23608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_525" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_526" unitRef="shares" decimals="INF">1408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_527" unitRef="shares" decimals="INF">38263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_528" unitRef="USD_per_Share" decimals="2">16.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_529" unitRef="USD_per_Share" decimals="2">83.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_530" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_531" unitRef="USD_per_Share" decimals="2">18.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2014To06_30_2015_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_532">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="P01_01_2017To01_31_2017_ThirdUpfrontMemberusgaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" id="Factid_533" unitRef="USD" decimals="-5">4000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="PAsOn04_28_2016_NatestoMemberusgaapBusinessAcquisitionAxis_SecondUpfrontMemberusgaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" id="Factid_534" unitRef="USD" decimals="-5">2000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>

  <us-gaap:BusinessAcquisitionSharePrice contextRef="PAsOn04_28_2016_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_535" unitRef="USD_per_Share" decimals="2">0.16</us-gaap:BusinessAcquisitionSharePrice>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn06_30_2017" id="Factid_536" unitRef="shares" decimals="INF">38263</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn06_30_2017_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_537" unitRef="shares" decimals="INF">1500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn06_30_2017_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_538" unitRef="shares" decimals="INF">36763</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="PAsOn06_30_2017_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_539" unitRef="USD_per_Share" decimals="2">14.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="PAsOn06_30_2017_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_540" unitRef="USD_per_Share" decimals="2">16.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P07_01_2016To06_30_2017" id="Factid_541" unitRef="USD_per_Share" decimals="2">16.31</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P07_01_2016To06_30_2017_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_542" unitRef="USD_per_Share" decimals="2">14.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="P07_01_2016To06_30_2017_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_543" unitRef="USD_per_Share" decimals="2">16.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2016To06_30_2017" id="Factid_544">P8Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2016To06_30_2017_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_545">P9Y10M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P07_01_2016To06_30_2017_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_546">P8Y4M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn06_30_2017" id="Factid_547" unitRef="shares" decimals="INF">19341</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn06_30_2017_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_548" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn06_30_2017_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_549" unitRef="shares" decimals="INF">19341</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <aytu:CostOfSaleForInvestment contextRef="P07_01_2016To06_30_2017_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_550" unitRef="USD" decimals="0">92000</aytu:CostOfSaleForInvestment>

  <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="P07_01_2016To06_30_2017_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_551" unitRef="USD" decimals="-5">1100000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>

  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss contextRef="P07_01_2016To06_30_2017_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_552" unitRef="USD" decimals="0">62000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss>

  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss contextRef="P07_01_2015To06_30_2016_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_553" unitRef="USD" decimals="0">972000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="P07_01_2016To06_30_2017" id="Factid_554" unitRef="USD_per_Share" decimals="2">16.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="P07_01_2016To06_30_2017_ExercisePriceRangeOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_555" unitRef="USD_per_Share" decimals="2">14.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="P07_01_2016To06_30_2017_ExercisePriceRangeTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_556" unitRef="USD_per_Share" decimals="2">16.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>

  <aytu:OneTimeNonrefundablePayments contextRef="P04_01_2016To04_28_2016_FirstMilestoneMemberusgaapTypeOfArrangementAxis_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_557" unitRef="USD" decimals="-5">2500000</aytu:OneTimeNonrefundablePayments>

  <aytu:SalesRevenueTarget contextRef="P04_01_2016To04_28_2016_FirstMilestoneMemberusgaapTypeOfArrangementAxis_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_558" unitRef="USD" decimals="-5">25000000</aytu:SalesRevenueTarget>

  <aytu:OneTimeNonrefundablePayments contextRef="P04_01_2016To04_28_2016_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis_SecondMilestoneMemberusgaapTypeOfArrangementAxis" id="Factid_559" unitRef="USD" decimals="-5">5000000</aytu:OneTimeNonrefundablePayments>

  <aytu:SalesRevenueTarget contextRef="P04_01_2016To04_28_2016_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis_SecondMilestoneMemberusgaapTypeOfArrangementAxis" id="Factid_560" unitRef="USD" decimals="-5">50000000</aytu:SalesRevenueTarget>

  <aytu:OneTimeNonrefundablePayments contextRef="P04_01_2016To04_28_2016_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis_ThirdMilestoneMemberusgaapTypeOfArrangementAxis" id="Factid_561" unitRef="USD" decimals="-5">7500000</aytu:OneTimeNonrefundablePayments>

  <aytu:SalesRevenueTarget contextRef="P04_01_2016To04_28_2016_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis_ThirdMilestoneMemberusgaapTypeOfArrangementAxis" id="Factid_562" unitRef="USD" decimals="-5">75000000</aytu:SalesRevenueTarget>

  <aytu:OneTimeNonrefundablePayments contextRef="P04_01_2016To04_28_2016_ForthMilestoneMemberusgaapTypeOfArrangementAxis_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_563" unitRef="USD" decimals="-5">10000000</aytu:OneTimeNonrefundablePayments>

  <aytu:SalesRevenueTarget contextRef="P04_01_2016To04_28_2016_ForthMilestoneMemberusgaapTypeOfArrangementAxis_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_564" unitRef="USD" decimals="-5">100000000</aytu:SalesRevenueTarget>

  <aytu:OneTimeNonrefundablePayments contextRef="P04_01_2016To04_28_2016_FifthMilestoneMemberusgaapTypeOfArrangementAxis_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_565" unitRef="USD" decimals="-5">12500000</aytu:OneTimeNonrefundablePayments>

  <aytu:SalesRevenueTarget contextRef="P04_01_2016To04_28_2016_FifthMilestoneMemberusgaapTypeOfArrangementAxis_LicenseAndSupplyAgreementMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_566" unitRef="USD" decimals="-5">125000000</aytu:SalesRevenueTarget>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2016To06_30_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_567" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2016To06_30_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_568" unitRef="USD" decimals="0">2502000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2015To06_30_2016_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_569" unitRef="USD" decimals="0">89000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2015To06_30_2016_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_570" unitRef="USD" decimals="0">814000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2016To06_30_2017" id="Factid_571" unitRef="USD" decimals="0">2502000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="P07_01_2015To06_30_2016" id="Factid_572" unitRef="USD" decimals="0">903000</us-gaap:AllocatedShareBasedCompensationExpense>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="PAsOn06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_573" unitRef="USD" decimals="-5">10500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_574" unitRef="USD" decimals="-5">1300000</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2015To06_30_2016_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_575" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfIntangibleAssets>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering contextRef="P07_01_2015To06_30_2016" id="Factid_576" unitRef="shares" decimals="INF">86667</aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering contextRef="P07_01_2015To06_30_2016" id="Factid_577" unitRef="shares" decimals="INF">5474</aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice contextRef="P07_01_2015To06_30_2016" id="Factid_578" unitRef="USD_per_Share" decimals="2">120.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice contextRef="P07_01_2015To06_30_2016" id="Factid_579" unitRef="USD_per_Share" decimals="2">120.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice>

  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="P07_01_2015To06_30_2016_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_580" unitRef="USD" decimals="-5">3200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>

  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="P07_01_2016To06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_581" unitRef="USD" decimals="-5">5700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>

  <us-gaap:AccretionExpense contextRef="P07_01_2016To06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_582" unitRef="USD" decimals="0">228000</us-gaap:AccretionExpense>

  <us-gaap:AccretionExpense contextRef="P07_01_2015To06_30_2016_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_583" unitRef="USD" decimals="0">228000</us-gaap:AccretionExpense>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2016To06_30_2017_MinimumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_584" unitRef="pure" decimals="4">1.5664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2016To06_30_2017_MaximumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_585" unitRef="pure" decimals="4">1.6922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2015To06_30_2016_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_586" unitRef="pure" decimals="2">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="P07_01_2016To06_30_2017_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_587" unitRef="pure" decimals="4">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="P07_01_2016To06_30_2017_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_588" unitRef="pure" decimals="4">0.0187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="P07_01_2015To06_30_2016_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_589" unitRef="pure" decimals="4">0.0107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="P07_01_2015To06_30_2016_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_590" unitRef="pure" decimals="4">0.0176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2016To06_30_2017_MinimumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_591">P3Y5M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2016To06_30_2017_MaximumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_592">P4Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2015To06_30_2016_MinimumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_593">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P07_01_2015To06_30_2016_MaximumMemberusgaapRangeAxis_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_594">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P07_01_2016To06_30_2017_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_595" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P07_01_2015To06_30_2016_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_596" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ConsolidationPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_597">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Principals of Consolidation&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;These consolidated financial statements include the accounts of Aytu and its wholly-owned subsidiary, Aytu Women&amp;#8217;s Health. All material intercompany transactions and balances have been eliminated.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConsolidationPolicyTextBlock>

  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_598">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Restricted cash consist primarily of a&amp;#160;certificate of deposit investment account. Aytu&amp;#8217;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year, Aytu has maintained balances in excess of federally insured limits.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>

  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_599">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Revenue Recognition&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;License Agreements and Royalties&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones and are recognized at the time the milestones are achieved. Royalties will be recognized as revenue when earned.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Product&amp;#160;&amp;amp; Service Sales&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company recognizes revenue only when all of the following criteria have been met:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.7in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Persuasive evidence of an arrangement exists,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="DISPLAY: none; FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Delivery has occurred or services have been performed,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The fee for the arrangement is fixed or determinable, and&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="DISPLAY: none; FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Persuasive evidence of an arrangement exists - The Company documents all terms of an arrangement in a written contract by the customer prior to recognizing revenue.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Delivery has occurred or services have been performed - The Company delivers all products prior to recognizing revenue. Equipment is considered delivered upon delivery to a customer's designated location.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Device sales are recorded when products are shipped to customers. Drug sales are recorded when the product arrives at the customer&amp;#8217;s dock. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;sales are recorded and are estimated at the time of sale.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;The fee for the arrangement is fixed or determinable - Prior to recognizing revenue, a customer's fee is either fixed or determinable under the terms of the written contract.&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Collectability is reasonably assured - The Company determines that collectability is reasonably assured prior to recognizing revenue. Collectability is assessed on a customer-by-customer basis based on criteria outlined by management. New customers are subject to a credit review process, which evaluates the customer's financial position and ultimately its ability to pay. The Company does not enter into arrangements unless collectability is reasonably assured at the outset. Existing customers are subject to ongoing credit evaluations based on payment history and other factors. If it is determined during the arrangement that collectability is not reasonably assured, revenue is recognized on a cash basis.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>

  <us-gaap:ReceivablesPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_600">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Accounts Receivable&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Accounts receivable are recorded at their net realized value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation allowance accordingly. As of June 30, 2017 we had an allowance for doubtful accounts of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;44,000&lt;/font&gt;, and as of June 30, 2016, there had been an allowance for doubtful accounts of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;41,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReceivablesPolicyTextBlock>

  <us-gaap:InventoryPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_601">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Inventories&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Aytu periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable value in the period that the impairment is first recognized. We currently have a reserve of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;311,000&lt;/font&gt; for slow moving inventory as of June 30, 2017 and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;199,000&lt;/font&gt; at June 30, 2016.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Inventory consist of the following:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Raw materials&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;442,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;77,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Work in process&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;442,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Finished goods&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;738,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;647,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Reserve&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(310,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(199,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;1,312,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;525,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryPolicyTextBlock>

  <us-gaap:MarketableSecuritiesTradingSecuritiesPolicy contextRef="P07_01_2016To06_30_2017" id="Factid_602">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Trading Securities&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"&gt; Trading securities are carried at fair value with realized and unrealized gains and losses recorded in earnings.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTradingSecuritiesPolicy>

  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_603">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Fixed Assets&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Fixed assets are recorded at cost. After being placed in service, the fixed assets are depreciated using the straight-line method over estimated useful lives. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Fixed assets consist of the following:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Useful&amp;#160;Lives&amp;#160;in&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Office equipment, furniture and other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2 - 5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;405,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;201,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Lab equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3 - 5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;111,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;90,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;287,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;45,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Manufacturing equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2 - 5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;90,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Less accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(246,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(112,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fixed assets, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;647,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;231,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu recorded the following depreciation expense in the respective periods:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Depreciation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;134,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;51,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_604" unitRef="shares" decimals="INF">68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="P07_01_2016To06_30_2017_LuoxisDiagnosticsMemberdeiLegalEntityAxis" id="Factid_605" unitRef="USD_per_Share" decimals="2">64.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_606">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Fixed assets consist of the following:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Useful&amp;#160;Lives&amp;#160;in&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Office equipment, furniture and other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2 - 5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;405,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;201,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Lab equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3 - 5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;111,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;90,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;287,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;45,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Manufacturing equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2 - 5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;90,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Less accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(246,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(112,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fixed assets, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;647,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;231,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu recorded the following depreciation expense in the respective periods:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Depreciation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;134,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;51,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2016To06_30_2017_MinimumMemberusgaapRangeAxis_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_607">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2016To06_30_2017_MaximumMemberusgaapRangeAxis_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_608">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2016To06_30_2017_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMemberusgaapRangeAxis" id="Factid_609">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2016To06_30_2017_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMemberusgaapRangeAxis" id="Factid_610">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2016To06_30_2017_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_611">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2016To06_30_2017_ManufacturingFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMemberusgaapRangeAxis" id="Factid_612">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P07_01_2016To06_30_2017_ManufacturingFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMemberusgaapRangeAxis" id="Factid_613">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <aytu:ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement contextRef="P07_01_2016To06_30_2017" id="Factid_614" unitRef="shares" decimals="INF">4402</aytu:ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement>

  <aytu:ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice contextRef="P07_01_2016To06_30_2017" id="Factid_615" unitRef="USD_per_Share" decimals="2">80.00</aytu:ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice>

  <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="P07_01_2016To06_30_2017" id="Factid_616">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Patents&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third party appraisal, was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;500,000&lt;/font&gt;. The Zertane patents were acquired in connection with the 2011 acquisition of DMI BioSciences by Ampio, the former parent company of Aytu, and were being amortized over the remaining U.S. patent lives of approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11&lt;/font&gt; years, which were to expire in March 2022. In fiscal 2016, we redirected our resources towards our commercial-stage products and the Company determined that this asset had no further value as the Company did not have the resources to complete the necessary clinical trials and bring it to market before the patents expired. The remaining fair value of the Zertane patents were expensed as of June 30, 2016.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The cost of the Luoxis patents were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;380,000&lt;/font&gt; when they were acquired in connection with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt; years, which expires in March 2028. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Patents consist of the following:&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Patents&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;880,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;880,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Less accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;(609,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;(583,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Patents, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;271,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;297,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Aytu recorded the following amortization expense in the respective periods:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Amortization expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;26,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;332,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Future amortization from the year ended June 30, 2017 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;146,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;271,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>

  <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="P07_01_2016To06_30_2017" id="Factid_617">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Goodwill&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Nuelle, ProstaScint and Primsol&amp;#160;purchase price allocations&amp;#160;were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May&amp;#160;20, 2015, Primsol that occurred on October 5, 2015 and Nuelle that occurred on May 5, 2017. There was an impairment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;74,000&lt;/font&gt; related to the ProstaScint goodwill for the year ended June 30, 2017.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>

  <aytu:ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice contextRef="P07_01_2016To06_30_2017" id="Factid_618" unitRef="USD_per_Share" decimals="2">15.00</aytu:ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice>

  <us-gaap:UseOfEstimates contextRef="P07_01_2016To06_30_2017" id="Factid_619">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Use of Estimates&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets, collectability of accounts receivable, and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>

  <us-gaap:IncomeTaxPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_620">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Income Taxes&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu has been included in the consolidated tax returns of Ampio, the former parent company of Aytu, for tax years ended on or before December 31, 2015. As of January 2016, due to the decrease in Ampio&amp;#8217;s ownership percentage of Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu's taxes were computed and reported on a "separate return" basis for these financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The amount of income taxes and related income tax positions taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company's policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB ASC 740-1 "Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109" (ASC 740-10) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant tax position requires recognition under ASC 740-10.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>

  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_621">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the graded method.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>

  <aytu:ShareBasedCompensationShareWarrantsExcercised contextRef="P07_01_2016To06_30_2017" id="Factid_622" unitRef="shares" decimals="INF">-149552</aytu:ShareBasedCompensationShareWarrantsExcercised>

  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P07_01_2016To06_30_2017" id="Factid_623">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Research and Development&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Research and development costs are expensed as incurred with expenses recorded in the respective period.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>

  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_624">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Income (Loss) Per Common Share&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. &lt;font style="BACKGROUND: transparent"&gt;Diluted net loss per share reflects the potential of securities that could share in the net loss of Aytu. Basic and diluted loss per share was the same in 2017 and 2016. Although there were common stock equivalents of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 367,312&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 126,239&lt;/font&gt; shares outstanding at June 30, 2017 and 2016, respectively, consisting of stock options and warrants; they were not included in the calculation of the diluted net loss per share because they would have been anti-dilutive.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>

  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P07_01_2016To06_30_2017" id="Factid_625">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted future cash&amp;#160;flows.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>

  <us-gaap:DerivativesPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_626">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Derivative Liability&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu accounts for liability warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial instruments and related warrants were calculated using a Monte Carlo based valuation model. We recorded a derivative expense at the inception of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods was recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income or expense for the warrants.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"&gt; The fair value of the warrants issued to the placement agents in connection with the registered offering were valued using the Black-Scholes valuation methodology. Changes in the fair value in subsequent periods were recorded to derivative income or expense.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DerivativesPolicyTextBlock>

  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_627">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Patents consist of the following:&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Patents&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;880,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;880,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Less accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;(609,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;(583,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Patents, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;271,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;297,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_628">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu recorded the following amortization expense in the respective periods:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Amortization expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;26,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;332,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>

  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P07_01_2016To06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_629">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Future amortization from the year ended June 30, 2017 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;146,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;271,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="PAsOn06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_630" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="PAsOn06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_631" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="PAsOn06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_632" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="PAsOn06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_633" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="PAsOn06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_634" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="PAsOn06_30_2017_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_635" unitRef="USD" decimals="0">146000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P03_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_636" unitRef="USD_per_Share" decimals="2">16.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P03_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_637" unitRef="shares" decimals="INF">36864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="P07_01_2016To06_30_2017_ZertanePatentsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_638">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P03_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMemberusgaapRangeAxis" id="Factid_639" unitRef="USD_per_Share" decimals="2">1111.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P03_01_2017To03_31_2017_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMemberusgaapRangeAxis" id="Factid_640" unitRef="USD_per_Share" decimals="2">64.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <aytu:FiniteLivedIntangibleAssetsExpirationMonthYear contextRef="P07_01_2016To06_30_2017_ZertanePatentsMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_641">2022-03</aytu:FiniteLivedIntangibleAssetsExpirationMonthYear>

  <aytu:FiniteLivedIntangibleAssetsExpirationMonthYear contextRef="P07_01_2016To06_30_2017_OrpMemberusgaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_642">2028-03</aytu:FiniteLivedIntangibleAssetsExpirationMonthYear>

  <aytu:CommonStockOptionRepricingProgramDescription contextRef="P07_01_2016To07_31_2016" id="Factid_643">Board of Directors approved a common stock option repricing program whereby previously granted and unexercised options held by our then current employees, consultants and directors with exercise prices above $120.00 per share were repriced on a one-for-one basis to $64.60 per share</aytu:CommonStockOptionRepricingProgramDescription>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="P07_01_2016To06_30_2017" id="Factid_644" unitRef="USD" decimals="0">34000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>

  <us-gaap:GoodwillImpairmentLoss contextRef="P07_01_2016To06_30_2017" id="Factid_645" unitRef="USD" decimals="0">74000</us-gaap:GoodwillImpairmentLoss>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P07_01_2016To07_31_2016_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_646" unitRef="shares" decimals="INF">15803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P07_01_2016To07_31_2016_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMemberusgaapRangeAxis" id="Factid_647" unitRef="USD_per_Share" decimals="2">134.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P07_01_2016To07_31_2016_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMemberusgaapRangeAxis" id="Factid_648" unitRef="USD_per_Share" decimals="2">362.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <aytu:LicenseAgreementTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_649">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note&amp;#160;4 &amp;#150; License Agreement/Revenue Recognition&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;During 2011, Ampio Pharmaceuticals, Inc., (&amp;#8220;Ampio&amp;#8221;), Aytu&amp;#8217;s former parent company, entered into a license, development and commercialization agreement with a major Korean pharmaceutical company which was assigned to Vyrix when it was formed in 2013. The agreement grants the pharmaceutical company exclusive rights to market Zertane in South Korea for the treatment of premature ejaculation (&amp;#8220;PE&amp;#8221;) and for a combination drug to be developed, utilizing Zertane and an erectile dysfunction drug. Upon signing of the agreement, Ampio received a $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;500,000&lt;/font&gt; upfront payment, the net proceeds of which were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;418,000&lt;/font&gt; after withholding of Korean tax. The upfront payment was deferred and was being recognized as license revenue over a ten-year period. Milestone payments of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.2&lt;/font&gt; million could have been earned and recognized contingent upon achievement of regulatory approvals and cumulative net sales targets, which could have taken several years. In addition, Aytu could have earned a royalty based on &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 25&lt;/font&gt;% of net sales, as defined, if the royalty exceeded the transfer price of the Zertane product. No royalties have been earned to date.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In April 2014, Vyrix entered into a Distribution and License Agreement (the &amp;#8220;Paladin Agreement&amp;#8221;) with Endo Ventures Limited, which acquired Paladin Labs Inc. (&amp;#8220;Paladin&amp;#8221;), whereby Paladin has exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub Saharan Africa, Colombia and Latin America. The Paladin Agreement expires on a country by country basis upon the later of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 15&lt;/font&gt; years after the first commercial sale of the product in that country or expiration of market exclusivity for Zertane in that country. Paladin paid $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250,000&lt;/font&gt; to Vyrix upon signing the Paladin Agreement and is obligated to make milestone payments aggregating up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.0&lt;/font&gt; million based upon achieving Canadian and South African product regulatory approval and achieving specific sales goals. The upfront payment was deferred and was being recognized as license revenue over a seven-year period. In addition, the Paladin Agreement provides that Paladin pay royalties based on sales volume.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;At the end of fiscal 2016, Aytu determined that the Zertane asset had no further value as Aytu did not have the resources to complete the necessary clinical trials and bring it to market before the patents expire. The remaining deferred revenue of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;426,000&lt;/font&gt; was recognized as of June 30, 2016.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:LicenseAgreementTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="P07_01_2016To07_31_2016" id="Factid_650" unitRef="USD" decimals="0">318000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>

  <aytu:FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_651">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The following table presents Aytu&amp;#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2017 and 2016, by level within the fair value hierarchy:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;Using&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;ASSETS&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Investment in Acerus&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;LIABILITIES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrant derivative liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Contingent consideration&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,648,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,648,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;June 30, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;ASSETS&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Investment in Acerus&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,041,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,041,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;LIABILITIES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrant derivative liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;276,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;276,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Contingent consideration&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,869,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,869,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock>

  <us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_652">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Significant assumptions in valuing the warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants, were as follows as of February 28, 2017, the date when the derivative instruments converted into equity, and at June 30, 2016:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; February&amp;#160;28,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;June&amp;#160;30,&amp;#160;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;160.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;75.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Equivalent term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.18&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.84&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.87&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.99&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock>

  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_653">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Derivative&amp;#160;Instruments&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance as of June 30, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;276,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrant issuances&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Change in fair value included in earnings (February 28, 2017)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(213,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Reclassification of warrant from liability to equity upon amendment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(63,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance as of June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="PAsOn06_30_2017_TwoThousandFifteenStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" id="Factid_654" unitRef="shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P02_01_2017To02_28_2017_WarrantMemberusgaapFinancialInstrumentAxis" id="Factid_655" unitRef="pure" decimals="3">1.607</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="P07_01_2015To06_30_2016_WarrantMemberusgaapFinancialInstrumentAxis" id="Factid_656" unitRef="pure" decimals="3">0.750</us-gaap:FairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P02_01_2017To02_28_2017_WarrantMemberusgaapFinancialInstrumentAxis" id="Factid_657">P4Y2M5D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="P07_01_2015To06_30_2016_WarrantMemberusgaapFinancialInstrumentAxis" id="Factid_658">P4Y10M2D</us-gaap:FairValueAssumptionsExpectedTerm>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P02_01_2017To02_28_2017_WarrantMemberusgaapFinancialInstrumentAxis" id="Factid_659" unitRef="pure" decimals="4">0.0187</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="P07_01_2015To06_30_2016_WarrantMemberusgaapFinancialInstrumentAxis" id="Factid_660" unitRef="pure" decimals="4">0.0099</us-gaap:FairValueAssumptionsRiskFreeInterestRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P02_01_2017To02_28_2017_WarrantMemberusgaapFinancialInstrumentAxis" id="Factid_661" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P07_01_2015To06_30_2016_WarrantMemberusgaapFinancialInstrumentAxis" id="Factid_662" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering contextRef="P07_01_2015To06_30_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_663" unitRef="shares" decimals="INF">5474</aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering>

  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="PAsOn02_28_2017_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_664" unitRef="USD" decimals="0">63000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn06_30_2016_BankersWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_665" unitRef="shares" decimals="INF">429</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_666">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note&amp;#160;6 &amp;#150; Income Taxes&lt;/font&gt;&lt;/strong&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;As previously discussed in Note 2 - Summary of Significant Accounting Policies, the Company has been included in the consolidated tax returns of Ampio for tax years ending on or before December 31, 2015. Beginning in January 2016, Aytu will file tax returns separate from Ampio. For all consolidated tax return periods, the Company's taxes have been computed and reported on a "separate return" basis. Ampio and Aytu did not have a tax sharing agreement for the consolidated return periods. Accordingly, certain tax attributes, e.g. net operating loss carryforwards, reflected in these financial statements, may or may not be available to Aytu. In January 2016, Ampio's ownership interest in Aytu fell below 80% so that Aytu will no longer be included in the Ampio consolidated tax return. The deconsolidation resulted in approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.5&lt;/font&gt; million of net operating loss carryforwards originating prior to the incorporation of Vyrix and Luoxis no longer being available to Aytu. Upon deconsolidation, the deferred tax asset and related valuation allowance for these pre-incorporation net operating losses have been removed.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Income tax benefit resulting from applying statutory rates in jurisdictions in which Aytu is taxed (Federal and various states) differs from the income tax provision (benefit) in the Aytu financial statements. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table reflects the reconciliation for the respective periods.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%" colspan="11"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%" colspan="5"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%" colspan="5"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Benefit at statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(7,653,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(34.00)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(9,581,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(34.00)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;State income taxes, net of federal benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(681,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3.02)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(853,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3.03)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Stock based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;116,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.51&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.03&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Interest on convertible debt&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;75,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.27&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Offering costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;203,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.90&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Contingent consideration&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.02&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Change in tax rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(11,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(0.05)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,922,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;35.19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8,672,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;30.77&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Reduction of net operating losses upon deconsolidation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,674,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5.94&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;100,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.45&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.02&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Net income tax provision (benefit)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Deferred tax assets (liabilities):&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Deferred revenue&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Deferred rent&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;3,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;5,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Accrued expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;127,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;445,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Net operating loss carry forward&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;15,435,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;9,202,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Intangibles&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;1,559,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;606,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Share-based coompensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;1,362,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;327,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Fixed assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;191,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Unrealized loss on investment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;360,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Capital loss carry forward&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;385,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Contribution carry forward&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;41,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;75,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;153,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Inventory&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;174,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;192,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Allowance for doubtful accounts&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;17,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;15,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Total deferred income tax assets (liabilities)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;19,369,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;11,305,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Less: Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(19,369,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(11,305,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Total deferred income tax assets (liabilities)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not it will realize the benefits of these deductible differences, net of the valuation allowance provided. The Company has federal net operating losses of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;42.3&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;24.8&lt;/font&gt; million as of June 30, 2017 and June&amp;#160;30, 2016, respectively that, subject to limitation, may be available in future tax years to offset taxable income. The available federal net operating losses, if not utilized to offset taxable income in future periods, will begin to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;expire in 2031 through 2036.&lt;/font&gt; The Company has state net operating losses of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;32.8&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;17.3&lt;/font&gt; million as of June 30, 2017 and June 30, 2016, respectively that, subject to limitation, may be available in future tax years to offset taxable income. The available state net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2036. Under the provisions of the Internal Revenue Code, substantial changes in the Company's ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. Net operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;As of June 30, 2017 and 2016, the Company has no liability for gross unrecognized tax benefits or related interest and penalties.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu has made its best estimates of certain income tax amounts included in the financial statements. Application of the Company&amp;#8217;s accounting policies and estimates, however, involves the exercise of judgement and use of assumptions as to future uncertainties and, as a result, could differ from these estimates. In arriving at its estimates, factors the Company considers include how accurate the estimates or assumptions have been in the past, how much the estimates or assumptions have changed and how reasonably likely such changes may have a material impact. Aytu has been historically included in the Ampio consolidated tax return. Under the general statute of limitations, the Company would not be subject to federal or Colorado income tax examinations for tax years prior to 2013 and 2012, respectively. However, given the net operating losses generated since inception, all tax years since inception are subject to examination.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn03_31_2017_BankersWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_667" unitRef="USD_per_Share" decimals="2">156.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn03_31_2017_BankersWarrantsMemberusgaapClassOfWarrantOrRightAxis_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" id="Factid_668" unitRef="USD_per_Share" decimals="2">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:RestructuringCharges contextRef="P01_01_2017To03_31_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_669" unitRef="USD" decimals="0">1500</us-gaap:RestructuringCharges>

  <aytu:ShareBasedCompensationShareWarrantsIssuedToInvestors contextRef="P07_01_2016To06_30_2017_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_670" unitRef="shares" decimals="INF">4402</aytu:ShareBasedCompensationShareWarrantsIssuedToInvestors>

  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_671">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The following table reflects the reconciliation for the respective periods.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%" colspan="11"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%" colspan="5"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%" colspan="5"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Benefit at statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(7,653,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(34.00)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(9,581,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(34.00)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;State income taxes, net of federal benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(681,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3.02)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(853,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3.03)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Stock based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;116,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.51&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.03&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Interest on convertible debt&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;75,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.27&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Offering costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;203,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.90&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Contingent consideration&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.02&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Change in tax rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(11,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(0.05)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,922,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;35.19&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;8,672,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;30.77&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Reduction of net operating losses upon deconsolidation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,674,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5.94&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;100,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.45&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.02&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div&gt;Net income tax provision (benefit)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>

  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_672">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Deferred tax assets (liabilities):&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Deferred revenue&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Deferred rent&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;3,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;5,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Accrued expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;127,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;445,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Net operating loss carry forward&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;15,435,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;9,202,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Intangibles&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;1,559,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;606,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Share-based coompensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;1,362,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;327,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Fixed assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;191,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Unrealized loss on investment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;360,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Capital loss carry forward&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;385,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Contribution carry forward&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;41,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;75,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;153,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Inventory&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;174,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;192,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Allowance for doubtful accounts&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;17,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;15,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Total deferred income tax assets (liabilities)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;19,369,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;11,305,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Less: Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(19,369,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(11,305,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"&gt; &lt;div&gt;Total deferred income tax assets (liabilities)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>

  <aytu:ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice contextRef="P07_01_2016To06_30_2017_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_673" unitRef="USD_per_Share" decimals="2">80.00</aytu:ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice>

  <aytu:ClassOfWarrantsAndRightsIssuanceCost contextRef="P07_01_2016To06_30_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" id="Factid_674" unitRef="USD" decimals="0">596000</aytu:ClassOfWarrantsAndRightsIssuanceCost>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn06_30_2017_AmpioPharmaceuticalsMemberdeiLegalEntityAxis" id="Factid_675" unitRef="USD" decimals="-5">4500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_676">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;Note&amp;#160;7 &amp;#150; Commitments and Contingencies&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Commitments and contingencies are described below and summarized by the following table as of June&amp;#160;30, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Prescription database&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,342,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;769,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;573,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Natesto&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Manufacturing/commercial supply agreements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Office lease&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;175,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;145,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;30,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16,517,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;914,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;603,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Prescription Database&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In May 2016, Aytu entered into an agreement with a company that will provide Aytu with prescription database information, whereby Aytu agreed to pay approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.9&lt;/font&gt; million over three years for access to the database of prescriptions written for Natesto. The payments have been broken down into quarterly payments, the first of which was made in November 2016, the second payment was made in January 2017 and the third payment was made in April 2017.&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Natesto&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In April 2016, the Company entered into an agreement with Acerus whereby Aytu agreed to pay $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8.0&lt;/font&gt; million for the exclusive U.S. rights to Natesto (see Note 1). The first payment totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.0&lt;/font&gt; million was paid in April, the second installment payment was paid in October 2016. The final payment totaling $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.0&lt;/font&gt; million was paid in January 2017. Additionally, Aytu is required to make the first milestone payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.5&lt;/font&gt; million even if the milestone is not reached and anticipates making the second milestone payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.0&lt;/font&gt; million along with the third milestone payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.5&lt;/font&gt; million.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Manufacturing/Commercial Supply Agreements&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In October 2015, Aytu entered into a Master Services Agreement with Biovest International, Inc. (&amp;#8220;Biovest&amp;#8221;). The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of its products for the ProstaScint product. In September 2016, Aytu entered into a Commercial Supply Agreement with Grand River Aseptic Manufacturing, Inc. (&amp;#8220;GRAM&amp;#8221;). The agreement provides that Aytu may engage GRAM from time to time to provide services in accordance with mutually agreed upon work orders. As of June 30, 2017, both contracts were on hold as the Company evaluates its strategic options for the ProstaScint product. If the contracts are not restarted, Aytu does not anticipate any future liability related to either contract.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&lt;i&gt;Office Lease&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In June 2015, Aytu entered into a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;37&lt;/font&gt; month operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,000&lt;/font&gt; a month, with total base rent over the term of the lease of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;112,000&lt;/font&gt;. In September 2015, the Company entered into a 37 month operating lease in Englewood, Colorado. This lease has an initial base rent of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,000&lt;/font&gt; a month with a total base rent over the term of the lease of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;318,000&lt;/font&gt;. The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Rent expense for the respective periods is as follows:&lt;/div&gt; &amp;#160;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div&gt;Rent expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"&gt; &lt;div&gt;139,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"&gt; &lt;div&gt;120,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

  <aytu:CommitmentsAndContingenciesDisclosureTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_677">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Commitments and contingencies are described below and summarized by the following table as of June&amp;#160;30, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Prescription database&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,342,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;769,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;573,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Natesto&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;15,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Manufacturing/commercial supply agreements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;Office lease&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;175,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;145,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;30,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;16,517,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;914,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;603,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;5,000,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,500,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:CommitmentsAndContingenciesDisclosureTableTextBlock>

  <us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_678">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Rent expense for the respective periods is as follows:&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"&gt; &lt;div&gt;Rent expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"&gt; &lt;div&gt;139,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"&gt; &lt;div&gt;120,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>

  <aytu:ShareBasedCompensationShareWarrantsIssuedToInvestors contextRef="P11_01_2016To11_30_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_679" unitRef="shares" decimals="INF">20077</aytu:ShareBasedCompensationShareWarrantsIssuedToInvestors>

  <aytu:ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice contextRef="P11_01_2016To11_30_2016_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_680" unitRef="USD_per_Share" decimals="2">37.20</aytu:ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice>

  <us-gaap:ContractualObligation contextRef="PAsOn06_30_2017" id="Factid_681" unitRef="USD" decimals="0">16517000</us-gaap:ContractualObligation>

  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="PAsOn06_30_2017" id="Factid_682" unitRef="USD" decimals="0">914000</us-gaap:ContractualObligationDueInNextTwelveMonths>

  <us-gaap:ContractualObligationDueInSecondYear contextRef="PAsOn06_30_2017" id="Factid_683" unitRef="USD" decimals="0">603000</us-gaap:ContractualObligationDueInSecondYear>

  <us-gaap:ContractualObligationDueInThirdYear contextRef="PAsOn06_30_2017" id="Factid_684" unitRef="USD" decimals="0">2500000</us-gaap:ContractualObligationDueInThirdYear>

  <us-gaap:ContractualObligationDueInFourthYear contextRef="PAsOn06_30_2017" id="Factid_685" unitRef="USD" decimals="0">5000000</us-gaap:ContractualObligationDueInFourthYear>

  <us-gaap:ContractualObligationDueInFifthYear contextRef="PAsOn06_30_2017" id="Factid_686" unitRef="USD" decimals="0">0</us-gaap:ContractualObligationDueInFifthYear>

  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="PAsOn06_30_2017" id="Factid_687" unitRef="USD" decimals="0">7500000</us-gaap:ContractualObligationDueAfterFifthYear>

  <aytu:ShareBasedCompensationShareWarrantsIssuedToInvestors contextRef="P11_01_2016To11_30_2016_OverAllotmentWarrantsMemberaytuOverAllotmentWarrantsAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_688" unitRef="shares" decimals="INF">301014</aytu:ShareBasedCompensationShareWarrantsIssuedToInvestors>

  <aytu:ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice contextRef="P11_01_2016To11_30_2016_OverAllotmentWarrantsMemberaytuOverAllotmentWarrantsAxis_PlacementAgentWarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_689" unitRef="USD_per_Share" decimals="2">37.20</aytu:ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice>

  <aytu:WarrantsModified contextRef="P07_01_2016To06_30_2017" id="Factid_690" unitRef="shares" decimals="INF">175522</aytu:WarrantsModified>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P07_01_2016To06_30_2017" id="Factid_691" unitRef="USD_per_Share" decimals="2">15.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn02_28_2017" id="Factid_692" unitRef="shares" decimals="INF">25541</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn02_28_2017" id="Factid_693" unitRef="USD_per_Share" decimals="2">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn02_28_2017_May2016WarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_694" unitRef="USD_per_Share" decimals="2">120.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn02_28_2017_October2016WarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_695" unitRef="USD_per_Share" decimals="2">37.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:FairValueAdjustmentOfWarrants contextRef="P02_01_2017To02_28_2017" id="Factid_696" unitRef="USD" decimals="0">23000</us-gaap:FairValueAdjustmentOfWarrants>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn02_28_2017_May2016WarrantsMemberusgaapClassOfWarrantOrRightAxis" id="Factid_697" unitRef="shares" decimals="INF">86667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn02_28_2017_BankersWarrantsMemberusgaapClassOfWarrantOrRightAxis_OtherRestructuringMemberusgaapRestructuringCostAndReserveAxis" id="Factid_698" unitRef="USD_per_Share" decimals="2">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn02_28_2017" id="Factid_699" unitRef="shares" decimals="INF">149552</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P02_01_2017To02_28_2017" id="Factid_700" unitRef="USD" decimals="-5">2200000</us-gaap:ProceedsFromIssuanceOfWarrants>

  <us-gaap:DerivativeLiabilities contextRef="PAsOn02_28_2017_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_701" unitRef="USD" decimals="0">178000</us-gaap:DerivativeLiabilities>

  <us-gaap:ContractualObligation contextRef="PAsOn04_30_2016_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_702" unitRef="USD" decimals="-5">8000000</us-gaap:ContractualObligation>

  <aytu:PaymentOfContractualObligations contextRef="P10_01_2016To10_31_2016_FirstInstallmentMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_703" unitRef="USD" decimals="-5">2000000</aytu:PaymentOfContractualObligations>

  <aytu:PaymentOfContractualObligations contextRef="P01_01_2017To01_31_2017_FirstInstallmentMemberusgaapRelatedPartyTransactionAxis_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_704" unitRef="USD" decimals="-5">4000000</aytu:PaymentOfContractualObligations>

  <aytu:FirstMilestonePayable contextRef="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_705" unitRef="USD" decimals="-5">2500000</aytu:FirstMilestonePayable>

  <aytu:SecondMilestonePayable contextRef="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_706" unitRef="USD" decimals="-5">5000000</aytu:SecondMilestonePayable>

  <aytu:ThirdMilestonePayable contextRef="PAsOn06_30_2017_NatestoMemberusgaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" id="Factid_707" unitRef="USD" decimals="-5">7500000</aytu:ThirdMilestonePayable>

  <us-gaap:DebtDisclosureTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_708">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note&amp;#160;8 &amp;#150; Convertible Promissory Notes&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth individual investors for the purchase and sale of convertible promissory notes (&amp;#8220;Notes&amp;#8221;) with an aggregate principal amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.2&lt;/font&gt; million. The sale of the Notes was pursuant to a private placement. Debt issuance costs totaled $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;401,000&lt;/font&gt;, which included the $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;103,000&lt;/font&gt; fair value of the placement agent warrants.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Notes were an unsecured obligation. Aytu did not have the right to prepay the Notes prior to the maturity date. Interest accrued on the Notes in the following amounts: (i)&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8&lt;/font&gt;% simple interest per annum for the first six months and (ii)&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 12&lt;/font&gt;% simple interest per annum thereafter if not converted during the first nine months. Interest accrued, was payable with the principal upon maturity, conversion or acceleration of the Notes and could have been paid in kind or in cash, in Aytu&amp;#8217;s sole discretion.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Placement agents for the offering sold the institutional portion of the offering of the Notes. Aytu sold the balance of the Notes to individuals and entities with whom Aytu had an established relationship. For Notes sold by the placement agent, Aytu paid the placement agent &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8&lt;/font&gt;% of the gross proceeds of Notes sold by the placement agents and was obligated to issue warrants for an amount of shares equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents in the private placement, in addition to a previously paid non-refundable retainer fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20,000&lt;/font&gt;. The placement agent warrants have a term of five years from the date of issuance of the related notes in July and August 2015, an exercise price equal to the conversion price per share at which the Notes are converted into common stock. Change in fair value is recorded in earnings. Fair value at the grant date was recorded as a debt discount and amortized over the term of the debt.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The warrants were recorded at fair value as long-term liabilities on the Balance Sheet and upon conversion were moved to equity classification.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Upon Aytu&amp;#8217;s adoption of ASU 2015-3, the issuance costs associated with the Notes were recorded as a long&amp;#150;term liability and were presented in the Balance Sheet as a direct reduction of the carrying amount of the Notes on their inception date.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Pursuant to the terms of the convertible promissory note agreements, if Aytu sold equity securities at any time while the Notes were outstanding in a financing transaction that was not a Qualified Financing (a public offering of Aytu stock resulting in gross proceeds of at least $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.0&lt;/font&gt; million (excluding indebtedness converted in such financing) prior to the maturity date of the Notes), the holders of the convertible promissory notes had the option, but not the obligation, to convert the outstanding principal and accrued interest as of the closing of such financings into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (a) the lowest cash price per share paid by purchasers of shares in such financing, or (b) $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;92.60&lt;/font&gt;. As a result of Aytu&amp;#8217;s sale of common stock on January 20, 2016, the Company was obligated to provide notice to the above-referenced noteholders of such stock sales. In accordance with the convertible note terms, noteholders had the option to convert their entire balance (inclusive of accrued but unpaid interest) into a number of shares of Aytu common stock equal to 120% of the number of shares calculated by dividing such note balance by $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;156.00&lt;/font&gt;, which was the per share purchase price paid in the equity financing described above. On February 10, 2015, the date of the conversion, an aggregate of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.1&lt;/font&gt; million of principal and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;143,000&lt;/font&gt; of accrued interest on the Notes converted into an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 32,830&lt;/font&gt; shares of Aytu&amp;#8217;s common stock under the original terms of the agreement.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In May 2016, Aytu completed a registered public offering which was considered a Qualified Financing and all outstanding Notes were automatically converted on the same terms as in the offering. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;At the insistence of the underwriters of the offering, all outstanding noteholders had signed lockup agreements which granted them an extra 10% on the conversion, increasing it to 130% of shares calculated by dividing such Note balance by $96.00&lt;/font&gt;, which was the per share purchase price in the registered offering. On May 6, 2016, the date of conversion, an aggregate of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.1&lt;/font&gt; million of principal and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;78,000&lt;/font&gt; of accrued interest on the Notes converted into an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 15,279&lt;/font&gt; shares of Aytu&amp;#8217;s common stock and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 15,279&lt;/font&gt; warrants.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In connection with the conversion of the Aytu Notes, Aytu was obligated to issue to the placement agents for the convertible note offering warrants for an amount of shares equal to 8% of the number of shares of Aytu&amp;#8217;s common stock for the Notes sold by the placement agents issued upon conversion of the Notes. As a result of the optional note conversion, on February 10, 2016, Aytu issued warrants to the placement agents to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,113&lt;/font&gt; shares of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;156.00&lt;/font&gt; per share. As a result of the second Note conversion, on May 6, 2016, Aytu issued warrants to the placement agents to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,129&lt;/font&gt; shares of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;96.00&lt;/font&gt; per share. These warrants are exercisable for five years from the date of issuance of the related Notes in July and August 2015. The warrants have a cashless exercise feature.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Also in connection with the conversion of the Notes, Aytu recorded a beneficial conversion feature of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.9&lt;/font&gt; million which was recorded as a debt discount; this amount represents that carrying amount of the Notes at the date of conversion. The&amp;#160;beneficial conversion feature was expensed upon conversion of the Notes to interest expense.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn01_20_2016_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_709" unitRef="USD_per_Share" decimals="2">156.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature contextRef="P07_01_2016To06_30_2017" id="Factid_710">At the insistence of the underwriters of the offering, all outstanding noteholders had signed lockup agreements which granted them an extra 10% on the conversion, increasing it to 130% of shares calculated by dividing such Note balance by $96.00</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_711">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note&amp;#160;9 &amp;#150; Common Stock&lt;/font&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;b&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Capital Stock&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;At June 30, 2017 and June 30, 2016, Aytu had &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 824,831&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 187,098&lt;/font&gt; common shares outstanding, respectively, and no preferred shares outstanding at either June 30, 2017 or June 30, 2016. The Company has &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100.0&lt;/font&gt;&lt;/font&gt;&amp;#160;million shares of common stock authorized with a par value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0001&lt;/font&gt;&lt;/font&gt;&amp;#160;per share and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50.0&lt;/font&gt;&lt;/font&gt;&amp;#160;million shares of preferred stock authorized with a par value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0001&lt;/font&gt;&lt;/font&gt; per share.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In May 2016, Aytu raised gross proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.5&lt;/font&gt; million through a public offering of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 78,125&lt;/font&gt; Units. Offering costs totaled $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.2&lt;/font&gt; million resulting in net proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.3&lt;/font&gt; million. Each Unit consisted of one share of Aytu common stock and a warrant to purchase one share of Aytu common stock. The common stock issued had a relative fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.2&lt;/font&gt; million. The warrants have an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;120.00&lt;/font&gt; per share and will expire five years from the date of issuance. These warrants have a relative fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.1&lt;/font&gt; million. We also granted the underwriters a 45-day option (the Over-Allotment Option) to purchase up to an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 11,719&lt;/font&gt; shares of common stock and/or warrants. The underwriters exercised &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 8,542&lt;/font&gt; of this over-allotment option for the warrants and paid $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.40&lt;/font&gt; per over-allotment warrant resulting in proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20,000&lt;/font&gt;. These warrants have the same terms as the warrants sold in the registered offering.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In July 2016, we entered into a purchase agreement (the &amp;#8216;&amp;#8216;Purchase Agreement&amp;#8217;&amp;#8217;), together with a registration rights agreement (the &amp;#8216;&amp;#8216;Registration Rights Agreement&amp;#8217;&amp;#8217;), with Lincoln Park Capital Fund, LLC (&amp;#8216;&amp;#8216;Lincoln Park&amp;#8217;&amp;#8217;). Upon signing the Purchase Agreement, Lincoln Park agreed to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6,684&lt;/font&gt; shares of our common stock for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;500,000&lt;/font&gt; as an initial purchase under the agreement. We also issued as a commitment fee to Lincoln Park of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,625&lt;/font&gt; shares of common stock. Between September 2016 and June 2017, Lincoln Park purchased an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10,000&lt;/font&gt; shares for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;240,000&lt;/font&gt;, the issuance costs related to these purchases totaled $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;91,000&lt;/font&gt;, resulting in net proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;649,000&lt;/font&gt;. We terminated the Purchase Agreement effective August 16, 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In July 2016, we issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 50,000&lt;/font&gt; shares of restricted stock as compensation to certain executive officers and directors, which vest in July 2026. This expense is included in sales, general and administrative. For the year ended June 30, 2017, the expense was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;725,000&lt;/font&gt;. The original fair value of the restricted stock was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.2&lt;/font&gt; million.&amp;#160;As of June 30, 2017, the remaining unrecognized expense is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.5&lt;/font&gt;&amp;#160;million. During fiscal 2017, one of the Company&amp;#8217;s executive officers resigned and his restricted stock vested in full upon this event. This resulted in the Company recognizing the remainder of the expense related to this executive&amp;#8217;s restricted stock grant of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;430,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In August 2016, we issued an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 7,123&lt;/font&gt; shares of common stock as bonuses for performance in 2016 to three executive officers.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In November 2016, we raised gross proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8.6&lt;/font&gt; million through a public offering of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 286,749&lt;/font&gt; Units. Offering costs totaled $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.0&lt;/font&gt; million resulting in net cash proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.6&lt;/font&gt; million. We also issued underwriter warrants in connection with the offering with a fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;293,000&lt;/font&gt;, resulting in net proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.3&lt;/font&gt; million. Each Unit consisted of one share of Aytu common stock and a warrant to purchase one share of Aytu common stock. The common stock issued had a relative fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.7&lt;/font&gt; million and a fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.4&lt;/font&gt; million. The investor warrants have an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;37.20&lt;/font&gt; per share and will expire five years from the date of issuance. These investor warrants have a relative fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.5&lt;/font&gt; million and a fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.2&lt;/font&gt; million. We also granted the underwriters a 45-day option (the Over-Allotment Option) to purchase up to an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 43,013&lt;/font&gt; shares of common stock and/or warrants. The underwriters purchased &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 14,263&lt;/font&gt; of this Over-Allotment Option for the warrants and paid $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.20&lt;/font&gt; per over-allotment warrant. These warrants have the same terms as the warrants sold in the registered offering. These warrants have a relative fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;173,000&lt;/font&gt;, a fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;208,000&lt;/font&gt;, and proceeds of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,000&lt;/font&gt;, which was the purchase price per the underwriting agreement.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2017, the Company consummated its warrant tender offer to exercise, at a temporarily reduced exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15.00&lt;/font&gt; per share, (i) outstanding warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 86,667&lt;/font&gt; shares of common stock with an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;120.00&lt;/font&gt; per share, which were originally issued to investors in the Company&amp;#8217;s May 2016 financing (the &amp;#8220;May 2016 Warrants&amp;#8221;), and (ii) outstanding warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 301,013&lt;/font&gt; shares of common stock with an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;37.20&lt;/font&gt; per share, which were originally issued to investors in the Company&amp;#8217;s October 2016 financing (the &amp;#8220;October 2016 Warrants&amp;#8221; and together with the May 2016 Warrants, the &amp;#8220;Original Warrants&amp;#8221;). Original warrants to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 149,552&lt;/font&gt; shares of common stock were tendered and exercised in the warrant tender offer, for aggregate gross proceeds to the Company of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.2&lt;/font&gt; million. Original warrants that were not tendered and exercised remain in effect at the pre-tender offer exercise prices of $120.00 per share and $37.20 per share, respectively (see Note 11).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In May 2017, we entered into a Merger Agreement with Nuelle, Inc. and its stockholders, pursuant to which Nuelle would become our wholly owned subsidiary (the &amp;#8220;Merger&amp;#8221;). The Merger closed on May 5, 2017. As part of the Merger, we issued to the Nuelle preferred stockholders an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 125,000&lt;/font&gt;&amp;#160;shares of our common stock.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P05_01_2016To05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_712" unitRef="USD" decimals="-5">7500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P05_01_2016To05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_713" unitRef="shares" decimals="INF">78125</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P05_01_2016To05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_714" unitRef="USD" decimals="-5">1200000</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="P05_01_2016To05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_715" unitRef="USD" decimals="-5">6300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>

  <us-gaap:EquityFairValueDisclosure contextRef="PAsOn05_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_716" unitRef="USD" decimals="-5">4200000</us-gaap:EquityFairValueDisclosure>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn05_31_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_717" unitRef="USD_per_Share" decimals="2">120.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:EquityFairValueDisclosure contextRef="PAsOn05_31_2016_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_718" unitRef="USD" decimals="-5">2100000</us-gaap:EquityFairValueDisclosure>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P05_01_2016To05_31_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_719" unitRef="shares" decimals="INF">11719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <aytu:UnderwritersExercisedOfOverallotmentOption contextRef="P05_01_2016To05_31_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_720" unitRef="shares" decimals="INF">8542</aytu:UnderwritersExercisedOfOverallotmentOption>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn05_31_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_721" unitRef="USD_per_Share" decimals="2">2.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P05_01_2016To05_31_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_722" unitRef="USD" decimals="0">20000</us-gaap:ProceedsFromIssuanceOfWarrants>

  <aytu:CommonStockSharesAgreedToPurchase contextRef="P07_01_2016To07_31_2016_LincolnParkCapitalFundLlcPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_723" unitRef="shares" decimals="INF">6684</aytu:CommonStockSharesAgreedToPurchase>

  <aytu:CommonStockValueAgreedToPurchase contextRef="P07_01_2016To07_31_2016_LincolnParkCapitalFundLlcPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_724" unitRef="USD" decimals="0">500000</aytu:CommonStockValueAgreedToPurchase>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P07_01_2016To07_31_2016_LincolnParkCapitalFundLlcPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_725" unitRef="shares" decimals="INF">2625</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P10_01_2016To06_30_2017_LincolnParkCapitalFundLlcPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_726" unitRef="shares" decimals="INF">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P10_01_2016To06_30_2017_LincolnParkCapitalFundLlcPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_727" unitRef="USD" decimals="0">240000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P10_01_2016To06_30_2017_LincolnParkCapitalFundLlcPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_728" unitRef="USD" decimals="0">91000</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P07_01_2016To06_30_2017_LincolnParkCapitalFundLlcPurchaseAgreementMemberusgaapTypeOfArrangementAxis" id="Factid_729" unitRef="USD" decimals="0">649000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="P07_01_2016To07_31_2016_DirectorMemberusgaapTitleOfIndividualAxis" id="Factid_730" unitRef="shares" decimals="INF">50000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="P07_01_2016To06_30_2017_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_731" unitRef="USD" decimals="-5">3200000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="PAsOn06_30_2017_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_732" unitRef="USD" decimals="-5">2500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>

  <us-gaap:StockOptionPlanExpense contextRef="P07_01_2016To06_30_2017_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_733" unitRef="USD" decimals="0">430000</us-gaap:StockOptionPlanExpense>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P08_01_2016To08_31_2016_ExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_734" unitRef="shares" decimals="INF">7123</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P11_01_2016To11_30_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_735" unitRef="USD" decimals="-5">8600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P11_01_2016To11_30_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_736" unitRef="shares" decimals="INF">286749</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P11_01_2016To11_30_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_737" unitRef="USD" decimals="-5">1000000</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="P11_01_2016To11_30_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_738" unitRef="USD" decimals="-5">7600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P11_01_2016To11_30_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_739" unitRef="USD" decimals="0">293000</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P11_01_2016To11_30_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_740" unitRef="USD" decimals="-5">7300000</us-gaap:ProceedsFromIssuanceOfWarrants>

  <aytu:EquityRelativeFairValue contextRef="PAsOn11_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_741" unitRef="USD" decimals="-5">3700000</aytu:EquityRelativeFairValue>

  <us-gaap:EquityFairValueDisclosure contextRef="PAsOn11_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_742" unitRef="USD" decimals="-5">4400000</us-gaap:EquityFairValueDisclosure>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn11_30_2016_IPOMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_743" unitRef="USD_per_Share" decimals="2">37.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <aytu:EquityRelativeFairValue contextRef="PAsOn11_30_2016_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_744" unitRef="USD" decimals="-5">3500000</aytu:EquityRelativeFairValue>

  <us-gaap:EquityFairValueDisclosure contextRef="PAsOn11_30_2016_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_745" unitRef="USD" decimals="-5">4200000</us-gaap:EquityFairValueDisclosure>

  <us-gaap:WarrantsAndRightsOutstanding contextRef="PAsOn11_30_2016" id="Factid_746" unitRef="USD" decimals="0">173000</us-gaap:WarrantsAndRightsOutstanding>

  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P11_01_2016To11_30_2016" id="Factid_747" unitRef="USD" decimals="0">3000</us-gaap:ProceedsFromIssuanceOfWarrants>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P11_01_2016To11_30_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_748" unitRef="shares" decimals="INF">43013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <aytu:UnderwritersExercisedOfOverallotmentOption contextRef="P11_01_2016To11_30_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_749" unitRef="shares" decimals="INF">14263</aytu:UnderwritersExercisedOfOverallotmentOption>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn11_30_2016_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_750" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:EquityFairValueDisclosure contextRef="PAsOn11_30_2016_OverAllotmentWarrantsMemberusgaapDebtInstrumentAxis" id="Factid_751" unitRef="USD" decimals="0">208000</us-gaap:EquityFairValueDisclosure>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn02_28_2017_May2016WarrantsMemberusgaapStatementClassOfStockAxis" id="Factid_752" unitRef="USD_per_Share" decimals="2">120.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn02_28_2017_October2016WarrantsMemberusgaapStatementClassOfStockAxis" id="Factid_753" unitRef="USD_per_Share" decimals="2">37.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn02_28_2017_May2016WarrantsMemberusgaapStatementClassOfStockAxis" id="Factid_754" unitRef="shares" decimals="INF">86667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn02_28_2017_October2016WarrantsMemberusgaapStatementClassOfStockAxis" id="Factid_755" unitRef="shares" decimals="INF">301013</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P05_01_2017To05_05_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_756" unitRef="shares" decimals="INF">125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:AssetsNoncurrent contextRef="PAsOn06_30_2017" id="Factid_757" unitRef="USD" decimals="0">11969955</us-gaap:AssetsNoncurrent>

  <us-gaap:AssetsNoncurrent contextRef="PAsOn06_30_2016" id="Factid_758" unitRef="USD" decimals="0">14222780</us-gaap:AssetsNoncurrent>

  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="PAsOn06_30_2017" id="Factid_759" unitRef="USD" decimals="0">75214</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>

  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="PAsOn06_30_2016" id="Factid_760" unitRef="USD" decimals="0">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn06_30_2017" id="Factid_761" unitRef="USD" decimals="0">2220400</us-gaap:AccountsPayableCurrent>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn06_30_2016" id="Factid_762" unitRef="USD" decimals="0">2322605</us-gaap:AccountsPayableCurrent>

  <us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn06_30_2017" id="Factid_763" unitRef="USD" decimals="0">782536</us-gaap:AccruedLiabilitiesCurrent>

  <us-gaap:AccruedLiabilitiesCurrent contextRef="PAsOn06_30_2016" id="Factid_764" unitRef="USD" decimals="0">1197106</us-gaap:AccruedLiabilitiesCurrent>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2015" id="Factid_765" unitRef="USD" decimals="0">15616452</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_766" unitRef="USD" decimals="0">6</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2015_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_767" unitRef="USD" decimals="0">38997787</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2015_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_768" unitRef="USD" decimals="0">-5000000</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2015_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_769" unitRef="USD" decimals="0">-18381341</us-gaap:StockholdersEquity>

  <us-gaap:SharesIssued contextRef="PAsOn06_30_2015_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_770" unitRef="shares" decimals="INF">59415</us-gaap:SharesIssued>

  <aytu:StockSubscriptionPayment contextRef="P07_01_2015To06_30_2016" id="Factid_771" unitRef="USD" decimals="0">5000000</aytu:StockSubscriptionPayment>

  <aytu:StockSubscriptionPayment contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_772" unitRef="USD" decimals="0">0</aytu:StockSubscriptionPayment>

  <aytu:StockSubscriptionPayment contextRef="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_773" unitRef="USD" decimals="0">0</aytu:StockSubscriptionPayment>

  <aytu:StockSubscriptionPayment contextRef="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_774" unitRef="USD" decimals="0">5000000</aytu:StockSubscriptionPayment>

  <aytu:StockSubscriptionPayment contextRef="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_775" unitRef="USD" decimals="0">0</aytu:StockSubscriptionPayment>

  <aytu:StockSubscriptionPaymentOfShares contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_776" unitRef="shares" decimals="INF">0</aytu:StockSubscriptionPaymentOfShares>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2015To06_30_2016" id="Factid_777" unitRef="USD" decimals="0">200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_778" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_779" unitRef="USD" decimals="0">200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_780" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_781" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_782" unitRef="shares" decimals="INF">1282</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P07_01_2015To06_30_2016" id="Factid_783" unitRef="USD" decimals="0">10090849</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_784" unitRef="USD" decimals="0">5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_785" unitRef="USD" decimals="0">10090844</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_786" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_787" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_788" unitRef="shares" decimals="INF">48108</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_789" unitRef="USD" decimals="0">0</aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote>

  <aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote contextRef="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_790" unitRef="USD" decimals="0">136828</aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote>

  <aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote contextRef="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_791" unitRef="USD" decimals="0">0</aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote>

  <aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote contextRef="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_792" unitRef="USD" decimals="0">0</aytu:AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote>

  <aytu:IssuanceOfStockIssuedDuringPeriodvalue contextRef="P07_01_2015To06_30_2016" id="Factid_793" unitRef="USD" decimals="0">4237874</aytu:IssuanceOfStockIssuedDuringPeriodvalue>

  <aytu:IssuanceOfStockIssuedDuringPeriodvalue contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_794" unitRef="USD" decimals="0">8</aytu:IssuanceOfStockIssuedDuringPeriodvalue>

  <aytu:IssuanceOfStockIssuedDuringPeriodvalue contextRef="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_795" unitRef="USD" decimals="0">4237866</aytu:IssuanceOfStockIssuedDuringPeriodvalue>

  <aytu:IssuanceOfStockIssuedDuringPeriodvalue contextRef="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_796" unitRef="USD" decimals="0">0</aytu:IssuanceOfStockIssuedDuringPeriodvalue>

  <aytu:IssuanceOfStockIssuedDuringPeriodvalue contextRef="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_797" unitRef="USD" decimals="0">0</aytu:IssuanceOfStockIssuedDuringPeriodvalue>

  <aytu:StockAndIssuedDuringPeriodshares contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_798" unitRef="shares" decimals="INF">78125</aytu:StockAndIssuedDuringPeriodshares>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="P07_01_2015To06_30_2016" id="Factid_799" unitRef="USD" decimals="0">2059895</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_800" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_801" unitRef="USD" decimals="0">2059895</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_802" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_803" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P07_01_2015To06_30_2016" id="Factid_804" unitRef="USD" decimals="0">20493</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_805" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_806" unitRef="USD" decimals="0">20493</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_807" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_808" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="P07_01_2015To06_30_2016" id="Factid_809" unitRef="USD" decimals="0">0</aytu:AdjustmentForRoundingOfValueDueToConversion>

  <aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_810" unitRef="USD" decimals="0">0</aytu:AdjustmentForRoundingOfValueDueToConversion>

  <aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_811" unitRef="USD" decimals="0">0</aytu:AdjustmentForRoundingOfValueDueToConversion>

  <aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_812" unitRef="USD" decimals="0">0</aytu:AdjustmentForRoundingOfValueDueToConversion>

  <aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_813" unitRef="USD" decimals="0">0</aytu:AdjustmentForRoundingOfValueDueToConversion>

  <aytu:AdjustmentForRoundingOfSharesDueToConversion contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_814" unitRef="shares" decimals="INF">168</aytu:AdjustmentForRoundingOfSharesDueToConversion>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P07_01_2015To06_30_2016" id="Factid_815" unitRef="USD" decimals="0">902946</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_816" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_817" unitRef="USD" decimals="0">902946</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_818" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_819" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_820" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2015To06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_821" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2015To06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_822" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2015To06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_823" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2015To06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_824" unitRef="USD" decimals="0">-28180084</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_825" unitRef="USD" decimals="0">19</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_826" unitRef="USD" decimals="0">56646659</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2016_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_827" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_828" unitRef="USD" decimals="0">-46561425</us-gaap:StockholdersEquity>

  <us-gaap:SharesIssued contextRef="PAsOn06_30_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_829" unitRef="shares" decimals="INF">187098</us-gaap:SharesIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P07_01_2016To06_30_2017" id="Factid_830" unitRef="USD" decimals="0">2502092</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_831" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_832" unitRef="USD" decimals="0">2502092</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_833" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_834" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_835" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="P07_01_2016To06_30_2017" id="Factid_836" unitRef="USD" decimals="0">724613</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_837" unitRef="USD" decimals="0">5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_838" unitRef="USD" decimals="0">724608</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_839" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_840" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>

  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_841" unitRef="shares" decimals="INF">50000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P07_01_2016To06_30_2017" id="Factid_842" unitRef="USD" decimals="0">509996</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_843" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_844" unitRef="USD" decimals="0">509996</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_845" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_846" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>

  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_847" unitRef="shares" decimals="INF">7123</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P07_01_2016To06_30_2017" id="Factid_848" unitRef="USD" decimals="0">596434</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_849" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_850" unitRef="USD" decimals="0">596434</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_851" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_852" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <aytu:IssuanceOfStockIssuedDuringPeriodvalue contextRef="P07_01_2016To06_30_2017" id="Factid_853" unitRef="USD" decimals="0">3671581</aytu:IssuanceOfStockIssuedDuringPeriodvalue>

  <aytu:IssuanceOfStockIssuedDuringPeriodvalue contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_854" unitRef="USD" decimals="0">29</aytu:IssuanceOfStockIssuedDuringPeriodvalue>

  <aytu:IssuanceOfStockIssuedDuringPeriodvalue contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_855" unitRef="USD" decimals="0">3671552</aytu:IssuanceOfStockIssuedDuringPeriodvalue>

  <aytu:IssuanceOfStockIssuedDuringPeriodvalue contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_856" unitRef="USD" decimals="0">0</aytu:IssuanceOfStockIssuedDuringPeriodvalue>

  <aytu:IssuanceOfStockIssuedDuringPeriodvalue contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_857" unitRef="USD" decimals="0">0</aytu:IssuanceOfStockIssuedDuringPeriodvalue>

  <aytu:StockAndIssuedDuringPeriodshares contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_858" unitRef="shares" decimals="INF">286749</aytu:StockAndIssuedDuringPeriodshares>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="P07_01_2016To06_30_2017" id="Factid_859" unitRef="USD" decimals="0">3470646</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_860" unitRef="USD" decimals="0">3470646</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_861" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_862" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P07_01_2016To06_30_2017" id="Factid_863" unitRef="USD" decimals="0">172629</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_864" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_865" unitRef="USD" decimals="0">172629</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_866" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_867" unitRef="USD" decimals="0">0</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>

  <aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts contextRef="P07_01_2016To06_30_2017" id="Factid_868" unitRef="USD" decimals="0">292630</aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts>

  <aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_869" unitRef="USD" decimals="0">0</aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts>

  <aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_870" unitRef="USD" decimals="0">292630</aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts>

  <aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_871" unitRef="USD" decimals="0">0</aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts>

  <aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_872" unitRef="USD" decimals="0">0</aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts>

  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_873" unitRef="shares" decimals="INF">149552</us-gaap:StockIssuedDuringPeriodSharesOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P07_01_2016To06_30_2017" id="Factid_874" unitRef="USD" decimals="0">1931123</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_875" unitRef="USD" decimals="0">15</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_876" unitRef="USD" decimals="0">1931108</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_877" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_878" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueOther>

  <aytu:Adjustmentstoadditionalpaidincapitalwarrantamendments contextRef="P07_01_2016To06_30_2017" id="Factid_879" unitRef="USD" decimals="0">64690</aytu:Adjustmentstoadditionalpaidincapitalwarrantamendments>

  <aytu:Adjustmentstoadditionalpaidincapitalwarrantamendments contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_880" unitRef="USD" decimals="0">0</aytu:Adjustmentstoadditionalpaidincapitalwarrantamendments>

  <aytu:Adjustmentstoadditionalpaidincapitalwarrantamendments contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_881" unitRef="USD" decimals="0">64690</aytu:Adjustmentstoadditionalpaidincapitalwarrantamendments>

  <aytu:Adjustmentstoadditionalpaidincapitalwarrantamendments contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_882" unitRef="USD" decimals="0">0</aytu:Adjustmentstoadditionalpaidincapitalwarrantamendments>

  <aytu:Adjustmentstoadditionalpaidincapitalwarrantamendments contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_883" unitRef="USD" decimals="0">0</aytu:Adjustmentstoadditionalpaidincapitalwarrantamendments>

  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="P07_01_2016To06_30_2017" id="Factid_884" unitRef="USD" decimals="0">1837500</us-gaap:StockIssuedDuringPeriodValueAcquisitions>

  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_885" unitRef="USD" decimals="0">12</us-gaap:StockIssuedDuringPeriodValueAcquisitions>

  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_886" unitRef="USD" decimals="0">1837488</us-gaap:StockIssuedDuringPeriodValueAcquisitions>

  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_887" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>

  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_888" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>

  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_889" unitRef="shares" decimals="INF">125000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_890" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_891" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_892" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_893" unitRef="USD" decimals="0">-22508304</us-gaap:NetIncomeLoss>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_894" unitRef="USD" decimals="0">82</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_895" unitRef="USD" decimals="0">73069463</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_896" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_897" unitRef="USD" decimals="0">-69069729</us-gaap:StockholdersEquity>

  <us-gaap:SharesIssued contextRef="PAsOn06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_898" unitRef="shares" decimals="INF">824831</us-gaap:SharesIssued>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_899" unitRef="shares" decimals="INF">19309</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2016To06_30_2017" id="Factid_900" unitRef="USD" decimals="0">648933</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_901" unitRef="USD" decimals="0">2</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2016To06_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_902" unitRef="USD" decimals="0">648931</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2016To06_30_2017_ReceivablesFromStockholderMemberusgaapStatementEquityComponentsAxis" id="Factid_903" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P07_01_2016To06_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" id="Factid_904" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts contextRef="P07_01_2015To06_30_2016" id="Factid_905" unitRef="USD" decimals="0">29754</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P07_01_2015To06_30_2016" id="Factid_906" unitRef="USD" decimals="0">1202231</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts contextRef="P07_01_2016To06_30_2017_LincolnparkMemberdeiLegalEntityAxis" id="Factid_907" unitRef="USD" decimals="0">90924</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P07_01_2016To06_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_908" unitRef="USD" decimals="0">997865</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P07_01_2016To06_30_2017_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_909" unitRef="USD" decimals="0">312159</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:RestrictedStockExpense contextRef="P07_01_2016To06_30_2017" id="Factid_910" unitRef="USD" decimals="0">724613</us-gaap:RestrictedStockExpense>

  <us-gaap:RestrictedStockExpense contextRef="P07_01_2015To06_30_2016" id="Factid_911" unitRef="USD" decimals="0">0</us-gaap:RestrictedStockExpense>

  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="P07_01_2016To06_30_2017" id="Factid_912" unitRef="USD" decimals="0">-61519</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>

  <us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 contextRef="P07_01_2015To06_30_2016" id="Factid_913" unitRef="USD" decimals="0">-971629</us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1>

  <aytu:Issuanceofcommonstocktoexecutives contextRef="P07_01_2016To06_30_2017" id="Factid_914" unitRef="USD" decimals="0">509996</aytu:Issuanceofcommonstocktoexecutives>

  <aytu:Issuanceofcommonstocktoexecutives contextRef="P07_01_2015To06_30_2016" id="Factid_915" unitRef="USD" decimals="0">0</aytu:Issuanceofcommonstocktoexecutives>

  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="P07_01_2016To06_30_2017" id="Factid_916" unitRef="USD" decimals="0">596434</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>

  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="P07_01_2015To06_30_2016" id="Factid_917" unitRef="USD" decimals="0">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>

  <us-gaap:GainLossOnDispositionOfAssets contextRef="P07_01_2016To06_30_2017" id="Factid_918" unitRef="USD" decimals="0">428374</us-gaap:GainLossOnDispositionOfAssets>

  <us-gaap:GainLossOnDispositionOfAssets contextRef="P07_01_2015To06_30_2016" id="Factid_919" unitRef="USD" decimals="0">0</us-gaap:GainLossOnDispositionOfAssets>

  <us-gaap:RestructuringCharges contextRef="P07_01_2016To06_30_2017" id="Factid_920" unitRef="USD" decimals="0">1507</us-gaap:RestructuringCharges>

  <us-gaap:RestructuringCharges contextRef="P07_01_2015To06_30_2016" id="Factid_921" unitRef="USD" decimals="0">0</us-gaap:RestructuringCharges>

  <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="P07_01_2016To06_30_2017" id="Factid_922" unitRef="USD" decimals="0">91864</us-gaap:PaymentsToAcquireLongtermInvestments>

  <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="P07_01_2015To06_30_2016" id="Factid_923" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireLongtermInvestments>

  <us-gaap:ProceedsFromSaleOfOtherProductiveAssets contextRef="P07_01_2016To06_30_2017" id="Factid_924" unitRef="USD" decimals="0">1750000</us-gaap:ProceedsFromSaleOfOtherProductiveAssets>

  <us-gaap:ProceedsFromSaleOfOtherProductiveAssets contextRef="P07_01_2015To06_30_2016" id="Factid_925" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromSaleOfOtherProductiveAssets>

  <us-gaap:CashAcquiredFromAcquisition contextRef="P07_01_2016To06_30_2017" id="Factid_926" unitRef="USD" decimals="0">613309</us-gaap:CashAcquiredFromAcquisition>

  <us-gaap:CashAcquiredFromAcquisition contextRef="P07_01_2015To06_30_2016" id="Factid_927" unitRef="USD" decimals="0">0</us-gaap:CashAcquiredFromAcquisition>

  <us-gaap:OtherPaymentsToAcquireBusinesses contextRef="P07_01_2016To06_30_2017" id="Factid_928" unitRef="USD" decimals="0">16082</us-gaap:OtherPaymentsToAcquireBusinesses>

  <us-gaap:OtherPaymentsToAcquireBusinesses contextRef="P07_01_2015To06_30_2016" id="Factid_929" unitRef="USD" decimals="0">0</us-gaap:OtherPaymentsToAcquireBusinesses>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P07_01_2016To06_30_2017" id="Factid_930" unitRef="USD" decimals="0">739857</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P07_01_2015To06_30_2016" id="Factid_931" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P07_01_2016To06_30_2017" id="Factid_932" unitRef="USD" decimals="0">90924</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P07_01_2015To06_30_2016" id="Factid_933" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfStockIssuanceCosts>

  <aytu:Proceedsfromissuanceofwarranttenderoffer contextRef="P07_01_2016To06_30_2017" id="Factid_934" unitRef="USD" decimals="0">2243282</aytu:Proceedsfromissuanceofwarranttenderoffer>

  <aytu:Proceedsfromissuanceofwarranttenderoffer contextRef="P07_01_2015To06_30_2016" id="Factid_935" unitRef="USD" decimals="0">0</aytu:Proceedsfromissuanceofwarranttenderoffer>

  <aytu:Paymentsforwarranttenderoffercost contextRef="P07_01_2016To06_30_2017" id="Factid_936" unitRef="USD" decimals="0">312159</aytu:Paymentsforwarranttenderoffercost>

  <aytu:Paymentsforwarranttenderoffercost contextRef="P07_01_2015To06_30_2016" id="Factid_937" unitRef="USD" decimals="0">0</aytu:Paymentsforwarranttenderoffercost>

  <aytu:Proceedsfromissuanceofcommonstockandwarrants contextRef="P07_01_2016To06_30_2017" id="Factid_938" unitRef="USD" decimals="0">8602499</aytu:Proceedsfromissuanceofcommonstockandwarrants>

  <aytu:Proceedsfromissuanceofcommonstockandwarrants contextRef="P07_01_2015To06_30_2016" id="Factid_939" unitRef="USD" decimals="0">7520493</aytu:Proceedsfromissuanceofcommonstockandwarrants>

  <aytu:Paymentsforregisteredofferingcosts contextRef="P07_01_2016To06_30_2017" id="Factid_940" unitRef="USD" decimals="0">997865</aytu:Paymentsforregisteredofferingcosts>

  <aytu:Paymentsforregisteredofferingcosts contextRef="P07_01_2015To06_30_2016" id="Factid_941" unitRef="USD" decimals="0">904914</aytu:Paymentsforregisteredofferingcosts>

  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P07_01_2016To06_30_2017" id="Factid_942" unitRef="USD" decimals="0">2852</us-gaap:ProceedsFromIssuanceOfWarrants>

  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P07_01_2015To06_30_2016" id="Factid_943" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfWarrants>

  <aytu:Fixedassetsincludedinaccountspayable contextRef="P07_01_2016To06_30_2017" id="Factid_944" unitRef="USD" decimals="0">10789</aytu:Fixedassetsincludedinaccountspayable>

  <aytu:Fixedassetsincludedinaccountspayable contextRef="P07_01_2015To06_30_2016" id="Factid_945" unitRef="USD" decimals="0">0</aytu:Fixedassetsincludedinaccountspayable>

  <aytu:Warrantsissuedinconnectionwithequityfinancingtoplacementagents contextRef="P07_01_2016To06_30_2017" id="Factid_946" unitRef="USD" decimals="0">292630</aytu:Warrantsissuedinconnectionwithequityfinancingtoplacementagents>

  <aytu:Warrantsissuedinconnectionwithequityfinancingtoplacementagents contextRef="P07_01_2015To06_30_2016" id="Factid_947" unitRef="USD" decimals="0">0</aytu:Warrantsissuedinconnectionwithequityfinancingtoplacementagents>

  <aytu:Warrantsamendedinconnectionwithwarranttenderoffer contextRef="P07_01_2016To06_30_2017" id="Factid_948" unitRef="USD" decimals="0">63182</aytu:Warrantsamendedinconnectionwithwarranttenderoffer>

  <aytu:Warrantsamendedinconnectionwithwarranttenderoffer contextRef="P07_01_2015To06_30_2016" id="Factid_949" unitRef="USD" decimals="0">0</aytu:Warrantsamendedinconnectionwithwarranttenderoffer>

  <us-gaap:AccretionExpense contextRef="P07_01_2015To06_30_2016" id="Factid_950" unitRef="USD" decimals="0">6000000</us-gaap:AccretionExpense>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P07_01_2016To06_30_2017" id="Factid_951" unitRef="USD" decimals="0">620325</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="P07_01_2015To06_30_2016" id="Factid_952" unitRef="USD" decimals="0">620325</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>

  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_953">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note 12 &amp;#150; Segment Information&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"&gt; Aytu manages our Company and aggregated our operational and financial information in accordance with two reportable segments: Aytu and Aytu Women&amp;#8217;s Health. The Aytu segment consists of our core male urology products.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; The Aytu Women&amp;#8217;s Health segment contains our women&amp;#8217;s health platform which consists of sexual wellness platform. Select financial information for these segments is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Revenue:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;3,175,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;2,562,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu Women's Health&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;47,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Consolidated revenue&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;3,222,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;2,562,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Consolidated net loss:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;(22,349,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;(28,180,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu Women's Health&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;(159,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Consolidated net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;(22,508,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;(28,180,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Total assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;11,779,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;24,343,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu Women's Health&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;3,220,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;14,999,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;24,343,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>

  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_954">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"&gt; The Aytu Women&amp;#8217;s Health segment contains our women&amp;#8217;s health platform which consists of sexual wellness platform. Select financial information for these segments is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Revenue:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;3,175,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;2,562,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu Women's Health&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;47,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Consolidated revenue&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;3,222,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;2,562,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Consolidated net loss:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;(22,349,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;(28,180,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu Women's Health&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;(159,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Consolidated net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;(22,508,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;(28,180,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Total assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;11,779,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;24,343,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Aytu Women's Health&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;3,220,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Total assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;14,999,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div&gt;24,343,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>

  <us-gaap:Revenues contextRef="P07_01_2016To06_30_2017_AytuBioscienceIncMemberusgaapStatementBusinessSegmentsAxis" id="Factid_955" unitRef="USD" decimals="0">3175000</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P07_01_2016To06_30_2017_AytuWomensHealthMemberusgaapStatementBusinessSegmentsAxis" id="Factid_956" unitRef="USD" decimals="0">47000</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P07_01_2015To06_30_2016_AytuBioscienceIncMemberusgaapStatementBusinessSegmentsAxis" id="Factid_957" unitRef="USD" decimals="0">2562000</us-gaap:Revenues>

  <us-gaap:Revenues contextRef="P07_01_2015To06_30_2016_AytuWomensHealthMemberusgaapStatementBusinessSegmentsAxis" id="Factid_958" unitRef="USD" decimals="0">0</us-gaap:Revenues>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2016To06_30_2017_AytuBioscienceIncMemberusgaapStatementBusinessSegmentsAxis" id="Factid_959" unitRef="USD" decimals="0">-22349000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2016To06_30_2017_AytuWomensHealthMemberusgaapStatementBusinessSegmentsAxis" id="Factid_960" unitRef="USD" decimals="0">-159000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2015To06_30_2016_AytuBioscienceIncMemberusgaapStatementBusinessSegmentsAxis" id="Factid_961" unitRef="USD" decimals="0">-28180000</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P07_01_2015To06_30_2016_AytuWomensHealthMemberusgaapStatementBusinessSegmentsAxis" id="Factid_962" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:Assets contextRef="PAsOn06_30_2016_AytuBioscienceIncMemberusgaapStatementBusinessSegmentsAxis" id="Factid_963" unitRef="USD" decimals="0">24343000</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn06_30_2016_AytuWomensHealthMemberusgaapStatementBusinessSegmentsAxis" id="Factid_964" unitRef="USD" decimals="0">0</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn06_30_2017_AytuBioscienceIncMemberusgaapStatementBusinessSegmentsAxis" id="Factid_965" unitRef="USD" decimals="0">11779000</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn06_30_2017_AytuWomensHealthMemberusgaapStatementBusinessSegmentsAxis" id="Factid_966" unitRef="USD" decimals="0">3220000</us-gaap:Assets>

  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_967" unitRef="shares" decimals="INF">125000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>

  <aytu:SalesRevenueTarget contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_968" unitRef="USD" decimals="-5">100000000</aytu:SalesRevenueTarget>

  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_969" unitRef="USD" decimals="-5">6900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>

  <aytu:RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_970" unitRef="USD" decimals="-5">24000000</aytu:RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales>

  <aytu:SalesRevenueTarget contextRef="P05_01_2017To05_31_2017_FirstMilestoneMemberusgaapTypeOfArrangementAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_971" unitRef="USD" decimals="-5">10000000</aytu:SalesRevenueTarget>

  <aytu:OneTimeNonrefundablePayments contextRef="P05_01_2017To05_31_2017_FirstMilestoneMemberusgaapTypeOfArrangementAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_972" unitRef="USD" decimals="-5">1000000</aytu:OneTimeNonrefundablePayments>

  <aytu:SalesRevenueTarget contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_SecondMilestoneMemberusgaapTypeOfArrangementAxis" id="Factid_973" unitRef="USD" decimals="-5">17500000</aytu:SalesRevenueTarget>

  <aytu:OneTimeNonrefundablePayments contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_SecondMilestoneMemberusgaapTypeOfArrangementAxis" id="Factid_974" unitRef="USD" decimals="-5">1800000</aytu:OneTimeNonrefundablePayments>

  <aytu:SalesRevenueTarget contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_ThirdMilestoneMemberusgaapTypeOfArrangementAxis" id="Factid_975" unitRef="USD" decimals="-5">25000000</aytu:SalesRevenueTarget>

  <aytu:OneTimeNonrefundablePayments contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_ThirdMilestoneMemberusgaapTypeOfArrangementAxis" id="Factid_976" unitRef="USD" decimals="-5">2500000</aytu:OneTimeNonrefundablePayments>

  <aytu:SalesRevenueTarget contextRef="P05_01_2017To05_31_2017_ForthMilestoneMemberusgaapTypeOfArrangementAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_977" unitRef="USD" decimals="-5">37500000</aytu:SalesRevenueTarget>

  <aytu:OneTimeNonrefundablePayments contextRef="P05_01_2017To05_31_2017_ForthMilestoneMemberusgaapTypeOfArrangementAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_978" unitRef="USD" decimals="-5">3800000</aytu:OneTimeNonrefundablePayments>

  <aytu:SalesRevenueTarget contextRef="P05_01_2017To05_31_2017_FifthMilestoneMemberusgaapTypeOfArrangementAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_979" unitRef="USD" decimals="-5">50000000</aytu:SalesRevenueTarget>

  <aytu:OneTimeNonrefundablePayments contextRef="P05_01_2017To05_31_2017_FifthMilestoneMemberusgaapTypeOfArrangementAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_980" unitRef="USD" decimals="-5">5000000</aytu:OneTimeNonrefundablePayments>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_981" unitRef="USD" decimals="0">22000</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2015To06_30_2016_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_982" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="PAsOn05_31_2017_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_983" unitRef="USD" decimals="-5">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="PAsOn05_31_2017_CustomerContractsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_984" unitRef="USD" decimals="0">80000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>

  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="PAsOn05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_985" unitRef="USD" decimals="0">160000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P05_01_2017To05_31_2017_MinimumMemberusgaapRangeAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_986">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P05_01_2017To05_31_2017_MaximumMemberusgaapRangeAxis_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_987">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>

  <us-gaap:PaymentsToAcquireBusinessesGross contextRef="P10_01_2016To10_31_2016_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_988" unitRef="USD" decimals="-5">2000000</us-gaap:PaymentsToAcquireBusinessesGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms contextRef="P07_01_2017To07_31_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_989">In July 2017, our stockholders approved an amendment to our 2015 Stock Option and Incentive Plan to (i) increase the number of authorized shares of common stock reserved for issuance thereunder from 2.0 million to 3.0 million, (ii) increase the number of shares that may be issued as incentive stock options from 2.0 million to 3.0 million, (iii) increase the maximum number of shares of common stock (A) underlying stock options or stock appreciation rights that may be granted to any one individual during any calendar year period, and (B) granted to any one individual that is intended to qualify as performance-based compensation under Section 162(m) of the Internal Revenue Code of 1986, as amended, for any performance cycle from 1.0 million to 2.0 million, and (iv) in the event that we effect a reverse stock split prior to November 14, 2018 (or such other date that is one year after the date of our 2018 annual meeting of stockholders), immediately after the effective time of such reverse stock split, (A) the maximum number of shares reserved under the Plan will be automatically increased to 3.0 million, (B) the maximum number of shares that may be issued pursuant to any type of award will be automatically increased to 3.0 million, (C) the number of shares that may be granted to any one individual during any one calendar year period as stock options or stock appreciation rights will be automatically increased to 2.0 million, and (D) the number of shares that may be issued in the form of incentive stock options will be automatically increased to 3.0 million.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>

  <us-gaap:StockholdersEquityReverseStockSplit contextRef="P08_01_2017To08_31_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_990">reverse stock split at a ratio of any whole number up to 1-for-20</us-gaap:StockholdersEquityReverseStockSplit>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P08_01_2017To08_11_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_991" unitRef="USD" decimals="-5">11800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:ConcentrationRiskCreditRisk contextRef="P07_01_2016To06_30_2017" id="Factid_992">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Concentration of Business Risks&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The following counterparties contributed greater than&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt;&lt;/font&gt;%&amp;#160;of the Company's total revenue during the year ended June 30, 2017 and 2016, respectively. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The revenue from these counterparties as a percentage of total revenue was as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer B&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The loss of one or more of the Company's significant partners or collaborators could have a material adverse effect on its business, operating results or financial condition. Although the Company is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management does not believe significant credit risk exists as of&amp;#160;June&amp;#160;30, 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of June 30, 2017, three customers accounted for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 60&lt;/font&gt;% of gross accounts receivable. As of June 30, 2016, one customer accounted for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 69&lt;/font&gt;% of gross accounts receivable.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer B&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;69&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>

  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="P08_01_2017To08_11_2017_ClassUnitsMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_993">Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares of common stock and were sold at a negotiated price of $3.00 per unit.</us-gaap:SaleOfStockDescriptionOfTransaction>

  <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_994">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The revenue from these counterparties as a percentage of total revenue was as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer B&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;&amp;#160;&lt;/div&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer B&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;69&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>

  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="P08_01_2017To08_11_2017_ClassBUnitsMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_995">Class B units consist of one (1) share of our newly created Series A Convertible Preferred Stock (the Series A Preferred Stock) and warrants to purchase one and one-half (1.5) shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at a negotiated price of $1,000.00 per unit to those purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding common stock following the offering.</us-gaap:SaleOfStockDescriptionOfTransaction>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2017To08_11_2017_CommonStockMemberusgaapStatementEquityComponentsAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_996" unitRef="shares" decimals="INF">3196665</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2017To08_11_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_997" unitRef="shares" decimals="INF">2250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn08_11_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_998" unitRef="shares" decimals="INF">5919998</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_999">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Inventory consist of the following:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Raw materials&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;442,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;77,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Work in process&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;442,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Finished goods&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;738,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;647,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Reserve&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(310,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(199,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;1,312,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;525,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2016To06_30_2017_CustomerOneMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_1000" unitRef="pure" decimals="2">0.34</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2016To06_30_2017_CustomerTwoMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_1001" unitRef="pure" decimals="2">0.22</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2016To06_30_2017_CustomerThreeMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_1002" unitRef="pure" decimals="2">0.18</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2016To06_30_2017_CustomerFourMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_1003" unitRef="pure" decimals="0">0</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2015To06_30_2016_CustomerOneMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_1004" unitRef="pure" decimals="0">0</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2015To06_30_2016_CustomerTwoMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_1005" unitRef="pure" decimals="0">0</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2015To06_30_2016_CustomerThreeMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_1006" unitRef="pure" decimals="0">0</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2015To06_30_2016_CustomerFourMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_1007" unitRef="pure" decimals="2">0.86</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2016To06_30_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerOneMemberusgaapConcentrationRiskByTypeAxis" id="Factid_1008" unitRef="pure" decimals="2">0.25</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2016To06_30_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerTwoMemberusgaapConcentrationRiskByTypeAxis" id="Factid_1009" unitRef="pure" decimals="2">0.17</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2016To06_30_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerThreeMemberusgaapConcentrationRiskByTypeAxis" id="Factid_1010" unitRef="pure" decimals="2">0.18</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2016To06_30_2017_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerFourMemberusgaapConcentrationRiskByTypeAxis" id="Factid_1011" unitRef="pure" decimals="0">0</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2015To06_30_2016_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerOneMemberusgaapConcentrationRiskByTypeAxis" id="Factid_1012" unitRef="pure" decimals="0">0</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2015To06_30_2016_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerTwoMemberusgaapConcentrationRiskByTypeAxis" id="Factid_1013" unitRef="pure" decimals="0">0</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2015To06_30_2016_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerThreeMemberusgaapConcentrationRiskByTypeAxis" id="Factid_1014" unitRef="pure" decimals="0">0</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2015To06_30_2016_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerFourMemberusgaapConcentrationRiskByTypeAxis" id="Factid_1015" unitRef="pure" decimals="2">0.69</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:InventoryRawMaterials contextRef="PAsOn06_30_2017" id="Factid_1016" unitRef="USD" decimals="0">442000</us-gaap:InventoryRawMaterials>

  <us-gaap:InventoryRawMaterials contextRef="PAsOn06_30_2016" id="Factid_1017" unitRef="USD" decimals="0">77000</us-gaap:InventoryRawMaterials>

  <us-gaap:InventoryWorkInProcess contextRef="PAsOn06_30_2017" id="Factid_1018" unitRef="USD" decimals="0">442000</us-gaap:InventoryWorkInProcess>

  <us-gaap:InventoryWorkInProcess contextRef="PAsOn06_30_2016" id="Factid_1019" unitRef="USD" decimals="0">0</us-gaap:InventoryWorkInProcess>

  <us-gaap:InventoryFinishedGoods contextRef="PAsOn06_30_2017" id="Factid_1020" unitRef="USD" decimals="0">738000</us-gaap:InventoryFinishedGoods>

  <us-gaap:InventoryFinishedGoods contextRef="PAsOn06_30_2016" id="Factid_1021" unitRef="USD" decimals="0">647000</us-gaap:InventoryFinishedGoods>

  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="PAsOn06_30_2016" id="Factid_1022" unitRef="USD" decimals="0">41000</us-gaap:AllowanceForDoubtfulAccountsReceivable>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2016To06_30_2017_CustomerConcentrationRiskMemberusgaapConcentrationRiskByBenchmarkAxis_MinimumMemberusgaapRangeAxis" id="Factid_1023" unitRef="pure" decimals="1">0.1</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2015To06_30_2016_CustomerConcentrationRiskMemberusgaapConcentrationRiskByBenchmarkAxis_MinimumMemberusgaapRangeAxis" id="Factid_1024" unitRef="pure" decimals="1">0.1</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="P01_01_2017To01_31_2017_AmpioPharmaceuticalsIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_1025" unitRef="USD" decimals="0">12000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>

  <us-gaap:InventoryValuationReserves contextRef="PAsOn06_30_2016" id="Factid_1026" unitRef="USD" decimals="0">199000</us-gaap:InventoryValuationReserves>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2016To06_30_2017_CustomerConcentrationRiskMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_1027" unitRef="pure" decimals="1">0.6</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:ConcentrationRiskPercentage1 contextRef="P07_01_2015To06_30_2016_CustomerFourMemberusgaapConcentrationRiskByBenchmarkAxis" id="Factid_1028" unitRef="pure" decimals="2">0.69</us-gaap:ConcentrationRiskPercentage1>

  <us-gaap:SharePrice contextRef="PAsOn06_30_2017_ConvertiblePromissoryNotesMemberusgaapLongtermDebtTypeAxis" id="Factid_1029" unitRef="USD_per_Share" decimals="2">92.60</us-gaap:SharePrice>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="PAsOn06_30_2017" id="Factid_1030" unitRef="USD" decimals="0">261155</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="PAsOn06_30_2016" id="Factid_1031" unitRef="USD" decimals="0">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn06_30_2017" id="Factid_1032" unitRef="USD" decimals="0">3610468</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn06_30_2016" id="Factid_1033" unitRef="USD" decimals="0">10104425</us-gaap:LiabilitiesCurrent>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="PAsOn06_30_2017" id="Factid_1034" unitRef="USD" decimals="0">7386782</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>

  <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="PAsOn06_30_2016" id="Factid_1035" unitRef="USD" decimals="0">3869122</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>

  <us-gaap:ProceedsFromConvertibleDebt contextRef="P07_01_2016To06_30_2017" id="Factid_1036" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromConvertibleDebt>

  <us-gaap:ProceedsFromConvertibleDebt contextRef="P07_01_2015To06_30_2016" id="Factid_1037" unitRef="USD" decimals="0">5175000</us-gaap:ProceedsFromConvertibleDebt>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017_ProstaScintMemberusgaapProductOrServiceAxis" id="Factid_1038" unitRef="USD" decimals="0">159000</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2015To06_30_2016_ProstaScintMemberusgaapProductOrServiceAxis" id="Factid_1039" unitRef="USD" decimals="0">159000</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017_DevelopedTechnologyRightsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_1040" unitRef="USD" decimals="0">54000</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis_TradeNamesMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_1041" unitRef="USD" decimals="0">7000</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:AmortizationOfIntangibleAssets contextRef="P07_01_2016To06_30_2017_CustomerContractsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis_ProstascintBusinessMemberusgaapBusinessAcquisitionAxis" id="Factid_1042" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfIntangibleAssets>

  <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_1043">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Shipping and Handling&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company's shipping and handling costs are included in cost of goods sold for all periods presented.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>

  <us-gaap:BusinessCombinationsPolicy contextRef="P07_01_2016To06_30_2017" id="Factid_1044">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Business Combinations&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company accounts for its business acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board&amp;#8217;s (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 805, &amp;#8220;Business Combinations&amp;#8221;, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessCombinationsPolicy>

  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P07_01_2016To06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_1045">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The estimated future amortization of Natesto after June 30, 2017 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,319,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,319,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,319,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,319,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,319,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,636,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9,231,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>

  <aytu:SalesRevenueTarget contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_SixthMilestoneMemberusgaapTypeOfArrangementAxis" id="Factid_1046" unitRef="USD" decimals="-5">100000000</aytu:SalesRevenueTarget>

  <aytu:OneTimeNonrefundablePayments contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis_SixthMilestoneMemberusgaapTypeOfArrangementAxis" id="Factid_1047" unitRef="USD" decimals="-5">10000000</aytu:OneTimeNonrefundablePayments>

  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="P05_01_2017To05_31_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_1048" unitRef="USD" decimals="-5">1900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>

  <us-gaap:AccretionExpense contextRef="P07_01_2016To06_30_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_1049" unitRef="USD" decimals="0">12000</us-gaap:AccretionExpense>

  <us-gaap:LiabilitiesAssumed1 contextRef="P07_01_2016To06_30_2017_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_1050" unitRef="USD" decimals="0">47000</us-gaap:LiabilitiesAssumed1>

  <us-gaap:AccretionExpense contextRef="P07_01_2015To06_30_2016_NuelleIncMemberusgaapBusinessAcquisitionAxis" id="Factid_1051" unitRef="USD" decimals="0">0</us-gaap:AccretionExpense>

  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_1052">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note 2 &amp;#150; Summary of Significant Accounting Policies&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Principals of Consolidation&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;These consolidated financial statements include the accounts of Aytu and its wholly-owned subsidiary, Aytu Women&amp;#8217;s Health. All material intercompany transactions and balances have been eliminated.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Cash, Cash Equivalents and Restricted Cash&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Restricted cash consist primarily of a&amp;#160;certificate of deposit investment account. Aytu&amp;#8217;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year, Aytu has maintained balances in excess of federally insured limits.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Revenue Recognition&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;License Agreements and Royalties&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones and are recognized at the time the milestones are achieved. Royalties will be recognized as revenue when earned.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Product&amp;#160;&amp;amp; Service Sales&lt;/font&gt;&lt;/i&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company recognizes revenue only when all of the following criteria have been met:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.7in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Persuasive evidence of an arrangement exists,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="DISPLAY: none; FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Delivery has occurred or services have been performed,&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The fee for the arrangement is fixed or determinable, and&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="DISPLAY: none; FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Persuasive evidence of an arrangement exists - The Company documents all terms of an arrangement in a written contract by the customer prior to recognizing revenue.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Delivery has occurred or services have been performed - The Company delivers all products prior to recognizing revenue. Equipment is considered delivered upon delivery to a customer's designated location.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Device sales are recorded when products are shipped to customers. Drug sales are recorded when the product arrives at the customer&amp;#8217;s dock. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;sales are recorded and are estimated at the time of sale.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"&gt;The fee for the arrangement is fixed or determinable - Prior to recognizing revenue, a customer's fee is either fixed or determinable under the terms of the written contract.&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Collectability is reasonably assured - The Company determines that collectability is reasonably assured prior to recognizing revenue. Collectability is assessed on a customer-by-customer basis based on criteria outlined by management. New customers are subject to a credit review process, which evaluates the customer's financial position and ultimately its ability to pay. The Company does not enter into arrangements unless collectability is reasonably assured at the outset. Existing customers are subject to ongoing credit evaluations based on payment history and other factors. If it is determined during the arrangement that collectability is not reasonably assured, revenue is recognized on a cash basis.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Estimated Sales Returns and Allowances&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu records estimated reductions in revenue for potential returns of products by customers. As a result, management must make estimates of potential future product returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different estimates, material differences in the amount of the Company&amp;#8217;s reported revenue could result. As of June 30, 2017 and 2016, we accrued $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;58,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;284,000&lt;/font&gt;, respectively, in our estimated returns allowance.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Shipping and Handling&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company's shipping and handling costs are included in cost of goods sold for all periods presented.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Accounts Receivable&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Accounts receivable are recorded at their net realized value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation allowance accordingly. As of June 30, 2017 we had an allowance for doubtful accounts of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;44,000&lt;/font&gt;, and as of June 30, 2016, there had been an allowance for doubtful accounts of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;41,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Concentration of Business Risks&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The following counterparties contributed greater than&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt;&lt;/font&gt;%&amp;#160;of the Company's total revenue during the year ended June 30, 2017 and 2016, respectively. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The revenue from these counterparties as a percentage of total revenue was as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer B&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;22&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;86&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The loss of one or more of the Company's significant partners or collaborators could have a material adverse effect on its business, operating results or financial condition. Although the Company is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management does not believe significant credit risk exists as of&amp;#160;June&amp;#160;30, 2017.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;We are also subject to credit risk from our accounts receivable related to our product sales. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of June 30, 2017, three customers accounted for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 60&lt;/font&gt;% of gross accounts receivable. As of June 30, 2016, one customer accounted for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 69&lt;/font&gt;% of gross accounts receivable.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer A&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer B&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;17&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer C&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"&gt; &lt;div&gt;Customer D&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;69&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Inventories&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Aytu periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable value in the period that the impairment is first recognized. We currently have a reserve of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;311,000&lt;/font&gt; for slow moving inventory as of June 30, 2017 and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;199,000&lt;/font&gt; at June 30, 2016.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Inventory consist of the following:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Raw materials&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;442,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;77,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Work in process&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;442,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Finished goods&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;738,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;647,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;Reserve&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(310,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;(199,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;1,312,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;525,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Trading Securities&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"&gt; Trading securities are carried at fair value with realized and unrealized gains and losses recorded in earnings.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Fixed Assets&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Fixed assets are recorded at cost. After being placed in service, the fixed assets are depreciated using the straight-line method over estimated useful lives. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Fixed assets consist of the following:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Useful&amp;#160;Lives&amp;#160;in&amp;#160;years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Office equipment, furniture and other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2 - 5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;405,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;201,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Lab equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3 - 5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;111,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;90,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;287,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;45,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Manufacturing equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2 - 5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;90,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Less accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(246,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(112,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Fixed assets, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;647,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;231,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu recorded the following depreciation expense in the respective periods:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Depreciation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;134,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;51,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;&amp;#160;&lt;/div&gt;&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Patents&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third party appraisal, was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;500,000&lt;/font&gt;. The Zertane patents were acquired in connection with the 2011 acquisition of DMI BioSciences by Ampio, the former parent company of Aytu, and were being amortized over the remaining U.S. patent lives of approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11&lt;/font&gt; years, which were to expire in March 2022. In fiscal 2016, we redirected our resources towards our commercial-stage products and the Company determined that this asset had no further value as the Company did not have the resources to complete the necessary clinical trials and bring it to market before the patents expired. The remaining fair value of the Zertane patents were expensed as of June 30, 2016.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The cost of the Luoxis patents were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;380,000&lt;/font&gt; when they were acquired in connection with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt; years, which expires in March 2028. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Patents consist of the following:&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"&gt; &lt;div&gt;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Patents&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;880,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;880,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Less accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;(609,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;(583,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Patents, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;271,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;297,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Aytu recorded the following amortization expense in the respective periods:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"&gt; &lt;div&gt;Year&amp;#160;Ended&amp;#160;June&amp;#160;30,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"&gt; &lt;div&gt;Amortization expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;26,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"&gt; &lt;div&gt;332,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Future amortization from the year ended June 30, 2017 is as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;25,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;146,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div&gt;271,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Business Combinations&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company accounts for its business acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board&amp;#8217;s (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 805, &amp;#8220;Business Combinations&amp;#8221;, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Goodwill&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Nuelle, ProstaScint and Primsol&amp;#160;purchase price allocations&amp;#160;were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May&amp;#160;20, 2015, Primsol that occurred on October 5, 2015 and Nuelle that occurred on May 5, 2017. There was an impairment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;74,000&lt;/font&gt; related to the ProstaScint goodwill for the year ended June 30, 2017.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Use of Estimates&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets, collectability of accounts receivable, and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Income Taxes&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu has been included in the consolidated tax returns of Ampio, the former parent company of Aytu, for tax years ended on or before December 31, 2015. As of January 2016, due to the decrease in Ampio&amp;#8217;s ownership percentage of Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu's taxes were computed and reported on a "separate return" basis for these financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The amount of income taxes and related income tax positions taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company's policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB ASC 740-1 "Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109" (ASC 740-10) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant tax position requires recognition under ASC 740-10.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Stock-Based Compensation&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the graded method.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Research and Development&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Research and development costs are expensed as incurred with expenses recorded in the respective period.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Income (Loss) Per Common Share&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. &lt;font style="BACKGROUND: transparent"&gt;Diluted net loss per share reflects the potential of securities that could share in the net loss of Aytu. Basic and diluted loss per share was the same in 2017 and 2016. Although there were common stock equivalents of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 367,312&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 126,239&lt;/font&gt; shares outstanding at June 30, 2017 and 2016, respectively, consisting of stock options and warrants; they were not included in the calculation of the diluted net loss per share because they would have been anti-dilutive.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted future cash&amp;#160;flows.&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Derivative Liability&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu accounts for liability warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial instruments and related warrants were calculated using a Monte Carlo based valuation model. We recorded a derivative expense at the inception of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods was recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income or expense for the warrants.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"&gt; The fair value of the warrants issued to the placement agents in connection with the registered offering were valued using the Black-Scholes valuation methodology. Changes in the fair value in subsequent periods were recorded to derivative income or expense.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Adoption of Newly Issued Accounting Pronouncements&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In November 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2016-18, "Statement of Cash Flows: Restricted Cash."&amp;#160; The amendments address diversity in practice that exists in the classification and presentation of changes in restricted cash on the statement of cash flows.&amp;#160; ASU 2016-18 is effective for the fiscal year commencing after December 15, 2017. During fiscal 2017, the Company early adopted this pronouncement, the impact of which was minimal, which is now shown on the statements of cash flows within cash and cash equivalents.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In August 2016, the FASB issued ASU 2016-15 &amp;#8220;Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments,&amp;#8221; which provides guidance on the presentation of certain cash receipts and cash payments in the statement of cash flows in order to reduce diversity in existing practice. ASU 2016-15 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted. During fiscal 2017, the Company early adopted this standard. The primary cash flow categorization that will impact the Company will be contingent consideration payments, however, no such payments have been made to date.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In March 2016, the FASB issued ASU 2016-09, &amp;#8220;Compensation &amp;#150;Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting.&amp;#8221; The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The amendments are expected to impact net income, earnings per share, and the statement of cash flows. Implementation and administration may present challenges to companies with significant share based payment activities. The amendments are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The Company adopted this standard during fiscal, 2017. Aytu has elected to account for forfeitures as they occur, rather than estimate expected forfeitures. Prior to adopting this standard, the Company had not estimated any forfeitures, therefore, no adjustments were necessary. Aytu is also operating at a net operating loss, therefore, there was no tax implication.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In July&amp;#160;2015, the FASB issued ASU 2015-11,&amp;#160;&amp;#8220;Simplifying the Measurement of Inventory.&amp;#8221;&amp;#160; ASU&amp;#160;2015-11 clarifies that inventory should be held at the lower of cost or net realizable value.&amp;#160; Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory.&amp;#160; ASU 2015-11 was effective for fiscal years and interim periods beginning after December&amp;#160;15, 2016. &amp;#160;ASU 2015-11 is required to be applied prospectively.&amp;#160; &lt;font style="COLOR: #333333"&gt;The&lt;/font&gt; amendments in ASU 2015-11 were adopted by the Company during fiscal 2017. The adoption of this standard did not have an impact on the Company&amp;#8217;s financial position or results of operations&lt;font style="COLOR: #333333"&gt;.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In August 2014, the FASB issued ASU 2014-15, &amp;#8220;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&amp;#8221; (&amp;#8220;ASU 2014-15&amp;#8221;). ASU 2014-15 is intended to define management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an organization&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016. The Company adopted this standard during fiscal 2017 and has included the required disclosure in the Company&amp;#8217;s financial statements (Note 3).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Recently Issued Accounting Pronouncements, Not Adopted as of June 30, 2017&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&amp;#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&amp;#160;(ASU 2017-09).&amp;#8221; ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of its adoption of this standard on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In January 2017, the FASB issued ASU 2017-04, &amp;#8220;Intangibles - Goodwill and Other (Topic 350).&amp;#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe that adoption of this amendment will have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In January 2017, the FASB issued ASU 2017-01, &amp;#8220;Business Combinations (Topic 805) Clarifying the Definition of a Business.&amp;#8221; The amendment clarifies the definition of a business, which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively for public business entities for interim and annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect an immediate impact on its financial statements from this codification however, if Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business combination or an asset purchase.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases (Topic 842).&amp;#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In January 2016, the FASB issued ASU No. 2016-01, &lt;i&gt;Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt; &lt;i&gt;(Topic 825)&lt;/i&gt;. ASU No. 2016-01 revises the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments to be recognized in net income. ASU No. 2016-01 is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. &amp;#160;Adopting ASU No. 2016-01 may result in a cumulative effect adjustment to the consolidated statement of equity retained earnings as of the beginning of the year of adoption. The Company is currently evaluating the impact of this standard on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In May 2014, the FASB issued ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the "New Revenue Standard"). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.&amp;#160; The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted for interim and annual periods beginning after December 5, 2017. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019. We will adopt the standard in our third quarter of fiscal 2018 and preliminarily expect to use the modified prospective method. However, we are continuing to evaluate the impact of the standard, and our adoption method is subject to change. We currently do not anticipate these standards to have a material impact on our consolidated financial statements outside of the expanded disclosure requirements.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>

  <aytu:EstimatedSalesReturnsAndAllowancesPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_1053">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Estimated Sales Returns and Allowances&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Aytu records estimated reductions in revenue for potential returns of products by customers. As a result, management must make estimates of potential future product returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different estimates, material differences in the amount of the Company&amp;#8217;s reported revenue could result. As of June 30, 2017 and 2016, we accrued $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;58,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;284,000&lt;/font&gt;, respectively, in our estimated returns allowance.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:EstimatedSalesReturnsAndAllowancesPolicyTextBlock>

  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_1054">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Adoption of Newly Issued Accounting Pronouncements&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In November 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2016-18, "Statement of Cash Flows: Restricted Cash."&amp;#160; The amendments address diversity in practice that exists in the classification and presentation of changes in restricted cash on the statement of cash flows.&amp;#160; ASU 2016-18 is effective for the fiscal year commencing after December 15, 2017. During fiscal 2017, the Company early adopted this pronouncement, the impact of which was minimal, which is now shown on the statements of cash flows within cash and cash equivalents.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In August 2016, the FASB issued ASU 2016-15 &amp;#8220;Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments,&amp;#8221; which provides guidance on the presentation of certain cash receipts and cash payments in the statement of cash flows in order to reduce diversity in existing practice. ASU 2016-15 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted. During fiscal 2017, the Company early adopted this standard. The primary cash flow categorization that will impact the Company will be contingent consideration payments, however, no such payments have been made to date.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In March 2016, the FASB issued ASU 2016-09, &amp;#8220;Compensation &amp;#150;Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting.&amp;#8221; The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The amendments are expected to impact net income, earnings per share, and the statement of cash flows. Implementation and administration may present challenges to companies with significant share based payment activities. The amendments are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The Company adopted this standard during fiscal, 2017. Aytu has elected to account for forfeitures as they occur, rather than estimate expected forfeitures. Prior to adopting this standard, the Company had not estimated any forfeitures, therefore, no adjustments were necessary. Aytu is also operating at a net operating loss, therefore, there was no tax implication.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In July&amp;#160;2015, the FASB issued ASU 2015-11,&amp;#160;&amp;#8220;Simplifying the Measurement of Inventory.&amp;#8221;&amp;#160; ASU&amp;#160;2015-11 clarifies that inventory should be held at the lower of cost or net realizable value.&amp;#160; Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory.&amp;#160; ASU 2015-11 was effective for fiscal years and interim periods beginning after December&amp;#160;15, 2016. &amp;#160;ASU 2015-11 is required to be applied prospectively.&amp;#160; &lt;font style="COLOR: #333333"&gt;The&lt;/font&gt; amendments in ASU 2015-11 were adopted by the Company during fiscal 2017. The adoption of this standard did not have an impact on the Company&amp;#8217;s financial position or results of operations&lt;font style="COLOR: #333333"&gt;.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In August 2014, the FASB issued ASU 2014-15, &amp;#8220;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&amp;#8221; (&amp;#8220;ASU 2014-15&amp;#8221;). ASU 2014-15 is intended to define management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an organization&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016. The Company adopted this standard during fiscal 2017 and has included the required disclosure in the Company&amp;#8217;s financial statements (Note 3).&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Recently Issued Accounting Pronouncements, Not Adopted as of June 30, 2017&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In May 2017, the FASB issued ASU No. 2017-09,&amp;#160;&amp;#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&amp;#160;(ASU 2017-09).&amp;#8221; ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of its adoption of this standard on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In January 2017, the FASB issued ASU 2017-04, &amp;#8220;Intangibles - Goodwill and Other (Topic 350).&amp;#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe that adoption of this amendment will have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In January 2017, the FASB issued ASU 2017-01, &amp;#8220;Business Combinations (Topic 805) Clarifying the Definition of a Business.&amp;#8221; The amendment clarifies the definition of a business, which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively for public business entities for interim and annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect an immediate impact on its financial statements from this codification however, if Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business combination or an asset purchase.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In February 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases (Topic 842).&amp;#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In January 2016, the FASB issued ASU No. 2016-01, &lt;i&gt;Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt; &lt;i&gt;(Topic 825)&lt;/i&gt;. ASU No. 2016-01 revises the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments to be recognized in net income. ASU No. 2016-01 is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. &amp;#160;Adopting ASU No. 2016-01 may result in a cumulative effect adjustment to the consolidated statement of equity retained earnings as of the beginning of the year of adoption. The Company is currently evaluating the impact of this standard on its financial statements.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;In May 2014, the FASB issued ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the "New Revenue Standard"). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.&amp;#160; The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted for interim and annual periods beginning after December 5, 2017. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019. We will adopt the standard in our third quarter of fiscal 2018 and preliminarily expect to use the modified prospective method. However, we are continuing to evaluate the impact of the standard, and our adoption method is subject to change. We currently do not anticipate these standards to have a material impact on our consolidated financial statements outside of the expanded disclosure requirements.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

  <us-gaap:InventoryValuationReserves contextRef="PAsOn06_30_2017" id="Factid_1055" unitRef="USD" decimals="0">310000</us-gaap:InventoryValuationReserves>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="PAsOn06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_1056" unitRef="USD" decimals="0">1319000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="PAsOn06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_1057" unitRef="USD" decimals="0">1319000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="PAsOn06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_1058" unitRef="USD" decimals="0">1319000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="PAsOn06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_1059" unitRef="USD" decimals="0">1319000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="PAsOn06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_1060" unitRef="USD" decimals="0">1319000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>

  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="PAsOn06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_1061" unitRef="USD" decimals="0">2636000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>

  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="PAsOn06_30_2017_NatestoMemberusgaapBusinessAcquisitionAxis" id="Factid_1062" unitRef="USD" decimals="0">9231000</us-gaap:FiniteLivedIntangibleAssetsNet>

  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="PAsOn06_30_2017" id="Factid_1063" unitRef="USD" decimals="0">58000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>

  <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="PAsOn06_30_2016" id="Factid_1064" unitRef="USD" decimals="0">284000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>

  <us-gaap:RestrictedCash contextRef="PAsOn06_30_2017" id="Factid_1065" unitRef="USD" decimals="-5">4000000</us-gaap:RestrictedCash>

  <aytu:IncomeTaxReconciliationOfFeringCosts contextRef="P07_01_2016To06_30_2017" id="Factid_1066" unitRef="USD" decimals="0">203000</aytu:IncomeTaxReconciliationOfFeringCosts>

  <aytu:IncomeTaxReconciliationOfFeringCosts contextRef="P07_01_2015To06_30_2016" id="Factid_1067" unitRef="USD" decimals="0">0</aytu:IncomeTaxReconciliationOfFeringCosts>

  <aytu:EffectiveIncomeTaxRateReconciliationOfferingCosts contextRef="P07_01_2016To06_30_2017" id="Factid_1068" unitRef="pure" decimals="4">0.0090</aytu:EffectiveIncomeTaxRateReconciliationOfferingCosts>

  <aytu:EffectiveIncomeTaxRateReconciliationOfferingCosts contextRef="P07_01_2015To06_30_2016" id="Factid_1069" unitRef="pure" decimals="2">0.00</aytu:EffectiveIncomeTaxRateReconciliationOfferingCosts>

  <aytu:IncomeTaxReconciliationContingentConsideration contextRef="P07_01_2016To06_30_2017" id="Factid_1070" unitRef="USD" decimals="0">4000</aytu:IncomeTaxReconciliationContingentConsideration>

  <aytu:IncomeTaxReconciliationContingentConsideration contextRef="P07_01_2015To06_30_2016" id="Factid_1071" unitRef="USD" decimals="0">0</aytu:IncomeTaxReconciliationContingentConsideration>

  <aytu:EffectiveIncomeTaxrateReconciliationContingentConsideration contextRef="P07_01_2016To06_30_2017" id="Factid_1072" unitRef="pure" decimals="4">0.0002</aytu:EffectiveIncomeTaxrateReconciliationContingentConsideration>

  <aytu:EffectiveIncomeTaxrateReconciliationContingentConsideration contextRef="P07_01_2015To06_30_2016" id="Factid_1073" unitRef="pure" decimals="2">0.00</aytu:EffectiveIncomeTaxrateReconciliationContingentConsideration>

  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="P07_01_2016To06_30_2017" id="Factid_1074" unitRef="USD" decimals="0">-11000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>

  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="P07_01_2015To06_30_2016" id="Factid_1075" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="P07_01_2016To06_30_2017" id="Factid_1076" unitRef="pure" decimals="4">-0.0005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="P07_01_2015To06_30_2016" id="Factid_1077" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>

  <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="PAsOn06_30_2017" id="Factid_1078" unitRef="USD" decimals="0">385000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>

  <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="PAsOn06_30_2016" id="Factid_1079" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>

  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="PAsOn06_30_2017" id="Factid_1080" unitRef="USD" decimals="0">41000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>

  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="PAsOn06_30_2016" id="Factid_1081" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>

  <aytu:NetOperatingLossesExpirationDescription contextRef="P07_01_2016To06_30_2017" id="Factid_1082">expire in 2031 through 2036.</aytu:NetOperatingLossesExpirationDescription>

  <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans contextRef="P07_01_2016To06_30_2017" id="Factid_1083">The Company matches 50% of the first 6% contributed to the plan by employees.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn06_30_2017" id="Factid_1084" unitRef="USD" decimals="-5">32800000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn06_30_2016" id="Factid_1085" unitRef="USD" decimals="-5">17300000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="P07_01_2016To06_30_2017" id="Factid_1086" unitRef="USD" decimals="0">99000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>

  <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_1087">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&lt;b&gt;Note 3 &amp;#150; Going Concern&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;As reflected in the accompanying financial statements, the Company had a net loss of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;22.5&lt;/font&gt; million and net cash used in operations of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;13.8&lt;/font&gt; million, for the year ended June 30, 2017. At June 30, 2017, Aytu had $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;878,000&lt;/font&gt; of cash, cash equivalents and restricted cash, stockholders&amp;#8217; equity of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4.0&lt;/font&gt; million and an accumulated deficit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;69.1&lt;/font&gt; million at June 30, 2017.&amp;#160;&amp;#160;In addition, the Company is in the early stage of commercialization and has not yet generated any profits. These factors raised substantial doubt about the Company&amp;#8217;s ability to continue as a going concern.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;However, with the completion of the August 2017 financing of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11.8&lt;/font&gt; million, the Company expects that its current cash resources plus this additional funding will be sufficient to fund operations through fiscal 2018 and into mid-fiscal 2019.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>

  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_1088">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;Note 1 &amp;#150; Business, Basis of Presentation, Merger and Business Combinations&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Aytu BioScience, Inc. (&amp;#8220;Aytu&amp;#8221;, the &amp;#8220;Company&amp;#8221; or &amp;#8220;we&amp;#8221;) was incorporated as Rosewind Corporation on August&amp;#160;9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June&amp;#160;8, 2015. Aytu is a commercial-stage specialty healthcare company concentrating on developing and commercializing products with an initial focus on urological diseases and conditions. Aytu is currently focused on addressing significant medical needs in the areas of hypogonadism, urological cancers, male infertility, and sexual wellness and vitality.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Through a multi-step reverse triangular merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (&amp;#8216;&amp;#8216;Vyrix&amp;#8217;&amp;#8217;) and Luoxis Diagnostics, Inc. (&amp;#8216;&amp;#8216;Luoxis&amp;#8217;&amp;#8217;) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding; On August 25, 2017, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding (herein referred to collectively as the &amp;#8220;Reverse Stock Splits&amp;#8221;). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;Business Combination&amp;#151;ProstaScint&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (&amp;#8220;Jazz Pharmaceuticals&amp;#8221;). Pursuant to the agreement, Aytu purchased assets related to the Jazz Pharmaceuticals&amp;#8217; product known as ProstaScint&lt;sup style="font-style:normal"&gt;&amp;#174;&lt;/sup&gt; (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &amp;#8216;&amp;#8216;ProstaScint Business&amp;#8217;&amp;#8217;), and assumed certain of Jazz Pharmaceuticals&amp;#8217; liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consists of the upfront payment of $1.0 million. We also agreed to pay an additional $500,000 which was paid after transfer for the ProstaScint-related product inventory and $227,000 which was paid September 30, 2015 (which represents a portion of certain FDA fees). We also will pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million.&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2017 at $54,000 using a discounted cash flow. The total fair value consideration for the purchase was $2.4 million.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company&amp;#8217;s allocation on consideration transferred for ProstaScint as of the purchase date May&amp;#160;20, 2015 was as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Estimated&lt;br/&gt; Fair Value&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 85%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Tangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;727,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,590,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;74,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,391,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Included in the intangible assets at May 2015 was developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. Amortization expense of $159,000 was recognized in both fiscal 2017 and 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; At June 30, 2017, the ProstaScint asset was impaired based upon sales projections that we intend to only sell this product through mid-fiscal 2019, when this product expires. The value for the intangible assets were adjusted to $54,000 for developed technology, $7,000 for trade names and $0 for customer contracts. The estimated future amortization of ProstaScint after June 30, 2017 is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center"&gt;&amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 40%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total ProstaScint&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 22%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;47,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;14,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;Business Combination&amp;#151;Primsol&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (&amp;#8220;FSC&amp;#8221;). Pursuant to the agreement, Aytu purchased assets related to FSC&amp;#8217;s product known as Primsol&amp;#174; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &amp;#8220;Primsol Business&amp;#8221;), and assumed certain of FSC&amp;#8217;s liabilities, including those related to the sale and marketing of Primsol arising after the closing.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Aytu paid $500,000 at closing for the purchase of the Primsol Business and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April 1, 2016, (b) $500,000 which was paid on July 1, 2016, and (c) $250,000 which was paid in November 2016 (together, the &amp;#8220;Installment Payments&amp;#8221;).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company&amp;#8217;s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 was as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center"&gt;&amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="white-space:nowrap;"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 85%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;Tangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;182,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,470,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;147,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;Total assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,799,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Included in tangible assets was $102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets was developed technology of $520,000, customer contracts of $810,000 and trade names of $140,000, each of which was being amortized over a six-year period. Amortization expense of $184,000 and $174,000 was recognized in fiscal 2017 and fiscal 2016, respectively.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;Divestiture &amp;#150; Primsol&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In March 2017, we entered into and closed on an Asset Purchase Agreement with Allegis Holdings, LLC (the &amp;#8220;Purchaser&amp;#8221;). Pursuant to the agreement, we sold to the Purchaser all of our assets related to our Primsol product, including certain intellectual property and contracts, inventory, work in process and all marketing assets and materials related solely to Primsol (together, the &amp;#8220;Primsol Asset&amp;#8221;). We retain any liability associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us $1,750,000 at the closing for the Primsol Asset. We recognized a gain of approximately $428,000 on the sale which is included in sales, general and administrative expense on our statement of operations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; We have evaluated this transaction and concluded that it is not significant to our business and therefore the results are included in continuing operations, as the criteria to be presented as discontinued operations was not satisfied.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;License and Supply Agreement&amp;#151;Natesto&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In April, 2016, Aytu entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto&amp;#174; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we acquired effective upon the expiration of the current licensee&amp;#8217;s rights, which occurred on June 30, 2016. The licensee&amp;#8217;s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="COLOR: #000000"&gt;Aytu paid Acerus an upfront fee of $2.0 million upon execution of the agreement. In October 2016, we paid an additional $2.0 million. In January 2017, Aytu paid the final upfront payment of $4.0 million. &lt;font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"&gt;Aytu also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5 million (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share. These shares were a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares until after August 29, 2016. During fiscal 2017, Aytu sold all of these shares. The gross proceeds from the sales totaled $1.1 million, the cost of the sales totaled $92,000, and we recognized a loss on investment of $62,000 and $972,000 during fiscal 2017 and 2016, respectively.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to the upfront payments, we must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million):&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; $2.5 million if net sales during any four consecutive calendar quarter period equal or exceed $25.0 million (the &amp;#8220;First Milestone&amp;#8221;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon trial work would no longer make the agreement economically viable for Acerus;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; $5.0 million if net sales during any four consecutive calendar quarter period equal or exceed $50.0 million;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; $7.5 million if net sales during any four consecutive calendar quarter period equal or exceed $75.0 milion;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; $10.0 million if net sales during any four consecutive calendar quarter period equal or exceed $100.0 million; and&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; $12.5 million if net sales during any four consecutive calendar quarter period equal or exceed $125.0 million.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The fair value of the net identifiable asset acquired totaled $10.5 million which is being amortized over eight years. The amortization expense for fiscal 2017 was $1.3 million&amp;#160;and zero for fiscal 2016. The estimated future amortization of Natesto after June 30, 2017 is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; WIDTH: 75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 22%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,319,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,319,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,319,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,319,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,319,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,636,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9,231,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The contingent consideration was valued at $3.2 million using a Monte Carlo simulation, as of June 30, 2016. The contingent consideration accretion expense for fiscal 2017 and 2016 was $228,000, and zero respectively. As of June 30, 2017, the contingent consideration was revalued and increased to $5.7 million based on increased future estimated sales performance of Natesto using a Monte Carlo simulation.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;Merger/Subsidiary&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In May 2017, Aytu Women&amp;#8217;s Health, LLC., a wholly-owned subsidiary of Aytu, acquired Nuelle, Inc., or Nuelle, a women&amp;#8217;s sexual health company. This transaction expanded our product portfolio with the addition of the Fiera&lt;sup style="font-style:normal"&gt;&amp;#174;&lt;/sup&gt; personal care device for women.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In the Merger, (i) each share of Nuelle common stock and each option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred stock was converted into the right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate of 125,000 shares of our common stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In addition, Nuelle preferred stockholders will be entitled to revenue earn-out payments equal to a designated percentage of net sales on tiers of net sales up to $100.0 million, with an average rate for all tiers in the mid-single digit range and a maximum aggregate payout of $6.9 million.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Nuelle stockholders additionally will be entitled to milestone earn-out payments of up to a potential aggregate of $24.0 million, upon the attainment by us of designated net sales thresholds over any sequential four calendar quarter period.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The first $1.0 million of earn-out payments will be paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock. The stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&amp;#8217;s portion of the earn-out by the average closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver notice to the Nuelle stockholders of the earn-out or any public disclosure by us of the earn-out being due and payable.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In the event that we do not make all of the required earn-out payments to the Nuelle stockholders before May 3, 2022, and we also close a divestiture before May 3, 2022 of any of the products acquired in the transaction, we will pay the Nuelle stockholders a combination of (i) cash in an amount equal to 10% of the value of all cash, securities and other property paid to us in the divestiture (cash is to be 60% of the total consideration), and (ii) shares of our common stock equal to the Nuelle stockholders&amp;#8217; portion of the divestiture payment divided by the average closing price of our common stock for the 10 trading days prior to the earlier of the closing date of the divestiture or the public disclosure of the divestiture (shares of common stock are to be 40% of the total consideration).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In addition to the upfront issuance of common stock, we must make the following one-time payments to the Nuelle stockholders within 90 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $24.0 million):&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;/font&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; Upon achieving the first occurrence of Net Sales of $10.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.0 million;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; Upon achieving the first occurrence of Net Sales of $17.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.8 million.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; Upon achieving the first occurrence of Net Sales of $25.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $2.5 million.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; Upon achieving the first occurrence of Net Sales of $37.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $3.8 million;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; Upon achieving the first occurrence of Net Sales of $50.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $5.0 million; and&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; &lt;font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"&gt; &amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-SIZE: 10pt"&gt; Upon achieving the first occurrence of Net Sales of $100.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $10.0 million.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company&amp;#8217;s allocation on consideration transferred for Nuelle as of the purchase date May&amp;#160;5, 2017 is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="white-space:nowrap;"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td colspan="2" style="white-space:nowrap;"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 85%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Tangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2,061,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,540,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;238,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,839,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Included in the intangible assets is developed technology of $1.3 million, customer contracts of $80,000 and trade names of $160,000, each of which will be amortized over a nine to twelve-year period. Amortization expense of $22,000 and $0 was recognized in fiscal 2017 and 2016, respectively.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Future amortization after the year ended June 30, 2017 is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 75%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 22%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;144,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Thereafter&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;798,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,518,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The contingent consideration was valued at $1.9 million using a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for fiscal 2017 and 2016 was $12,000, and zero respectively.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Additionally, we assumed liabilities of $47,000.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>

  <aytu:IssuanceOfCommonStockToNuelleShareHolders contextRef="P07_01_2016To06_30_2017" id="Factid_1089" unitRef="USD" decimals="0">1837500</aytu:IssuanceOfCommonStockToNuelleShareHolders>

  <aytu:IssuanceOfCommonStockToNuelleShareHolders contextRef="P07_01_2015To06_30_2016" id="Factid_1090" unitRef="USD" decimals="0">0</aytu:IssuanceOfCommonStockToNuelleShareHolders>

  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="PAsOn06_30_2017" id="Factid_1091" unitRef="USD" decimals="0">191000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>

  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="PAsOn06_30_2016" id="Factid_1092" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>

  <aytu:PreferredStockConversionPricePerShare contextRef="PAsOn08_15_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_1093" unitRef="USD_per_Share" decimals="2">3.00</aytu:PreferredStockConversionPricePerShare>

  <aytu:IncrementalCommonSharesDueToConversionOfPreferredStock contextRef="PAsOn08_15_2017_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_1094" unitRef="shares" decimals="INF">750000</aytu:IncrementalCommonSharesDueToConversionOfPreferredStock>

  <aytu:SecuritiesPurchaseAgreementCashFeePercentage contextRef="P08_01_2017To08_11_2017_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_1095" unitRef="pure" decimals="2">0.09</aytu:SecuritiesPurchaseAgreementCashFeePercentage>

  <aytu:ClassOfWarrantOrRightPercentageOfSharesToBeIssued contextRef="PAsOn08_11_2017_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_1096" unitRef="pure" decimals="1">0.1</aytu:ClassOfWarrantOrRightPercentageOfSharesToBeIssued>

  <aytu:FairValueConsiderationTextBlock contextRef="P07_01_2016To06_30_2017" id="Factid_1097">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;Note&amp;#160;5 &amp;#150; Fair Value Considerations&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted future cash&amp;#160;flows. The valuation policies are determined by the Chief Financial Officer and approved by the Company&amp;#8217;s Board of Directors.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu&amp;#8217;s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"&gt; &lt;table style="BORDER-BOTTOM-COLOR: #000000; BORDER-TOP-COLOR: #000000; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-RIGHT-COLOR: #000000; BORDER-LEFT-COLOR: #000000" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr&gt; &lt;td style="WIDTH: 15%; VERTICAL-ALIGN: top"&gt; &lt;div&gt;&lt;font style="COLOR: #000000; FONT-SIZE: 10pt"&gt; Level&amp;#160;1:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 85%; VERTICAL-ALIGN: bottom"&gt; &lt;div&gt;&lt;font style="COLOR: #000000; FONT-SIZE: 10pt"&gt;Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;div&gt;&lt;font style="COLOR: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&lt;font style="COLOR: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div&gt;&lt;font style="COLOR: #000000; FONT-SIZE: 10pt"&gt; Level&amp;#160;2:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom"&gt; &lt;div&gt;&lt;font style="COLOR: #000000; FONT-SIZE: 10pt"&gt;Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt; &lt;div&gt;&lt;font style="COLOR: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;&lt;font style="COLOR: #000000"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="VERTICAL-ALIGN: top"&gt; &lt;div&gt;&lt;font style="COLOR: #000000; FONT-SIZE: 10pt"&gt; Level&amp;#160;3:&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom"&gt; &lt;div&gt;&lt;font style="COLOR: #000000; FONT-SIZE: 10pt"&gt;Unobservable inputs that are supported by little or no market activity.&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="left"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; Aytu&amp;#8217;s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Aytu&amp;#8217;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The following table presents Aytu&amp;#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2017 and 2016, by level within the fair value hierarchy:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Fair&amp;#160;Value&amp;#160;Measurements&amp;#160;Using&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;1&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Level&amp;#160;3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;ASSETS&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Investment in Acerus&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;LIABILITIES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrant derivative liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Contingent consideration&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,648,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,648,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;June 30, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;ASSETS&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Investment in Acerus&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,041,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,041,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;LIABILITIES&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrant derivative liability&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;276,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;276,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Contingent consideration&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,869,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;3,869,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The estimated fair value of the Company&amp;#8217;s investment, which is classified as Level 1 (quoted price is available), was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.0&lt;/font&gt; million as of June 30, 2016. This investment was sold during fiscal 2017.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;The warrant derivative liability was valued using the Black-Scholes valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. The warrants related to the warrant derivative liability are not actively traded and therefore classified as Level 3. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Significant assumptions in valuing the warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants, were as follows as of February 28, 2017, the date when the derivative instruments converted into equity, and at June 30, 2016:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; February&amp;#160;28,&amp;#160;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;June&amp;#160;30,&amp;#160;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;160.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;75.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Equivalent term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.18&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4.84&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.87&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.99&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"&gt; &amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"&gt; &lt;table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; Derivative&amp;#160;Instruments&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance as of June 30, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;276,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrant issuances&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Change in fair value included in earnings (February 28, 2017)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(213,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Reclassification of warrant from liability to equity upon amendment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;(63,000)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Balance as of June 30, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The contingent consideration was valued using the Monte-Carlo valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Contingent consideration is not actively traded and therefore classified as Level 3.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; As of June 30, 2016, we had $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.9&lt;/font&gt; million in contingent consideration. During fiscal 2017, this balance increased to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7.6&lt;/font&gt; million as a result of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;305,000&lt;/font&gt; in accretion, which is included in our interest expense, as well as an increase of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.9&lt;/font&gt; million related to our Nuelle merger and adjustments of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.5&lt;/font&gt; million related to the revaluation of our ProstaScint and Natesto products.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:FairValueConsiderationTextBlock>

  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="PAsOn06_30_2016" id="Factid_1098" unitRef="USD" decimals="-5">3900000</us-gaap:BusinessCombinationContingentConsiderationLiability>

  <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="PAsOn06_30_2017" id="Factid_1099" unitRef="USD" decimals="-5">7600000</us-gaap:BusinessCombinationContingentConsiderationLiability>

  <us-gaap:NoncashMergerRelatedCosts contextRef="P07_01_2016To06_30_2017" id="Factid_1100" unitRef="USD" decimals="-5">1900000</us-gaap:NoncashMergerRelatedCosts>

  <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="P07_01_2016To06_30_2017" id="Factid_1101" unitRef="USD" decimals="-5">1500000</us-gaap:RestructuringAndRelatedCostIncurredCost>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>aytu-20170630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 30-Aug-2017 [07:46:22] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.aytubio.com/20170630" elementFormDefault="qualified" xmlns:aytu="http://www.aytubio.com/20170630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.aytubio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>102 - Statement - Consolidated Balance Sheets</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>103 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>104 - Statement - Consolidated Statements of Operations</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>105 - Statement - Consolidated Statements of Stockholders&#39; Equity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" id="ConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>106 - Statement - Consolidated Statements of Stockholders&#39; Equity (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>107 - Statement - Consolidated Statements of Cash Flows</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>108 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinations" id="BusinessBasisOfPresentationMergerAndBusinessCombinations">
        <link:definition>109 - Disclosure - Business, Basis of Presentation, Merger and Business Combinations</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>110 - Disclosure - Summary of Significant Accounting Policies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/GoingConcern" id="GoingConcern">
        <link:definition>111 - Disclosure - Going Concern</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/LicenseAgreementrevenueRecognition" id="LicenseAgreementrevenueRecognition">
        <link:definition>112 - Disclosure - License Agreement/Revenue Recognition</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderations" id="FairValueConsiderations">
        <link:definition>113 - Disclosure - Fair Value Considerations</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>114 - Disclosure - Income Taxes</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>115 - Disclosure - Commitments and Contingencies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/ConvertiblePromissoryNotes" id="ConvertiblePromissoryNotes">
        <link:definition>116 - Disclosure - Convertible Promissory Notes</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/CommonStock" id="CommonStock">
        <link:definition>117 - Disclosure - Common Stock</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EquityInstruments" id="EquityInstruments">
        <link:definition>118 - Disclosure - Equity Instruments</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>119 - Disclosure - Related Party Transactions</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SegmentInformation" id="SegmentInformation">
        <link:definition>120 - Disclosure - Segment Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
        <link:definition>121 - Disclosure - Employee Benefit Plan</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>122 - Disclosure - Subsequent Events</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>123 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsTables" id="BusinessBasisOfPresentationMergerAndBusinessCombinationsTables">
        <link:definition>124 - Disclosure - Business, Basis of Presentation, Merger and Business Combinations (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>125 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderationsTables" id="FairValueConsiderationsTables">
        <link:definition>126 - Disclosure - Fair Value Considerations (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>127 - Disclosure - Income Taxes (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>128 - Disclosure - Commitments and Contingencies (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsTables" id="EquityInstrumentsTables">
        <link:definition>129 - Disclosure - Equity Instruments (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SegmentInformationTables" id="SegmentInformationTables">
        <link:definition>130 - Disclosure - Segment Information (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails" id="BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails">
        <link:definition>131 - Disclosure - Business, Basis of Presentation, Merger and Business Combinations (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1" id="BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1">
        <link:definition>132 - Disclosure - Business, Basis of Presentation, Merger and Business Combinations (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetailsTextual" id="BusinessBasisOfPresentationMergerAndBusinessCombinationsDetailsTextual">
        <link:definition>133 - Disclosure - Business, Basis of Presentation, Merger and Business Combinations (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>134 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
        <link:definition>135 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2" id="SummaryOfSignificantAccountingPoliciesDetails2">
        <link:definition>136 - Disclosure - Summary of Significant Accounting Policies (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3" id="SummaryOfSignificantAccountingPoliciesDetails3">
        <link:definition>137 - Disclosure - Summary of Significant Accounting Policies (Details 3)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4" id="SummaryOfSignificantAccountingPoliciesDetails4">
        <link:definition>138 - Disclosure - Summary of Significant Accounting Policies (Details 4)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5" id="SummaryOfSignificantAccountingPoliciesDetails5">
        <link:definition>139 - Disclosure - Summary of Significant Accounting Policies (Details 5)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6" id="SummaryOfSignificantAccountingPoliciesDetails6">
        <link:definition>140 - Disclosure - Summary of Significant Accounting Policies (Details 6)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
        <link:definition>141 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/GoingConcernDetailsTextual" id="GoingConcernDetailsTextual">
        <link:definition>142 - Disclosure - Going Concern (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/LicenseAgreementrevenueRecognitionDetailsTextual" id="LicenseAgreementrevenueRecognitionDetailsTextual">
        <link:definition>143 - Disclosure - License Agreement/Revenue Recognition (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails" id="FairValueConsiderationsDetails">
        <link:definition>144 - Disclosure - Fair Value Considerations (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails1" id="FairValueConsiderationsDetails1">
        <link:definition>145 - Disclosure - Fair Value Considerations (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails2" id="FairValueConsiderationsDetails2">
        <link:definition>146 - Disclosure - Fair Value Considerations (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetailsTextual" id="FairValueConsiderationsDetailsTextual">
        <link:definition>147 - Disclosure - Fair Value Considerations (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>148 - Disclosure - Income Taxes (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>149 - Disclosure - Income Taxes (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
        <link:definition>150 - Disclosure - Income Taxes (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>151 - Disclosure - Commitments and Contingencies (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>152 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
        <link:definition>153 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/ConvertiblePromissoryNotesDetailsTextual" id="ConvertiblePromissoryNotesDetailsTextual">
        <link:definition>154 - Disclosure - Convertible Promissory Notes (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/CommonStockDetailsTextual" id="CommonStockDetailsTextual">
        <link:definition>155 - Disclosure - Common Stock (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails" id="EquityInstrumentsDetails">
        <link:definition>156 - Disclosure - Equity Instruments (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails1" id="EquityInstrumentsDetails1">
        <link:definition>157 - Disclosure - Equity Instruments (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails2" id="EquityInstrumentsDetails2">
        <link:definition>158 - Disclosure - Equity Instruments (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails3" id="EquityInstrumentsDetails3">
        <link:definition>159 - Disclosure - Equity Instruments (Details 3)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails4" id="EquityInstrumentsDetails4">
        <link:definition>160 - Disclosure - Equity Instruments (Details 4)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails5" id="EquityInstrumentsDetails5">
        <link:definition>161 - Disclosure - Equity Instruments (Details 5)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EquityInstrumentsDetailsTextual" id="EquityInstrumentsDetailsTextual">
        <link:definition>162 - Disclosure - Equity Instruments (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/RelatedPartyTransactionsDetailsTextual" id="RelatedPartyTransactionsDetailsTextual">
        <link:definition>163 - Disclosure - Related Party Transactions (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SegmentInformationDetails" id="SegmentInformationDetails">
        <link:definition>164 - Disclosure - Segment Information (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/EmployeeBenefitPlanDetailsTextual" id="EmployeeBenefitPlanDetailsTextual">
        <link:definition>165 - Disclosure - Employee Benefit Plan (Details textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.aytubio.com/role/SubsequentEventsDetailsTextual" id="SubsequentEventsDetailsTextual">
        <link:definition>166 - Disclosure - Subsequent Events (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20170630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20170630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20170630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20170630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_DocumentAndEntityInformationAbstract" />

  <element name="PrepaidResearchAndDevelopmentRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_PrepaidResearchAndDevelopmentRelatedParty" />

  <element name="CoreAndDevelopedTechnologyNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_CoreAndDevelopedTechnologyNet" />

  <element name="PrimsolBusinessMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_PrimsolBusinessMember" />

  <element name="PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" />

  <element name="AmpioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_AmpioMember" />

  <element name="ProductsAndServicesRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_ProductsAndServicesRevenue" />

  <element name="ResearchAndDevelopmentRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_ResearchAndDevelopmentRelatedParty" />

  <element name="OperatingLeaseMonthlyRentalPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_OperatingLeaseMonthlyRentalPayment" />

  <element name="StockSubscriptionPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_StockSubscriptionPayment" />

  <element name="StockSubscriptionPaymentOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_StockSubscriptionPaymentOfShares" />

  <element name="PrepaidExpensesAmortizationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_PrepaidExpensesAmortizationPeriod" />

  <element name="SecondInstallmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_SecondInstallmentMember" />

  <element name="FirstInstallmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_FirstInstallmentMember" />

  <element name="AfterAmendmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_AfterAmendmentMember" />

  <element name="AmortizationOfBeneficialConversionFeature" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_AmortizationOfBeneficialConversionFeature" />

  <element name="AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" />

  <element name="IncreaseDecreaseInAccruedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_IncreaseDecreaseInAccruedCompensation" />

  <element name="AssumptionsUsedToDetermineFairValueOptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="aytu_AssumptionsUsedToDetermineFairValueOptionsTable" />

  <element name="LuoxisDiagnosticsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_LuoxisDiagnosticsMember" />

  <element name="AssumptionsUsedToDetermineFairValueOptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems" />

  <element name="Proceedsfromissuanceofwarranttenderoffer" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_Proceedsfromissuanceofwarranttenderoffer" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" />

  <element name="ProstascintBusinessMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ProstascintBusinessMember" />

  <element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" />

  <element name="UnrecognizedShareBasedCompensationExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_UnrecognizedShareBasedCompensationExpenses" />

  <element name="JazzPharmaceuticalsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_JazzPharmaceuticalsIncMember" />

  <element name="SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable" />

  <element name="EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems" />

  <element name="ProstaScintMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ProstaScintMember" />

  <element name="ShareBasedCompensationShareWarrantsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsOutstanding" />

  <element name="BusinessCombinationContingentConsiderationPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_BusinessCombinationContingentConsiderationPercentage" />

  <element name="ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" />

  <element name="ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" />

  <element name="TwoThousandFifteenStockOptionAndIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" />

  <element name="SheduleOfCommonStockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="aytu_SheduleOfCommonStockTable" />

  <element name="LabEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_LabEquipmentMember" />

  <element name="ConvertiblePromissoryNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ConvertiblePromissoryNotesMember" />

  <element name="PlacementAgentsCashFeePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_PlacementAgentsCashFeePercentage" />

  <element name="CommitmentsAndContingenciesDisclosureTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" />

  <element name="SheduleOfCommitmentsAndContingenciesRentExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable" />

  <element name="CommitmentsAndContingenciesRentExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_CommitmentsAndContingenciesRentExpenseLineItems" />

  <element name="FairValueConsiderationTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_FairValueConsiderationTextBlock" />

  <element name="FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock" />

  <element name="OperatingLeasesMonthlyBaseRentInitialYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_OperatingLeasesMonthlyBaseRentInitialYear" />

  <element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" />

  <element name="AccruedCompensationCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_AccruedCompensationCurrent" />

  <element name="IssuanceOfCommonStockToNuelleShareHolders" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_IssuanceOfCommonStockToNuelleShareHolders" />

  <element name="PaidOnApril12016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_PaidOnApril12016Member" />

  <element name="NoLaterThanJuly012016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_NoLaterThanJuly012016Member" />

  <element name="NoLaterThanSeptember302016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_NoLaterThanSeptember302016Member" />

  <element name="PrescriptionDatabaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_PrescriptionDatabaseMember" />

  <element name="PrimsolBusinessPurchaseIncludedInPrimsolPayableGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross" />

  <element name="BusinessCombinationConsiderationTransferredInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_BusinessCombinationConsiderationTransferredInventory" />

  <element name="BusinessCombinationConsiderationTransferredProductInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_BusinessCombinationConsiderationTransferredProductInventory" />

  <element name="BusinessCombinationConsiderationTransferredWorkInProcessInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" />

  <element name="AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" />

  <element name="Paymentsforwarranttenderoffercost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_Paymentsforwarranttenderoffercost" />

  <element name="DebtConversionAccruedInterestAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_DebtConversionAccruedInterestAmount" />

  <element name="WarrantsIssuedToPurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_WarrantsIssuedToPurchaseOfCommonStock" />

  <element name="WarrantsExercisePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_WarrantsExercisePricePerShare" />

  <element name="AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" />

  <element name="Fixedassetsincludedinaccountspayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_Fixedassetsincludedinaccountspayable" />

  <element name="Warrantsissuedinconnectionwithequityfinancingtoplacementagents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents" />

  <element name="Warrantsamendedinconnectionwithwarranttenderoffer" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_Warrantsamendedinconnectionwithwarranttenderoffer" />

  <element name="PaymentOfContractualObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_PaymentOfContractualObligations" />

  <element name="ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" />

  <element name="ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" />

  <element name="EstimatedSalesReturnsAndAllowancesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" />

  <element name="WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" />

  <element name="PrimsolBusinessPurchaseIncludedInPrimsolPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" />

  <element name="LicenseAgreementTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_LicenseAgreementTextBlock" />

  <element name="AdjustmentForRoundingOfValueDueToConversion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_AdjustmentForRoundingOfValueDueToConversion" />

  <element name="AdjustmentForRoundingOfSharesDueToConversion" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_AdjustmentForRoundingOfSharesDueToConversion" />

  <element name="NatestoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_NatestoMember" />

  <element name="ManufacturingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ManufacturingAgreementMember" />

  <element name="SecondUpfrontMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_SecondUpfrontMember" />

  <element name="Proceedsfromissuanceofcommonstockandwarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_Proceedsfromissuanceofcommonstockandwarrants" />

  <element name="Paymentsforregisteredofferingcosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_Paymentsforregisteredofferingcosts" />

  <element name="ThirdUpfrontMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ThirdUpfrontMember" />

  <element name="OneTimeNonrefundablePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_OneTimeNonrefundablePayments" />

  <element name="SalesRevenueTarget" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_SalesRevenueTarget" />

  <element name="FirstMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_FirstMilestoneMember" />

  <element name="SecondMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_SecondMilestoneMember" />

  <element name="ThirdMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ThirdMilestoneMember" />

  <element name="ForthMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ForthMilestoneMember" />

  <element name="FifthMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_FifthMilestoneMember" />

  <element name="LicenseAndSupplyAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_LicenseAndSupplyAgreementMember" />

  <element name="BusinessDescriptionAndBasisOfPresentationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="aytu_BusinessDescriptionAndBasisOfPresentationTable" />

  <element name="BusinessDescriptionAndBasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_BusinessDescriptionAndBasisOfPresentationLineItems" />

  <element name="RevenueRecognitionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="aytu_RevenueRecognitionTable" />

  <element name="VyrixPharmaceuticalsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_VyrixPharmaceuticalsIncMember" />

  <element name="RevenueRecognitionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_RevenueRecognitionLineItems" />

  <element name="PotentialMilestonePaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_PotentialMilestonePaymentsReceivable" />

  <element name="PercentageOfRoyaltyRateOfNetSales" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_PercentageOfRoyaltyRateOfNetSales" />

  <element name="AgreementExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_AgreementExpirationPeriod" />

  <element name="EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" />

  <element name="EffectiveIncomeTaxRateReconciliationOfferingCosts" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" />

  <element name="EffectiveIncomeTaxrateReconciliationContingentConsideration" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" />

  <element name="ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" />

  <element name="ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" />

  <element name="ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" />

  <element name="ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" />

  <element name="ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" />

  <element name="ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" />

  <element name="EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" />

  <element name="IncomeTaxReconciliationOfFeringCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_IncomeTaxReconciliationOfFeringCosts" />

  <element name="IncomeTaxReconciliationContingentConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_IncomeTaxReconciliationContingentConsideration" />

  <element name="ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" />

  <element name="ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" />

  <element name="ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" />

  <element name="ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" />

  <element name="AmpioPharmaceuticalsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_AmpioPharmaceuticalsMember" />

  <element name="ZertanePatentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ZertanePatentsMember" />

  <element name="OrpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_OrpMember" />

  <element name="FiniteLivedIntangibleAssetsExpirationMonthYear" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" />

  <element name="OfficeLeaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_OfficeLeaseMember" />

  <element name="UnderwritersExercisedOfOverallotmentOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_UnderwritersExercisedOfOverallotmentOption" />

  <element name="IssuanceOfStockIssuedDuringPeriodvalue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_IssuanceOfStockIssuedDuringPeriodvalue" />

  <element name="ExercisePriceRangeOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ExercisePriceRangeOneMember" />

  <element name="ExercisePriceRangeTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ExercisePriceRangeTwoMember" />

  <element name="PlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_PlacementAgentWarrantsMember" />

  <element name="InvestorsWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_InvestorsWarrantsMember" />

  <element name="ConvertiblePromissoryNotesMay2016Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ConvertiblePromissoryNotesMay2016Member" />

  <element name="ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />

  <element name="StockOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_StockOptionsMember" />

  <element name="CostOfSaleForInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_CostOfSaleForInvestment" />

  <element name="ShareBasedCompensationShareWarrantsExcercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsExcercised" />

  <element name="ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" />

  <element name="CommonStockOptionRepricingProgramDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_CommonStockOptionRepricingProgramDescription" />

  <element name="BankersWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_BankersWarrantsMember" />

  <element name="OverAllotmentWarrantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="aytu_OverAllotmentWarrantsAxis" />

  <element name="ShareBasedCompensationShareWarrantsIssuedToInvestors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors" />

  <element name="ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice" />

  <element name="ClassOfWarrantsAndRightsIssuanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_ClassOfWarrantsAndRightsIssuanceCost" />

  <element name="OverAllotmentWarrantsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_OverAllotmentWarrantsDomain" />

  <element name="OverAllotmentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_OverAllotmentWarrantsMember" />

  <element name="WarrantsModified" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_WarrantsModified" />

  <element name="May2016WarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_May2016WarrantsMember" />

  <element name="October2016WarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_October2016WarrantsMember" />

  <element name="FirstMilestonePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_FirstMilestonePayable" />

  <element name="SecondMilestonePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_SecondMilestonePayable" />

  <element name="ThirdMilestonePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_ThirdMilestonePayable" />

  <element name="CommonStockSharesAgreedToPurchase" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_CommonStockSharesAgreedToPurchase" />

  <element name="CommonStockValueAgreedToPurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_CommonStockValueAgreedToPurchase" />

  <element name="LincolnParkCapitalFundLlcPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" />

  <element name="EquityRelativeFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_EquityRelativeFairValue" />

  <element name="CommonStockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_CommonStockLineItems" />

  <element name="StockAndIssuedDuringPeriodshares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_StockAndIssuedDuringPeriodshares" />

  <element name="AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" />

  <element name="Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" />

  <element name="Adjustmentstoadditionalpaidincapitalwarrantamendments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments" />

  <element name="LincolnparkMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_LincolnparkMember" />

  <element name="Issuanceofcommonstocktoexecutives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_Issuanceofcommonstocktoexecutives" />

  <element name="PaymentsForDepositsInvestingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_PaymentsForDepositsInvestingActivities" />

  <element name="NatestoBusinessPurchaseIncludedInNatestoPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_NatestoBusinessPurchaseIncludedInNatestoPayable" />

  <element name="WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" />

  <element name="AytuBioscienceIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_AytuBioscienceIncMember" />

  <element name="AytuWomensHealthMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_AytuWomensHealthMember" />

  <element name="NuelleIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_NuelleIncMember" />

  <element name="RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales" />

  <element name="SixthMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_SixthMilestoneMember" />

  <element name="ClassUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ClassUnitsMember" />

  <element name="ClassBUnitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_ClassBUnitsMember" />

  <element name="CustomerOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_CustomerOneMember" />

  <element name="CustomerTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_CustomerTwoMember" />

  <element name="CustomerThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_CustomerThreeMember" />

  <element name="CustomerFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_CustomerFourMember" />

  <element name="AmpioPharmaceuticalsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_AmpioPharmaceuticalsIncMember" />

  <element name="SummaryOfSignificantAccountingPolicyLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_SummaryOfSignificantAccountingPolicyLineItems" />

  <element name="DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" />

  <element name="NetOperatingLossesExpirationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_NetOperatingLossesExpirationDescription" />

  <element name="PreferredStockConversionPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="aytu_PreferredStockConversionPricePerShare" />

  <element name="IncrementalCommonSharesDueToConversionOfPreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" />

  <element name="SecuritiesPurchaseAgreementCashFeePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aytu_SecuritiesPurchaseAgreementCashFeePercentage" />

  <element name="ClassOfWarrantOrRightPercentageOfSharesToBeIssued" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>aytu-20170630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 30-Aug-2017 [07:46:22] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinations" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinations" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommonStock" roleURI="http://www.aytubio.com/role/CommonStock" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommitmentsAndContingencies" roleURI="http://www.aytubio.com/role/CommitmentsAndContingencies" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPolicies" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxes" roleURI="http://www.aytubio.com/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxesDetails" roleURI="http://www.aytubio.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxesDetails1" roleURI="http://www.aytubio.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" />

  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AccruedCompensationCurrent" xlink:label="loc_aytu_AccruedCompensationCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_aytu_AccruedCompensationCurrent" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedRentCurrent" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" use="optional" order="40" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="50" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProductsAndServicesRevenue" xlink:label="loc_aytu_ProductsAndServicesRevenue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues" xlink:to="loc_aytu_ProductsAndServicesRevenue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues" xlink:to="loc_us-gaap_LicensesRevenue" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_CostOfRevenue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ResearchAndDevelopmentRelatedParty" xlink:label="loc_aytu_ResearchAndDevelopmentRelatedParty" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_aytu_ResearchAndDevelopmentRelatedParty" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets" use="optional" order="70" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnInvestments" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AssetImpairmentCharges" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RestrictedStockExpense" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmortizationOfBeneficialConversionFeature" xlink:label="loc_aytu_AmortizationOfBeneficialConversionFeature" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_aytu_AmortizationOfBeneficialConversionFeature" use="optional" order="70" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_OtherNoncashExpense" use="optional" order="80" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="90" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="100" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="110" weight="-1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" use="optional" order="120" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="130" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="140" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="150" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_aytu_IncreaseDecreaseInAccruedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_aytu_IncreaseDecreaseInAccruedCompensation" use="optional" order="160" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidRent" use="optional" order="170" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" use="optional" order="180" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" use="optional" order="190" weight="-1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Issuanceofcommonstocktoexecutives" xlink:label="loc_aytu_Issuanceofcommonstocktoexecutives" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_aytu_Issuanceofcommonstocktoexecutives" use="optional" order="200" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" order="210" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets" use="optional" order="220" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RestructuringCharges" use="optional" order="230" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromLongtermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromLongtermInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsForProceedsFromLongtermInvestments" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments" use="optional" order="40" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" use="optional" order="60" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition" use="optional" order="70" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses" use="optional" order="80" weight="-1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PaymentsForDepositsInvestingActivities" xlink:label="loc_aytu_PaymentsForDepositsInvestingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_aytu_PaymentsForDepositsInvestingActivities" use="optional" order="90" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="20" weight="-1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Proceedsfromissuanceofwarranttenderoffer" xlink:label="loc_aytu_Proceedsfromissuanceofwarranttenderoffer" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_aytu_Proceedsfromissuanceofwarranttenderoffer" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Paymentsforwarranttenderoffercost" xlink:label="loc_aytu_Paymentsforwarranttenderoffercost" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_aytu_Paymentsforwarranttenderoffercost" use="optional" order="40" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" order="60" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts" use="optional" order="70" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent" use="optional" order="80" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Proceedsfromissuanceofcommonstockandwarrants" xlink:label="loc_aytu_Proceedsfromissuanceofcommonstockandwarrants" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_aytu_Proceedsfromissuanceofcommonstockandwarrants" use="optional" order="90" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Paymentsforregisteredofferingcosts" xlink:label="loc_aytu_Paymentsforregisteredofferingcosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_aytu_Paymentsforregisteredofferingcosts" use="optional" order="100" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants" use="optional" order="110" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" use="optional" order="120" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear" use="optional" order="60" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsNoncurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CoreAndDevelopedTechnologyNet" xlink:label="loc_aytu_CoreAndDevelopedTechnologyNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_aytu_CoreAndDevelopedTechnologyNet" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaap_IndefiniteLivedContractualRights" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_IndefiniteLivedContractualRights" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_Goodwill" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="70" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xlink:label="loc_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" use="optional" order="80" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent" use="optional" order="90" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidResearchAndDevelopmentRelatedParty" xlink:label="loc_aytu_PrepaidResearchAndDevelopmentRelatedParty" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_aytu_PrepaidResearchAndDevelopmentRelatedParty" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_ShortTermInvestments" use="optional" order="70" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" use="optional" order="60" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterials" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcess" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoods" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryValuationReserves" use="optional" order="40" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" use="optional" order="70" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" use="optional" order="80" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" use="optional" order="90" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" use="optional" order="100" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" use="optional" order="110" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory" use="optional" order="120" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" use="optional" order="130" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="20" weight="-1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>aytu-20170630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 30-Aug-2017 [07:46:22] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#DocumentAndEntityInformation" roleURI="http://www.aytubio.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.aytubio.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.aytubio.com/role/RelatedPartyTransactionsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails1" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails3" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails3" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetailsTextual" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinationsTables" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsTables" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails4" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails4" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinationsDetailsTextual" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommonStockDetailsTextual" roleURI="http://www.aytubio.com/role/CommonStockDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConvertiblePromissoryNotesDetailsTextual" roleURI="http://www.aytubio.com/role/ConvertiblePromissoryNotesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommitmentsAndContingenciesDetails1" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#FairValueConsiderationsDetailsTextual" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#FairValueConsiderationsDetails" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#FairValueConsiderationsDetails1" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#FairValueConsiderationsDetails2" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails2" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails5" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails5" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails3" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EmployeeBenefitPlanDetailsTextual" roleURI="http://www.aytubio.com/role/EmployeeBenefitPlanDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#LicenseAgreementrevenueRecognitionDetailsTextual" roleURI="http://www.aytubio.com/role/LicenseAgreementrevenueRecognitionDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxesDetails" roleURI="http://www.aytubio.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails4" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails6" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxesDetails1" roleURI="http://www.aytubio.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.aytubio.com/role/IncomeTaxesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails5" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails2" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails2" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#GoingConcernDetailsTextual" roleURI="http://www.aytubio.com/role/GoingConcernDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SegmentInformationDetails" roleURI="http://www.aytubio.com/role/SegmentInformationDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1389" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_LegalEntityAxis_4" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1388" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_1388" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1388_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_1388_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1387" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1387" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1390" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1387" xlink:to="loc_us-gaap_ClassOfStockDomain_1390" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1390_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1387" xlink:to="loc_us-gaap_ClassOfStockDomain_1390_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_DocumentType_5" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_13" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_13" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_14" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityVoluntaryFilers_14" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_15" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityCurrentReportingStatus_15" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1383" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityFilerCategory_1383" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1384" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityPublicFloat_1384" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1385" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_TradingSymbol_1385" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1386" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1386" use="optional" order="22" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1560" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_61" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_SubsequentEventTable_61" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_62" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_62" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_62" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_62" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_66" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65" xlink:to="loc_aytu_PrimsolBusinessMember_66" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_63" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_63" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_77" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_63" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_77" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_77_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_63" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_77_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_78" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_77" xlink:to="loc_us-gaap_SubsequentEventMember_78" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_76" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_StatementScenarioAxis_76" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_80" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_76" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_80" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_80_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_76" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_80_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_79" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_79" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_100" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_79" xlink:to="loc_us-gaap_RelatedPartyDomain_100" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_100_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_79" xlink:to="loc_us-gaap_RelatedPartyDomain_100_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_99" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_RangeAxis_99" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_671" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_99" xlink:to="loc_us-gaap_RangeMember_671" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_671_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_99" xlink:to="loc_us-gaap_RangeMember_671_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_670" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_DebtInstrumentAxis_670" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_681" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_670" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_681" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_681_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_670" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_681_default" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_680" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_680" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_684" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_680" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_684" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_684_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_680" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_684_default" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_683" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_683" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_742" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_683" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_742" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_742_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_683" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_742_default" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_741" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_TypeOfArrangementAxis_741" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_745" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_741" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_745" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_745_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_741" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_745_default" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_744" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_FinancialInstrumentAxis_744" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_837" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_744" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_837" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_837_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_744" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_837_default" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_836" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_836" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_840" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_836" xlink:to="loc_us-gaap_EquityComponentDomain_840" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_840_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_836" xlink:to="loc_us-gaap_EquityComponentDomain_840_default" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1566" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_840" xlink:to="loc_us-gaap_CommonStockMember_1566" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_839" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_839" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_843" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_839" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_843" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_843_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_839" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_843_default" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_844" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_843" xlink:to="loc_us-gaap_OverAllotmentOptionMember_844" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_842" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_842" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_848" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_842" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_848" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_848_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_842" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_848_default" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_847" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_dei_LegalEntityAxis_847" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1043" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_847" xlink:to="loc_dei_EntityDomain_1043" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1043_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_847" xlink:to="loc_dei_EntityDomain_1043_default" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1042" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1042" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1561" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1042" xlink:to="loc_us-gaap_ClassOfStockDomain_1561" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1561_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1042" xlink:to="loc_us-gaap_ClassOfStockDomain_1561_default" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassUnitsMember" xlink:label="loc_aytu_ClassUnitsMember_1562" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1561" xlink:to="loc_aytu_ClassUnitsMember_1562" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassBUnitsMember" xlink:label="loc_aytu_ClassBUnitsMember_1563" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1561" xlink:to="loc_aytu_ClassBUnitsMember_1563" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1567" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1561" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1567" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_674" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_674" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_831" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_831" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1050" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1050" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_1554" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_1554" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1557" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1557" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_1559" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_1559" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PreferredStockConversionPricePerShare" xlink:label="loc_aytu_PreferredStockConversionPricePerShare_1646" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_aytu_PreferredStockConversionPricePerShare_1646" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:label="loc_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_1647" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_1647" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:label="loc_aytu_SecuritiesPurchaseAgreementCashFeePercentage_1648" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_aytu_SecuritiesPurchaseAgreementCashFeePercentage_1648" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:label="loc_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_1649" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_1649" use="optional" order="63" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_26" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_StatementTable_26" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_27" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_26" xlink:to="loc_us-gaap_StatementClassOfStockAxis_27" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_28" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_27" xlink:to="loc_us-gaap_ClassOfStockDomain_28" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_28_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_27" xlink:to="loc_us-gaap_ClassOfStockDomain_28_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_31" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_AssetsAbstract_31" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_32" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_AssetsCurrentAbstract_32" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1485" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1485" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_38" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_38" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_40" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_InventoryNet_40" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_41" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_41" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidResearchAndDevelopmentRelatedParty" xlink:label="loc_aytu_PrepaidResearchAndDevelopmentRelatedParty_43" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_aytu_PrepaidResearchAndDevelopmentRelatedParty_43" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_969" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_ShortTermInvestments_969" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_45" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_AssetsCurrent_45" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_46" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_46" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CoreAndDevelopedTechnologyNet" xlink:label="loc_aytu_CoreAndDevelopedTechnologyNet_52" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_aytu_CoreAndDevelopedTechnologyNet_52" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaap_IndefiniteLivedContractualRights_56" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_IndefiniteLivedContractualRights_56" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames_57" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames_57" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_940" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_940" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_58" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_Goodwill_58" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_60" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_60" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xlink:label="loc_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent_64" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent_64" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_67" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_67" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_68" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_AssetsNoncurrent_68" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_69" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_Assets_69" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_71" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_71" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1486" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_AccountsPayableCurrent_1486" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1487" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1487" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_941" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_941" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AccruedCompensationCurrent" xlink:label="loc_aytu_AccruedCompensationCurrent_73" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_aytu_AccruedCompensationCurrent_73" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent_942" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_AccruedRentCurrent_942" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1488" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1488" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_83" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_LiabilitiesCurrent_83" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_85" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_85" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_90" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_90" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_93" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_93" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_95" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_Liabilities_95" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_96" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_CommitmentsAndContingencies_96" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_98" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_StockholdersEquityAbstract_98" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_98" xlink:to="loc_us-gaap_PreferredStockValue_101" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_98" xlink:to="loc_us-gaap_CommonStockValue_102" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_104" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_98" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_104" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_105" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_98" xlink:to="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_105" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_106" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_98" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_106" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_107" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_StockholdersEquity_107" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_108" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_108" use="optional" order="47" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/RelatedPartyTransactionsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_934" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_934" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_115" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_115" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_133" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_115" xlink:to="loc_us-gaap_RelatedPartyDomain_133" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_133_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_115" xlink:to="loc_us-gaap_RelatedPartyDomain_133_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioMember" xlink:label="loc_aytu_AmpioMember_134" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_133" xlink:to="loc_aytu_AmpioMember_134" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioPharmaceuticalsIncMember" xlink:label="loc_aytu_AmpioPharmaceuticalsIncMember_1598" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_133" xlink:to="loc_aytu_AmpioPharmaceuticalsIncMember_1598" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_123" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_DebtInstrumentAxis_123" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_142" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_123" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_142" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_142_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_123" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_142_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_136" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_dei_LegalEntityAxis_136" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_159" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_136" xlink:to="loc_dei_EntityDomain_159" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_159_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_136" xlink:to="loc_dei_EntityDomain_159_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_157" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_157" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_196" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_157" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_196" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_196_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_157" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_196_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondInstallmentMember" xlink:label="loc_aytu_SecondInstallmentMember_197" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_196" xlink:to="loc_aytu_SecondInstallmentMember_197" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstInstallmentMember" xlink:label="loc_aytu_FirstInstallmentMember_198" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_196" xlink:to="loc_aytu_FirstInstallmentMember_198" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_195" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_195" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_200" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_195" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_200" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_200_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_195" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_200_default" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AfterAmendmentMember" xlink:label="loc_aytu_AfterAmendmentMember_201" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_200" xlink:to="loc_aytu_AfterAmendmentMember_201" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_StatementScenarioAxis_199" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_206" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_199" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_206" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_206_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_199" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_206_default" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_207" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_206" xlink:to="loc_us-gaap_ScenarioPlanMember_207" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_205" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_RangeAxis_205" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_935" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_205" xlink:to="loc_us-gaap_RangeMember_935" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_935_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_205" xlink:to="loc_us-gaap_RangeMember_935_default" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OperatingLeaseMonthlyRentalPayment" xlink:label="loc_aytu_OperatingLeaseMonthlyRentalPayment_187" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_934" xlink:to="loc_aytu_OperatingLeaseMonthlyRentalPayment_187" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidExpensesAmortizationPeriod" xlink:label="loc_aytu_PrepaidExpensesAmortizationPeriod_190" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_934" xlink:to="loc_aytu_PrepaidExpensesAmortizationPeriod_190" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_203" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_934" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_203" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1596" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_934" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1596" use="optional" order="32" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_804" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_119" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_StatementTable_119" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_120" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_119" xlink:to="loc_us-gaap_StatementClassOfStockAxis_120" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_121" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_120" xlink:to="loc_us-gaap_ClassOfStockDomain_121" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_121_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_120" xlink:to="loc_us-gaap_ClassOfStockDomain_121_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_122" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_119" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_122" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_805" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_122" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_805" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_805_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_122" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_805_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_125" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_125" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_126" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_126" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_127" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_PreferredStockSharesIssued_127" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_129" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_129" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_130" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_130" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_131" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_CommonStockSharesIssued_131" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_132" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_132" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_141" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_138" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_StatementTable_138" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_139" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_138" xlink:to="loc_us-gaap_StatementClassOfStockAxis_139" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_140" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_139" xlink:to="loc_us-gaap_ClassOfStockDomain_140" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_140_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_139" xlink:to="loc_us-gaap_ClassOfStockDomain_140_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_1392" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_RevenuesAbstract_1392" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProductsAndServicesRevenue" xlink:label="loc_aytu_ProductsAndServicesRevenue_143" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1392" xlink:to="loc_aytu_ProductsAndServicesRevenue_143" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_145" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1392" xlink:to="loc_us-gaap_LicensesRevenue_145" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_146" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1392" xlink:to="loc_us-gaap_Revenues_146" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_147" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_OperatingExpensesAbstract_147" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_149" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_CostOfRevenue_149" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_150" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_150" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ResearchAndDevelopmentRelatedParty" xlink:label="loc_aytu_ResearchAndDevelopmentRelatedParty_151" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_aytu_ResearchAndDevelopmentRelatedParty_151" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_152" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_152" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_945" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_945" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1277" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1277" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1278" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1278" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_702" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_OperatingExpenses_702" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_153" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_OperatingIncomeLoss_153" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_155" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" xlink:to="loc_us-gaap_InterestExpense_155" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_1393" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" xlink:to="loc_us-gaap_GainLossOnInvestments_1393" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_659" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_659" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_156" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_156" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_161" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_NetIncomeLoss_161" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_163" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_163" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_165" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_165" use="optional" order="26" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_175" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_171" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StatementTable_171" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_172" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_171" xlink:to="loc_us-gaap_StatementClassOfStockAxis_172" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_173" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_172" xlink:to="loc_us-gaap_ClassOfStockDomain_173" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_173_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_172" xlink:to="loc_us-gaap_ClassOfStockDomain_173_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_174" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_171" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_174" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_176" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_174" xlink:to="loc_us-gaap_EquityComponentDomain_176" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_176_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_174" xlink:to="loc_us-gaap_EquityComponentDomain_176_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_177" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_176" xlink:to="loc_us-gaap_CommonStockMember_177" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_178" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_176" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_178" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_179" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_176" xlink:to="loc_us-gaap_ReceivablesFromStockholderMember_179" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_180" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_176" xlink:to="loc_us-gaap_RetainedEarningsMember_180" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockholdersEquity_185" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_186" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_SharesIssued_186" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockSubscriptionPayment" xlink:label="loc_aytu_StockSubscriptionPayment_975" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_StockSubscriptionPayment_975" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockSubscriptionPaymentOfShares" xlink:label="loc_aytu_StockSubscriptionPaymentOfShares_976" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_StockSubscriptionPaymentOfShares_976" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_724" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_724" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_725" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_725" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_726" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_726" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_727" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_727" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" xlink:label="loc_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote_807" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote_807" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:label="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_1280" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_1280" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:label="loc_aytu_AdjustmentForRoundingOfValueDueToConversion_703" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_AdjustmentForRoundingOfValueDueToConversion_703" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:label="loc_aytu_AdjustmentForRoundingOfSharesDueToConversion_704" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_AdjustmentForRoundingOfSharesDueToConversion_704" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_188" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_188" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_189" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_189" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1489" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1489" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1490" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1490" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1491" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1491" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1492" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1492" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1493" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1493" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IssuanceOfStockIssuedDuringPeriodvalue" xlink:label="loc_aytu_IssuanceOfStockIssuedDuringPeriodvalue_970" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_IssuanceOfStockIssuedDuringPeriodvalue_970" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockAndIssuedDuringPeriodshares" xlink:label="loc_aytu_StockAndIssuedDuringPeriodshares_971" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_StockAndIssuedDuringPeriodshares_971" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xlink:label="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing_1279" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing_1279" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xlink:label="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts_1494" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts_1494" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_1495" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_1495" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_1496" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_1496" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments" xlink:label="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments_1497" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments_1497" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1498" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1498" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1499" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1499" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_191" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_NetIncomeLoss_191" use="optional" order="40" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_215" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_212" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_StatementTable_212" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_213" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_212" xlink:to="loc_us-gaap_StatementClassOfStockAxis_213" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_214" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_213" xlink:to="loc_us-gaap_ClassOfStockDomain_214" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_214_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_213" xlink:to="loc_us-gaap_ClassOfStockDomain_214_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_216" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_216" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_217" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_216" xlink:to="loc_us-gaap_NetIncomeLoss_217" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_216" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_219" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_219" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_991" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_AssetImpairmentCharges_991" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_218" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_ShareBasedCompensation_218" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_1510" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_RestrictedStockExpense_1510" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_661" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_661" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmortizationOfBeneficialConversionFeature" xlink:label="loc_aytu_AmortizationOfBeneficialConversionFeature_728" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_aytu_AmortizationOfBeneficialConversionFeature_728" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_992" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_OtherNoncashExpense_992" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_663" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_663" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_220" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_1511" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_1511" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Issuanceofcommonstocktoexecutives" xlink:label="loc_aytu_Issuanceofcommonstocktoexecutives_1512" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_aytu_Issuanceofcommonstocktoexecutives_1512" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1513" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1513" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_1514" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_1514" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1515" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_RestructuringCharges_1515" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_228" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_228" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_230" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_230" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_231" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_231" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_235" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_235" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1395" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1395" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_aytu_IncreaseDecreaseInAccruedCompensation_240" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_aytu_IncreaseDecreaseInAccruedCompensation_240" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent_245" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidRent_245" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_246" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_246" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_248" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_216" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_248" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_255" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_255" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_995" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_995" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromLongtermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromLongtermInvestments_996" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_PaymentsForProceedsFromLongtermInvestments_996" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_1516" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_1516" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets_1517" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets_1517" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_994" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_994" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_1518" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_1518" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1519" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1519" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PaymentsForDepositsInvestingActivities" xlink:label="loc_aytu_PaymentsForDepositsInvestingActivities_653" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_aytu_PaymentsForDepositsInvestingActivities_653" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_256" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_256" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_999" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_999" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1002" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1002" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Proceedsfromissuanceofwarranttenderoffer" xlink:label="loc_aytu_Proceedsfromissuanceofwarranttenderoffer_1520" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_aytu_Proceedsfromissuanceofwarranttenderoffer_1520" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Paymentsforwarranttenderoffercost" xlink:label="loc_aytu_Paymentsforwarranttenderoffercost_1521" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_aytu_Paymentsforwarranttenderoffercost_1521" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_262" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_262" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_263" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_263" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_730" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_730" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent_655" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent_655" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Proceedsfromissuanceofcommonstockandwarrants" xlink:label="loc_aytu_Proceedsfromissuanceofcommonstockandwarrants_1522" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_aytu_Proceedsfromissuanceofcommonstockandwarrants_1522" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Paymentsforregisteredofferingcosts" xlink:label="loc_aytu_Paymentsforregisteredofferingcosts_1523" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_aytu_Paymentsforregisteredofferingcosts_1523" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1524" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1524" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_729" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_729" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_267" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_267" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_271" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_272" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_272" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IssuanceOfCommonStockToNuelleShareHolders" xlink:label="loc_aytu_IssuanceOfCommonStockToNuelleShareHolders_1644" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_IssuanceOfCommonStockToNuelleShareHolders_1644" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Fixedassetsincludedinaccountspayable" xlink:label="loc_aytu_Fixedassetsincludedinaccountspayable_1525" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_Fixedassetsincludedinaccountspayable_1525" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents" xlink:label="loc_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents_1526" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents_1526" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Warrantsamendedinconnectionwithwarranttenderoffer" xlink:label="loc_aytu_Warrantsamendedinconnectionwithwarranttenderoffer_1527" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_Warrantsamendedinconnectionwithwarranttenderoffer_1527" use="optional" order="63" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" xlink:label="loc_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes_667" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes_667" use="optional" order="64" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xlink:label="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable_665" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable_665" use="optional" order="65" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_731" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_731" use="optional" order="66" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoBusinessPurchaseIncludedInNatestoPayable" xlink:label="loc_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable_1004" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable_1004" use="optional" order="67" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" xlink:label="loc_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants_1005" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants_1005" use="optional" order="68" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" xlink:label="loc_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote_808" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote_808" use="optional" order="69" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" xlink:label="loc_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion_809" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion_809" use="optional" order="70" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_810" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_810" use="optional" order="71" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails">
    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:label="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:label="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable_249" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable_249" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_251" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable_249" xlink:to="loc_us-gaap_RangeAxis_251" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_252" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_251" xlink:to="loc_us-gaap_RangeMember_252" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_252_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_251" xlink:to="loc_us-gaap_RangeMember_252_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_253" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_252" xlink:to="loc_us-gaap_MinimumMember_253" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_254" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_252" xlink:to="loc_us-gaap_MaximumMember_254" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_257" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable_249" xlink:to="loc_dei_LegalEntityAxis_257" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_258" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_257" xlink:to="loc_dei_EntityDomain_258" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_258_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_257" xlink:to="loc_dei_EntityDomain_258_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LuoxisDiagnosticsMember" xlink:label="loc_aytu_LuoxisDiagnosticsMember_259" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_258" xlink:to="loc_aytu_LuoxisDiagnosticsMember_259" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_264" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_264" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_266" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_266" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_268" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_268" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_270" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_270" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_269" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_269" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_277" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_277" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_278" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_277" xlink:to="loc_dei_LegalEntityAxis_278" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_280" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_278" xlink:to="loc_dei_EntityDomain_280" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_280_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_278" xlink:to="loc_dei_EntityDomain_280_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LuoxisDiagnosticsMember" xlink:label="loc_aytu_LuoxisDiagnosticsMember_281" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_280" xlink:to="loc_aytu_LuoxisDiagnosticsMember_281" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_285" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_285" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_287" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_287" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_288" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_288" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_289" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_289" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_291" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_291" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_294" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_294" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1407" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1407" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_301" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_301" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_299" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_299" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_302" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_302" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_303" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_303" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1408" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1408" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_306" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_306" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_308" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_308" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_309" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_308" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_309" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_660" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_308" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_660" use="optional" order="23" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_332" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_320" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_332" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_320" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_322" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_320" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_322" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_329" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_322" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_329" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_329_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_322" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_329_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_330" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_329" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_330" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_331" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_329" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_331" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_328" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_320" xlink:to="loc_us-gaap_AwardTypeAxis_328" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_333" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_333" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_333_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_333_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_325" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_332" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_325" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="loc_aytu_UnrecognizedShareBasedCompensationExpenses_326" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_332" xlink:to="loc_aytu_UnrecognizedShareBasedCompensationExpenses_326" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_327" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_327" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_385" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_PlanNameAxis_385" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_387" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_385" xlink:to="loc_us-gaap_PlanNameDomain_387" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_387_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_385" xlink:to="loc_us-gaap_PlanNameDomain_387_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="loc_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_389" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_387" xlink:to="loc_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_389" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_386" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_AwardTypeAxis_386" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_392" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_386" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_392" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_392_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_386" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_392_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_393" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_392" xlink:to="loc_us-gaap_EmployeeStockOptionMember_393" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_391" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_391" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_695" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_391" xlink:to="loc_us-gaap_EquityComponentDomain_695" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_695_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_391" xlink:to="loc_us-gaap_EquityComponentDomain_695_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1446" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_695" xlink:to="loc_us-gaap_WarrantMember_1446" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_694" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_694" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_719" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_694" xlink:to="loc_us-gaap_RelatedPartyDomain_719" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_719_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_694" xlink:to="loc_us-gaap_RelatedPartyDomain_719_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_718" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_718" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_718" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1326_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_718" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1326_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PlacementAgentWarrantsMember" xlink:label="loc_aytu_PlacementAgentWarrantsMember_1327" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" xlink:to="loc_aytu_PlacementAgentWarrantsMember_1327" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_InvestorsWarrantsMember" xlink:label="loc_aytu_InvestorsWarrantsMember_1328" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" xlink:to="loc_aytu_InvestorsWarrantsMember_1328" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BankersWarrantsMember" xlink:label="loc_aytu_BankersWarrantsMember_1423" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" xlink:to="loc_aytu_BankersWarrantsMember_1423" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_May2016WarrantsMember" xlink:label="loc_aytu_May2016WarrantsMember_1441" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" xlink:to="loc_aytu_May2016WarrantsMember_1441" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_October2016WarrantsMember" xlink:label="loc_aytu_October2016WarrantsMember_1442" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" xlink:to="loc_aytu_October2016WarrantsMember_1442" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1325" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_DebtInstrumentAxis_1325" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1330" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1325" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1330" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1330_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1325" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1330_default" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ConvertiblePromissoryNotesMay2016Member" xlink:label="loc_aytu_ConvertiblePromissoryNotesMay2016Member_1331" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1330" xlink:to="loc_aytu_ConvertiblePromissoryNotesMay2016Member_1331" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1329" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_RangeAxis_1329" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1416" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_1329" xlink:to="loc_us-gaap_RangeMember_1416" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1416_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_1329" xlink:to="loc_us-gaap_RangeMember_1416_default" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1417" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1416" xlink:to="loc_us-gaap_MaximumMember_1417" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1418" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1416" xlink:to="loc_us-gaap_MinimumMember_1418" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1415" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1415" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1426" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1415" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1426" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1426_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1415" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1426_default" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1427" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1426" xlink:to="loc_us-gaap_OtherRestructuringMember_1427" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1425" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1425" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1429" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1425" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1429" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1429_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1425" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1429_default" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1430" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1429" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1430" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsAxis" xlink:label="loc_aytu_OverAllotmentWarrantsAxis_1428" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_aytu_OverAllotmentWarrantsAxis_1428" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsDomain" xlink:label="loc_aytu_OverAllotmentWarrantsDomain_1436" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_aytu_OverAllotmentWarrantsAxis_1428" xlink:to="loc_aytu_OverAllotmentWarrantsDomain_1436" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsDomain" xlink:label="loc_aytu_OverAllotmentWarrantsDomain_1436_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_aytu_OverAllotmentWarrantsAxis_1428" xlink:to="loc_aytu_OverAllotmentWarrantsDomain_1436_default" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsMember" xlink:label="loc_aytu_OverAllotmentWarrantsMember_1437" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_OverAllotmentWarrantsDomain_1436" xlink:to="loc_aytu_OverAllotmentWarrantsMember_1437" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes_821" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes_821" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice_822" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice_822" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1220" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1313" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1313" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PlacementAgentsCashFeePercentage" xlink:label="loc_aytu_PlacementAgentsCashFeePercentage_1314" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_PlacementAgentsCashFeePercentage_1314" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo_1316" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo_1316" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1317" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1317" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders_1318" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders_1318" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice_1319" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice_1319" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_1320" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_1320" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice_1321" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice_1321" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_1322" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_1322" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_1323" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_1323" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_1324" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_1324" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1413" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1413" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1414" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1414" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockOptionRepricingProgramDescription" xlink:label="loc_aytu_CommonStockOptionRepricingProgramDescription_1419" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_CommonStockOptionRepricingProgramDescription_1419" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_1420" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_1420" use="optional" order="63" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1422" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1422" use="optional" order="64" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1424" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1424" use="optional" order="65" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1431" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_RestructuringCharges_1431" use="optional" order="66" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors_1432" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors_1432" use="optional" order="67" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice_1433" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice_1433" use="optional" order="68" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassOfWarrantsAndRightsIssuanceCost" xlink:label="loc_aytu_ClassOfWarrantsAndRightsIssuanceCost_1434" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ClassOfWarrantsAndRightsIssuanceCost_1434" use="optional" order="69" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantsModified" xlink:label="loc_aytu_WarrantsModified_1438" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_WarrantsModified_1438" use="optional" order="70" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1439" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1439" use="optional" order="71" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1440" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1440" use="optional" order="72" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1443" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1443" use="optional" order="73" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1444" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1444" use="optional" order="74" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_1445" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_DerivativeLiabilities_1445" use="optional" order="75" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsTables">
    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_1059" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_300" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_1059" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_300" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1048" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_1059" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1048" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1053" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_1059" xlink:to="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1053" use="optional" order="3" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1054" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1053" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1054" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1054" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1054" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055_default" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_1057" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055" xlink:to="loc_aytu_ProstascintBusinessMember_1057" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_1056" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055" xlink:to="loc_aytu_PrimsolBusinessMember_1056" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_1617" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055" xlink:to="loc_aytu_NatestoMember_1617" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_312" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_310" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_310" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_311" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_310" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_311" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_313" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_311" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_313" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_313_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_311" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_313_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_314" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_313" xlink:to="loc_aytu_ProstascintBusinessMember_314" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_1044" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_313" xlink:to="loc_aytu_PrimsolBusinessMember_1044" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_319" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312" xlink:to="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_319" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_321" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_321" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_323" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312" xlink:to="loc_us-gaap_Goodwill_323" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_324" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_324" use="optional" order="10" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails4">
    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems" xlink:label="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems_350" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable" xlink:label="loc_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable_344" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems_350" xlink:to="loc_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable_344" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_346" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable_344" xlink:to="loc_us-gaap_StatementClassOfStockAxis_346" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_348" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_346" xlink:to="loc_us-gaap_ClassOfStockDomain_348" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_348_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_346" xlink:to="loc_us-gaap_ClassOfStockDomain_348_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems_350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding_370" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding_370" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes_763" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes_763" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_1147" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_1147" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo_1148" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo_1148" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_1149" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_1149" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders_1150" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders_1150" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement_1409" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement_1409" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsExcercised" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsExcercised_1412" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsExcercised_1412" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems_350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_377" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_377" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice_764" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice_764" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_1151" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_1151" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice_1152" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice_1152" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_1153" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_1153" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice_1154" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice_1154" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice_1410" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice_1410" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice_1411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice_1411" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_359" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems_350" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_359" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xlink:label="loc_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm_381" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_359" xlink:to="loc_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm_381" use="optional" order="24" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1399" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_338" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_338" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_338" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_338" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_340" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" xlink:to="loc_aytu_ProstascintBusinessMember_340" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_JazzPharmaceuticalsIncMember" xlink:label="loc_aytu_JazzPharmaceuticalsIncMember_341" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" xlink:to="loc_aytu_JazzPharmaceuticalsIncMember_341" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_688" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" xlink:to="loc_aytu_PrimsolBusinessMember_688" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_1008" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" xlink:to="loc_aytu_NatestoMember_1008" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NuelleIncMember" xlink:label="loc_aytu_NuelleIncMember_1547" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" xlink:to="loc_aytu_NuelleIncMember_1547" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_342" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_StatementScenarioAxis_342" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_343" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_342" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_343" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_343_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_342" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_343_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PaidOnApril12016Member" xlink:label="loc_aytu_PaidOnApril12016Member_697" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_343" xlink:to="loc_aytu_PaidOnApril12016Member_697" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NoLaterThanJuly012016Member" xlink:label="loc_aytu_NoLaterThanJuly012016Member_698" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_343" xlink:to="loc_aytu_NoLaterThanJuly012016Member_698" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NoLaterThanSeptember302016Member" xlink:label="loc_aytu_NoLaterThanSeptember302016Member_699" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_343" xlink:to="loc_aytu_NoLaterThanSeptember302016Member_699" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_347" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_ProductOrServiceAxis_347" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_349" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_347" xlink:to="loc_us-gaap_ProductsAndServicesDomain_349" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_349_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_347" xlink:to="loc_us-gaap_ProductsAndServicesDomain_349_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstaScintMember" xlink:label="loc_aytu_ProstaScintMember_351" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_349" xlink:to="loc_aytu_ProstaScintMember_351" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_353" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_353" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_356" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_356" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_357" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355" xlink:to="loc_us-gaap_TradeNamesMember_357" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="loc_us-gaap_CustomerContractsMember_358" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355" xlink:to="loc_us-gaap_CustomerContractsMember_358" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_360" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_RangeAxis_360" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_361" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_360" xlink:to="loc_us-gaap_RangeMember_361" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_361_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_360" xlink:to="loc_us-gaap_RangeMember_361_default" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_362" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_361" xlink:to="loc_us-gaap_MaximumMember_362" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1553" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_361" xlink:to="loc_us-gaap_MinimumMember_1553" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_363" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_363" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_973" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_363" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_973" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_973_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_363" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_973_default" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondUpfrontMember" xlink:label="loc_aytu_SecondUpfrontMember_974" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_973" xlink:to="loc_aytu_SecondUpfrontMember_974" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ThirdUpfrontMember" xlink:label="loc_aytu_ThirdUpfrontMember_1009" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_973" xlink:to="loc_aytu_ThirdUpfrontMember_1009" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_972" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_972" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_988" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_972" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_988" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_988_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_972" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_988_default" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_987" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_TypeOfArrangementAxis_987" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_987" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_987" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014_default" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstMilestoneMember" xlink:label="loc_aytu_FirstMilestoneMember_1015" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_FirstMilestoneMember_1015" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondMilestoneMember" xlink:label="loc_aytu_SecondMilestoneMember_1016" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_SecondMilestoneMember_1016" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ThirdMilestoneMember" xlink:label="loc_aytu_ThirdMilestoneMember_1017" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_ThirdMilestoneMember_1017" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ForthMilestoneMember" xlink:label="loc_aytu_ForthMilestoneMember_1018" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_ForthMilestoneMember_1018" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FifthMilestoneMember" xlink:label="loc_aytu_FifthMilestoneMember_1019" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_FifthMilestoneMember_1019" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SixthMilestoneMember" xlink:label="loc_aytu_SixthMilestoneMember_1550" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_SixthMilestoneMember_1550" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1013" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1013" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1021" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1013" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1021" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1021_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1013" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1021_default" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LicenseAndSupplyAgreementMember" xlink:label="loc_aytu_LicenseAndSupplyAgreementMember_1022" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1021" xlink:to="loc_aytu_LicenseAndSupplyAgreementMember_1022" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1020" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1020" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1400" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1020" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1400" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1400_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1020" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1400_default" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1401" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1400" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1401" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_366" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_366" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_368" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_368" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_369" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_369" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_371" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_371" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_372" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_372" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_374" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_374" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationContingentConsiderationPercentage" xlink:label="loc_aytu_BusinessCombinationContingentConsiderationPercentage_375" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_BusinessCombinationContingentConsiderationPercentage_375" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_376" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_376" use="optional" order="63" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_379" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_379" use="optional" order="64" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_687" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_687" use="optional" order="65" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationConsiderationTransferredInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredInventory_714" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredInventory_714" use="optional" order="66" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationConsiderationTransferredProductInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredProductInventory_715" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredProductInventory_715" use="optional" order="67" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory_716" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory_716" use="optional" order="68" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_984" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_984" use="optional" order="69" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_985" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_985" use="optional" order="70" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1010" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1010" use="optional" order="71" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OneTimeNonrefundablePayments" xlink:label="loc_aytu_OneTimeNonrefundablePayments_1011" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_OneTimeNonrefundablePayments_1011" use="optional" order="72" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SalesRevenueTarget" xlink:label="loc_aytu_SalesRevenueTarget_1012" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_SalesRevenueTarget_1012" use="optional" order="73" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1397" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1397" use="optional" order="74" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_1398" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_1398" use="optional" order="75" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CostOfSaleForInvestment" xlink:label="loc_aytu_CostOfSaleForInvestment_1402" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_CostOfSaleForInvestment_1402" use="optional" order="76" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1403" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1403" use="optional" order="77" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss_1404" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss_1404" use="optional" order="78" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_1405" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_AccretionExpense_1405" use="optional" order="79" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales" xlink:label="loc_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales_1548" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales_1548" use="optional" order="80" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_1551" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_1551" use="optional" order="81" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1552" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1552" use="optional" order="82" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_1619" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_LiabilitiesAssumed1_1619" use="optional" order="83" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommonStockDetailsTextual">
    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockLineItems" xlink:label="loc_aytu_CommonStockLineItems_1479" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SheduleOfCommonStockTable" xlink:label="loc_aytu_SheduleOfCommonStockTable_409" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_SheduleOfCommonStockTable_409" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_StatementClassOfStockAxis_411" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_645" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_411" xlink:to="loc_us-gaap_ClassOfStockDomain_645" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_645_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_411" xlink:to="loc_us-gaap_ClassOfStockDomain_645_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_May2016WarrantsMember" xlink:label="loc_aytu_May2016WarrantsMember_1482" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_645" xlink:to="loc_aytu_May2016WarrantsMember_1482" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_October2016WarrantsMember" xlink:label="loc_aytu_October2016WarrantsMember_1483" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_645" xlink:to="loc_aytu_October2016WarrantsMember_1483" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_644" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_644" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_966" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_644" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_966" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_966_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_644" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_966_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_967" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_966" xlink:to="loc_us-gaap_IPOMember_967" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_968" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_966" xlink:to="loc_us-gaap_OverAllotmentOptionMember_968" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_965" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_965" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1293" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_965" xlink:to="loc_us-gaap_EquityComponentDomain_1293" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1293_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_965" xlink:to="loc_us-gaap_EquityComponentDomain_1293_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1294" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1293" xlink:to="loc_us-gaap_CommonStockMember_1294" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1295" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1293" xlink:to="loc_us-gaap_WarrantMember_1295" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1292" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1292" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1458" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1292" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1458" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1458_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1292" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1458_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:label="loc_aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember_1459" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1458" xlink:to="loc_aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember_1459" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_1457" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_TitleOfIndividualAxis_1457" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1468" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1457" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1468" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1468_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1457" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1468_default" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_1469" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1468" xlink:to="loc_us-gaap_DirectorMember_1469" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_1476" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1468" xlink:to="loc_us-gaap_ExecutiveOfficerMember_1476" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1467" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1467" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1471" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1467" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1471" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1471_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1467" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1471_default" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1470" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_AwardTypeAxis_1470" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1474" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1474" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1474_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1474_default" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1475" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1474" xlink:to="loc_us-gaap_RestrictedStockMember_1475" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1473" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_DebtInstrumentAxis_1473" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1480" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1473" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1480" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1480_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1473" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1480_default" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsMember" xlink:label="loc_aytu_OverAllotmentWarrantsMember_1481" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1480" xlink:to="loc_aytu_OverAllotmentWarrantsMember_1481" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_415" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_415" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_416" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_416" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_417" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_417" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_418" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_418" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_820" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_820" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_956" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_956" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_958" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_958" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_963" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_963" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_UnderwritersExercisedOfOverallotmentOption" xlink:label="loc_aytu_UnderwritersExercisedOfOverallotmentOption_1275" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_UnderwritersExercisedOfOverallotmentOption_1275" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_1290" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_EquityFairValueDisclosure_1290" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1291" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1291" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1357" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1357" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1358" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1358" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1359" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1359" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1454" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1454" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockSharesAgreedToPurchase" xlink:label="loc_aytu_CommonStockSharesAgreedToPurchase_1455" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_CommonStockSharesAgreedToPurchase_1455" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockValueAgreedToPurchase" xlink:label="loc_aytu_CommonStockValueAgreedToPurchase_1456" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_CommonStockValueAgreedToPurchase_1456" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1460" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1460" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1461" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1461" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1462" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1462" use="optional" order="56" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1464" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1464" use="optional" order="57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1465" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1465" use="optional" order="58" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_1466" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockOptionPlanExpense_1466" use="optional" order="59" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:label="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_1477" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_1477" use="optional" order="60" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EquityRelativeFairValue" xlink:label="loc_aytu_EquityRelativeFairValue_1478" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_EquityRelativeFairValue_1478" use="optional" order="61" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1484" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1484" use="optional" order="62" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="loc_aytu_UnrecognizedShareBasedCompensationExpenses_1643" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_UnrecognizedShareBasedCompensationExpenses_1643" use="optional" order="63" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConvertiblePromissoryNotesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionLineItems" xlink:label="loc_us-gaap_DebtConversionLineItems_850" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionTable" xlink:label="loc_us-gaap_DebtConversionTable_436" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtConversionTable_436" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_437" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_437" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_441" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_437" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_441" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_441_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_437" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_441_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ConvertiblePromissoryNotesMember" xlink:label="loc_aytu_ConvertiblePromissoryNotesMember_443" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_441" xlink:to="loc_aytu_ConvertiblePromissoryNotesMember_443" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_439" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_439" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_446" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_439" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_446" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_446_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_439" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_446_default" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_444" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_RangeAxis_444" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_451" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_444" xlink:to="loc_us-gaap_RangeMember_451" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_451_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_444" xlink:to="loc_us-gaap_RangeMember_451_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_452" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_451" xlink:to="loc_us-gaap_MinimumMember_452" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_946" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_451" xlink:to="loc_us-gaap_MaximumMember_946" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_450" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_450" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_816" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_450" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_816" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_816_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_450" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_816_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_815" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_815" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_851" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_815" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_851" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_851_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_815" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_851_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_511" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_511" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_512" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_512" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_513" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_513" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_521" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_521" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_522" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_522" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_526" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_526" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PlacementAgentsCashFeePercentage" xlink:label="loc_aytu_PlacementAgentsCashFeePercentage_527" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_aytu_PlacementAgentsCashFeePercentage_527" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_784" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_784" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_DebtConversionAccruedInterestAmount" xlink:label="loc_aytu_DebtConversionAccruedInterestAmount_785" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_aytu_DebtConversionAccruedInterestAmount_785" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_786" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_786" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_789" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_789" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantsIssuedToPurchaseOfCommonStock" xlink:label="loc_aytu_WarrantsIssuedToPurchaseOfCommonStock_791" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_aytu_WarrantsIssuedToPurchaseOfCommonStock_791" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantsExercisePricePerShare" xlink:label="loc_aytu_WarrantsExercisePricePerShare_792" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_aytu_WarrantsExercisePricePerShare_792" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_800" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_800" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_947" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_947" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_1123" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_1123" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1604" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_SharePrice_1604" use="optional" order="36" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_426" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_426" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_426" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_426" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_690" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" xlink:to="loc_us-gaap_OfficeEquipmentMember_690" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LabEquipmentMember" xlink:label="loc_aytu_LabEquipmentMember_429" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" xlink:to="loc_aytu_LabEquipmentMember_429" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_428" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_428" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaap_ManufacturingFacilityMember_691" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" xlink:to="loc_us-gaap_ManufacturingFacilityMember_691" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_430" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="loc_us-gaap_RangeAxis_430" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_431" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_430" xlink:to="loc_us-gaap_RangeMember_431" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_431_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_430" xlink:to="loc_us-gaap_RangeMember_431_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_433" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_431" xlink:to="loc_us-gaap_MinimumMember_433" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_432" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_431" xlink:to="loc_us-gaap_MaximumMember_432" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_438" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_438" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_440" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_440" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_445" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_445" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_442" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_442" use="optional" order="17" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_542" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_542" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_543" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_542" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_543" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_543" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_543" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytu_PrescriptionDatabaseMember_948" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" xlink:to="loc_aytu_PrescriptionDatabaseMember_948" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_949" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" xlink:to="loc_aytu_NatestoMember_949" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ManufacturingAgreementMember" xlink:label="loc_aytu_ManufacturingAgreementMember_547" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" xlink:to="loc_aytu_ManufacturingAgreementMember_547" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytu_OfficeLeaseMember_548" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" xlink:to="loc_aytu_OfficeLeaseMember_548" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_550" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligation_550" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_551" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_551" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_552" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_552" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_553" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_553" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_554" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_554" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_555" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_555" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_556" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_556" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails1">
    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommitmentsAndContingenciesRentExpenseLineItems" xlink:label="loc_aytu_CommitmentsAndContingenciesRentExpenseLineItems_558" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable" xlink:label="loc_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable_557" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aytu_CommitmentsAndContingenciesRentExpenseLineItems_558" xlink:to="loc_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable_557" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_562" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable_557" xlink:to="loc_us-gaap_StatementClassOfStockAxis_562" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_563" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_562" xlink:to="loc_us-gaap_ClassOfStockDomain_563" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_563_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_562" xlink:to="loc_us-gaap_ClassOfStockDomain_563_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_560" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_CommitmentsAndContingenciesRentExpenseLineItems_558" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_560" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_569" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_OtherCommitmentsAxis_569" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_573" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_569" xlink:to="loc_us-gaap_OtherCommitmentsDomain_573" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_573_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_569" xlink:to="loc_us-gaap_OtherCommitmentsDomain_573_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_572" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_572" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_572" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_572" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_951" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576" xlink:to="loc_aytu_NatestoMember_951" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytu_PrescriptionDatabaseMember_1273" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576" xlink:to="loc_aytu_PrescriptionDatabaseMember_1273" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytu_OfficeLeaseMember_1274" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576" xlink:to="loc_aytu_OfficeLeaseMember_1274" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_575" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_StatementGeographicalAxis_575" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_580" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_575" xlink:to="loc_us-gaap_SegmentGeographicalDomain_580" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_580_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_575" xlink:to="loc_us-gaap_SegmentGeographicalDomain_580_default" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_579" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_579" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_961" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_579" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_961" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_961_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_579" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_961_default" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_960" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_960" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_960" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1242" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1242_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_960" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1242_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1241" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1241" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1448" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1241" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1448" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1448_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1241" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1448_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstInstallmentMember" xlink:label="loc_aytu_FirstInstallmentMember_1449" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1448" xlink:to="loc_aytu_FirstInstallmentMember_1449" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OperatingLeasesMonthlyBaseRentInitialYear" xlink:label="loc_aytu_OperatingLeasesMonthlyBaseRentInitialYear_591" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_aytu_OperatingLeasesMonthlyBaseRentInitialYear_591" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_593" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_593" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_594" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_us-gaap_LeaseAndRentalExpense_594" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_602" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_us-gaap_ContractualObligation_602" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PaymentOfContractualObligations" xlink:label="loc_aytu_PaymentOfContractualObligations_813" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_aytu_PaymentOfContractualObligations_813" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstMilestonePayable" xlink:label="loc_aytu_FirstMilestonePayable_1451" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_aytu_FirstMilestonePayable_1451" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondMilestonePayable" xlink:label="loc_aytu_SecondMilestonePayable_1452" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_aytu_SecondMilestonePayable_1452" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ThirdMilestonePayable" xlink:label="loc_aytu_ThirdMilestonePayable_1453" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_aytu_ThirdMilestonePayable_1453" use="optional" order="31" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_584" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" xlink:to="loc_us-gaap_StatementClassOfStockAxis_584" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_585" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_584" xlink:to="loc_us-gaap_ClassOfStockDomain_585" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_585_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_584" xlink:to="loc_us-gaap_ClassOfStockDomain_585_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_586" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_586" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_738" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_586" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_738" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_738_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_586" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_738_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_737" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" xlink:to="loc_us-gaap_FinancialInstrumentAxis_737" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1286" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_737" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1286" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1286_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_737" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1286_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1052" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_1052" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1650" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1650" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts_1652" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_NoncashMergerRelatedCosts_1652" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_1653" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_1653" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xlink:label="loc_us-gaap_AccretionExpenseIncludingAssetRetirementObligations_1654" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_AccretionExpenseIncludingAssetRetirementObligations_1654" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_603" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_596" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_603" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_596" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_597" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_596" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_597" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_597" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_597" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_599" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_599" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_600" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_600" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_601" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_601" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1065" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_603" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1065" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1066" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1065" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_1066" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_604" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_603" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_604" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_605" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_604" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_605" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1356" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_604" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1356" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_610" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" xlink:to="loc_us-gaap_TransactionTypeAxis_610" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_611" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_610" xlink:to="loc_us-gaap_TransactionDomain_611" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_611_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_610" xlink:to="loc_us-gaap_TransactionDomain_611_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_613" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" xlink:to="loc_us-gaap_FinancialInstrumentAxis_613" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_614" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_613" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_614" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_614_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_613" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_614_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_615" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_614" xlink:to="loc_us-gaap_WarrantMember_615" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_616" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" xlink:to="loc_us-gaap_RangeAxis_616" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_617" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_616" xlink:to="loc_us-gaap_RangeMember_617" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_617_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_616" xlink:to="loc_us-gaap_RangeMember_617_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_624" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_624" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_625" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_625" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_626" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_626" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1421" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1421" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_630" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_630" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_631" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_630" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_631" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_632" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_631" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_632" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_632_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_631" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_632_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_633" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_632" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_633" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_635" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_635" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:label="loc_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_648" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" xlink:to="loc_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_648" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_733" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_733" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_711" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_708" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_StatementTable_708" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_709" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_708" xlink:to="loc_us-gaap_StatementClassOfStockAxis_709" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_710" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_709" xlink:to="loc_us-gaap_ClassOfStockDomain_710" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_710_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_709" xlink:to="loc_us-gaap_ClassOfStockDomain_710_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross" xlink:label="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross_712" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross_712" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1396" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1396" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount" xlink:label="loc_us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount_827" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount_827" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_713" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_713" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_1256" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_AccretionExpense_1256" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_768" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xlink:to="loc_us-gaap_StatementClassOfStockAxis_768" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_769" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_768" xlink:to="loc_us-gaap_ClassOfStockDomain_769" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_769_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_768" xlink:to="loc_us-gaap_ClassOfStockDomain_769_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_771" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xlink:to="loc_us-gaap_RangeAxis_771" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1169" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_771" xlink:to="loc_us-gaap_RangeMember_1169" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1169_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_771" xlink:to="loc_us-gaap_RangeMember_1169_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1171" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1169" xlink:to="loc_us-gaap_MinimumMember_1171" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1170" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1169" xlink:to="loc_us-gaap_MaximumMember_1170" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1168" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1168" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1207" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1168" xlink:to="loc_us-gaap_EquityComponentDomain_1207" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1207_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1168" xlink:to="loc_us-gaap_EquityComponentDomain_1207_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1208" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1207" xlink:to="loc_us-gaap_WarrantMember_1208" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_774" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_774" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_775" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_775" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_776" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_776" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_777" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_777" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_778" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_778" use="optional" order="18" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1610" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1564" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1564" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1565" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1565" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_913" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_913" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_914" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_914" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1261" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1261" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_915" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_915" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1608" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_StatementTable_1608" use="optional" order="7" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1609" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1608" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1609" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1611" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1609" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1611" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1611_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1609" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1611_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_1612" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1611" xlink:to="loc_us-gaap_PatentsMember_1612" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1505" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_979" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1505" xlink:to="loc_us-gaap_StatementTable_979" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_980" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_979" xlink:to="loc_us-gaap_StatementClassOfStockAxis_980" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_981" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_980" xlink:to="loc_us-gaap_ClassOfStockDomain_981" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_981_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_980" xlink:to="loc_us-gaap_ClassOfStockDomain_981_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_982" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_979" xlink:to="loc_dei_LegalEntityAxis_982" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1502" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_982" xlink:to="loc_dei_EntityDomain_1502" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1502_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_982" xlink:to="loc_dei_EntityDomain_1502_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LincolnparkMember" xlink:label="loc_aytu_LincolnparkMember_1503" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1502" xlink:to="loc_aytu_LincolnparkMember_1503" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1501" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_979" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1501" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1506" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1501" xlink:to="loc_us-gaap_EquityComponentDomain_1506" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1506_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1501" xlink:to="loc_us-gaap_EquityComponentDomain_1506_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1507" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1506" xlink:to="loc_us-gaap_CommonStockMember_1507" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1508" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1506" xlink:to="loc_us-gaap_WarrantMember_1508" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_990" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1505" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_990" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_983" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1505" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_983" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1099" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1098" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1099" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1098" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1100" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1098" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1100" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1100" xlink:to="loc_us-gaap_ClassOfStockDomain_1101" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1101_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1100" xlink:to="loc_us-gaap_ClassOfStockDomain_1101_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1099" xlink:to="loc_us-gaap_Depreciation_1102" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1027" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1027" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1028" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1027" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1028" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1028" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1028" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_1031" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029" xlink:to="loc_aytu_ProstascintBusinessMember_1031" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_1032" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029" xlink:to="loc_aytu_PrimsolBusinessMember_1032" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_1622" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029" xlink:to="loc_aytu_NatestoMember_1622" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1035" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1035" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1036" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1036" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1037" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1037" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1038" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1038" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1039" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1039" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1040" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1040" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1041" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1041" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EmployeeBenefitPlanDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1071" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1068" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1071" xlink:to="loc_us-gaap_StatementTable_1068" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1069" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1068" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1069" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1070" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1069" xlink:to="loc_us-gaap_ClassOfStockDomain_1070" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1070_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1069" xlink:to="loc_us-gaap_ClassOfStockDomain_1070_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="loc_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_1276" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1071" xlink:to="loc_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_1276" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1642" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1071" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1642" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/LicenseAgreementrevenueRecognitionDetailsTextual">
    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_RevenueRecognitionLineItems" xlink:label="loc_aytu_RevenueRecognitionLineItems_1079" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_RevenueRecognitionTable" xlink:label="loc_aytu_RevenueRecognitionTable_1073" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_aytu_RevenueRecognitionTable_1073" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1076" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytu_RevenueRecognitionTable_1073" xlink:to="loc_dei_LegalEntityAxis_1076" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1077" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1076" xlink:to="loc_dei_EntityDomain_1077" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1077_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1076" xlink:to="loc_dei_EntityDomain_1077_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_VyrixPharmaceuticalsIncMember" xlink:label="loc_aytu_VyrixPharmaceuticalsIncMember_1078" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1077" xlink:to="loc_aytu_VyrixPharmaceuticalsIncMember_1078" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioMember" xlink:label="loc_aytu_AmpioMember_1082" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1077" xlink:to="loc_aytu_AmpioMember_1082" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PotentialMilestonePaymentsReceivable" xlink:label="loc_aytu_PotentialMilestonePaymentsReceivable_1080" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_aytu_PotentialMilestonePaymentsReceivable_1080" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PercentageOfRoyaltyRateOfNetSales" xlink:label="loc_aytu_PercentageOfRoyaltyRateOfNetSales_1081" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_aytu_PercentageOfRoyaltyRateOfNetSales_1081" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_1083" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_us-gaap_DeferredRevenue_1083" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_1084" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_1084" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AgreementExpirationPeriod" xlink:label="loc_aytu_AgreementExpirationPeriod_1086" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_aytu_AgreementExpirationPeriod_1086" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxHolidayLineItems" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems_1112" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxHolidayTable" xlink:label="loc_us-gaap_IncomeTaxHolidayTable_1108" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_1112" xlink:to="loc_us-gaap_IncomeTaxHolidayTable_1108" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_1108" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1114" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1115" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1114" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1115" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1115_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1114" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1115_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_1112" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1127" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1127" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1128" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1128" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1129" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1129" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" xlink:label="loc_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt_1130" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt_1130" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" xlink:label="loc_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts_1633" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts_1633" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" xlink:label="loc_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration_1635" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration_1635" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1134" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1134" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1131" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1131" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1135" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1135" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1132" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1132" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1133" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1133" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1137" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1137" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1139" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1139" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1140" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1140" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" xlink:label="loc_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt_1155" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt_1155" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncomeTaxReconciliationOfFeringCosts" xlink:label="loc_aytu_IncomeTaxReconciliationOfFeringCosts_1632" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_IncomeTaxReconciliationOfFeringCosts_1632" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="loc_aytu_IncomeTaxReconciliationContingentConsideration_1634" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_IncomeTaxReconciliationContingentConsideration_1634" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1157" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1157" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1156" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1156" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1158" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1158" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1159" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1159" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1160" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1160" use="optional" order="27" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1117" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1111" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1117" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1111" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1113" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1111" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1113" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1118" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1113" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1118" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1118_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1113" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1118_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_1119" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1118" xlink:to="loc_us-gaap_PatentsMember_1119" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1116" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1117" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1116" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1120" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1117" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1120" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1122" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1117" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1122" use="optional" order="8" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1141" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1141" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1142" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1141" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1142" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1218" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1218" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1218_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1218_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_1219" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1218" xlink:to="loc_us-gaap_PatentsMember_1219" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1211" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1211" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1212" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1212" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1213" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1213" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1214" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1214" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1215" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1215" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1216" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1216" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1221" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1221" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1179" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1176" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1179" xlink:to="loc_us-gaap_StatementTable_1176" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1177" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1176" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1177" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1178" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1177" xlink:to="loc_us-gaap_ClassOfStockDomain_1178" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1178_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1177" xlink:to="loc_us-gaap_ClassOfStockDomain_1178_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1179" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossCurrent_1181" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossCurrent_1181" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1182" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1194" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1194" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1183" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1183" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1184" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1185" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1645" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1645" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_1187" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_1187" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1636" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1636" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_1637" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_1637" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_1188" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_1188" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_1189" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_1189" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_1190" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_1190" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1191" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1191" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1192" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1192" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1193" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1193" use="optional" order="21" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/IncomeTaxesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1203" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1197" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_StatementTable_1197" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1198" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1197" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1198" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1199" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1198" xlink:to="loc_us-gaap_ClassOfStockDomain_1199" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1199_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1198" xlink:to="loc_us-gaap_ClassOfStockDomain_1199_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1200" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1197" xlink:to="loc_dei_LegalEntityAxis_1200" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1204" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1200" xlink:to="loc_dei_EntityDomain_1204" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1204_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1200" xlink:to="loc_dei_EntityDomain_1204_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioPharmaceuticalsMember" xlink:label="loc_aytu_AmpioPharmaceuticalsMember_1205" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1204" xlink:to="loc_aytu_AmpioPharmaceuticalsMember_1205" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1201" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1201" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1202" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1202" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NetOperatingLossesExpirationDescription" xlink:label="loc_aytu_NetOperatingLossesExpirationDescription_1639" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_aytu_NetOperatingLossesExpirationDescription_1639" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SummaryOfSignificantAccountingPolicyLineItems" xlink:label="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1224" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_StatementTable_1224" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1225" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1225" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1226" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1225" xlink:to="loc_us-gaap_ClassOfStockDomain_1226" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1226_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1225" xlink:to="loc_us-gaap_ClassOfStockDomain_1226_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1227" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1227" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1231" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1227" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1231" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1231_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1227" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1231_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ZertanePatentsMember" xlink:label="loc_aytu_ZertanePatentsMember_1232" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1231" xlink:to="loc_aytu_ZertanePatentsMember_1232" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OrpMember" xlink:label="loc_aytu_OrpMember_1233" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1231" xlink:to="loc_aytu_OrpMember_1233" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1271" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1283" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1271" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1283" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1283_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1271" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1283_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_1282" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_MajorCustomersAxis_1282" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1342" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_1282" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_1342" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1342_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_1282" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_1342_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1341" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1341" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1345" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1341" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1345" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1345_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1341" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1345_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1595" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1345" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1595" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerFourMember" xlink:label="loc_aytu_CustomerFourMember_1597" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1345" xlink:to="loc_aytu_CustomerFourMember_1597" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1344" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1344" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1352" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1344" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1352" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1352_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1344" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1352_default" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockOptionsMember" xlink:label="loc_aytu_StockOptionsMember_1353" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1352" xlink:to="loc_aytu_StockOptionsMember_1353" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1355" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1352" xlink:to="loc_us-gaap_WarrantMember_1355" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1351" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_RangeAxis_1351" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1601" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_1351" xlink:to="loc_us-gaap_RangeMember_1601" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1601_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_1351" xlink:to="loc_us-gaap_RangeMember_1601_default" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1602" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_1601" xlink:to="loc_us-gaap_MinimumMember_1602" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_1228" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_1228" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1234" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1234" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1235" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1235" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:label="loc_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear_1236" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear_1236" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1238" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1238" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1348" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1348" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1354" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1354" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_1603" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_InventoryValuationReserves_1603" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1625" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1625" use="optional" order="38" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1267" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1264" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1267" xlink:to="loc_us-gaap_StatementTable_1264" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1265" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1264" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1265" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1266" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1265" xlink:to="loc_us-gaap_ClassOfStockDomain_1266" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1266_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1265" xlink:to="loc_us-gaap_ClassOfStockDomain_1266_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1268" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1267" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1268" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1302" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1298" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_StatementTable_1298" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1299" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1298" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1299" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1300" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1299" xlink:to="loc_us-gaap_ClassOfStockDomain_1300" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1300_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1299" xlink:to="loc_us-gaap_ClassOfStockDomain_1300_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1301" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1298" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1301" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1303" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1301" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1303" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1303_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1301" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1303_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="loc_aytu_ExercisePriceRangeOneMember_1304" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1303" xlink:to="loc_aytu_ExercisePriceRangeOneMember_1304" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="loc_aytu_ExercisePriceRangeTwoMember_1305" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1303" xlink:to="loc_aytu_ExercisePriceRangeTwoMember_1305" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1307" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1307" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1308" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1308" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1333" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1333" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1310" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1310" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1311" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1311" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1334" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1334" use="optional" order="15" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/GoingConcernDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1629" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1365" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_StatementTable_1365" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1366" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1365" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1366" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1367" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1366" xlink:to="loc_us-gaap_ClassOfStockDomain_1367" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1367_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1366" xlink:to="loc_us-gaap_ClassOfStockDomain_1367_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1368" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1365" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1368" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1630" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1368" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1630" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1630_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1368" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1630_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1631" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1630" xlink:to="loc_us-gaap_SubsequentEventMember_1631" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1369" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_NetIncomeLoss_1369" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1370" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1370" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1372" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1372" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1626" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1626" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1627" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_RestrictedCash_1627" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1628" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1628" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SegmentInformationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1540" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1536" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1540" xlink:to="loc_us-gaap_StatementTable_1536" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1537" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1536" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1537" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1538" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1537" xlink:to="loc_us-gaap_ClassOfStockDomain_1538" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1538_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1537" xlink:to="loc_us-gaap_ClassOfStockDomain_1538_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1539" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1536" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1539" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1541" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1539" xlink:to="loc_us-gaap_SegmentDomain_1541" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1541_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1539" xlink:to="loc_us-gaap_SegmentDomain_1541_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AytuBioscienceIncMember" xlink:label="loc_aytu_AytuBioscienceIncMember_1542" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1541" xlink:to="loc_aytu_AytuBioscienceIncMember_1542" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AytuWomensHealthMember" xlink:label="loc_aytu_AytuWomensHealthMember_1543" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1541" xlink:to="loc_aytu_AytuWomensHealthMember_1543" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1544" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1540" xlink:to="loc_us-gaap_Revenues_1544" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1545" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1540" xlink:to="loc_us-gaap_NetIncomeLoss_1545" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1546" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1540" xlink:to="loc_us-gaap_Assets_1546" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1570" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1570" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1571" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1570" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1571" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1572" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1571" xlink:to="loc_us-gaap_ClassOfStockDomain_1572" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1572_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1571" xlink:to="loc_us-gaap_ClassOfStockDomain_1572_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_1574" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_InventoryRawMaterials_1574" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_1575" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_InventoryWorkInProcess_1575" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_1576" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_InventoryFinishedGoods_1576" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_1620" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_InventoryValuationReserves_1620" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1577" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_InventoryNet_1577" use="optional" order="9" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1590" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1590" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1581" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1581" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1582" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1581" xlink:to="loc_us-gaap_ClassOfStockDomain_1582" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1582_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1581" xlink:to="loc_us-gaap_ClassOfStockDomain_1582_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1583" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1583" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1585" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1583" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1585" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1585_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1583" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1585_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerOneMember" xlink:label="loc_aytu_CustomerOneMember_1586" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1585" xlink:to="loc_aytu_CustomerOneMember_1586" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerTwoMember" xlink:label="loc_aytu_CustomerTwoMember_1587" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1585" xlink:to="loc_aytu_CustomerTwoMember_1587" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerThreeMember" xlink:label="loc_aytu_CustomerThreeMember_1588" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1585" xlink:to="loc_aytu_CustomerThreeMember_1588" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerFourMember" xlink:label="loc_aytu_CustomerFourMember_1589" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1585" xlink:to="loc_aytu_CustomerFourMember_1589" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1584" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1584" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1591" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1584" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1591" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1591_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1584" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1591_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_1592" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1591" xlink:to="loc_us-gaap_SalesRevenueNetMember_1592" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_1593" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1591" xlink:to="loc_us-gaap_AccountsReceivableMember_1593" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1594" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1590" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1594" use="optional" order="17" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>aytu-20170630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 30-Aug-2017 [07:46:22] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_DocumentAndEntityInformationAbstract" xlink:label="loc_aytu_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract" xlink:to="lab_aytu_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidResearchAndDevelopmentRelatedParty" xlink:label="loc_aytu_PrepaidResearchAndDevelopmentRelatedParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PrepaidResearchAndDevelopmentRelatedParty" xml:lang="en-US">Prepaid Research And Development Related Party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_PrepaidResearchAndDevelopmentRelatedParty" xml:lang="en-US">Prepaid research and development - related party (Note 11)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PrepaidResearchAndDevelopmentRelatedParty" xml:lang="en-US">Prepaid research and development related party.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PrepaidResearchAndDevelopmentRelatedParty" xlink:to="lab_aytu_PrepaidResearchAndDevelopmentRelatedParty" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Fixed assets, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Fixed assets, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CoreAndDevelopedTechnologyNet" xlink:label="loc_aytu_CoreAndDevelopedTechnologyNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CoreAndDevelopedTechnologyNet" xml:lang="en-US">Core And Developed Technology Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_CoreAndDevelopedTechnologyNet" xml:lang="en-US">Developed technology, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_CoreAndDevelopedTechnologyNet" xml:lang="en-US">Core and developed technology net.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CoreAndDevelopedTechnologyNet" xlink:to="lab_aytu_CoreAndDevelopedTechnologyNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaap_IndefiniteLivedContractualRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedContractualRights" xml:lang="en-US">Indefinite-Lived Contractual Rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IndefiniteLivedContractualRights" xml:lang="en-US">Customer contracts, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedContractualRights" xlink:to="lab_us-gaap_IndefiniteLivedContractualRights" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedTradeNames" xml:lang="en-US">Indefinite-Lived Trade Names</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IndefiniteLivedTradeNames" xml:lang="en-US">Trade names, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedTradeNames" xlink:to="lab_us-gaap_IndefiniteLivedTradeNames" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Natesto asset</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Patents, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Patents, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Patents, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PrimsolBusinessMember" xml:lang="en-US">Primsol Business [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PrimsolBusinessMember" xlink:to="lab_aytu_PrimsolBusinessMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xlink:label="loc_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xml:lang="en-US">Prepaid Research And Development Related Party Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xml:lang="en-US">Long-term portion of prepaid research and development - related party (Note 11)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xml:lang="en-US">Prepaid research and development related party noncurrent.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xlink:to="lab_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xml:lang="en-US">Deposits Assets, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xml:lang="en-US">Deposits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent" xml:lang="en-US">Assets, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent" xml:lang="en-US">Total long-term assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable and other</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Contingent consideration</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Contingent consideration</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred rent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Warrant derivative liability</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 7)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 824,831 in 2017 and 187,098 in 2016</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xml:lang="en-US">Receivable from Shareholders or Affiliates for Issuance of Capital Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xml:lang="en-US">Ampio stock subscription</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:to="lab_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders&#39; equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders&#39; equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, authorized shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, par value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, authorized shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, issued shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, outstanding shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioMember" xlink:label="loc_aytu_AmpioMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AmpioMember" xml:lang="en-US">Ampio [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AmpioMember" xlink:to="lab_aytu_AmpioMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProductsAndServicesRevenue" xlink:label="loc_aytu_ProductsAndServicesRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ProductsAndServicesRevenue" xml:lang="en-US">Products And Services Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ProductsAndServicesRevenue" xml:lang="en-US">Product and service revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ProductsAndServicesRevenue" xml:lang="en-US">Products and services revenue.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ProductsAndServicesRevenue" xlink:to="lab_aytu_ProductsAndServicesRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicensesRevenue" xml:lang="en-US">Licenses Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LicensesRevenue" xml:lang="en-US">License revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue" xlink:to="lab_us-gaap_LicensesRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Total revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of sales</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ResearchAndDevelopmentRelatedParty" xlink:label="loc_aytu_ResearchAndDevelopmentRelatedParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ResearchAndDevelopmentRelatedParty" xml:lang="en-US">Research And Development Related Party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ResearchAndDevelopmentRelatedParty" xml:lang="en-US">Research and development - related party (Note 11)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ResearchAndDevelopmentRelatedParty" xml:lang="en-US">Research and development related party.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ResearchAndDevelopmentRelatedParty" xlink:to="lab_aytu_ResearchAndDevelopmentRelatedParty" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Sales, general and administrative</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Costs and Expenses, Related Party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Sales, general and administrative - related party (Note 11)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest (expense)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other (expense)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of Aytu common shares outstanding (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders&#39; Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesFromStockholderMember" xml:lang="en-US">Receivables from Stockholder [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ReceivablesFromStockholderMember" xml:lang="en-US">Ampio Stock Subscription [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesFromStockholderMember" xlink:to="lab_us-gaap_ReceivablesFromStockholderMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OperatingLeaseMonthlyRentalPayment" xlink:label="loc_aytu_OperatingLeaseMonthlyRentalPayment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_OperatingLeaseMonthlyRentalPayment" xml:lang="en-US">Operating Lease Monthly Rental Payment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_OperatingLeaseMonthlyRentalPayment" xml:lang="en-US">Operating Lease Monthly Rental Payment.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_OperatingLeaseMonthlyRentalPayment" xlink:to="lab_aytu_OperatingLeaseMonthlyRentalPayment" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockSubscriptionPayment" xlink:label="loc_aytu_StockSubscriptionPayment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_StockSubscriptionPayment" xml:lang="en-US">Stock Subscription Payment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_StockSubscriptionPayment" xml:lang="en-US">Ampio stock subscription</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_StockSubscriptionPayment" xml:lang="en-US">Amount of stock subscription payment.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_StockSubscriptionPayment" xlink:to="lab_aytu_StockSubscriptionPayment" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockSubscriptionPaymentOfShares" xlink:label="loc_aytu_StockSubscriptionPaymentOfShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_StockSubscriptionPaymentOfShares" xml:lang="en-US">Stock Subscription Payment Of Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_StockSubscriptionPaymentOfShares" xml:lang="en-US">Ampio stock subscription (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_StockSubscriptionPaymentOfShares" xml:lang="en-US">During period shares of subscription payment.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_StockSubscriptionPaymentOfShares" xlink:to="lab_aytu_StockSubscriptionPaymentOfShares" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidExpensesAmortizationPeriod" xlink:label="loc_aytu_PrepaidExpensesAmortizationPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PrepaidExpensesAmortizationPeriod" xml:lang="en-US">Prepaid Expenses Amortization Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PrepaidExpensesAmortizationPeriod" xml:lang="en-US">Prepaid expenses amortization period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PrepaidExpensesAmortizationPeriod" xlink:to="lab_aytu_PrepaidExpensesAmortizationPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock subscription</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock subscription (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondInstallmentMember" xlink:label="loc_aytu_SecondInstallmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SecondInstallmentMember" xml:lang="en-US">Second Installment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SecondInstallmentMember" xlink:to="lab_aytu_SecondInstallmentMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstInstallmentMember" xlink:label="loc_aytu_FirstInstallmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_FirstInstallmentMember" xml:lang="en-US">First Installment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_FirstInstallmentMember" xlink:to="lab_aytu_FirstInstallmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AfterAmendmentMember" xlink:label="loc_aytu_AfterAmendmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AfterAmendmentMember" xml:lang="en-US">After Amendment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AfterAmendmentMember" xlink:to="lab_aytu_AfterAmendmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xml:lang="en-US">Property Subject to or Available for Operating Lease, Net, Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioPlanMember" xml:lang="en-US">Scenario, Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioPlanMember" xlink:to="lab_us-gaap_ScenarioPlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, amortization and accretion</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset Impairment Charges</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetImpairmentCharges" xml:lang="en-US">Asset impairment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockExpense" xml:lang="en-US">Restricted Stock or Unit Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockExpense" xml:lang="en-US">Issuance of restricted stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense" xlink:to="lab_us-gaap_RestrictedStockExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Financing Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of debt issuance costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmortizationOfBeneficialConversionFeature" xlink:label="loc_aytu_AmortizationOfBeneficialConversionFeature" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AmortizationOfBeneficialConversionFeature" xml:lang="en-US">Amortization Of Beneficial Conversion Feature</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_AmortizationOfBeneficialConversionFeature" xml:lang="en-US">Amortization of beneficial conversion feature</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_AmortizationOfBeneficialConversionFeature" xml:lang="en-US">This element represents the amount of amortization of beneficial conversion feature.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AmortizationOfBeneficialConversionFeature" xlink:to="lab_aytu_AmortizationOfBeneficialConversionFeature" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashExpense" xml:lang="en-US">Other Noncash Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNoncashExpense" xml:lang="en-US">Noncash interest expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative (income) expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative income (expense)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">(Increase) in accounts receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Decrease (increase) in inventory</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xml:lang="en-US">Amortization Of Prepaid Research And Development Due To Related Parties</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xml:lang="en-US">Amortization of prepaid research and development - related party (Note 11)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xml:lang="en-US">Amortization of prepaid research and development due to related parties.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:to="lab_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">(Increase) decrease in prepaid expenses and other</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase in accounts payable and other</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">(Decrease) increase in accrued liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_aytu_IncreaseDecreaseInAccruedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_IncreaseDecreaseInAccruedCompensation" xml:lang="en-US">Increase Decrease In Accrued Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_IncreaseDecreaseInAccruedCompensation" xml:lang="en-US">(Decrease) increase in accrued compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_IncreaseDecreaseInAccruedCompensation" xml:lang="en-US">Increase decrease in accrued compensation.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_IncreaseDecreaseInAccruedCompensation" xlink:to="lab_aytu_IncreaseDecreaseInAccruedCompensation" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:label="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AssumptionsUsedToDetermineFairValueOptionsTable" xml:lang="en-US">Assumptions Used To Determine Fair Value Options [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:to="lab_aytu_AssumptionsUsedToDetermineFairValueOptionsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows used in investing activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of fixed assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LuoxisDiagnosticsMember" xlink:label="loc_aytu_LuoxisDiagnosticsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_LuoxisDiagnosticsMember" xml:lang="en-US">Luoxis Diagnostics [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_LuoxisDiagnosticsMember" xlink:to="lab_aytu_LuoxisDiagnosticsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from financing activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:label="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems" xml:lang="en-US">Assumptions Used To Determine Fair Value Options [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:to="lab_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Issuance of common stock to Lincoln Park</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Costs related to the sale of common stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk free interest rate, Minimum</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Proceedsfromissuanceofwarranttenderoffer" xlink:label="loc_aytu_Proceedsfromissuanceofwarranttenderoffer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_Proceedsfromissuanceofwarranttenderoffer" xml:lang="en-US">ProceedsFromIssuanceOfWarrantTenderOffer</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_Proceedsfromissuanceofwarranttenderoffer" xml:lang="en-US">Warrant tender offer</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_Proceedsfromissuanceofwarranttenderoffer" xml:lang="en-US">The cash inflow due to proceeds from issuance of warrant tender offer.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_Proceedsfromissuanceofwarranttenderoffer" xlink:to="lab_aytu_Proceedsfromissuanceofwarranttenderoffer" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk free interest rate, Maximum</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk free interest rate, Maximum</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (years)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Contractual term (years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net change in cash and cash equivalents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents at end of period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Non-cash transactions:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Warrants Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options, Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Options, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of Options, Exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of Options, Forfeited/Cancelled</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Options Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xml:lang="en-US">Available for grant at June 30, 2017</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:to="lab_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Warrants, Weighted Average Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited/Cancelled</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Cancelled | $ / shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Remaining Contractual Term [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Weighted Average Remaining Contractual Life</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life, Outstanding (in years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ProstascintBusinessMember" xml:lang="en-US">Prostascint Business [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ProstascintBusinessMember" xlink:to="lab_aytu_ProstascintBusinessMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Tangible Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xml:lang="en-US">Tangible assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xml:lang="en-US">Business combination recognized identifiable assets acquired and liabilities assumed tangible assets.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="lab_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xml:lang="en-US">Intangible assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Total assets acquired</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="loc_aytu_UnrecognizedShareBasedCompensationExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_UnrecognizedShareBasedCompensationExpenses" xml:lang="en-US">Unrecognized Share Based Compensation Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_UnrecognizedShareBasedCompensationExpenses" xml:lang="en-US">Unrecognized expense at June 30, 2017</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_UnrecognizedShareBasedCompensationExpenses" xml:lang="en-US">Unrecognized share based compensation expenses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_UnrecognizedShareBasedCompensationExpenses" xlink:to="lab_aytu_UnrecognizedShareBasedCompensationExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted average remaining years to vest (in years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_JazzPharmaceuticalsIncMember" xlink:label="loc_aytu_JazzPharmaceuticalsIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_JazzPharmaceuticalsIncMember" xml:lang="en-US">Jazz Pharmaceuticals Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_JazzPharmaceuticalsIncMember" xlink:to="lab_aytu_JazzPharmaceuticalsIncMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable" xlink:label="loc_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable" xml:lang="en-US">Shedule of Equity Instruments Warrants Issued In Conjunction With Its Senior Convertible Debentures [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable" xlink:to="lab_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductOrServiceAxis" xml:lang="en-US">Products and Services [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis" xlink:to="lab_us-gaap_ProductOrServiceAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductsAndServicesDomain" xml:lang="en-US">Products and Services [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain" xlink:to="lab_us-gaap_ProductsAndServicesDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems" xlink:label="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems" xml:lang="en-US">Equity Instruments Warrants Issued In Conjunction With Its Senior Convertible Debentures [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems" xlink:to="lab_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstaScintMember" xlink:label="loc_aytu_ProstaScintMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ProstaScintMember" xml:lang="en-US">Prosta Scint [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ProstaScintMember" xlink:to="lab_aytu_ProstaScintMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xml:lang="en-US">Developed Technology Rights [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeNamesMember" xml:lang="en-US">Trade Names [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="loc_us-gaap_CustomerContractsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerContractsMember" xml:lang="en-US">Customer Contracts [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerContractsMember" xlink:to="lab_us-gaap_CustomerContractsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders&#39; Equity, Reverse Stock Split</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsOutstanding" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsOutstanding" xml:lang="en-US">Number of Warrants Outstanding, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsOutstanding" xml:lang="en-US">Number of Warrants Outstanding, Ending Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsOutstanding" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Purchase of ProstaScint Business</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationContingentConsiderationPercentage" xlink:label="loc_aytu_BusinessCombinationContingentConsiderationPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_BusinessCombinationContingentConsiderationPercentage" xml:lang="en-US">Business Combination Contingent Consideration Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_BusinessCombinationContingentConsiderationPercentage" xml:lang="en-US">Business combination contingent consideration percentage.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_BusinessCombinationContingentConsiderationPercentage" xlink:to="lab_aytu_BusinessCombinationContingentConsiderationPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xml:lang="en-US">Contingent consideration related to the ProstaScint purchase</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Ending Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Patents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Patents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xlink:label="loc_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class Of Warrant Or Rights Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted Average Remaining Contractual Life, Warrants Outstanding (in years)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xml:lang="en-US">Class of warrant or rights weighted average remaining contractual term.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xlink:to="lab_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="loc_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xml:lang="en-US">Two Thousand Fifteen Stock Option And Incentive Plan [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xml:lang="en-US">2015 Stock Option and Incentive Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:to="lab_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#39; Equity Note Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SheduleOfCommonStockTable" xlink:label="loc_aytu_SheduleOfCommonStockTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SheduleOfCommonStockTable" xml:lang="en-US">Shedule Of Common Stock [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SheduleOfCommonStockTable" xlink:to="lab_aytu_SheduleOfCommonStockTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office equipment and furniture [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LabEquipmentMember" xlink:label="loc_aytu_LabEquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_LabEquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_LabEquipmentMember" xlink:to="lab_aytu_LabEquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionTable" xlink:label="loc_us-gaap_DebtConversionTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionTable" xml:lang="en-US">Debt Conversion [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionTable" xlink:to="lab_us-gaap_DebtConversionTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Fixed assets, gross</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation and amortization</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated useful lives</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ConvertiblePromissoryNotesMember" xlink:label="loc_aytu_ConvertiblePromissoryNotesMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ConvertiblePromissoryNotesMember" xml:lang="en-US">Convertible Promissory Notes [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ConvertiblePromissoryNotesMember" xlink:to="lab_aytu_ConvertiblePromissoryNotesMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xml:lang="en-US">Unamortized Debt Issuance Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from convertible promissory notes, net (Note 8)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Terms of Conversion Feature</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="lab_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PlacementAgentsCashFeePercentage" xlink:label="loc_aytu_PlacementAgentsCashFeePercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PlacementAgentsCashFeePercentage" xml:lang="en-US">Placement Agents Cash Fee Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PlacementAgentsCashFeePercentage" xml:lang="en-US">Placement Agents Cash Fee Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PlacementAgentsCashFeePercentage" xlink:to="lab_aytu_PlacementAgentsCashFeePercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:label="loc_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xml:lang="en-US">Commitments And Contingencies Disclosure [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xml:lang="en-US">Commitments And Contingencies Disclosure Table [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:to="lab_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock" xml:lang="en-US">Schedule of Rent Expense [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xml:lang="en-US">Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligation" xml:lang="en-US">Contractual Obligation, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ContractualObligation" xml:lang="en-US">Total</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xml:lang="en-US">2018</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xml:lang="en-US">Contractual Obligation, Due in Second Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xml:lang="en-US">2019</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:to="lab_us-gaap_ContractualObligationDueInSecondYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xml:lang="en-US">Contractual Obligation, Due in Third Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xml:lang="en-US">2020</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:to="lab_us-gaap_ContractualObligationDueInThirdYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xml:lang="en-US">Contractual Obligation, Due in Fourth Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xml:lang="en-US">2021</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFourthYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xml:lang="en-US">Contractual Obligation, Due in Fifth Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xml:lang="en-US">2022</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFifthYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear" xml:lang="en-US">Contractual Obligation, Due after Fifth Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear" xml:lang="en-US">Thereafter</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueAfterFifthYear" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable" xlink:label="loc_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable" xml:lang="en-US">Shedule Of Commitments And Contingencies Rent Expense [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable" xlink:to="lab_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Rent expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommitmentsAndContingenciesRentExpenseLineItems" xlink:label="loc_aytu_CommitmentsAndContingenciesRentExpenseLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CommitmentsAndContingenciesRentExpenseLineItems" xml:lang="en-US">Commitments And Contingencies Rent Expense [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CommitmentsAndContingenciesRentExpenseLineItems" xlink:to="lab_aytu_CommitmentsAndContingenciesRentExpenseLineItems" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FairValueConsiderationTextBlock" xlink:label="loc_aytu_FairValueConsiderationTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_FairValueConsiderationTextBlock" xml:lang="en-US">Fair Value Consideration [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_FairValueConsiderationTextBlock" xml:lang="en-US">Fair value consideration.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_FairValueConsiderationTextBlock" xlink:to="lab_aytu_FairValueConsiderationTextBlock" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock" xlink:label="loc_aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock" xml:lang="en-US">Financial Assets And Liabilities Not Measured At Fair Value On Recurring Basis [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock" xml:lang="en-US">Financial assets and liabilities not measured at fair value on recurring basis.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock" xlink:to="lab_aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xml:lang="en-US">Other Commitments [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xml:lang="en-US">Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:to="lab_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xml:lang="en-US">Other Commitments [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis" xlink:to="lab_us-gaap_StatementGeographicalAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain" xlink:to="lab_us-gaap_SegmentGeographicalDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OperatingLeasesMonthlyBaseRentInitialYear" xlink:label="loc_aytu_OperatingLeasesMonthlyBaseRentInitialYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_OperatingLeasesMonthlyBaseRentInitialYear" xml:lang="en-US">Operating Leases Monthly Base Rent Initial Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_OperatingLeasesMonthlyBaseRentInitialYear" xml:lang="en-US">Operating leases monthly base rent initial year.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_OperatingLeasesMonthlyBaseRentInitialYear" xlink:to="lab_aytu_OperatingLeasesMonthlyBaseRentInitialYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Term of Contract</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">ASSETS</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransactionTypeAxis" xml:lang="en-US">Transaction Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransactionDomain" xml:lang="en-US">Transaction [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Equivalent term (years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance as of June 30, 2016</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance as of June 30, 2017</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:label="loc_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Warrant issuances</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xml:lang="en-US">Warrant issuances</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xml:lang="en-US">Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity&#39;s own assumption about the assumptions market participants would use in pricing.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:to="lab_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value included in earnings (February 28, 2017)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xml:lang="en-US">Reclassification of warrant from liability to equity upon amendment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payments to Acquire Intangible Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Purchase of Natesto assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromLongtermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromLongtermInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromLongtermInvestments" xml:lang="en-US">Payments for (Proceeds from) Long-term Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromLongtermInvestments" xml:lang="en-US">Investment in Acerus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromLongtermInvestments" xlink:to="lab_us-gaap_PaymentsForProceedsFromLongtermInvestments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Natesto payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AccruedCompensationCurrent" xlink:label="loc_aytu_AccruedCompensationCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AccruedCompensationCurrent" xml:lang="en-US">Accrued Compensation Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_AccruedCompensationCurrent" xml:lang="en-US">Accrued compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_AccruedCompensationCurrent" xml:lang="en-US">Accrued compensation current.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AccruedCompensationCurrent" xlink:to="lab_aytu_AccruedCompensationCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Gain (Loss) on Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">(Loss) on investment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Life, Excercisable (in years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidRent" xml:lang="en-US">Increase (Decrease) in Prepaid Rent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidRent" xml:lang="en-US">(Decrease) increase in deferred rent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidRent" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidRent" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IssuanceOfCommonStockToNuelleShareHolders" xlink:label="loc_aytu_IssuanceOfCommonStockToNuelleShareHolders" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_IssuanceOfCommonStockToNuelleShareHolders" xml:lang="en-US">Issuance of Common Stock to Nuelle Share Holders</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_IssuanceOfCommonStockToNuelleShareHolders" xml:lang="en-US">Issuance of common stock to Nuelle share holders for non cash transaction.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_IssuanceOfCommonStockToNuelleShareHolders" xlink:to="lab_aytu_IssuanceOfCommonStockToNuelleShareHolders" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain" xml:lang="en-US">Deferred Revenue [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of intangible assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaap_ManufacturingFacilityMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xml:lang="en-US">Manufacturing Facility [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xml:lang="en-US">Manufacturing equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturingFacilityMember" xlink:to="lab_us-gaap_ManufacturingFacilityMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PaidOnApril12016Member" xlink:label="loc_aytu_PaidOnApril12016Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PaidOnApril12016Member" xml:lang="en-US">Paid on April 1, 2016 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PaidOnApril12016Member" xlink:to="lab_aytu_PaidOnApril12016Member" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NoLaterThanJuly012016Member" xlink:label="loc_aytu_NoLaterThanJuly012016Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_NoLaterThanJuly012016Member" xml:lang="en-US">No Later Than July 01, 2016 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_NoLaterThanJuly012016Member" xml:lang="en-US">No Later Than July 01, 2016 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_NoLaterThanJuly012016Member" xlink:to="lab_aytu_NoLaterThanJuly012016Member" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NoLaterThanSeptember302016Member" xlink:label="loc_aytu_NoLaterThanSeptember302016Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_NoLaterThanSeptember302016Member" xml:lang="en-US">No Later Than September 30, 2016 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_NoLaterThanSeptember302016Member" xlink:to="lab_aytu_NoLaterThanSeptember302016Member" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytu_PrescriptionDatabaseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PrescriptionDatabaseMember" xml:lang="en-US">Prescription Database [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PrescriptionDatabaseMember" xlink:to="lab_aytu_PrescriptionDatabaseMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross" xlink:label="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross" xml:lang="en-US">Primsol Business Purchase Included In Primsol Payable Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross" xml:lang="en-US">Represents the amount of primsol business purchase included in primsol payable gross amount.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross" xlink:to="lab_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationConsiderationTransferredInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredInventory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_BusinessCombinationConsiderationTransferredInventory" xml:lang="en-US">Business Combination Consideration Transferred Inventory</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_BusinessCombinationConsiderationTransferredInventory" xml:lang="en-US">Represents the amount of business combination consideration transferred to inventory.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_BusinessCombinationConsiderationTransferredInventory" xlink:to="lab_aytu_BusinessCombinationConsiderationTransferredInventory" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationConsiderationTransferredProductInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredProductInventory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_BusinessCombinationConsiderationTransferredProductInventory" xml:lang="en-US">Business Combination Consideration Transferred Product Inventory</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_BusinessCombinationConsiderationTransferredProductInventory" xml:lang="en-US">Represents the amount of business combination consideration transferred to primsol related product inventory.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_BusinessCombinationConsiderationTransferredProductInventory" xlink:to="lab_aytu_BusinessCombinationConsiderationTransferredProductInventory" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xml:lang="en-US">Business Combination Consideration Transferred Work In Process Inventory</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xml:lang="en-US">Represents the amount of business combination consideration transferred to work in process inventory.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xlink:to="lab_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of convertible promissory notes and interest to common stock, net of $29,754 conversion costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of convertible promissory notes and interest to common stock, net of $29,754 conversion costs (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" xlink:label="loc_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" xml:lang="en-US">Adjustment To Additional Capital Issuance Of Warrants Related To Convertible Promissory Note</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" xml:lang="en-US">Issuance of warrants related to the convertible promissory notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" xml:lang="en-US">Reclassification of liability based warrants to equity presentation related to the convertible promissory notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" xml:lang="en-US">The value of adjustment made to the additional paid in capital with regard to issuance of warrants related to convertible promissory notes.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" xlink:to="lab_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">(Decrease) in deferred revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Paymentsforwarranttenderoffercost" xlink:label="loc_aytu_Paymentsforwarranttenderoffercost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_Paymentsforwarranttenderoffercost" xml:lang="en-US">PaymentsForWarrantTenderOfferCost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_aytu_Paymentsforwarranttenderoffercost" xml:lang="en-US">Warrant tender offer cost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_Paymentsforwarranttenderoffercost" xml:lang="en-US">The cash outflow due to payment for warrant tender offer cost.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_Paymentsforwarranttenderoffercost" xlink:to="lab_aytu_Paymentsforwarranttenderoffercost" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of Debt Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Debt issuance costs (Note 8)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders&#39; Equity Note, Warrants or Rights [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_DebtConversionAccruedInterestAmount" xlink:label="loc_aytu_DebtConversionAccruedInterestAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_DebtConversionAccruedInterestAmount" xml:lang="en-US">Debt Conversion Accrued Interest Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_DebtConversionAccruedInterestAmount" xml:lang="en-US">The amount of the accrued interest on debt being converted in a noncash (or part noncash) transaction. &#34;Part noncash&#34; refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_DebtConversionAccruedInterestAmount" xlink:to="lab_aytu_DebtConversionAccruedInterestAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantsIssuedToPurchaseOfCommonStock" xlink:label="loc_aytu_WarrantsIssuedToPurchaseOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_WarrantsIssuedToPurchaseOfCommonStock" xml:lang="en-US">Warrants Issued to Purchase of common stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_WarrantsIssuedToPurchaseOfCommonStock" xml:lang="en-US">The number of warrants issued during the period for the purchase of common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_WarrantsIssuedToPurchaseOfCommonStock" xlink:to="lab_aytu_WarrantsIssuedToPurchaseOfCommonStock" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantsExercisePricePerShare" xlink:label="loc_aytu_WarrantsExercisePricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_WarrantsExercisePricePerShare" xml:lang="en-US">Warrants Exercise Price Per share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_WarrantsExercisePricePerShare" xml:lang="en-US">Exercise price of warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_WarrantsExercisePricePerShare" xlink:to="lab_aytu_WarrantsExercisePricePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:label="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xml:lang="en-US">Adjustments To Additional Paid In Capital Warrants Issued In Connection With Equity Financing To Placement Agents For Over Allotment Option</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xml:lang="en-US">Warrants issued in connection with registered offering to the placement agents for the over-allotment option</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xml:lang="en-US">The value of adjustment made to the additional paid in capital with regard to issuance of warrants in connection with equity financing to the placement agents for the over-allotment option.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:to="lab_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Fixedassetsincludedinaccountspayable" xlink:label="loc_aytu_Fixedassetsincludedinaccountspayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_Fixedassetsincludedinaccountspayable" xml:lang="en-US">FixedAssetsIncludedInAccountsPayable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_Fixedassetsincludedinaccountspayable" xml:lang="en-US">Fixed assets included in accounts payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_Fixedassetsincludedinaccountspayable" xml:lang="en-US">The fair value of fixed assets included in accounts payable in noncash investing or financing activities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_Fixedassetsincludedinaccountspayable" xlink:to="lab_aytu_Fixedassetsincludedinaccountspayable" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents" xlink:label="loc_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents" xml:lang="en-US">WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents" xml:lang="en-US">Warrants issued in connection with the equity financing to the placement agents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents" xml:lang="en-US">Fair value of warrants issued in connection with equity financing to the placement agents.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents" xlink:to="lab_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Warrantsamendedinconnectionwithwarranttenderoffer" xlink:label="loc_aytu_Warrantsamendedinconnectionwithwarranttenderoffer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_Warrantsamendedinconnectionwithwarranttenderoffer" xml:lang="en-US">WarrantsAmendedInConnectionWithWarrantTenderOffer</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_Warrantsamendedinconnectionwithwarranttenderoffer" xml:lang="en-US">Warrants amended in connection with warrant tender offer</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_Warrantsamendedinconnectionwithwarranttenderoffer" xml:lang="en-US">Fair value of warrants amended in connection with warrant tender offer.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_Warrantsamendedinconnectionwithwarranttenderoffer" xlink:to="lab_aytu_Warrantsamendedinconnectionwithwarranttenderoffer" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PaymentOfContractualObligations" xlink:label="loc_aytu_PaymentOfContractualObligations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PaymentOfContractualObligations" xml:lang="en-US">Payment Of Contractual Obligations</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PaymentOfContractualObligations" xml:lang="en-US">The amount of payment made towards contractual obligations.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PaymentOfContractualObligations" xlink:to="lab_aytu_PaymentOfContractualObligations" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" xml:lang="en-US">Share Based Compensation Share Warrants Issued on Convertible Promisory Notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" xml:lang="en-US">Warrants issued to placement agents for convertible promissory notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" xml:lang="en-US">Number of warrants issued upon conversion of promissory notes.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Issued on Convertible Promisory Notes, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" xml:lang="en-US">Warrants issued to placement agents for convertible promissory notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants issued upon conversion of convertible promissory notes.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount" xlink:label="loc_us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount" xml:lang="en-US">Standardized Measure of Discounted Future Net Cash Flow Relating to Proved Oil and Gas Reserves, Accretion of Discount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount" xlink:to="lab_us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Potential number of shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionLineItems" xlink:label="loc_us-gaap_DebtConversionLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionLineItems" xml:lang="en-US">Debt Conversion [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionLineItems" xlink:to="lab_us-gaap_DebtConversionLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" xlink:label="loc_aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" xml:lang="en-US">Estimated Sales Returns And Allowances [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" xml:lang="en-US">Estimated sales returns and allowances policy.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" xlink:to="lab_aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xml:lang="en-US">Receivables, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesTradingSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesTradingSecuritiesPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesTradingSecuritiesPolicy" xml:lang="en-US">Marketable Securities, Trading Securities, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTradingSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesTradingSecuritiesPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" xlink:label="loc_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" xml:lang="en-US">Warrant Derivative Liability Related To The Issuance Of The Convertible Promissory Notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" xml:lang="en-US">Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" xml:lang="en-US">The amount of noncash represents warrant derivative liability related to the issuance of the convertible promissory notes.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" xlink:to="lab_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xlink:label="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xml:lang="en-US">Primsol Business Purchase Included In Primsol Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xml:lang="en-US">Primsol asset purchase included in primsol payable, $1,250,000 less future accretion of $173,000</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xml:lang="en-US">The amount of primsol business purchases included in primsol payable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xlink:to="lab_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xml:lang="en-US">Payments of Debt Restructuring Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsOfDebtRestructuringCosts" xml:lang="en-US">Costs related to the conversion of the convertible promissory notes to equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtRestructuringCosts" xlink:to="lab_us-gaap_PaymentsOfDebtRestructuringCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromContributionsFromParent" xml:lang="en-US">Proceeds from Contributions from Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromContributionsFromParent" xml:lang="en-US">Ampio stock subscription payment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromParent" xlink:to="lab_us-gaap_ProceedsFromContributionsFromParent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LicenseAgreementTextBlock" xlink:label="loc_aytu_LicenseAgreementTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_LicenseAgreementTextBlock" xml:lang="en-US">License Agreement [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_LicenseAgreementTextBlock" xml:lang="en-US">License Agreement [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_LicenseAgreementTextBlock" xlink:to="lab_aytu_LicenseAgreementTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:label="loc_aytu_AdjustmentForRoundingOfValueDueToConversion" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AdjustmentForRoundingOfValueDueToConversion" xml:lang="en-US">Adjustment For Rounding Of Value Due To Conversion</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_AdjustmentForRoundingOfValueDueToConversion" xml:lang="en-US">Adjustment for rounding of shares due to stock split</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_AdjustmentForRoundingOfValueDueToConversion" xml:lang="en-US">It refers to adjustment for rounding of values due to conversion.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:to="lab_aytu_AdjustmentForRoundingOfValueDueToConversion" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:label="loc_aytu_AdjustmentForRoundingOfSharesDueToConversion" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AdjustmentForRoundingOfSharesDueToConversion" xml:lang="en-US">Adjustment For Rounding Of Shares Due To Conversion</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_AdjustmentForRoundingOfSharesDueToConversion" xml:lang="en-US">Adjustment for rounding of shares due to stock split (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_AdjustmentForRoundingOfSharesDueToConversion" xml:lang="en-US">It refers to adjustment for rounding of shares due to conversion.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:to="lab_aytu_AdjustmentForRoundingOfSharesDueToConversion" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xml:lang="en-US">Postemployment Benefits [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRentCurrent" xml:lang="en-US">Accrued Rent, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedRentCurrent" xml:lang="en-US">Deferred rent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrent" xlink:to="lab_us-gaap_AccruedRentCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xml:lang="en-US">Impairment of intangible assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_NatestoMember" xml:lang="en-US">Natesto [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_NatestoMember" xlink:to="lab_aytu_NatestoMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ManufacturingAgreementMember" xlink:label="loc_aytu_ManufacturingAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ManufacturingAgreementMember" xml:lang="en-US">Manufacturing Agreement [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ManufacturingAgreementMember" xml:lang="en-US">Manufacturing/commercial supply agreements</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ManufacturingAgreementMember" xlink:to="lab_aytu_ManufacturingAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermInvestments" xml:lang="en-US">Short-term Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShortTermInvestments" xml:lang="en-US">Investment in Acerus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock-based compensation (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondUpfrontMember" xlink:label="loc_aytu_SecondUpfrontMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SecondUpfrontMember" xml:lang="en-US">Second Upfront [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SecondUpfrontMember" xlink:to="lab_aytu_SecondUpfrontMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xml:lang="en-US">Issuance of restricted stock (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xml:lang="en-US">Payments to Acquire Long-term Investments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xml:lang="en-US">Sale of investment in Acerus cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xml:lang="en-US">Proceeds from Sale of Other Productive Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xml:lang="en-US">Sales of Primsol assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xml:lang="en-US">Payments to Acquire Other Productive Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xml:lang="en-US">Purchase of Primsol asset</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Proceedsfromissuanceofcommonstockandwarrants" xlink:label="loc_aytu_Proceedsfromissuanceofcommonstockandwarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_Proceedsfromissuanceofcommonstockandwarrants" xml:lang="en-US">ProceedsFromIssuanceOfCommonStockAndWarrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_Proceedsfromissuanceofcommonstockandwarrants" xml:lang="en-US">Registerd offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_Proceedsfromissuanceofcommonstockandwarrants" xml:lang="en-US">The amount of cash inflow from the issuance of common stock and warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_Proceedsfromissuanceofcommonstockandwarrants" xlink:to="lab_aytu_Proceedsfromissuanceofcommonstockandwarrants" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Paymentsforregisteredofferingcosts" xlink:label="loc_aytu_Paymentsforregisteredofferingcosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_Paymentsforregisteredofferingcosts" xml:lang="en-US">PaymentsForRegisteredOfferingCosts</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_aytu_Paymentsforregisteredofferingcosts" xml:lang="en-US">Registered offering costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_Paymentsforregisteredofferingcosts" xml:lang="en-US">The amount of cash outflow for the payment of costs on issuance of registered offering.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_Paymentsforregisteredofferingcosts" xlink:to="lab_aytu_Paymentsforregisteredofferingcosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Conversion of convertible promissory notes and interest of $221,000 to common stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ThirdUpfrontMember" xlink:label="loc_aytu_ThirdUpfrontMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ThirdUpfrontMember" xml:lang="en-US">Third Upfront [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ThirdUpfrontMember" xlink:to="lab_aytu_ThirdUpfrontMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OneTimeNonrefundablePayments" xlink:label="loc_aytu_OneTimeNonrefundablePayments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_OneTimeNonrefundablePayments" xml:lang="en-US">One Time Non-Refundable Payments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_OneTimeNonrefundablePayments" xml:lang="en-US">Amount represents the one time non-refundable payments based on sales revenue.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_OneTimeNonrefundablePayments" xlink:to="lab_aytu_OneTimeNonrefundablePayments" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SalesRevenueTarget" xlink:label="loc_aytu_SalesRevenueTarget" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SalesRevenueTarget" xml:lang="en-US">Sales Revenue Target</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_SalesRevenueTarget" xml:lang="en-US">The amount sales revenue target for non-refundable payment criteria.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SalesRevenueTarget" xlink:to="lab_aytu_SalesRevenueTarget" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstMilestoneMember" xlink:label="loc_aytu_FirstMilestoneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_FirstMilestoneMember" xml:lang="en-US">First Milestone [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_FirstMilestoneMember" xlink:to="lab_aytu_FirstMilestoneMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondMilestoneMember" xlink:label="loc_aytu_SecondMilestoneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SecondMilestoneMember" xml:lang="en-US">Second Milestone [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SecondMilestoneMember" xlink:to="lab_aytu_SecondMilestoneMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ThirdMilestoneMember" xlink:label="loc_aytu_ThirdMilestoneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ThirdMilestoneMember" xml:lang="en-US">Third Milestone [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ThirdMilestoneMember" xlink:to="lab_aytu_ThirdMilestoneMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ForthMilestoneMember" xlink:label="loc_aytu_ForthMilestoneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ForthMilestoneMember" xml:lang="en-US">Forth Milestone [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ForthMilestoneMember" xlink:to="lab_aytu_ForthMilestoneMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FifthMilestoneMember" xlink:label="loc_aytu_FifthMilestoneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_FifthMilestoneMember" xml:lang="en-US">Fifth Milestone [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_FifthMilestoneMember" xlink:to="lab_aytu_FifthMilestoneMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LicenseAndSupplyAgreementMember" xlink:label="loc_aytu_LicenseAndSupplyAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_LicenseAndSupplyAgreementMember" xml:lang="en-US">License And Supply Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_LicenseAndSupplyAgreementMember" xlink:to="lab_aytu_LicenseAndSupplyAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">2018</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">2018</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">2019</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">2019</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">2020</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">2020</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">2021</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">2021</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">2022</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">2022</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Thereafter</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Thereafter</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investment in Acerus</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Fair Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_BusinessDescriptionAndBasisOfPresentationTable" xml:lang="en-US">Business Description And Basis Of Presentation [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="lab_aytu_BusinessDescriptionAndBasisOfPresentationTable" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xml:lang="en-US">Business Description And Basis Of Presentation [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="lab_aytu_BusinessDescriptionAndBasisOfPresentationLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Financial Liabilities Fair Value Disclosure [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">LIABILITIES</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionAbstract" xml:lang="en-US">Revenue Recognition [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAbstract" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_RevenueRecognitionTable" xlink:label="loc_aytu_RevenueRecognitionTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_RevenueRecognitionTable" xml:lang="en-US">Revenue Recognition [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_RevenueRecognitionTable" xlink:to="lab_aytu_RevenueRecognitionTable" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_VyrixPharmaceuticalsIncMember" xlink:label="loc_aytu_VyrixPharmaceuticalsIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_VyrixPharmaceuticalsIncMember" xml:lang="en-US">Vyrix Pharmaceuticals Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_VyrixPharmaceuticalsIncMember" xlink:to="lab_aytu_VyrixPharmaceuticalsIncMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_RevenueRecognitionLineItems" xlink:label="loc_aytu_RevenueRecognitionLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_RevenueRecognitionLineItems" xml:lang="en-US">Revenue Recognition [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_RevenueRecognitionLineItems" xlink:to="lab_aytu_RevenueRecognitionLineItems" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PotentialMilestonePaymentsReceivable" xlink:label="loc_aytu_PotentialMilestonePaymentsReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PotentialMilestonePaymentsReceivable" xml:lang="en-US">Potential Milestone Payments Receivable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PotentialMilestonePaymentsReceivable" xml:lang="en-US">Potential Milestone Payments Receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PotentialMilestonePaymentsReceivable" xlink:to="lab_aytu_PotentialMilestonePaymentsReceivable" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PercentageOfRoyaltyRateOfNetSales" xlink:label="loc_aytu_PercentageOfRoyaltyRateOfNetSales" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PercentageOfRoyaltyRateOfNetSales" xml:lang="en-US">Percentage Of Royalty Rate Of Net Sales</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PercentageOfRoyaltyRateOfNetSales" xml:lang="en-US">Percentage Of Royalty Rate Of Net Sales</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PercentageOfRoyaltyRateOfNetSales" xlink:to="lab_aytu_PercentageOfRoyaltyRateOfNetSales" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenue" xml:lang="en-US">Deferred Revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xml:lang="en-US">Proceeds from License Fees Received</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AgreementExpirationPeriod" xlink:label="loc_aytu_AgreementExpirationPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AgreementExpirationPeriod" xml:lang="en-US">Agreement Expiration Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_AgreementExpirationPeriod" xml:lang="en-US">Agreement expiration period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AgreementExpirationPeriod" xlink:to="lab_aytu_AgreementExpirationPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxHolidayTable" xlink:label="loc_us-gaap_IncomeTaxHolidayTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxHolidayTable" xml:lang="en-US">Income Tax Holiday [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayTable" xlink:to="lab_us-gaap_IncomeTaxHolidayTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxHolidayLineItems" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxHolidayLineItems" xml:lang="en-US">Income Tax Holiday [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems" xlink:to="lab_us-gaap_IncomeTaxHolidayLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PatentsMember" xml:lang="en-US">Patents [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Less accumulated armortization</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Benefit at statutory rate,Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income taxes, net of federal benefit, Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Stock based compensation, Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" xlink:label="loc_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" xml:lang="en-US">Effective Income Tax Rate Reconciliation Percentage Interest On Convertible Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" xml:lang="en-US">Interest on convertible debt, Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) relating to interest on convertible debt.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" xlink:to="lab_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" xlink:label="loc_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" xml:lang="en-US">Effective Income Tax Rate Reconciliation Offering Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" xml:lang="en-US">Offering costs, Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" xml:lang="en-US">It represents rate of percentage to effective tax rate reconciliation of offering costs.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" xlink:to="lab_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" xlink:label="loc_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" xml:lang="en-US">Effective Income TaxRate Reconciliation Contingent Consideration</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" xml:lang="en-US">Contingent consideration, Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" xml:lang="en-US">It represents rate of percentage to effective tax rate reconciliation of contingent consideration.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" xlink:to="lab_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Change in tax rate, Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance, Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xml:lang="en-US">Reduction of net operating losses upon deconsolidation, Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Other, Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Net income tax provision (benefit), Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Benefit at statutory rate, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Registered Offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xml:lang="en-US">Warrants issued to investors in connection with the registered offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xml:lang="en-US">Number of warrants issued upon the registered offering.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Convertible Promisory Notes,Two</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" xml:lang="en-US">Warrants issued to placement agents for convertible promissory notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" xml:lang="en-US">Number of warrants issued upon conversion of promissory two notes.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xml:lang="en-US">Warrants issued to placement agents for the registered offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xml:lang="en-US">Number of warrants issued upon placement agents for registered offering.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Registered Offering,Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xml:lang="en-US">Warrants issued to investors in connection with the registered offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants issued upon the registered offering.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Convertible Promisory Two Notes,Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" xml:lang="en-US">Warrants issued to placement agents for convertible promissory notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants issued upon conversion of convertible promissory two notes.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering,Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xml:lang="en-US">Warrants issued to placement agents for the registered offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants issued upon placement agents for the registered offering.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income taxes, net of federal benefit, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Stock based compensation, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" xlink:label="loc_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" xml:lang="en-US">Effective Income Tax Rate Reconciliation Interest On Cnvertible Debt</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" xml:lang="en-US">Interest on convertible debt, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) relating to interest on convertible debt.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" xlink:to="lab_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncomeTaxReconciliationOfFeringCosts" xlink:label="loc_aytu_IncomeTaxReconciliationOfFeringCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_IncomeTaxReconciliationOfFeringCosts" xml:lang="en-US">Income Tax Reconciliation Of fering Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_IncomeTaxReconciliationOfFeringCosts" xml:lang="en-US">Offering costs, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_IncomeTaxReconciliationOfFeringCosts" xml:lang="en-US">It represents income tax reconsilation of offering costs.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_IncomeTaxReconciliationOfFeringCosts" xlink:to="lab_aytu_IncomeTaxReconciliationOfFeringCosts" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="loc_aytu_IncomeTaxReconciliationContingentConsideration" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_IncomeTaxReconciliationContingentConsideration" xml:lang="en-US">Income Tax Reconciliation Contingent Consideration</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_IncomeTaxReconciliationContingentConsideration" xml:lang="en-US">Contingent consideration, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_IncomeTaxReconciliationContingentConsideration" xml:lang="en-US">It represents income tax reconsilation of contingent consideration.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_IncomeTaxReconciliationContingentConsideration" xlink:to="lab_aytu_IncomeTaxReconciliationContingentConsideration" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Change in tax rate, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Convirtible Note Holders</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" xml:lang="en-US">Warrants issued to convertible note holders who converted May 5, 2016</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Convertible Note Holders</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" xml:lang="en-US">Number of warrants issued upon convertible notes holders.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xml:lang="en-US">Share Based Compensation Share Warrants Issued As Part Of Settlement</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xml:lang="en-US">Issuance of settlement warrants to initial investors</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xml:lang="en-US">Number of warrants issued as part of a settlement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Convertible Note Holders,Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" xml:lang="en-US">Warrants issued to convertible note holders who converted May 5, 2016</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants issued upon convertible note holders.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Issued As Part Of Settlement Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xml:lang="en-US">Issuance of settlement warrants to initial investors</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants issued as part of a settlement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Deferred tax assets (liabilities):</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossCurrent" xml:lang="en-US">Deferred Tax Assets, Gross, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossCurrent" xml:lang="en-US">Deferred revenue</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xml:lang="en-US">Deferred rent</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carry forward</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangibles</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Share-based coompensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Fixed assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xml:lang="en-US">Deferred Tax Assets, Unrealized Losses on Trading Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xml:lang="en-US">Unrealized loss on investment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:to="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xml:lang="en-US">Capital loss carry forward</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xml:lang="en-US">Contribution carry forward</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xml:lang="en-US">Deferred Tax Assets, Derivative Instruments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xml:lang="en-US">Warrant liability</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US">Deferred Tax Assets, Inventory</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US">Inventory</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Provision for Loan Losses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xml:lang="en-US">Allowance for doubtful accounts</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioPharmaceuticalsMember" xlink:label="loc_aytu_AmpioPharmaceuticalsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AmpioPharmaceuticalsMember" xml:lang="en-US">Ampio Pharmaceuticals [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AmpioPharmaceuticalsMember" xlink:to="lab_aytu_AmpioPharmaceuticalsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ZertanePatentsMember" xlink:label="loc_aytu_ZertanePatentsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ZertanePatentsMember" xml:lang="en-US">Zertane Patents [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ZertanePatentsMember" xlink:to="lab_aytu_ZertanePatentsMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OrpMember" xlink:label="loc_aytu_OrpMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_OrpMember" xml:lang="en-US">Orp [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_OrpMember" xml:lang="en-US">ORP [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_OrpMember" xlink:to="lab_aytu_OrpMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:label="loc_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" xml:lang="en-US">Finite Lived Intangible Assets Expiration Month Year</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" xml:lang="en-US">Finite lived intangible assets expiration month year.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:to="lab_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill, Impairment Loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Common stock issued to executives</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Common stock issued to executives (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortizationAbstract" xlink:label="loc_us-gaap_DepreciationAndAmortizationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortizationAbstract" xml:lang="en-US">Depreciation, Depletion and Amortization [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationAbstract" xlink:to="lab_us-gaap_DepreciationAndAmortizationAbstract" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytu_OfficeLeaseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_OfficeLeaseMember" xml:lang="en-US">Office Lease [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_OfficeLeaseMember" xlink:to="lab_aytu_OfficeLeaseMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_UnderwritersExercisedOfOverallotmentOption" xlink:label="loc_aytu_UnderwritersExercisedOfOverallotmentOption" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_UnderwritersExercisedOfOverallotmentOption" xml:lang="en-US">Underwriters Exercised of Over-Allotment Option</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_UnderwritersExercisedOfOverallotmentOption" xml:lang="en-US">Number of underwriters exercised of this over-allotment option.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_UnderwritersExercisedOfOverallotmentOption" xlink:to="lab_aytu_UnderwritersExercisedOfOverallotmentOption" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="loc_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xml:lang="en-US">Description of Defined Contribution Pension and Other Postretirement Plans</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="lab_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Issuance of warrants to initial investors</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IssuanceOfStockIssuedDuringPeriodvalue" xlink:label="loc_aytu_IssuanceOfStockIssuedDuringPeriodvalue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_IssuanceOfStockIssuedDuringPeriodvalue" xml:lang="en-US">Issuance of Stock Issued During Period,Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_IssuanceOfStockIssuedDuringPeriodvalue" xml:lang="en-US">Issuance of common stock, net of issuance costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_IssuanceOfStockIssuedDuringPeriodvalue" xml:lang="en-US">Amount of stock issued during the reporting period,</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_IssuanceOfStockIssuedDuringPeriodvalue" xlink:to="lab_aytu_IssuanceOfStockIssuedDuringPeriodvalue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis" xlink:to="lab_us-gaap_MajorCustomersAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityFairValueDisclosure" xml:lang="en-US">Equity, Fair Value Disclosure</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueDisclosure" xlink:to="lab_us-gaap_EquityFairValueDisclosure" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="loc_aytu_ExercisePriceRangeOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ExercisePriceRangeOneMember" xml:lang="en-US">Exercise Price Range One [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ExercisePriceRangeOneMember" xlink:to="lab_aytu_ExercisePriceRangeOneMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="loc_aytu_ExercisePriceRangeTwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ExercisePriceRangeTwoMember" xml:lang="en-US">Exercise Price Range Two [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ExercisePriceRangeTwoMember" xlink:to="lab_aytu_ExercisePriceRangeTwoMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xml:lang="en-US">Range of Exercise Prices</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US">Number of Options Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Weighted Average Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life, Outstanding (in years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PlacementAgentWarrantsMember" xlink:label="loc_aytu_PlacementAgentWarrantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PlacementAgentWarrantsMember" xml:lang="en-US">Placement Agent warrants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PlacementAgentWarrantsMember" xlink:to="lab_aytu_PlacementAgentWarrantsMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_InvestorsWarrantsMember" xlink:label="loc_aytu_InvestorsWarrantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_InvestorsWarrantsMember" xml:lang="en-US">Investors Warrants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_InvestorsWarrantsMember" xlink:to="lab_aytu_InvestorsWarrantsMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ConvertiblePromissoryNotesMay2016Member" xlink:label="loc_aytu_ConvertiblePromissoryNotesMay2016Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ConvertiblePromissoryNotesMay2016Member" xml:lang="en-US">Convertible Promissory Notes May 2016 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ConvertiblePromissoryNotesMay2016Member" xlink:to="lab_aytu_ConvertiblePromissoryNotesMay2016Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US">Number of Options Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US">Weighted Average Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="loc_aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xml:lang="en-US">Tabular disclosure of share-based payment award, warrants, valuation assumptions.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="lab_aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockOptionsMember" xlink:label="loc_aytu_StockOptionsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_StockOptionsMember" xml:lang="en-US">Stock Options [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_StockOptionsMember" xlink:to="lab_aytu_StockOptionsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted Aytu net loss per common share (in dollars per share)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense), Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other (expense)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccretionExpense" xml:lang="en-US">Accretion Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionExpense" xlink:to="lab_us-gaap_AccretionExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Gain (Loss) on Disposition of Business</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CostOfSaleForInvestment" xlink:label="loc_aytu_CostOfSaleForInvestment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CostOfSaleForInvestment" xml:lang="en-US">Cost Of Sale For Investment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_CostOfSaleForInvestment" xml:lang="en-US">The cost of sale of investments.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CostOfSaleForInvestment" xlink:to="lab_aytu_CostOfSaleForInvestment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities, Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Number of Options, Cancelled</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsExcercised" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsExcercised" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsExcercised" xml:lang="en-US">Share Based Compensation Share Warrants Excercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsExcercised" xml:lang="en-US">Warrants exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsExcercised" xml:lang="en-US">Share based compensation share warrants exercised.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsExcercised" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsExcercised" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Excercised Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xml:lang="en-US">Warrants exercised</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xml:lang="en-US">It represents share based compensation share warrants weighted average exercise price.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockOptionRepricingProgramDescription" xlink:label="loc_aytu_CommonStockOptionRepricingProgramDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CommonStockOptionRepricingProgramDescription" xml:lang="en-US">Common Stock Option Repricing Program Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_CommonStockOptionRepricingProgramDescription" xml:lang="en-US">Describe the common stock option repricing program.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CommonStockOptionRepricingProgramDescription" xlink:to="lab_aytu_CommonStockOptionRepricingProgramDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BankersWarrantsMember" xlink:label="loc_aytu_BankersWarrantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_BankersWarrantsMember" xml:lang="en-US">Bankers Warrants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_BankersWarrantsMember" xlink:to="lab_aytu_BankersWarrantsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherRestructuringMember" xml:lang="en-US">Other Restructuring [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsAxis" xlink:label="loc_aytu_OverAllotmentWarrantsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_OverAllotmentWarrantsAxis" xml:lang="en-US">Over Allotment Warrants [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_OverAllotmentWarrantsAxis" xlink:to="lab_aytu_OverAllotmentWarrantsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Warrant amendment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors" xml:lang="en-US">Share Based Compensation Share Warrants Issued To Investors</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors" xml:lang="en-US">Number of warrants issued to investors.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Share Warrants Issued Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants issued to investors.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice" xlink:to="lab_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassOfWarrantsAndRightsIssuanceCost" xlink:label="loc_aytu_ClassOfWarrantsAndRightsIssuanceCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ClassOfWarrantsAndRightsIssuanceCost" xml:lang="en-US">Class Of Warrants And Rights Issuance Cost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ClassOfWarrantsAndRightsIssuanceCost" xml:lang="en-US">The amount of non cash expenses generated on issue of warrants.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ClassOfWarrantsAndRightsIssuanceCost" xlink:to="lab_aytu_ClassOfWarrantsAndRightsIssuanceCost" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsDomain" xlink:label="loc_aytu_OverAllotmentWarrantsDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_OverAllotmentWarrantsDomain" xml:lang="en-US">Over Allotment Warrants [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_OverAllotmentWarrantsDomain" xlink:to="lab_aytu_OverAllotmentWarrantsDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsMember" xlink:label="loc_aytu_OverAllotmentWarrantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_OverAllotmentWarrantsMember" xml:lang="en-US">Over Allotment Warrants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_OverAllotmentWarrantsMember" xlink:to="lab_aytu_OverAllotmentWarrantsMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantsModified" xlink:label="loc_aytu_WarrantsModified" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_WarrantsModified" xml:lang="en-US">Warrants Modified</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_WarrantsModified" xml:lang="en-US">Number of warrants modified during the reporting period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_WarrantsModified" xlink:to="lab_aytu_WarrantsModified" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_May2016WarrantsMember" xlink:label="loc_aytu_May2016WarrantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_May2016WarrantsMember" xml:lang="en-US">May 2016 Warrants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_May2016WarrantsMember" xlink:to="lab_aytu_May2016WarrantsMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_October2016WarrantsMember" xlink:label="loc_aytu_October2016WarrantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_October2016WarrantsMember" xml:lang="en-US">October 2016 Warrants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_October2016WarrantsMember" xlink:to="lab_aytu_October2016WarrantsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Over-allotment warrants purchased by placement agents</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstMilestonePayable" xlink:label="loc_aytu_FirstMilestonePayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_FirstMilestonePayable" xml:lang="en-US">First Milestone Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_FirstMilestonePayable" xml:lang="en-US">It represents the amount of first milestone payment which is require to make.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_FirstMilestonePayable" xlink:to="lab_aytu_FirstMilestonePayable" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondMilestonePayable" xlink:label="loc_aytu_SecondMilestonePayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SecondMilestonePayable" xml:lang="en-US">Second Milestone Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_SecondMilestonePayable" xml:lang="en-US">It represents the amount of second milestone payment which is require to make.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SecondMilestonePayable" xlink:to="lab_aytu_SecondMilestonePayable" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ThirdMilestonePayable" xlink:label="loc_aytu_ThirdMilestonePayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ThirdMilestonePayable" xml:lang="en-US">Third Milestone Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ThirdMilestonePayable" xml:lang="en-US">It represents the amount of third milestone payment which is require to make.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ThirdMilestonePayable" xlink:to="lab_aytu_ThirdMilestonePayable" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockSharesAgreedToPurchase" xlink:label="loc_aytu_CommonStockSharesAgreedToPurchase" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CommonStockSharesAgreedToPurchase" xml:lang="en-US">Common Stock Shares Agreed To Purchase</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_CommonStockSharesAgreedToPurchase" xml:lang="en-US">The number of common stock shares agreed to purchase in the purchase agreement entered during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CommonStockSharesAgreedToPurchase" xlink:to="lab_aytu_CommonStockSharesAgreedToPurchase" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockValueAgreedToPurchase" xlink:label="loc_aytu_CommonStockValueAgreedToPurchase" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CommonStockValueAgreedToPurchase" xml:lang="en-US">Common Stock Value Agreed To Purchase</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_CommonStockValueAgreedToPurchase" xml:lang="en-US">The amount of common stock agreed to purchase in the purchase agreement entered during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CommonStockValueAgreedToPurchase" xlink:to="lab_aytu_CommonStockValueAgreedToPurchase" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:label="loc_aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xml:lang="en-US">Lincoln Park Capital Fund Llc Purchase Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:to="lab_aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionPlanExpense" xml:lang="en-US">Stock or Unit Option Plan Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense" xlink:to="lab_us-gaap_StockOptionPlanExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DirectorMember" xml:lang="en-US">Director [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember" xlink:to="lab_us-gaap_DirectorMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExecutiveOfficerMember" xlink:to="lab_us-gaap_ExecutiveOfficerMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EquityRelativeFairValue" xlink:label="loc_aytu_EquityRelativeFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_EquityRelativeFairValue" xml:lang="en-US">Equity Relative Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_EquityRelativeFairValue" xml:lang="en-US">Relative fair value of the entity&#39;s equity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_EquityRelativeFairValue" xlink:to="lab_aytu_EquityRelativeFairValue" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockLineItems" xlink:label="loc_aytu_CommonStockLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CommonStockLineItems" xlink:to="lab_aytu_CommonStockLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xml:lang="en-US">Current contingent consideration</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockAndIssuedDuringPeriodshares" xlink:label="loc_aytu_StockAndIssuedDuringPeriodshares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_StockAndIssuedDuringPeriodshares" xml:lang="en-US">Stock And Issued During Period,Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_StockAndIssuedDuringPeriodshares" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_StockAndIssuedDuringPeriodshares" xml:lang="en-US">Number of stock issued during the reporting period,</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_StockAndIssuedDuringPeriodshares" xlink:to="lab_aytu_StockAndIssuedDuringPeriodshares" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xlink:label="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xml:lang="en-US">Adjustments To Additional Paid In Capital Warrants Issued In Connection With Equity Financing</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xml:lang="en-US">Warrants issued in connection with registered offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xml:lang="en-US">The value of adjustment made to the additional paid in capital with regard to issuance of warrants in connection with equity financing.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xlink:to="lab_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xlink:label="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xml:lang="en-US">AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsNoncashIssuanceCosts</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xml:lang="en-US">Warrants issued in connection with the registered offering to the placement agents, non-cash issuance costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xml:lang="en-US">The value of adjustment made to the additional paid in capital with regard to issuance of Warrants issued in connection with equity financing to the placement agents, non-cash issuance costs.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xlink:to="lab_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Warrant tender offer, net of $312,159 in issuance costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Warrant tender offer, net of $312,159 in issuance costs (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments" xlink:label="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments" xml:lang="en-US">AdjustmentsToAdditionalPaidInCapitalWarrantAmendments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments" xml:lang="en-US">Warrant amendments</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments" xml:lang="en-US">Amount of increase in additional paid up capital resulting from warrants amendments.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments" xlink:to="lab_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Investment in Subsidiary</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Investment in Subsidiary (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LincolnparkMember" xlink:label="loc_aytu_LincolnparkMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_LincolnparkMember" xml:lang="en-US">LincolnPark [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_LincolnparkMember" xlink:to="lab_aytu_LincolnparkMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xml:lang="en-US">Loss on investment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Issuanceofcommonstocktoexecutives" xlink:label="loc_aytu_Issuanceofcommonstocktoexecutives" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_Issuanceofcommonstocktoexecutives" xml:lang="en-US">IssuanceOfCommonStockToExecutives</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_Issuanceofcommonstocktoexecutives" xml:lang="en-US">Common stock issued to executives</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_Issuanceofcommonstocktoexecutives" xml:lang="en-US">Fair value of common stock issued.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_Issuanceofcommonstocktoexecutives" xlink:to="lab_aytu_Issuanceofcommonstocktoexecutives" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of warrants to initial investors</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US">Gain on sale of asset</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xml:lang="en-US">Cash Acquired from Acquisition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xml:lang="en-US">Cash proceed from Nuelle</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xml:lang="en-US">Other Payments to Acquire Businesses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xml:lang="en-US">Cost related to Nuelle acquisition</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PaymentsForDepositsInvestingActivities" xlink:label="loc_aytu_PaymentsForDepositsInvestingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PaymentsForDepositsInvestingActivities" xml:lang="en-US">Payments For Deposits Investing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_aytu_PaymentsForDepositsInvestingActivities" xml:lang="en-US">Deposits</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PaymentsForDepositsInvestingActivities" xml:lang="en-US">Payments for Deposits Investing Activities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PaymentsForDepositsInvestingActivities" xlink:to="lab_aytu_PaymentsForDepositsInvestingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in investing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Sale of stock subscription</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoBusinessPurchaseIncludedInNatestoPayable" xlink:label="loc_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable" xml:lang="en-US">Natesto Business Purchase Included In Natesto Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable" xml:lang="en-US">Natesto asset purchase included in Natesto payable, $6,000,000 less future accretion of $620,325</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable" xml:lang="en-US">The amount of Natestol business purchases included in Natestol payable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable" xlink:to="lab_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" xlink:label="loc_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" xml:lang="en-US">Warrant Derivative Liability to Issuance Of The Registered Offering Placement Agent Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" xml:lang="en-US">Warrant derivative liability related to the issuance of the registered offering placement agent warrants (Note 8)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" xml:lang="en-US">The amount of noncash warrant derivative liability related to the issuance of register offering placement agent warrant.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" xlink:to="lab_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AytuBioscienceIncMember" xlink:label="loc_aytu_AytuBioscienceIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AytuBioscienceIncMember" xml:lang="en-US">AYTU Bioscience, Inc. [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AytuBioscienceIncMember" xlink:to="lab_aytu_AytuBioscienceIncMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AytuWomensHealthMember" xlink:label="loc_aytu_AytuWomensHealthMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AytuWomensHealthMember" xml:lang="en-US">Aytu Women&#39;s Health [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AytuWomensHealthMember" xlink:to="lab_aytu_AytuWomensHealthMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NuelleIncMember" xlink:label="loc_aytu_NuelleIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_NuelleIncMember" xml:lang="en-US">Nuelle, Inc. [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_NuelleIncMember" xlink:to="lab_aytu_NuelleIncMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales" xlink:label="loc_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales" xml:lang="en-US">Revenue Earn-Out Payments Equal to Designated Percentage of Net Sales</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales" xml:lang="en-US">Amount represents the revenue earnout payments based on sales revenue.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales" xlink:to="lab_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SixthMilestoneMember" xlink:label="loc_aytu_SixthMilestoneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SixthMilestoneMember" xml:lang="en-US">Sixth Milestone [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SixthMilestoneMember" xlink:to="lab_aytu_SixthMilestoneMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_us-gaap_SaleOfStockDescriptionOfTransaction" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassUnitsMember" xlink:label="loc_aytu_ClassUnitsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ClassUnitsMember" xml:lang="en-US">Class A Units [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ClassUnitsMember" xlink:to="lab_aytu_ClassUnitsMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassBUnitsMember" xlink:label="loc_aytu_ClassBUnitsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ClassBUnitsMember" xml:lang="en-US">Class B Units [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ClassBUnitsMember" xlink:to="lab_aytu_ClassBUnitsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterials" xml:lang="en-US">Inventory, Raw Materials, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryRawMaterials" xml:lang="en-US">Raw materials</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcess" xml:lang="en-US">Inventory, Work in Process, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryWorkInProcess" xml:lang="en-US">Work in process</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Inventory, Finished Goods, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Finished goods</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryValuationReserves" xml:lang="en-US">Inventory Valuation Reserves</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InventoryValuationReserves" xml:lang="en-US">Reserve</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerOneMember" xlink:label="loc_aytu_CustomerOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CustomerOneMember" xml:lang="en-US">Customer One [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_CustomerOneMember" xml:lang="en-US">Customer A [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CustomerOneMember" xlink:to="lab_aytu_CustomerOneMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerTwoMember" xlink:label="loc_aytu_CustomerTwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CustomerTwoMember" xml:lang="en-US">Customer Two [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_CustomerTwoMember" xml:lang="en-US">Customer B [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CustomerTwoMember" xlink:to="lab_aytu_CustomerTwoMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerThreeMember" xlink:label="loc_aytu_CustomerThreeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CustomerThreeMember" xml:lang="en-US">Customer Three [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_CustomerThreeMember" xml:lang="en-US">Customer C [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CustomerThreeMember" xlink:to="lab_aytu_CustomerThreeMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerFourMember" xlink:label="loc_aytu_CustomerFourMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_CustomerFourMember" xml:lang="en-US">Customer Four [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aytu_CustomerFourMember" xml:lang="en-US">Customer D [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_CustomerFourMember" xlink:to="lab_aytu_CustomerFourMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Sales Revenue, Net [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioPharmaceuticalsIncMember" xlink:label="loc_aytu_AmpioPharmaceuticalsIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_AmpioPharmaceuticalsIncMember" xml:lang="en-US">Ampio Pharmaceuticals, Inc [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_AmpioPharmaceuticalsIncMember" xlink:to="lab_aytu_AmpioPharmaceuticalsIncMember" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SummaryOfSignificantAccountingPolicyLineItems" xlink:label="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SummaryOfSignificantAccountingPolicyLineItems" xml:lang="en-US">Summary Of Significant Accounting Policy [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="lab_aytu_SummaryOfSignificantAccountingPolicyLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Issuance date fair value per share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" xlink:label="loc_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" xml:lang="en-US">Debt Instrument Convertible Beneficial Conversion Feature Net Of Accretion</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" xml:lang="en-US">Beneficial conversion feature related to convertible promissory notes</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" xml:lang="en-US">Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion after deducting accretion expenses related to unconverted convertible promissory note.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" xlink:to="lab_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities Assumed</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xml:lang="en-US">Reduction of net operating losses upon deconsolidation, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="lab_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Other, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income tax benefit</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Net income tax provision (benefit), Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred income tax assets (liabilities)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less: Valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NetOperatingLossesExpirationDescription" xlink:label="loc_aytu_NetOperatingLossesExpirationDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_NetOperatingLossesExpirationDescription" xml:lang="en-US">Net Operating Losses Expiration Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_NetOperatingLossesExpirationDescription" xml:lang="en-US">It represents description of operating losses expiration</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_NetOperatingLossesExpirationDescription" xlink:to="lab_aytu_NetOperatingLossesExpirationDescription" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xml:lang="en-US">Debt issuance costs related to notes that converted to equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Total deferred income tax assets (liabilities)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PreferredStockConversionPricePerShare" xlink:label="loc_aytu_PreferredStockConversionPricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_PreferredStockConversionPricePerShare" xml:lang="en-US">Preferred Stock Conversion Price Per Share</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_PreferredStockConversionPricePerShare" xml:lang="en-US">The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_PreferredStockConversionPricePerShare" xlink:to="lab_aytu_PreferredStockConversionPricePerShare" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:label="loc_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xml:lang="en-US">Incremental Common Shares Due To Conversion Of Preferred Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xml:lang="en-US">The number of shares by which the common shares outstanding will increase in case of conversion of preferred stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:to="lab_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:label="loc_aytu_SecuritiesPurchaseAgreementCashFeePercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_SecuritiesPurchaseAgreementCashFeePercentage" xml:lang="en-US">Securities Purchase Agreement Cash Fee Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_SecuritiesPurchaseAgreementCashFeePercentage" xml:lang="en-US">The percentage of cash fee to underwriters incurred in securities purchase agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:to="lab_aytu_SecuritiesPurchaseAgreementCashFeePercentage" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:label="loc_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xml:lang="en-US">Class Of Warrant Or Right, Percentage Of Shares To be Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xml:lang="en-US">The warrants to be issued as a percentage of shares issued in the transaction.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:to="lab_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashMergerRelatedCosts" xml:lang="en-US">Noncash Merger Related Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashMergerRelatedCosts" xlink:to="lab_us-gaap_NoncashMergerRelatedCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xlink:label="loc_us-gaap_AccretionExpenseIncludingAssetRetirementObligations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xml:lang="en-US">Accretion Expense, Including Asset Retirement Obligations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xlink:to="lab_us-gaap_AccretionExpenseIncludingAssetRetirementObligations" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>aytu-20170630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 30-Aug-2017 [07:46:22] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#DocumentAndEntityInformation" roleURI="http://www.aytubio.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPolicies" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#GoingConcern" roleURI="http://www.aytubio.com/role/GoingConcern" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#LicenseAgreementrevenueRecognition" roleURI="http://www.aytubio.com/role/LicenseAgreementrevenueRecognition" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#FairValueConsiderations" roleURI="http://www.aytubio.com/role/FairValueConsiderations" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxes" roleURI="http://www.aytubio.com/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommitmentsAndContingencies" roleURI="http://www.aytubio.com/role/CommitmentsAndContingencies" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConvertiblePromissoryNotes" roleURI="http://www.aytubio.com/role/ConvertiblePromissoryNotes" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommonStock" roleURI="http://www.aytubio.com/role/CommonStock" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstruments" roleURI="http://www.aytubio.com/role/EquityInstruments" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#RelatedPartyTransactions" roleURI="http://www.aytubio.com/role/RelatedPartyTransactions" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SegmentInformation" roleURI="http://www.aytubio.com/role/SegmentInformation" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EmployeeBenefitPlan" roleURI="http://www.aytubio.com/role/EmployeeBenefitPlan" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SubsequentEvents" roleURI="http://www.aytubio.com/role/SubsequentEvents" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinationsTables" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsTables" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#FairValueConsiderationsTables" roleURI="http://www.aytubio.com/role/FairValueConsiderationsTables" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxesTables" roleURI="http://www.aytubio.com/role/IncomeTaxesTables" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.aytubio.com/role/ConsolidatedBalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesTables" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsTables" roleURI="http://www.aytubio.com/role/EquityInstrumentsTables" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SegmentInformationTables" roleURI="http://www.aytubio.com/role/SegmentInformationTables" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinationsDetailsTextual" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails3" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails4" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails5" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetails6" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#GoingConcernDetailsTextual" roleURI="http://www.aytubio.com/role/GoingConcernDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#LicenseAgreementrevenueRecognitionDetailsTextual" roleURI="http://www.aytubio.com/role/LicenseAgreementrevenueRecognitionDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#FairValueConsiderationsDetails" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#FairValueConsiderationsDetails1" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#FairValueConsiderationsDetails2" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetails2" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#FairValueConsiderationsDetailsTextual" roleURI="http://www.aytubio.com/role/FairValueConsiderationsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxesDetails" roleURI="http://www.aytubio.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxesDetails1" roleURI="http://www.aytubio.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.aytubio.com/role/IncomeTaxesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommitmentsAndContingenciesDetails1" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConvertiblePromissoryNotesDetailsTextual" roleURI="http://www.aytubio.com/role/ConvertiblePromissoryNotesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#CommonStockDetailsTextual" roleURI="http://www.aytubio.com/role/CommonStockDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails1" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails1" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails2" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails2" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails3" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails3" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails4" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails4" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetails5" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetails5" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EquityInstrumentsDetailsTextual" roleURI="http://www.aytubio.com/role/EquityInstrumentsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.aytubio.com/role/RelatedPartyTransactionsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SegmentInformationDetails" roleURI="http://www.aytubio.com/role/SegmentInformationDetails" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#EmployeeBenefitPlanDetailsTextual" roleURI="http://www.aytubio.com/role/EmployeeBenefitPlanDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.aytubio.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="aytu-20170630.xsd#BusinessBasisOfPresentationMergerAndBusinessCombinations" roleURI="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinations" />

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_DocumentAndEntityInformationAbstract" xlink:label="loc_aytu_DocumentAndEntityInformationAbstract_2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_DocumentAndEntityInformationAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_LegalEntityAxis_4" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1388" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_1388" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1387" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1387" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1390" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1387" xlink:to="loc_us-gaap_ClassOfStockDomain_1390" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_1389" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_1389" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_DocumentType_5" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_13" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_13" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_14" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityVoluntaryFilers_14" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_15" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityCurrentReportingStatus_15" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_1383" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityFilerCategory_1383" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1384" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityPublicFloat_1384" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_1385" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_TradingSymbol_1385" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1386" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_1389" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1386" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_885" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_886" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_885" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_886" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/GoingConcern">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1361" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_1362" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1361" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_1362" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/LicenseAgreementrevenueRecognition">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_917" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LicenseAgreementTextBlock" xlink:label="loc_aytu_LicenseAgreementTextBlock_918" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_917" xlink:to="loc_aytu_LicenseAgreementTextBlock_918" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_561" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FairValueConsiderationTextBlock" xlink:label="loc_aytu_FairValueConsiderationTextBlock_564" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_561" xlink:to="loc_aytu_FairValueConsiderationTextBlock_564" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_920" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_922" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_920" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_922" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_534" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_539" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_534" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_539" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConvertiblePromissoryNotes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_422" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_424" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_422" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_424" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommonStock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_404" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_405" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_404" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_405" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_232" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_233" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_232" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_233" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_111" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_111" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_113" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_26" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_24" xlink:to="loc_us-gaap_StatementTable_26" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_27" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26" xlink:to="loc_us-gaap_StatementClassOfStockAxis_27" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_28" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_27" xlink:to="loc_us-gaap_ClassOfStockDomain_28" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_29" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26" xlink:to="loc_us-gaap_StatementLineItems_29" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_31" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_AssetsAbstract_31" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_32" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_AssetsCurrentAbstract_32" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1485" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1485" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_38" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_38" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_40" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_InventoryNet_40" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_41" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_41" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidResearchAndDevelopmentRelatedParty" xlink:label="loc_aytu_PrepaidResearchAndDevelopmentRelatedParty_43" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_aytu_PrepaidResearchAndDevelopmentRelatedParty_43" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_969" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_ShortTermInvestments_969" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_45" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_32" xlink:to="loc_us-gaap_AssetsCurrent_45" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_46" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_46" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CoreAndDevelopedTechnologyNet" xlink:label="loc_aytu_CoreAndDevelopedTechnologyNet_52" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_aytu_CoreAndDevelopedTechnologyNet_52" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaap_IndefiniteLivedContractualRights_56" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_IndefiniteLivedContractualRights_56" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="loc_us-gaap_IndefiniteLivedTradeNames_57" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_IndefiniteLivedTradeNames_57" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_940" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_940" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_58" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_Goodwill_58" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_60" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_60" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent" xlink:label="loc_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent_64" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent_64" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_67" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_67" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_68" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_AssetsNoncurrent_68" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_69" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31" xlink:to="loc_us-gaap_Assets_69" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_71" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_71" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_1486" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_AccountsPayableCurrent_1486" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1487" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1487" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_941" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_941" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AccruedCompensationCurrent" xlink:label="loc_aytu_AccruedCompensationCurrent_73" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_aytu_AccruedCompensationCurrent_73" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent_942" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_AccruedRentCurrent_942" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1488" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1488" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_83" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_71" xlink:to="loc_us-gaap_LiabilitiesCurrent_83" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_85" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_85" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_90" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_90" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_93" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_93" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_95" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_Liabilities_95" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_96" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_CommitmentsAndContingencies_96" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_98" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_StockholdersEquityAbstract_98" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_98" xlink:to="loc_us-gaap_PreferredStockValue_101" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_98" xlink:to="loc_us-gaap_CommonStockValue_102" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_104" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_98" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_104" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock" xlink:label="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_105" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_98" xlink:to="loc_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock_105" use="optional" order="44" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_98" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_106" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_StockholdersEquity_107" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_108" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SegmentInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1529" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1530" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1529" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1530" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EmployeeBenefitPlan">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_932" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_933" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_932" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_933" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_30" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_21" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_30" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_888" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1406" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1406" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_889" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_889" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_890" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_890" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock" xlink:label="loc_aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock_891" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock_891" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_1607" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_1607" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_892" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_892" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1558" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1558" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_893" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_893" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesTradingSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesTradingSecuritiesPolicy_1338" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_MarketableSecuritiesTradingSecuritiesPolicy_1338" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_894" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_894" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_896" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_896" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_897" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_897" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_898" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_898" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_899" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_UseOfEstimates_899" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_900" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_900" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_901" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_901" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_902" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_902" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1339" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1339" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_903" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_903" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_1340" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_1340" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_905" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_905" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_298" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1053" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_298" xlink:to="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1053" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1054" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1053" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1054" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1054" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_1057" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055" xlink:to="loc_aytu_ProstascintBusinessMember_1057" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_1056" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055" xlink:to="loc_aytu_PrimsolBusinessMember_1056" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_1617" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1055" xlink:to="loc_aytu_NatestoMember_1617" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_1059" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationTable_1053" xlink:to="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_1059" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_300" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_1059" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_300" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1048" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_BusinessDescriptionAndBasisOfPresentationLineItems_1059" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1048" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_912" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1608" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_912" xlink:to="loc_us-gaap_StatementTable_1608" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1609" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1608" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1609" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1611" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1609" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1611" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_1612" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1611" xlink:to="loc_us-gaap_PatentsMember_1612" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1610" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1608" xlink:to="loc_us-gaap_StatementLineItems_1610" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1564" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1564" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1565" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1565" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_913" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_913" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_914" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_914" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1261" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1261" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_915" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1610" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_915" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock" xlink:label="loc_aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock_567" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="loc_aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock_567" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_570" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_570" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_571" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_571" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_924" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_925" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_924" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_925" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_926" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_924" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_926" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedBalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_118" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_119" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_118" xlink:to="loc_us-gaap_StatementTable_119" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_120" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_119" xlink:to="loc_us-gaap_StatementClassOfStockAxis_120" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_121" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_120" xlink:to="loc_us-gaap_ClassOfStockDomain_121" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_122" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_119" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_122" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_805" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_122" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_805" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_804" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_119" xlink:to="loc_us-gaap_StatementLineItems_804" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_125" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_125" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_126" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_126" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_127" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_PreferredStockSharesIssued_127" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_129" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_129" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_130" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_130" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_CommonStockSharesIssued_131" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_132" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_804" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_132" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_535" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:label="loc_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock_540" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_535" xlink:to="loc_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock_540" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_541" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_535" xlink:to="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_541" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_238" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_239" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1337" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1337" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_241" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_242" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="loc_aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_746" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236" xlink:to="loc_aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_746" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SegmentInformationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1532" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1533" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1532" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_1533" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_307" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_310" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_307" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_310" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_311" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_310" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_311" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_313" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_311" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_313" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_314" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_313" xlink:to="loc_aytu_ProstascintBusinessMember_314" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_1044" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_313" xlink:to="loc_aytu_PrimsolBusinessMember_1044" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_312" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_310" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_312" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:label="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_319" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312" xlink:to="loc_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_319" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_321" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_321" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_323" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312" xlink:to="loc_us-gaap_Goodwill_323" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_324" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_312" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_324" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1026" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1027" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1026" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1027" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1028" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1027" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1028" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1028" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_1031" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029" xlink:to="loc_aytu_ProstascintBusinessMember_1031" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_1032" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029" xlink:to="loc_aytu_PrimsolBusinessMember_1032" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_1622" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1029" xlink:to="loc_aytu_NatestoMember_1622" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1027" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1035" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1035" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1036" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1036" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1037" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1037" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1038" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1038" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1039" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1039" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1040" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1040" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1041" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1034" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1041" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_336" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_336" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_338" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_338" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_338" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytu_ProstascintBusinessMember_340" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" xlink:to="loc_aytu_ProstascintBusinessMember_340" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_JazzPharmaceuticalsIncMember" xlink:label="loc_aytu_JazzPharmaceuticalsIncMember_341" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" xlink:to="loc_aytu_JazzPharmaceuticalsIncMember_341" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_688" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" xlink:to="loc_aytu_PrimsolBusinessMember_688" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_1008" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" xlink:to="loc_aytu_NatestoMember_1008" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NuelleIncMember" xlink:label="loc_aytu_NuelleIncMember_1547" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_339" xlink:to="loc_aytu_NuelleIncMember_1547" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_342" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_StatementScenarioAxis_342" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_343" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_342" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_343" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PaidOnApril12016Member" xlink:label="loc_aytu_PaidOnApril12016Member_697" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_343" xlink:to="loc_aytu_PaidOnApril12016Member_697" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NoLaterThanJuly012016Member" xlink:label="loc_aytu_NoLaterThanJuly012016Member_698" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_343" xlink:to="loc_aytu_NoLaterThanJuly012016Member_698" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NoLaterThanSeptember302016Member" xlink:label="loc_aytu_NoLaterThanSeptember302016Member_699" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_343" xlink:to="loc_aytu_NoLaterThanSeptember302016Member_699" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_347" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_ProductOrServiceAxis_347" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_349" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_347" xlink:to="loc_us-gaap_ProductsAndServicesDomain_349" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProstaScintMember" xlink:label="loc_aytu_ProstaScintMember_351" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_349" xlink:to="loc_aytu_ProstaScintMember_351" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_353" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_353" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_353" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_356" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_356" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_357" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355" xlink:to="loc_us-gaap_TradeNamesMember_357" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="loc_us-gaap_CustomerContractsMember_358" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_355" xlink:to="loc_us-gaap_CustomerContractsMember_358" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_360" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_RangeAxis_360" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_361" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_360" xlink:to="loc_us-gaap_RangeMember_361" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_362" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_361" xlink:to="loc_us-gaap_MaximumMember_362" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1553" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_361" xlink:to="loc_us-gaap_MinimumMember_1553" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_363" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_363" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_973" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_363" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_973" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondUpfrontMember" xlink:label="loc_aytu_SecondUpfrontMember_974" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_973" xlink:to="loc_aytu_SecondUpfrontMember_974" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ThirdUpfrontMember" xlink:label="loc_aytu_ThirdUpfrontMember_1009" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_973" xlink:to="loc_aytu_ThirdUpfrontMember_1009" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_972" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_972" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_988" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_972" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_988" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_987" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_TypeOfArrangementAxis_987" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_987" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstMilestoneMember" xlink:label="loc_aytu_FirstMilestoneMember_1015" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_FirstMilestoneMember_1015" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondMilestoneMember" xlink:label="loc_aytu_SecondMilestoneMember_1016" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_SecondMilestoneMember_1016" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ThirdMilestoneMember" xlink:label="loc_aytu_ThirdMilestoneMember_1017" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_ThirdMilestoneMember_1017" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ForthMilestoneMember" xlink:label="loc_aytu_ForthMilestoneMember_1018" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_ForthMilestoneMember_1018" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FifthMilestoneMember" xlink:label="loc_aytu_FifthMilestoneMember_1019" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_FifthMilestoneMember_1019" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SixthMilestoneMember" xlink:label="loc_aytu_SixthMilestoneMember_1550" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1014" xlink:to="loc_aytu_SixthMilestoneMember_1550" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1013" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1013" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1021" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1013" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1021" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LicenseAndSupplyAgreementMember" xlink:label="loc_aytu_LicenseAndSupplyAgreementMember_1022" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1021" xlink:to="loc_aytu_LicenseAndSupplyAgreementMember_1022" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1020" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1020" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1400" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1020" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1400" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1401" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1400" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1401" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1399" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_337" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1399" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_366" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_366" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_368" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_368" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_369" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_369" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_371" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_371" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_372" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_374" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_374" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationContingentConsiderationPercentage" xlink:label="loc_aytu_BusinessCombinationContingentConsiderationPercentage_375" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_BusinessCombinationContingentConsiderationPercentage_375" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_376" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_376" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_379" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_379" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_687" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_687" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationConsiderationTransferredInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredInventory_714" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredInventory_714" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationConsiderationTransferredProductInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredProductInventory_715" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredProductInventory_715" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory" xlink:label="loc_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory_716" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory_716" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_984" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_984" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_985" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_985" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1010" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1010" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OneTimeNonrefundablePayments" xlink:label="loc_aytu_OneTimeNonrefundablePayments_1011" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_OneTimeNonrefundablePayments_1011" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SalesRevenueTarget" xlink:label="loc_aytu_SalesRevenueTarget_1012" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_SalesRevenueTarget_1012" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1397" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_1397" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_1398" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_1398" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CostOfSaleForInvestment" xlink:label="loc_aytu_CostOfSaleForInvestment_1402" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_CostOfSaleForInvestment_1402" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1403" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_1403" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss_1404" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss_1404" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_1405" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_AccretionExpense_1405" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales" xlink:label="loc_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales_1548" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales_1548" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_1551" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_1551" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1552" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1552" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_1619" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1399" xlink:to="loc_us-gaap_LiabilitiesAssumed1_1619" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1579" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1579" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1581" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1581" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1582" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1581" xlink:to="loc_us-gaap_ClassOfStockDomain_1582" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1583" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1583" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1585" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1583" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1585" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerOneMember" xlink:label="loc_aytu_CustomerOneMember_1586" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1585" xlink:to="loc_aytu_CustomerOneMember_1586" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerTwoMember" xlink:label="loc_aytu_CustomerTwoMember_1587" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1585" xlink:to="loc_aytu_CustomerTwoMember_1587" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerThreeMember" xlink:label="loc_aytu_CustomerThreeMember_1588" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1585" xlink:to="loc_aytu_CustomerThreeMember_1588" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerFourMember" xlink:label="loc_aytu_CustomerFourMember_1589" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1585" xlink:to="loc_aytu_CustomerFourMember_1589" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1584" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1584" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1591" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1584" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1591" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_1592" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1591" xlink:to="loc_us-gaap_SalesRevenueNetMember_1592" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_1593" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1591" xlink:to="loc_us-gaap_AccountsReceivableMember_1593" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1590" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1580" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1590" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1594" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1590" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1594" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_137" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_138" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_137" xlink:to="loc_us-gaap_StatementTable_138" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_139" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_138" xlink:to="loc_us-gaap_StatementClassOfStockAxis_139" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_140" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_139" xlink:to="loc_us-gaap_ClassOfStockDomain_140" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_141" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_138" xlink:to="loc_us-gaap_StatementLineItems_141" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_1392" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_RevenuesAbstract_1392" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ProductsAndServicesRevenue" xlink:label="loc_aytu_ProductsAndServicesRevenue_143" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1392" xlink:to="loc_aytu_ProductsAndServicesRevenue_143" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_145" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1392" xlink:to="loc_us-gaap_LicensesRevenue_145" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_146" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1392" xlink:to="loc_us-gaap_Revenues_146" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_147" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_OperatingExpensesAbstract_147" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_149" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_CostOfRevenue_149" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_150" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ResearchAndDevelopmentRelatedParty" xlink:label="loc_aytu_ResearchAndDevelopmentRelatedParty_151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_aytu_ResearchAndDevelopmentRelatedParty_151" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_152" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_152" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_945" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_945" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1277" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1277" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1278" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1278" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_702" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_OperatingExpenses_702" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_153" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_147" xlink:to="loc_us-gaap_OperatingIncomeLoss_153" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_155" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" xlink:to="loc_us-gaap_InterestExpense_155" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_1393" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" xlink:to="loc_us-gaap_GainLossOnInvestments_1393" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_659" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_659" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_156" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_154" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_156" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_161" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_NetIncomeLoss_161" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_163" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_141" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_165" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1569" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1570" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1569" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1570" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1571" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1570" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1571" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1572" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1571" xlink:to="loc_us-gaap_ClassOfStockDomain_1572" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1570" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_1574" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_InventoryRawMaterials_1574" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_1575" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_InventoryWorkInProcess_1575" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_1576" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_InventoryFinishedGoods_1576" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_1620" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_InventoryValuationReserves_1620" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1577" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573" xlink:to="loc_us-gaap_InventoryNet_1577" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_423" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_423" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_426" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_426" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_426" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_690" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" xlink:to="loc_us-gaap_OfficeEquipmentMember_690" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LabEquipmentMember" xlink:label="loc_aytu_LabEquipmentMember_429" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" xlink:to="loc_aytu_LabEquipmentMember_429" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_428" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_428" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaap_ManufacturingFacilityMember_691" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_427" xlink:to="loc_us-gaap_ManufacturingFacilityMember_691" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_430" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="loc_us-gaap_RangeAxis_430" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_431" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_430" xlink:to="loc_us-gaap_RangeMember_431" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_433" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_431" xlink:to="loc_us-gaap_MinimumMember_433" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_432" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_431" xlink:to="loc_us-gaap_MaximumMember_432" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_425" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_438" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_438" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_440" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_440" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_445" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_445" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_442" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_434" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_442" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_998" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1098" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_998" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1098" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1098" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1100" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1100" xlink:to="loc_us-gaap_ClassOfStockDomain_1101" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1099" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1098" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1099" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1099" xlink:to="loc_us-gaap_Depreciation_1102" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1110" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1111" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1110" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1111" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1111" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1113" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1118" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1113" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1118" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_1119" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1118" xlink:to="loc_us-gaap_PatentsMember_1119" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1117" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1111" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1117" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1116" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1117" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1116" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1120" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1117" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1120" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1122" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1117" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1122" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortizationAbstract" xlink:label="loc_us-gaap_DepreciationAndAmortizationAbstract_1263" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1264" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DepreciationAndAmortizationAbstract_1263" xlink:to="loc_us-gaap_StatementTable_1264" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1265" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1264" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1265" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1266" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1265" xlink:to="loc_us-gaap_ClassOfStockDomain_1266" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1267" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1264" xlink:to="loc_us-gaap_StatementLineItems_1267" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1268" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1267" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1268" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1125" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1141" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1125" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1141" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1142" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1141" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1142" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1218" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1218" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_1219" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1218" xlink:to="loc_us-gaap_PatentsMember_1219" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1141" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1211" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1211" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1212" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1213" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1213" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1214" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1214" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1215" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1215" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1216" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1221" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1217" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1221" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1223" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1224" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1223" xlink:to="loc_us-gaap_StatementTable_1224" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1225" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1225" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1226" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1225" xlink:to="loc_us-gaap_ClassOfStockDomain_1226" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1227" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1227" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1231" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1227" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1231" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ZertanePatentsMember" xlink:label="loc_aytu_ZertanePatentsMember_1232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1231" xlink:to="loc_aytu_ZertanePatentsMember_1232" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OrpMember" xlink:label="loc_aytu_OrpMember_1233" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1231" xlink:to="loc_aytu_OrpMember_1233" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1271" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1283" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1271" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1283" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_1282" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_MajorCustomersAxis_1282" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_1342" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_1282" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_1342" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1341" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1341" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1345" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1341" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1345" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_1595" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1345" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_1595" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CustomerFourMember" xlink:label="loc_aytu_CustomerFourMember_1597" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1345" xlink:to="loc_aytu_CustomerFourMember_1597" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1344" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1344" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1352" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1344" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1352" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockOptionsMember" xlink:label="loc_aytu_StockOptionsMember_1353" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1352" xlink:to="loc_aytu_StockOptionsMember_1353" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1355" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1352" xlink:to="loc_us-gaap_WarrantMember_1355" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1351" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_us-gaap_RangeAxis_1351" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1601" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_1351" xlink:to="loc_us-gaap_RangeMember_1601" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1602" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1601" xlink:to="loc_us-gaap_MinimumMember_1602" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SummaryOfSignificantAccountingPolicyLineItems" xlink:label="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1224" xlink:to="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_1228" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_1228" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1234" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1234" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1235" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_1235" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:label="loc_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear_1236" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear_1236" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_1238" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_1238" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1348" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1348" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1354" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_1603" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_InventoryValuationReserves_1603" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1625" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SummaryOfSignificantAccountingPolicyLineItems_1600" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_1625" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/GoingConcernDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1364" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1365" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1364" xlink:to="loc_us-gaap_StatementTable_1365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1366" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1365" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1367" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1366" xlink:to="loc_us-gaap_ClassOfStockDomain_1367" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1368" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1365" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1368" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1630" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1368" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1630" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1631" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1630" xlink:to="loc_us-gaap_SubsequentEventMember_1631" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1629" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1365" xlink:to="loc_us-gaap_StatementLineItems_1629" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1369" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_NetIncomeLoss_1369" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1370" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1370" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1372" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1626" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1626" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1627" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_RestrictedCash_1627" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1628" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1629" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1628" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/LicenseAgreementrevenueRecognitionDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaap_RevenueRecognitionAbstract_1072" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_RevenueRecognitionTable" xlink:label="loc_aytu_RevenueRecognitionTable_1073" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAbstract_1072" xlink:to="loc_aytu_RevenueRecognitionTable_1073" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1076" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RevenueRecognitionTable_1073" xlink:to="loc_dei_LegalEntityAxis_1076" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1077" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1076" xlink:to="loc_dei_EntityDomain_1077" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_VyrixPharmaceuticalsIncMember" xlink:label="loc_aytu_VyrixPharmaceuticalsIncMember_1078" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1077" xlink:to="loc_aytu_VyrixPharmaceuticalsIncMember_1078" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioMember" xlink:label="loc_aytu_AmpioMember_1082" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1077" xlink:to="loc_aytu_AmpioMember_1082" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_RevenueRecognitionLineItems" xlink:label="loc_aytu_RevenueRecognitionLineItems_1079" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RevenueRecognitionTable_1073" xlink:to="loc_aytu_RevenueRecognitionLineItems_1079" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PotentialMilestonePaymentsReceivable" xlink:label="loc_aytu_PotentialMilestonePaymentsReceivable_1080" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_aytu_PotentialMilestonePaymentsReceivable_1080" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PercentageOfRoyaltyRateOfNetSales" xlink:label="loc_aytu_PercentageOfRoyaltyRateOfNetSales_1081" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_aytu_PercentageOfRoyaltyRateOfNetSales_1081" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_1083" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_us-gaap_DeferredRevenue_1083" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_1084" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_1084" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AgreementExpirationPeriod" xlink:label="loc_aytu_AgreementExpirationPeriod_1086" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_RevenueRecognitionLineItems_1079" xlink:to="loc_aytu_AgreementExpirationPeriod_1086" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_595" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_596" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_595" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_596" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_597" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_596" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_597" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_597" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_599" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_599" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_600" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_600" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_601" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_598" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_601" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_603" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_596" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_603" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1065" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_603" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1065" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1066" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1065" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_1066" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_604" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_603" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_604" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_605" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_604" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_605" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1356" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_604" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1356" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_170" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_171" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_170" xlink:to="loc_us-gaap_StatementTable_171" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_172" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_171" xlink:to="loc_us-gaap_StatementClassOfStockAxis_172" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_173" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_172" xlink:to="loc_us-gaap_ClassOfStockDomain_173" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_174" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_171" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_174" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_176" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_174" xlink:to="loc_us-gaap_EquityComponentDomain_176" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_177" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_176" xlink:to="loc_us-gaap_CommonStockMember_177" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_178" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_176" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_178" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_176" xlink:to="loc_us-gaap_ReceivablesFromStockholderMember_179" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_176" xlink:to="loc_us-gaap_RetainedEarningsMember_180" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_175" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_171" xlink:to="loc_us-gaap_StatementLineItems_175" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockholdersEquity_185" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_186" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_SharesIssued_186" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockSubscriptionPayment" xlink:label="loc_aytu_StockSubscriptionPayment_975" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_StockSubscriptionPayment_975" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockSubscriptionPaymentOfShares" xlink:label="loc_aytu_StockSubscriptionPaymentOfShares_976" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_StockSubscriptionPaymentOfShares_976" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_724" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_724" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_725" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_725" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_726" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_726" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_727" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_727" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" xlink:label="loc_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote_807" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote_807" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:label="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_1280" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_1280" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:label="loc_aytu_AdjustmentForRoundingOfValueDueToConversion_703" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_AdjustmentForRoundingOfValueDueToConversion_703" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:label="loc_aytu_AdjustmentForRoundingOfSharesDueToConversion_704" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_AdjustmentForRoundingOfSharesDueToConversion_704" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_188" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_188" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_189" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_189" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1489" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1489" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1490" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1490" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1491" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1491" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1492" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1492" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1493" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1493" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IssuanceOfStockIssuedDuringPeriodvalue" xlink:label="loc_aytu_IssuanceOfStockIssuedDuringPeriodvalue_970" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_IssuanceOfStockIssuedDuringPeriodvalue_970" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_StockAndIssuedDuringPeriodshares" xlink:label="loc_aytu_StockAndIssuedDuringPeriodshares_971" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_StockAndIssuedDuringPeriodshares_971" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xlink:label="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing_1279" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing_1279" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xlink:label="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts_1494" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts_1494" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_1495" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_1495" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_1496" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_1496" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments" xlink:label="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments_1497" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments_1497" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1498" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_1498" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1499" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1499" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_191" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_NetIncomeLoss_191" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_192" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_StockholdersEquity_192" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_193" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_175" xlink:to="loc_us-gaap_SharesIssued_193" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_608" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_608" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_610" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" xlink:to="loc_us-gaap_TransactionTypeAxis_610" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_611" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_610" xlink:to="loc_us-gaap_TransactionDomain_611" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_613" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" xlink:to="loc_us-gaap_FinancialInstrumentAxis_613" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_614" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_613" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_614" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_615" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_614" xlink:to="loc_us-gaap_WarrantMember_615" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_616" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" xlink:to="loc_us-gaap_RangeAxis_616" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_617" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_616" xlink:to="loc_us-gaap_RangeMember_617" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_609" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_624" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_624" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_625" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_625" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_626" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_626" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1421" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_620" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1421" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_629" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_630" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_629" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_630" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_631" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_630" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_631" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_632" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_631" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_632" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_633" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_632" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_633" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_630" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_635" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_635" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:label="loc_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_648" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" xlink:to="loc_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_648" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_733" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_733" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_634" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/FairValueConsiderationsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_582" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_582" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_584" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" xlink:to="loc_us-gaap_StatementClassOfStockAxis_584" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_585" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_584" xlink:to="loc_us-gaap_ClassOfStockDomain_585" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_586" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_586" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_738" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_586" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_738" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_737" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" xlink:to="loc_us-gaap_FinancialInstrumentAxis_737" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1286" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_737" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1286" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_583" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1052" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_1052" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1650" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1650" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="loc_us-gaap_NoncashMergerRelatedCosts_1652" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_NoncashMergerRelatedCosts_1652" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_1653" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_1653" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xlink:label="loc_us-gaap_AccretionExpenseIncludingAssetRetirementObligations_1654" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1285" xlink:to="loc_us-gaap_AccretionExpenseIncludingAssetRetirementObligations_1654" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1107" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxHolidayTable" xlink:label="loc_us-gaap_IncomeTaxHolidayTable_1108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1107" xlink:to="loc_us-gaap_IncomeTaxHolidayTable_1108" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_1108" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1114" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1114" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1115" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxHolidayLineItems" xlink:label="loc_us-gaap_IncomeTaxHolidayLineItems_1112" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayTable_1108" xlink:to="loc_us-gaap_IncomeTaxHolidayLineItems_1112" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxHolidayLineItems_1112" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1127" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1127" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1128" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1128" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1129" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_1129" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt" xlink:label="loc_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt_1130" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt_1130" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" xlink:label="loc_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts_1633" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts_1633" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" xlink:label="loc_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration_1635" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration_1635" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1134" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1131" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1135" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1132" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1132" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1133" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1133" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1137" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1137" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1139" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1139" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1140" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1140" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt" xlink:label="loc_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt_1155" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt_1155" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncomeTaxReconciliationOfFeringCosts" xlink:label="loc_aytu_IncomeTaxReconciliationOfFeringCosts_1632" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_IncomeTaxReconciliationOfFeringCosts_1632" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="loc_aytu_IncomeTaxReconciliationContingentConsideration_1634" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_aytu_IncomeTaxReconciliationContingentConsideration_1634" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1157" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1157" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1156" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1156" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1158" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1158" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1159" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1160" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1121" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1160" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1175" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1176" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1175" xlink:to="loc_us-gaap_StatementTable_1176" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1177" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1176" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1177" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1178" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1177" xlink:to="loc_us-gaap_ClassOfStockDomain_1178" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1179" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1176" xlink:to="loc_us-gaap_StatementLineItems_1179" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1179" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossCurrent_1181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossCurrent_1181" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_1182" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1194" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_1194" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1183" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1183" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1184" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1185" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1645" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1645" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_1187" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_1187" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1636" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_1636" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_1637" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_1637" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_1188" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_1188" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_1189" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_1189" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_1190" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_1190" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1191" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1191" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1192" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1192" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1193" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1180" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1193" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/IncomeTaxesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1196" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1197" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1196" xlink:to="loc_us-gaap_StatementTable_1197" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1198" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1197" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1198" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1198" xlink:to="loc_us-gaap_ClassOfStockDomain_1199" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1200" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1197" xlink:to="loc_dei_LegalEntityAxis_1200" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1204" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1200" xlink:to="loc_dei_EntityDomain_1204" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioPharmaceuticalsMember" xlink:label="loc_aytu_AmpioPharmaceuticalsMember_1205" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1204" xlink:to="loc_aytu_AmpioPharmaceuticalsMember_1205" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1197" xlink:to="loc_us-gaap_StatementLineItems_1203" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1201" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1201" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1202" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NetOperatingLossesExpirationDescription" xlink:label="loc_aytu_NetOperatingLossesExpirationDescription_1639" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1203" xlink:to="loc_aytu_NetOperatingLossesExpirationDescription_1639" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_536" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_542" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_536" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_542" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_543" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_542" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_543" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_543" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytu_PrescriptionDatabaseMember_948" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" xlink:to="loc_aytu_PrescriptionDatabaseMember_948" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_949" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" xlink:to="loc_aytu_NatestoMember_949" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ManufacturingAgreementMember" xlink:label="loc_aytu_ManufacturingAgreementMember_547" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" xlink:to="loc_aytu_ManufacturingAgreementMember_547" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytu_OfficeLeaseMember_548" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_545" xlink:to="loc_aytu_OfficeLeaseMember_548" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_542" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_550" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligation_550" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_551" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_551" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_552" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_552" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_553" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_553" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_554" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_554" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_555" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_555" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_556" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_544" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_556" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_537" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable" xlink:label="loc_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable_557" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_537" xlink:to="loc_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable_557" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_562" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable_557" xlink:to="loc_us-gaap_StatementClassOfStockAxis_562" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_563" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_562" xlink:to="loc_us-gaap_ClassOfStockDomain_563" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommitmentsAndContingenciesRentExpenseLineItems" xlink:label="loc_aytu_CommitmentsAndContingenciesRentExpenseLineItems_558" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommitmentsAndContingenciesRentExpenseTable_557" xlink:to="loc_aytu_CommitmentsAndContingenciesRentExpenseLineItems_558" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_560" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommitmentsAndContingenciesRentExpenseLineItems_558" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_560" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_538" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_538" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaap_OtherCommitmentsAxis_569" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_OtherCommitmentsAxis_569" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaap_OtherCommitmentsDomain_573" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_569" xlink:to="loc_us-gaap_OtherCommitmentsDomain_573" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_572" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_572" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_572" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoMember" xlink:label="loc_aytu_NatestoMember_951" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576" xlink:to="loc_aytu_NatestoMember_951" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytu_PrescriptionDatabaseMember_1273" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576" xlink:to="loc_aytu_PrescriptionDatabaseMember_1273" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytu_OfficeLeaseMember_1274" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_576" xlink:to="loc_aytu_OfficeLeaseMember_1274" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_575" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_StatementGeographicalAxis_575" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_580" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_575" xlink:to="loc_us-gaap_SegmentGeographicalDomain_580" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_579" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_579" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_961" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_579" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_961" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_960" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_960" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_960" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1242" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1241" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1448" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1241" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1448" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstInstallmentMember" xlink:label="loc_aytu_FirstInstallmentMember_1449" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1448" xlink:to="loc_aytu_FirstInstallmentMember_1449" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_568" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OperatingLeasesMonthlyBaseRentInitialYear" xlink:label="loc_aytu_OperatingLeasesMonthlyBaseRentInitialYear_591" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_aytu_OperatingLeasesMonthlyBaseRentInitialYear_591" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_593" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_593" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_594" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_us-gaap_LeaseAndRentalExpense_594" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_602" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_us-gaap_ContractualObligation_602" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PaymentOfContractualObligations" xlink:label="loc_aytu_PaymentOfContractualObligations_813" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_aytu_PaymentOfContractualObligations_813" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstMilestonePayable" xlink:label="loc_aytu_FirstMilestonePayable_1451" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_aytu_FirstMilestonePayable_1451" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondMilestonePayable" xlink:label="loc_aytu_SecondMilestonePayable_1452" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_aytu_SecondMilestonePayable_1452" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ThirdMilestonePayable" xlink:label="loc_aytu_ThirdMilestonePayable_1453" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_1447" xlink:to="loc_aytu_ThirdMilestonePayable_1453" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_978" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_979" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_978" xlink:to="loc_us-gaap_StatementTable_979" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_980" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_979" xlink:to="loc_us-gaap_StatementClassOfStockAxis_980" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_981" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_980" xlink:to="loc_us-gaap_ClassOfStockDomain_981" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_982" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_979" xlink:to="loc_dei_LegalEntityAxis_982" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1502" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_982" xlink:to="loc_dei_EntityDomain_1502" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LincolnparkMember" xlink:label="loc_aytu_LincolnparkMember_1503" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1502" xlink:to="loc_aytu_LincolnparkMember_1503" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1501" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_979" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1501" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1506" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1501" xlink:to="loc_us-gaap_EquityComponentDomain_1506" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1507" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1506" xlink:to="loc_us-gaap_CommonStockMember_1507" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1508" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1506" xlink:to="loc_us-gaap_WarrantMember_1508" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1505" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_979" xlink:to="loc_us-gaap_StatementLineItems_1505" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_990" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1505" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_990" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_983" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1505" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_983" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConvertiblePromissoryNotesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_435" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionTable" xlink:label="loc_us-gaap_DebtConversionTable_436" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_435" xlink:to="loc_us-gaap_DebtConversionTable_436" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_437" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_437" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_437" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_441" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ConvertiblePromissoryNotesMember" xlink:label="loc_aytu_ConvertiblePromissoryNotesMember_443" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_441" xlink:to="loc_aytu_ConvertiblePromissoryNotesMember_443" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_439" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_439" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_446" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_439" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_446" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_444" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_RangeAxis_444" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_451" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_444" xlink:to="loc_us-gaap_RangeMember_451" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_452" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_451" xlink:to="loc_us-gaap_MinimumMember_452" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_946" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_451" xlink:to="loc_us-gaap_MaximumMember_946" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_450" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_450" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_816" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_450" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_816" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_815" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_815" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_851" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_815" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_851" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionLineItems" xlink:label="loc_us-gaap_DebtConversionLineItems_850" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_436" xlink:to="loc_us-gaap_DebtConversionLineItems_850" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_511" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_511" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_512" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_512" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_513" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_513" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_521" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_521" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_522" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_522" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_526" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_526" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PlacementAgentsCashFeePercentage" xlink:label="loc_aytu_PlacementAgentsCashFeePercentage_527" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_aytu_PlacementAgentsCashFeePercentage_527" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_784" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_784" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_DebtConversionAccruedInterestAmount" xlink:label="loc_aytu_DebtConversionAccruedInterestAmount_785" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_aytu_DebtConversionAccruedInterestAmount_785" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_786" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_786" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_789" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_789" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantsIssuedToPurchaseOfCommonStock" xlink:label="loc_aytu_WarrantsIssuedToPurchaseOfCommonStock_791" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_aytu_WarrantsIssuedToPurchaseOfCommonStock_791" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantsExercisePricePerShare" xlink:label="loc_aytu_WarrantsExercisePricePerShare_792" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_aytu_WarrantsExercisePricePerShare_792" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_800" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_800" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_947" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_947" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_1123" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_1123" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1604" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_850" xlink:to="loc_us-gaap_SharePrice_1604" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/CommonStockDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_406" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SheduleOfCommonStockTable" xlink:label="loc_aytu_SheduleOfCommonStockTable_409" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_406" xlink:to="loc_aytu_SheduleOfCommonStockTable_409" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_StatementClassOfStockAxis_411" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_645" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_411" xlink:to="loc_us-gaap_ClassOfStockDomain_645" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_May2016WarrantsMember" xlink:label="loc_aytu_May2016WarrantsMember_1482" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_645" xlink:to="loc_aytu_May2016WarrantsMember_1482" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_October2016WarrantsMember" xlink:label="loc_aytu_October2016WarrantsMember_1483" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_645" xlink:to="loc_aytu_October2016WarrantsMember_1483" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_644" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_644" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_966" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_644" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_966" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_967" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_966" xlink:to="loc_us-gaap_IPOMember_967" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_968" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_966" xlink:to="loc_us-gaap_OverAllotmentOptionMember_968" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_965" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_965" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1293" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_965" xlink:to="loc_us-gaap_EquityComponentDomain_1293" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1294" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1293" xlink:to="loc_us-gaap_CommonStockMember_1294" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1295" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1293" xlink:to="loc_us-gaap_WarrantMember_1295" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1292" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1292" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1458" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1292" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1458" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:label="loc_aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember_1459" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1458" xlink:to="loc_aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember_1459" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_1457" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_TitleOfIndividualAxis_1457" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1468" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_1457" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1468" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_1469" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1468" xlink:to="loc_us-gaap_DirectorMember_1469" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_1476" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1468" xlink:to="loc_us-gaap_ExecutiveOfficerMember_1476" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1467" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1467" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1471" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1467" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1471" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1470" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_AwardTypeAxis_1470" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1474" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1474" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1475" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1474" xlink:to="loc_us-gaap_RestrictedStockMember_1475" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1473" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_us-gaap_DebtInstrumentAxis_1473" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1480" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1473" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1480" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsMember" xlink:label="loc_aytu_OverAllotmentWarrantsMember_1481" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1480" xlink:to="loc_aytu_OverAllotmentWarrantsMember_1481" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockLineItems" xlink:label="loc_aytu_CommonStockLineItems_1479" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfCommonStockTable_409" xlink:to="loc_aytu_CommonStockLineItems_1479" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_415" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_415" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_416" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_416" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_417" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_417" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_418" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_418" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_820" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_820" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_956" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_956" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_958" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_958" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_963" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_963" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_UnderwritersExercisedOfOverallotmentOption" xlink:label="loc_aytu_UnderwritersExercisedOfOverallotmentOption_1275" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_UnderwritersExercisedOfOverallotmentOption_1275" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_1290" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_EquityFairValueDisclosure_1290" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1291" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1291" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1357" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1357" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1358" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1358" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1359" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1359" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1454" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1454" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockSharesAgreedToPurchase" xlink:label="loc_aytu_CommonStockSharesAgreedToPurchase_1455" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_CommonStockSharesAgreedToPurchase_1455" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockValueAgreedToPurchase" xlink:label="loc_aytu_CommonStockValueAgreedToPurchase_1456" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_CommonStockValueAgreedToPurchase_1456" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1460" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1460" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1461" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1461" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1462" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1462" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1464" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1464" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1465" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1465" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_1466" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_StockOptionPlanExpense_1466" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:label="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_1477" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_1477" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EquityRelativeFairValue" xlink:label="loc_aytu_EquityRelativeFairValue_1478" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_EquityRelativeFairValue_1478" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1484" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1484" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="loc_aytu_UnrecognizedShareBasedCompensationExpenses_1643" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_CommonStockLineItems_1479" xlink:to="loc_aytu_UnrecognizedShareBasedCompensationExpenses_1643" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_247" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AssumptionsUsedToDetermineFairValueOptionsTable" xlink:label="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable_249" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_247" xlink:to="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable_249" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_251" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable_249" xlink:to="loc_us-gaap_RangeAxis_251" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_252" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_251" xlink:to="loc_us-gaap_RangeMember_252" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_253" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_252" xlink:to="loc_us-gaap_MinimumMember_253" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_254" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_252" xlink:to="loc_us-gaap_MaximumMember_254" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_257" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable_249" xlink:to="loc_dei_LegalEntityAxis_257" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_258" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_257" xlink:to="loc_dei_EntityDomain_258" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LuoxisDiagnosticsMember" xlink:label="loc_aytu_LuoxisDiagnosticsMember_259" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_258" xlink:to="loc_aytu_LuoxisDiagnosticsMember_259" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems" xlink:label="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsTable_249" xlink:to="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_264" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_264" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_266" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_266" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_268" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_268" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_270" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_270" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_269" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems_261" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_269" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_276" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_277" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_276" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_277" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_278" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_277" xlink:to="loc_dei_LegalEntityAxis_278" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_280" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_278" xlink:to="loc_dei_EntityDomain_280" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_LuoxisDiagnosticsMember" xlink:label="loc_aytu_LuoxisDiagnosticsMember_281" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_280" xlink:to="loc_aytu_LuoxisDiagnosticsMember_281" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_277" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_285" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_285" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_287" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_287" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_288" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_289" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_289" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_290" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_290" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_291" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_291" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_294" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant_294" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1407" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_284" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1407" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_301" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_301" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_299" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_299" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_302" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_302" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_303" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_303" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1408" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1408" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_304" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_304" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_306" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_306" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_308" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_279" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_308" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_309" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_308" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_309" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_660" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_308" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_660" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1297" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1298" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1297" xlink:to="loc_us-gaap_StatementTable_1298" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1299" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1298" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1300" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1299" xlink:to="loc_us-gaap_ClassOfStockDomain_1300" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1301" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1298" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1301" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1303" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1301" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1303" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="loc_aytu_ExercisePriceRangeOneMember_1304" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1303" xlink:to="loc_aytu_ExercisePriceRangeOneMember_1304" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="loc_aytu_ExercisePriceRangeTwoMember_1305" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1303" xlink:to="loc_aytu_ExercisePriceRangeTwoMember_1305" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1302" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1298" xlink:to="loc_us-gaap_StatementLineItems_1302" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1307" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1307" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1308" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_1308" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1333" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1333" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1310" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1310" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1311" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1311" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1334" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1302" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_1334" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_315" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_320" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_315" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_320" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_322" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_320" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_322" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_329" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_322" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_329" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_330" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_329" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_330" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_331" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_329" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_331" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_328" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_320" xlink:to="loc_us-gaap_AwardTypeAxis_328" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_333" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_333" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_332" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_332" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_325" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_332" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_325" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="loc_aytu_UnrecognizedShareBasedCompensationExpenses_326" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_332" xlink:to="loc_aytu_UnrecognizedShareBasedCompensationExpenses_326" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_327" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_327" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_317" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable" xlink:label="loc_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable_344" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_317" xlink:to="loc_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable_344" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_346" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable_344" xlink:to="loc_us-gaap_StatementClassOfStockAxis_346" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_348" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_346" xlink:to="loc_us-gaap_ClassOfStockDomain_348" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems" xlink:label="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems_350" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_SheduleOfEquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesTable_344" xlink:to="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems_350" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems_350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding_370" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding_370" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes_763" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes_763" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_1147" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_1147" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo_1148" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo_1148" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_1149" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_1149" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders_1150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders_1150" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement_1409" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement_1409" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsExcercised" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsExcercised_1412" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsExcercised_1412" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding_382" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_352" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsOutstanding_382" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems_350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_377" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_377" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice_764" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice_764" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_1151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_1151" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice_1152" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice_1152" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_1153" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_1153" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice_1154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice_1154" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice_1410" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice_1410" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice_1411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice_1411" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_383" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_354" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_383" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_359" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_EquityInstrumentsWarrantsIssuedInConjunctionWithItsSeniorConvertibleDebenturesLineItems_350" xlink:to="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_359" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm" xlink:label="loc_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm_381" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_359" xlink:to="loc_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm_381" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_766" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_766" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_768" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xlink:to="loc_us-gaap_StatementClassOfStockAxis_768" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_769" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_768" xlink:to="loc_us-gaap_ClassOfStockDomain_769" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_771" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xlink:to="loc_us-gaap_RangeAxis_771" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1169" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_771" xlink:to="loc_us-gaap_RangeMember_1169" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1171" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1169" xlink:to="loc_us-gaap_MinimumMember_1171" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1170" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1169" xlink:to="loc_us-gaap_MaximumMember_1170" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1168" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1168" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1207" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1168" xlink:to="loc_us-gaap_EquityComponentDomain_1207" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1208" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1207" xlink:to="loc_us-gaap_WarrantMember_1208" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_774" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_774" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_775" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_775" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_776" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_776" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_777" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_777" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_778" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1206" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_778" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EquityInstrumentsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_318" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_318" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_385" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_PlanNameAxis_385" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_387" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_385" xlink:to="loc_us-gaap_PlanNameDomain_387" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="loc_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_389" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_387" xlink:to="loc_aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_389" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_386" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_AwardTypeAxis_386" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_392" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_386" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_392" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_393" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_392" xlink:to="loc_us-gaap_EmployeeStockOptionMember_393" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_391" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_391" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_695" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_391" xlink:to="loc_us-gaap_EquityComponentDomain_695" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1446" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_695" xlink:to="loc_us-gaap_WarrantMember_1446" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_694" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_694" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_719" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_694" xlink:to="loc_us-gaap_RelatedPartyDomain_719" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_718" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_718" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_718" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PlacementAgentWarrantsMember" xlink:label="loc_aytu_PlacementAgentWarrantsMember_1327" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" xlink:to="loc_aytu_PlacementAgentWarrantsMember_1327" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_InvestorsWarrantsMember" xlink:label="loc_aytu_InvestorsWarrantsMember_1328" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" xlink:to="loc_aytu_InvestorsWarrantsMember_1328" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_BankersWarrantsMember" xlink:label="loc_aytu_BankersWarrantsMember_1423" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" xlink:to="loc_aytu_BankersWarrantsMember_1423" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_May2016WarrantsMember" xlink:label="loc_aytu_May2016WarrantsMember_1441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" xlink:to="loc_aytu_May2016WarrantsMember_1441" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_October2016WarrantsMember" xlink:label="loc_aytu_October2016WarrantsMember_1442" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1326" xlink:to="loc_aytu_October2016WarrantsMember_1442" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1325" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_DebtInstrumentAxis_1325" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1330" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1325" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1330" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ConvertiblePromissoryNotesMay2016Member" xlink:label="loc_aytu_ConvertiblePromissoryNotesMay2016Member_1331" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1330" xlink:to="loc_aytu_ConvertiblePromissoryNotesMay2016Member_1331" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1329" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_RangeAxis_1329" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_1416" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_1329" xlink:to="loc_us-gaap_RangeMember_1416" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1417" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1416" xlink:to="loc_us-gaap_MaximumMember_1417" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1418" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_1416" xlink:to="loc_us-gaap_MinimumMember_1418" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1415" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1415" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1426" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1415" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1426" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_1427" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1426" xlink:to="loc_us-gaap_OtherRestructuringMember_1427" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1425" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1425" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1429" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1425" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1429" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1430" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1429" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1430" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsAxis" xlink:label="loc_aytu_OverAllotmentWarrantsAxis_1428" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_aytu_OverAllotmentWarrantsAxis_1428" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsDomain" xlink:label="loc_aytu_OverAllotmentWarrantsDomain_1436" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_OverAllotmentWarrantsAxis_1428" xlink:to="loc_aytu_OverAllotmentWarrantsDomain_1436" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OverAllotmentWarrantsMember" xlink:label="loc_aytu_OverAllotmentWarrantsMember_1437" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytu_OverAllotmentWarrantsDomain_1436" xlink:to="loc_aytu_OverAllotmentWarrantsMember_1437" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_384" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes_821" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes_821" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice_822" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice_822" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1220" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1313" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1313" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PlacementAgentsCashFeePercentage" xlink:label="loc_aytu_PlacementAgentsCashFeePercentage_1314" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_PlacementAgentsCashFeePercentage_1314" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo_1316" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo_1316" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1317" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1317" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders_1318" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders_1318" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice_1319" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice_1319" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_1320" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_1320" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice_1321" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice_1321" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_1322" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_1322" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_1323" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_1323" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_1324" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_1324" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1413" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1413" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1414" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1414" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_CommonStockOptionRepricingProgramDescription" xlink:label="loc_aytu_CommonStockOptionRepricingProgramDescription_1419" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_CommonStockOptionRepricingProgramDescription_1419" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_1420" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_1420" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1422" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1422" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1424" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1424" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1431" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_RestructuringCharges_1431" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors_1432" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors_1432" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice" xlink:label="loc_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice_1433" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice_1433" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassOfWarrantsAndRightsIssuanceCost" xlink:label="loc_aytu_ClassOfWarrantsAndRightsIssuanceCost_1434" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_ClassOfWarrantsAndRightsIssuanceCost_1434" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantsModified" xlink:label="loc_aytu_WarrantsModified_1438" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_aytu_WarrantsModified_1438" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1439" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1439" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1440" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1440" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1443" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1443" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1444" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1444" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_1445" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1435" xlink:to="loc_us-gaap_DerivativeLiabilities_1445" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_211" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_212" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_211" xlink:to="loc_us-gaap_StatementTable_212" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_213" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_212" xlink:to="loc_us-gaap_StatementClassOfStockAxis_213" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_214" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_213" xlink:to="loc_us-gaap_ClassOfStockDomain_214" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_215" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_212" xlink:to="loc_us-gaap_StatementLineItems_215" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_216" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_217" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_216" xlink:to="loc_us-gaap_NetIncomeLoss_217" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_216" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_219" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_219" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_991" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_AssetImpairmentCharges_991" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_218" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_ShareBasedCompensation_218" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_1510" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_RestrictedStockExpense_1510" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_661" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_661" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmortizationOfBeneficialConversionFeature" xlink:label="loc_aytu_AmortizationOfBeneficialConversionFeature_728" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_aytu_AmortizationOfBeneficialConversionFeature_728" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_992" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_OtherNoncashExpense_992" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_663" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_663" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_220" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_1511" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1_1511" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Issuanceofcommonstocktoexecutives" xlink:label="loc_aytu_Issuanceofcommonstocktoexecutives_1512" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_aytu_Issuanceofcommonstocktoexecutives_1512" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1513" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_1513" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_1514" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_1514" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1515" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_RestructuringCharges_1515" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_225" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_228" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_228" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_230" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_230" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_231" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_231" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_235" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_235" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1395" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1395" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_aytu_IncreaseDecreaseInAccruedCompensation_240" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_aytu_IncreaseDecreaseInAccruedCompensation_240" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidRent_245" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidRent_245" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_246" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1394" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_246" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_248" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_216" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_248" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_255" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_255" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_995" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_995" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromLongtermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromLongtermInvestments_996" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_PaymentsForProceedsFromLongtermInvestments_996" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_1516" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_1516" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets_1517" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets_1517" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_994" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_994" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_1518" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_1518" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1519" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1519" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PaymentsForDepositsInvestingActivities" xlink:label="loc_aytu_PaymentsForDepositsInvestingActivities_653" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_aytu_PaymentsForDepositsInvestingActivities_653" use="optional" order="41" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_256" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_250" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_256" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_999" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_999" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1002" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1002" use="optional" order="45" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Proceedsfromissuanceofwarranttenderoffer" xlink:label="loc_aytu_Proceedsfromissuanceofwarranttenderoffer_1520" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_aytu_Proceedsfromissuanceofwarranttenderoffer_1520" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Paymentsforwarranttenderoffercost" xlink:label="loc_aytu_Paymentsforwarranttenderoffercost_1521" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_aytu_Paymentsforwarranttenderoffercost_1521" use="optional" order="47" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_262" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_262" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_263" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_263" use="optional" order="49" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_us-gaap_PaymentsOfDebtRestructuringCosts_730" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_PaymentsOfDebtRestructuringCosts_730" use="optional" order="50" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromContributionsFromParent" xlink:label="loc_us-gaap_ProceedsFromContributionsFromParent_655" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_ProceedsFromContributionsFromParent_655" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Proceedsfromissuanceofcommonstockandwarrants" xlink:label="loc_aytu_Proceedsfromissuanceofcommonstockandwarrants_1522" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_aytu_Proceedsfromissuanceofcommonstockandwarrants_1522" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Paymentsforregisteredofferingcosts" xlink:label="loc_aytu_Paymentsforregisteredofferingcosts_1523" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_aytu_Paymentsforregisteredofferingcosts_1523" use="optional" order="53" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1524" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1524" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_729" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_729" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_267" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_260" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_267" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_271" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_272" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_272" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_273" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_273" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IssuanceOfCommonStockToNuelleShareHolders" xlink:label="loc_aytu_IssuanceOfCommonStockToNuelleShareHolders_1644" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_IssuanceOfCommonStockToNuelleShareHolders_1644" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Fixedassetsincludedinaccountspayable" xlink:label="loc_aytu_Fixedassetsincludedinaccountspayable_1525" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_Fixedassetsincludedinaccountspayable_1525" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents" xlink:label="loc_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents_1526" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents_1526" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_Warrantsamendedinconnectionwithwarranttenderoffer" xlink:label="loc_aytu_Warrantsamendedinconnectionwithwarranttenderoffer_1527" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_Warrantsamendedinconnectionwithwarranttenderoffer_1527" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes" xlink:label="loc_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes_667" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes_667" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable" xlink:label="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable_665" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable_665" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_731" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_731" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_NatestoBusinessPurchaseIncludedInNatestoPayable" xlink:label="loc_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable_1004" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable_1004" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants" xlink:label="loc_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants_1005" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants_1005" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote" xlink:label="loc_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote_808" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote_808" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion" xlink:label="loc_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion_809" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion_809" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_810" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_274" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_810" use="optional" order="72" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/RelatedPartyTransactionsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_112" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_112" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_115" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_133" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_115" xlink:to="loc_us-gaap_RelatedPartyDomain_133" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioMember" xlink:label="loc_aytu_AmpioMember_134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_133" xlink:to="loc_aytu_AmpioMember_134" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AmpioPharmaceuticalsIncMember" xlink:label="loc_aytu_AmpioPharmaceuticalsIncMember_1598" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_133" xlink:to="loc_aytu_AmpioPharmaceuticalsIncMember_1598" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_123" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_DebtInstrumentAxis_123" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_142" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_123" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_142" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_136" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_dei_LegalEntityAxis_136" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_136" xlink:to="loc_dei_EntityDomain_159" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_157" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_157" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_196" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_157" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_196" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecondInstallmentMember" xlink:label="loc_aytu_SecondInstallmentMember_197" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_196" xlink:to="loc_aytu_SecondInstallmentMember_197" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_FirstInstallmentMember" xlink:label="loc_aytu_FirstInstallmentMember_198" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_196" xlink:to="loc_aytu_FirstInstallmentMember_198" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_195" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_195" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_200" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_195" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_200" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AfterAmendmentMember" xlink:label="loc_aytu_AfterAmendmentMember_201" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_200" xlink:to="loc_aytu_AfterAmendmentMember_201" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_StatementScenarioAxis_199" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_206" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_199" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_206" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_207" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_206" xlink:to="loc_us-gaap_ScenarioPlanMember_207" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_205" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_RangeAxis_205" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_935" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_205" xlink:to="loc_us-gaap_RangeMember_935" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_934" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_114" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_934" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_OperatingLeaseMonthlyRentalPayment" xlink:label="loc_aytu_OperatingLeaseMonthlyRentalPayment_187" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_934" xlink:to="loc_aytu_OperatingLeaseMonthlyRentalPayment_187" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrepaidExpensesAmortizationPeriod" xlink:label="loc_aytu_PrepaidExpensesAmortizationPeriod_190" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_934" xlink:to="loc_aytu_PrepaidExpensesAmortizationPeriod_190" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_934" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_203" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1596" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_934" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1596" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SegmentInformationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1535" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1536" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1535" xlink:to="loc_us-gaap_StatementTable_1536" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1537" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1536" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1537" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1538" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1537" xlink:to="loc_us-gaap_ClassOfStockDomain_1538" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1539" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1536" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1539" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_1541" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1539" xlink:to="loc_us-gaap_SegmentDomain_1541" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AytuBioscienceIncMember" xlink:label="loc_aytu_AytuBioscienceIncMember_1542" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1541" xlink:to="loc_aytu_AytuBioscienceIncMember_1542" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_AytuWomensHealthMember" xlink:label="loc_aytu_AytuWomensHealthMember_1543" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1541" xlink:to="loc_aytu_AytuWomensHealthMember_1543" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1540" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1536" xlink:to="loc_us-gaap_StatementLineItems_1540" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1544" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1540" xlink:to="loc_us-gaap_Revenues_1544" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1545" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1540" xlink:to="loc_us-gaap_NetIncomeLoss_1545" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_1546" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1540" xlink:to="loc_us-gaap_Assets_1546" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/EmployeeBenefitPlanDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_1067" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1068" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_1067" xlink:to="loc_us-gaap_StatementTable_1068" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1069" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1068" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1069" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1070" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1069" xlink:to="loc_us-gaap_ClassOfStockDomain_1070" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1071" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1068" xlink:to="loc_us-gaap_StatementLineItems_1071" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="loc_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_1276" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1071" xlink:to="loc_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_1276" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1642" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1071" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1642" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_61" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_25" xlink:to="loc_us-gaap_SubsequentEventTable_61" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_62" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_62" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_62" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytu_PrimsolBusinessMember_66" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65" xlink:to="loc_aytu_PrimsolBusinessMember_66" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_63" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_63" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_77" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_63" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_77" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_78" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_77" xlink:to="loc_us-gaap_SubsequentEventMember_78" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_76" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_StatementScenarioAxis_76" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_76" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_80" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_79" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_79" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_79" xlink:to="loc_us-gaap_RelatedPartyDomain_100" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_99" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_RangeAxis_99" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_671" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_99" xlink:to="loc_us-gaap_RangeMember_671" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_670" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_DebtInstrumentAxis_670" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_681" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_670" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_681" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_680" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_680" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_684" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_680" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_684" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_683" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_683" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_742" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_683" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_742" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_741" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_TypeOfArrangementAxis_741" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_745" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_741" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_745" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_744" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_FinancialInstrumentAxis_744" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_837" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_744" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_837" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_836" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_836" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_840" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_836" xlink:to="loc_us-gaap_EquityComponentDomain_840" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1566" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_840" xlink:to="loc_us-gaap_CommonStockMember_1566" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_839" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_839" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_843" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_839" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_843" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_844" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_843" xlink:to="loc_us-gaap_OverAllotmentOptionMember_844" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_842" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_842" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_848" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_842" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_848" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_847" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_dei_LegalEntityAxis_847" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1043" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_847" xlink:to="loc_dei_EntityDomain_1043" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1042" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1042" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1561" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1042" xlink:to="loc_us-gaap_ClassOfStockDomain_1561" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassUnitsMember" xlink:label="loc_aytu_ClassUnitsMember_1562" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1561" xlink:to="loc_aytu_ClassUnitsMember_1562" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassBUnitsMember" xlink:label="loc_aytu_ClassBUnitsMember_1563" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1561" xlink:to="loc_aytu_ClassBUnitsMember_1563" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1567" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1561" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1567" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1560" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_61" xlink:to="loc_us-gaap_SubsequentEventLineItems_1560" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_674" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_674" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_831" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_831" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1050" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1050" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_1554" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_1554" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_1557" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_1557" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_1559" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_1559" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PreferredStockConversionPricePerShare" xlink:label="loc_aytu_PreferredStockConversionPricePerShare_1646" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_aytu_PreferredStockConversionPricePerShare_1646" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:label="loc_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_1647" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_1647" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:label="loc_aytu_SecuritiesPurchaseAgreementCashFeePercentage_1648" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_aytu_SecuritiesPurchaseAgreementCashFeePercentage_1648" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:label="loc_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_1649" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1560" xlink:to="loc_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_1649" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_707" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_708" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_707" xlink:to="loc_us-gaap_StatementTable_708" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_709" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_708" xlink:to="loc_us-gaap_StatementClassOfStockAxis_709" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_710" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_709" xlink:to="loc_us-gaap_ClassOfStockDomain_710" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_711" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_708" xlink:to="loc_us-gaap_StatementLineItems_711" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="aytu-20170630.xsd#aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross" xlink:label="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross_712" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross_712" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_1396" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_1396" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount" xlink:label="loc_us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount_827" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount_827" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_713" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_713" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_1256" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_AccretionExpense_1256" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_283" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_286" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_283" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841175968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Aug. 15, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AYTU BIOSCIENCE, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001385818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AYTU<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,021,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841776016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 802,328<span></span>
</td>
<td class="nump">$ 8,054,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">75,214<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">528,039<span></span>
</td>
<td class="nump">162,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,312,221<span></span>
</td>
<td class="nump">524,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">310,760<span></span>
</td>
<td class="nump">215,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PrepaidResearchAndDevelopmentRelatedParty', window );">Prepaid research and development - related party (Note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">121,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investment in Acerus</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,041,362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,028,562<span></span>
</td>
<td class="nump">10,120,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">647,254<span></span>
</td>
<td class="nump">231,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CoreAndDevelopedTechnologyNet', window );">Developed technology, net</a></td>
<td class="nump">1,337,333<span></span>
</td>
<td class="nump">1,159,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedContractualRights', window );">Customer contracts, net</a></td>
<td class="nump">77,667<span></span>
</td>
<td class="nump">1,353,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTradeNames', window );">Trade names, net</a></td>
<td class="nump">164,037<span></span>
</td>
<td class="nump">194,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Natesto asset</a></td>
<td class="nump">9,231,072<span></span>
</td>
<td class="nump">10,549,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">238,426<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">271,278<span></span>
</td>
<td class="nump">296,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent', window );">Long-term portion of prepaid research and development - related party (Note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">213,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">11,969,955<span></span>
</td>
<td class="nump">14,222,780<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">14,998,517<span></span>
</td>
<td class="nump">24,343,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and other</a></td>
<td class="nump">2,220,400<span></span>
</td>
<td class="nump">2,322,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">782,536<span></span>
</td>
<td class="nump">1,197,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Natesto payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,379,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">339,704<span></span>
</td>
<td class="nump">1,200,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Deferred rent</a></td>
<td class="nump">6,673<span></span>
</td>
<td class="nump">4,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current contingent consideration</a></td>
<td class="nump">261,155<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,610,468<span></span>
</td>
<td class="nump">10,104,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">7,386,782<span></span>
</td>
<td class="nump">3,869,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">8,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">275,992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,998,701<span></span>
</td>
<td class="nump">14,257,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 824,831 in 2017 and 187,098 in 2016</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">73,069,463<span></span>
</td>
<td class="nump">56,646,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock', window );">Ampio stock subscription</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(69,069,729)<span></span>
</td>
<td class="num">(46,561,425)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">3,999,816<span></span>
</td>
<td class="nump">10,085,253<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 14,998,517<span></span>
</td>
<td class="nump">$ 24,343,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CoreAndDevelopedTechnologyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Core and developed technology net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CoreAndDevelopedTechnologyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PrepaidResearchAndDevelopmentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PrepaidResearchAndDevelopmentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development related party noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PrepaidResearchAndDevelopmentRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedContractualRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights with an indefinite period of benefit that arose from a contractual arrangement with a third party (not including franchise rights and license agreements).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedContractualRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTradeNames">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTradeNames</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from owners or affiliates of the reporting entity related to issuance of the entity's capital stock before cash payment is received (does not include amounts due from officers or directors). This element would also include the receivable for proceeds from the issuance of shares under employee stock option exercises which proceeds have not been received as of the reporting date due to the timing of the transaction date versus the settlement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818765744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">824,831<span></span>
</td>
<td class="nump">187,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">824,831<span></span>
</td>
<td class="nump">187,098<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842920544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ProductsAndServicesRevenue', window );">Product and service revenue</a></td>
<td class="nump">$ 3,221,590<span></span>
</td>
<td class="nump">$ 2,050,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">511,607<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,221,590<span></span>
</td>
<td class="nump">2,562,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">1,417,355<span></span>
</td>
<td class="nump">957,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">959,857<span></span>
</td>
<td class="nump">6,127,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ResearchAndDevelopmentRelatedParty', window );">Research and development - related party (Note 11)</a></td>
<td class="nump">387,960<span></span>
</td>
<td class="nump">191,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="nump">17,442,627<span></span>
</td>
<td class="nump">8,517,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Sales, general and administrative - related party (Note 11)</a></td>
<td class="nump">165,131<span></span>
</td>
<td class="nump">307,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">1,265,125<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,708,771<span></span>
</td>
<td class="nump">664,707<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,346,826<span></span>
</td>
<td class="nump">24,266,842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,125,236)<span></span>
</td>
<td class="num">(21,704,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest (expense)</a></td>
<td class="num">(2,534,358)<span></span>
</td>
<td class="num">(5,491,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) on investment</a></td>
<td class="num">(61,519)<span></span>
</td>
<td class="num">(971,629)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative income (expense)</a></td>
<td class="nump">212,809<span></span>
</td>
<td class="num">(12,572)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense)</a></td>
<td class="num">(2,383,068)<span></span>
</td>
<td class="num">(6,475,687)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,508,304)<span></span>
</td>
<td class="num">$ (28,180,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of Aytu common shares outstanding (in shares)</a></td>
<td class="nump">466,024<span></span>
</td>
<td class="nump">87,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted Aytu net loss per common share (in dollars per share)</a></td>
<td class="num">$ (48.30)<span></span>
</td>
<td class="num">$ (323.70)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ProductsAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products and services revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ProductsAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ResearchAndDevelopmentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ResearchAndDevelopmentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for other than temporary impairments (OTTI) of the subject investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (c)-(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839417808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Ampio Stock Subscription [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2015</a></td>
<td class="nump">$ 15,616,452<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 38,997,787<span></span>
</td>
<td class="num">$ (5,000,000)<span></span>
</td>
<td class="num">$ (18,381,341)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_StockSubscriptionPayment', window );">Ampio stock subscription</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_StockSubscriptionPaymentOfShares', window );">Ampio stock subscription (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock subscription</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock subscription (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes and interest to common stock, net of $29,754 conversion costs</a></td>
<td class="nump">10,090,849<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">10,090,844<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible promissory notes and interest to common stock, net of $29,754 conversion costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote', window );">Issuance of warrants related to the convertible promissory notes</a></td>
<td class="nump">136,828<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">136,828<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption', window );">Warrants issued in connection with registered offering to the placement agents for the over-allotment option</a></td>
<td class="nump">20,493<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,493<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentForRoundingOfValueDueToConversion', window );">Adjustment for rounding of shares due to stock split</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentForRoundingOfSharesDueToConversion', window );">Adjustment for rounding of shares due to stock split (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">902,946<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">902,946<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfStockIssuedDuringPeriodvalue', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">4,237,874<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">4,237,866<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_StockAndIssuedDuringPeriodshares', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing', window );">Warrants issued in connection with registered offering</a></td>
<td class="nump">2,059,895<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,059,895<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,180,084)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(28,180,084)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2016</a></td>
<td class="nump">10,085,253<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">56,646,659<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(46,561,425)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock subscription</a></td>
<td class="nump">648,933<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">648,931<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock subscription (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote', window );">Issuance of warrants related to the convertible promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption', window );">Warrants issued in connection with registered offering to the placement agents for the over-allotment option</a></td>
<td class="nump">172,629<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">172,629<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,502,092<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,502,092<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock</a></td>
<td class="nump">724,613<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">724,608<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued to executives</a></td>
<td class="nump">509,996<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">509,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued to executives (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants to initial investors</a></td>
<td class="nump">596,434<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">596,434<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfStockIssuedDuringPeriodvalue', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">3,671,581<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">3,671,552<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_StockAndIssuedDuringPeriodshares', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing', window );">Warrants issued in connection with registered offering</a></td>
<td class="nump">3,470,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,470,646<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts', window );">Warrants issued in connection with the registered offering to the placement agents, non-cash issuance costs</a></td>
<td class="nump">292,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">292,630<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Warrant tender offer, net of $312,159 in issuance costs</a></td>
<td class="nump">1,931,123<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">1,931,108<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Warrant tender offer, net of $312,159 in issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments', window );">Warrant amendments</a></td>
<td class="nump">64,690<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">64,690<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Investment in Subsidiary</a></td>
<td class="nump">1,837,500<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">1,837,488<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Investment in Subsidiary (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,508,304)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(22,508,304)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2017</a></td>
<td class="nump">$ 3,999,816<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 73,069,463<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (69,069,729)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentForRoundingOfSharesDueToConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to adjustment for rounding of shares due to conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentForRoundingOfSharesDueToConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentForRoundingOfValueDueToConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to adjustment for rounding of values due to conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentForRoundingOfValueDueToConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of adjustment made to the additional paid in capital with regard to issuance of warrants related to convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of adjustment made to the additional paid in capital with regard to issuance of warrants in connection with equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of adjustment made to the additional paid in capital with regard to issuance of warrants in connection with equity financing to the placement agents for the over-allotment option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid up capital resulting from warrants amendments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Adjustmentstoadditionalpaidincapitalwarrantamendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of adjustment made to the additional paid in capital with regard to issuance of Warrants issued in connection with equity financing to the placement agents, non-cash issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfStockIssuedDuringPeriodvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock issued during the reporting period,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfStockIssuedDuringPeriodvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockAndIssuedDuringPeriodshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the reporting period,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockAndIssuedDuringPeriodshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockSubscriptionPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock subscription payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockSubscriptionPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockSubscriptionPaymentOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>During period shares of subscription payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockSubscriptionPaymentOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79512289&amp;loc=d3e4724-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ReceivablesFromStockholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ReceivablesFromStockholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823491200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,202,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 997,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">312,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=aytu_LincolnparkMember', window );">LincolnPark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs</a></td>
<td class="nump">$ 90,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 20A<br> -URI http://asc.fasb.org/extlink&amp;oid=79512289&amp;loc=SL6757427-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=aytu_LincolnparkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=aytu_LincolnparkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839389216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,508,304)<span></span>
</td>
<td class="num">$ (28,180,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and accretion</a></td>
<td class="nump">4,364,680<span></span>
</td>
<td class="nump">874,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment</a></td>
<td class="nump">1,265,125<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,502,092<span></span>
</td>
<td class="nump">902,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Issuance of restricted stock</a></td>
<td class="nump">724,613<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">182,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AmortizationOfBeneficialConversionFeature', window );">Amortization of beneficial conversion feature</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,943,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Noncash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">221,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative (income) expense</a></td>
<td class="num">(212,809)<span></span>
</td>
<td class="nump">12,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties', window );">Amortization of prepaid research and development - related party (Note 11)</a></td>
<td class="nump">335,454<span></span>
</td>
<td class="nump">121,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1', window );">Loss on investment</a></td>
<td class="nump">61,519<span></span>
</td>
<td class="nump">971,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Issuanceofcommonstocktoexecutives', window );">Common stock issued to executives</a></td>
<td class="nump">509,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of warrants to initial investors</a></td>
<td class="nump">596,434<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of asset</a></td>
<td class="num">(428,374)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Warrant amendment</a></td>
<td class="nump">1,507<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) in accounts receivable</a></td>
<td class="num">(355,031)<span></span>
</td>
<td class="num">(5,369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventory</a></td>
<td class="nump">195,427<span></span>
</td>
<td class="num">(485,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">(Increase) decrease in prepaid expenses and other</a></td>
<td class="num">(95,202)<span></span>
</td>
<td class="nump">155,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and other</a></td>
<td class="nump">493,217<span></span>
</td>
<td class="nump">698,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">(Decrease) increase in accrued liabilities</a></td>
<td class="num">(414,570)<span></span>
</td>
<td class="nump">925,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncreaseDecreaseInAccruedCompensation', window );">(Decrease) increase in accrued compensation</a></td>
<td class="num">(861,226)<span></span>
</td>
<td class="nump">1,004,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidRent', window );">(Decrease) increase in deferred rent</a></td>
<td class="num">(4,200)<span></span>
</td>
<td class="nump">10,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">(Decrease) in deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(511,607)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(13,829,652)<span></span>
</td>
<td class="num">(10,657,449)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(111,608)<span></span>
</td>
<td class="num">(252,932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of Natesto assets</a></td>
<td class="num">(6,000,000)<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromLongtermInvestments', window );">Investment in Acerus</a></td>
<td class="nump">1,071,707<span></span>
</td>
<td class="num">(2,012,991)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Sale of investment in Acerus cost</a></td>
<td class="num">(91,864)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherProductiveAssets', window );">Sales of Primsol assets</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Purchase of Primsol asset</a></td>
<td class="num">(750,000)<span></span>
</td>
<td class="num">(1,040,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash proceed from Nuelle</a></td>
<td class="nump">613,309<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cost related to Nuelle acquisition</a></td>
<td class="num">(16,082)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PaymentsForDepositsInvestingActivities', window );">Deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(3,534,538)<span></span>
</td>
<td class="num">(5,303,925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock to Lincoln Park</a></td>
<td class="nump">739,857<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs related to the sale of common stock</a></td>
<td class="num">(90,924)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Proceedsfromissuanceofwarranttenderoffer', window );">Warrant tender offer</a></td>
<td class="nump">2,243,282<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Paymentsforwarranttenderoffercost', window );">Warrant tender offer cost</a></td>
<td class="num">(312,159)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible promissory notes, net (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(298,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtRestructuringCosts', window );">Costs related to the conversion of the convertible promissory notes to equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(29,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromParent', window );">Ampio stock subscription payment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Proceedsfromissuanceofcommonstockandwarrants', window );">Registerd offering</a></td>
<td class="nump">8,602,499<span></span>
</td>
<td class="nump">7,520,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Paymentsforregisteredofferingcosts', window );">Registered offering costs</a></td>
<td class="num">(997,865)<span></span>
</td>
<td class="num">(904,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Over-allotment warrants purchased by placement agents</a></td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Sale of stock subscription</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,187,542<span></span>
</td>
<td class="nump">16,662,503<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(7,176,648)<span></span>
</td>
<td class="nump">701,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">8,054,190<span></span>
</td>
<td class="nump">7,353,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">877,542<span></span>
</td>
<td class="nump">8,054,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfCommonStockToNuelleShareHolders', window );">Issuance of Common Stock to Nuelle Share Holders</a></td>
<td class="nump">1,837,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Fixedassetsincludedinaccountspayable', window );">Fixed assets included in accounts payable</a></td>
<td class="nump">10,789<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents', window );">Warrants issued in connection with the equity financing to the placement agents</a></td>
<td class="nump">292,630<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Warrantsamendedinconnectionwithwarranttenderoffer', window );">Warrants amended in connection with warrant tender offer</a></td>
<td class="nump">63,182<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes', window );">Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">102,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable', window );">Primsol asset purchase included in primsol payable, $1,250,000 less future accretion of $173,000</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,077,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes and interest of $221,000 to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,396,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable', window );">Natesto asset purchase included in Natesto payable, $6,000,000 less future accretion of $620,325</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,379,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants', window );">Warrant derivative liability related to the issuance of the registered offering placement agent warrants (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">297,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote', window );">Reclassification of liability based warrants to equity presentation related to the convertible promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">136,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion', window );">Beneficial conversion feature related to convertible promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,943,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Debt issuance costs related to notes that converted to equity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (218,494)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of adjustment made to the additional paid in capital with regard to issuance of warrants related to convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AmortizationOfBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of amortization of beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AmortizationOfBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of prepaid research and development due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion after deducting accretion expenses related to unconverted convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Fixedassetsincludedinaccountspayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of fixed assets included in accounts payable in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Fixedassetsincludedinaccountspayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncreaseDecreaseInAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncreaseDecreaseInAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfCommonStockToNuelleShareHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to Nuelle share holders for non cash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfCommonStockToNuelleShareHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Issuanceofcommonstocktoexecutives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Issuanceofcommonstocktoexecutives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NatestoBusinessPurchaseIncludedInNatestoPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of Natestol business purchases included in Natestol payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NatestoBusinessPurchaseIncludedInNatestoPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentsForDepositsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Deposits Investing Activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentsForDepositsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Paymentsforregisteredofferingcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for the payment of costs on issuance of registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Paymentsforregisteredofferingcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Paymentsforwarranttenderoffercost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow due to payment for warrant tender offer cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Paymentsforwarranttenderoffercost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of primsol business purchases included in primsol payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Proceedsfromissuanceofcommonstockandwarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from the issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Proceedsfromissuanceofcommonstockandwarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Proceedsfromissuanceofwarranttenderoffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow due to proceeds from issuance of warrant tender offer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Proceedsfromissuanceofwarranttenderoffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of noncash represents warrant derivative liability related to the issuance of the convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of noncash warrant derivative liability related to the issuance of register offering placement agent warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Warrantsamendedinconnectionwithwarranttenderoffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants amended in connection with warrant tender offer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Warrantsamendedinconnectionwithwarranttenderoffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with equity financing to the placement agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Warrantsissuedinconnectionwithequityfinancingtoplacementagents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investments in debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesGrossUnrealizedGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of long-term investments which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from parent as a source of financing that is recorded as additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823911520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross', window );">Primsol Business Purchase Included In Primsol Payable Gross</a></td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="nump">221,000<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount', window );">Standardized Measure of Discounted Future Net Cash Flow Relating to Proved Oil and Gas Reserves, Accretion of Discount</a></td>
<td class="nump">173,000<span></span>
</td>
<td class="nump">173,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="nump">$ 620,325<span></span>
</td>
<td class="nump">620,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of primsol business purchase included in primsol payable gross amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PrimsolBusinessPurchaseIncludedInPrimsolPayableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of discount for the standardized measure of discounted future net cash flow related to proved oil and gas reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 235<br> -Section 50<br> -Paragraph 35<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=68064819&amp;loc=d3e62500-109447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832183056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Merger and Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Note 1 &#150; Business, Basis of Presentation, Merger and Business Combinations</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Business</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Aytu BioScience, Inc. (&#8220;Aytu&#8221;, the &#8220;Company&#8221; or &#8220;we&#8221;) was incorporated as Rosewind Corporation on August&#160;9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June&#160;8, 2015. Aytu is a commercial-stage specialty healthcare company concentrating on developing and commercializing products with an initial focus on urological diseases and conditions. Aytu is currently focused on addressing significant medical needs in the areas of hypogonadism, urological cancers, male infertility, and sexual wellness and vitality.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Basis of Presentation</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Through a multi-step reverse triangular merger, on April 16, 2015, Vyrix Pharmaceuticals, Inc. (&#8216;&#8216;Vyrix&#8217;&#8217;) and Luoxis Diagnostics, Inc. (&#8216;&#8216;Luoxis&#8217;&#8217;) merged with and into our Company (herein referred to as the Merger) and we abandoned our pre-merger business plans to solely pursue the specialty healthcare market, including the business of Vyrix and Luoxis. In the Merger, we acquired the RedoxSYS, MiOXSYS and Zertane products. On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding; On August 25, 2017, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding (herein referred to collectively as the &#8220;Reverse Stock Splits&#8221;). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Business Combination&#151;ProstaScint</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-SIZE: 10pt">In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (&#8220;Jazz Pharmaceuticals&#8221;). Pursuant to the agreement, Aytu purchased assets related to the Jazz Pharmaceuticals&#8217; product known as ProstaScint<sup style="font-style:normal">&#174;</sup> (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the &#8216;&#8216;ProstaScint Business&#8217;&#8217;), and assumed certain of Jazz Pharmaceuticals&#8217; liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consists of the upfront payment of $1.0 million. We also agreed to pay an additional $500,000 which was paid after transfer for the ProstaScint-related product inventory and $227,000 which was paid September 30, 2015 (which represents a portion of certain FDA fees). We also will pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million.</font> <font style="FONT-SIZE: 10pt">The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2017 at $54,000 using a discounted cash flow. The total fair value consideration for the purchase was $2.4 million.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company&#8217;s allocation on consideration transferred for ProstaScint as of the purchase date May&#160;20, 2015 was as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> <div style="CLEAR:both;CLEAR: both">Estimated<br/> Fair Value</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 85%"> <div style="CLEAR:both;CLEAR: both">Tangible assets</div> </td> <td style="WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> <div style="CLEAR:both;CLEAR: both">727,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">Intangible assets</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">1,590,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">Goodwill</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">74,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">Total assets acquired</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">2,391,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Included in the intangible assets at May 2015 was developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. Amortization expense of $159,000 was recognized in both fiscal 2017 and 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> At June 30, 2017, the ProstaScint asset was impaired based upon sales projections that we intend to only sell this product through mid-fiscal 2019, when this product expires. The value for the intangible assets were adjusted to $54,000 for developed technology, $7,000 for trade names and $0 for customer contracts. The estimated future amortization of ProstaScint after June 30, 2017 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center">&#160;</div> <table style="WIDTH: 40%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">Total ProstaScint</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 75%"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 22%"> <div style="CLEAR:both;CLEAR: both">47,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">2019</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">14,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">2020</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">2021</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">2022</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">Thereafter</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">61,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Business Combination&#151;Primsol</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (&#8220;FSC&#8221;). Pursuant to the agreement, Aytu purchased assets related to FSC&#8217;s product known as Primsol&#174; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the &#8220;Primsol Business&#8221;), and assumed certain of FSC&#8217;s liabilities, including those related to the sale and marketing of Primsol arising after the closing.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Aytu paid $500,000 at closing for the purchase of the Primsol Business and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April 1, 2016, (b) $500,000 which was paid on July 1, 2016, and (c) $250,000 which was paid in November 2016 (together, the &#8220;Installment Payments&#8221;).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company&#8217;s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 was as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center">&#160;</div> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div style="CLEAR:both;CLEAR: both"><b>&#160;</b></div> </td> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both"><b>&#160;</b></div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"> <div style="CLEAR:both;CLEAR: both"><b>Fair Value</b></div> </td> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both"><b>&#160;</b></div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td colspan="2" style="white-space:nowrap;"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 85%"> <div style="CLEAR:both;CLEAR: both">&#160;Tangible assets</div> </td> <td style="WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> <div style="CLEAR:both;CLEAR: both">182,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;Intangible assets</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">1,470,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td> <div style="CLEAR:both;CLEAR: both">&#160;Goodwill</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">147,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;Total assets acquired</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">1,799,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Included in tangible assets was $102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets was developed technology of $520,000, customer contracts of $810,000 and trade names of $140,000, each of which was being amortized over a six-year period. Amortization expense of $184,000 and $174,000 was recognized in fiscal 2017 and fiscal 2016, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Divestiture &#150; Primsol</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In March 2017, we entered into and closed on an Asset Purchase Agreement with Allegis Holdings, LLC (the &#8220;Purchaser&#8221;). Pursuant to the agreement, we sold to the Purchaser all of our assets related to our Primsol product, including certain intellectual property and contracts, inventory, work in process and all marketing assets and materials related solely to Primsol (together, the &#8220;Primsol Asset&#8221;). We retain any liability associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us $1,750,000 at the closing for the Primsol Asset. We recognized a gain of approximately $428,000 on the sale which is included in sales, general and administrative expense on our statement of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> We have evaluated this transaction and concluded that it is not significant to our business and therefore the results are included in continuing operations, as the criteria to be presented as discontinued operations was not satisfied.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>License and Supply Agreement&#151;Natesto</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In April, 2016, Aytu entered into and closed a license and supply agreement to acquire the exclusive U.S. rights to Natesto&#174; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation, or Acerus, which rights we acquired effective upon the expiration of the current licensee&#8217;s rights, which occurred on June 30, 2016. The licensee&#8217;s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: #000000">Aytu paid Acerus an upfront fee of $2.0 million upon execution of the agreement. In October 2016, we paid an additional $2.0 million. In January 2017, Aytu paid the final upfront payment of $4.0 million. <font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif">Aytu also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5 million (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share. These shares were a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares until after August 29, 2016. During fiscal 2017, Aytu sold all of these shares. The gross proceeds from the sales totaled $1.1 million, the cost of the sales totaled $92,000, and we recognized a loss on investment of $62,000 and $972,000 during fiscal 2017 and 2016, respectively.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In addition to the upfront payments, we must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> $2.5 million if net sales during any four consecutive calendar quarter period equal or exceed $25.0 million (the &#8220;First Milestone&#8221;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon trial work would no longer make the agreement economically viable for Acerus;</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> $5.0 million if net sales during any four consecutive calendar quarter period equal or exceed $50.0 million;</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> $7.5 million if net sales during any four consecutive calendar quarter period equal or exceed $75.0 milion;</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> $10.0 million if net sales during any four consecutive calendar quarter period equal or exceed $100.0 million; and</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> $12.5 million if net sales during any four consecutive calendar quarter period equal or exceed $125.0 million.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The fair value of the net identifiable asset acquired totaled $10.5 million which is being amortized over eight years. The amortization expense for fiscal 2017 was $1.3 million&#160;and zero for fiscal 2016. The estimated future amortization of Natesto after June 30, 2017 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; WIDTH: 75%"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 22%"> <div style="CLEAR:both;CLEAR: both">1,319,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">2019</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">1,319,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">2020</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">1,319,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">2021</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">1,319,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center"> <div style="CLEAR:both;CLEAR: both">2022</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">1,319,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">Thereafter</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">2,636,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">9,231,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The contingent consideration was valued at $3.2 million using a Monte Carlo simulation, as of June 30, 2016. The contingent consideration accretion expense for fiscal 2017 and 2016 was $228,000, and zero respectively. As of June 30, 2017, the contingent consideration was revalued and increased to $5.7 million based on increased future estimated sales performance of Natesto using a Monte Carlo simulation.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>Merger/Subsidiary</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In May 2017, Aytu Women&#8217;s Health, LLC., a wholly-owned subsidiary of Aytu, acquired Nuelle, Inc., or Nuelle, a women&#8217;s sexual health company. This transaction expanded our product portfolio with the addition of the Fiera<sup style="font-style:normal">&#174;</sup> personal care device for women.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In the Merger, (i) each share of Nuelle common stock and each option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred stock was converted into the right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate of 125,000 shares of our common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In addition, Nuelle preferred stockholders will be entitled to revenue earn-out payments equal to a designated percentage of net sales on tiers of net sales up to $100.0 million, with an average rate for all tiers in the mid-single digit range and a maximum aggregate payout of $6.9 million.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Nuelle stockholders additionally will be entitled to milestone earn-out payments of up to a potential aggregate of $24.0 million, upon the attainment by us of designated net sales thresholds over any sequential four calendar quarter period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The first $1.0 million of earn-out payments will be paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock. The stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&#8217;s portion of the earn-out by the average closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver notice to the Nuelle stockholders of the earn-out or any public disclosure by us of the earn-out being due and payable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In the event that we do not make all of the required earn-out payments to the Nuelle stockholders before May 3, 2022, and we also close a divestiture before May 3, 2022 of any of the products acquired in the transaction, we will pay the Nuelle stockholders a combination of (i) cash in an amount equal to 10% of the value of all cash, securities and other property paid to us in the divestiture (cash is to be 60% of the total consideration), and (ii) shares of our common stock equal to the Nuelle stockholders&#8217; portion of the divestiture payment divided by the average closing price of our common stock for the 10 trading days prior to the earlier of the closing date of the divestiture or the public disclosure of the divestiture (shares of common stock are to be 40% of the total consideration).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In addition to the upfront issuance of common stock, we must make the following one-time payments to the Nuelle stockholders within 90 days of the occurrence of the following events (provided that, the maximum aggregate amount payable under such milestone payments will be $24.0 million):&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></font></div> </div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> Upon achieving the first occurrence of Net Sales of $10.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.0 million;</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> Upon achieving the first occurrence of Net Sales of $17.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $1.8 million.</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> Upon achieving the first occurrence of Net Sales of $25.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $2.5 million.</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> Upon achieving the first occurrence of Net Sales of $37.5 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $3.8 million;</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> Upon achieving the first occurrence of Net Sales of $50.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $5.0 million; and</font></div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <font style="FONT-FAMILY: Symbol; COLOR: black; FONT-SIZE: 10pt"> &#8901;</font></font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> Upon achieving the first occurrence of Net Sales of $100.0 million over any sequential four calendar quarter period, Aytu will make a one-time payment to the Nuelle security holders of an amount equal to $10.0 million.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company&#8217;s allocation on consideration transferred for Nuelle as of the purchase date May&#160;5, 2017 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both"><b>&#160;</b></div> </td> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both"><b>&#160;</b></div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"> <div style="CLEAR:both;CLEAR: both"><b>Fair Value</b></div> </td> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both"><b>&#160;</b></div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap;"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td colspan="2" style="white-space:nowrap;"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 85%"> <div style="CLEAR:both;CLEAR: both">Tangible assets</div> </td> <td style="WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> <div style="CLEAR:both;CLEAR: both">2,061,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">Intangible assets</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">1,540,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">Goodwill</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">238,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">Total assets acquired</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">3,839,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Included in the intangible assets is developed technology of $1.3 million, customer contracts of $80,000 and trade names of $160,000, each of which will be amortized over a nine to twelve-year period. Amortization expense of $22,000 and $0 was recognized in fiscal 2017 and 2016, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Future amortization after the year ended June 30, 2017 is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 75%"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 22%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">2019</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">2020</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">2021</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">2022</div> </td> <td> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">Thereafter</div> </td> <td style="PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">798,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> <div style="CLEAR:both;CLEAR: both">1,518,000</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The contingent consideration was valued at $1.9 million using a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for fiscal 2017 and 2016 was $12,000, and zero respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Additionally, we assumed liabilities of $47,000.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832323232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 2 &#150; Summary of Significant Accounting Policies</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Principals of Consolidation</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">These consolidated financial statements include the accounts of Aytu and its wholly-owned subsidiary, Aytu Women&#8217;s Health. All material intercompany transactions and balances have been eliminated.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Cash, Cash Equivalents and Restricted Cash</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Restricted cash consist primarily of a&#160;certificate of deposit investment account. Aytu&#8217;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year, Aytu has maintained balances in excess of federally insured limits.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Revenue Recognition</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">License Agreements and Royalties</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones and are recognized at the time the milestones are achieved. Royalties will be recognized as revenue when earned.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Product&#160;&amp; Service Sales</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company recognizes revenue only when all of the following criteria have been met:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.7in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Persuasive evidence of an arrangement exists,</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="DISPLAY: none; FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Delivery has occurred or services have been performed,</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The fee for the arrangement is fixed or determinable, and</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="DISPLAY: none; FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Collectability is reasonably assured.</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Persuasive evidence of an arrangement exists - The Company documents all terms of an arrangement in a written contract by the customer prior to recognizing revenue.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Delivery has occurred or services have been performed - The Company delivers all products prior to recognizing revenue. Equipment is considered delivered upon delivery to a customer's designated location.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Device sales are recorded when products are shipped to customers. Drug sales are recorded when the product arrives at the customer&#8217;s dock. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related</font> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">sales are recorded and are estimated at the time of sale.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">The fee for the arrangement is fixed or determinable - Prior to recognizing revenue, a customer's fee is either fixed or determinable under the terms of the written contract.</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Collectability is reasonably assured - The Company determines that collectability is reasonably assured prior to recognizing revenue. Collectability is assessed on a customer-by-customer basis based on criteria outlined by management. New customers are subject to a credit review process, which evaluates the customer's financial position and ultimately its ability to pay. The Company does not enter into arrangements unless collectability is reasonably assured at the outset. Existing customers are subject to ongoing credit evaluations based on payment history and other factors. If it is determined during the arrangement that collectability is not reasonably assured, revenue is recognized on a cash basis.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Estimated Sales Returns and Allowances</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu records estimated reductions in revenue for potential returns of products by customers. As a result, management must make estimates of potential future product returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different estimates, material differences in the amount of the Company&#8217;s reported revenue could result. As of June 30, 2017 and 2016, we accrued $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">58,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">284,000</font>, respectively, in our estimated returns allowance.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Shipping and Handling</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company's shipping and handling costs are included in cost of goods sold for all periods presented.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Accounts Receivable</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Accounts receivable are recorded at their net realized value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation allowance accordingly. As of June 30, 2017 we had an allowance for doubtful accounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">44,000</font>, and as of June 30, 2016, there had been an allowance for doubtful accounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41,000</font>.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Concentration of Business Risks</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following counterparties contributed greater than&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font></font>%&#160;of the Company's total revenue during the year ended June 30, 2017 and 2016, respectively. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The revenue from these counterparties as a percentage of total revenue was as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The loss of one or more of the Company's significant partners or collaborators could have a material adverse effect on its business, operating results or financial condition. Although the Company is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management does not believe significant credit risk exists as of&#160;June&#160;30, 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">We are also subject to credit risk from our accounts receivable related to our product sales. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of June 30, 2017, three customers accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60</font>% of gross accounts receivable. As of June 30, 2016, one customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 69</font>% of gross accounts receivable.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Inventories</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Aytu periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable value in the period that the impairment is first recognized. We currently have a reserve of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">311,000</font> for slow moving inventory as of June 30, 2017 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">199,000</font> at June 30, 2016.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Inventory consist of the following:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>442,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>77,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Work in process</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>442,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>738,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>647,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="48%"> <div>Reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>(310,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>(199,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,312,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>525,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Trading Securities</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"> Trading securities are carried at fair value with realized and unrealized gains and losses recorded in earnings.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Fixed Assets</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Fixed assets are recorded at cost. After being placed in service, the fixed assets are depreciated using the straight-line method over estimated useful lives. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fixed assets consist of the following:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">Estimated</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div style="CLEAR:both;CLEAR: both">June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both"> Useful&#160;Lives&#160;in&#160;years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Office equipment, furniture and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2 - 5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">405,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">201,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Lab equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3 - 5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">111,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">90,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">287,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">45,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Manufacturing equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2 - 5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">90,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">7,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Less accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">(246,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">(112,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Fixed assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">647,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">231,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu recorded the following depreciation expense in the respective periods:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Depreciation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">134,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">51,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Patents</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third party appraisal, was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font>. The Zertane patents were acquired in connection with the 2011 acquisition of DMI BioSciences by Ampio, the former parent company of Aytu, and were being amortized over the remaining U.S. patent lives of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11</font> years, which were to expire in March 2022. In fiscal 2016, we redirected our resources towards our commercial-stage products and the Company determined that this asset had no further value as the Company did not have the resources to complete the necessary clinical trials and bring it to market before the patents expired. The remaining fair value of the Zertane patents were expensed as of June 30, 2016.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The cost of the Luoxis patents were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">380,000</font> when they were acquired in connection with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> years, which expires in March 2028. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Patents consist of the following:</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>880,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>880,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(609,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(583,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patents, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>271,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>297,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Aytu recorded the following amortization expense in the respective periods:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Amortization expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>26,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>332,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Future amortization from the year ended June 30, 2017 is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>146,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>271,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Business Combinations</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company accounts for its business acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 805, &#8220;Business Combinations&#8221;, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Goodwill</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Nuelle, ProstaScint and Primsol&#160;purchase price allocations&#160;were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May&#160;20, 2015, Primsol that occurred on October 5, 2015 and Nuelle that occurred on May 5, 2017. There was an impairment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">74,000</font> related to the ProstaScint goodwill for the year ended June 30, 2017.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Use of Estimates</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets, collectability of accounts receivable, and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Income Taxes</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu has been included in the consolidated tax returns of Ampio, the former parent company of Aytu, for tax years ended on or before December 31, 2015. As of January 2016, due to the decrease in Ampio&#8217;s ownership percentage of Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu's taxes were computed and reported on a "separate return" basis for these financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The amount of income taxes and related income tax positions taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company's policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB ASC 740-1 "Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109" (ASC 740-10) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant tax position requires recognition under ASC 740-10.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock-Based Compensation</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the graded method.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Research and Development</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Research and development costs are expensed as incurred with expenses recorded in the respective period.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Income (Loss) Per Common Share</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. <font style="BACKGROUND: transparent">Diluted net loss per share reflects the potential of securities that could share in the net loss of Aytu. Basic and diluted loss per share was the same in 2017 and 2016. Although there were common stock equivalents of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 367,312</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 126,239</font> shares outstanding at June 30, 2017 and 2016, respectively, consisting of stock options and warrants; they were not included in the calculation of the diluted net loss per share because they would have been anti-dilutive.</font></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Fair Value of Financial Instruments</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted future cash&#160;flows.</div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Derivative Liability</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu accounts for liability warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial instruments and related warrants were calculated using a Monte Carlo based valuation model. We recorded a derivative expense at the inception of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods was recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income or expense for the warrants.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"> The fair value of the warrants issued to the placement agents in connection with the registered offering were valued using the Black-Scholes valuation methodology. Changes in the fair value in subsequent periods were recorded to derivative income or expense.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Adoption of Newly Issued Accounting Pronouncements</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In November 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-18, "Statement of Cash Flows: Restricted Cash."&#160; The amendments address diversity in practice that exists in the classification and presentation of changes in restricted cash on the statement of cash flows.&#160; ASU 2016-18 is effective for the fiscal year commencing after December 15, 2017. During fiscal 2017, the Company early adopted this pronouncement, the impact of which was minimal, which is now shown on the statements of cash flows within cash and cash equivalents.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In August 2016, the FASB issued ASU 2016-15 &#8220;Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments,&#8221; which provides guidance on the presentation of certain cash receipts and cash payments in the statement of cash flows in order to reduce diversity in existing practice. ASU 2016-15 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted. During fiscal 2017, the Company early adopted this standard. The primary cash flow categorization that will impact the Company will be contingent consideration payments, however, no such payments have been made to date.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09, &#8220;Compensation &#150;Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting.&#8221; The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The amendments are expected to impact net income, earnings per share, and the statement of cash flows. Implementation and administration may present challenges to companies with significant share based payment activities. The amendments are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The Company adopted this standard during fiscal, 2017. Aytu has elected to account for forfeitures as they occur, rather than estimate expected forfeitures. Prior to adopting this standard, the Company had not estimated any forfeitures, therefore, no adjustments were necessary. Aytu is also operating at a net operating loss, therefore, there was no tax implication.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In July&#160;2015, the FASB issued ASU 2015-11,&#160;&#8220;Simplifying the Measurement of Inventory.&#8221;&#160; ASU&#160;2015-11 clarifies that inventory should be held at the lower of cost or net realizable value.&#160; Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory.&#160; ASU 2015-11 was effective for fiscal years and interim periods beginning after December&#160;15, 2016. &#160;ASU 2015-11 is required to be applied prospectively.&#160; <font style="COLOR: #333333">The</font> amendments in ASU 2015-11 were adopted by the Company during fiscal 2017. The adoption of this standard did not have an impact on the Company&#8217;s financial position or results of operations<font style="COLOR: #333333">.</font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In August 2014, the FASB issued ASU 2014-15, &#8220;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern&#8221; (&#8220;ASU 2014-15&#8221;). ASU 2014-15 is intended to define management&#8217;s responsibility to evaluate whether there is substantial doubt about an organization&#8217;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016. The Company adopted this standard during fiscal 2017 and has included the required disclosure in the Company&#8217;s financial statements (Note 3).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Recently Issued Accounting Pronouncements, Not Adopted as of June 30, 2017</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2017, the FASB issued ASU No. 2017-09,&#160;&#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&#160;(ASU 2017-09).&#8221; ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of its adoption of this standard on its financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In January 2017, the FASB issued ASU 2017-04, &#8220;Intangibles - Goodwill and Other (Topic 350).&#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe that adoption of this amendment will have a material impact on its financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In January 2017, the FASB issued ASU 2017-01, &#8220;Business Combinations (Topic 805) Clarifying the Definition of a Business.&#8221; The amendment clarifies the definition of a business, which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively for public business entities for interim and annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect an immediate impact on its financial statements from this codification however, if Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business combination or an asset purchase.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842).&#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In January 2016, the FASB issued ASU No. 2016-01, <i>Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities</i> <i>(Topic 825)</i>. ASU No. 2016-01 revises the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments to be recognized in net income. ASU No. 2016-01 is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. &#160;Adopting ASU No. 2016-01 may result in a cumulative effect adjustment to the consolidated statement of equity retained earnings as of the beginning of the year of adoption. The Company is currently evaluating the impact of this standard on its financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2014, the FASB issued ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the "New Revenue Standard"). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.&#160; The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted for interim and annual periods beginning after December 5, 2017. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019. We will adopt the standard in our third quarter of fiscal 2018 and preliminarily expect to use the modified prospective method. However, we are continuing to evaluate the impact of the standard, and our adoption method is subject to change. We currently do not anticipate these standards to have a material impact on our consolidated financial statements outside of the expanded disclosure requirements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832186832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Substantial Doubt about Going Concern [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 3 &#150; Going Concern</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As reflected in the accompanying financial statements, the Company had a net loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22.5</font> million and net cash used in operations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13.8</font> million, for the year ended June 30, 2017. At June 30, 2017, Aytu had $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">878,000</font> of cash, cash equivalents and restricted cash, stockholders&#8217; equity of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.0</font> million and an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">69.1</font> million at June 30, 2017.&#160;&#160;In addition, the Company is in the early stage of commercialization and has not yet generated any profits. These factors raised substantial doubt about the Company&#8217;s ability to continue as a going concern.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">However, with the completion of the August 2017 financing of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11.8</font> million, the Company expects that its current cash resources plus this additional funding will be sufficient to fund operations through fiscal 2018 and into mid-fiscal 2019.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832323232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement/Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_LicenseAgreementTextBlock', window );">License Agreement [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note&#160;4 &#150; License Agreement/Revenue Recognition</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During 2011, Ampio Pharmaceuticals, Inc., (&#8220;Ampio&#8221;), Aytu&#8217;s former parent company, entered into a license, development and commercialization agreement with a major Korean pharmaceutical company which was assigned to Vyrix when it was formed in 2013. The agreement grants the pharmaceutical company exclusive rights to market Zertane in South Korea for the treatment of premature ejaculation (&#8220;PE&#8221;) and for a combination drug to be developed, utilizing Zertane and an erectile dysfunction drug. Upon signing of the agreement, Ampio received a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> upfront payment, the net proceeds of which were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">418,000</font> after withholding of Korean tax. The upfront payment was deferred and was being recognized as license revenue over a ten-year period. Milestone payments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.2</font> million could have been earned and recognized contingent upon achievement of regulatory approvals and cumulative net sales targets, which could have taken several years. In addition, Aytu could have earned a royalty based on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% of net sales, as defined, if the royalty exceeded the transfer price of the Zertane product. No royalties have been earned to date.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In April 2014, Vyrix entered into a Distribution and License Agreement (the &#8220;Paladin Agreement&#8221;) with Endo Ventures Limited, which acquired Paladin Labs Inc. (&#8220;Paladin&#8221;), whereby Paladin has exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub Saharan Africa, Colombia and Latin America. The Paladin Agreement expires on a country by country basis upon the later of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font> years after the first commercial sale of the product in that country or expiration of market exclusivity for Zertane in that country. Paladin paid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> to Vyrix upon signing the Paladin Agreement and is obligated to make milestone payments aggregating up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.0</font> million based upon achieving Canadian and South African product regulatory approval and achieving specific sales goals. The upfront payment was deferred and was being recognized as license revenue over a seven-year period. In addition, the Paladin Agreement provides that Paladin pay royalties based on sales volume.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">At the end of fiscal 2016, Aytu determined that the Zertane asset had no further value as Aytu did not have the resources to complete the necessary clinical trials and bring it to market before the patents expire. The remaining deferred revenue of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">426,000</font> was recognized as of June 30, 2016.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832179968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueConsiderationTextBlock', window );">Fair Value Consideration [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note&#160;5 &#150; Fair Value Considerations</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted future cash&#160;flows. The valuation policies are determined by the Chief Financial Officer and approved by the Company&#8217;s Board of Directors.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu&#8217;s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"> <table style="BORDER-BOTTOM-COLOR: #000000; BORDER-TOP-COLOR: #000000; WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-RIGHT-COLOR: #000000; BORDER-LEFT-COLOR: #000000" cellspacing="0" cellpadding="0" align="center"> <tr> <td style="WIDTH: 15%; VERTICAL-ALIGN: top"> <div><font style="COLOR: #000000; FONT-SIZE: 10pt"> Level&#160;1:</font></div> </td> <td style="WIDTH: 85%; VERTICAL-ALIGN: bottom"> <div><font style="COLOR: #000000; FONT-SIZE: 10pt">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</font></div> </td> </tr> <tr> <td> <div><font style="COLOR: #000000">&#160;</font></div> </td> <td> <div><font style="COLOR: #000000">&#160;</font></div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top"> <div><font style="COLOR: #000000; FONT-SIZE: 10pt"> Level&#160;2:</font></div> </td> <td style="VERTICAL-ALIGN: bottom"> <div><font style="COLOR: #000000; FONT-SIZE: 10pt">Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and</font></div> </td> </tr> <tr> <td> <div><font style="COLOR: #000000">&#160;</font></div> </td> <td> <div><font style="COLOR: #000000">&#160;</font></div> </td> </tr> <tr> <td style="VERTICAL-ALIGN: top"> <div><font style="COLOR: #000000; FONT-SIZE: 10pt"> Level&#160;3:</font></div> </td> <td style="VERTICAL-ALIGN: bottom"> <div><font style="COLOR: #000000; FONT-SIZE: 10pt">Unobservable inputs that are supported by little or no market activity.</font></div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="left"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Aytu&#8217;s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Aytu&#8217;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table presents Aytu&#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2017 and 2016, by level within the fair value hierarchy:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> Fair&#160;Value&#160;Measurements&#160;Using</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="51%"> <div style="CLEAR:both;CLEAR: both">June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">ASSETS</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Investment in Acerus</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">LIABILITIES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrant derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,648,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,648,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="51%"> <div style="CLEAR:both;CLEAR: both">June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">ASSETS</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Investment in Acerus</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,041,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,041,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">LIABILITIES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrant derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">276,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">276,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,869,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,869,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The estimated fair value of the Company&#8217;s investment, which is classified as Level 1 (quoted price is available), was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million as of June 30, 2016. This investment was sold during fiscal 2017.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The warrant derivative liability was valued using the Black-Scholes valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. The warrants related to the warrant derivative liability are not actively traded and therefore classified as Level 3. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Significant assumptions in valuing the warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants, were as follows as of February 28, 2017, the date when the derivative instruments converted into equity, and at June 30, 2016:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> February&#160;28,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both">June&#160;30,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="62%"> <div style="CLEAR:both;CLEAR: both">Warrants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">160.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">75.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Equivalent term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">4.18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">4.84</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">1.87</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">0.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Derivative&#160;Instruments</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">Balance as of June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">276,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">Warrant issuances</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">Change in fair value included in earnings (February 28, 2017)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">(213,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">Reclassification of warrant from liability to equity upon amendment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">(63,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">Balance as of June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The contingent consideration was valued using the Monte-Carlo valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Contingent consideration is not actively traded and therefore classified as Level 3.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of June 30, 2016, we had $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.9</font> million in contingent consideration. During fiscal 2017, this balance increased to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.6</font> million as a result of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">305,000</font> in accretion, which is included in our interest expense, as well as an increase of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.9</font> million related to our Nuelle merger and adjustments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million related to the revaluation of our ProstaScint and Natesto products.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823029056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></strong></div> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note&#160;6 &#150; Income Taxes</font></strong> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As previously discussed in Note 2 - Summary of Significant Accounting Policies, the Company has been included in the consolidated tax returns of Ampio for tax years ending on or before December 31, 2015. Beginning in January 2016, Aytu will file tax returns separate from Ampio. For all consolidated tax return periods, the Company's taxes have been computed and reported on a "separate return" basis. Ampio and Aytu did not have a tax sharing agreement for the consolidated return periods. Accordingly, certain tax attributes, e.g. net operating loss carryforwards, reflected in these financial statements, may or may not be available to Aytu. In January 2016, Ampio's ownership interest in Aytu fell below 80% so that Aytu will no longer be included in the Ampio consolidated tax return. The deconsolidation resulted in approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.5</font> million of net operating loss carryforwards originating prior to the incorporation of Vyrix and Luoxis no longer being available to Aytu. Upon deconsolidation, the deferred tax asset and related valuation allowance for these pre-incorporation net operating losses have been removed.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Income tax benefit resulting from applying statutory rates in jurisdictions in which Aytu is taxed (Federal and various states) differs from the income tax provision (benefit) in the Aytu financial statements. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table reflects the reconciliation for the respective periods.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%" colspan="11"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Benefit at statutory rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7,653,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(34.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(9,581,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(34.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>State income taxes, net of federal benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(681,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3.02)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(853,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3.03)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Stock based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>116,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.51</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Interest on convertible debt</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>75,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div>Offering costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>203,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div>Contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div>Change in tax rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(11,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(0.05)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,922,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>35.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,672,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>30.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Reduction of net operating losses upon deconsolidation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,674,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.45</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Net income tax provision (benefit)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Deferred income taxes arise from temporary differences in the recognition of certain items for income tax and financial reporting purposes. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Deferred tax assets (liabilities):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Deferred revenue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Deferred rent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>3,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>5,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>127,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>445,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Net operating loss carry forward</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>15,435,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>9,202,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Intangibles</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,559,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>606,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Share-based coompensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,362,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>327,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Fixed assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>191,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Unrealized loss on investment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>360,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"> <div>Capital loss carry forward</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>385,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"> <div>Contribution carry forward</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>41,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>75,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>153,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>174,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>192,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Allowance for doubtful accounts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>17,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>15,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total deferred income tax assets (liabilities)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>19,369,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>11,305,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Less: Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(19,369,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(11,305,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total deferred income tax assets (liabilities)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than not it will realize the benefits of these deductible differences, net of the valuation allowance provided. The Company has federal net operating losses of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">42.3</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24.8</font> million as of June 30, 2017 and June&#160;30, 2016, respectively that, subject to limitation, may be available in future tax years to offset taxable income. The available federal net operating losses, if not utilized to offset taxable income in future periods, will begin to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">expire in 2031 through 2036.</font> The Company has state net operating losses of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">32.8</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">17.3</font> million as of June 30, 2017 and June 30, 2016, respectively that, subject to limitation, may be available in future tax years to offset taxable income. The available state net operating losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2036. Under the provisions of the Internal Revenue Code, substantial changes in the Company's ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. Net operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which they are generated has been closed by statute. The amount subject to disallowance is limited to the NOL utilized. Accordingly, the Company may be subject to examination for prior NOLs generated as such NOLs are utilized.</font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As of June 30, 2017 and 2016, the Company has no liability for gross unrecognized tax benefits or related interest and penalties.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu has made its best estimates of certain income tax amounts included in the financial statements. Application of the Company&#8217;s accounting policies and estimates, however, involves the exercise of judgement and use of assumptions as to future uncertainties and, as a result, could differ from these estimates. In arriving at its estimates, factors the Company considers include how accurate the estimates or assumptions have been in the past, how much the estimates or assumptions have changed and how reasonably likely such changes may have a material impact. Aytu has been historically included in the Ampio consolidated tax return. Under the general statute of limitations, the Company would not be subject to federal or Colorado income tax examinations for tax years prior to 2013 and 2012, respectively. However, given the net operating losses generated since inception, all tax years since inception are subject to examination.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832198864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Note&#160;7 &#150; Commitments and Contingencies</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Commitments and contingencies are described below and summarized by the following table as of June&#160;30, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2019</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2020</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2021</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2022</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Prescription database</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,342,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>769,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>573,000</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Natesto</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,500,000</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Manufacturing/commercial supply agreements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Office lease</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>175,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>145,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>30,000</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16,517,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>914,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>603,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Prescription Database</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In May 2016, Aytu entered into an agreement with a company that will provide Aytu with prescription database information, whereby Aytu agreed to pay approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.9</font> million over three years for access to the database of prescriptions written for Natesto. The payments have been broken down into quarterly payments, the first of which was made in November 2016, the second payment was made in January 2017 and the third payment was made in April 2017.</div> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Natesto</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In April 2016, the Company entered into an agreement with Acerus whereby Aytu agreed to pay $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.0</font> million for the exclusive U.S. rights to Natesto (see Note 1). The first payment totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.0</font> million was paid in April, the second installment payment was paid in October 2016. The final payment totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.0</font> million was paid in January 2017. Additionally, Aytu is required to make the first milestone payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5</font> million even if the milestone is not reached and anticipates making the second milestone payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million along with the third milestone payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.5</font> million.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Manufacturing/Commercial Supply Agreements</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In October 2015, Aytu entered into a Master Services Agreement with Biovest International, Inc. (&#8220;Biovest&#8221;). The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of its products for the ProstaScint product. In September 2016, Aytu entered into a Commercial Supply Agreement with Grand River Aseptic Manufacturing, Inc. (&#8220;GRAM&#8221;). The agreement provides that Aytu may engage GRAM from time to time to provide services in accordance with mutually agreed upon work orders. As of June 30, 2017, both contracts were on hold as the Company evaluates its strategic options for the ProstaScint product. If the contracts are not restarted, Aytu does not anticipate any future liability related to either contract.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Office Lease</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June 2015, Aytu entered into a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37</font> month operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,000</font> a month, with total base rent over the term of the lease of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">112,000</font>. In September 2015, the Company entered into a 37 month operating lease in Englewood, Colorado. This lease has an initial base rent of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,000</font> a month with a total base rent over the term of the lease of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">318,000</font>. The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Rent expense for the respective periods is as follows:</div> &#160;</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Rent expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>139,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>120,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832201584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note&#160;8 &#150; Convertible Promissory Notes</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth individual investors for the purchase and sale of convertible promissory notes (&#8220;Notes&#8221;) with an aggregate principal amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.2</font> million. The sale of the Notes was pursuant to a private placement. Debt issuance costs totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">401,000</font>, which included the $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">103,000</font> fair value of the placement agent warrants.</font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Notes were an unsecured obligation. Aytu did not have the right to prepay the Notes prior to the maturity date. Interest accrued on the Notes in the following amounts: (i)&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% simple interest per annum for the first six months and (ii)&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% simple interest per annum thereafter if not converted during the first nine months. Interest accrued, was payable with the principal upon maturity, conversion or acceleration of the Notes and could have been paid in kind or in cash, in Aytu&#8217;s sole discretion.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Placement agents for the offering sold the institutional portion of the offering of the Notes. Aytu sold the balance of the Notes to individuals and entities with whom Aytu had an established relationship. For Notes sold by the placement agent, Aytu paid the placement agent <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% of the gross proceeds of Notes sold by the placement agents and was obligated to issue warrants for an amount of shares equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents in the private placement, in addition to a previously paid non-refundable retainer fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font>. The placement agent warrants have a term of five years from the date of issuance of the related notes in July and August 2015, an exercise price equal to the conversion price per share at which the Notes are converted into common stock. Change in fair value is recorded in earnings. Fair value at the grant date was recorded as a debt discount and amortized over the term of the debt.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The warrants were recorded at fair value as long-term liabilities on the Balance Sheet and upon conversion were moved to equity classification.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Upon Aytu&#8217;s adoption of ASU 2015-3, the issuance costs associated with the Notes were recorded as a long&#150;term liability and were presented in the Balance Sheet as a direct reduction of the carrying amount of the Notes on their inception date.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Pursuant to the terms of the convertible promissory note agreements, if Aytu sold equity securities at any time while the Notes were outstanding in a financing transaction that was not a Qualified Financing (a public offering of Aytu stock resulting in gross proceeds of at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million (excluding indebtedness converted in such financing) prior to the maturity date of the Notes), the holders of the convertible promissory notes had the option, but not the obligation, to convert the outstanding principal and accrued interest as of the closing of such financings into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (a) the lowest cash price per share paid by purchasers of shares in such financing, or (b) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">92.60</font>. As a result of Aytu&#8217;s sale of common stock on January 20, 2016, the Company was obligated to provide notice to the above-referenced noteholders of such stock sales. In accordance with the convertible note terms, noteholders had the option to convert their entire balance (inclusive of accrued but unpaid interest) into a number of shares of Aytu common stock equal to 120% of the number of shares calculated by dividing such note balance by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">156.00</font>, which was the per share purchase price paid in the equity financing described above. On February 10, 2015, the date of the conversion, an aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.1</font> million of principal and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">143,000</font> of accrued interest on the Notes converted into an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 32,830</font> shares of Aytu&#8217;s common stock under the original terms of the agreement.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2016, Aytu completed a registered public offering which was considered a Qualified Financing and all outstanding Notes were automatically converted on the same terms as in the offering. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">At the insistence of the underwriters of the offering, all outstanding noteholders had signed lockup agreements which granted them an extra 10% on the conversion, increasing it to 130% of shares calculated by dividing such Note balance by $96.00</font>, which was the per share purchase price in the registered offering. On May 6, 2016, the date of conversion, an aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.1</font> million of principal and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">78,000</font> of accrued interest on the Notes converted into an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,279</font> shares of Aytu&#8217;s common stock and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,279</font> warrants.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with the conversion of the Aytu Notes, Aytu was obligated to issue to the placement agents for the convertible note offering warrants for an amount of shares equal to 8% of the number of shares of Aytu&#8217;s common stock for the Notes sold by the placement agents issued upon conversion of the Notes. As a result of the optional note conversion, on February 10, 2016, Aytu issued warrants to the placement agents to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,113</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">156.00</font> per share. As a result of the second Note conversion, on May 6, 2016, Aytu issued warrants to the placement agents to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,129</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">96.00</font> per share. These warrants are exercisable for five years from the date of issuance of the related Notes in July and August 2015. The warrants have a cashless exercise feature.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Also in connection with the conversion of the Notes, Aytu recorded a beneficial conversion feature of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.9</font> million which was recorded as a debt discount; this amount represents that carrying amount of the Notes at the date of conversion. The&#160;beneficial conversion feature was expensed upon conversion of the Notes to interest expense.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839437232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note&#160;9 &#150; Common Stock</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Capital Stock</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">At June 30, 2017 and June 30, 2016, Aytu had <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 824,831</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 187,098</font> common shares outstanding, respectively, and no preferred shares outstanding at either June 30, 2017 or June 30, 2016. The Company has <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100.0</font></font>&#160;million shares of common stock authorized with a par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font></font>&#160;per share and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50.0</font></font>&#160;million shares of preferred stock authorized with a par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font></font> per share.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2016, Aytu raised gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.5</font> million through a public offering of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 78,125</font> Units. Offering costs totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million resulting in net proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.3</font> million. Each Unit consisted of one share of Aytu common stock and a warrant to purchase one share of Aytu common stock. The common stock issued had a relative fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.2</font> million. The warrants have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">120.00</font> per share and will expire five years from the date of issuance. These warrants have a relative fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million. We also granted the underwriters a 45-day option (the Over-Allotment Option) to purchase up to an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,719</font> shares of common stock and/or warrants. The underwriters exercised <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,542</font> of this over-allotment option for the warrants and paid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.40</font> per over-allotment warrant resulting in proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font>. These warrants have the same terms as the warrants sold in the registered offering.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In July 2016, we entered into a purchase agreement (the &#8216;&#8216;Purchase Agreement&#8217;&#8217;), together with a registration rights agreement (the &#8216;&#8216;Registration Rights Agreement&#8217;&#8217;), with Lincoln Park Capital Fund, LLC (&#8216;&#8216;Lincoln Park&#8217;&#8217;). Upon signing the Purchase Agreement, Lincoln Park agreed to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,684</font> shares of our common stock for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> as an initial purchase under the agreement. We also issued as a commitment fee to Lincoln Park of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,625</font> shares of common stock. Between September 2016 and June 2017, Lincoln Park purchased an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000</font> shares for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">240,000</font>, the issuance costs related to these purchases totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">91,000</font>, resulting in net proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">649,000</font>. We terminated the Purchase Agreement effective August 16, 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In July 2016, we issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font> shares of restricted stock as compensation to certain executive officers and directors, which vest in July 2026. This expense is included in sales, general and administrative. For the year ended June 30, 2017, the expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">725,000</font>. The original fair value of the restricted stock was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.2</font> million.&#160;As of June 30, 2017, the remaining unrecognized expense is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.5</font>&#160;million. During fiscal 2017, one of the Company&#8217;s executive officers resigned and his restricted stock vested in full upon this event. This resulted in the Company recognizing the remainder of the expense related to this executive&#8217;s restricted stock grant of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">430,000</font>.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In August 2016, we issued an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,123</font> shares of common stock as bonuses for performance in 2016 to three executive officers.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In November 2016, we raised gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.6</font> million through a public offering of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 286,749</font> Units. Offering costs totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million resulting in net cash proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.6</font> million. We also issued underwriter warrants in connection with the offering with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">293,000</font>, resulting in net proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.3</font> million. Each Unit consisted of one share of Aytu common stock and a warrant to purchase one share of Aytu common stock. The common stock issued had a relative fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.7</font> million and a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.4</font> million. The investor warrants have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37.20</font> per share and will expire five years from the date of issuance. These investor warrants have a relative fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.5</font> million and a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.2</font> million. We also granted the underwriters a 45-day option (the Over-Allotment Option) to purchase up to an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43,013</font> shares of common stock and/or warrants. The underwriters purchased <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14,263</font> of this Over-Allotment Option for the warrants and paid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.20</font> per over-allotment warrant. These warrants have the same terms as the warrants sold in the registered offering. These warrants have a relative fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">173,000</font>, a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">208,000</font>, and proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,000</font>, which was the purchase price per the underwriting agreement.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2017, the Company consummated its warrant tender offer to exercise, at a temporarily reduced exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.00</font> per share, (i) outstanding warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 86,667</font> shares of common stock with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">120.00</font> per share, which were originally issued to investors in the Company&#8217;s May 2016 financing (the &#8220;May 2016 Warrants&#8221;), and (ii) outstanding warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 301,013</font> shares of common stock with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37.20</font> per share, which were originally issued to investors in the Company&#8217;s October 2016 financing (the &#8220;October 2016 Warrants&#8221; and together with the May 2016 Warrants, the &#8220;Original Warrants&#8221;). Original warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 149,552</font> shares of common stock were tendered and exercised in the warrant tender offer, for aggregate gross proceeds to the Company of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.2</font> million. Original warrants that were not tendered and exercised remain in effect at the pre-tender offer exercise prices of $120.00 per share and $37.20 per share, respectively (see Note 11).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2017, we entered into a Merger Agreement with Nuelle, Inc. and its stockholders, pursuant to which Nuelle would become our wholly owned subsidiary (the &#8220;Merger&#8221;). The Merger closed on May 5, 2017. As part of the Merger, we issued to the Nuelle preferred stockholders an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 125,000</font>&#160;shares of our common stock.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832183056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Note&#160;10 &#150; Equity Instruments</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock Option Repricing</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In March 2017, our Board of Directors approved a common stock option repricing program whereby all previously granted and unexercised options were repriced on a one-for-one basis to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16.40</font> per share which represented the closing price of our common stock as of the date of the repricing. There was no other modification to the vesting schedule of the previously issued options. As a result, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 36,864</font> unexercised options originally granted to purchase common stock at prices ranging from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">64.60</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,111.20</font> per share were repriced under this program.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">We treated the repricing as a modification of the original awards and calculated additional compensation costs for the difference between the fair value of the modified award and the fair value of the original award on the modification date. The repricing resulted in an incremental stock-based compensation expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34,000</font>. The full expense was recognized during fiscal 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In July 2016, our <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Board of Directors approved a common stock option repricing program whereby previously granted and unexercised options held by our then current employees, consultants and directors with exercise prices above $120.00 per share were repriced on a one-for-one basis to $64.60 per share</font> which represented the per share fair value of our common stock as of the date of the repricing. There was no other modification to the vesting schedule of the previously issued options. As a result, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,803</font> unexercised options originally granted to purchase common stock at prices ranging from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">134.40</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">362.40</font> per share were repriced under this program.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">We treated the repricing as a modification of the original awards and calculated additional compensation costs for the difference between the fair value of the modified award and the fair value of the original award on the modification date. The repricing resulted in an incremental stock-based compensation expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">318,000</font>. Expense related to vested shares was expensed on the repricing date and expense related to unvested shares is being amortized over the remaining vesting period of such stock options.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Options</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On June&#160;1, 2015, Aytu&#8217;s stockholders approved the 2015 Stock Option and Incentive Plan (the &#8220;2015 Plan&#8221;), which, as amended in November 2016, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 100,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Pursuant to the 2015 Stock Plan, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000</font> shares of its common stock, are reserved for issuance. The fair value of options granted was calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> The assumptions used for the year ended June 30, 2017 are as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>178% - 185%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>75%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.97% - 1.88%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.16% - 1.90%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.0 -6.5</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3.75 - 6.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock option activity is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Weighted<br/> Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Remaining<br/> Contractual&#160;Life&#160;in</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Outstanding June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>16,340</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>360.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Forfeited/Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(209)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>362.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Outstanding June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>16,131</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>360.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>9.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>23,608</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>18.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(1,408)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>83.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(68)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>64.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Outstanding June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>38,263</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>16.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>8.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Exercisable at June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="8%"> <div>19,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>16.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>7.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Available for grant at June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="8%"> <div>61,737</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table details the options outstanding at June 30, 2017 by range of exercise prices:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 86%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted Average Remaining Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Range&#160;of&#160;Exercise&#160;Prices</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of Options Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted Average Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Life of Options Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of Options Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted Average Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>14.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>9.85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>16.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>36,763</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>16.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>8.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>19,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>16.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>38,263</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>16.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>8.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>19,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>16.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and sales, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes stock-based compensation expense for the years ended June&#160;30, 2017 and 2016:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>Research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>89,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>Selling, general and administrative expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>2,502,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>814,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>2,502,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>903,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Unrecognized expense at June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>775,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Weighted average remaining years to vest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>1.81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Warrants</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of all warrants is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining&#160;Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Life&#160;in&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>444</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,087.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agents for convertible promissory notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>156.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to investors in connection with the registered offering</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>86,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>120.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agents for convertible promissory notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>96.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agents for the registered offering</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,474</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>120.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to convertible note holders who converted May 5, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>120.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>110,108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>124.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Issuance of settlement warrants to initial investors</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,402</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>80.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to investors in connection with the registered offering</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>301,014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agents for the registered offering</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,077</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(149,552)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>286,049</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50.29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.23</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with our private placement of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.2</font> million of convertible notes in July and August 2015, the Company was obligated to issue to the placement agents&#8217; warrants for an amount of shares equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8</font>% of the number of shares of our common stock issued upon conversion of the notes and any accrued interest. The placement agents warrants have a term of five years from the date of issuance of the related notes in July and August 2015, an exercise price equal to 100% of the price per share at which equity securities were sold in our next equity financing, and provide for cashless exercise.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with the conversions of the notes in February 2016 and May 2016, which were triggered by an equity financing in January 2016 and our public offering of common stock and warrants in May 2016, respectively, we issued warrants to the placement agents to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,115</font> shares of our common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">156.00</font> per share, and an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,129</font> shares of our common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">96.00</font> per share. These warrants have a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">87,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font>, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Also in connection with the conversion of the notes in May 2016, the noteholders that converted also received <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,279</font> warrants (see Note 9). These warrants have a term of five years with an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">120.00</font> per share. These warrants are accounted for under equity treatment and have a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">480,000</font>.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with our May 2016 public offering, we issued warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,474</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">120.00</font> and a term of five years to the underwriters of the public offering. These warrants are accounted for under liability accounting and are fair valued at each reporting period (see Note 6).</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Also in connection with our May 2016 public offering, we issued to investors warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 86,667</font> shares of common stock, which includes the over-allotment warrants, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">120.00</font> with a term of five years. These warrants are accounted for under equity treatment (see Note 10).</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Included in the warrant balance at June 30, 2016 are warrants to purchase of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,474</font> shares of common stock issued to the underwriters of our May registered offering. These warrants were accounted for under liability accounting and were fair valued at each reporting period (see Note 7). On February 28, 2017, these warrants had a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">63,000</font>. Upon the amendment to these warrant agreements, in connection with the closing of our warrant tender offer, this value was reclassified from liability accounting to equity after we removed any provision in the amendment that could cause this to be paid in cash.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Included in the warrant balance at June 30, 2016 are warrants to purchase of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 429</font> shares of common stock issued to the bankers that assisted us with our Notes (see Note 9). In March 2017, the Company reduced the exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">156.00</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.00</font>. This modification resulted in an expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,500</font> which was recognized during the quarter ended March 31, 2017 in sales, general and administrative.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During fiscal 2017, Aytu issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,402</font> shares of common stock to initial investors of the Company at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80.00</font> and a term of five years from July 2016. These warrants generated a non-cash expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">596,000</font> for the year ended June 30, 2017, which is included in sales, general and administrative expense. These warrants are accounted for under equity treatment.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with our November 2016 public offering, we issued to the underwriters of the public offering warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,077</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37.20</font> and a term of five years. These warrants are accounted for under equity treatment. In February, we reduced the exercise price of these warrants to $15.00.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Also in connection with our November 2016 public offering, we issued to investors warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 301,014</font> shares of common stock, which includes the over-allotment warrants, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37.20</font> with a term of five years. These warrants are accounted for under equity treatment (see Note 10).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2017, the Company consummated its warrant tender offer to exercise, at a temporarily reduced exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.00</font> per share, (i) outstanding warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 86,667</font> shares of common stock with an exercise price of $120.00 per share, which were originally issued to investors in the Company&#8217;s May 2016 financing (the &#8220;May 2016 Warrants&#8221;), and (ii) outstanding warrants to purchase 301,014 shares of common stock with an exercise price of $37.20 per share, which were originally issued to investors in the Company&#8217;s October 2016 financing (the &#8220;October 2016 Warrants&#8221; and together with the May 2016 Warrants, the &#8220;Original Warrants&#8221;). Original Warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 149,552</font> shares of common stock were tendered and exercised in the warrant tender offer, for aggregate gross proceeds to the Company of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.2</font> million. Original warrants that were not exercised remain in effect at the pre-tender offer exercise prices of $120.00 per share and $37.20 per share, respectively. The incremental fair value, which had no book impact, was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">178,000</font>.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company also reduced the exercise prices of an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25,541</font> warrants to purchase shares of common stock, which were originally issued as underwriters&#8217; compensation in the May 2016 and October 2016 financings, from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">120.00</font> per share and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37.20</font> per share, respectively, to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.00</font> per share. The amended warrants related to the May 2016 financing adjusted the accounting for these warrants from liability classification to equity. The incremental fair value of these warrant modifications, which had no book impact, was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">23,000</font>.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">All warrants were valued using the Black-Scholes option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the selling price or fair market value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and expected life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. During fiscal 2017, Aytu modified <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 175,522</font> warrants. We used the value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.20</font> per the valuation of our common stock issued in March 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Significant assumptions in valuing the warrants issued and modified during the year ended June 30, 2017 were as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="30%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>156.64% - 169.22%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>75%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1.63% - 1.87%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1.07 - 1.76%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Contractual term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>3.46 - 4.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>4.2 - 5.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823041200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 11 &#150; Related Party Transactions</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Services Agreement</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In July 2015, Aytu entered into an agreement with Ampio, whereby Aytu agreed to pay Ampio a set amount per month for shared overhead, which includes costs related to the shared corporate staff and other miscellaneous overhead expenses. This agreement was amended in November 2015, April 2016, July 2016, and again in January 2017 resulting in an amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,000</font> per month. This agreement was terminated in June 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Sponsored Research Agreement</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio&#8217;s director and Chief Scientific Officer, Dr.&#160;Bar-Or. The agreement, which was amended in January 2015 and provided for Luoxis (now Aytu) to pay $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,000</font> per month to TRLLC in consideration for services related to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">615,000</font> which was being amortized over the contractual term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60.5</font> months and was divided between current and long-term on the balance sheet; as of September 2014, this amount had been paid in full. This agreement was terminated in March 2017.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832299856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 12 &#150; Segment Information</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"> Aytu manages our Company and aggregated our operational and financial information in accordance with two reportable segments: Aytu and Aytu Women&#8217;s Health. The Aytu segment consists of our core male urology products.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> The Aytu Women&#8217;s Health segment contains our women&#8217;s health platform which consists of sexual wellness platform. Select financial information for these segments is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Revenue:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>3,175,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>2,562,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu Women's Health</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>47,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Consolidated revenue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>3,222,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>2,562,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Consolidated net loss:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>(22,349,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>(28,180,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu Women's Health</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>(159,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Consolidated net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>(22,508,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>(28,180,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>11,779,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>24,343,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu Women's Health</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>3,220,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>14,999,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>24,343,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770701296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Compensation and Employee Benefit Plans [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></b> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></b> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 13 &#150; Employee Benefit Plan</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu has a 401(k) plan that allows participants to contribute a portion of their salary, subject to eligibility requirements and annual IRS limits. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company matches 50% of the first 6% contributed to the plan by employees.</font> In fiscal 2017, the Company&#8217;s match was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">99,000</font>.</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823082352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Note 14 &#150; Subsequent Events</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>In July 2017, our stockholders approved an amendment to our 2015 Stock Option and Incentive Plan to (i) increase the number of authorized shares of common stock reserved for issuance thereunder from 2.0 million to 3.0 million, (ii) increase the number of shares that may be issued as incentive stock options from 2.0 million to 3.0 million, (iii) increase the maximum number of shares of common stock (A) underlying stock options or stock appreciation rights that may be granted to any one individual during any calendar year period, and (B) granted to any one individual that is intended to qualify as &#8220;performance-based compensation&#8221; under Section 162(m) of the Internal Revenue Code of 1986, as amended, for any performance cycle from 1.0 million to 2.0 million, and (iv) in the event that we effect a reverse stock split prior to November 14, 2018 (or such other date that is one year after the date of our 2018 annual meeting of stockholders), immediately after the effective time of such reverse stock split, (A) the maximum number of shares reserved under the Plan will be automatically increased to 3.0 million, (B) the maximum number of shares that may be issued pursuant to any type of award will be automatically increased to 3.0 million, (C) the number of shares that may be granted to any one individual during any one calendar year period as stock options or stock appreciation rights will be automatically increased to 2.0 million, and (D) the number of shares that may be issued in the form of incentive stock options will be automatically increased to 3.0 million.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In July 2017, our stockholders also approved an amendment to our Certificate of Incorporation to effect a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">reverse stock split at a ratio of any whole number up to 1-for-20</font>, as determined by our board of directors, at any time before November 14, 2018 (or such other date that is one year after the date of our 2018 annual meeting of stockholders), if and as determined by our board of directors.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">August 11, 2017, our board of directors approved a reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding, which was effected on August 25, 2017. This adjustment is reflected in this Annual Report.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On August 11, 2017, we entered into a Securities Purchase Agreement with various investors pursuant to which we agreed to sell Class A and Class B equity units for gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11.8</font> million. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares of common stock and were sold at a negotiated price of $3.00 per unit.</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Class B units consist of one (1) share of our newly created Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;) and warrants to purchase one and one-half (1.5) shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at a negotiated price of $1,000.00 per unit to those purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding common stock following the offering.</font> These Series A Preferred Shares concert into common shares at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.00</font> per share, which when fully exercised will increase the common shares outstanding by <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 750,000</font> shares. The offering closed on August 15, 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In the offering, we issued an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,196,665</font> shares of our common stock, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,250</font> shares of Series A Preferred Stock and warrants to purchase up to an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,919,998</font> shares of our common stock.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px"> We incurred certain expenses related to this transaction to attorneys and underwriters inclusive of a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9</font>% cash fee and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the aggregate number of shares issued in the transaction.</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In connection with the closing of the financing, we terminated the Purchase Agreement, dated as of July 27, 2016, by and between us and Lincoln Park Capital Fund, LLC. The termination was effective on August 16, 2017.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828430688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Principals of Consolidation</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">These consolidated financial statements include the accounts of Aytu and its wholly-owned subsidiary, Aytu Women&#8217;s Health. All material intercompany transactions and balances have been eliminated.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Cash, Cash Equivalents and Restricted Cash</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Restricted cash consist primarily of a&#160;certificate of deposit investment account. Aytu&#8217;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year, Aytu has maintained balances in excess of federally insured limits.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Revenue Recognition</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">License Agreements and Royalties</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Payments received upon signing of license agreements are for the right to use the license and are deferred and amortized over the lesser of the license term or patent life of the licensed drug. Milestone payments relate to obtaining regulatory approval, cumulative sales targets, and other projected milestones and are recognized at the time the milestones are achieved. Royalties will be recognized as revenue when earned.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Product&#160;&amp; Service Sales</font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company recognizes revenue only when all of the following criteria have been met:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 0.7in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Persuasive evidence of an arrangement exists,</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="DISPLAY: none; FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Delivery has occurred or services have been performed,</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The fee for the arrangement is fixed or determinable, and</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="DISPLAY: none; FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.2in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="19"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Collectability is reasonably assured.</font></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Persuasive evidence of an arrangement exists - The Company documents all terms of an arrangement in a written contract by the customer prior to recognizing revenue.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Delivery has occurred or services have been performed - The Company delivers all products prior to recognizing revenue. Equipment is considered delivered upon delivery to a customer's designated location.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Device sales are recorded when products are shipped to customers. Drug sales are recorded when the product arrives at the customer&#8217;s dock. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related</font> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">sales are recorded and are estimated at the time of sale.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">The fee for the arrangement is fixed or determinable - Prior to recognizing revenue, a customer's fee is either fixed or determinable under the terms of the written contract.</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Collectability is reasonably assured - The Company determines that collectability is reasonably assured prior to recognizing revenue. Collectability is assessed on a customer-by-customer basis based on criteria outlined by management. New customers are subject to a credit review process, which evaluates the customer's financial position and ultimately its ability to pay. The Company does not enter into arrangements unless collectability is reasonably assured at the outset. Existing customers are subject to ongoing credit evaluations based on payment history and other factors. If it is determined during the arrangement that collectability is not reasonably assured, revenue is recognized on a cash basis.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock', window );">Estimated Sales Returns And Allowances [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Estimated Sales Returns and Allowances</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu records estimated reductions in revenue for potential returns of products by customers. As a result, management must make estimates of potential future product returns and other allowances related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different estimates, material differences in the amount of the Company&#8217;s reported revenue could result. As of June 30, 2017 and 2016, we accrued $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">58,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">284,000</font>, respectively, in our estimated returns allowance.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling Cost, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Shipping and Handling</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company's shipping and handling costs are included in cost of goods sold for all periods presented.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Accounts Receivable</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Accounts receivable are recorded at their net realized value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation allowance accordingly. As of June 30, 2017 we had an allowance for doubtful accounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">44,000</font>, and as of June 30, 2016, there had been an allowance for doubtful accounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41,000</font>.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Concentration of Business Risks</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following counterparties contributed greater than&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font></font>%&#160;of the Company's total revenue during the year ended June 30, 2017 and 2016, respectively. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The revenue from these counterparties as a percentage of total revenue was as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The loss of one or more of the Company's significant partners or collaborators could have a material adverse effect on its business, operating results or financial condition. Although the Company is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management does not believe significant credit risk exists as of&#160;June&#160;30, 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">We are also subject to credit risk from our accounts receivable related to our product sales. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of June 30, 2017, three customers accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60</font>% of gross accounts receivable. As of June 30, 2016, one customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 69</font>% of gross accounts receivable.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Inventories</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Inventories consist of raw materials, work in process and finished goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Aytu periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable value in the period that the impairment is first recognized. We currently have a reserve of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">311,000</font> for slow moving inventory as of June 30, 2017 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">199,000</font> at June 30, 2016.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Inventory consist of the following:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>442,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>77,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Work in process</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>442,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>738,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>647,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="48%"> <div>Reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>(310,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>(199,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,312,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>525,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTradingSecuritiesPolicy', window );">Marketable Securities, Trading Securities, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Trading Securities</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"> Trading securities are carried at fair value with realized and unrealized gains and losses recorded in earnings.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Fixed Assets</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Fixed assets are recorded at cost. After being placed in service, the fixed assets are depreciated using the straight-line method over estimated useful lives. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fixed assets consist of the following:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">Estimated</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div style="CLEAR:both;CLEAR: both">June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both"> Useful&#160;Lives&#160;in&#160;years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Office equipment, furniture and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2 - 5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">405,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">201,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Lab equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3 - 5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">111,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">90,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">287,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">45,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Manufacturing equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2 - 5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">90,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">7,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Less accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">(246,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">(112,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Fixed assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">647,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">231,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu recorded the following depreciation expense in the respective periods:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Depreciation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">134,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">51,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Patents</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent third party appraisal, was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font>. The Zertane patents were acquired in connection with the 2011 acquisition of DMI BioSciences by Ampio, the former parent company of Aytu, and were being amortized over the remaining U.S. patent lives of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11</font> years, which were to expire in March 2022. In fiscal 2016, we redirected our resources towards our commercial-stage products and the Company determined that this asset had no further value as the Company did not have the resources to complete the necessary clinical trials and bring it to market before the patents expired. The remaining fair value of the Zertane patents were expensed as of June 30, 2016.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The cost of the Luoxis patents were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">380,000</font> when they were acquired in connection with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> years, which expires in March 2028. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Patents consist of the following:</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>880,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>880,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(609,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(583,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patents, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>271,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>297,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Aytu recorded the following amortization expense in the respective periods:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Amortization expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>26,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>332,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Future amortization from the year ended June 30, 2017 is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>146,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>271,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Business Combinations</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company accounts for its business acquisitions under the acquisition method of accounting as indicated in the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 805, &#8220;Business Combinations&#8221;, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Goodwill</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Nuelle, ProstaScint and Primsol&#160;purchase price allocations&#160;were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May&#160;20, 2015, Primsol that occurred on October 5, 2015 and Nuelle that occurred on May 5, 2017. There was an impairment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">74,000</font> related to the ProstaScint goodwill for the year ended June 30, 2017.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets, collectability of accounts receivable, and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Income Taxes</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu has been included in the consolidated tax returns of Ampio, the former parent company of Aytu, for tax years ended on or before December 31, 2015. As of January 2016, due to the decrease in Ampio&#8217;s ownership percentage of Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu's taxes were computed and reported on a "separate return" basis for these financial statements. Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The amount of income taxes and related income tax positions taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company's policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB ASC 740-1 "Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109" (ASC 740-10) and tax position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant tax position requires recognition under ASC 740-10.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Compensation Related Costs, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock-Based Compensation</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu accounts for share based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the graded method.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Research and Development</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Research and development costs are expensed as incurred with expenses recorded in the respective period.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Income (Loss) Per Common Share</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. <font style="BACKGROUND: transparent">Diluted net loss per share reflects the potential of securities that could share in the net loss of Aytu. Basic and diluted loss per share was the same in 2017 and 2016. Although there were common stock equivalents of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 367,312</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 126,239</font> shares outstanding at June 30, 2017 and 2016, respectively, consisting of stock options and warrants; they were not included in the calculation of the diluted net loss per share because they would have been anti-dilutive.</font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Fair Value of Financial Instruments</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable securities is based on quoted market prices, if available, or estimated discounted future cash&#160;flows.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Derivative Liability</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu accounts for liability warrants by recording the fair value of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial instruments and related warrants were calculated using a Monte Carlo based valuation model. We recorded a derivative expense at the inception of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods was recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income or expense for the warrants.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"> The fair value of the warrants issued to the placement agents in connection with the registered offering were valued using the Black-Scholes valuation methodology. Changes in the fair value in subsequent periods were recorded to derivative income or expense.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Adoption of Newly Issued Accounting Pronouncements</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In November 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-18, "Statement of Cash Flows: Restricted Cash."&#160; The amendments address diversity in practice that exists in the classification and presentation of changes in restricted cash on the statement of cash flows.&#160; ASU 2016-18 is effective for the fiscal year commencing after December 15, 2017. During fiscal 2017, the Company early adopted this pronouncement, the impact of which was minimal, which is now shown on the statements of cash flows within cash and cash equivalents.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In August 2016, the FASB issued ASU 2016-15 &#8220;Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments,&#8221; which provides guidance on the presentation of certain cash receipts and cash payments in the statement of cash flows in order to reduce diversity in existing practice. ASU 2016-15 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted. During fiscal 2017, the Company early adopted this standard. The primary cash flow categorization that will impact the Company will be contingent consideration payments, however, no such payments have been made to date.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09, &#8220;Compensation &#150;Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting.&#8221; The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The amendments are expected to impact net income, earnings per share, and the statement of cash flows. Implementation and administration may present challenges to companies with significant share based payment activities. The amendments are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. The Company adopted this standard during fiscal, 2017. Aytu has elected to account for forfeitures as they occur, rather than estimate expected forfeitures. Prior to adopting this standard, the Company had not estimated any forfeitures, therefore, no adjustments were necessary. Aytu is also operating at a net operating loss, therefore, there was no tax implication.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In July&#160;2015, the FASB issued ASU 2015-11,&#160;&#8220;Simplifying the Measurement of Inventory.&#8221;&#160; ASU&#160;2015-11 clarifies that inventory should be held at the lower of cost or net realizable value.&#160; Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory.&#160; ASU 2015-11 was effective for fiscal years and interim periods beginning after December&#160;15, 2016. &#160;ASU 2015-11 is required to be applied prospectively.&#160; <font style="COLOR: #333333">The</font> amendments in ASU 2015-11 were adopted by the Company during fiscal 2017. The adoption of this standard did not have an impact on the Company&#8217;s financial position or results of operations<font style="COLOR: #333333">.</font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In August 2014, the FASB issued ASU 2014-15, &#8220;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern&#8221; (&#8220;ASU 2014-15&#8221;). ASU 2014-15 is intended to define management&#8217;s responsibility to evaluate whether there is substantial doubt about an organization&#8217;s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016. The Company adopted this standard during fiscal 2017 and has included the required disclosure in the Company&#8217;s financial statements (Note 3).</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Recently Issued Accounting Pronouncements, Not Adopted as of June 30, 2017</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2017, the FASB issued ASU No. 2017-09,&#160;&#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&#160;(ASU 2017-09).&#8221; ASU 2017-09 clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact of its adoption of this standard on its financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In January 2017, the FASB issued ASU 2017-04, &#8220;Intangibles - Goodwill and Other (Topic 350).&#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe that adoption of this amendment will have a material impact on its financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In January 2017, the FASB issued ASU 2017-01, &#8220;Business Combinations (Topic 805) Clarifying the Definition of a Business.&#8221; The amendment clarifies the definition of a business, which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively for public business entities for interim and annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The Company does not expect an immediate impact on its financial statements from this codification however, if Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business combination or an asset purchase.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases (Topic 842).&#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its adoption of this standard on its financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In January 2016, the FASB issued ASU No. 2016-01, <i>Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities</i> <i>(Topic 825)</i>. ASU No. 2016-01 revises the classification and measurement of investments in certain equity investments and the presentation of certain fair value changes for certain financial liabilities measured at fair value. ASU No. 2016-01 requires the change in fair value of many equity investments to be recognized in net income. ASU No. 2016-01 is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. &#160;Adopting ASU No. 2016-01 may result in a cumulative effect adjustment to the consolidated statement of equity retained earnings as of the beginning of the year of adoption. The Company is currently evaluating the impact of this standard on its financial statements.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2014, the FASB issued ASU 2014-09, Topic 606, Revenue from Contracts with Customers (the "New Revenue Standard"). The amendments in this ASU provide a single model for use in accounting for revenue arising from contracts with customers and supersedes current revenue recognition guidance, including industry-specific revenue guidance. The core principle of the new ASU is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB issued ASU 2015-14 which deferred the effective date of the New Revenue Standard. In 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12 to clarify, among other things, the implementation guidance related to principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract.&#160; The New Revenue Standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted for interim and annual periods beginning after December 5, 2017. The amendments in this update are to be applied on a retrospective basis, either to each prior reporting period presented or by presenting the cumulative effect of applying the update recognized at the date of initial application. The New Revenue Standard will be effective for the Company in fiscal 2019. We will adopt the standard in our third quarter of fiscal 2018 and preliminarily expect to use the modified prospective method. However, we are continuing to evaluate the impact of the standard, and our adoption method is subject to change. We currently do not anticipate these standards to have a material impact on our consolidated financial statements outside of the expanded disclosure requirements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated sales returns and allowances policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EstimatedSalesReturnsAndAllowancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTradingSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that are classified as trading securities. This policy also may describe the entity's accounting treatment for transfers between investment categories and how the fair values of such securities are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTradingSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82851458&amp;loc=d3e221937-122793<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68075638&amp;loc=d3e60635-111653<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68080631&amp;loc=d3e61069-111654<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819187584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Merger and Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Future amortization after the year ended June 30, 2017 is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">798,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">1,518,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The Company&#8217;s allocation on consideration transferred for ProstaScint as of the purchase date May&#160;20, 2015 was as follows: <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Estimated</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Tangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">727,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">1,590,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">74,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Total assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">2,391,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The estimated future amortization of ProstaScint after June 30, 2017 is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 40%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div style="CLEAR:both;CLEAR: both">Total&#160;ProstaScint</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">47,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div style="CLEAR:both;CLEAR: both">2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">14,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div style="CLEAR:both;CLEAR: both">2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div style="CLEAR:both;CLEAR: both">2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div style="CLEAR:both;CLEAR: both">2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div style="CLEAR:both;CLEAR: both">Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="28%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">61,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The Company&#8217;s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 was as follows: <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Tangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">182,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">1,470,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">147,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Total assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">1,799,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font>&#160;</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company&#8217;s allocation on consideration transferred for Nuelle as of the purchase date May&#160;5, 2017 is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Tangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">2,061,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">1,540,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Goodwill</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">238,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Total assets acquired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div style="CLEAR:both;CLEAR: both">3,839,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The estimated future amortization of Natesto after June 30, 2017 is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">1,319,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">1,319,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">1,319,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">1,319,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">1,319,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">2,636,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">9,231,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessDescriptionAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823432912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The revenue from these counterparties as a percentage of total revenue was as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif ">&#160;</div><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Inventory consist of the following:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>442,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>77,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Work in process</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>442,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>738,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>647,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="48%"> <div>Reserve</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>(310,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>(199,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,312,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>525,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Fixed assets consist of the following:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">Estimated</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div style="CLEAR:both;CLEAR: both">June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both"> Useful&#160;Lives&#160;in&#160;years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Office equipment, furniture and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2 - 5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">405,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">201,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Lab equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3 - 5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">111,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">90,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">287,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">45,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Manufacturing equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">2 - 5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">90,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">7,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Less accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">(246,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">(112,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div style="CLEAR:both;CLEAR: both">Fixed assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">647,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">231,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu recorded the following depreciation expense in the respective periods:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.25in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="25%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div style="CLEAR:both;CLEAR: both">Depreciation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">134,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">51,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Patents consist of the following:</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">&#160;</font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patents</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>880,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>880,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Less accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(609,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(583,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Patents, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>271,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>297,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Finite-lived Intangible Assets Amortization Expense [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Aytu recorded the following amortization expense in the respective periods:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Amortization expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>26,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>332,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Future amortization after the year ended June 30, 2017 is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">144,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">798,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">1,518,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Future amortization from the year ended June 30, 2017 is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>146,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>271,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6327-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823009920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock', window );">Financial Assets And Liabilities Not Measured At Fair Value On Recurring Basis [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table presents Aytu&#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2017 and 2016, by level within the fair value hierarchy:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="47%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> Fair&#160;Value&#160;Measurements&#160;Using</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level&#160;3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="51%"> <div style="CLEAR:both;CLEAR: both">June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">ASSETS</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Investment in Acerus</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">LIABILITIES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrant derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,648,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,648,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="51%"> <div style="CLEAR:both;CLEAR: both">June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">ASSETS</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Investment in Acerus</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,041,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,041,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">LIABILITIES</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Warrant derivative liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">276,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">276,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div style="CLEAR:both;CLEAR: both">Contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,869,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">3,869,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock', window );">Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Significant assumptions in valuing the warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants, were as follows as of February 28, 2017, the date when the derivative instruments converted into equity, and at June 30, 2016:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> February&#160;28,&#160;2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both">June&#160;30,&#160;2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; TEXT-DECORATION: underline" width="62%"> <div style="CLEAR:both;CLEAR: both">Warrants:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">160.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">75.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Equivalent term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">4.18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">4.84</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">1.87</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">0.99</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="62%"> <div style="CLEAR:both;CLEAR: both">Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Derivative&#160;Instruments</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">Balance as of June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">276,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">Warrant issuances</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">Change in fair value included in earnings (February 28, 2017)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">(213,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">Reclassification of warrant from liability to equity upon amendment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">(63,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="73%"> <div style="CLEAR:both;CLEAR: both">Balance as of June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets and liabilities not measured at fair value on recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FinancialAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823049408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table reflects the reconciliation for the respective periods.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%" colspan="11"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="2%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Benefit at statutory rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(7,653,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(34.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(9,581,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(34.00)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>State income taxes, net of federal benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(681,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3.02)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(853,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3.03)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Stock based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>116,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.51</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Interest on convertible debt</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>75,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div>Offering costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>203,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div>Contingent consideration</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>4,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="50%"> <div>Change in tax rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(11,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(0.05)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,922,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>35.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,672,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>30.77</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Reduction of net operating losses upon deconsolidation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,674,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.45</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="50%"> <div>Net income tax provision (benefit)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The approximate tax effects of significant temporary differences which comprise the deferred tax assets and liabilities are as follows for the respective periods:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Deferred tax assets (liabilities):</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Deferred revenue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Deferred rent</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>3,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>5,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Accrued expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>127,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>445,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Net operating loss carry forward</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>15,435,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>9,202,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Intangibles</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,559,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>606,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Share-based coompensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>1,362,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>327,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Fixed assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>191,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Unrealized loss on investment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>360,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"> <div>Capital loss carry forward</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>385,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"> <div>Contribution carry forward</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>41,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrant liability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>75,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>153,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Inventory</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>174,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>192,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Allowance for doubtful accounts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>17,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>15,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total deferred income tax assets (liabilities)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>19,369,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>11,305,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Less: Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(19,369,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(11,305,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total deferred income tax assets (liabilities)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823137264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock', window );">Commitments And Contingencies Disclosure [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Commitments and contingencies are described below and summarized by the following table as of June&#160;30, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2018</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2019</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2020</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2021</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2022</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Prescription database</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,342,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>769,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>573,000</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Natesto</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,500,000</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Manufacturing/commercial supply agreements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>Office lease</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>175,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>145,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>30,000</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>16,517,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>914,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>603,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,500,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRentExpenseTableTextBlock', window );">Schedule of Rent Expense [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Rent expense for the respective periods is as follows:</div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="7%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="47%"> <div>Rent expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>139,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>120,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies Disclosure Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommitmentsAndContingenciesDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals.  Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823152384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The assumptions used for the year ended June 30, 2017 are as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 65%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="27%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>178% - 185%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>75%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0.97% - 1.88%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>1.16% - 1.90%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5.0 -6.5</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>3.75 - 6.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0%</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock option activity is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Weighted<br/> Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Remaining<br/> Contractual&#160;Life&#160;in</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Outstanding June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>16,340</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>360.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Forfeited/Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(209)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>362.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Outstanding June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>16,131</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>360.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>9.33</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>23,608</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>18.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(1,408)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>83.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Cancelled</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>(68)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>64.60</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Outstanding June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>38,263</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>16.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>8.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Exercisable at June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="8%"> <div>19,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>16.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>7.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="52%"> <div>Available for grant at June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="8%"> <div>61,737</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table details the options outstanding at June 30, 2017 by range of exercise prices:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="WIDTH: 86%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Weighted Average Remaining Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div>Range&#160;of&#160;Exercise&#160;Prices</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of Options Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted Average Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="16%" colspan="2"> <div>Life of Options Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Number of Options Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div>Weighted Average Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div>14.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>1,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>9.85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>14.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>16.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>36,763</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>16.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>8.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>19,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>16.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>38,263</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>16.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>8.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>19,341</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>16.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table summarizes stock-based compensation expense for the years ended June&#160;30, 2017 and 2016:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>Research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>89,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>Selling, general and administrative expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>2,502,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>814,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>2,502,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>903,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Unrecognized expense at June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>775,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Weighted average remaining years to vest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>1.81</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">A summary of all warrants is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted&#160;Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining&#160;Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise&#160;Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Life&#160;in&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding June 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>444</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,087.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agents for convertible promissory notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>156.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to investors in connection with the registered offering</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>86,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>120.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agents for convertible promissory notes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>96.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agents for the registered offering</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,474</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>120.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to convertible note holders who converted May 5, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>120.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding June 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>110,108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>124.02</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Issuance of settlement warrants to initial investors</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,402</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>80.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to investors in connection with the registered offering</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>301,014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants issued to placement agents for the registered offering</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,077</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Warrants exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(149,552)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Outstanding June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>286,049</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50.29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.23</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Significant assumptions in valuing the warrants issued and modified during the year ended June 30, 2017 were as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="30%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>156.64% - 169.22%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div>75%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1.63% - 1.87%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>1.07 - 1.76%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Contractual term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>3.46 - 4.67</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>4.2 - 5.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div>0%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment award, warrants, valuation assumptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ScheduleOfSharebasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823144560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman', serif; BACKGROUND: transparent; FONT-SIZE: 10pt"> The Aytu Women&#8217;s Health segment contains our women&#8217;s health platform which consists of sexual wellness platform. Select financial information for these segments is as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="5"> <div>Year&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Revenue:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>3,175,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>2,562,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu Women's Health</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>47,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Consolidated revenue</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>3,222,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>2,562,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Consolidated net loss:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>(22,349,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>(28,180,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu Women's Health</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>(159,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Consolidated net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>(22,508,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>(28,180,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>11,779,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>24,343,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Aytu Women's Health</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>3,220,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>14,999,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div>24,343,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8813-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842681760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business, Basis of Presentation, Merger and Business Combinations (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>May 05, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Oct. 05, 2015</div></th>
<th class="th"><div>May 31, 2015</div></th>
<th class="th"><div>May 20, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 238,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 727,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,590,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 2,391,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,061,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed tangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828168560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business, Basis of Presentation, Merger and Business Combinations (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 271,278<span></span>
</td>
<td class="nump">$ 296,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2018</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2019</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2018</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2019</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2020</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2021</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2022</a></td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">1,518,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2018</a></td>
<td class="nump">1,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2019</a></td>
<td class="nump">1,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2020</a></td>
<td class="nump">1,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2021</a></td>
<td class="nump">1,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2022</a></td>
<td class="nump">1,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,636,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 9,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6856532448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Merger and Business Combinations (Details Textual)<br> CAD / shares in Units, $ / shares in Units, CAD in Millions</strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 05, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 28, 2016 </div>
<div>CAD </div>
<div>CAD / shares</div>
</th>
<th class="th">
<div>Oct. 05, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 20, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding; On August 25, 2017, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding (herein referred to collectively as the Reverse Stock Splits). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Business Combination, Contingent Consideration, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,386,782<span></span>
</td>
<td class="nump">$ 3,869,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,708,771<span></span>
</td>
<td class="nump">664,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ThirdUpfrontMember', window );">Third Upfront [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business Combination, Consideration Transferred, Liabilities Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=aytu_ProstaScintMember', window );">Prosta Scint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,391,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Business Combination, Contingent Consideration, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationPercentage', window );">Business Combination Contingent Consideration Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationConsiderationTransferredProductInventory', window );">Business Combination Consideration Transferred Product Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,590,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member] | Customer Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember', window );">Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember', window );">Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember', window );">Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Customer Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business Combination, Consideration Transferred, Liabilities Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationConsiderationTransferredInventory', window );">Business Combination Consideration Transferred Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationConsiderationTransferredProductInventory', window );">Business Combination Consideration Transferred Product Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory', window );">Business Combination Consideration Transferred Work In Process Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (Loss) on Disposition of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member] | Customer Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member] | Paid on April 1, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business Combination, Consideration Transferred, Liabilities Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member] | No Later Than July 01, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business Combination, Consideration Transferred, Liabilities Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member] | No Later Than September 30, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business Combination, Consideration Transferred, Liabilities Incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,245,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned | CAD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business Acquisition, Share Price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 0.207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228,000<span></span>
</td>
<td class="nump">228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | License And Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CostOfSaleForInvestment', window );">Cost Of Sale For Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Proceeds from Sale of Available-for-sale Securities, Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss', window );">Available-for-sale Securities, Gross Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="nump">972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | First Milestone [Member] | License And Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | Second Milestone [Member] | License And Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | Third Milestone [Member] | License And Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | Forth Milestone [Member] | License And Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | Fifth Milestone [Member] | License And Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | Second Upfront [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Business Combination, Contingent Consideration, Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High</a></td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales', window );">Revenue Earn-Out Payments Equal to Designated Percentage of Net Sales</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities Assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | First Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | Second Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | Third Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | Forth Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="nump">37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | Fifth Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | Sixth Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonrefundablePayments', window );">One Time Non-Refundable Payments</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales Revenue Target</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member] | Customer Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationConsiderationTransferredInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of business combination consideration transferred to inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationConsiderationTransferredInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationConsiderationTransferredProductInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of business combination consideration transferred to primsol related product inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationConsiderationTransferredProductInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of business combination consideration transferred to work in process inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationConsiderationTransferredWorkInProcessInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CostOfSaleForInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cost of sale of investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CostOfSaleForInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OneTimeNonrefundablePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the one time non-refundable payments based on sales revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OneTimeNonrefundablePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the revenue earnout payments based on sales revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RevenueEarnoutPaymentsEqualToDesignatedPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SalesRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount sales revenue target for non-refundable payment criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SalesRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss before deducting unrealized gain on investments in available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) from sale or disposal of an organization or integrated set of activities (for example, but not limited to, a partnership or corporation) engaged in providing a product or service in a commercial, industrial, or professional environment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ThirdUpfrontMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ThirdUpfrontMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=aytu_ProstaScintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=aytu_ProstaScintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=aytu_PaidOnApril12016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=aytu_PaidOnApril12016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=aytu_NoLaterThanJuly012016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=aytu_NoLaterThanJuly012016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=aytu_NoLaterThanSeptember302016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=aytu_NoLaterThanSeptember302016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=aytu_LicenseAndSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=aytu_LicenseAndSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_FirstMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_FirstMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_SecondMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_SecondMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_ThirdMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_ThirdMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_ForthMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_ForthMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_FifthMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_FifthMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_SecondUpfrontMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_SecondUpfrontMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_SixthMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_SixthMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818679392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerOneMember', window );">Customer A [Member] | Sales Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerOneMember', window );">Customer A [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerTwoMember', window );">Customer B [Member] | Sales Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerTwoMember', window );">Customer B [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerThreeMember', window );">Customer C [Member] | Sales Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerThreeMember', window );">Customer C [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerFourMember', window );">Customer D [Member] | Sales Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerFourMember', window );">Customer D [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813924880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 442,000<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">442,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">738,000<span></span>
</td>
<td class="nump">647,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve</a></td>
<td class="num">(310,000)<span></span>
</td>
<td class="num">(199,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">$ 1,312,221<span></span>
</td>
<td class="nump">$ 524,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842708272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">$ (246,000)<span></span>
</td>
<td class="num">$ (112,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">647,254<span></span>
</td>
<td class="nump">231,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment and furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 405,000<span></span>
</td>
<td class="nump">201,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment and furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment and furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 111,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 287,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832210576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 134,000<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841856656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 4) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 271,278<span></span>
</td>
<td class="nump">$ 296,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents</a></td>
<td class="nump">880,000<span></span>
</td>
<td class="nump">880,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated armortization</a></td>
<td class="num">(609,000)<span></span>
</td>
<td class="num">(583,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 271,000<span></span>
</td>
<td class="nump">$ 297,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822989040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 5) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 1,708,771<span></span>
</td>
<td class="nump">$ 664,707<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828468144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 6) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 271,278<span></span>
</td>
<td class="nump">$ 296,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2018</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2019</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2020</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2021</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2022</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 271,000<span></span>
</td>
<td class="nump">$ 297,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829635168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for Doubtful Accounts Receivable</a></td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="nump">74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves</a></td>
<td class="nump">310,000<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 284,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">367,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=aytu_CustomerFourMember', window );">Customer Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ZertanePatentsMember', window );">Zertane Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear', window );">Finite Lived Intangible Assets Expiration Month Year</a></td>
<td class="text">2022-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=aytu_OrpMember', window );">Orp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear', window );">Finite Lived Intangible Assets Expiration Month Year</a></td>
<td class="text">2028-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets expiration month year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FiniteLivedIntangibleAssetsExpirationMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SummaryOfSignificantAccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SummaryOfSignificantAccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=aytu_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=aytu_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=aytu_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ZertanePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=aytu_ZertanePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=aytu_OrpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=aytu_OrpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828876832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,508,304)<span></span>
</td>
<td class="num">$ (28,180,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,829,652)<span></span>
</td>
<td class="num">(10,657,449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,069,729)<span></span>
</td>
<td class="num">(46,561,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">877,542<span></span>
</td>
<td class="nump">8,054,190<span></span>
</td>
<td class="nump">$ 7,353,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 648,933<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828946096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement/Revenue Recognition (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=aytu_VyrixPharmaceuticalsIncMember', window );">Vyrix Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PotentialMilestonePaymentsReceivable', window );">Potential Milestone Payments Receivable</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AgreementExpirationPeriod', window );">Agreement Expiration Period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=aytu_AmpioMember', window );">Ampio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RevenueRecognitionLineItems', window );"><strong>Revenue Recognition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PotentialMilestonePaymentsReceivable', window );">Potential Milestone Payments Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PercentageOfRoyaltyRateOfNetSales', window );">Percentage Of Royalty Rate Of Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AgreementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AgreementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PercentageOfRoyaltyRateOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Royalty Rate Of Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PercentageOfRoyaltyRateOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RevenueRecognitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RevenueRecognitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=aytu_VyrixPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=aytu_VyrixPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=aytu_AmpioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=aytu_AmpioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842532480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Considerations (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in Acerus</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,041,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">275,992<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">7,386,782<span></span>
</td>
<td class="nump">3,869,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in Acerus</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,041,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in Acerus</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in Acerus</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 7,648,000<span></span>
</td>
<td class="nump">$ 3,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82895926&amp;loc=d3e24584-111560<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806980928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Details 1) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">160.70%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Equivalent term (years)</a></td>
<td class="text">4 years 2 months 5 days<span></span>
</td>
<td class="text">4 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.87%<span></span>
</td>
<td class="nump">0.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807318528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Details 2) - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of June 30, 2016</a></td>
<td class="nump">$ 276,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances', window );">Warrant issuances</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value included in earnings (February 28, 2017)</a></td>
<td class="num">(213,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Reclassification of warrant from liability to equity upon amendment</a></td>
<td class="num">(63,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of June 30, 2017</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807357040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, Fair Value Disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,041,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability</a></td>
<td class="nump">7,600,000<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Noncash Merger Related Costs</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring and Related Cost, Incurred Cost</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82895926&amp;loc=d3e24584-111560<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829278576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Benefit at statutory rate,Percentage</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit, Percentage</a></td>
<td class="num">(3.02%)<span></span>
</td>
<td class="num">(3.03%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation, Percentage</a></td>
<td class="nump">0.51%<span></span>
</td>
<td class="nump">0.03%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt', window );">Interest on convertible debt, Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts', window );">Offering costs, Percentage</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration', window );">Contingent consideration, Percentage</a></td>
<td class="nump">0.02%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rate, Percentage</a></td>
<td class="num">(0.05%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, Percentage</a></td>
<td class="nump">35.19%<span></span>
</td>
<td class="nump">30.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Reduction of net operating losses upon deconsolidation, Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">5.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, Percentage</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net income tax provision (benefit), Percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Benefit at statutory rate, Amount</a></td>
<td class="num">$ (7,653,000)<span></span>
</td>
<td class="num">$ (9,581,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit, Amount</a></td>
<td class="num">(681,000)<span></span>
</td>
<td class="num">(853,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation, Amount</a></td>
<td class="nump">116,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt', window );">Interest on convertible debt, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncomeTaxReconciliationOfFeringCosts', window );">Offering costs, Amount</a></td>
<td class="nump">203,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncomeTaxReconciliationContingentConsideration', window );">Contingent consideration, Amount</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rate, Amount</a></td>
<td class="num">(11,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, Amount</a></td>
<td class="nump">7,922,000<span></span>
</td>
<td class="nump">8,672,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Reduction of net operating losses upon deconsolidation, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,674,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, Amount</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net income tax provision (benefit), Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) relating to interest on convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents rate of percentage to effective tax rate reconciliation of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) relating to interest on convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents rate of percentage to effective tax rate reconciliation of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncomeTaxReconciliationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents income tax reconsilation of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncomeTaxReconciliationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncomeTaxReconciliationOfFeringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents income tax reconsilation of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncomeTaxReconciliationOfFeringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842893648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets (liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">127,000<span></span>
</td>
<td class="nump">445,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">15,435,000<span></span>
</td>
<td class="nump">9,202,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">1,559,000<span></span>
</td>
<td class="nump">606,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based coompensation</a></td>
<td class="nump">1,362,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">191,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities', window );">Unrealized loss on investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carry forward</a></td>
<td class="nump">385,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Contribution carry forward</a></td>
<td class="nump">41,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Warrant liability</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">174,000<span></span>
</td>
<td class="nump">192,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses', window );">Allowance for doubtful accounts</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets (liabilities)</a></td>
<td class="nump">19,369,000<span></span>
</td>
<td class="nump">11,305,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(19,369,000)<span></span>
</td>
<td class="num">(11,305,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred income tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31938-109318<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the provision for loan losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829646448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred Tax Assets, Operating Loss Carryforwards</a></td>
<td class="nump">$ 15,435,000<span></span>
</td>
<td class="nump">$ 9,202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="nump">17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_NetOperatingLossesExpirationDescription', window );">Net Operating Losses Expiration Description</a></td>
<td class="text">expire in 2031 through 2036.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=aytu_AmpioPharmaceuticalsMember', window );">Ampio Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred Tax Assets, Operating Loss Carryforwards</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,300,000<span></span>
</td>
<td class="nump">$ 24,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NetOperatingLossesExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents description of operating losses expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NetOperatingLossesExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=aytu_AmpioPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=aytu_AmpioPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841116192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 16,517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2018</a></td>
<td class="nump">914,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2019</a></td>
<td class="nump">603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2020</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2021</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember', window );">Prescription Database [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">1,342,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2018</a></td>
<td class="nump">769,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2019</a></td>
<td class="nump">573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2020</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2021</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_ManufacturingAgreementMember', window );">Manufacturing/commercial supply agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember', window );">Office Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2018</a></td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2019</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_ManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_ManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831757216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesRentExpenseLineItems', window );"><strong>Commitments And Contingencies Rent Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommitmentsAndContingenciesRentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommitmentsAndContingenciesRentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6850949296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FirstMilestonePayable', window );">First Milestone Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SecondMilestonePayable', window );">Second Milestone Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ThirdMilestonePayable', window );">Third Milestone Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember', window );">Natesto [Member] | First Installment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PaymentOfContractualObligations', window );">Payment Of Contractual Obligations</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember', window );">Prescription Database [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,342,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember', window );">Office Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems', window );"><strong>Unrecorded Unconditional Purchase Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OperatingLeasesMonthlyBaseRentInitialYear', window );">Operating Leases Monthly Base Rent Initial Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lessee Leasing Arrangements, Operating Leases, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">37 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FirstMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of first milestone payment which is require to make.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FirstMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLeasesMonthlyBaseRentInitialYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases monthly base rent initial year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLeasesMonthlyBaseRentInitialYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentOfContractualObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment made towards contractual obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentOfContractualObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SecondMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of second milestone payment which is require to make.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SecondMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ThirdMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of third milestone payment which is require to make.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ThirdMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=aytu_FirstInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=aytu_FirstInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829560752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 06, 2016</div></th>
<th class="th"><div>Feb. 10, 2016</div></th>
<th class="th"><div>Feb. 10, 2015</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jan. 20, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized Debt Issuance Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative Liability, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 275,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature', window );">Debt Instrument, Convertible, Terms of Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">At the insistence of the underwriters of the offering, all outstanding noteholders had signed lockup agreements which granted them an extra 10% on the conversion, increasing it to 130% of shares calculated by dividing such Note balance by $96.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt Related Commitment Fees and Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PlacementAgentsCashFeePercentage', window );">Placement Agents Cash Fee Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,325<span></span>
</td>
<td class="nump">$ 620,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsIssuedToPurchaseOfCommonStock', window );">Warrants Issued to Purchase of common stock</a></td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsExercisePricePerShare', window );">Warrants Exercise Price Per share</a></td>
<td class="nump">$ 96.00<span></span>
</td>
<td class="nump">$ 156.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=aytu_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_DebtConversionAccruedInterestAmount', window );">Debt Conversion Accrued Interest Amount</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">15,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Debt Instrument, Convertible, Beneficial Conversion Feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Debt Conversion, Converted Instrument, Warrants or Options Issued</a></td>
<td class="nump">15,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=aytu_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=aytu_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DebtConversionAccruedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the accrued interest on debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DebtConversionAccruedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PlacementAgentsCashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Placement Agents Cash Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PlacementAgentsCashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsIssuedToPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued during the period for the purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsIssuedToPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=aytu_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=aytu_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6854442512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 05, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824,831<span></span>
</td>
<td class="nump">824,831<span></span>
</td>
<td class="nump">187,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 648,933<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,924<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">739,857<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption', window );">Adjustments To Additional Paid In Capital Warrants Issued In Connection With Equity Financing To Placement Agents For Over Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,629<span></span>
</td>
<td class="nump">20,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_UnrecognizedShareBasedCompensationExpenses', window );">Unrecognized Share Based Compensation Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_OverAllotmentWarrantsMember', window );">Over Allotment Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Equity, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock or Unit Option Plan Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember', window );">Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember', window );">Lincoln Park Capital Fund Llc Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockSharesAgreedToPurchase', window );">Common Stock Shares Agreed To Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockValueAgreedToPurchase', window );">Common Stock Value Agreed To Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Equity, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,309<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption', window );">Adjustments To Additional Paid In Capital Warrants Issued In Connection With Equity Financing To Placement Agents For Over Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityRelativeFairValue', window );">Equity Relative Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Equity, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityRelativeFairValue', window );">Equity Relative Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_UnderwritersExercisedOfOverallotmentOption', window );">Underwriters Exercised of Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption', window );">Adjustments To Additional Paid In Capital Warrants Issued In Connection With Equity Financing To Placement Agents For Over Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_May2016WarrantsMember', window );">May 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_October2016WarrantsMember', window );">October 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of adjustment made to the additional paid in capital with regard to issuance of warrants in connection with equity financing to the placement agents for the over-allotment option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockSharesAgreedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock shares agreed to purchase in the purchase agreement entered during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockSharesAgreedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockValueAgreedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of common stock agreed to purchase in the purchase agreement entered during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockValueAgreedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EquityRelativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Relative fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EquityRelativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_UnderwritersExercisedOfOverallotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of underwriters exercised of this over-allotment option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_UnderwritersExercisedOfOverallotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_UnrecognizedShareBasedCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized share based compensation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_UnrecognizedShareBasedCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_OverAllotmentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_OverAllotmentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_May2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_May2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_October2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_October2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830760480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details) - Luoxis Diagnostics [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems', window );"><strong>Assumptions Used To Determine Fair Value Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">1.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="nump">1.88%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems', window );"><strong>Assumptions Used To Determine Fair Value Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">178.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems', window );"><strong>Assumptions Used To Determine Fair Value Options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">185.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AssumptionsUsedToDetermineFairValueOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=aytu_LuoxisDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=aytu_LuoxisDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828944224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 1) - Luoxis Diagnostics [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning Balance</a></td>
<td class="nump">16,131<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">23,608<span></span>
</td>
<td class="nump">16,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited/Cancelled</a></td>
<td class="num">(1,408)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending Balance</a></td>
<td class="nump">38,263<span></span>
</td>
<td class="nump">16,131<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable</a></td>
<td class="nump">19,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant', window );">Available for grant at June 30, 2017</a></td>
<td class="nump">61,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, Cancelled</a></td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 360.2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">18.20<span></span>
</td>
<td class="nump">360.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="nump">83.20<span></span>
</td>
<td class="nump">362.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled | $ / shares</a></td>
<td class="nump">64.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">16.31<span></span>
</td>
<td class="nump">$ 360.2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding (in years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">9 years 3 months 29 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Excercisable (in years)</a></td>
<td class="text">7 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Available For Grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=aytu_LuoxisDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=aytu_LuoxisDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830182176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 2)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">38,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 16.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding (in years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable | shares</a></td>
<td class="nump">19,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 16.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember', window );">Exercise Price Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of Exercise Prices</a></td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding (in years)</a></td>
<td class="text">9 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember', window );">Exercise Price Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of Exercise Prices</a></td>
<td class="nump">$ 16.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">36,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 16.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding (in years)</a></td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable | shares</a></td>
<td class="nump">19,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 16.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828607072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 2,502,000<span></span>
</td>
<td class="nump">$ 903,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_UnrecognizedShareBasedCompensationExpenses', window );">Unrecognized expense at June 30, 2017</a></td>
<td class="nump">$ 775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining years to vest (in years)</a></td>
<td class="text">1 year 9 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 2,502,000<span></span>
</td>
<td class="nump">$ 814,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_UnrecognizedShareBasedCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized share based compensation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_UnrecognizedShareBasedCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839404896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 4) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstanding', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">110,108<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes', window );">Warrants issued to placement agents for convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering', window );">Warrants issued to investors in connection with the registered offering</a></td>
<td class="nump">301,014<span></span>
</td>
<td class="nump">86,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo', window );">Warrants issued to placement agents for convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering', window );">Warrants issued to placement agents for the registered offering</a></td>
<td class="nump">20,077<span></span>
</td>
<td class="nump">5,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders', window );">Warrants issued to convertible note holders who converted May 5, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement', window );">Issuance of settlement warrants to initial investors</a></td>
<td class="nump">4,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsExcercised', window );">Warrants exercised</a></td>
<td class="num">(149,552)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstanding', window );">Number of Warrants Outstanding, Ending Balance</a></td>
<td class="nump">286,049<span></span>
</td>
<td class="nump">110,108<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Warrants, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="nump">$ 124.02<span></span>
</td>
<td class="nump">$ 1,087.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice', window );">Warrants issued to placement agents for convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice', window );">Warrants issued to investors in connection with the registered offering</a></td>
<td class="nump">37.2<span></span>
</td>
<td class="nump">120.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice', window );">Warrants issued to placement agents for convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice', window );">Warrants issued to placement agents for the registered offering</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">120.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice', window );">Warrants issued to convertible note holders who converted May 5, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice', window );">Issuance of settlement warrants to initial investors</a></td>
<td class="nump">80.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice', window );">Warrants exercised</a></td>
<td class="nump">15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending Balance</a></td>
<td class="nump">$ 50.29<span></span>
</td>
<td class="nump">$ 124.02<span></span>
</td>
<td class="nump">$ 1,087.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Life, Warrants Outstanding (in years)</a></td>
<td class="text">4 years 2 months 23 days<span></span>
</td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
<td class="text">4 years 8 months 16 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsExcercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation share warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsExcercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents share based compensation share warrants weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued as part of a settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued as part of a settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon convertible note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon conversion of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon conversion of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon conversion of promissory two notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon conversion of convertible promissory two notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon convertible notes holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon placement agents for registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon placement agents for the registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon the registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon the registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Share Warrants Outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823435248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 5) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="nump">1.63%<span></span>
</td>
<td class="nump">1.07%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="nump">1.87%<span></span>
</td>
<td class="nump">1.76%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">156.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (years)</a></td>
<td class="text">3 years 5 months 16 days<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">169.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (years)</a></td>
<td class="text">4 years 8 months 1 day<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6851240496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes', window );">Share Based Compensation Share Warrants Issued on Convertible Promisory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued on Convertible Promisory Notes, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PlacementAgentsCashFeePercentage', window );">Placement Agents Cash Fee Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo', window );">Share Based Compensation Share Warrants Issued On Convertible Promisory Notes,Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders', window );">Share Based Compensation Share Warrants Issued On Convertible Note Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued On Convertible Note Holders,Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering', window );">Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,077<span></span>
</td>
<td class="nump">5,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued On Convertible Promisory Two Notes,Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering,Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering', window );">Share Based Compensation Share Warrants Issued On Registered Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,014<span></span>
</td>
<td class="nump">86,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued On Registered Offering,Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.2<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockOptionRepricingProgramDescription', window );">Common Stock Option Repricing Program Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Board of Directors approved a common stock option repricing program whereby previously granted and unexercised options held by our then current employees, consultants and directors with exercise prices above $120.00 per share were repriced on a one-for-one basis to $64.60 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,507<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsModified', window );">Warrants Modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,852<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ClassOfWarrantsAndRightsIssuanceCost', window );">Class Of Warrants And Rights Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aytu_ConvertiblePromissoryNotesMay2016Member', window );">Convertible Promissory Notes May 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants Not Settleable in Cash, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders', window );">Share Based Compensation Share Warrants Issued On Convertible Note Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued On Convertible Note Holders,Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_PlacementAgentWarrantsMember', window );">Placement Agent warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes', window );">Share Based Compensation Share Warrants Issued on Convertible Promisory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued on Convertible Promisory Notes, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo', window );">Share Based Compensation Share Warrants Issued On Convertible Promisory Notes,Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants Not Settleable in Cash, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering', window );">Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued On Convertible Promisory Two Notes,Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering,Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors', window );">Share Based Compensation Share Warrants Issued To Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_PlacementAgentWarrantsMember', window );">Placement Agent warrants [Member] | Over Allotment Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors', window );">Share Based Compensation Share Warrants Issued To Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_InvestorsWarrantsMember', window );">Investors Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering', window );">Share Based Compensation Share Warrants Issued On Registered Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice', window );">Share Based Compensation Share Warrants Issued On Registered Offering,Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_BankersWarrantsMember', window );">Bankers Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 156.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_BankersWarrantsMember', window );">Bankers Warrants [Member] | Other Restructuring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">15.00<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_May2016WarrantsMember', window );">May 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_October2016WarrantsMember', window );">October 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 16.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">36,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1,111.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 64.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember', window );">2015 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantsAndRightsIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non cash expenses generated on issue of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantsAndRightsIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockOptionRepricingProgramDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the common stock option repricing program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockOptionRepricingProgramDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PlacementAgentsCashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Placement Agents Cash Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PlacementAgentsCashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon convertible note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon conversion of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon conversion of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon conversion of promissory two notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon conversion of convertible promissory two notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon convertible notes holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon placement agents for registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon placement agents for the registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon the registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon the registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued to investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued to investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants modified during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aytu_ConvertiblePromissoryNotesMay2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aytu_ConvertiblePromissoryNotesMay2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OverAllotmentWarrantsAxis=aytu_OverAllotmentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OverAllotmentWarrantsAxis=aytu_OverAllotmentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_InvestorsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_InvestorsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_BankersWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_BankersWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_May2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_May2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aytu_October2016WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aytu_October2016WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831237472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aytu_AmpioMember', window );">Ampio [Member] | Second Installment [Member] | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet', window );">Property Subject to or Available for Operating Lease, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aytu_AmpioMember', window );">Ampio [Member] | Second Installment [Member] | After Amendment [Member] | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OperatingLeaseMonthlyRentalPayment', window );">Operating Lease Monthly Rental Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aytu_AmpioMember', window );">Ampio [Member] | First Installment [Member] | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PrepaidExpensesAmortizationPeriod', window );">Prepaid Expenses Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aytu_AmpioPharmaceuticalsIncMember', window );">Ampio Pharmaceuticals, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OperatingLeaseMonthlyRentalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Monthly Rental Payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OperatingLeaseMonthlyRentalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PrepaidExpensesAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PrepaidExpensesAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, by major property class, net of accumulated depreciation, subject to or available for lease as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164653&amp;loc=d3e41551-112718<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aytu_AmpioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aytu_AmpioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=aytu_SecondInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=aytu_SecondInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=aytu_AfterAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=aytu_AfterAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=aytu_FirstInstallmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=aytu_FirstInstallmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aytu_AmpioPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aytu_AmpioPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823171840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, Total</a></td>
<td class="nump">$ 3,221,590<span></span>
</td>
<td class="nump">$ 2,562,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="num">(22,508,304)<span></span>
</td>
<td class="num">(28,180,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">14,998,517<span></span>
</td>
<td class="nump">24,343,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember', window );">AYTU Bioscience, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, Total</a></td>
<td class="nump">3,175,000<span></span>
</td>
<td class="nump">2,562,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="num">(22,349,000)<span></span>
</td>
<td class="num">(28,180,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">11,779,000<span></span>
</td>
<td class="nump">24,343,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuWomensHealthMember', window );">Aytu Women's Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues, Total</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="num">(159,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 3,220,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuWomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_AytuWomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842456432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Description of Defined Contribution Pension and Other Postretirement Plans</a></td>
<td class="text">The Company matches 50% of the first 6% contributed to the plan by employees.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 99,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans. Includes, but is not limited to, plan utilized, employee group covered, and employer matching contributions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6852165168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2017</div></th>
<th class="th"><div>May 05, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Aug. 15, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 648,933<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding; On August 25, 2017, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding (herein referred to collectively as the Reverse Stock Splits). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,309<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">5,919,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In July 2017, our stockholders approved an amendment to our 2015 Stock Option and Incentive Plan to (i) increase the number of authorized shares of common stock reserved for issuance thereunder from 2.0 million to 3.0 million, (ii) increase the number of shares that may be issued as incentive stock options from 2.0 million to 3.0 million, (iii) increase the maximum number of shares of common stock (A) underlying stock options or stock appreciation rights that may be granted to any one individual during any calendar year period, and (B) granted to any one individual that is intended to qualify as performance-based compensation under Section 162(m) of the Internal Revenue Code of 1986, as amended, for any performance cycle from 1.0 million to 2.0 million, and (iv) in the event that we effect a reverse stock split prior to November 14, 2018 (or such other date that is one year after the date of our 2018 annual meeting of stockholders), immediately after the effective time of such reverse stock split, (A) the maximum number of shares reserved under the Plan will be automatically increased to 3.0 million, (B) the maximum number of shares that may be issued pursuant to any type of award will be automatically increased to 3.0 million, (C) the number of shares that may be granted to any one individual during any one calendar year period as stock options or stock appreciation rights will be automatically increased to 2.0 million, and (D) the number of shares that may be issued in the form of incentive stock options will be automatically increased to 3.0 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">reverse stock split at a ratio of any whole number up to 1-for-20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock', window );">Incremental Common Shares Due To Conversion Of Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Class A Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of Stock, Description of Transaction</a></td>
<td class="text">Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares of common stock and were sold at a negotiated price of $3.00 per unit.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Class B Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of Stock, Description of Transaction</a></td>
<td class="text">Class B units consist of one (1) share of our newly created Series A Convertible Preferred Stock (the Series A Preferred Stock) and warrants to purchase one and one-half (1.5) shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at a negotiated price of $1,000.00 per unit to those purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding common stock following the offering.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PreferredStockConversionPricePerShare', window );">Preferred Stock Conversion Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SecuritiesPurchaseAgreementCashFeePercentage', window );">Securities Purchase Agreement Cash Fee Percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued', window );">Class Of Warrant Or Right, Percentage Of Shares To be Issued</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">3,196,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The warrants to be issued as a percentage of shares issued in the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncrementalCommonSharesDueToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares by which the common shares outstanding will increase in case of conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncrementalCommonSharesDueToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SecuritiesPurchaseAgreementCashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of cash fee to underwriters incurred in securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SecuritiesPurchaseAgreementCashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4582445-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569655-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of significant modifications (such as a change in expiration dating, vesting rights, or exercise prices) to an equity-based compensation plan, including the terms of the modifications.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_ClassUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_ClassUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_ClassBUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_ClassBUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKC_\+L+.&[NS_]CX+-@V\.LNVB]02P,$%     @ UDH?2YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MH0C[MKNU\;X>6KKAH:TN8[N:W7OFU7]02P,$%     @ UDH?2RA-0:D^!@
MD20  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6R-FF%OVS80AO^*X>^I
MQ2-%D4428+9E;, &%!VV?583)3%J6YZM)-V_GV0KKGGW2F(_U);S\HYWDOC<
M4;I]KP[?CR]E64]^;#>[X]WTI:[WGV>SX\-+N2V.GZI]N6O^\E0=MD7='!Z>
M9\?]H2P>3X.VFQDEB9UMB_5N>G][^NW+X?ZV>JTWZUWYY3 YOFZWQ>&_>;FI
MWN^F:OKQP]?U\TO=_C"[O]T7S^6?9?W7_LNA.9I=K#RNM^7NN*YVDT/Y=#?]
M17U>&=,.."G^7I?OQZOODS:4;U7UO3WX[?%NFK0S*C?E0]V:*)J/MW)1;C:M
MI68>_W9&IQ>?[<#K[Q_65Z?@FV"^%<=R46W^63_6+W=3-YT\ED_%ZZ;^6KW_
M6G8!I=-)%_WOY5NY:>3M3!H?#]7F>/I_\O!ZK*MM9Z69RK;X<?Y<[TZ?[YW]
MCV%X '4#Z#) Z<$!NAN@+P.(!@>8;H"Y#-!V<$#:#4A_#C"# VPWP/Z<DC^=
MCW.R3ME?%G5Q?WNHWB>'\P6T+]KK5'VVS?E]:'\\G<[3WYH3<&Q^?;M727H[
M>VL-=9KY64.!QH::!=)DH6:)-"[4Y$CC0\T*:%1RT<R:>"]!$PR:3@9,8$"Q
MH,^:[*39G36I5=:DQ"*70I:;I51HYWV6.9:@7 IOTN3TCV4 ")733FFC<!XT
MS(,&>>#AG37IE:O4&Y5B-P:Z,<)-Q@*:&^D%!;XP(G"F6$I+3)%'^EH-60JB
M3F'4*4BN9N&DL2XL=&&!"\,R:X4+0HFUHXF-,Y1+&<_KD"((.H-!9R!HMF(M
M,N%"D2/LQ4$O#GAA]_7<22])XA-GV(*U<"*Y;,++7E/L=.92R-,[I @"]S!P
M#P)GZ]3""Q?&72_E@1N58/ DP!&CP;P3!7G1UA'3+3K=T.4;:2H'.I[A04D8
M>P]T%8C=\]@5N.&,YTL(D(G0HRSEXY96@Y(P<DQ>!=!+' :=:& B"R4)**(>
MM9*/2U:#DC!BS%@%($N*AR,IJVS?_80AJR1E%1'/K&2:3\@;4<V-<S;25 YT
M(L?1I%48M0JPEL2-$@U;A6FK &Z)XU9)NAG23:EG^'0D<1U/<8\M*W(\#MU!
M21@]QJX"W"7.727!F[EK6>@)HU<!]A)GKY*8HR3USHLI2?B*2SG25@Z$(L_1
M^%68OPH .!'WL23P#3GEDJ9BX/%+J8A_5)*/2U91<PJ;,UP9$*@,B)4@<P(X
M;SREE/+[GF1MP%F[!-92:XVU*5/F0"F:,RFY,;9I'DW?C4"X3"!0)HC2AR22
ME<L2WT,/ZNF(44O,US:2++3&>2TR+N%,/.$]IA1/]SBA!R5A[)C0A-I@OHP0
M(+375UL3H2?,: *,%C4O1=.0, T)=9Z\NB1)0Y61)=ZZ=+JAY3/25 YTXEQ&
M,YHPHPDQFJ^>!%K9-*'$BZV=\:XXUE8.A"+Z:$839C0A1HN[4S*ZSPOF,R$^
MB^M+<C C8\4."(WWQCVFQ-8AT(D,1].9,)T)T%GSYH0D"=-@IR3<FL,4U(""
M?'F<:\"MQ'O/ZWD]WA]'FLJ!CF=Y4!+&CL&G ?BTV)B4X,NNK_;0$<:>!MCC
M.)MK"9C46Z-YI:7'>])(4SG0B21'8T_W;/ZBQI0C7TOL:9NIU/$.MA,&S.=5
M5I\QOJ6> Z$(?T@2AH]9K%&_S*FO)8O)V<ST8%]C(&O4GO*&1DOT:9,EEC?4
MRUAA#H0BB]&\U9BW&O"67\US#1CIR8IU4X_C-M)4#G0B]FC::DQ;#6BK^;,S
M#;:BFS)78KD3A@^<>/0]Q@0*@5"$'UT&:%P&:% &: $>L+%M_/4='[K"U-6(
MNKPCU)*ZS3WAQ47FQR^R*$LYD(DD#TG")V>X"C"H"N =@P&]L--9*I^>@5:8
M=V8]QHSCUQ@0BB=HT86 P86 084 ;U$,Z( I[:VW#"X%#"@%Q+Z+D="]H<:7
MTPFO!LQX-0"LB6>5XX5 U)S"#.""P(""P(@'M9+SNJD2'7\XM@!")ZXUJ<ET
M8KVQ_-D$4(H\2,E-<]-:GU$/KDW/XVI0&1A>[QA9&3@R3O/G[[.K%S':EW7^
M* [/Z]UQ\JVJZVI[>O/BJ:KJLK&9?&JLO93%X^5@4S[5[=>L^7XXOR1S/JBK
M??<"T.SR%M+]_U!+ P04    " #62A]+O1T.B2P"  !F!@  &    'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;(U5;6^;,!#^*X@?4(-Y"Q5!*IFF3=JDJ-.Z
MSPZY!%0;,]L)W;^?;0BEB;ON2VP?][R<PQW%P,6S; "4]\)H)]=^HU1_CY"L
M&V!$WO$>.OWDP 4C2A_%$<E> -E;$*,(!T&*&&D[ORQL;"O*@I\4;3O8"D^>
M&"/B3P64#VL_]"^!Q_;8*!- 9=&3(_P ];/?"GU",\N^9=#)EG>>@,/:?PCO
M-V%@ #;CJ85!+O:>*67'^;,Y?-VO_< X @JU,A1$+V?8 *6&2?OX/9'ZLZ8!
M+O<7]L^V>%W,CDC8</JKW:MF[:]\;P\'<J+JD0]?8"HH\;VI^F]P!JK3C1.M
M47,J[:]7GZ3B;&+15AAY&=>VL^LP\5]@;@"> '@&A.D_ =$$B%X!L2U^=&9+
M_404*0O!!T^,_U9/S$L1WD?Z,FL3M'=GG^EJI8Z>RS#&!3H;HBFG&G/P,F?.
M0)I]EL NB0K?P*\$-K<9$78K1,XB(HN/WQ0176F,.9G-Z487>9;$;IG8*1,[
M9.(KF?A&)L0!QM$[-Y8XA9);H2!S$Z1.@O1CIU5ZXS3/LU6:N'4RIT[FT'F'
M8.4D6/V'T3$G61B-0APFN5LG=^KD#IW43:"'DK-1@H]?LFI*>G.I08ZOWS*T
MZ$X&XF@'F?1J?NJ4Z8-%=!Z6#]AT]U6\,D/4=OTKS3B!OQ-Q;#OI[;C2L\-V
M^(%S!=IE<*?OLM%#?SY0."BSS?1>C)-O/"C>3U,=S9^6\B]02P,$%     @
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MNIH;C%4'HEDYL1J'HEF326UQ:EW-367'%? TR;7':4X2.2;U/ !AS0X&J@-
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MP_@UEN_[T_FUTX^A?YK.YBU?#PC>_ M02P,$%     @ UDH?2V<@OU8E @
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M.2YX;6QM4V%OVR 0_2N('U!BDJ599%MJ6E6;M$E1IW6?B7VV4<%X@./NW^_
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M8CR^;.Q_98P'E+*YP1%J\(/-AH+*A^,MGNTX9J/A33?](#9_X_PO4$L#!!0
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M7S;VOS'& TI);G"$.OQ@JR&A\>%XAV<[C]EL>#,L/XBMW[C\"U!+ P04
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MU;.G9"K^&UQ!^O"@Q.<H4-JXDJ*W#M7$XJ4H\3KNK8[[,-XD^PFV#N 3@,^
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M_H/-AH#:A>.M/YMQS$;#Z6[Z063^QL4_4$L#!!0    ( -9*'TMUZAIAM@$
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MDK119%MJ6E6;M$E1IVV?B7U^48'S ,?=OQ]@UW4[?P'NN.>YYXXC'="\V ;
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M7#B^\V<SC]EL.!R6'\36;US^ 5!+ P04    " #62A]+')YJ4[<!  #2 P
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MV?>=_4"+;NBIL[&Q7_\#4$L#!!0    ( -9*'TO!^@.+)P(  &$'   9
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MQ:O!H39N^\7NU?R69\/(81E3LOXKBG]02P,$%     @ UDH?2T2BKDGU 0
MRP4  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL=53O;ILP$'\5Y >H
M"0DAB0"IZ31MTB9%G=9]=L@%4&W,;!.ZMY]M"&/T^B7V';\_=W9\:2_5JZX
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M4*L^6428Q3%Z1X]P^AJM<.WIZSD]_D!@@PILO,#FOQ9WBQ8QS!XWB5&3^+W
M-ER88)@/3G*+FFP1@6AA@F'6N$F"FB2(P&9A@F%BW&2'FNP0@>W"!,,DN,D>
M-=DC LN+QS#+BZ>SQR1 E7Z,Z*"07>-'V"P[3:K'R#_&?_!AS'UGJJP;'9RE
ML4_:/[RKE 9L*>&#_7]4=K). 8>K<=O$[M4P7X; R'8<G72:W_E?4$L#!!0
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M_[*Q_XW6#KR4Y,J/4.<_V&((:%PX[OW93&,V&4[W\P\BRS<NWP%02P,$%
M  @ UDH?2R.$Q?BS @  2@H  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&ULC5;1;ILP%/T5Q <4; .&*HFTDK:;M$E5JVW/;N(DJ( 9.$GW][/!98 O
M35X"=LXY]]SK:^/%6=1OS8%SZ;P7>=DLW8.4U:WG-9L#+UAS(RI>JG]VHBZ8
M5,-Z[S55S=FV)16YAWT_\@J6E>YJT<X]U:N%.,H\*_E3[33'HF#UWSN>B_/2
M1>['Q'.V/T@]X:T6%=OS%RY_5D^U&GF]RC8K>-EDHG1JOENZ7]#M(PHUH47\
MROBY&;P[.I57(=[TX-MVZ?K:$<_Y1FH)IAXGGO(\UTK*QQ\CZO8Q-7'X_J'^
MT":ODGEE#4]%_CO;RL/2C5UGRW?LF,MG<?[*34*AZYCLO_,3SQ5<.U$Q-B)O
MVE]G<VRD*(R*LE*P]^Z9E>WS;/0_:# !&P+N"2CXE$ ,@?PGD$\)@2$$UT8(
M#2&\EA 90G2M)6H(=$+PNNJVR[5FDJT6M3@[===Q%=.-C6ZI:HB-GFS7O_U/
MK5BC9D\K0LG".VDA@[GK,'B P6-$:B,(#<:8-8"9R-Q#,N$8\P!AHC'F$<+0
M'N.I@O15P6!5<"M 1@(Q+$!  =(*! .!@$ZJVD%H"RF[JI(XP)-<U@ ,(]_W
M83<!Z":PW! TDTX("H37UR,"!2+; 4TFJQ99F5),9S.E8!QJQXG]29P.$P[B
MH##Q9P/%8*#XX@(_QE8<&LQ&2< H"9 .FFR(Q&X0'<:?I@W@2#+?2<B'SPO?
MMH3QC,3,D8.N[R8$[T^$+_=3:D"CC/T(696Y!X HQO.5@;<\LO>\U7NI 8V;
M+[!7ZQX"!G2^2Q&\\Y&]]:=]FAI,.#Z) $LVKK,TXP@^2E!XN:=3 QJN"(E)
M GBR@8@FB6W*&WP0]2WK!ZOW6=DXKT*J;VO[!=P)(;D2]6^4Z$%=[/I!SG=2
MOU+U7G>WFVX@165N;EY_?5S] U!+ P04    " #62A]+9#*X./<"   <#@
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M%.*@NM-$GS?]?J4?*%D/>['@MB'<_ %02P,$%     @ UDH?2_#D?JC/"0
M!D(  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULE5S9<MM($OP5!C_
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MNB%(+'=?3+#[L%X\7^R^=6%T^.J'R_\#4$L#!!0    ( -9*'TM$>_\YP (
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M<A\9,3=VTVGGGIEJE=D]+>,TF0<G2]1A5BV&7F!(CP@,>W\$14>LZ%4X_7C
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M:FADQ1M/P&GK?PPW.V+T5O"K@DY.^IYQ<N#\V01?CUL_,$# H%"F M7-%7;
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MRG2)[HO^C>H#Q=OA^47C-R#_!U!+ P04    " #62A]+^Z CJ$$#   R#P
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M.VD[3<U<]CV_7VC1#N\9&A_5X@]02P,$%     @ UTH?2Q4A6=8P P  .@X
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MK'&>T0RQ%.9F(#<#N(/-M&83((+\#TZ4@XER(!$-$N63BA@IRBR8Q\U4AM_
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MEJ^#E$IH0G*G"4]Z'Q\>"G%0[6VB[^MN*>T>E#SW"W<P;/WK_U!+ P04
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M@9P(TB51U4JM%%W5Z[-#-@&=P=1VPO7O:QM""5AI7V)[F9F=7<=VVG+Q+@L
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MKT+SAX.1_3379/ZY%/\ 4$L#!!0    ( -=*'TM= U)F*0,  $@-   9
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MFD9&#Z*Z#>4]K_?V=4.PLSZW.,WA:?D?4$L#!!0    ( -=*'TM^+K4NHP,
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M=C=6^U7_AMT?-/*@OQYXIT\8B[]02P,$%     @ UTH?2Q]07H!Q!@  -28
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MTXG-4$A R)6@Y,K1E>9Y2#9S#M09"JBO$N17>=I]KI@A.,QG()E*T$P50!M
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M=8;LO] ;K11<*U$Q<E8)<W7RJY"L'EB4E)J\]/>R,?>N?Q+[@QOLX \._NB
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MYOU\[3>2M<._ QI_8+9_ %!+ P04    " #72A]+GIA='DX#  "M#0  &0
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MR?NF'R#ZA>"U'HZ\84+;_ -02P,$%     @ UTH?2WIM>;>G @  DPH  !D
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MW?[9LGB]>R5K]Z&NGM/K9I/].V\7_P-02P,$%     @ UTH?2Z#:XAY3 @
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M?T[ U53B%+\EGEG76Y\@53'0#KZ#_3&<M8O(PM(P =(P)9&&ML2/Z?&4>WP
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M:*W_=8.#=!S'&%@US"^-+,^]^@M02P,$%     @ UTH?2]'LL=>' P  ;1
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M<9/RVVH=]D"IGL:[[$C8(-7[E >1@IS4S-3@W\=#V_E=R-*@W\[D5>)3&'E
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MMO)1H%W[2:3.'E&SW\>#[YVUQV%7YPL[_/@N"D(1[6$FXE;%5^DFNH3R#<A
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M_UUBA0[2JEQD3V0XZ5*&!RV>*@J=6CUDOX)JE5JT<= S@GVLESG""K$=RT7
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M>[C@?%.M0>$R LB^K9")(09B2%0(DJ!4,SH$P^PLI(1K12#L^%0H\^%O+,<
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M[>0(=E)R=.%&'9^>ZS^ONVN8.):BV;JXU[0+&B>!T4-\'3&W(72.WF(I+OC
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M4$N.%U2,._D)U0*'(7<MHQ6$4 U?]@"Y7U$%G1RC08)V0<Q'1-:557I0V[I
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M..E/Y_;*D LF961WW3N@8$]H>>T,=4&E(;5:8EM@%\SRO#['XBJ%7$AI=HH
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M/SM.75O(RT'J["*FB#"<JH2*I0/Z1R7K^#>E)C"O:"--P3'KGMINAFK*3$Q
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M#KF;>4P?UW,O,/*?#9TDW(U7J^?98O<L,'LN CK*HNI?;MJ'/)>#MG66 5C
M:D]=8@4^CUL!_V91D@9V\P\EUC!KC(WG9>C>.FF+.OT:=7S+)%[/$H?#VT[^
M53DX6LS3 Q,8&VA@R#S.5TL%5&B&AY *< ['.2S3:C TZP9!;#3["AXY]4H>
MY+1RL8$$U>5<?M$PNIL]6Y0KBR4]62YUEO.@L5DSP2 06^TVF5@_%H,]6FP[
M:15>1E*Q#SG(C0A7I@&)KQG8\P!DFJ7+*>.F6??<2T#4;%;_8B2U^G,-'3C?
M]E9?9=H2BWE.=(L:%<8:85N/1TLB ND-Q0?VIK_B'& 4J>R4(_92(2"$$%T\
M5MZ)]*<]1Q-SKOIBJ LYIW3GT=^G7[=D.;!IUX?Y%OOU[@+G[;W#V;LNZEM(
MJT\P<';C! 7GZM,-#!?J ;'B7&:#OO5C"$$NW$-J<\@BM%RX^L3Q5O- SH4;
M@J7TLQ@)1A?<#H2GL]<]B%$7--H@:)TU)@*NLWYM!V,7ZAWA[.R-01_)\#(.
MAE:M:L"[4)/^<^?1*#0Y7+X6?$?%73Y,_.XZ91KW:$>\I.PI[Z#8JI).LG17
M:DMFGB40U.3^6(=H?+OAN"2"1J5JT$!OC8W[J5<&#'3-+H07Z* PB11H$:L/
M)M#6!VDS3_E;$"C0UC#XT )=Y.N&#/2)>PN?C.%U3ZW #2P7;X;?9ST;?8B!
M]8BP6HIS 'G&ADH)U571,2XDKZ-M(FM0%JFP6#XOZ 6-W'SEJCF6(O:1]OI)
MM'O8K/;W#_A'9D76"!U#6>_A=S$,(B/6B]N548PA?8_U46"Z4'Z(STMT=>*<
MK-&E3'=UH7+2ALTU)ESAB80KK&4B"^(+.NX0 DK)0\W76\\@?PS#3A91!0/+
M8H+\M1QE]0$J!+I:"V9&N%J,-%_[=<8F=H.F H\*MNQH=SE[=JGI+'\Z3[FR
MVYRGF-?#%4$2@5$%3;T2]N/B6^2>:HC1(/UMA14!Z/5H1B%W!$HAX%A<E@7D
MI+F@7=*5%P*1RFW#.J-N9Z4'9XG%(U;85 TS+M"K8YN5]':I,7;."6.G 152
MC''FIC/2O24>'F1^M(B0:#OUU#Q!K&XQ_FVUIOKKSL#.1'W!;>X1ISXOV>6$
M3 ]?=QJ'Q[.&!EQ^K1C)HK;8W 'LKG+H1@5!)C)!G5R(#SFE\;:N A$K.B<X
MD9QQA2@Q,H9"/VWF.X0SXM\D4D],6%AF["N"'TGLHX?97<1._PB4LE^;V+ B
M"O>>H1>A44PT#>P0R!DV_#V*7"*[MAPX);K>\/F84R;AI(\%O\D87+A';]DH
M]!4AM[_/:4C;/72$) M/&*&#@J_O"!G*N9I: 2-YL-#5(Q\N[KA3HW.ID(ZF
M NF(3$G00N!1IQ".SA1@DKID2]''WJHEN+!+&2S1Z$S[^&'Y-$F!7CWUW(>E
M5$U1)]74-,NA)V+RS2C<&!/-N^4(3*@XZ0'@'HX1D])J96N8W*T9JU6^HA<L
MO>CO N14>R 5KD:)V\=44*/0"C2X!,Y7W_W"IFFSLC[^OE_X/Q:&$_81U@4=
MV*;AXI>S#=(&+[U0)2MG#H? R\^6NIU9-1KUYYI9;"*B6150NT\POOS.E B)
M<9F-Z#(&C**7!Y'^6OBY!WI7)EL)WUC%40LWHHE[)SNN7\-<*K>>*VBT-\S^
MHC3CPIT+A1I#!.\=\7-3 F<0\[Y91=,[_9S">,2SI<HZ4+X,SBAL50+Q?4$@
M/@Z[XU1P,$QHT;IW,![MXCNZKL.K7-QC%\[':X :C/! [>IT/".L8[A%JTFC
M  PJ>.>1#>)ZZM$+E8:ONO-ZTS).3"U[C[67WE8?UXO5<X[N7IOO>"C\B,GG
M*U(3(>PGJ1CBXCPQ-=]SOC,"]N-"8Z*2&7O/EY&;5&'5$5G)1&+V2J%SV =*
M0NQS*PT0O^0H[:D?N,JM<)D3C_27C8._$HZPV!)'7-CR=K58(A_]ASI9'_9H
MR5W<:N&J1A1CC?'X77D*EY.\!;#/.SJR/(Q@+0Z?K:S$/(&D5UQH?08L9=SE
M12@$Q\4YY=/U<@\OX%N5[,AU7@_+[,:_M#Y,9^/U2]"+?CQ.!8C_&^-B+M7F
M.#$2/IN/&0WPCH FKJ&[WK&%)';>N5W 84/.6:^T*WV#H=G[N%_]F&-"D]G]
M<H6@50'W5 ,\E'SP;C"J$EU!4# R4X%*/]> Q.2 _[28J!OW,Y9";KD\95:P
MY$Q,L%"_92&UVHV,QXZ6'0;12I?7D3-8R9GXP5*\L,?,Q*-_J12YQTZWGHR;
MS3S-RN]]S_< @0E59X#$"%7<!_=F0=57%HBCH_Q^OEP*%YF%RUK@J,,Y&FJ4
M5*>Z1EE'+HDZ/0A51]W!F^#]UG&MD<.AQHB\HZ_(%="P>(VMJVS!LY&5];S;
M6EFSQB;K!!X_ [1>/<8@8=3,-^&*9VY0M?#NBSIP(;H9U9@YQD!Y]@V<KGV3
M$F>)THFS7,_MYMYHY*<_;G6:"__01](K,9%C2MQNB2&NEX8!-:M /,/)/WP@
M*N'$'KY:SKPJ%X& >U_*$M_>:O?.S+V.K@'<//D=I6WB:KP_H9"U%PN.E9%+
MMZ1V\?;C>635RH+A/2%5J3#\!T)$O"B9(TH]7KIF:I$3([6(LE;Z!/77P*<*
M;3;%"M81,I0D'5 OA4O7N<->(0-%C3;;I%IH.]3VS37/;&$]-ULDJO .+*^6
M[MR[7G$WJ[P.KRTQF=?"RZ4GL[57DS9BYY(%^(T5/9#VG0PGM2]J+.=K;JQ*
M>:ZA  <9U@GSH&04]H\]UXMT9+](.?.%P]KBS&/A>QH.*Z9IK:Y'NN'T&]6K
MZ5KST%I6FW+Z%4CM&[_/B0BUF7A\3GP*8O&AK!D7@(XE4Y>R=+UIXXT91</>
M+\*]@_#UNAV0??PO@K6_7<OQFR^:TPIRI6\^G^;RM;8'I6*Q1?]CIOKV(WF3
M]7V%F13TZ*R,OLHQ_R-I\3>K^\WL,>36>;3"QP(FE&?SR5:D?L<0\ED1%)Y3
MJ6Y4\VMN_@G1X.$QLM[DW^>K_7;QK+Q>4(R&IX%60_.C\ $3'$$5C*T'R0VD
M0^$J%.5LB0+V@R[E^\5.F5WOU A)?BQENXQF7V'0T3O.-:9!Y2DAE!BTX'DS
M!+XG8$GTK?M*,6P@H;T3*4W7/J^25]#ED_GJ$V6SNF5SVAEZ_& 9RKU0ROKH
MM.>I4*KC!P2<] N2GSAMUAM,Q'&WVA8]E\G"(F\J@BZS(7-.P'P;>"49I@!M
MF@[9U$4W%X9\/=76_H(!WR$@^=U1E$G%)[2I[M!X>DWO!]*6S)>1B.VO9>PM
M,4O]^@@:I^HSK)L58[\Z'B\-FVK(Y"IG%OTLNP%4VJ/45*J+'LV6_\A?5!#'
M1\>C>(#]WE&V/Z4EW2J+O<GZ7V*'W+8W1#;<S_#8:WAM53=08?^B-**%RGC!
MG!&*#"Z[R+3[=D9="Y/:[S<E?34O9QO@N(3G/KMM'"ML/E@LV M3+6S!M13Q
M(C0HK,O''+_"$LZ *N+P&GIG51%F(= SH^O]U_^FW"\KO J*)J:2_S?Y;GC<
M]AO.;8H9QZ*IC/]N,>W2V)0'_940 )A**H?I]_*O/Y1+$(G0+4MI-6L #V5*
MBYZXT12<@3]Q$/'$2PDRVH\N?N-W6W7K2(A9'33$D"T^2!YWLI[IWVX^8W:K
MK9G=RN^IX,B%6,G29/0K;9XZX3L^X?95H>..4(A'S+E<!-.H,+Q+V%_)XL0U
M= DBS";?S87D*?+;EUO&;)[(W6;+9\3?O'T $AD*9W14M7XC$LS>4SY/ZDHH
M4_';&H<.#%#)\E: F'N<4 U$2U%I0Y(.#G*U1""'0DE/$&\)5*@1@S2]<QW@
M4@O_1QO+*,#!WN8185(![C(%1=@2C\C?(/*)X</+2 IFOOH,B MBL/M-5.N^
MA+*=^8&,8<B)%);JHINI&TXE%"LE'>-,LL+K3:* 8"N;7"2K(X>MM M,2*17
MQ![[^L\8NO?WSYW" V4']/P<?<U5BF&49>1,S*?NME:/Y2X?67BQNB[/MS,]
M$*$GBV<*XBCTO.+MH7U1X)4;\18Q)Z'B2U81'E5\TLZ7%!F"VMH[B;KQC+$C
ML*NSC;"DK5ETPWWL'!U4-$,=SK?DIT1)<J$8(MK/OU&J-VB,>"^LHHI+-FA;
M[-XU&W^2+.T\'D@^0H[_Z",LL;>.5W=D1TDFXRRF1(:/U&5,9(%C,WJ+;I]O
M%YR1,"EN4VIN$\UR_OU 9);+,;<=$C?.ZDEECW.G)5S#.FVPP7-$6\4=30;$
M",91!S<)0V]$,CY,JJM6"A>0%IK2E%*G]!UFQ@=J#*-:XN(^YCF)!$@IQHD\
MB*/YXV-^!UM/&?54.[G".-EA0A"LAH-P##XF&@L2I3IT8I.P+!UFA*=$\H)C
MN\)+%:@'!B$)_<X^"$<5'3D.WGJ_P4.^DT2W>U[3=&9DP&X\@N.#ZB-?^[3@
M%]>)08IL<%)K3,(FU),:$^$E9'JF=-E0T,?'FJVE=5V[SL6,#@Q.EK8,ENP)
M"%>->K^F\#52LZ56%%I)Z_4H-07;Z 03J:S,H*<+2N%KQHY4W\!&@@#2Z4Q%
M?E[_DXZ3U7!\24FJ"@B?LOD]-<^IRNF0 _UTD@-/?DW"]59X4VC25K%P2Y$4
M$U64#[/%-VBD.SSP72%8DO2;6X2$IBU9YO>KW9Q$ZK6,;WG7ERI1'*>UO=7K
M=U2Q?K)4]3)0%MG\":@/:8]<4.!<X?.C9&XH['C402I7)4M?#\0Z&-;VELM)
M:4\Q:ZI[U^#V6W%49V@XR/Y-GX*ZFY1@YG-SHX0\O4(5-\]'."7$\.$^ISM'
M>E+,\:+Y1NA6',=YB\BTE*)5O*_6\+XB8-*GU1YU[_3,0-0!V(K5TQ(>=IM<
MJ&\G"%<G]\J,?"VM%2)AX,]FN&PCVO(N8.#-6BA7#HWTQX^%AM'0I5]'"3EB
M+&I$PCJS)I15S]&%TG 7(3F930*+!';NB=\,'>="**$UQ5^VV]V?_P502P,$
M%     @ UTH?2^]^.V%Y @  9@X   T   !X;"]S='EL97,N>&ULU9=M;]HP
M$,>_BF6FJ94FDD"!=DTB=4R5)FU3I?)B[RI#G,22'S+'8=!/7SO. ]!!!^NF
M)B^(?>?[W\_.$0X_5VN*[U.,%5@QRO, IDIE'QTG7Z28H;PO,LRU)Q:2(:6G
M,G'R3&(4Y2:(46?@NF.'(<)AZ/."W3*5@X4HN K@I#$!&S\5$0[@P]G[GX50
MU^^ O?<^]'INWWTXO][UG%6N<PBLSI<H@-[X CI_+KQ7=D=T=(QHW]77 6!]
M[<B/CY0_)+XC/7E!>GKS>>])M[X]9WUYK+A[6/X9_=6>!"WK[\DFK@ETJI(+
M_5CPMO*&T!JT,F(8+!$-X!11,I?$1,6($;JVYH$Q+ 05$BA=\CJS9RSYHW5[
M=F:^#94.(US(,K?-8#_GU?(=1STS@(32!G  K2'T,Z04EOQ63\K%I?&9"U3C
MV3K3A(E$:V\P@FU >=-)YD)&6#9I/%B;0I_BV.!(DJ3FKD3F&*=2@NE!1% B
M."H9ZHAJH&47F-)[\ZKX$6]IKV)@UYA'XD)@*.JAWG4U;)^:?6:;:E9[4_;B
M)%V0D:50GPJ]'5[.3=7A.XECLBKGJ[@!T.HHR^CZAI*$,VPW\V)"[\2$H8_J
M/" 5DCQJ/5,J"VW $H(EEHHL-BV_),IF>*7J<EK%IS(/.LC\VN><8(XEHIO0
MNO;?\BG_9^+AY.^1R[?*+O K,IH?_0Y CKH .>X"9"=J\K(+D%=O'W+8 4;3
M</Y;2*?JA#;:K:UFJ[&">4&H(KS"34D48<MCNMT ?C=M--UJ>=J>2\LK--=_
M^K;T=6R$8U10=6>V6#H#V(Z_&G!OW*R:-1(!;,??<$0*5G;T3OO/,GP"4$L#
M!!0    ( -=*'TOK!;;4>P0  #8K   /    >&PO=V]R:V)O;VLN>&ULQ9I=
M3^,X%(;_BM4K1AIMF]@.'P*D@6%72*.9"M#<KDSJ%HO$[L0I _]^G70K3MCP
M:F\.O6J3.LE3-S[/R3D]_1V:Q_L0'L5S7?EX-GEHV_7)=!K+!UN;^$=86Y\^
M68:F-FW:;%;3N&ZL6<0':]NZFN:S63&MC?.3\]/=N>;-]/RT>_/3V=_Q=7^W
M*4S9NB=[9^[/)K-)&C<E _N3[EZW1"?-_V$*RZ4K[==0;FKKVRU48RO3NN#C
M@UO'B?"FMF>3W1#QQ2_$E6]=^R*N_?94:>Q$])>^7IQ-LO2^-6TZYLE%=U_9
MB6A.7/J@N5YD'3@?Y&7:#I5;I*LOQ(6IC"^MN.WGA@#F ##?&Z XF!L"*0&D
M_$#(VPZB.R"*L!0_UK8AD I JKU!WK:A)) :0.I]0A8$L@"0Q=X@+TU\()"'
M /)PGY!'!/((0![Q0EYLHO,VQL]I:4?7P\T;&]-!;V/D,8 \YH6\W=2U:5[Z
M>]"MO$N'F2ZLEV78I+!. _D,1?(9+^9?P?F52#][:9N!7:!>F/WR+0WST8HO
MJ\;V-^#?-_;)^HT5-[8,*XJ))),Q6^9/XQKQTU2)JULW;F&;[2 *B 23,1OF
MVI>AMN+./-L!$_))QBZ4NG;M-JJ8E..DF6O3+6A]Z8:0R"<9OU">;--V5TVA
M)=0NQI#6\O?0#AF13C)VG]1U\+V%'RD3LD?&K(^K7YMMPAK;IA\[F"VDC(S9
M&3?=SN2TN6D2X%UC?.P2_3>+%?DBXQ:&7?6)_WBVGR-)Y,R2N*K757BQ5EQ8
M;Y>N%?.445,X)(N<61:WF_MH?VVZJ;MZ>G/+Y? 9A%D/, /()<5$DLB9)0&S
MJ5Q13.2-G-D;>#8UQ43FR)G-\6Y.( [NS'U%,9$\<F9YT,Q@2V;C)PJ'+)*S
M/X2 %$$<4$RDE)Q9*?^5W>A,(J?D'^^4,4:)Y"*9Y0+CC\PH)M*,9-8,QLPI
M)I*.9)8.QJ32D;#TQ2P=&,TEE8Y$TI'[E(ZDTI%(.I)9.AB3UK\DDHYDE@[&
M/*282#^263\8D]; )-*/9-8/QCRFF$A!<I]U,#6C56YD(<5L(8Q)+:20A12S
MA0;E.G'PU;;&55'<V>=V8RKJ=(4LI)@M! MXBEI((0LI9@N!9+V;68H)6S#,
M%H*8BEI((0NI_3WZ)$QJ(84LI)@MA#&IA12RD&*VT/ )[=^%/EC@2#Z*63ZC
M="(;\"'K*&;KC/.-A$F-I*.9I0,?=#65CD;2T>SM?H1)'WTTDHYF;_HC3"H=
MC:2C^=O^[_86TJU*,9%T] ?T:7;M!;R"8..?V3EC-9B16*F1<#2S< #C,&)J
MY!O]X:V;5\I\0(F\H_=0<]M1R@$ELH]FM@^B5)2R0/8IN+LZ@%(/*)%\"F;Y
M(,H4C2@FDD_!+)_W^XL]+L5$\BFXZVYC!>&1@%D@]13,ZAEM-[[^ZA03N:=@
MK[J]:3P.-4DQX=_.>OU,^\'Q_'21OK&WB^_I$C'M+TU5SAO1O6S_[Z)TUZ5>
M;JKJ,NW[X;\%T^WOS['['^OY/U!+ P04    " #72A]+;.FO/C,"  #+)P
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M(\HZ'<O>ML-W21Z<V[S/9],?XJ[^ U!+ 0(4 Q0    ( -9*'TL?(\\#P
M !,"   +              "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M -9*'TMF\PM@@@   +$    0              "  >D   !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ UDH?2PQR"=?O    *P(  !$
M ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ UDH?2YE<G",0
M!@  G"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #62A]+>NR"A*<"   ""@  &               @ 'X"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ UDH?2QW99% C
M!0  .!D  !@              ( !U0L  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( -9*'TN4S5$0( (  .<&   8              "
M 2X1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #62A]+
MC._C5[X#   _#P  &               @ &$$P  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ UDH?2RA-0:D^!@  D20  !@
M     ( !>!<  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M -9*'TN]'0Z)+ (  &8&   8              "  >P=  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #62A]+XKGJ<DT'   L*   &
M            @ %.(   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ UDH?2V<@OU8E @  /P8  !@              ( !T2<  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -9*'TOMLX^LMP$  -(#
M   8              "  2PJ  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #62A]+8;586[8!  #2 P  &0              @ $9+
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -9*'TL/RU5I
MLP$  -(#   9              "  08N  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ UDH?2[EWC+JW 0  T@,  !D
M ( !\"\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #6
M2A]++Q3G[[8!  #2 P  &0              @ '>,0  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -9*'TO3>V2+MP$  -(#   9
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M970Q."YX;6Q02P$"% ,4    " #62A]+4><J&K<!  #2 P  &0
M    @ %O/0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M -9*'TO&MI4KM@$  -(#   9              "  5T_  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ UDH?2QR>:E.W 0  T@,  !D
M             ( !2D$  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #62A]+7B#B,;@!  #2 P  &0              @ $X0P  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -9*'TL[#T7*PP(
M .0+   9              "  2=%  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ UDH?2\'Z XLG @  80<  !D              ( !
M(4@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #62A]+
M433BZ ,"   T!@  &0              @ %_2@  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( -9*'TO%6Q]$S0$  )P$   9
M      "  ;E,  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ UDH?2U@;DAS& 0  -P0  !D              ( !O4X  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #62A]++'YXY<0!   W!
M&0              @ &Z4   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( -9*'TM$HJY)]0$  ,L%   9              "  ;52  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ UDH?2XNQJ,>W
M 0  T@,  !D              ( !X50  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " #62A]+(X3%^+,"  !*"@  &0
M@ '/5@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( -9*
M'TMD,K@X]P(  !P.   9              "  ;E9  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ UDH?2_#D?JC/"0  !D(  !D
M         ( !YUP  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    " #62A]+1'O_.< "   ?#   &0              @ 'M9@  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -9*'TLORH].$P(   \&
M   9              "  >1I  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ UDH?2_N@(ZA! P  ,@\  !D              ( !+FP
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #62A]+>= P
MW> !  !G!   &0              @ &F;P  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( -9*'TM4X[;(#P(   4&   9
M  "  ;UQ  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
MUDH?2W"4($_6 0  * 0  !D              ( ! W0  'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " #62A]+ENQC0#8"  !@!P  &0
M            @ $0=@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( -=*'TL5(5G6, ,  #H.   9              "  7UX  !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ UTH?2VF?"P=H @
MR@<  !D              ( !Y'L  'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " #72A]+J5V%W70"  "+"   &0              @ &#
M?@  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( -=*'TO;
MN@U?YP(  -H,   9              "  2Z!  !X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ UTH?2U98G, , @  "P8  !D
M     ( !3(0  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -=*'TM:5%+],P(  )P&   9              "
M <Z1  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ UTH?
M2_2([8BS P  6!0  !D              ( !.)0  'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " #72A]+"@@&*]\!  !H!   &0
M        @ $BF   >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( -=*'TM= U)F*0,  $@-   9              "  3B:  !X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ UTH?2WXNM2ZC P  SA
M !D              ( !F)T  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " #72A]+'U!>@'$&   U)@  &0              @ %RH0
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( -=*'TN&7)\^
M;@(  ,P(   9              "  1JH  !X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ UTH?2YZ871Y. P  K0T  !D
M ( !OZH  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #7
M2A]+>FUYMZ<"  "3"@  &0              @ %$K@  >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( -=*'TN!D*:X2@(  %P'   9
M          "  2*Q  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#
M%     @ UTH?2\Y2JOA- P  .@X  !D              ( !H[,  'AL+W=O
M<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #72A]+">)4<W0"  #,
M"   &0              @ $GMP  >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM
M;%!+ 0(4 Q0    ( -=*'TM50A42M@8  /\F   9              "  =*Y
M  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ UTH?2Z#:
MXAY3 @  H0<  !D              ( !O\   'AL+W=O<FMS:&5E=',O<VAE
M970V,RYX;6Q02P$"% ,4    " #72A]+I:]#A*0"   Z"0  &0
M    @ %)PP  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M -=*'TL]$[S)PP$  /H#   9              "  23&  !X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ UTH?2]'LL=>' P  ;1   !D
M             ( !'L@  'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    " #72A]+NM#$.7N6   >8@( %               @ '<RP  >&PO
M<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " #72A]+[WX[87D"  !F#@
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:+GAM;%!+!08     2P!+ '\4  !J;@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>271</ContextCount>
  <ElementCount>441</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - Business, Basis of Presentation, Merger and Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinations</Role>
      <ShortName>Business, Basis of Presentation, Merger and Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Disclosure - License Agreement/Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/LicenseAgreementrevenueRecognition</Role>
      <ShortName>License Agreement/Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - Fair Value Considerations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderations</Role>
      <ShortName>Fair Value Considerations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>115 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>116 - Disclosure - Convertible Promissory Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.aytubio.com/role/ConvertiblePromissoryNotes</Role>
      <ShortName>Convertible Promissory Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>117 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>118 - Disclosure - Equity Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstruments</Role>
      <ShortName>Equity Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>119 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>120 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>121 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>122 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>123 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>124 - Disclosure - Business, Basis of Presentation, Merger and Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsTables</Role>
      <ShortName>Business, Basis of Presentation, Merger and Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinations</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>125 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>126 - Disclosure - Fair Value Considerations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderationsTables</Role>
      <ShortName>Fair Value Considerations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FairValueConsiderations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>127 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>128 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>129 - Disclosure - Equity Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsTables</Role>
      <ShortName>Equity Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstruments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SegmentInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>131 - Disclosure - Business, Basis of Presentation, Merger and Business Combinations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails</Role>
      <ShortName>Business, Basis of Presentation, Merger and Business Combinations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>132 - Disclosure - Business, Basis of Presentation, Merger and Business Combinations (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetails1</Role>
      <ShortName>Business, Basis of Presentation, Merger and Business Combinations (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>133 - Disclosure - Business, Basis of Presentation, Merger and Business Combinations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsDetailsTextual</Role>
      <ShortName>Business, Basis of Presentation, Merger and Business Combinations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/BusinessBasisOfPresentationMergerAndBusinessCombinationsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>134 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>135 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>136 - Disclosure - Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>137 - Disclosure - Summary of Significant Accounting Policies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>138 - Disclosure - Summary of Significant Accounting Policies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>139 - Disclosure - Summary of Significant Accounting Policies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>140 - Disclosure - Summary of Significant Accounting Policies (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>141 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>142 - Disclosure - Going Concern (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/GoingConcernDetailsTextual</Role>
      <ShortName>Going Concern (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/GoingConcern</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>143 - Disclosure - License Agreement/Revenue Recognition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/LicenseAgreementrevenueRecognitionDetailsTextual</Role>
      <ShortName>License Agreement/Revenue Recognition (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/LicenseAgreementrevenueRecognition</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>144 - Disclosure - Fair Value Considerations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderationsDetails</Role>
      <ShortName>Fair Value Considerations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>145 - Disclosure - Fair Value Considerations (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderationsDetails1</Role>
      <ShortName>Fair Value Considerations (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>146 - Disclosure - Fair Value Considerations (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderationsDetails2</Role>
      <ShortName>Fair Value Considerations (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>147 - Disclosure - Fair Value Considerations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/FairValueConsiderationsDetailsTextual</Role>
      <ShortName>Fair Value Considerations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>148 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>149 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>150 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>151 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>152 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>153 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>154 - Disclosure - Convertible Promissory Notes (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.aytubio.com/role/ConvertiblePromissoryNotesDetailsTextual</Role>
      <ShortName>Convertible Promissory Notes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/ConvertiblePromissoryNotes</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>155 - Disclosure - Common Stock (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/CommonStockDetailsTextual</Role>
      <ShortName>Common Stock (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/CommonStock</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>156 - Disclosure - Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetails</Role>
      <ShortName>Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>157 - Disclosure - Equity Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetails1</Role>
      <ShortName>Equity Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>158 - Disclosure - Equity Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetails2</Role>
      <ShortName>Equity Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>159 - Disclosure - Equity Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetails3</Role>
      <ShortName>Equity Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>160 - Disclosure - Equity Instruments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetails4</Role>
      <ShortName>Equity Instruments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>161 - Disclosure - Equity Instruments (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetails5</Role>
      <ShortName>Equity Instruments (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>162 - Disclosure - Equity Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EquityInstrumentsDetailsTextual</Role>
      <ShortName>Equity Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>163 - Disclosure - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/RelatedPartyTransactionsDetailsTextual</Role>
      <ShortName>Related Party Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>164 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SegmentInformationTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>165 - Disclosure - Employee Benefit Plan (Details textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/EmployeeBenefitPlanDetailsTextual</Role>
      <ShortName>Employee Benefit Plan (Details textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="aytu-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>166 - Disclosure - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/SubsequentEventsDetailsTextual</Role>
      <ShortName>Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aytubio.com/role/SubsequentEvents</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aytu-20170630.xml</File>
    <File>aytu-20170630.xsd</File>
    <File>aytu-20170630_cal.xml</File>
    <File>aytu-20170630_def.xml</File>
    <File>aytu-20170630_lab.xml</File>
    <File>aytu-20170630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0001144204-17-046061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-17-046061-xbrl.zip
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M<\.-F</7KJ&_7.#R^@W%+AN,?M3]V\_W,K3G@;9-3:ETY+ F^(Q"\!DQ^'0
M/L4O4!_6=H%Z##X"@\^QPD=H$#YDG?T;K,;S78AW6G#+N$,O+KMJ@WD&]GK
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M!#X^=.R-"7/MB><1K4S+T8PYS@B5@+H %NL/;,FSWKQ+ :'L"F9D;EK%L2:
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M9LQM"'K<I4M6#N#%<0U9_DE*=R?G@S&HQU <AWG)&KQ2<J,B'Z1[G_/>H#_
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M$LL#FO\.7&R4SUUA:H1S4+!SD8],*G%.*L(9/LT -E_7A+-7$QLO>)>J@37
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MB,W.X;\0-]C@\"$"JS:O,+CH)82B).OB!U^8)(@P">TDW@+/Z;$+A&)1>1M
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MN%6S*=1]QZV&;)53(&R3(&Q33?<5CT^/1&@XD5508!1GO2H\M"6-SL1!:V<
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M39JX$P#B>XOP+V<^G EX'5A&S<G!E=<U49 8=HDVR4;T3<1RNV#SE,UQ%\^
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M [?@OZ 04**AD+2C3:M70_6 JY7482!R^\QE@CJA2V4/N0MT("@&;XW@V@]
M3T.:Z'%IP3Z'?-L=^\'"$,=F!51RM<)+(FK6C2-Q!"&6,SOQ1CHK1#V4=:&.
M^%'N/[,$0PY3T6@@%/<0C8*M"8KF4>OYL4_<%A"7&\F#B43_Q!N4L4-H+R4A
M8BC6]L:,B-D/0.<$6+^!':VR>):(FRP9-\PAJI)I,*A%1#9M>?RB:%J?,='0
MB[W*4N@5+;+NIKQ-M,64_608?#\ 7108787+\XR.9CO@%R\\.H/K<XZ.%IVF
MWPSSGD]FWTVY[<#2,A@.E8'*TP38B>B:"I-%]!W2._QY./($%=Q)/?^M>_V+
M4L[>\7^".$I+6;?OUBQ_W+(HL2,\]\A"DDF'] 3O<Q>$SGC>O3:9K<SD<LOT
MN"I-G7R'S\8/U2HGR2-Q"\;D;]63?X8Y?._X,EB-).L:P"NIMG'8+RW?2Q32
M?/@G'IN! X4!W^LS>$^DT>AG: OY*3MPM/*9B"V39W_>829IV%!P.9I5^;A*
M"JAH>,K?SV*@DY%X53Z0@- 7GI082+<8LY,4@5CZ;+>\HC:GO"*S!RE!8QQ4
MP>QZ?@94P8:4J_@_ _ L'\5?F);/#B=DY"1YRYG,'69@/J/ZB8Q)59< EH=0
MIR*PQ/34)N8//,UQ/7+O>3\)!T1:?DE% C<K;MN=51.MBJXIWXQ)<)N-IX4Y
MDO/<.T7(VW6PFZ5FHSHGDS(K&A<;ZW.4!K!%-JZ0+7B"43!^%4;R(Y&62'?D
MU-F*! 2^"OGM+B=S\XG;,]R).?*HM(.3E:GLT_"4-1N:CBNJ(NTQP[BA]G\"
M=8*E3FG3 ]XH]IGUAJ9.@^-SXNA$)SD17B2(G\4\)DZ%Y$[E=&W&R?M^2Z\W
M(Z:[CC.541*EA@0R/N;[Y%#KY^&--? <%(TC1<,HN/$!($KFJ%B>)^S0C;.H
M8P7(3.KM9Q2="6M83/AH^0!W!$,U;K2&(;75%4-4*)< I:CGJHJH: PU;2F*
MGL0+E0Q,+\QA"8U_$<X]I.(G\R>7H,2U,X[&SLAYP>7/PYY@+"GB)'BP4B(/
M'D"DN+FDSB0L% 2P^=P&.4+&G#EV*;)@HS\ZO >RYO. NGV6&*592+.9'9+W
M7<7<F*ZBY,PP+@##A2N>#Z5%K%-A:7P8G?FDBP.00:$($N#7OY74 HQBWQ!\
M\($)VF>1=AM1@?7Y83A-#N#OR3 \5($CQD3XI N_A-//01 >[-Q3-&:C=)SO
MY1MX03 J S$.\?/<P,7^!O&6])6,4[(T?BM3=HI%NAQ,:XK[Z>.O(#SG'CN&
MDG+CY1AML")JM=E61)G\ +*2D7;83@(4:+59&C6>,%0N"XJ8>3:SP@CP_0!T
MDP0V@:F;K$C*B"T '*DM%KIIQ6MD#(,,3/@ODRPR[V0X2F/$E@".XSW*X_W>
MKE?2Y<3ZI^8]F9KO)'P/&]L,9G4IV=0TF<8V<0\?]=/YM].S;[<*_R?DQ_GI
M[;^.5=>!N6M1_6+BU22[-WHZIH'O)4.TF[\E?80_7UY<=*]N8"464 \=279"
M+O]]=OWEXO+',<&\2ACQ .P,QY%@&P,M?CBHA-]'U+;C[_/6LU9_QO7[&&V^
M95%CTSW$=0)N]S>\[!#ZF3V:VAGHZ\A(0/5 UT"ZS6>H^ OD;8J.,Q2\Z5>4
MP.DW$,5OEA1>WX]5)SP8?B\ZOZ_2(#\K#JJ-K#BH/6\ENEZWW1SV/\\;$]XR
M>;2*01Y:Z@#-^]'/4@MG<9PJ#1ZM00![VZ==9W!UN5-&EVL)UL;'#+; NI]6
MXS=R2*JMHW*M]EMAJ<0PA6&*#3%%NVG80#][87N=KF?9"]=<_B3/#W[RH@L=
MFU\;< O1QGV6UB^WZDKGESOMW$1=<?;XC8%;4)*NM!5%MUN&HO53WKMU]C][
MKB^HY:O>WUC,\TY5\>1VZ[N.5IT!5R/O92515R\W6B#J&N56;A?*%6>'WQBX
MA23H1KD&]-PL5\S^:J>X=^MUGTYDF!H[SH!;?,^D8OP1 ZZAXSW;V 4W_[T^
MQS3-3IZ8?LU.NLOG0"^>,OZB=EOEKMZK(AB54QHM1>'U&-->3XAZYM"A8R_P
MCWO\B=DG+^:F)N.+Y).=K"S[4:0?8^3_\3Z0AWU*1\>G7&*'TT"PR][G3$GB
M=5CT]MF3OKS!XKA/6,-Q1<>J^N26/?F?',_Z^?'77W[]A9 _Z-@/CC]A91"3
M$L:YYVXT3-P>\!R,%9_W."ZA*R7S9=?Z;\ %L[NN?1$5Q'$FNYA0SNQ;ZO9Y
M\B@VBO!ASFO6^W!PU967;J5Y!__%W*6[*\&'TG/BV;^JAC"!1/#BW]14DN.*
MND]<'A!N RU0R^?V7:-3/2"!R\/!O]^<'A";61PX3R*:/]8J+=BDRA_OMPQC
MC,IX9S8YT[GK3\QUB5T%;@?4_=/S[$?N.-M%<&TA@JO-1D4A.!?(I]&^&XS4
M%Y-<O3.!D'EKW22B=L%HC850USOUHZW1P6P>^X(-']D%7M S32C=(?:]_EO-
M>A:V&OP&B+E]9,X#^PI8&LQ"5NNN7MD0LIJ+F:;1F,#5ZR!Y'5XPH?SVT=LN
M.EI;1$<$P :P,,!C\*WBH;UM/" (K\?$E[#4<(N(Z&P9$0C!!O" C=&VBH>C
M;>,!GGT='KK8W7XGR#BJ+$1&^ZCS"F1,@+$"1KXQ?[M +[9?J\WJTE##4J<!
MN[$&S X<< ^>N0'=1RKL&ZPCO@PK0/\=UQIWTZK06U30B;\PB8A*^ZY2122T
M;KT4(5/0U0X^3KF*:0&@CT6 H;<6.FIDRJ4KA3^4R TZ=N2EZL;B5(O>3K4,
M4 7F+_5:#GLQFH):4U"[7$%MRQ34+AT'K+>TB7SJ5$%3H JJ">BS)5*UMBFH
MU>*85B<\&'XO.K^O73%9?XL%M6U#'ALC#U-0:W2 ]L#IDKCPANO^=E_B5RL^
M[(:@#4$;@BY$QNSV<J=G:6;3U\* 6_RB@!D"K=KNJ!+5SEK%^/J#O&=[;(AZ
M&:(N8F>)_=?8V\NCGJ6Q36<)4R2P'T4",P1<I7S4CCI+='+4VUL$>L]VV9#U
M4L9HN=H*R?JH@&4P^Z_!<_*Y36\) ^Y^.2C-<H4<MLK-O81WSS;84/0R%%TO
MMYN@N5OEVCI$K;EV*KSBWJWK;=I+&'#WS359RQ_1'](]VUI#RUNC9<WU4'%;
M3!2T^<-F:[N6J1S+MIC(CM[%"Y^Y/WYUM5A]/ZK%9M3)/*.SHM=GJ?V/;PVF
M$0'@=;&F0FTY0%<18GM:H=8Q%6I+J]>FR84K#FS9BH*CQ04%A8;3[&'QX31[
MJ"#ZP7A_X&=K/[L/3-#^.ODJ>8.M2^14)SP8_5D@V%;@VV\!-EQ)H?5Z!837
M[.6D#(:?[L5[]>>W+H7UA&V%3;UF0\I=\,^RNYJYN"3%PP7O99HM<+> >#&:
MUVC>_2FF?RWK1^%AL\7[N\5G3TQ87&;D]I7@EE'7>[SEV##I[?*T)OE$VTNU
MFJ6N+P-?^M3%*/M$3\+B99H5,[4HOUNC-XP-@0[>;'1<=4]/S[_]>7@=K2(^
M[-4=19WG*#HL')T8MG@M6_S#<(/A!L,-1DD8MM#,JHYIYN+L2Y@YMAK-;"]C
M<I:E_:>@;A0!+U1Z:#%%IH[9L+N6B=O#P0RA5VV5ZHW<KK\UU+T]ZM;+_MTI
M4==;E7+-$+7FX.HDLK6 =P8E%WA[WZ9QNMLP<'S8DYMYJJ/KHB.X.LFZO%UV
MXY._<<+6RS(U]&SH64]!K06\6AJE.E*SQD;I;B.F7SS18]QG]OO/U,5R0!,]
MW41"TAMPUE=#2 '=^7>URE%N_?KT9@9]P"V^2;OC8&NM;$X0= >WH':M";;F
M3LTFOS:37[O.58-[Z_'H"*Y)G=HZBF9G$53KU<(1RQOEC>(:MCL-<^6;16"(
MNGB&;9&H^ZA<KQ=NLPMJYA8J?&L27@L![A[)O9TZ^;5ZJ57I%&Z[#747S%3=
M;19WQ^2[:@^N3A);"WA-"+;XMJG)=\V=.G0$5R=95R2OW.0':@YN\0U30\^&
MGO44U%K JZ51JB,U:VR4YI3O:EP6O<$MJ*S;;89JM=2H=$R.JN;@%M\,W2E5
M=^HF/JH]N$8\%\$4U9&:-39%=QL?S;W@2D=')=>"*[T=\SP*KG;JNK]KY6?+
MZLT+^H"KGRW;U$;(SR#I5J/<,EFIFH-;4%O6A%5SIV9-RJUV&T*=5V[5-E[.
M"F9;'<PVVPON<7Y],*)#1=:*"-,XZK7!HJUZIU1KY58#H#>'Z0-N\:WCW6;"
MMLKY%2(:FBZ>=9RW0%_I&,,TVM#15LXE!Y:"U4*HKX>YK*,CE:^YO)7J_.R*
M=<*8QI&UM=$XR[8X*M4;ILN!YN#J9S!KG:$+!G-^1H6AZ3=G,.^4N-OE(W,C
MJGX&\VZ#R]T'RAUE+O<\0?K8WD ;PUE'KVH/X\QOSW#.#XVSCJRKI7;=\)CF
MX.ID9&@!KY9GUH::#34;:MZ5D?S>1\,Q.U",BL\79]WK8\#Z8!+@6P7O-X#W
M6L$[!8E:U+/IMS7NRU_4_BKC^-X3-A,?#@"%T5(4)H^KE<IO)T0]<^C0L1?X
MQSW^Q.R3 X*YQG)$+>[VU7OX?41M._J>C"^23W:RS.Q'D7Z,T?W'^T >]BD=
M'=]8 V8'#KOLW0RH8)^H9/9G;SABKJ0^]]P;W[-^7H[PH^Q:/G_@_O@6A[EE
M3_XG!_[X\==??OV%D#^6'A%_E=W 'WB"_\WL[RX@)C/-E4-=^6D<-Z.X$MQB
MU]3MIS,2RW-]^'+->A\.KBKMNTKU#KL'WWJ5UEV]@I_;!X3;'PZ^4%BR?=<X
M:AQ\G**$K]WK/\^!U&%W29)V'NXVF:*&4OA#B=PPP7ODX 7"NCC_=G88>WTQ
MUR;3<3?\-_*G6/DS=?B]X"4)X!]*G&F24:M A@2>Z;L?#BP&"!"K4/L6%Y7,
MW(-MB:>>&.7W*83^7IHQ5,QFMP-T)1W'>\1\I9![;.:#ERF)#W_S0F(D7B:K
M:=KA)/=C(I!FB-<C+*(D,D)2DL<*8[A6/= W9T\W@TPR)957!'L5&7D2OH>J
M<C +J$U-$[IXY]].SY!? >\GY,?YZ>V_\,^5C%H**2>:+'JBT_HM\;U *5YT
MKVY@6 NHC8XDZ+M+4(1?+BY_'),'+CF\OY04?D7 )\3/.HI^@4[O+&W!M+,J
MO?;; :("@(6-JVW6G,D9SFU:ICIM8=UL80%!,UN8)VBOW[+6XBW[P=!W93;I
M/C!!P2:Y9D/*7;1;/H,Z%F"C!M0QVZD1:(8C"P^:V<+M'UVN5N"J$T&\8.NJ
M>$.*.J^7?H[C$NDO*D(AWRKE[)X:MBX.O@7#>R8P=! %ODBF@LKL\][L\S/#
M+.9MHEC:['1Q=OH%$_R"]YCAY\+O\LIR.Y/-;_9Y;_;9R.T-VO!Y9&8NQ,P&
M*YD+EWB^'<3,P$RU4:[HG)<^$Q'%S+'1B!^*F[2^'0S-2&>NEIJ&,?2&UBB*
M7?*#412Z0VL4Q=8QU)QUPVM'Y^(GPQ>&+W)1&#K?26.8PAA/QGC*CQ\TB5 M
M41:QL=B=7LRQ/<AGQ9CR['VP+J3[VBE]ES2?7Z-T;=ECAG*HMTIMK1M$[I&U
M9"3^3DC:2'SMH=6I<%=;TIX1[NF4ZXVB[;6Q98PMLR/!GVOO/JWY0QMHC2UC
M;)GBQVY>&][3P>[1 EPM99N&,4OM&QUK>_:ES;4@.AT)Y'LMB-;\I0VTQ;>4
MM@?Y;$LIOTM!#$47S?K1EK1G1GVT[MYM;"%C"Q78%M+^Q@>C.32TA=:]Y&3_
MHD0:4O""[IYOHEOFJWM;/NNFB2\// ?&D6?_#;@_OF8/\)FI/]R,'.ZOT0ZS
M>?#QT@U;)G94Q\1FB3PR(AAW+4^,/$&QO))*0D$] 0GZW"*GS*&/ !Z)GP!X
M2(  IG_ZD[E,4(=\C@<A%_214-<FU@#!M(D7".+2(2,]H&AR[4GVR.'/GS-C
M^A[ICOV ?.+>C<69:[$2.7>M<DD-!!3/++4Z6*["!) (-@65"A?<)8\#;@T(
MH_ _EC<<PH@R12*\9#'^@"L!X"7N%Q8,9Q]4%QG@T&-2K96K[4;XV$3'R3*)
M\1>UG&R5PD6GRW,]?Z#FV_XB9RSP!!?8#?J!]$FM&7;%S&^)M<J,)9)W,#E0
M' S58T+ 4+#SV(N189]9YHR1 +'C9T3Q1)$\430O_UDF7<>))D:Z&,&:HF]#
M+W!]B2#X RYA>" MGPSH P@6QEQ"[?\ 6L+Y8&Z<3\T3(@;!@&]R]KSEC#!X
MF37G]\;-2HW/GO2_>"(5*5=T/&2NWQ6JARE^E "L9ZFGY\D>' 5D"XJ8R0:]
M:\B'UGZTRTUFWEYG6AD,AQ1EO0R)_O >]P7Y(-D8PI[P<WA!"M+9F%$A"0/1
M:2L9DNK6I'\M4C3ND6[-:C>,T3UL3YNQ\N*N HL;ULY;RT3_VI3]GHYIX'O)
M$.WFICO:SEV//@UNU[V^:$:$1[_6;YI<N) W;!,-03K9AB#-9X#^!0(UTZ$-
M!6OZ]9F$+2 R=#G"UPD/AIO7BSGNLCOCFOS>6=S_9\TKY?*&T.SO\OO;>K/[
M6YP\JS6O#IHEMZ_!W:;"&BB_QP8OVO%&Z/;&KM,ZW54U1T-13PD6@UN 6OLB
MH*.]E\1A>,'P@N&%0F9HQV>P%V=?<*SZKN_+7<F:N)D3B,V+6'2\AE%'</7+
M-=A"A<J:H,^0@KEUVC'T;.AY"_3<.2I5\FN7HR-1O\E8P US'.[V2Z0?)9-@
M3(#:0^YRZ6.*R ,S80$#KM:^CG%F##4;:C;;:UQSXYKO[(2O>,[./C=7V9Q?
M5"LU*S7C&ADF,4RR('A0;1@6V:_HP>XSP/;6_M2^<'<Q!>30K+Q(!;O;09Z.
MEHCA+6W(P_#69GGKJ%(WG*6E ;/;"$G^!HR.MJR.X"X2 EE95K!P<7[XT#*<
M;+C!<(/A!IVY01,S8;=QCN^N8);7=['+2%)@3OV)GA3K%$GMK3%9<#?-^&&;
MBA2WVTWC:.D/KDXM*[6 5TM[0$=JUL0>,&&#_$E!1W"-HV0<)<,-!5?S.\UM
M*/#V[K^:WZW;_X,A^6+OQ@<F:!];=@XI=[$?7=A5SO?( Y.^L0?U!E<GL5<D
MY[U:[NC<,-S0MF:TK06\6JIT':EY0?=P^]6=.9,6X"\W(I_XHO:A(%W)=]A5
M>'YKX^=]D;]Y/OM!<5Y?7HIK9%?YFO;$[3UK3[Q7/7V[44_D,3;2IHY#'J.=
M)UQB1^^P@[(TG8TW)=BR+8<OE&I8W' XU2XS.PQ//;ZE[L*HP_:IMW"K;KJ1
M%@:VB=["U<7-* L-J-G$R;!) <$T6SBUA0G W3 $5D"X=0F ZH0'HT +!-LJ
MC/LM&-ZS3'M^KU= @,UFAB"]=9FK)VRK[.!U?&"40OP9?%-!+3^@3@&!-\K4
M*-,W='?"BW9R%&TSF[S'FQQ?()JB1%TE:O9\C_?\@O<R^\W=]#->?_5V^7WO
M\X!F*?/+S#6JV9*?YAIDL+?'R3J"NX6V"_N:%[0VBBK/<=1H- I'*H8S=M60
M9#V&:!:9(:JE2J==KIDR.,W!U4U?K&\S:H*/&;Q0*Q_5"D<8!<VLG^I67-&F
MI^0L*_M'FKDD V9C<OW(H9;*G2.TCQETZE)WRW,?F/ Q 8:,8-GPN"?& +.?
MWQ4%.I9LZ BN3MG*VC9<G6U!5/-S-PUU;X^ZW\H51#.)NMDJFR["NH-;H />
M'&FYP!O\-HW;W8:09QBWW,7:44_ ;RX:M2ZSL 8$1O$'Q!]@M6F?2^ $>-SK
M]9C - +C.&D-[A[9MUO$P0SQV6F56BW30DUS<(MOX.Z6JJNU2HX&KJ%J386V
M+F'=@AFX.M*SQ@:NB=X6V7/2$=P]LFYW'KVM'15NNPUU%\RXW2U1'YG@K?[@
M%M6V-<';_.E98]LV]^#M3-O6!&T+Z1[ND5F[VY! L]1HFTQ?S<$MOEEK8K:&
MJG.7V29FNS?TK+%=FWO,-AN>Q9@LB5I+DL=!\D=X\BL=DZ:J@6L9C^GUE;%O
M($:P&D+V)496;99J;1/YU1S<XIO(.Z;J7$UD0]4:B743^MU+>C9M'C)M'G(S
M<75TGG0$5[>R78U#81NM:J]62M5*IW#D\D:YH[C6[:X#P(URQ92H:PYN4:W;
MW=)RH]PV-WCI9]?N-LR;/Y?KZ.+H"*Y.F0AZP&L\]@*#:\C9D/,>@5M4D]/0
M<_[TK''.P6Z#K.=2!M2U&-Y7*)GO.V$6;7)MH6J,P'U.G;1!@O%@] 97)SU?
MJ%!3H]0PD2;=P37QT]6(NF/R9_4'MZBVK,F?S9^>-;9E<\^?+5)3+QW])!W!
MW2/S=K>A@'JE6JI4<ZL0,_3]5@S<'9-UGE<Y&*+65&B;8.W>T+/&!JYI?%!0
MITE'</?(L-UM7*!6*57:IENMYN 6WZ[=<>)KTP1NM0>WJ':M"=SF3\\:V[4Y
M!6Y9=+6W;=P?T\5@EUT,],#(#,GYKMHX*C6;M7\:CM ;W.);M[LE[%RM6T/4
M&@EQ$[7=2WK6I+9KMQ':_$E!1T='1W +U*2@$.C04BX:9M!4SVM"[8:<#3EK
M9+8:>LZ?GC4Q6W<;@)W7:BNW,U4='9H7PXYUL)-L+[C'^?7!2)Z!V'D8V9<@
M5JW3*E4:IJ&LYN":V.QJ9-VLE,W]>+J#6U0C=[>DW"C7ZH7;VAV9M^]]"IHY
M_3KQ3CPLH@@? _0+FXD/!["*"&%J,<?52N6W$Z*>.73HV O\XQY_8O;) 5",
MX\@1M<"L5._A]Q&U[>A[,KY(/MGQI_?9CR+]&*_XC_>!/.Q3.CJ^L0;,#AQV
MV;OQ/>MG=$'"V7\#[H^_>3Z+DPLNQ36*9WG+GOQ/#CSY\==??OV%D#_HV ^R
MHPRH8/=4,ON*CC&SMOM(A1V/\F_J!!1+R+I2!L,1?I*WN*AD6"PS\^'+->M]
M.+BJM.\JU3OL6GOK55IW]0I^;A\0;G\X^$(MG]MWC:/.P<=H)V/4?NU>_WD.
ME #D09+<C9!<R*TBNF] =-=(=*7PAQ*Y88+WR 1AQ,-]OCCK7A\# PU.+LZ_
MG1W&[DQ,U,ETW W_C?PI2O],'7XO>$E25QY*G&F2CJLC_V V)>6WC!YL1#SU
MQ"B_3Z'P]]*,H2K14#>\[_(>MRCF6*>;C@6%#T ,Z#)AOO7C5&XV>%-DZ-GP
M)GRQ Q$_-V94$.;:\.N$IT4>F6 P >EYCN,]RF.%2 0A(?Y]PBJ9DE<K CJQ
M_JEY3Z;E:_@>ZH_! 0%0^^Z'@U"9O<0L*TV3T1^QJE0_G7\[/4/F!=R?D!_G
MI[?_PA= 5\U;2RAOGTF"IV,:^%XR1+OY6Q*N!PUST;VZ@9580#UT)$%Y7()6
M^7)Q^>.8/'")%\B\*(_GKF>M,,CZYL+F+8/&IH_J= )N]XE4.X1^IBG4SD!?
M1T8"J@>Z!M)M/D/%7R!O4W2<H>!-OZ($3K^!*'ZSI/#ZL*=.>##\7G1^7^4<
M.BL.JHVL.*C-*!5:*ZB=P_[GF9CPELECG>M%]D,\:'+TM;U3T%EJX>QIQ"R\
M0_'!<\"Q=[@_-L>AQ0!7E]0M74[_U\;'#+:H-EOE5N,W<DBJK:-RK?9;8:G$
M,(5AB@TQ1;MIV$ _>V%[!TJS[(5K+G^2GF",<"1P)GTBJ,_,&9,!MV"GI;.T
M?KE55SJ_W&GG)NJ*L\=O#-R"DG2EK2BZW3(4K9_RWJVS_]ES?4$M/Z . 5(>
MDG=X'"MS*Z[6T:HSX&KDO:PDZNKE1@M$7:/<,KVP#+A[0-"-<@WHN5DV7;#T
M4]R[];I/^0.WF6N3,6>.Z0YDP-T#SZ1B_!$#KJ'C/=O8!0GVK\\Q35+F9^;J
MS_^B]D'++/X-)]_'.?UQ<4 TBKSUNM9_ R[8IT!RETG)Y)_"DW(J6;\9)>LW
M;SWX7 \_WUW!DSZ5@  _?OTK&]XS$4B<)/Y-S2"Y6M\3EU,Y_D<')'!Y.-'W
MF],#8C.+ \'+#P>'S8./U9!VT[*&EU8^4;T0_^VS-[SGKD+19\ -F$Q"?;D%
M],D>$P+P*CP[L/QS]P%&]\1X5QAH(G?-PT#EX&,S@O^U\$Q3P.RA?"!>>'YB
MT M.[U7^QS?/M0(8V_4GD=.5E^ZFD5)=B)1:K3U!%*\"9@F*F372%1.HEFB?
M[8Y4:AFLC +!LFBI'7RLE"N=A92R&([U2:2+<JBO^NW+SP/\>.[>#M@U?KKL
M70:^Y8'\?FE+4(RQ?_'^8'<(K2^6/K7FE/3)#26;W9ONT M<_[(W[Q60IGYU
M=[O06,CLK59C@WNP%.A+8/N:65[?Y7\S^QP<<)_W."I<];J,-)/==>UX)SF3
M2CG#C^J1[4O0Y@NDW7B9M%\)XS06E1'S"8T8F&/$7#F]29_&Z2-9.^<+Y4)Q
M0L:^B?,3_YVD)UY3?UH4SRPRO+L(/$#7*:=]%_#,K0BY-N,7K$^=,X#4'R-&
M[[YREP^#81;YBH%GH+NU6#17R^U.IC9S^YC8 ^33IV61WWX)^9WF&T5^,X/\
MUO+(G\)OYR6[H[U'^,5,IB^"@:X(\YAPPD@0;);"IY!\M #)#67<58[:6T+S
M IAWC^N0[[>)ZVKE15Q7.]N2UPM@UHRN-R(\JM67<5UMO7FZW@RN%SF($:Z/
M*OG3-1CAPN=_J]DN>_ "S,<3TW(ISK\2?"@]9VW[N+K ]0.GH]J9=#H6KW@C
M\$U2P*OA6^Q45=NO@2\-1RZFFV<1RT4J_I:)X;33N3L#O@H^T57SKRG>V J,
MQ<7FTA9YM078;/W5^OHF\+FF[%Z%.MN S_I?1P:?&Z+/CJ+/>G[XW+2#%&>"
M;-X1G\+<(C<%%,NVK(M9<.J"V(W8;K5%/DG.B+T2GL68+;\(;PC/@7''?5CA
M92\]?)M"33U"31M04X\"FZ\WVFJ+CX6J[>;48>'+ZYX&]4_*W0M/RDOWACJ9
M)[<$W]T-<QSN]O]D+A/4Z;IVUQZ"6I ^QJ,?&.Z."\O,#G7NXMG!C0\;A3M[
MX5ET#KIJ"]'5J'4FL#4/](WI@\N0XC)=E7\P[#W'[.X#0-]GUVP(:X#?,PGI
M*$)KVY1HM3KH@LY?C:^UQND&U,'Z0&Y,G$5+^%,E!YSC"1_W[%GG^IO%8];C
MD+@PF26X\V]?#C[6ZJW*)N(J\R%\AD1L?GBN>L^=JFYSX;-J6*G^>!G+P>B.
MQ:WBJ/DRCK*"?N7%;YJ&OGBBQY303-"\5?RT7L9/M;%)$IH!X*9QF!$%WP+$
MPHS#O]=CKOTRYNJ=6JN^.=0]@VN+B)N2H3&]@\*UV%;0V9E4G7<C)N[48J?/
MEEKE>G4K.%T$\LJ8EJNSP?(HW[ ,.%H2]9UZN;:*5;QA'&Q\#^+1<]^!>F69
M'5C1)]DH]!O'_:0ED1OBJ\M*G<YF27]Y\/5U!AJ9'6BNO0. W*O*)L+ F_,#
M5LCZS*3BG(?YC=/F6C7CN%83Q_5VP(7]?=03\.PLKS4S]0T;4>SLX8S3]""U
M L0@+&L&3E_(LFM,Y_B^#N!M9[HV[FJ=,-+S#= @?6\Y-Q\&VAZ&%QSVJ&2O
MY3"\8L+L]& 9F!5+S#/.UD'@%+S-)>5DI9P]6EZXT.542NAZ=0-_X G<E^\N
M("KCB5TY-%5E:EP5@0[M8Y7W&4N#2#XL,EZG@%["-UK*PM\X#!JB[N[Y0)<N
MRQ+:*Q;Y:?Q\]!E$NH1'5FU67E3C;W2[;A^]W6Y79PGV:K5U8:]G)LF:TSZ?
M;I'U]XGUN8LVRR<*PUFLJCL/+NM+5AOE9YRH"8KW:/MWS=.-I1S9,(K3*-+V
M;TKH?!\!1M2G"S[D_C*^[12&E_98EXF3;08*W3"F@1QLU%XA!]_N-NU<7M5?
M(:]VN4T[DXVO.A&>0FYC^7/>G8-38"SK(-XP>?/HKVKE:\ML[7:W=N<BL15S
M;4%V=M/^8/07K+Q<.6346"8$<51O;,LPFP^#AJC308XM$8/8=KRHJ'NU<\%T
MI#MOJ480GSWI7_8PH>^+)[ ;B/2'S\XUYIUBPERN9%W7O@E&(V?<[0NFSKPF
M,JR90WT\^A+^.'-*H4X]UHWO-Q?W1#FJI2U1YL"W*(,US&[L/E#N(-;@/?SE
MAEF!4 =)X1VYFF-H02:LZIM3G>Z;LS("GA4US7U>)=Y]=P6C#A+PQ=*)AKEA
M;W%B;*LV61NU"N#;P-I4?GEN6%M<,G?4WB#:-BHJ+[S'UT6YF@T-_/(I*'3#
MF ;F4W/98^%M1KF*MTV[MIR:+7VY2=D40+?8</";!R*J%[@V"K&X[]P4CAL9
M'*=Y#5^XD/Y7[J"8G>2!V_$(56^:/J0D<GXBO?U"XLA$^[E%>)E ((I[><T>
MF!NP6RKZ;)HTBXZVSE)HB_'V'!V;);<=XB%*9%I^DZ80]T*[QTF\;9O>BH.W
MU@*'*(.W?20XE9JX-MY><)/:.Y5OQ4'; O\H@[9=D1LX$/Z@"'JA]4*F:[6R
M4_E6'+R]D+\:XVUG!,=[!4'<"UT>J[LVX(J"M]9R>'N9X))HA^-@'3:S9WLI
M41WW4A[:-9.,"FL :#F%*1UOA"B)1EBK$+RUP,R?+.-9#HPM K_->OC6 K.]
MHJSVJ0C6[I$Q&>K; B4L,, !!9TCO1"P36IH+SYDZ%0;>>-B042R_4*#=-U(
M>6KUB^/O1Y7Z!A:_DZ;-J>!:5Q6U7[09EVA"ON%.S1OHS[<V.EXR!>M3V-AY
M9[ZU(5M@JTTIX:5 "@V3^3'1^':0L'_$)=!('P0G TJX[/48=I-8@W&7J$'J
MM%JM=FPWO69YZP)ZY5 KM#&QF@W+NC<"^A*Y-,U&N[$ZY,NL=W.;_KAZ;?,B
MK"S=)Z%6*:?F]+8 V";);!AQ2U>FK(FXUX*4_XT3FQ6_G1="J/7:1N_ZV-0]
M$SO"\6:4=^>%<&NSG3^.NY8EV*I>Z=H(66SHUJ8ZL$VO;<VU;XAA%J=[K+KV
MV:)K]Q=0+&JZ>A<)T8GC\-B3#+.B</&>BU0X V-9VW5&^^UJN=EJ-?;GIH37
M[,*"5JVOW87F2[O0.JK5WN@N3(J&5R+ZA3MOS+4@68I_):X777$3=?;?2&^W
M8M^BL%&4+[KU)KXD9*<7LA3@DI!7HOSE.W"J%7,'SB91?K3$53CMG5[/LH#*
MU^G#M9E+$K9H-1Y556__YM?JR\6+>]'>?V>6X!$V<VO\U?E:?1N(G90+VR39
MND)L[6OUY:K,?<3L%DFVD>\U-)LVT%>^EN*5Z%OD^YG;*5YO+2QR^7+&+\;^
M/(?;:IXK^&2-;P$;GQS/^KGZ ?M1^^#C_W+\$YL_$.F/'?;AX&OW^L_S;\>D
M,O+AW],)^7+Y[?:85/$[IE5)\HT]DFMO2-U2^$.)W##!>^3@?_7]$S(UW.>+
ML^[U\;WG#TXNSK^='?[K[/S/?\%XKB< GR<DF8Z[X;^1'TYY^*7[]?SBKV/R
MF3K\7O"2I*X\E#C3"?G4_?Q__KR^_/[M])CXF"TUHMBS,7KSYOS_GL&*JR,_
M7=)[6)/.ZY.^\-P^?L5O//[0@QV-ESHQZ^]3>_%[*9HZ.T,EFF'%D7Y70_T^
M?ZSW.!A^N1+<M?@(&(-X/3)!FQ//J2\)4.\G@=5]:S:S!^1_T>'HY'^JK<K)
M<]2\"0S<#E@8S(^(A-FDQUT*!$0=&#T2SY( 23F!S8@_8(1:%IY^*/+JCOV
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M<@Z+".@$='L!T6=/^I)X/<(DNF)<#C"C=A22<PGED>32Q]_@&8?UJ:.ZR?5
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M;)0BO3FEPD^Y] 6_#T(E#?SZS$(E[Y!"LTJ,.A0$9?K$A$Y3ZOW,M4%/PY]
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M,Q*()0&Y#->PS8%SRWPIQ5[%-2(:[=C[C\\]L_]V5"S_.YR,7/:,US];;\0
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ML(<? &@,_T>.*\J)CHL519P(9T^9#*P3_(XO/T;0,>.$].!IWP)32;TQT,&
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M[G"O8QOP-^8^LQ1ZMG+3LWAR)B&%2='R):BEJ ]*0*F>$Z/:/:@&O/(],%J
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M2.![]/6.>NP.5_7JIF6*1;T]'*#'7KVOEJ/__>777W[]A9 _9L>Z8'WFNLR
M03J<,X]W;./:I(\PCF<RGAP&CRKUX,L=ZW\^NE6:#XKZH"EJH^<HC8>J@I^;
M1\0T/A]]HP"@\=!H:D=?IGCYHW/W_0ID"?A#QC62@%]DBI^5X \5<L]<LT^.
M%HC&]=7-Y7%4RXG48CR=:0?_1MZ4KIQ3RWQTS0JG-C_F.%-2$]10D,3,?:!
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MV(AC],B /C/RR."91]?Y&_YC."]V0./_]:D+) =,HZ<K8KJ^Z7(/YWH9F/J
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M+CQ]3L%900*'EAWRC> 5\++P*&1/X$Q$F<I=1^P^64 XQH &.%3"1 )3R3@
M06$-/ ASAP@.?@Z=:W^MI3Y5FX%UUC'7LZH8I-J<PQ_@R:7]9+$7QP&7<>Y8
M$",8S@P_J+T!EK3GLB0JV9:&)U6UE<*37HP!+B3%3[;Y7\8%J  VQHIV )E(
M^ZF.GM>$!S"#%1$ %F^.02$8X@@,F(_?";DP^WU@L8T!S"/S7K F*[+QQ#@V
M\Z*)Q3QNK+(21 VZ12&([)M,1"A10&#&1M5]5[QF,)@0A4I\PW@.T^YC 5OB
MMY-"#0U)4/D.YXY(&<5($/5@'(Y5,)!OTS$XEB\H!E&6Y;SPT[P%X+7T7X(>
MIBY4,NPK)UH?/Z\N>G_B"\IO1P3B^"?[\U'P=&S''#8F(V@F?N+UE/J>,QZB
M4?]MW"$^[UY?=V[O 1(=B$!'G)V1[K\N[[Y==W^>DF>3FS#B$=&99:%Y!I/P
M^4@)OH\@]8F^SX-GI1U^$0W>V38N;A=GK5GP0JO285CT2K)2(-B,(]@ K0$1
M!R$&.:W/8/MO1MT)QI>VP8S)5XR7)M\@C]M5BI1E#V_IB"$UO/C]^:4@0=P&
M-.,F0)O=)*"H3<GI ^%TX[ Y+4WX0;&[7 @6N)+WH/!O[ G^DL$2?RG@!WYN
M4IJ[CE?M5F#WWFPV* -ZJ\ARWGTU)=TTLXQ=4JOM0]\24P;TI)1F2ZDF-V[E
MW+@5?9FT41[%&A[1W@@))( YQ0[,&1'/'%OTS?&]T[[YRHRSA6V2\?CN^),1
M??H4_^A./D80__')Y\=/E(Y.<165Z8G67,<VSAT;&[7,UDW&+TRN6P[W7=9C
MK]Y7R]'__O+K+[_^0L@?],WS<[Z*4X[?%PM\X,L=ZW\^NE6:#XKZ@/63GJ,T
M'JH*?FX>$=/X?/2-ZIYI/#2:S:,O4XVQE9<LD#*MG%A'Z^^=(,48*EJM>IRE
MHG%KB)T[C\P@C\QR7L13W!\.J6O^%__X%K2910=4+-46LD_'R]82?0^Q?NVT
MA'18[^JCF&&\%G8QNSL[,:VI[=BIQ]?4BD4#OA>-V$07K^C#5LN'H2S>JVIV
M];Z'RWLDKP^"U^!O6I+5A\+JMF3U@2"X][*LK9)TEP]/*<M2EA5-E:P^$ 3W
M7Y8UR>J#8'4/C]Z@?0#ZL!F^=XWCM!K0;=H!3(?<]2@#>EL\N+&DK;M";\VI
M5&O:H3?WRH">%/.U'C[:D.LL2H">%/*U'DG?7/6BFF+N-)8GTDLEEDJ\A;/D
MI?I*]97J*]57JJ]47ZF^\B87*=Y2O*5XE[2%4> VP)061OSL_BWP.3=RNVG&
MRK"%<],&JT"<T_H/6[]'48JL%-G=<*)24J6D[D@QHKR\E)JXR]S;54U\S\WQ
M4B.E1I:7>[NJD>_).Z1&2HTL+_=V52-E7B4E=3<D=>M7F9=!8DM23E_OCH#$
MK6&?],G%8SRX>(PF+P4\T,Y*&=#;(^-5(,YE<K-24J6D2DF5DBHE5:[ZDYI8
M<NY)3=P?7DI-W&7N24W<'UY*3=QE[AV2)DI)E9(J)?40"^KK79_>[?=-/;Q6
M^I"[)ZL>H%4V%F^< +O:,U2;]4/O&$J9/S29KTF9ES)_6#)?E8L*I4I+E=XG
ME9;;:*0V2VV6VKQ?W);:++7Y,+592KN4=BGM.R?M)>F/K'?#P?;=>!E:80OU
MN@IZ;3C^(\Z_?0YOX;"R)>E2HH9PH;<7-"IUM2E/=I?:(K5EL;:TU9I4%:DJ
M4E46JTI#6?4JA;+%F#+$E)9 6H+5+<%[3FZ2MD#:@C*)M[0%[[,%6S^K5MH"
M:0ND+2B%+3CHK0I22:22[,1!6650EGC?ZI-'@?>3KXEWHF&1)/@8L,0UF/OY
M"* ("22 .545Y;<S(IXYMNB;XWNG??.5&6='1&<6WF6NF_:3> ^_CZAAA-_'
MX[OC3T;TZ5/\HSOY&$'\QR?ZYOFGY\YP:'KBS*N.;9P[M@=C,ULW&;\PN6XY
MW'=9#U_JL5?OJ^7H?W_Y]9=??R'D#Y\?/U$Z.KW7!\SP+=;MW\$PEZ\C9O.I
M5X@. \.7.];_?'2K-!\4]4%3U$;/41H/504_-X^(:7P^^D9USS0>&LW6T9>0
M.1&U?G3NOE\!<X'C\"_4FT "2$_(S0W(S1W*327X0X7<,]?LDP2OH^'.KR\[
M=Z>@)X.D#$X-=38M;"N#$4"!-"(L(!+I.R[Q!HRXC(\8(/[,R @>=0Q.3$XH
MAP<LRWGAITGQ&DMJ43C%-#6ZY5[\Z>KFXA*14TQ0Q9]7%[T_\04P#81:YI/]
M^2AX.M:I%9(^P[#74^I[SGB(1OVWL64Z[UY?=V[O 1(=<*4C#FK;!7W^=MW]
M>4J>36["B LU82X\*W66(QJ49DU%K5EP@%\Z#(O.8$J!8#..8 .T!D0<A!CD
MM#Z#[;\9=2<87]H&,R9?_^G;;/*MJE1VE2)E63M2.F)(#2]^75@I2!"W <VX
M"=!FB],0!4E.'PBG&X?-:6G"#XK=Y4*PP K20>'?V!/\)8,E_E+ #WR]?IJ[
MCA?G#KG(70;T5I'E';\<?!F[I%;;A]Z**0-Z4DJSI523#<.]:1@NT?"+>H2B
MQW@_H"[[2CDSSITA/DP]T['%7W]2UZ6VQZ\X]YG1<Z[L9[SPWN7)CJ&J3CJ&
M\#GH&#8>;BVJB_MZ.D_P/]%8/]CPD;D^1UC/+<IYMQ_^U'7O4(TZKR:?ZC:V
MCXAOF\%L' &#!PRFFR!P_//1U<VWHR^:HC2;8==T%8Q6(\E/AA SH_/,7/K$
M+E_QQB+.;ET\=W&C-&HI,1K]=7_Q,&+N@X X3BKMZ$NU>:(IRQ(J"\_IAC-V
MJ5V\QHE:W4?+?!)C)HG1X5U[7FNYI281B8.O''U1&W6U"39K(N^I\^4"ZL)G
M5_8-0-5[8=8S^P'/#/@2D&J9D+;5VF(X4T'(#_P] V@-;$XM 78U$^R&4LT)
M]F3R_ #W!J:[++RU3'BUND@@\P \GCP_O-\<W_4&2P)<SP0X@#<7P)/9EX#8
M["\-<",3X'R@1M/FA;33A]Q[%6";F< V\XI#<O[->,0NF,^.93EB14_2V./$
MJ3^CJ2_03;06N]*JHBIJ;?=\:0FHV]ZV$Q8CCC%P#+-O,F/Y]5UM9;&8J,UZ
M7=-")*:GG%F%EHID!U]Z$J3_^C9YY):^"6Z\4->X_%_?]-ZN;.ZYOE@'U_4&
MS.T-J-T=X1#\>T A^U:LS)JBD?CQ@GKL&S7=?U'+9RO00LW)5+4NF%HZE&<L
M<IHP=WV/>]3&5"3%%FL/6BN--%J.P+Q>KZDQ<[Q@\ES )D1__",/?^7J$AA4
M\S,WX556 6OMN#W\H&\HS.\P8>U:7H)HRBY0I*M[#M#@O52I+V?8"R7*6)$[
MQG]\+MS7Y*TI>Z:%]JP)]FR>R&='>UHR_,^</!?[;GPD=[</Z8+OFI[)^#FU
M+&9\?9O&?-VBW5QLK5J-1J.Y@'_Y$5J_>'^E]M_,Y4M1Y4'XDSN&_B6\;3G^
M7N*'<X=['=N OS'WF:70M%4V^UF,N$UAF:, I=;:$ ^M371N74=GS.#?7&>(
MX2"UXR1:V@J(U5#SK,!Q'<R -I5'90,P#>X%A";/%)?,7YOTT;0$KIF2'(X4
ME\1[#\(8M#A!1(1AE&.S,&J?0F=!U:C92B"3"MZJA:S:. .Y 7@A XKC\)?M
M,ATKQ<9?-I9+3!R$6K>^JP\@\)L,_/7M'-Y^<MRW;O\*T(Z>,%*0S2@\(>]:
MN2H,B90AC#^[_=1'I[-;)99_*0_5X//#-]/E'H:M(-(X6-*H6( =A+FN]]8#
M/G-$!:)A-$>;HEI&W4M(?$2U/ 19G7B*&E-.-21>L_3$RRC"(?%J*Q-/(/[#
MM! +F\&;HKF240[:&,H993PA+_4XRJEH) LAHEQ:2DPS(D+$M)Y@;CH>"51%
MH;64F&84#Q'39H*GJ6C,>KI'+[87;^4]=4VEM'OJN/E?=DI:)W73)JIZHICV
MHN&OKVXNCZ/51U%G>(P-#"/^C;RI=C$$0^:C:U8XV+ACCH@DF\/JR)O,_!@U
M0?M Z0B&Q' ?IA#[4$D94PG'O'&\V":>5K2-KZZ<$;!BS\SU<*L;@3!H:'(.
MPD;P#2ZZL C!N"4[ABO1/]X>G8HA#YGJIR=0WB=$BQOI0F10Y)^^]4:H;9".
M_P09- '-KU=(!PP,0:/!# )1I0VR1$:AX2+TR64B\.7DQ?0&Q(2XP/3\P "*
ML0:0)!";>>3%<<4#0';3 #<+'Z..1+1]=3(LO,@I"+'31_,TENG11*81#DX^
M!LQN01)P%DAY]%T]^ST B=H )8 ))A@',&W='"%L0\<'VL$$_UB2D!\$)3^D
MD[)^HB6DC@Q-RP)JG) >(!CAA,@*<,D+Y8@V9BD>\1Q"$<1G 6I4ZS\A:+F)
M&:8R0! .Y/8<"," )85"7U/4\3*;"(,*>1F8.G).MWSP<0+X0F=58\?JC>G6
MIZ9+GD4A/"38F"# 3_S?ES"C.YE5\[W5^=S&K3@3,V')/A"P-]$\YJ*A@2B+
M8XT#K=LX4#L)K)YA&FAGR( ^LV!_/58\4$U'+AO1MY@>@]:B$7/$GX84:U+>
M&S% D4_(%2[>!E-'J*Z[?F!&)V^:P9=@ASZ:X< R\5/RT?P]R>ZB%*Z5X.MO
MA)O#$1@F,X)SQ%R@C.T/QY:YCTD#//=*AL':$[30'\TX@,LR*1-"HFJY8<0:
M(:/8)"<03R*_0I<!E#8"SS9!P39M%N(PRYA*8([#+$!X#V%XQD[#'P'K(NY6
MPGDX%EN 3C (LY@;%%\21AZ)I3N^9022],B8#;. < 'O_P:/B&_#1YWR004_
MH/!%CDQMGG'<;\! &KGN,B&>TLA)(Y>!T6W24TX"+*??9T(A0* "1YX,V$80
MH\6D=_QX7)I#VS@>X9%:(BQ)2#P8PDFD%R@  !+45H5>O0R<83#0@!IHAD$-
M0>M,/@"M=;&,A/67@3DZ(=\ ^&!4,>?C6UHT$,:I0JO2@H5UFL\0\R?7X>@(
M@NHS_G4AU %ET.B$O@?#*T>$>FP<WPCN810[CEB#PCYA_XMA-#S?FH+!%L7[
MV)/AKUB7IO8;T #S?A%0HJ$35BUNR^*<%+ $4(WC=3#"KF/X>O#W^,@1FM,Q
M;(1NZ.QF?A=F#]<7"_$+XV#V;#H^AYQ$<-5V[&.7]7W;$$"#):1@RUW29ZSP
M*#ZVVCQB<Q# SXM! \-."?B3(4+3QR-XWAC%Y 9R%H$T!@/XVSB0#^GL!D73
M,*,!.J3G8:@C8=L)Z0?OC_F/H\3X%_R*#E*PGU O#.%C'LEE,2\)_'3@ZQ#\
M8B ;)^1\@(L_$)I8(&YR$E6Z\!= #]SI$UB$;Y-G8+) $#&A$2BC>(]?@\^4
M&)C/H#L3 HV8@FR#Y?DOQD8 DQ@A(J4@';P@G=Y^((IJ-%8;$81/A,.+2QN(
MBN783\="$*Q8<RX,G[^&CN=^P%@@1=.&3(P^!(D2=HJ)WAS1L=UI]DV=RE!J
M?Q#]"UD_$S=3PQE% 4WG_B]A28^KE2#R2=930"@<W12&>!SXQQ+%I %#N9R4
M71,"&EAN\0YX,(X;=XW([4U)K#"%)HSLP?#@3N.AEPX:\C;)!I,^.5  $Y,&
MG04(BDQSOUDLTX+WI@6Q.F/D8<>Q84:9-5;EK6"*/8G_0Y/*QXM$T(1C'(C;
MZ3#HL-BT(CFQY9L8\T&H9(-2B"Q]TC&&MS!J 17!?)Z2_P<BG6"%\+?QXQ\A
M1O0A;-83>4H G AP0?U\RPLGFHW.80*+48BO"BX 3Q4RPP(P^<A>L8 :@(,!
M#3-LQGDB#"/<AS!M3)'?,\I*"8OP>V#2!L 3<'TY6,I%VB5R/&$_*N31]P2M
MQ=_&A; *$9&A&"?X*<:^6#$=0[BPN#6NT- )();#0_8D$>1!Z$E3,Y:@\4!'
MI@<SA"F+'4N$QN&OJBGC!"@V$,X4CJ932_>#*!LR%)&71F6A)1 *DQL+N!9,
M\9'^'OS%><'?L7XS$WR+W 7>C'H; 7M"N&8X7L%2T,?'WXN5R;9VTIC.9CKH
M?0(-B8B=+#F-VR^3M  =SS^I[5.0(DB1T)TV*HG\;R:5!;D#8C,4+:1+*,GT
M$8(RS.: L+8>YCXQZ0UX)Z9$.$2I#OD!+E@XT+&'CHNX,%7"IE42XR4E?4J@
MP8EB8<*=U#$^BD8'QP0.C40H!*@>OAT6[0)Y^'VQ\,9IMTA<,R55$$0@&($)
MOQ;;A*DW3N9T?I"I(FN?"'74J NE/:QEXD.A2YA8=8-QW34?,71"KI^0KDV^
ML4=72)$:2%&]DLB0D_EL)=G"*SK7KYVHZ08;)DH:A&+I74MI>L4$;FQU$LV"
MJ9Q]FC"%EN"K6J55G0(P*> )@Y$0=A\\7%AR=,TG$VN+B6AC'%'(F%7&K%D8
M@=W_0=]"3Q,9U9'%4 70?SV9'/7$F D%)Z8+=(:#"W+%&VF!I'#VEI4(!>(]
M0M\#,,%]P3-O,0T,%9/3811*TW&!,P+CI%"5['A1S1ZQCI40A;J]0&P8B_XB
M$"HSN$T[1VX^V8 /+@;S1XDE'8*&HI07]/V'0142 G4 ZK>( G%3#?;2A:!:
M1+DBT5"K@;?+X=]NIOU;>W67%/(A)B 3EG0#F6K$ YC(]6S,[:C;<3O-5LF]
M#L0"6K.]FM=!:JT=F(QE)])S2<\5]UR@-S8+ZAE3&4N\SR:\FE"TT,/-Z0>&
MN=-,3RUJ[L[D0A-?N$(G<5Y2,U_[(CAR=#W#IF)6XW$F0YVD< "JP"]NJYW9
MI"(*&,+)QD281T?,5B<+$-=IXBJJ6IUGX9(&S4MI^Q7NB68SOXE?364#%POK
M W\]Q82$8RTM^;6Y#F;SY)\-<N+4[PT8C_7+,-()X1%=<-2Y57K--UF]YJ#5
M/=W:QNH6EKXF].@S+$C*MH-TA)D8=2SNB.5MN;QAW!%.FF[DD=FL;^HFV/[8
M.Z$$KJ$F-&4@HN!\DGUDK&@X T3PVJ7 R[HL[ /RH*F1V=D+5T_,9B-")R>2
MF$T.A"\\?3;;R0;+>L*0/WQC@3KOZ%F#<S8_I>V1FIQG$MM.<SXFH-CSG;;7
M';=-!?M+8^]-=N$(@L>WC5T[]A/6#7#.WMMH=L]Z4\E[2D_@PI/8YD(C-_X]
M+'"(;9+A^]]"65MZ]YBJ''TYR$)&#O;,H_+,(448GH28!UO.<<I"-O>IJMS<
M5YK-?>WDYCX1F@K>S]IHN9EOVP)@%BL)YV'G>PZ_3<GY_4 4?"%>RT>J0=6B
M*;*Q^%^B1!H]7*&)<$NK55K5J3)T\3745K.BM)-KYL=I=IAW3WQZ)7:'J?56
M$>#88K\5! %8QI]]!8-F9N(NH"E".LD_-(*\-EJJ,( @N4A$BR6:HDRM(TI^
M&>M&E)C,JV#XWL!QQ<+J8#,L&='8MLI"DZ8BQ\(3VQ0U#P%BR]P+EMQ"&5I?
MF9\QT=]KEL:J7OMM\ _&L\WV[EUJ8DDB92WF"+Z]0D+K@=4ON.-Y4D^OY7@#
MU_&?A +-+B,M5/F;K8JJ34'Q%^3U_(1THSG7N*M?G7,F07*!+)[1$&=)H2 T
M3JJI()R02PH),Q(C6*?!Q<J*/F3D+#3KJ8OIQ)*-J$2=:!UDOQB$ (FAPOZ$
MV(88[CQ\9E/'#Q1<7,PZ(F*J[+[^[H\X'76.)0[V,@!X6!S$19)Y>@TS38NP
M@; )VFIS5E6<D)\  A:B8T6@9+6)DEK]V ![%:X3_8A/X%'<Q^.SN$EPK/'O
M"8'S1R1<$V%$)S\5'$"KE:::LV%E&Y\@ZATO41 2E< RDJ:B4XE*O38EU:)Z
M9W*QH>^8CDD84C=J%D\Z6R!I8AUIP?)02Y'M*9 B,Y(PAVLSA?/VELYHS.SB
ML@3!1(,]8YG3?L<6AQ1$B1YM$$6],"*N@APOQ4HYBBFP7.-U&HVSV,?HQ#G2
MB9Z.K>>(?<0-)<X3$TEUF&4$,A8>;^$&Y]+FFO,N_F)XH.WBZ<6LUZ:M.Y9-
M;JG[-XD*8M_ H%7(]?7YY/2GY(3QM^:,?T+$AD%L&$0;069)4TG.+Y U$K:_
M4!O:J#1:M7EFWO'=V=4VQ6Y<4F8-DVANVB!JX-CP>(BQSQLO[YXLY!Y[V#"@
M$GU1!-D,K"SNTP?:)4A:=*"M51K3<7:ZISPA7YGW@N>PW+.1)YIR0L,FQ3>L
M($T)0(2^L59OG\*%$(?"6:[59B=+W1P;+1L)UN[PR6K;-64L[;1CR#:8K=3:
M*3[Z9^")39M&\>.LR2 ,W*\H7D8+:M1@-513^N/]0'3&'X?FKN!JX5PC +*.
MJS4@%_0F)4&Q$G-\<XO8XL9</!\%XWW=]X+-;'W(']T@T@ZVG3LNCQ;4X]$N
MX_5@FJ*)8KDY7D:"1W^,#P#$78NX*Z]"GIC-W&B[I &J$3IZW.;U+8SP,5N$
MH 5?3)3G T,3C8]+5HHM^VCU.6>XC'<DS1XQ.$/9PL&JSDO^)_K3$4Q.H97+
MAL!2-("^.'$88A>L L=85'#NE'2E,T7J$Q(>'-HWN0[T#"#% DSRO*'$DN$4
M@02J!PLW@O-"^2P;4#H#P>O[5G@,FT@NV;,(/7KA6^ ?)J<M1(V>B%11H!>0
MT0@6-\=E,.'ES!BH"01F@ N.NBF\2E1-R1/WV[0>D@^9++=->)&U+GQN5E0M
MY[IS3AX=V^=AT#EB;A_I:0<;JT2@+)0$HIX4A99BNA^(@IC>.,^3Y$@(ZC9:
M.*V3QK9;.%JK46G6IJJP&^WAS#E69"8K"D^A6%-JU)S#BIGT/U9UGM0LYZP"
MGVQ4"DI-ZVP0M&>WW6\RM6S*1E@L%FZFRW2 U%I;<+4Y7.B)9<G!09<;[\6)
M._G6T8J;A]&&V#RG ;\!-L_KM.YN-Q"/#<F[>W!A-W!2T2RVAEFK:(TI&*-V
M8"H--]4.5%+U*[T=N):FW!9;XVHSS?.MU]DJLZ<-!$LZU^9?TW"<.C)BZNRB
ML)$QU@NQHE0>3[-?B%[%MH=/"FI1A0@#+G\X%,4?$[<+1>$4"\M$?28.X8O<
M?T7L#(:?AR/'I:YIO04'>(IBW)KW:L]?K%/!"R,2"Z/C>Z[7T[.$K*C1:.;R
M1M%E/-M<SS2V!>(DRK .#-Q+/^1\;@TS6M48.^4LT?_6E+/Q(]&]H_&+B2KC
MZS,VS*XJWN^3,WK8$+^R8MZ"V!7>K+V(98G'4M@FF)9<%8$CS' ZL"WQ@:.&
M0YHLG)#QSZG\7^]1"+5VI5[7\LD#,B&PB&&I?K*6+"1^FMVL!(>.C%&8*AQ-
MW1^PWCJ2-C<?2.&!.( 6<;8=;Q[>02M!G(4O^K[1_NV1RXX3SB.I1$'8$UBJ
MJ0SO'T(?XBH0WP]#/G(6;-T&+_F[#$[V ]').OEFV@JO'\Q] G&8K#$0IN?&
M9Y8%XG%EZR="<C!PX;%]P97$O7*!(0U>(B_B+J)'!OK-Q,JB%W@'I,MYP2X<
M]Q^Y:9@8*LUX-0%*TGQA4AF".+DE$/&IAPL?\ 29$77')QT$#\>['J$1"*&;
MVO 2;?!>KR%,Z19/Q&_^,JS]/"PA]_;RU'WI5X*I06OX%HCN&/_"[!)X(7Z9
MOF6Z'MN37A]?T7UUVTU<L#Z6R7MJL6Y?3#1[8(*ZX+[Q\:VY2P&<$TMQ, /?
M")KQ"\(#X8QC>G7S#5!M@4PO1'0*YFE,P^NQ>0C)55A6/!=]CC7BM^ .;U6;
M8F,6G#,XA:''-]<91@]>!0L<;T43*=;.61N""V[L;E2G$<P+]#2V@?KB_3Q"
MIB<ZG'* R02KX*@! 7P".P]L+Q(Z&!6#-L=&NJ=@N."F[MHT"^<".HW1.=[?
MTNV'L737%2N*+\/X2IQJ,OZ1A[_RM.-:WLW#9M[#642<-\%T)02*X6LX[*H\
M;2VX9UY=E:>";%^Q$'T>6\?606"?!'!?WR:/A,K>@5#=",K'_+L@UI4=&+7O
M(L7(H[U8C![7HH.Q5I&$]F)SK*KP6,P<%X]PXE[[OV)5_DBTC&X?\:5)?#=(
M)TU93*=6O::%E]KGQV'])J(@ J@Y309N6RK88*1YD,EKFY2"C!A- =07.[X)
MV F9CSFM(*P1&9/1<\;+M.<?AM0<(QFN^,<%_^&&$]QO<FWIT2CC/"R..Y[?
MU>W']#<%[QQ!6Z/1JH72OQ";>;@+4ULRU#/B.6!Y%)3GPF2I8#SX^S?'O6?N
MLRB\;)<.]<4BH#5RA^TSV!61J*A*VAEA:Z1)(X?SS)6T+<AE5LA--TZ+9K9I
MK!60O.9/Z3:.?49X"=BWU4)3/CQE;VQI\AR3MT;$VYF(-VKM'"XQALU29N!N
MO)P]\-<89-XPK]L'N])G)IX^F,]J7H1;2A+(FQY& E?CJZ!GD:_F" KK2^A_
M'GR6,0WOI,]$?*8&BI-)#)I^!&A5S<ZYJM-Y]'MQF4DTAR/+>6,L]#'IB<N-
M8P=;-,20O(<K8.._HU;>.-Z_&> 1[5N9C!2\U,6V6F] [3#%28G'WTW,!>5!
M;;H\N#7D4R4T^.W6HO9EN&-EC7)7S;1)M6J*U,W 5VBLUHIAUQI;G<MH]T$W
MV'RPK/6IY:BDJEIUS1%99A"B3A"'SU7E/46KZH+"8ZNQK0)YL6CF""JU5J-9
M:V^N0EXL@AF1HJB0*YNOD!>+X():8W-:4)>ND(MLLV/\Q^>BG@%VNS->LGM+
M3>/*#J.\J-@0R ;\>;R#X:?I#<(:9[2J!!+5Z&*+CKC7 HQ!2MTD%^6*J;=4
MLZ-+K5V=)-_;(L=[BE5K)5Y-62"&>1HU<^I5 :GNPJ6_XRKY;-P3P^K]C9G:
MHH"R&:_&S('Q'=V(8I%9$-#5:EON,KW;#M:J.4O&8MU0037CE<7S??VEVH*V
M;[6^,=%\)R(+HJS5FY\1RSJV$?"L&UL_FH'0%'P9S5EP"6JSFH N:]+B+?<4
MJ-DEL>H*QG=C3<?U>J;6XA 7LC2U6OZFXWKIE*<Y6],:U;)T'0NG0%W)Z4*4
MXCS(^ZQO N]HCCCFR0M44E#."')$C[&UW;4GVH/6"JHS/^@;HIR&Y-CAA+/.
M8Z^6D[UK68=2/$7"9?COI<HVXJ;,06[$A9H ,--]W&;&^#D8%&9\?9L>;]T"
MDZ/FU6HT&LT%5,F/T";I4Y#XY.C4@G--N->"B?2N5:9-L7 #_E_0Y/V)5CU/
MEU:4S]];4.MPSCQ^X]A +Q=7NV>T :9@S X55;7=:+?KL>;Z]%3O &4J:JUG
MMS(AWM"T9DO)#\JDB'].^0 "<?P/LNT9/#]RS#L/KQ6<DZ3-)5IV=0B\BUJ;
M@+DD&.O#8HK>C8PR#6"A%(9!1Q<W/'*(CG'9_/FR,MI8$)AHFE*+ZU#Z?.^&
M:II\"Y9D536MH=17@ KOE+\VZ:-I!:9O:7)E=Z&:+:U>;23@2I^Q"-"F:9:]
MI@FL35-55H%M=O-%!E#U*: R"@^*N"92;=3J6M9.C_>!4X"K:607)QIK!'Y.
MQ7M51!:4+EKM=K/9:JX1GSNF,S!LH**B)!)[>U64LOW:<7VZ[;0&E/!84V9<
M4A=/PDR/[7(@DNWVCM56M:56:^I2F,1:P&O6D6:>13/MFEJ?*OZ$T"6J-L$2
M4_^1ZZX9-/"#RL^<Q07UV.*"*9/8S'9N8^'(G+8PV(H@<[9?W!PJQ1JF9K97
MW1Q:A=NG9IZ%QIO$KQ!CU<SVZH7@ QEJ>*_Q9C0K1SZY"*\(Y"(VH>:Q;@L6
MYZYQX<SRH!?!HFQ?7QY4"S:."Y9+E(O-A5O05NY,>NN8%V);6]DQRU:VBJ]+
MHUM:GB)>:SH]+'2GQ>1J^^B:>W'Q_:0\NKQA;F6',ZJBM)56CI5^^>#;.+)%
M,'Y!6+2SI"G6]+<65$\"0:KM++6*=Q;9I9J<QK.4E"K&N62'C!NF3V"U2V.3
M\JQ?::E**Z<WRDVEJ86N\76NH?F873IT%]P,TG-B(]^""IF<.ZXX'&=35,N.
M3F?7\1:$7@F(5ZRM;V?'N6JUT=):>TS-PGU!>V$@O<>T+,1;M/-5&]=+P<D
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M)\@5J,<,\9,S8BX-UIV(GT-W#M_,B03!9X)1FFM@*$S0M1#OQ2&N4'D1,?)
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M3JMO)M" 79O/L[-]??M!_^.XYQ;E_+W*L2C2JRY.(M='Q?*R\-P'NS5D+N;
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MS0,8'T=Q&<3(,$K?=89$.U'($(P) @$S5B=?*S#]_/G#2;T!]<B0OI%')N9
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M1)0Z Q9PAHF2!BD\RCH#29Y\<]AWGJ24D1 -%P2=4M)%^[#9JC[[9U]Y27_
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M>1:KU^[%1;7DF>FSGANY/-M%!S?$H+L[MUG[0&OA!!\]?EG7CB,@UR^$B;Q
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M&T+R6N4LM#;HW'LC7H6D[9WM-2?9[JS:,(?=61O>61=[K4=1QYW5#.#ZBI0
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MLE2&#FAECRK6>:'[$LV\P&L%GBC?,JFV'-I .E KL1@!:O,8M6UTSR6-\8
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M-A)Y73>(G?FK3.##;01-?&5#T+.=LS\[W3]Q:]Q&G=,_CSOX^>R%P_U_O/B
M**S^G]W.^<4+)PNY>.7WFW<O')]Y'!8IP>G_W#T_/NMW.G__VVH#V>CP^\;P
M3TO#O^@L'/[: U<K]TY6(+AUOU_2Q>D7"1?[)7##%!;Q_5\9GXREW,H'?YE\
M#N?2_**[F.87P*^=G'N6'\-61C]#\MYC)%]_X+187U39!UJE*RHMDL#F^((
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MH 6T@);MHX7(4GAU081UIU@2%P>DL;WQQ]?%@?@C6"$B#; "[8 TP JT ](
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M "M@!:R %; "5L *6"$B#K"R32M?4BG J"),'31*22FT]N"0RD]![3K0 EI
M"V@!+<NF9;]\G.;N3C #9L#,QC-#9'E,ZL4P*@I3-L64(I2T3#&I8"62N4 +
M: $MH 6T+)N6@]V3XU.D/H(:4 -JUK8\WHMXPQ.CC^/?>?ZFM>KU97ZPEAX(
M[,O9[5]5/:BB])-_G6A*BN?<DXU0[BKNJ[P2H6Q.RJC4B4;#;>K%ZN#6$ZWL
MU.UD7.O)N#63L;/[3%/%85.3\C"M6C%MVD G1K<1(ZJW!!-*D\<CX;(FER'K
M<B\6+&BR2/_M/&AWN-]+)OADOU3^H)@<'H>VRQY:TFDQJ9CC<:5D4^I6N&(U
MT14>*['W/^/ --P)I2/,9;S+I6=(^$-_5U_X[SF'LF/'LO/\8$J%XN0,M:7G
MR< W/=+CF:C;56#UEAP?B^V."CR7N7$H_7O6E,KAGKFX7'A9K9>D7%L"D5&Y
MAQ?VD-B)L$KHLEB9F3"*^-GCSH_\G=,*/)'\V4;56%M$K< -O."^QQK"X;$2
M^GH>L7;@:A44[4;@2OT-[GD#G0Z%)[KF[EICXW;'-*.2[W#7#852]JJFX%&L
M/_5KQO7Z'='-2U]%86QT1ADM&HY&F98M1U%@FWAQE#P4>I[T/1WS!Z_'HI"[
MAA[?-5\.13/05SR'U4%AWMEXD1HVH6YW\M[7]W.FY:.UQPA],!TO#6V7-;C2
M'=:S,S M:B#[H7$YZT4Q<X)V6U^EHL#Y80?>Y:$,8J4-D1,%H1'H/0_=J9LJ
M;3JT?(Q FH'G!0^J#_B5:(0Q#WML_\1"7MZU7W-U![2A$G[R:=3CL8DTL=JN
M",WD25]/G_@9VY&83FG%F# =E<WF\XU/\XG^3]WWP[2S-NY8:42U[GW*.7H^
M1/B:2S;7;<:<T:3U?FG(ZO7%Y77=RO\#^U:]J/_'?$$[Q[/Z8IVX06^&L]=Y
MK/ X"H9-G!R]T\[KS>W%Y6U>NZNULZ]WNB>.UE7>4=H3O=$NZE7MYEN%=:62
MNL4<<X3GJ0YWM*I_RA63SQUMC@:?9_5GH9<N QG,[Y$O?RERO+_>-2NEL:]A
MN=[7PL\W]?K-EV'G6:GS:'P=Z?9!("*<\IAP3C6%&AD-A=;[_7D%-7P6C"2F
M'PIC'_338:W:DPEMH:0+ &4MH!C/9B0L[>),,+)(>>.-9&13=SK\4HWL!9[1
M_20!54&XD%*0_9?UI&\.ZS=?G[6%5(1#)$]K46F=;(,J4=$5F)7T=0%F!68E
MLV9EE3[@X%5Q[?)*M[5?)+./>@'?[Y_ XQ'20<F@12G]8%5FF6P>PORV6 NG
ML$AL:JFZDH9NO$M[T# 7,!>9,Q?EHT+J*4OTK 5A7VUUV_H6\-4N?\:RRSVS
M_R4289N][PD>JC_27@7 $E/;&DO4$J].1/-;XL-"Z21M5<F<:L!LT)$&-=W8
M%K-Q<IBVJA!6#<*>'*FHVZU4/_+-4)AMC=J5$RIB(8]$VDL#F&2LJ3.WIBX5
M3A"!RP0?L!:P%FE;BV+A]#1M5:%G+0C[;:0B<!>R*UWANZPGA>>FO1"  <8*
M.G,KZ&(A_;1T>@:8(A^P%K 6L!84K<4+9U4L*]'8-CTSFW3#<F@GQCH;RNP/
M=$M.+5@9".8 @22-W::Y)PG&(C*Y[6'48IR%P@E\1WHR.? @:#*GQ?U[87/R
M[4D%$Z=V-*7/]>7<&R;DF^,/GCU'X&D#+FM)$?+0:?66E^4^F6I=.#+)UB3G
M&)GOR'Q?7U)K^0 )O2L<^K8F]+*+X0$G(YE51R>=0'-6%:^D)"88ETT>^J*)
M86^S+%F34A9M"/& U )FY3/W]'I$/'<&7]I1&(0OJ84OM^4 WOFCEBD7I\D@
M,NM[ 5TZ(+-[80$#/:CG*I6*C:5>9(6 34!TI$'-/]Z.34 H3[D1EIF4ZWQN
MX_PF2C\6XI>^X\6N/:>6"1[ZTK]7[/V3HV^1PD?"BE-RKC?A2)PE6NSW^Z4#
MXU*#E(VPW*1\ZELQ>.'J#-_:#HY,;^K>CYT#/SQLG,4=4ZJ@+7S7!.KA3ZS\
MI0_\]/GDM9QG "6O_?UQNH^ #,*&&/<\,>[4TL@RZ%R\:I:T2\#<(&Z8[M$1
MV%M?RJTN2CZG& D'TM=W$B9JJ2[V*$A_S_ J=^BM\2;S[A6>ZW:CC7L1&V;-
M)7]C4]_=37ZQR^[,]"2=,WM5G1GU[9\OV_5%7RWRYSST D)%N\YGC4&JA6MR
MK4_KH=NKT.VSI_L33)TQUN+N<JL4'A1.)^:7#:H42G\F7 5V\:0HH2ENIO6U
MT?<]I>^$PM9=BX+E=KA<.'Z^PUK[S?9T%7N1D=URI50\&K[O'MY82X@[>IA&
M)&.U)\=#XD$<C@Y $8\=X2NQ:WKZ(+0Q,3WVAZ):>J=+LZ9VK#"@Z>!UK#LC
MM!D,[T68U)AS_Q<G=2C5"GIU]&JO$A,[LM"Z#Z:C7\- 1?S.D<;PZFY>FUI^
M^O).&+BQHTWIS*>P]9;LGO%&$&HUMGNY^X.Q?DG%;#?_D"0\Y#W>"^*HTI2/
MPOWPZI[P8?OA\"=W:"G'?PQ'/PZ\DX][O!?%E2LNPW_,P^I\'+.Z>(P^>X'S
MX\_??_O]-\8^QBI_SWFG\MD\T?1#YCQH-Z1OKQT]0R::J T#>X9EW=ZM:'[*
M?3U3-W[Q^/M!\;LQ+#DF73VGYC'C?B\53T]R^H$EDTO_OKO(,5<X4CN0ZE,N
M?Y3[\^#4^H(?]][0G=6.J#P]HM.71U0^7OZ(K@/?X:KUQ4)UFZCVN59?-=GO
M8OE[L61GH1[,ZG_)>,\O];\T/2,S;S[=RUMA_! GLN;\S'?'KJWZ3AR&R<^+
M]+GT2I^/IOK\BUVQ(_CXKWS^*@BBZR 2^JGI6".A[Y3/#P;H2?]'I:DOT0Z4
MJ.D/[-'^*@P,\JTHZE3V]AX>'@J/C= K!.']WGZQ>+!G_KQG+LSUKX]Z'7V]
M'KK0+IR;^],VOO>D=?W[CWNF*5DQ_[>]^#]02P,$%     @ UTH?2^B3CVV,
M%P  UB\! !$   !A>71U+3(P,3<P-C,P+GAS9.U=;6_;.I;^/L#\!VT66-P!
MQDV<E][;[NT,G*2YDT%:!XD[G=W%8L!(M,VI+/J25!+?Q?[W/:0D6[)$BI+L
ME.WJ2^M()/6<\_#E\) \_/G/SXO0>\2,$QJ].QB^.CKP<.33@$2S=P>?)E>#
MGPZ\/__I][_[^5\& ^\7'&&&! Z\AY5WB02:,.1_X5E^;_AJ^.J-!S].C@:C
M>#8X/AK^Z/W7T8]O3U^_/3[^;^]_;C_\K_?^?N(-O*>GIU<!E"!4":]\NO &
M _D=[L_Q GD"L1D6']$"\R7R\;N#N1#+MX>',A]:B?B!4)GI4'[BZ/6)A!WB
M!8[$%66+2SQ%<2C>'?P:HY!,"0X./) SXF]E5HNR5.)"NJ>35Y3-(,G1\/#O
M'V[N%<JLU)!$7PJIGQ]8F*4_.92O'Q#'67+Y-A#K#/G$9X?)RW72T%#NWV^@
MX'RAQ)"81%R@R-^ *(%.11R^>?/F4+W-DL9\,$-HN4X\1?Q!)4U?*,4-CH:#
MDV&6Q:=Q)-BJ*"/'_JL9?3Q,7U9EBQF#ZJ?+E[ZMR!A@4IT'7LCDI\7D^-F?
M5Z>7;RK*)]$CYJ(Z2_).9CHI9HH0\7EU'O6JXCN<^-49X(5,/BPF!P+$:HEY
M)37J3=4WQ))I/@)O*KX2X"7#OFSWVOKUYA QG]$0 P)?#/#S,D01$I2MKN#O
MM4)H%,6+ZD("P0XEXD-(-(!4F!%_G:\^4YH!>A#/^QE%$86N!;HD];=\LER2
M:$K3/^&!K-]O)> )9/?DCT]WU]J>04EV2?U8]C"C*'@?"2)6UU B6ZCO''@$
ME&-,L?YV]O4 3TE$%,KAT1#ZQ"Q[_B<4Y25E>;G"?C[<+N'WO]LN/N8X&$=_
M4K^!/PZEJ;RRTTCSITG,>3<?:9K31Z$?A]J/IMD."U3DBFS#T06-. U)("OK
M.0IEAW<_QUCPA"#]:S,[QT#)/:@/I_3DR_'2@KRDI)Z:IM3<(NC5Q1P+ JAJ
M>"JF-9-V8D^:]T.AX#_T)%J0N-8M'T_'2VD8 I"*AJ9)9R;OU$3>ID2/3KU-
MF3UM#6F[%]3_,J=A  ;\^U]C&&7,]%6D-]-X9D]CONQ_^]>3-__N)5_H2>U,
M:DT/VR2SF>[7W>GNN^*.]%\@/K\*Z5--3[Q)9J;T1WM*99&>*K,GK2UI#9JJ
M)H^9SI_:T-FW24MZSV-.(LSY.>($&+K-R?T!LQEF,)W+TES0Q0.)\D93Z]QF
MRM_(^23A?DAYS##\D97Q1T]]27*=_]8?O>1K'H*Y9Y;6RW^PYU_#_WV\6""V
M@F&4S"(RA<82B9&O_%TDFMU"0_,)3MFV3&OD=GBTS6U:JAIA-^5ZFX*]K.2>
M1 V)OU!0$_2+/F:I7Z?PQ$S(<)L0E==+,_<ZU^C\AO@XXG@T8U@-0 P_XBC&
M=]BGLT2(A F+=&9^CK?Y24OTUD4>WB5E>KE">]XTO%TAPOZ&PAA+.X($12>
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M68FV9TJB#8X6>SZB;6< 1#!5? Q!*VXCSE\('?V*(NMU"Y[R8!AKV]\B3SB
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M !Z!\-,-V6I"H7;5<4W885GDA9_PFR9MZ&HT Z D$GIOQ-D:'OD=1 ?'*7.
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MU]E!@E\=)"0I])._1-.A*N#I0C4L:8O2\"EL5YW)#O2$V"0UEV"U,QD"4ED
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M=*K9LGYS4H E[)=W81M?@&GU(U\!W=,JE0)F&)U_"*T$@2&)0K6'_?H6.C"
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MW8=W?K)S$V5+< B_KG/J3)?7P^PA&K\4G[^S+(CRNM#$_(_Y]*^Y+!U;I_Y
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MTWF;BSZ;RIMI2_2_.U5'H(S=G?+:PJ16MA-=JUVP!&@((G[1V\ B5](=*(9
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MT?Y<4$P"PIP<%K5@1N/,T5J%FJ=0F9/.F:_LL7S.V;]+?A+V-DT2JAI4Q2U
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M:%%21LEX",-4G21C^B>^M$J"**Z3?PR>\R+S ]EYI:$W@!H/"81#=IMTS>J
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MW2T7@(A=>DI7?R[IMKI7V60V\F^X:4VN(M23R/?;B0$LW#)4"U7P@LW:A "
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M72=HAUF)&3B.O))(I@QEHK1PG\:I>1@*HO3\PLVGX*Q)0N:]"!7W=F2&27E
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MAIV]@O 3UKQ6^^/0?=C5N\RC=*Y\@0DK#S2ZQ6WUARZTZQ[)_!*_/ :'PTO
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MN@<VE'(T# ["O]D_6APVB/- (X4MUBTU4P!OE9^8*39$2H9/+.^*)/PL )3
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MM#=4.@H<N*RV&D[?4PEM;FD_I3"X&>5DYO9L^QR0&/I%72G;]8VXG;4^9+=
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M-+,?;]/MY6#:I/]5YN9Y$MH]IM9!A(E0I_:'7UV=Q'4]/F4EO18(O$G0U"N
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MQ)LKFT:N!;>^.1I@;<;VNXI*@T>4]OLT8;?=]^FG(XYCS,S]KVD<X4P8L6S
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MS4=T[-7$*<,YXW3^$Q2J*E+AZZQCC>R>K_=[V$=*^;L'+ZZ*%=HY")5H<\9
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M*XEZX#-9FKVB)"TP?[".5,$LM/%OO_[Z_>;=NW?\S99F8G>_*3#%]%A-2G-
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MB'!@K5V7CU9BJ#.U:@+(YI1ZR'!(1D>J,S.TFSF83#N]',ZDS<\N8SX,N@E
M!K_FWD>/(6 XXXN&WV+4)#RP<08O))RG>] =Z\T67N)[9"9U]MHT*;=SVY<@
MB^H[FVV>'_?LIC6',+2PP-$' F_1)Q&L;R7PM_!M^_&5%O0Y"+H$AF_Y,Q?M
MKZ+69]'#*VJW*S^-V+<[L6JM[V]0U0-4=8%MQMS>J[I0<2W^*\&Q!TM :V8[
M"%"U:[,VHU;#=(_O@\]_36,2!:^J GN"]@YB5,?[/8SDA':(-D1E2_=W>5JZ
M'\9#*A7OHE;C91+AW1+U&O48.:S9J"FI+#6@87%*M1M-AEA<O]%\?!TXP>VQ
M>$HS4KQN/Q-9)3P1@3LWV.^YQ _63=%/T-@#K,GU+_2$$N6[FT ']ZD:DZC@
M3M7)1'HEN=P>FTRO?+C;UAX,U:PJ& F7KNA#N@^([#A%3.*!.ZI[K^>0>'.?
MD"08![53&AL$FSB23K=GK]\'?T^S\SC(M<H43V/G '^3I!YBLUZGQ2=1RGC.
M: ^1/'>H+=[:!1!ZD0N##@7M[-_(]?HYN'_COWL02"C5[.!J3:Q6/RIYA.%Q
M?XQI+Z-VVK $*%.8>56W0RBQ<;F.AE,G5WWI0]!ON<P)?H1/J0Y!%Q']"E+%
M@I9\0:84T)?"%G)$F]2ST(&S/2O^N-OAL* =K1=2<"IZGB8%28XD>;P^8'[#
MF9<_=5_AT<A26>P+UNU].=WT+:'FC%K+<19WUF6Q0648EU?9,0MCIF\\JP#&
MYF7\0T$[^XRSG/:&_ZL /T"[Q0(J?@S@^J+(K[-K?B]QF>=''+V7WMQ/YNG@
MFG^Z_,/+]H<"-<PVJ&:'&GX;5'%$:89*GH@S=6\LL^$PO,9?! NNIYB>T187
M.*)F'=\507&D'7GM-#:>7@RY>S*UF.ID^K02%*ADCFKN?:)Z\G&[]%Q'56<X
MH;OM A21UPK(0.HF<-J]\UC0=/1FV1EVXY=#@1[#DZ]7M!MQW6XT36,9MEZZ
M$(D6IOL.QI2]YLC8MMKC?#6?81:SL[!NN,2$RUEP.1-<P-7RKO2B#]R?U/*?
MC/M0&<H4OZ%G)7XYC$]I$N'H2)O1K7I9X&X\^N@\S<WWN_,^YJ5S,=;8=)?3
M^513Q%88B0@?/"%7-%N3=T4:_HRX(L)6\]-S1]/,<(J3FF.#,])5=+K6#-IE
M4F *SN*ZVNA!9V$'..* EF5O-Q5F.:U,=3(M2T$5?W2=H-87$'S"C3=964FU
MP%0/84O@B#97^Y#9PFNE&JTG?6ODZ8JN>*)R$_JQ#%.O1A=VQ0O&"<KP(64'
M3\TRL$K_0&_*U=\7;%6,JR!V:<L,Q[3+R2,J4MI0K'[7J5$+^ZM.(M4JSFIE
MWWP-R*#C!I.",.E_ B/__&U?TLF>M6+$EF5K%0E8RH&JI*Z%":'!*3E'E627
M!3@Y7K0R9V=AX X/C7.DG@K78PY>C;7)NH--2=*.BD[!@8T:M;&KDECTHDXI
M&WR97XX]TG&B_\I)5%Z0Z;LG Y:N'96)]#HN:\QC-1Q1AZ57OFN.(EH"ANVF
M_OJS.=(NYME"@=K\\W'&/D+A[28Z"+_.^,Z?(&WP,OF8!+! 7^9R4<34RS,[
MH0:FG\UQEO!>0\ET_0O$Y4_@M/722%NYB=,[8Y.;P92S-!T;\-,55&60((.
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M5>D3;("[C6YQ4]!\U5*T\Z99*CFTBB7,>Z'JE:U,0V?-@5K][O1)BU>5.EF
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M+2AH;NI<2RRDD2I9LJS"31M8ND4KU#7S>QI<(!3$0]"-*0/V(!+7&;KS&-8
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M (+$=E%&L7@020'U?+1LWI=Q,#RJ%"$:PV*[H'?RP=G"M)^+BD\N9@-$NPT
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M22WO@IKAN*G052 1)>BE2;&1%U'"Z@6UDV53)5!@1'+ ]#).[W[5XQ*S*G>
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M(BK0QK)U0$\ROY>>1.&41X6MS?W99#9Y7=Y5=^(^WDFDK^$T1FIXH^-SYTY
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M-NH[H"SE!7*;)8]#4H[?6BF 3F*\[LA"(K!ZORV9O9R*[$L8AXMBH9YTZ^4
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M^P@003;,*+ M2#(/7XZ&\O+EV8>/KL:(C13OO'Z)Z(D%+W'XKX(=Y#%,[+-
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M%9(2BQ>#,P3?VFT2SW.6+J[8<ZYQCUY4',@8C"FAR>C'.1F"UVT7G7+PBRO
MR9&$Z147EIYPZV@&X9FR=K/^?#B'T":S@)26(=QL[>/-^M$1D:5)IAQB?>J
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M:>7:#]AXD12QRD<IJN*=CDB,::G0= Q,NY <YSJSE33+7\#&)/PWFY9HEV$
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M#$JX'>1FL[!X+&^W+O7\*5FGI)O5[C!CRX=69>^<1L)TTP7$ !PB6L?OF:X
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MN*9_%:8L@+:5FX;M@IP"$HM",]&)U4 (<1!7\S]_8T'!LTY,9K,P8&IIBRL
M)><DW"@VI2Z%.HA+]C>PW5FPS?L^_$NA,G&>I!;GLZ?KOQJ5X_ORG8I<N>9+
MZ_$Q0>(6E5J(1L+?0C>(*_;CKWXZU4AQNU6.$^#T,DWS42W"X?B>O,48]DLX
MDO)T'SQ!V%(6FY/PY?NFS+W_7II%.!L;2N+I?>3'W&6ID137_N>X.$A8_D5*
M@GCNNJ-A$!?]'UB6IV&0LZF>-TA8GA-"PHG0H;3%ZB6C8X"W^XW>%%J-3:>^
MX.8+$0K&\<7[+N2JM:)@57B0*IF;NT*)Z0AX#P_-2_A;L4>:H=)X%0Z5Q#%
M(0N!Y5^-RO$5?/2UOO44="O)AHV6Y2KMU%QG/J.JL SB/GP-7Y7I9USD+TG*
M<P/K!=?LUO).W#YIH)*:,L)&#&@0M]MK*._]=))6%_G_[D>%+"&*06W@RJEU
MMK7PY< &<2G]?M55TT$OKP@,N3?(&HM>!U,'-]E=2[W!Z-=K !ASZH&UH05R
M;(@V],NHM[?<38H\R_UX&L9SDV6_5LW[>.3>=-M^W=]#A,B[7^:R>OKW58+F
MFSC,0S^Z+YZC,)C, (I<^-IM>!>G/=P$&,)#U*)?5K+E7=_E,722/H3SEWPK
M.]SZC]GRKYDLTU&C]H#/'BX9+: BJM,O0YS29(U9K)?9GGZODDHN7[+^/4TR
M^4.8UK_F79RYM_ :JUUG1"!*Z=AL^$<,W?B:ACE+UUDKIY,9-Z+YVS<9,5N4
M?@O>Z,BM-\A,(YJA0\3<KXC!ZL[-M1^FY?[\*LR"*,GD^9G1.CQZOX<;5Q4>
M1-#],DZN%M!Q/*U64+UCBJP:I\=]?BIC<6M 0A+D],M"65)298*\*OANNUJH
M2AV_8U_+O\@O<FO4]T;'!"X/F*_]!M@09>B7I1(!7!W46VC#3@.<LAZ>0(S
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MM@!A73BI4-Y1-1*^V@@@H0+1G%[F_5CM&I:W*.M//.J<^475O-&'#R0N/!]
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M::QWF!W^,0F=Q/JSD:-?AX?B;=_XARS4OS[ N!_D34A)^']02P$"% ,4
M" #72A]+* ]^JCV[ 0#](AX $0              @ $     87ET=2TR,#$W
M,#8S,"YX;6Q02P$"% ,4    " #72A]+Z)./;8P7  #6+P$ $0
M    @ %LNP$ 87ET=2TR,#$W,#8S,"YX<V102P$"% ,4    " #72A]+T8?#
M+HH0  #*#0$ %0              @ $GTP$ 87ET=2TR,#$W,#8S,%]C86PN
M>&UL4$L! A0#%     @ UTH?2WOC]BV9>P  *CT( !4              ( !
MY.,! &%Y='4M,C Q-S V,S!?9&5F+GAM;%!+ 0(4 Q0    ( -=*'TN5]6A
M,J(  .[?"  5              "  ;!? @!A>71U+3(P,3<P-C,P7VQA8BYX
M;6Q02P$"% ,4    " #72A]+V[S _Q:#   A( D %0              @ $5
M @, 87ET=2TR,#$W,#8S,%]P<F4N>&UL4$L%!@     &  8 B@$  %Z% P
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
